All	DT

live	VB

births	NNS

>	JJR

or	CC

=	JJ

23	CD

weeks	NNS

at	IN

the	DT

University	NNP

of	IN

Vermont	NNP

in	IN

1995	CD

(	NN

n	NN

=	JJ

2395	CD

)	NN

were	VBD

retrospectively	RB

analyzed	VBN

for	IN

delivery	NN

route	NN

,	,

indication	NN

for	IN

cesarean	NN

,	,

gestational	JJ

age	NN

,	,

parity	NN

,	,

and	CC

practice	NN

group	NN

(	NN

to	TO

reflect	VB

risk	NN

status	NN

)	NN

The	DT

total	NN

cesarean	NN

rate	NN

was	VBD

14.4	CD

%	NN

(	NN

344	CD

of	IN

2395	CD

)	NN

,	,

and	CC

the	DT

primary	JJ

rate	NN

was	VBD

11.4	CD

%	NN

(	NN

244	CD

of	IN

2144	CD

)	NN

Abnormal	JJ

presentation	NN

was	VBD

the	DT

most	RBS

common	JJ

indication	NN

(	NN

25.6	CD

%	NN

,	,

88	CD

of	IN

344	CD

)	NN

The	DT

``	``

corrected	VBN

''	''

cesarean	NN

rate	NN

(	NN

maternal-fetal	JJ

medicine	NN

and	CC

transported	VBN

patients	NNS

excluded	VBN

)	NN

was	VBD

12.4	CD

%	NN

(	NN

273	CD

of	IN

2194	CD

)	NN

,	,

and	CC

the	DT

``	``

corrected	VBN

''	''

primary	JJ

rate	NN

was	VBD

9.6	CD

%	NN

(	NN

190	CD

of	IN

1975	CD

)	NN

Furthermore	RB

,	,

when	WRB

all	DT

deliveries	NNS

were	VBD

analyzed	VBN

,	,

regardless	RB

of	IN

risk	NN

status	NN

but	CC

limited	JJ

to	TO

gestational	JJ

age	NN

>	JJR

or	CC

=	JJ

36	CD

weeks	NNS

,	,

the	DT

rates	NNS

did	VBD

not	RB

change	NN

(	NN

12.6	CD

%	NN

,	,

280	CD

of	IN

2214	CD

;	:

primary	JJ

9.2	CD

%	NN

,	,

183	CD

of	IN

1994	CD

)	NN

Arrest	NN

of	IN

dilation	NN

was	VBD

the	DT

most	RBS

common	JJ

indication	NN

in	IN

both	DT

``	``

corrected	VBN

''	''

subgroups	NNS

(	NN

23.4	CD

and	CC

24.6	CD

%	NN

,	,

respectively	RB

)	NN

Cesarean	NNP

rates	NNS

at	IN

tertiary	JJ

care	NN

hospitals	NNS

should	MD

be	VB

compared	VBN

with	IN

rates	NNS

at	IN

community	NN

hospitals	NNS

only	RB

after	IN

correcting	VBG

for	IN

dissimilar	JJ

patient	NN

groups	NNS

or	CC

gestational	JJ

age	NN

In	IN

the	DT

third	JJ

trimester	NN

,	,

the	DT

amniotic	JJ

fluid	NN

index	NN

(	NN

AFI	NNP

)	NN

may	MD

be	VB

affected	VBN

by	IN

maternal	JJ

fluid	NN

status	NN

As	IN

the	DT

ambient	JJ

temperature	NN

increases	NNS

,	,

there	RB

is	VBZ

an	DT

increase	NN

in	IN

insensible	JJ

fluid	NN

loss	NN

and	CC

the	DT

potential	NN

for	IN

dehydration	NN

We	PRP

hypothesize	VB

that	IN

as	IN

temperature	NN

increases	NNS

there	RB

would	MD

be	VB

a	DT

concomitant	JJ

decrease	NN

in	IN

AFI	NNP

From	IN

June	NNP

11	CD

to	TO

August	NNP

16	CD

,	,

1993	CD

,	,

during	IN

a	DT

period	NN

of	IN

unusual	JJ

high	JJ

heat	NN

,	,

42	CD

women	NNS

with	IN

singleton	NN

pregnancies	NNS

between	IN

27	CD

and	CC

40	CD

weeks	NNS

'	''

gestation	NN

undergoing	VBG

serial	NN

antenatal	JJ

testing	NN

had	VBD

AFI	NNP

determinations	NNS

recorded	VBN

at	IN

least	JJS

weekly	RB

The	DT

daily	RB

high	JJ

ambient	JJ

temperature	NN

in	IN

our	PRP$

urban	JJ

area	NN

was	VBD

subsequently	RB

obtained	VBN

A	DT

2-	CD

,	,

3-	CD

,	,

and	CC

4-day	JJ

mean	VB

temperature	NN

prior	RB

to	TO

the	DT

test	NN

date	NN

was	VBD

compared	VBN

to	TO

AFI	NNP

using	VBG

a	DT

Spearman-rank	JJ

Correlation	NN

The	DT

daily	RB

high	JJ

temperature	NN

ranged	VBD

from	IN

71	CD

to	TO

104	CD

degrees	NNS

F	NN

and	CC

AFI	NNP

values	NNS

ranged	VBD

from	IN

1.7	CD

to	TO

24.7	CD

cm	NN

during	IN

the	DT

study	NN

period	NN

There	EX

was	VBD

a	DT

significant	JJ

correlation	NN

between	IN

the	DT

2-	CD

,	,

3-	CD

,	,

and	CC

4-day	JJ

mean	VB

temperature	NN

and	CC

AFI	NNP

,	,

with	IN

the	DT

4-day	JJ

mean	VB

being	VBG

the	DT

most	RBS

significant	JJ

(	NN

r	NN

=	JJ

0.31	CD

,	,

p	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

Fluctuations	NNS

in	IN

ambient	JJ

temperature	NN

are	VBP

inversely	RB

correlated	VBD

to	TO

changes	NNS

in	IN

AFI	NNP

This	DT

relationship	NN

should	MD

be	VB

taken	VBN

into	IN

account	NN

when	WRB

interpreting	VBG

the	DT

AFI	NNP

as	IN

a	DT

measure	NN

of	IN

fetal	JJ

well-being	NN

This	DT

study	NN

tested	VBN

the	DT

hypothesis	NN

that	IN

to	TO

reduce	VB

the	DT

rate	NN

of	IN

macrosomic	JJ

infants	NNS

in	IN

gestational	JJ

diabetes	NN

cases	NNS

,	,

good	JJ

glycemic	JJ

control	NN

should	MD

be	VB

initiated	VBN

before	IN

34	CD

completed	VBN

gestational	JJ

weeks	NNS

The	DT

study	NN

population	NN

included	VBN

84	CD

women	NNS

with	IN

gestational	JJ

diabetes	NN

,	,

ascertained	VBN

by	IN

universal	JJ

screening	NN

of	IN

all	DT

women	NNS

attending	VBG

the	DT

antenatal	JJ

clinic	NN

of	IN

the	DT

Hadassah	NNP

Medical	NNP

Center	NNP

,	,

over	IN

a	DT

2-year	JJ

period	NN

The	DT

60	CD

women	NNS

(	NN

71	CD

%	NN

)	NN

,	,

who	WP

initiated	VBN

treatment	NN

before	IN

34	CD

completed	VBN

weeks	NNS

,	,

composed	VBN

the	DT

``	``

early	RB

''	''

group	NN

The	DT

24	CD

women	NNS

(	NN

29	CD

%	NN

)	NN

,	,

who	WP

initiated	VBN

treatment	NN

after	IN

the	DT

34th	JJ

week	NN

,	,

composed	VBN

the	DT

``	``

late	RB

''	''

group	NN

All	DT

patients	NNS

were	VBD

managed	VBN

by	IN

an	DT

intensified	VBN

protocol	NN

,	,

including	VBG

stringent	JJ

glycemic	JJ

control	NN

In	IN

the	DT

``	``

early	RB

''	''

and	CC

``	``

late	RB

''	''

groups	NNS

,	,

mean	VB

gestational	JJ

age	NN

at	IN

the	DT

beginning	VBG

of	IN

treatment	NN

was	VBD

30.0	CD

+/-	CC

3.8	CD

and	CC

36.2	CD

+/-	CC

1.2	CD

weeks	NNS

,	,

and	CC

duration	NN

of	IN

treatment	NN

was	VBD

9.6	CD

+/-	CC

4.1	CD

and	CC

3.7	CD

+/-	CC

1.8	CD

weeks	NNS

,	,

respectively	RB

Maternal	JJ

characteristics	NNS

were	VBD

similar	JJ

in	IN

the	DT

two	CD

groups	NNS

The	DT

rate	NN

of	IN

macrosomic	JJ

and	CC

large-for-gestational-age	JJ

infants	NNS

were	VBD

5	CD

and	CC

11	CD

%	NN

,	,

respectively	RB

,	,

in	IN

the	DT

early	RB

group	NN

as	IN

compared	VBN

to	TO

25	CD

and	CC

29	CD

%	NN

in	IN

the	DT

``	``

late	RB

''	''

group	NN

(	NN

p	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

No	DT

significant	JJ

differences	NNS

were	VBD

found	VBN

between	IN

the	DT

two	CD

groups	NNS

in	IN

the	DT

mode	NN

of	IN

delivery	NN

or	CC

Apgar	NNP

scores	NNS

We	PRP

conclude	VBP

that	IN

to	TO

reduce	VB

the	DT

rate	NN

of	IN

macrosomic	JJ

infants	NNS

in	IN

gestational	JJ

diabetes	NN

cases	NNS

,	,

good	JJ

glycemic	JJ

control	NN

should	MD

be	VB

initiated	VBN

before	IN

34	CD

completed	VBN

gestational	JJ

weeks	NNS

Our	PRP$

aim	NN

was	VBD

to	TO

investigate	VB

the	DT

contribution	NN

of	IN

certain	JJ

antenatally	RB

detectable	JJ

markers	NNS

leading	VBG

to	TO

the	DT

diagnosis	NN

of	IN

trisomic	JJ

fetuses	NNS

we	PRP

observed	VBN

over	IN

a	DT

period	NN

of	IN

6	CD

years	NNS

In	IN

our	PRP$

study	NN

,	,

we	PRP

specifically	RB

analyzed	VBN

the	DT

role	NN

played	VBN

by	IN

advanced	VBN

maternal	JJ

age	NN

and	CC

sonographically	RB

discovered	VBN

abnormalities	NNS

in	IN

the	DT

detection	NN

of	IN

autosomal	JJ

trisomies	NNS

All	DT

together	RB

,	,

27	CD

fetuses	NNS

had	VBD

this	DT

disorder	NN

,	,

representing	VBG

28.7	CD

%	NN

(	NN

27	CD

of	IN

94	CD

)	NN

of	IN

all	DT

cytogenetic	JJ

aberrations	NNS

detected	VBN

at	IN

our	PRP$

center	NN

over	IN

the	DT

same	JJ

period	NN

Down	NN

syndrome	NN

(	NN

12	CD

cases	NNS

)	NN

and	CC

Edward	NNP

syndrome	NN

(	NN

11	CD

cases	NNS

)	NN

were	VBD

the	DT

most	RBS

common	JJ

trisomies	NNS

,	,

while	IN

4	CD

cases	NNS

of	IN

Patau	NN

syndrome	NN

were	VBD

also	RB

diagnosed	VBN

The	DT

most	RBS

common	JJ

indication	NN

leading	VBG

to	TO

diagnosis	NN

was	VBD

abnormal	JJ

ultrasound	NN

finding	NN

(	NN

48.2	CD

%	NN

)	NN

,	,

followed	VBN

by	IN

advanced	VBN

maternal	JJ

age	NN

(	NN

44.4	CD

%	NN

)	NN

However	RB

,	,

63	CD

%	NN

of	IN

the	DT

trisomic	JJ

fetuses	NNS

belonged	VBD

to	TO

mothers	NNS

aged	JJ

35	CD

years	NNS

and	CC

above	IN

Down	NN

syndrome	NN

fetuses	NNS

(	NN

41.7	CD

%	NN

)	NN

had	VBD

prenatally	RB

detected	VBN

sonographic	JJ

anomalies	NNS

,	,

63.6	CD

%	NN

for	IN

Edward	NNP

syndrome	NN

,	,

and	CC

all	DT

fetuses	NNS

with	IN

Patau	NN

syndrome	NN

(	NN

4	CD

of	IN

4	CD

)	NN

showed	VBD

abnormal	JJ

sonographic	JJ

signs	NNS

Trisomy	NNP

21	CD

presented	VBN

with	IN

the	DT

following	VBG

features	NNS

:	:

hydramnios	NNS

,	,

complex	NN

malformations	NNS

,	,

pyelectasis	NN

,	,

and	CC

duodenal	JJ

atresia	NN

Trisomy	NNP

18	CD

fetuses	NNS

showed	VBD

hydramnios	NNS

,	,

intrauterine	JJ

growth	NN

retardation	NN

,	,

microcephaly	NN

,	,

spina	NN

bifida	NN

,	,

and	CC

nonimmune	JJ

hydrops	NNS

fetalis	NN

Signs	NNS

observed	VBN

in	IN

fetuses	NNS

with	IN

trisomy	NN

13	CD

were	VBD

:	:

hydrocephalus	NN

,	,

intrauterine	JJ

growth	NN

retardation	NN

,	,

oligoanhydramnios	NNS

,	,

complex	NN

malformations	NNS

,	,

severe	JJ

fetal	JJ

bradycardia	NN

and	CC

hydronephrosis	NN

The	DT

objective	NN

of	IN

this	DT

study	NN

was	VBD

to	TO

determine	VB

if	IN

the	DT

rate	NN

of	IN

preeclampsia	NN

is	VBZ

increased	VBN

in	IN

triplet	NN

as	IN

compared	VBN

to	TO

twin	NN

gestations	NNS

Fifty-three	CD

triplet	NN

pregnancies	NNS

between	IN

1986	CD

and	CC

1993	CD

at	IN

The	DT

New	NNP

York	NNP

Hospital-Cornell	NNP

Medical	NNP

Center	NNP

were	VBD

reviewed	VBN

These	DT

were	VBD

matched	VBN

for	IN

maternal	JJ

age	NN

,	,

parity	NN

,	,

and	CC

race	NN

to	TO

twin	NN

gestations	NNS

(	NN

N	NN

=	JJ

53	CD

)	NN

from	IN

the	DT

same	JJ

population	NN

Severe	JJ

preeclampsia	NN

was	VBD

defined	VBN

by	IN

standard	NN

criteria	NNS

Student	NN

's	POS

t-test	NN

,	,

Fisher	NNP

exact	JJ

test	NN

,	,

and	CC

Chi-square	JJ

were	VBD

used	VBN

for	IN

statistical	JJ

analysis	NN

The	DT

rate	NN

of	IN

severe	JJ

preeclampsia	NN

was	VBD

increased	VBN

significantly	RB

in	IN

the	DT

triplet	NN

group	NN

12	CD

of	IN

53	CD

(	NN

22.6	CD

%	NN

)	NN

as	IN

compared	VBN

with	IN

the	DT

twin	NN

group	NN

3	CD

of	IN

53	CD

(	NN

5.7	CD

%	NN

)	NN

(	NN

OR	NN

=	JJ

4.9	CD

,	,

95	CD

%	NN

CI	NN

1.2-23.5	CD

,	,

p	NN

=	JJ

0.02	CD

)	NN

The	DT

rate	NN

of	IN

overall	RB

preeclampsia	NN

was	VBD

not	RB

significantly	RB

different	JJ

in	IN

the	DT

triplet	NN

18	CD

of	IN

53	CD

(	NN

33.96	CD

%	NN

)	NN

or	CC

twin	NN

12	CD

of	IN

53	CD

(	NN

22.6	CD

%	NN

)	NN

groups	NNS

In	IN

this	DT

retrospective	NN

,	,

case-controlled	JJ

study	NN

,	,

the	DT

rate	NN

of	IN

severe	JJ

pre-eclampsia	NN

was	VBD

significantly	RB

increased	VBN

in	IN

triplet	NN

gestations	NNS

as	IN

compared	VBN

to	TO

twins	NNS

although	IN

the	DT

overall	RB

rate	NN

of	IN

preeclampsia	NN

was	VBD

not	RB

This	DT

information	NN

may	MD

be	VB

useful	JJ

in	IN

counseling	NN

patients	NNS

with	IN

high	JJ

order	NN

multifetal	JJ

gestations	NNS

We	PRP

conducted	VBN

a	DT

survey	NN

and	CC

audit	NN

of	IN

thermal	JJ

equipment	NN

use	NN

in	IN

very	RB

low-birth-weight	JJ

infants	NNS

in	IN

five	CD

Ohio	NNP

neonatal	JJ

intensive	JJ

care	NN

units	NNS

(	NN

NICUs	NNS

)	NN

to	TO

document	NN

regional	JJ

practice	NN

The	DT

survey	NN

indicated	VBD

a	DT

variety	NN

of	IN

thermal	JJ

care	NN

styles	NNS

Two	CD

NICUs	NNS

preferred	VBN

to	TO

admit	VB

infants	NNS

to	TO

incubators	NNS

,	,

the	DT

other	JJ

three	CD

favoring	VBG

radiant	JJ

warmers	NNS

These	DT

three	CD

NICUs	NNS

moved	VBN

infants	NNS

from	IN

radiant	JJ

warmers	NNS

into	IN

incubators	NNS

at	IN

significantly	RB

different	JJ

mean	VB

ages	NNS

The	DT

audit	NN

demonstrated	VBN

inconsistent	JJ

use	NN

of	IN

plastic	NN

covers	NNS

,	,

warming	VBG

mattresses	NNS

,	,

and	CC

added	VBN

humidity	NN

under	IN

radiant	JJ

warmers	NNS

,	,

and	CC

discrepancies	NNS

between	IN

survey	NN

responses	NNS

and	CC

actual	JJ

use	NN

within	IN

NICUs	NNS

Inter-NICU	NNP

variability	NN

of	IN

thermal	JJ

equipment	NN

use	NN

may	MD

complicate	VB

fluid	NN

management	NN

This	DT

report	NN

describes	VBZ

a	DT

full-term	JJ

newborn	JJ

with	IN

massive	JJ

fetomaternal	JJ

hemorrhage	NN

Fetal	JJ

movements	NNS

were	VBD

decreased	VBN

48	CD

hr	NN

prior	RB

to	TO

delivery	NN

On	IN

the	DT

day	NN

of	IN

delivery	NN

,	,

they	PRP

were	VBD

absent	JJ

The	DT

nonstress	NN

test	NN

was	VBD

abnormal	JJ

with	IN

low	JJ

biophysical	JJ

profile	NN

and	CC

decreased	VBN

beat-to-beat	NN

variability	NN

The	DT

infant	NN

presented	VBN

with	IN

extreme	JJ

pallor	NN

,	,

hypotonia	NN

,	,

hepatosplenomegaly	RB

,	,

and	CC

ascites	NNS

The	DT

initial	JJ

hemoglobin	NN

was	VBD

2.2	CD

g/dL	NN

,	,

the	DT

Kleihauer-Betke	NNP

stain	VB

was	VBD

27.6	CD

%	NN

(	NN

highest	JJS

level	NN

ever	RB

reported	VBN

)	NN

Right	RB

temporal	JJ

and	CC

cerebellar	NN

hemorrhages	NNS

were	VBD

present	JJ

Sequelae	NNP

include	VB

severe	JJ

developmental	JJ

delay	NN

and	CC

asymmetric	JJ

double	RB

hemiplegia	NN

Omphalocele-Exstrophy-Imperforate	JJ

anus-Spinal	JJ

defects	NNS

(	NN

OEIS	NNS

complex	NN

)	NN

,	,

a	DT

combination	NN

of	IN

omphalocele	NN

,	,

exstrophy	NN

of	IN

the	DT

bladder	NN

,	,

an	DT

imperforate	NN

anus	NN

and	CC

spinal	JJ

defects	NNS

,	,

arises	VBZ

from	IN

a	DT

single	JJ

localized	JJ

defect	NN

in	IN

the	DT

early	RB

development	NN

of	IN

the	DT

mesoderm	NN

that	IN

will	MD

later	RB

contribute	VB

to	TO

infraumbilical	JJ

mesenchyme	NN

,	,

cloacal	JJ

septum	NN

,	,

and	CC

caudal	NN

vertebrae	NNS

In	IN

this	DT

report	NN

,	,

we	PRP

document	NN

the	DT

perinatal	JJ

features	NNS

of	IN

two	CD

cases	NNS

of	IN

OEIS	NNS

complex	NN

associated	VBN

with	IN

meningomyeloceles	NNS

and	CC

severe	JJ

lower	JJR

limb	NN

defects	NNS

,	,

and	CC

discuss	VB

the	DT

prenatal	JJ

diagnosis	NN

,	,

inheritance	NN

,	,

and	CC

differential	JJ

diagnosis	NN

of	IN

this	DT

association	NN

of	IN

malformations	NNS

Although	IN

long-term	JJ

survival	NN

can	MD

be	VB

achieved	VBN

by	IN

successful	JJ

corrective	JJ

surgery	NN

,	,

the	DT

associated	VBN

structural	JJ

defects	NNS

such	JJ

as	IN

large	JJ

meningomyelocele	NN

and	CC

severe	JJ

limb	NN

aplasia	NN

or	CC

hypoplasia	NN

,	,

as	IN

seen	VBN

in	IN

our	PRP$

patient	NN

,	,

can	MD

influence	NN

the	DT

patient	NN

's	POS

quality	NN

of	IN

life	NN

.	.

We	PRP

would	MD

like	IN

to	TO

emphasize	VB

that	IN

an	DT

accurate	JJ

prenatal	JJ

diagnosis	NN

of	IN

OEIS	NNS

complex	NN

and	CC

associated	VBN

malformations	NNS

is	VBZ

important	JJ

for	IN

the	DT

detailed	VBN

counseling	NN

of	IN

the	DT

family	NN

as	IN

well	RB

as	IN

appropriate	JJ

perinatal	JJ

management	NN

by	IN

the	DT

obstetricians	NNS

,	,

pediatric	JJ

surgeons	NNS

,	,

urologists	NNS

,	,

neurosurgeons	NNS

,	,

and	CC

neonatologists	NNS

Nonimmune	JJ

hydrops	NNS

fetails	NNS

diagnosed	VBN

at	IN

21	CD

weeks	NNS

'	''

gestation	NN

with	IN

profound	JJ

ascites	NNS

,	,

hydrothorax	NN

,	,

and	CC

pericardial	JJ

effusion	NN

receded	VBN

gradually	RB

with	IN

regression	NN

of	IN

a	DT

subchorial	NN

placental	JJ

lucencies	NNS

immediately	RB

below	IN

the	DT

umbilical	JJ

cord	NN

insertion	NN

Careful	JJ

inspection	NN

of	IN

the	DT

delivered	VBN

placenta	NN

revealed	VBD

that	IN

there	RB

was	VBD

a	DT

yellowish	JJ

lesion	NN

of	IN

fibrin	JJ

deposits	NNS

below	IN

the	DT

cord	NN

insertion	NN

site	NN

,	,

which	WDT

resulted	VBD

from	IN

the	DT

absorption	NN

of	IN

hematoma	NN

A	DT

subchorial	NN

placental	JJ

hematoma	NN

,	,

which	WDT

detected	VBN

as	IN

a	DT

subchorial	NN

placental	JJ

lucencies	NNS

by	IN

ultrasonography	NN

,	,

can	MD

be	VB

a	DT

cause	NN

of	IN

reversible	JJ

nonimmune	JJ

hydrops	NNS

fetalis	NN

The	DT

mitochondrial	JJ

diseases	NNS

are	VBP

uncommon	JJ

multisystem	NN

disorders	NNS

characterized	VBN

by	IN

the	DT

presence	NN

of	IN

functionally	RB

and/or	CC

structurally	RB

abnormal	JJ

mitochondria	NN

As	IN

there	RB

have	VB

been	VBN

few	JJ

reports	NNS

of	IN

the	DT

obstetrical	JJ

care	NN

of	IN

affected	VBN

patients	NNS

,	,

we	PRP

wish	NN

to	TO

document	NN

two	CD

pregnancies	NNS

in	IN

a	DT

woman	NN

with	IN

a	DT

Chronic	JJ

Progressive	JJ

External	JJ

Ophthalmoplegia	NNP

(	NN

Kearns-Sayre-like	JJ

syndrome	NN

)	NN

Both	DT

pregnancies	NNS

were	VBD

complicated	VBN

by	IN

preterm	NN

labor	NN

and	CC

hypertension	NN

CONTEXT	NN

:	:

Four	CD

genetic	JJ

loci	NNS

have	VB

been	VBN

identified	VBN

as	IN

contributing	VBG

to	TO

Alzheimer	NN

disease	NN

(	NN

AD	NN

)	NN

,	,

including	VBG

the	DT

amyloid	NN

precursor	NN

protein	NN

gene	NN

,	,

the	DT

presenilin	NN

1	CD

gene	NN

,	,

the	DT

presenilin	NN

2	CD

gene	NN

,	,

and	CC

the	DT

apolipoprotein	NN

E	NN

gene	NN

,	,

but	CC

do	VB

not	RB

account	NN

for	IN

all	DT

the	DT

genetic	JJ

risk	NN

for	IN

AD	NN

OBJECTIVE	NN

:	:

To	TO

identify	VB

additional	JJ

genetic	JJ

risk	NN

factors	NNS

for	IN

late-onset	NN

AD	NN

DESIGN	NN

:	:

A	DT

complete	JJ

genomic	JJ

screen	NN

was	VBD

performed	VBN

(	NN

N=280	NN

markers	NNS

)	NN

Critical	JJ

values	NNS

for	IN

chromosomal	JJ

regional	JJ

follow-up	NN

were	VBD

a	DT

P	NN

value	NN

of	IN

.05	CD

or	CC

less	JJR

for	IN

affected	VBN

relative	JJ

pair	NN

analysis	NN

or	CC

sibpair	NN

analysis	NN

,	,

a	DT

parametric	JJ

lod	NN

score	NN

of	IN

1.0	CD

or	CC

greater	JJR

,	,

or	CC

both	DT

Regional	NNP

follow-up	NN

included	VBN

analysis	NN

of	IN

additional	JJ

markers	NNS

and	CC

a	DT

second	JJ

data	NNS

set	NN

SETTING	VBG

:	:

Clinic	NNP

populations	NNS

in	IN

the	DT

continental	JJ

United	NNP

States	NNPS

PATIENTS	NNS

:	:

>	JJR

From	IN

a	DT

series	NN

of	IN

multiplex	JJ

families	NNS

affected	VBN

with	IN

late-onset	NN

(	NN

>	JJR

or	CC

=60	CD

years	NNS

)	NN

AD	NN

ascertained	VBN

during	IN

the	DT

last	JJ

14	CD

years	NNS

(	NN

National	NNP

Insititute	NNP

of	IN

Neurological	JJ

Disorders	NNS

and	CC

Stroke-Alzheimer	NNP

's	POS

Disease	NN

and	CC

Related	VBN

Disorders	NNS

Association	NNP

diagnostic	JJ

criteria	NNS

)	NN

and	CC

for	IN

which	WDT

DNA	NN

has	VBZ

been	VBN

obtained	VBN

,	,

a	DT

subset	NN

of	IN

16	CD

families	NNS

(	NN

135	CD

total	NN

family	NN

members	NNS

,	,

52	CD

of	IN

whom	WP

were	VBD

patients	NNS

with	IN

AD	NN

)	NN

was	VBD

used	VBN

for	IN

the	DT

genomic	JJ

screen	NN

A	DT

second	JJ

subset	NN

of	IN

38	CD

families	NNS

(	NN

216	CD

total	NN

family	NN

members	NNS

,	,

89	CD

of	IN

whom	WP

were	VBD

patients	NNS

with	IN

AD	NN

)	NN

was	VBD

used	VBN

for	IN

the	DT

follow-up	NN

analysis	NN

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

Linkage	NN

analysis	NN

results	NNS

generated	VBN

using	VBG

both	DT

genetic	JJ

model-dependent	JJ

(	NN

lod	NN

score	NN

)	NN

and	CC

model-independent	JJ

methods	NNS

RESULTS	NNS

:	:

Fifteen	CD

chromosomal	JJ

regions	NNS

warranted	VBN

initial	JJ

follow-up	NN

Follow-up	JJ

analyses	NNS

revealed	VBD

4	CD

regions	NNS

of	IN

continued	VBN

interest	NN

on	IN

chromosomes	NNS

4	CD

,	,

6	CD

,	,

12	CD

,	,

and	CC

20	CD

,	,

with	IN

the	DT

strongest	JJS

results	NNS

observed	VBN

forchromosome	NN

12	CD

Peak	JJ

2-point	JJ

affecteds-only	RB

lod	NN

scores	NNS

(	NN

n=54	NN

)	NN

were	VBD

1.3	CD

,	,

1.6	CD

,	,

2.7	CD

,	,

and	CC

2.2	CD

and	CC

affected	VBN

relative	JJ

pairs	NNS

P	NN

values	NNS

(	NN

n=54	NN

)	NN

were	VBD

.04	NN

,	,

.03	CD

,	,

.14	NN

,	,

and	CC

.04	NN

for	IN

D12S373	NN

,	,

D12S1057	NN

,	,

D12S1042	NN

,	,

and	CC

D12S390	NN

,	,

respectively	RB

Sibpair	NNP

analysis	NN

(	NN

n=54	NN

)	NN

resulted	VBD

in	IN

maximum	NN

lod	NN

scores	NNS

(	NN

MLSs	NNS

)	NN

of	IN

1.5	CD

,	,

2.6	CD

,	,

3.2	CD

,	,

and	CC

2.3	CD

for	IN

these	DT

markers	NNS

,	,

with	IN

a	DT

peak	NN

multipoint	NN

MLS	NN

of	IN

3.5	CD

A	DT

priori	FW

stratification	NN

by	IN

APOE	NN

genotype	NN

identified	VBN

27	CD

families	NNS

that	IN

had	VBD

at	IN

least	JJS

1	CD

member	NN

with	IN

AD	NN

whose	WP$

genotype	NN

did	VBD

not	RB

contain	VB

an	DT

APOE*4	NN

allele	NN

Analysis	NN

of	IN

these	DT

27	CD

families	NNS

resulted	VBD

in	IN

MLSs	NNS

of	IN

1.0	CD

,	,

2.4	CD

,	,

3.7	CD

,	,

and	CC

3.3	CD

and	CC

a	DT

peak	NN

multipoint	NN

MLS	NN

of	IN

3.9	CD

CONCLUSIONS	NNS

:	:

A	DT

complete	JJ

genomic	JJ

screen	NN

in	IN

families	NNS

affected	VBN

with	IN

late-onset	NN

AD	NN

identified	VBN

4	CD

regions	NNS

of	IN

interest	NN

after	IN

follow-up	NN

Chromosome	NN

12	CD

gave	VBD

the	DT

strongest	JJS

and	CC

most	RBS

consistent	JJ

results	NNS

with	IN

a	DT

peak	NN

multipoint	NN

MLS	NN

of	IN

3.5	CD

,	,

suggesting	VBG

that	IN

this	DT

region	NN

contains	VBZ

a	DT

new	JJ

susceptibility	NN

gene	NN

for	IN

AD	NN

Additional	JJ

analyses	NNS

are	VBP

necessary	JJ

to	TO

identify	VB

the	DT

chromosome	NN

12	CD

susceptibility	NN

gene	NN

for	IN

AD	NN

and	CC

to	TO

follow	VB

up	RB

the	DT

regions	NNS

of	IN

interest	NN

on	IN

chromosomes	NNS

4	CD

,	,

6	CD

,	,

and	CC

20	CD

CONTEXT	NN

:	:

A	DT

mutation	NN

in	IN

the	DT

BRCA1	NN

gene	NN

may	MD

confer	VB

substantial	JJ

risk	NN

for	IN

breast	NN

and/or	CC

ovarian	JJ

cancer	NN

However	RB

,	,

knowledge	NN

regarding	VBG

all	DT

possible	JJ

mutations	NNS

and	CC

the	DT

relationship	NN

between	IN

risk	NN

factors	NNS

and	CC

mutations	NNS

is	VBZ

incomplete	JJ

OBJECTIVES	NNS

:	:

To	TO

identify	VB

BRCA1	NN

mutations	NNS

and	CC

to	TO

determine	VB

factors	NNS

that	IN

best	RB

predict	VB

presence	NN

of	IN

a	DT

deleterious	JJ

BRCA1	NN

mutation	NN

in	IN

patients	NNS

with	IN

breast	NN

and/or	CC

ovarian	JJ

cancer	NN

DESIGN	NN

:	:

A	DT

complete	JJ

sequence	NN

analysis	NN

of	IN

the	DT

BRCA1	NN

coding	VBG

sequence	NN

and	CC

flanking	VBG

intronic	JJ

regions	NNS

was	VBD

performed	VBN

in	IN

798	CD

women	NNS

in	IN

a	DT

collaborative	JJ

effort	NN

involving	VBG

institutions	NNS

from	IN

the	DT

United	NNP

States	NNPS

,	,

Italy	NNP

,	,

Germany	NNP

,	,

Finland	NNP

,	,

and	CC

Switzerland	NNP

PARTICIPANTS	NNS

:	:

Institutions	NNS

selected	VBN

798	CD

persons	NNS

representing	VBG

families	NNS

(	NN

1	CD

person	NN

for	IN

each	DT

family	NN

)	NN

thought	NN

to	TO

be	VB

at	IN

elevated	JJ

a	DT

priori	FW

risk	NN

of	IN

BRCA1	NN

mutation	NN

due	JJ

to	TO

potential	NN

risk	NN

factors	NNS

,	,

such	JJ

as	IN

multiple	JJ

cases	NNS

of	IN

breast	NN

cancer	NN

,	,

early	RB

age	NN

of	IN

breast	NN

cancer	NN

diagnosis	NN

,	,

and	CC

cases	NNS

of	IN

ovarian	JJ

cancer	NN

No	DT

participant	NN

was	VBD

from	IN

a	DT

family	NN

in	IN

which	WDT

genetic	JJ

markers	NNS

showed	VBD

linkage	NN

to	TO

the	DT

BRCA1	NN

locus	NN

MAJOR	NN

OUTCOME	NN

MEASURES	NNS

:	:

Sequence	NN

variants	NNS

detected	VBN

in	IN

this	DT

sample	NN

are	VBP

presented	VBN

along	IN

with	IN

analyses	NNS

designed	VBN

to	TO

determine	VB

predictive	JJ

characteristics	NNS

of	IN

those	DT

testing	NN

positive	JJ

for	IN

BRCA1	NN

mutations	NNS

RESULTS	NNS

:	:

In	IN

102	CD

women	NNS

(	NN

12.8	CD

%	NN

)	NN

,	,

clearly	RB

deleterious	JJ

mutations	NNS

were	VBD

detected	VBN

Fifty	CD

new	JJ

genetic	JJ

alterations	NNS

were	VBD

found	VBN

including	VBG

24	CD

deleterious	JJ

mutations	NNS

,	,

24	CD

variants	NNS

of	IN

unknown	JJ

significance	NN

,	,

and	CC

2	CD

rare	JJ

polymorphisms	NNS

In	IN

a	DT

subset	NN

of	IN

71	CD

Ashkenazi	NNP

Jewish	JJ

women	NNS

,	,

only	RB

2	CD

distinct	JJ

deleterious	JJ

mutations	NNS

were	VBD

found	VBN

:	:

185delAG	NN

in	IN

17	CD

cases	NNS

and	CC

5382insC	NN

in	IN

7	CD

cases	NNS

A	DT

bias	NN

in	IN

prior	RB

reports	NNS

for	IN

mutations	NNS

in	IN

exon	NN

11	CD

was	VBD

revealed	VBD

Characteristics	NNS

of	IN

a	DT

patient	NN

's	POS

specific	JJ

diagnosis	NN

(	NN

unilateral	JJ

or	CC

bilateral	JJ

breast	NN

cancer	NN

,	,

with	IN

or	CC

without	IN

ovarian	JJ

cancer	NN

)	NN

,	,

early	RB

age	NN

at	IN

diagnosis	NN

,	,

Ashkenazi	NNP

Jewish	JJ

ethnicity	NN

,	,

and	CC

family	NN

history	NN

of	IN

cancer	NN

were	VBD

positively	RB

associated	VBN

with	IN

the	DT

probability	NN

of	IN

her	PRP$

carrying	VBG

a	DT

deleterious	JJ

BRCA1	NN

mutation	NN

CONCLUSIONS	NNS

:	:

Using	VBG

logistic	JJ

regression	NN

analysis	NN

,	,

we	PRP

provide	VB

a	DT

method	NN

for	IN

evaluating	VBG

the	DT

probability	NN

of	IN

a	DT

woman	NN

's	POS

carrying	VBG

a	DT

deleterious	JJ

BRCA1	NN

mutation	NN

for	IN

a	DT

wide	JJ

range	NN

of	IN

cases	NNS

,	,

which	WDT

can	MD

be	VB

an	DT

important	JJ

tool	NN

for	IN

clinicians	NNS

as	IN

they	PRP

incorporate	VB

genetic	JJ

susceptibility	NN

testing	NN

into	IN

their	PRP$

medical	JJ

practice	NN

CONTEXT	NN

:	:

Approximately	RB

9	CD

%	NN

of	IN

prostate	NN

cancer	NN

cases	NNS

have	VB

been	VBN

estimated	VBN

to	TO

result	NN

from	IN

inheritance	NN

of	IN

mutated	VBN

prostate	NN

cancer	NN

susceptibility	NN

genes	NNS

Few	JJ

data	NNS

exist	VB

as	IN

to	TO

whether	IN

there	RB

are	VBP

clinical	JJ

differences	NNS

between	IN

prostate	NN

cancers	NNS

that	IN

are	VBP

inherited	VBN

and	CC

those	DT

that	IN

occur	VB

in	IN

the	DT

general	JJ

population	NN

OBJECTIVE	NN

:	:

To	TO

investigate	VB

phenotypic	JJ

characteristics	NNS

of	IN

families	NNS

potentially	RB

linked	VBN

to	TO

the	DT

hereditary	JJ

prostate	NN

cancer	NN

1	CD

(	NN

HPC1	NN

)	NN

locus	NN

on	IN

chromosome	NN

1q24-25	NN

DESIGN	NN

:	:

Retrospective	JJ

case	NN

study	NN

in	IN

which	WDT

clinical	JJ

data	NNS

were	VBD

extracted	VBN

from	IN

medical	JJ

and	CC

pathological	JJ

records	NNS

FAMILIES	NNS

:	:

A	DT

total	NN

of	IN

74	CD

North	NNP

American	NNP

families	NNS

with	IN

hereditary	JJ

prostate	NN

cancer	NN

Prostate	NN

cancer	NN

cases	NNS

from	IN

the	DT

National	NNP

Cancer	NN

Data	NNS

Base	NN

were	VBD

used	VBN

as	IN

a	DT

reference	NN

population	NN

for	IN

comparison	NN

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

The	DT

families	NNS

were	VBD

divided	VBN

into	IN

2	CD

groups	NNS

:	:

either	DT

potentially	RB

linked	VBN

(	NN

33	CD

families	NNS

with	IN

133	CD

men	NNS

with	IN

prostate	NN

cancer	NN

)	NN

,	,

and	CC

thus	RB

likely	RB

to	TO

be	VB

carrying	VBG

an	DT

altered	JJ

HPC1	NN

gene	NN

,	,

or	CC

potentially	RB

unlinked	JJ

(	NN

41	CD

families	NNS

with	IN

172	CD

men	NNS

with	IN

prostate	NN

cancer	NN

)	NN

,	,

on	IN

the	DT

basis	NN

of	IN

haplotype	NN

analysis	NN

in	IN

the	DT

region	NN

of	IN

HPC1	NN

The	DT

age	NN

at	IN

diagnosis	NN

of	IN

prostate	NN

cancer	NN

,	,

serum	NN

prostate-specific	JJ

antigen	NN

levels	NNS

,	,

digital	JJ

rectal	JJ

examination	NN

status	NN

,	,

stage	NN

,	,

grade	NN

,	,

primary	JJ

treatment	NN

of	IN

prostate	NN

cancers	NNS

,	,

and	CC

occurrence	NN

of	IN

other	JJ

cancers	NNS

were	VBD

compared	VBN

between	IN

the	DT

groups	NNS

RESULTS	NNS

:	:

The	DT

mean	VB

age	NN

at	IN

diagnosis	NN

of	IN

prostate	NN

cancer	NN

for	IN

men	NNS

in	IN

potentially	RB

linked	VBN

families	NNS

was	VBD

significantly	RB

lower	JJR

than	IN

for	IN

men	NNS

in	IN

potentially	RB

unlinked	JJ

families	NNS

(	NN

63.7	CD

vs	CC

65.9	CD

years	NNS

,	,

respectively	RB

,	,

P=.01	NN

;	:

mean	VB

age	NN

at	IN

diagnosis	NN

in	IN

the	DT

reference	NN

population	NN

was	VBD

71.6	CD

years	NNS

)	NN

Higher-grade	JJ

cancers	NNS

(	NN

grade	NN

3	CD

)	NN

were	VBD

more	RBR

common	JJ

in	IN

potentially	RB

linked	VBN

families	NNS

,	,

and	CC

advanced-stage	NN

disease	NN

was	VBD

found	VBN

in	IN

41	CD

%	NN

of	IN

the	DT

case	NN

patients	NNS

in	IN

potentially	RB

linked	VBN

families	NNS

compared	VBN

with	IN

31	CD

%	NN

in	IN

both	DT

the	DT

potentially	RB

unlinked	JJ

families	NNS

and	CC

the	DT

reference	NN

groups	NNS

(	NN

P=.03	NN

for	IN

the	DT

latter	JJ

comparison	NN

)	NN

In	IN

the	DT

other	JJ

clinical	JJ

parameters	NNS

,	,

we	PRP

found	VBN

no	DT

significant	JJ

differences	NNS

between	IN

the	DT

groups	NNS

A	DT

modest	JJ

excess	NN

of	IN

breast	NN

cancer	NN

and	CC

colon	NN

cancer	NN

was	VBD

found	VBN

in	IN

potentially	RB

linked	VBN

families	NNS

in	IN

comparison	NN

with	IN

potentially	RB

unlinked	JJ

families	NNS

,	,

but	CC

this	DT

difference	NN

was	VBD

not	RB

statistically	RB

significant	JJ

CONCLUSIONS	NNS

:	:

Families	NNS

that	IN

provide	VB

evidence	NN

for	IN

segregation	NN

of	IN

an	DT

altered	JJ

HPC1	NN

gene	NN

are	VBP

characterized	VBN

by	IN

multiple	JJ

cases	NNS

of	IN

prostate	NN

cancer	NN

that	IN

,	,

in	IN

most	RBS

respects	NNS

,	,

are	VBP

indistinguishable	JJ

from	IN

nonhereditary	JJ

cases	NNS

However	RB

,	,

3	CD

characteristics	NNS

were	VBD

observed	VBN

:	:

younger	JJR

age	NN

at	IN

diagnosis	NN

,	,

higher-grade	JJ

tumors	NNS

,	,

and	CC

more	RBR

advanced-stage	NN

disease	NN

Our	PRP$

study	NN

shows	NNS

that	IN

a	DT

significant	JJ

fraction	NN

of	IN

hereditary	JJ

prostate	NN

cancers	NNS

are	VBP

diagnosed	VBN

in	IN

advanced	VBN

stages	NNS

,	,

emphasizing	VBG

the	DT

clinical	JJ

importance	NN

of	IN

early	RB

detection	NN

in	IN

men	NNS

potentially	RB

carrying	VBG

prostate	NN

cancer	NN

susceptibility	NN

genes	NNS

These	DT

findings	NNS

support	NN

the	DT

current	JJ

recommendations	NNS

to	TO

screen	NN

men	NNS

with	IN

a	DT

positive	JJ

family	NN

history	NN

of	IN

prostate	NN

cancer	NN

beginning	VBG

at	IN

age	NN

40	CD

years	NNS

CONTEXT	NN

:	:

Susceptibility	NN

to	TO

multiple	JJ

sclerosis	NN

(	NN

MS	NN

)	NN

involves	VBZ

a	DT

genetically	RB

complex	NN

autoimmune	JJ

component	NN

However	RB

,	,

except	IN

for	IN

genes	NNS

in	IN

the	DT

HLA	NN

system	NN

,	,

specific	JJ

susceptibility	NN

loci	NNS

are	VBP

unknown	JJ

or	CC

unconfirmed	JJ

OBJECTIVE	NN

:	:

To	TO

investigate	VB

several	JJ

loci	NNS

spanning	VBG

3	CD

candidate	NN

regions	NNS

for	IN

a	DT

role	NN

in	IN

multiple	JJ

sclerosis	NN

(	NN

MS	NN

)	NN

susceptibility	NN

in	IN

2	CD

ethnic	JJ

groups	NNS

using	VBG

both	DT

single-locus	NN

and	CC

haplotype	NN

analyses	NNS

The	DT

3	CD

regions	NNS

include	VB

HLA	NN

on	IN

chromosome	NN

6p21.3	NN

,	,

APOE	NN

on	IN

chromosome	NN

19ql	NN

3.2	CD

,	,

and	CC

MBP	NN

(	NN

myelin	JJ

basic	JJ

protein	NN

)	NN

on	IN

chromosome	NN

18q23	NN

DESIGN	NN

:	:

Case-control	JJ

association	NN

testing	NN

SUBJECTS	NNS

:	:

A	DT

total	NN

of	IN

120	CD

Caucasian	JJ

patients	NNS

with	IN

MS	NN

and	CC

107	CD

unrelated	JJ

control	NN

individuals	NNS

from	IN

California	NNP

,	,

and	CC

32	CD

patients	NNS

and	CC

32	CD

unrelated	JJ

control	NN

individuals	NNS

from	IN

Beijing	NNP

,	,

China	NNP

All	DT

patients	NNS

with	IN

MS	NN

were	VBD

diagnosed	VBN

as	IN

having	VBG

clinically	RB

definite	JJ

disease	NN

according	VBG

to	TO

published	VBN

criteria	NNS

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

Chi2	NN

Testing	VBG

of	IN

loci	NNS

and	CC

individual	JJ

alleles	NNS

and	CC

haplotypes	NNS

Haplotype	NN

frequencies	NNS

were	VBD

estimated	VBN

with	IN

standard	NN

maximum	NN

likelihood	NN

methods	NNS

RESULTS	NNS

:	:

The	DT

HLA	NN

effect	NN

is	VBZ

due	JJ

to	TO

the	DT

class	NN

II	NNP

DR2	NN

haplotype	NN

,	,

DRB1*1501-DQA1*0102-DRB1*0602	NN

;	:

contributions	NNS

to	TO

MS	NN

susceptibility	NN

from	IN

additional	JJ

DRB1-DQB1	NN

alleles	NNS

or	CC

other	JJ

HLA	NN

region	NN

loci	NNS

were	VBD

not	RB

observed	VBN

Variation	NN

within	IN

the	DT

MBP	NN

locus	NN

on	IN

chromosome	NN

18q23	NN

showed	VBD

no	DT

effect	NN

in	IN

MS	NN

The	DT

distribution	NN

of	IN

haplotypes	NNS

from	IN

5	CD

loci	NNS

within	IN

the	DT

chromosome	NN

19q13.2	NN

region	NN

,	,

including	VBG

D19S178	NN

,	,

D19S574	NN

,	,

APOE	NN

,	,

APOC2	NN

,	,

and	CC

D19S219	NN

,	,

differed	VBN

between	IN

patient	NN

and	CC

control	NN

samples	NNS

D19S574	NN

showed	VBD

a	DT

significant	JJ

effect	NN

(	NN

P=.015	NN

)	NN

in	IN

Caucasian	JJ

patients	NNS

with	IN

MS	NN

due	JJ

to	TO

the	DT

increased	VBN

frequency	NN

of	IN

a	DT

single	JJ

allele	NN

(	NN

P=.002	NN

)	NN

The	DT

APOE	NN

variation	NN

,	,

prominent	JJ

in	IN

other	JJ

neurological	JJ

diseases	NNS

,	,

showed	VBD

no	DT

influence	NN

on	IN

MS	NN

susceptibility	NN

,	,

despite	IN

its	PRP$

location	NN

within	IN

the	DT

chromosome	NN

19q13.2	NN

region	NN

Interaction	NN

effects	NNS

between	IN

DR2	NN

and	CC

chromosome	NN

19q13.2	NN

or	CC

MBP	NN

in	IN

MS	NN

susceptibility	NN

were	VBD

not	RB

apparent	JJ

CONCLUSIONS	NNS

:	:

The	DT

significant	JJ

chromosome	NN

19q13.2	NN

single-locus	NN

and	CC

multilocus	NN

haplotype	NN

associations	NNS

with	IN

MS	NN

in	IN

Caucasian	JJ

and	CC

Chinese	JJ

patient	NN

samples	NNS

indicate	VBP

an	DT

effect	NN

from	IN

a	DT

nearby	RB

disease	NN

susceptibility	NN

locus	NN

These	DT

initial	JJ

observations	NNS

are	VBP

an	DT

encouraging	VBG

step	NN

toward	IN

the	DT

description	NN

of	IN

non-HLA	JJ

genetic	JJ

susceptibility	NN

to	TO

MS	NN

<	JJR

TO_SEE	NN

>	JJR

CONTEXT	NN

:	:

There	EX

is	VBZ

a	DT

substantial	JJ

risk	NN

of	IN

a	DT

second	JJ

cancer	NN

for	IN

persons	NNS

with	IN

hereditary	JJ

retinoblastoma	NN

,	,

which	WDT

is	VBZ

enhanced	VBN

by	IN

radiotherapy	NN

<	JJR

TO_SEE	NN

>	JJR

OBJECTIVE	NN

:	:

To	TO

examine	VB

long-term	JJ

risk	NN

of	IN

new	JJ

primary	JJ

cancers	NNS

in	IN

survivors	NNS

of	IN

childhood	NN

retinoblastoma	NN

and	CC

quantify	VB

the	DT

role	NN

of	IN

radiotherapy	NN

in	IN

sarcoma	NN

development	NN

DESIGN	NN

:	:

Cohort	NN

incidence	NN

study	NN

of	IN

patients	NNS

with	IN

retinoblastoma	NN

followed	VBN

for	IN

a	DT

median	NN

of	IN

20	CD

years	NNS

,	,

and	CC

nested	JJ

case-control	JJ

study	NN

of	IN

a	DT

radiation	NN

dose-response	NN

relationship	NN

for	IN

bone	NN

and	CC

soft	JJ

tissue	NN

sarcomas	NNS

SETTING/PARTICIPANTS	NN

:	:

A	DT

total	NN

of	IN

1604	CD

patients	NNS

with	IN

retinoblastoma	NN

who	WP

survived	VBD

at	IN

least	JJS

1	CD

year	NN

after	IN

diagnosis	NN

,	,

identified	VBN

from	IN

hospital	NN

records	NNS

in	IN

Massachusetts	NNP

and	CC

New	NNP

York	NNP

during	IN

1914	CD

to	TO

1984	CD

RESULTS	NNS

:	:

Incidence	NN

of	IN

subsequent	JJ

cancers	NNS

was	VBD

statistically	RB

significantly	RB

elevated	JJ

only	RB

in	IN

the	DT

961	CD

patients	NNS

with	IN

hereditary	JJ

retinoblastoma	NN

,	,

in	IN

whom	WP

190	CD

cancers	NNS

were	VBD

diagnosed	VBN

,	,

vs	CC

6.3	CD

expected	VBN

in	IN

the	DT

general	JJ

population	NN

(	NN

relative	JJ

risk	NN

(	NN

RR	NN

)	NN

,	,

30	CD

(	NN

95	CD

%	NN

confidence	NN

interval	NN

,	,

26-47	CD

)	NN

)	NN

Cumulative	JJ

incidence	NN

(	NN

+/-SE	NN

)	NN

of	IN

a	DT

second	JJ

cancer	NN

at	IN

50	CD

years	NNS

after	IN

diagnosis	NN

was	VBD

51.0	CD

%	NN

(	NN

+/-6.2	NN

%	NN

)	NN

for	IN

hereditary	JJ

retinoblastoma	NN

,	,

and	CC

5.0	CD

%	NN

(	NN

+/-3.0	NN

%	NN

)	NN

for	IN

nonhereditary	JJ

retinoblastoma	NN

All	DT

114	CD

sarcomas	NNS

of	IN

diverse	JJ

histologic	JJ

types	NNS

occurred	VBD

in	IN

patients	NNS

with	IN

hereditary	JJ

retinoblastoma	NN

For	IN

soft	JJ

tissue	NN

sarcomas	NNS

,	,

the	DT

RRs	SYM

showed	VBD

a	DT

stepwise	JJ

increase	NN

at	IN

all	DT

dose	NN

categories	NNS

,	,

and	CC

were	VBD

statistically	RB

significant	JJ

at	IN

10	CD

to	TO

29.9	CD

Gy	NN

and	CC

30	CD

to	TO

59.9	CD

Gy	NN

A	DT

radiation	NN

risk	NN

for	IN

all	DT

sarcomas	NNS

combined	VBN

was	VBD

evident	JJ

at	IN

doses	NNS

above	IN

5	CD

Gy	NN

,	,

rising	VBG

to	TO

10.7-fold	RB

at	IN

doses	NNS

of	IN

60	CD

Gy	NN

or	CC

greater	JJR

(	NN

P	NN

&	CC

#	#

60	CD

;	:

.05	CD

)	NN

<	JJR

TO_SEE	NN

>	JJR

CONCLUSIONS	NNS

:	:

Genetic	JJ

predisposition	NN

has	VBZ

a	DT

substantial	JJ

impact	NN

on	IN

risk	NN

of	IN

subsequent	JJ

cancers	NNS

in	IN

retinoblastoma	NN

patients	NNS

,	,

which	WDT

is	VBZ

further	RB

increased	VBN

by	IN

radiation	NN

treatment	NN

A	DT

radiation	NN

dose-response	NN

relationship	NN

is	VBZ

demonstrated	VBN

for	IN

all	DT

sarcomas	NNS

and	CC

,	,

for	IN

the	DT

first	RB

time	NN

in	IN

humans	NNS

,	,

for	IN

soft	JJ

tissue	NN

sarcomas	NNS

Retinoblastoma	NN

patients	NNS

should	MD

be	VB

examined	VBN

for	IN

new	JJ

cancers	NNS

and	CC

followed	VBN

into	IN

later	RB

life	NN

to	TO

determine	VB

whether	IN

their	PRP$

extraordinary	JJ

cancer	NN

risk	NN

extends	VBZ

to	TO

common	JJ

cancers	NNS

of	IN

adulthood	NN

The	DT

objective	NN

of	IN

this	DT

study	NN

was	VBD

to	TO

determine	VB

the	DT

rate	NN

of	IN

recent	JJ

cocaine	NN

use	NN

among	IN

a	DT

metropolitan	JJ

population	NN

of	IN

predominantly	RB

Hispanic	JJ

and	CC

African-American	JJ

women	NNS

with	IN

preterm	NN

premature	JJ

rupture	NN

of	IN

the	DT

membranes	NNS

(	NN

PROM	NN

)	NN

and	CC

to	TO

ascertain	VB

the	DT

impact	NN

of	IN

cocaine	NN

on	IN

the	DT

latency	NN

period	NN

between	IN

rupture	NN

of	IN

membranes	NNS

and	CC

delivery	NN

Urine	NN

toxicology	NN

screens	NNS

were	VBD

prospectively	RB

obtained	VBN

on	IN

147	CD

women	NNS

with	IN

preterm	NN

PROM	NN

The	DT

urine	NN

screen	NN

did	VBD

not	RB

influence	NN

management	NN

decisions	NNS

All	DT

women	NNS

were	VBD

expectantly	RB

managed	VBN

without	IN

tocolytics	NNS

until	IN

37	CD

weeks	NNS

'	''

gestation	NN

unless	IN

they	PRP

developed	VBN

clinical	JJ

chorioamnionitis	NN

,	,

or	CC

nonreassuring	VBG

fetal	JJ

heart	NN

rate	NN

tracing	VBG

or	CC

biophysical	JJ

profile	NN

Demographic	JJ

information	NN

,	,

hours	NNS

from	IN

rupture	NN

of	IN

membranes	NNS

to	TO

delivery	NN

,	,

gestational	JJ

age	NN

,	,

and	CC

birth	NN

weight	NN

at	IN

delivery	NN

were	VBD

compared	VBN

using	VBG

Fisher	NNP

's	POS

exact	JJ

,	,

Mann-Whitney	NNP

U	NNP

,	,

and	CC

randomization	NN

tests	NNS

where	WRB

appropriate	JJ

The	DT

rate	NN

of	IN

positive	JJ

urine	NN

drug	NN

screens	NNS

for	IN

cocaine	NN

was	VBD

8.2	CD

%	NN

Women	NNS

in	IN

the	DT

cocaine	NN

positive	JJ

group	NN

were	VBD

of	IN

higher	JJR

parity	NN

(	NN

3	CD

,	,

(	NN

0-7	CD

)	NN

vs.	CC

1	CD

,	,

(	NN

0-6	CD

)	NN

,	,

p	NN

=	JJ

0.001	CD

)	NN

and	CC

tended	VBD

to	TO

be	VB

older	JJR

(	NN

27	CD

,	,

(	NN

23-42	CD

)	NN

vs.	CC

25	CD

,	,

(	NN

14-40	CD

)	NN

)	NN

There	EX

was	VBD

a	DT

higher	JJR

rate	NN

of	IN

recent	JJ

cocaine	NN

use	NN

among	IN

African-American	JJ

women	NNS

(	NN

20.4	CD

%	NN

)	NN

as	IN

compared	VBN

to	TO

non-African-Americans	NNS

(	NN

1.2	CD

%	NN

,	,

p	NN

=	JJ

0.0001	CD

)	NN

Cocaine-positive	JJ

women	NNS

presented	VBN

at	IN

an	DT

earlier	RB

gestational	JJ

age	NN

(	NN

32	CD

weeks	NNS

'	''

,	,

(	NN

24-34	CD

)	NN

vs.	CC

33	CD

weeks	NNS

'	''

,	,

(	NN

23-36	CD

)	NN

,	,

p	NN

=	JJ

0.02	CD

)	NN

and	CC

had	VBD

a	DT

significantly	RB

longer	RB

membrane	NN

rupture	NN

to	TO

delivery	NN

interval	NN

than	IN

women	NNS

with	IN

a	DT

negative	JJ

urine	NN

drug	NN

screen	NN

(	NN

174	CD

hr	NN

,	,

(	NN

6-475	CD

)	NN

vs.	CC

33	CD

hours	NNS

(	NN

1-833	CD

)	NN

,	,

p	NN

=	JJ

0.01	CD

)	NN

There	EX

was	VBD

no	DT

significant	JJ

difference	NN

in	IN

the	DT

reason	NN

for	IN

delivery	NN

between	IN

the	DT

two	CD

groups	NNS

of	IN

patients	NNS

Recent	JJ

cocaine	NN

use	NN

among	IN

women	NNS

with	IN

preterm	NN

PROM	NN

is	VBZ

common	JJ

in	IN

only	RB

some	DT

segments	NNS

of	IN

an	DT

urban	JJ

population	NN

Women	NNS

with	IN

recent	JJ

cocaine	NN

use	NN

present	JJ

with	IN

ruptured	VBN

membranes	NNS

at	IN

an	DT

earlier	RB

gestational	JJ

age	NN

and	CC

may	MD

actually	RB

have	VB

a	DT

longer	RB

latency	NN

period	NN

than	IN

women	NNS

who	WP

do	VB

not	RB

use	NN

cocaine	NN

The	DT

objective	NN

of	IN

this	DT

article	NN

is	VBZ

to	TO

explore	VB

attitudes	NNS

of	IN

an	DT

inner-city	NN

,	,

pregnant	JJ

cohort	NN

about	IN

general	JJ

and	CC

HIV-related	JJ

prenatal	JJ

care	NN

Responses	NNS

to	TO

an	DT

interview	NN

at	IN

initial	JJ

prenatal	JJ

care	NN

enrollment	NN

were	VBD

compared	VBN

using	VBG

Chi-square	JJ

and	CC

Fisher	NNP

's	POS

exact	JJ

tests	NNS

Of	IN

75	CD

women	NNS

,	,

drug	NN

users	NNS

(	NN

51	CD

%	NN

)	NN

were	VBD

more	RBR

likely	RB

to	TO

say	VB

that	IN

they	PRP

would	MD

defer	VB

initiating	VBG

prenatal	JJ

care	NN

(	NN

P	NN

=	JJ

0.03	CD

)	NN

and	CC

to	TO

minimize	VB

the	DT

risk	NN

of	IN

drug	NN

or	CC

alcohol	NN

use	NN

to	TO

the	DT

fetus	NN

(	NN

P	NN

=	JJ

0.04	CD

)	NN

Most	JJS

(	NN

85	CD

%	NN

)	NN

viewed	VBN

pregnancy	NN

as	IN

inappropriate	JJ

for	IN

HIV	NN

infected	JJ

women	NNS

and	CC

primarily	RB

drug	NN

users	NNS

(	NN

P	NN

=	JJ

0.06	CD

)	NN

would	MD

abort	VB

if	IN

HIV	NN

infected	JJ

Over	IN

half	NN

thought	NN

HIV	NN

transmission	NN

occurred	VBD

most	RBS

times	NNS

or	CC

always	RB

Only	RB

20	CD

%	NN

had	VBD

heard	VBN

of	IN

a	DT

drug	NN

to	TO

reduce	VB

this	DT

risk	NN

,	,

but	CC

95	CD

%	NN

would	MD

take	VB

such	JJ

a	DT

therapy	NN

These	DT

inner-city	NN

,	,

pregnant	JJ

women	NNS

disapproved	VBN

of	IN

pregnancy	NN

if	IN

HIV	NN

infected	JJ

and	CC

thought	NN

the	DT

risk	NN

of	IN

transmission	NN

was	VBD

high	JJ

They	PRP

knew	VBD

little	RB

of	IN

how	WRB

to	TO

reduce	VB

this	DT

risk	NN

but	CC

nearly	RB

all	DT

would	MD

accept	VB

a	DT

drug	NN

to	TO

prevent	VB

transmission	NN

The	DT

association	NN

of	IN

parvovirus	NN

B19	NN

infection	NN

and	CC

hydrops	NNS

fetalis	NN

is	VBZ

well	RB

known	VBN

However	RB

,	,

the	DT

association	NN

of	IN

parvovirus	NN

and	CC

fetal	JJ

pleural	JJ

or	CC

pericardial	JJ

effusions	NNS

has	VBZ

not	RB

been	VBN

reported	VBN

We	PRP

present	JJ

five	CD

cases	NNS

of	IN

isolated	VBN

pleural	JJ

or	CC

pericardial	JJ

effusion	NN

with	IN

documented	VBN

maternal	JJ

parvovirus	NN

infection	NN

in	IN

four	CD

of	IN

these	DT

pregnancies	NNS

In	IN

the	DT

absence	NN

of	IN

structural	JJ

or	CC

karyotypic	JJ

abnormalities	NNS

,	,

spontaneous	JJ

resolution	NN

of	IN

the	DT

effusion	NN

portends	VBZ

for	IN

a	DT

successful	JJ

pregnancy	NN

outcome	NN

BACKGROUND	NN

:	:

Cochlear	JJ

implantation	NN

is	VBZ

nowadays	RB

a	DT

reliable	JJ

and	CC

well-accepted	JJ

method	NN

of	IN

auditory	NN

rehabilitation	NN

in	IN

selected	VBN

adults	NNS

and	CC

children	NNS

METHODS	NNS

:	:

We	PRP

present	JJ

rehabilitation	NN

data	NNS

on	IN

21	CD

adult	JJ

patients	NNS

provided	VBN

with	IN

the	DT

Nucleus	NN

CI22	NN

M	NN

cochlear	NN

implant	VB

using	VBG

the	DT

SPEAK	VB

strategy	NN

RESULTS	NNS

:	:

Results	NNS

of	IN

first	RB

tune-up	NN

show	NN

an	DT

open	JJ

set	NN

speech	NN

understanding	VBG

in	IN

approximately	RB

50	CD

%	NN

of	IN

patients	NNS

Long-term	JJ

results	NNS

also	RB

reveal	VB

further	RB

improvement	NN

in	IN

patients	NNS

who	WP

had	VBD

no	DT

open	JJ

set	NN

speech	NN

understanding	VBG

Our	PRP$

data	NNS

seem	VB

to	TO

indicate	VBP

similar	JJ

results	NNS

in	IN

comparison	NN

to	TO

other	JJ

groups	NNS

using	VBG

the	DT

CIS	NN

strategy	NN

CONCLUSIONS	NNS

:	:

In	IN

adults	NNS

,	,

open	JJ

set	NN

speech	NN

understanding	VBG

can	MD

be	VB

achieved	VBN

even	RB

at	IN

the	DT

first	RB

tune-up	NN

Results	NNS

of	IN

early	RB

rehabilitation	NN

seem	VB

to	TO

be	VB

influenced	VBN

by	IN

duration	NN

and	CC

etiology	NN

of	IN

deafness	NN

,	,

experience	NN

with	IN

hearing	NN

aids	NNS

,	,

and	CC

other	JJ

factors	NNS

Adverse	JJ

drug	NN

effects	NNS

are	VBP

manifold	NN

and	CC

heterogenous	JJ

Many	JJ

situations	NNS

may	MD

hamper	VB

the	DT

signalling	NN

(	NN

i.e	NN

.	.

the	DT

detection	NN

of	IN

early	RB

warning	VBG

signs	NNS

)	NN

of	IN

adverse	JJ

effects	NNS

and	CC

new	JJ

signals	NNS

often	RB

differ	VB

from	IN

previous	JJ

experiences	NNS

Signals	NNS

have	VB

qualitative	JJ

and	CC

quantitative	JJ

aspects	NNS

Different	JJ

categories	NNS

of	IN

adverse	JJ

effects	NNS

need	NN

different	JJ

methods	NNS

for	IN

detection	NN

Current	JJ

pharmacovigilance	NN

is	VBZ

predominantly	RB

based	VBN

on	IN

spontaneous	JJ

reporting	VBG

and	CC

is	VBZ

mainly	RB

helpful	JJ

in	IN

detecting	VBG

type	NN

B	NN

effects	NNS

(	NN

those	DT

effects	NNS

that	IN

are	VBP

often	RB

allergic	JJ

or	CC

idiosyncratic	JJ

reactions	NNS

,	,

characteristically	RB

occurring	VBG

in	IN

only	RB

a	DT

minority	NN

of	IN

patients	NNS

and	CC

usually	RB

unrelated	JJ

to	TO

dosage	NN

and	CC

that	IN

are	VBP

serious	JJ

,	,

unexpected	JJ

and	CC

unpredictable	JJ

)	NN

and	CC

unusual	JJ

type	NN

A	DT

effects	NNS

(	NN

those	DT

effects	NNS

that	IN

are	VBP

related	JJ

to	TO

the	DT

pharmacological	JJ

effects	NNS

of	IN

the	DT

drug	NN

and	CC

are	VBP

dosage-related	JJ

)	NN

Examples	NNS

of	IN

other	JJ

sources	NNS

of	IN

signals	NNS

are	VBP

prescription	NN

event	NN

monitoring	VBG

,	,

large	JJ

automated	VBN

data	NNS

resources	NNS

on	IN

morbidity	NN

and	CC

drug	NN

use	NN

(	NN

including	VBG

record	NN

linkage	NN

)	NN

,	,

case-control	JJ

surveillance	NN

and	CC

follow-up	NN

studies	NNS

Type	NN

C	NN

effects	NNS

(	NN

those	DT

effects	NNS

related	JJ

to	TO

an	DT

increased	VBN

frequency	NN

of	IN

'spontaneous	JJ

'	''

disease	NN

)	NN

are	VBP

difficult	JJ

to	TO

study	NN

,	,

however	RB

,	,

and	CC

continue	VB

to	TO

pose	VB

a	DT

pharmacoepidemiological	JJ

challenge	NN

Seven	CD

basic	JJ

considerations	NNS

can	MD

be	VB

identified	VBN

that	IN

determine	VB

the	DT

evidence	NN

contained	VBN

in	IN

a	DT

signal	NN

:	:

quantitative	JJ

strength	NN

of	IN

the	DT

association	NN

,	,

consistency	NN

of	IN

the	DT

data	NNS

,	,

exposure	NN

response	NN

relationship	NN

,	,

biological	JJ

plausibility	NN

,	,

experimental	JJ

findings	NNS

,	,

possible	JJ

analogies	NNS

and	CC

the	DT

nature	NN

and	CC

quality	NN

of	IN

the	DT

data	NNS

A	DT

proposal	NN

is	VBZ

made	VBN

for	IN

a	DT

standard	NN

signal	NN

management	NN

procedure	NN

at	IN

pharmacovigilance	NN

centres	NNS

,	,

including	VBG

the	DT

following	VBG

steps	NNS

:	:

signal	NN

delineation	NN

,	,

literature	NN

search	NN

,	,

preliminary	JJ

inventory	NN

of	IN

data	NNS

,	,

collection	NN

of	IN

additional	JJ

information	NN

,	,

consultation	NN

with	IN

the	DT

World	NNP

Health	NNP

Organization	NNP

Centre	NNP

for	IN

International	NNP

Drug	NN

Monitoring	NN

and	CC

the	DT

relevant	JJ

drug	NN

companies	NNS

,	,

aggregated	VBN

data	NNS

assessment	NN

and	CC

a	DT

report	NN

in	IN

writing	VBG

A	DT

better	RB

understanding	VBG

of	IN

the	DT

conditions	NNS

and	CC

mechanisms	NNS

involved	VBN

in	IN

the	DT

detection	NN

of	IN

adverse	JJ

drug	NN

effects	NNS

may	MD

further	RB

improve	VB

strategies	NNS

for	IN

pharmacovigilance	NN

OBJECTIVE	NN

:	:

To	TO

study	NN

the	DT

safety	NN

and	CC

efficacy	NN

of	IN

methylphenidate	NN

in	IN

children	NNS

with	IN

the	DT

dual	JJ

diagnosis	NN

of	IN

epilepsy	NN

and	CC

attention	NN

deficit	NN

hyperactivity	NN

disorder	NN

(	NN

ADHD	NN

)	NN

STUDY	NN

DESIGN	NN

:	:

Thirty	CD

children	NNS

,	,

aged	JJ

6.4	CD

to	TO

16.4	CD

years	NNS

,	,

with	IN

epilepsy	NN

and	CC

ADHD	NN

were	VBD

studied	VBN

during	IN

a	DT

4-month	JJ

period	NN

During	IN

the	DT

initial	JJ

2	CD

months	NNS

of	IN

the	DT

study	NN

,	,

the	DT

children	NNS

were	VBD

treated	VBN

with	IN

antiepileptic	JJ

drugs	NNS

(	NN

AEDs	NNS

)	NN

only	RB

,	,

and	CC

for	IN

the	DT

remaining	VBG

2	CD

months	NNS

,	,

methylphenidate	NN

was	VBD

added	VBN

at	IN

a	DT

morning	NN

dose	NN

of	IN

0.3	CD

mg/kg	NN

They	PRP

underwent	VBD

neurologic	JJ

assessment	NN

,	,

brain	NN

computed	VBN

tomography	NN

,	,

IQ	NNP

testing	NN

,	,

and	CC

assessment	NN

with	IN

the	DT

Childhood	NN

Behavior	NN

Checklist	NNP

at	IN

baseline	NN

before	IN

methylphenidate	NN

therapy	NN

Electroencephalography	NN

,	,

AED	NN

determinations	NNS

,	,

and	CC

the	DT

continuous-performance	NN

task	NN

(	NN

CPT	NNP

)	NN

test	NN

were	VBD

done	VBN

at	IN

baseline	NN

and	CC

after	IN

2	CD

months	NNS

of	IN

methylphenidate	NN

therapy	NN

A	DT

double-blind	JJ

,	,

crossover	NN

design	NN

was	VBD

used	VBN

to	TO

compare	VB

the	DT

effects	NNS

of	IN

methylphenidate	NN

versus	CC

placebo	NN

on	IN

an	DT

electroencephalogram	NN

,	,

AED	NN

levels	NNS

,	,

and	CC

the	DT

CPT	NNP

On	IN

the	DT

2	CD

days	NNS

of	IN

testing	NN

,	,

the	DT

child	NN

received	VBN

AEDs	NNS

and	CC

a	DT

capsule	NN

containing	VBG

either	DT

placebo	NN

or	CC

methylphenidate	NN

RESULTS	NNS

:	:

None	NN

of	IN

the	DT

25	CD

children	NNS

of	IN

this	DT

sample	NN

who	WP

were	VBD

seizure	NN

free	JJ

had	VBD

attacks	NNS

while	IN

taking	VBG

methylphenidate	NN

Of	IN

the	DT

5	CD

children	NNS

with	IN

seizures	NNS

,	,

3	CD

had	VBD

an	DT

increase	NN

in	IN

attacks	NNS

,	,

whereas	IN

the	DT

other	JJ

2	CD

showed	VBD

no	DT

change	NN

or	CC

a	DT

reduction	NN

There	EX

were	VBD

no	DT

significant	JJ

changes	NNS

in	IN

AED	NN

levels	NNS

or	CC

electroencephalographic	JJ

findings	NNS

Methylphenidate	NNP

benefited	VBN

70	CD

%	NN

of	IN

children	NNS

according	VBG

to	TO

parental	JJ

report	NN

;	:

methylphenidate	NN

also	RB

enhanced	VBN

performance	NN

on	IN

the	DT

CPT	NNP

Side	NN

effects	NNS

of	IN

methylphenidate	NN

were	VBD

mild	JJ

and	CC

transient	JJ

CONCLUSION	NN

:	:

Methylphenidate	NNP

is	VBZ

effective	JJ

in	IN

treating	VBG

children	NNS

with	IN

epilepsy	NN

and	CC

ADHD	NN

and	CC

safe	JJ

in	IN

children	NNS

who	WP

are	VBP

seizure	NN

free	JJ

Caution	NN

is	VBZ

warranted	VBN

for	IN

those	DT

still	RB

having	VBG

seizures	NNS

while	IN

receiving	VBG

AED	NN

therapy	NN

The	DT

temporal	JJ

properties	NNS

of	IN

semantic	JJ

and	CC

phonological	JJ

processes	NNS

in	IN

speech	NN

production	NN

were	VBD

investigated	VBN

in	IN

a	DT

new	JJ

experimental	JJ

paradigm	NN

using	VBG

movement-related	JJ

brain	NN

potentials	NNS

The	DT

main	JJ

experimental	JJ

task	NN

was	VBD

picture	NN

naming	VBG

In	IN

addition	NN

,	,

a	DT

2-choice	NN

reaction	NN

go/no-go	NN

procedure	NN

was	VBD

included	VBN

,	,

involving	VBG

a	DT

semantic	JJ

and	CC

a	DT

phonological	JJ

categorization	NN

of	IN

the	DT

picture	NN

name	NN

Lateralized	VBN

readiness	NN

potentials	NNS

(	NN

LRPs	NNS

)	NN

were	VBD

derived	VBN

to	TO

test	NN

whether	IN

semantic	JJ

and	CC

phonological	JJ

information	NN

activated	VBN

motor	NN

processes	NNS

at	IN

separate	JJ

moments	NNS

in	IN

time	NN

An	DT

LRP	NN

was	VBD

only	RB

observed	VBN

on	IN

no-go	JJ

trials	NNS

when	WRB

the	DT

semantic	JJ

(	NN

not	RB

the	DT

phonological	JJ

)	NN

decision	NN

determined	VBN

the	DT

response	NN

hand	NN

Varying	JJ

the	DT

position	NN

of	IN

the	DT

critical	JJ

phoneme	NN

in	IN

the	DT

picture	NN

name	NN

did	VBD

not	RB

affect	VB

the	DT

onset	NN

of	IN

the	DT

LRP	NN

but	CC

rather	RB

influenced	VBN

when	WRB

the	DT

LRP	NN

began	VBD

to	TO

differ	VB

on	IN

go	VB

and	CC

no-go	JJ

trials	NNS

and	CC

allowed	VBN

the	DT

duration	NN

of	IN

phonological	JJ

encoding	VBG

of	IN

a	DT

word	NN

to	TO

be	VB

estimated	VBN

These	DT

results	NNS

provide	VB

electrophysiological	JJ

evidence	NN

for	IN

early	RB

semantic	JJ

activation	NN

and	CC

later	RB

phonological	JJ

encoding	VBG

The	DT

effects	NNS

of	IN

alanine	NN

and	CC

glycine	NN

substitution	NN

for	IN

tryptophan	NN

upon	IN

the	DT

species	NNS

heterogeneity	NN

of	IN

gramicidin	NN

A	DT

analogs	NNS

incorporated	VBN

into	IN

SDS	NN

micelles	NNS

have	VB

been	VBN

investigated	VBN

The	DT

sequential	JJ

replacement	NN

of	IN

the	DT

four	CD

tryptophan	NN

residues	NNS

in	IN

gramicidin	NN

A	DT

at	IN

positions	NNS

15	CD

,	,

13	CD

,	,

11	CD

,	,

and	CC

9	CD

with	IN

glycine	NN

showed	VBD

that	IN

there	RB

was	VBD

no	DT

detectable	JJ

effect	NN

at	IN

position	NN

15	CD

but	CC

increasing	VBG

heterogeneity	NN

of	IN

species	NNS

in	IN

the	DT

micelles	NNS

proceeding	VBG

toward	IN

the	DT

interior	NN

of	IN

the	DT

micelle	NN

at	IN

position	NN

9	CD

The	DT

replacement	NN

of	IN

tryptophan	NN

at	IN

positions	NNS

15	CD

and	CC

9	CD

with	IN

alanine	NN

was	VBD

found	VBN

to	TO

produce	VB

more	RBR

species	NNS

heterogeneity	NN

than	IN

found	VBN

with	IN

glycine	NN

substitution	NN

at	IN

the	DT

same	JJ

positions	NNS

An	DT

increase	NN

in	IN

the	DT

SDS	NN

concentration	NN

reduces	VBZ

the	DT

number	NN

of	IN

different	JJ

species	NNS

present	JJ

in	IN

micelles	NNS

With	IN

the	DT

Gly-11	NN

,	,

Gly-13	NN

,	,

and	CC

Gly-15	NN

analogs	NNS

,	,

the	DT

increase	NN

in	IN

SDS	NN

concentration	NN

results	NNS

in	IN

the	DT

formation	NN

of	IN

a	DT

single	JJ

species	NNS

;	:

however	RB

,	,

for	IN

the	DT

Gly-9	NN

,	,

Ala-9	NN

,	,

and	CC

Ala-15	NN

analogs	NNS

,	,

heterogeneity	NN

remains	NNS

Molecular	JJ

dynamics	NNS

in	IN

torsion-angle	NN

space	NN

was	VBD

applied	VBN

to	TO

nuclear	JJ

magnetic	JJ

resonance	NN

structure	NN

calculation	NN

using	VBG

nuclear	JJ

Overhauser	NNP

effect-derived	JJ

distances	NNS

and	CC

J-coupling-constant-derived	JJ

dihedral	JJ

angle	NN

restraints	NNS

Compared	VBN

to	TO

two	CD

other	JJ

commonly	RB

used	VBN

algorithms	NNS

,	,

molecular	JJ

dynamics	NNS

in	IN

Cartesian	JJ

space	NN

and	CC

metric-matrix	NN

geometry	NN

combined	VBN

with	IN

Cartesian	JJ

molecular	JJ

dynamics	NNS

,	,

the	DT

method	NN

shows	NNS

increased	VBN

computational	JJ

efficiency	NN

and	CC

success	NN

rate	NN

for	IN

large	JJ

proteins	NNS

,	,

and	CC

it	PRP

shows	NNS

a	DT

dramatically	RB

increased	VBN

radius	NN

of	IN

convergence	NN

for	IN

DNA	NN

The	DT

torsion-angle	NN

molecular	JJ

dynamics	NNS

algorithm	NN

starts	NNS

from	IN

an	DT

extended	VBN

strand	NN

conformation	NN

and	CC

proceeds	NNS

in	IN

four	CD

stages	NNS

:	:

high-temperature	JJ

torsion-angle	NN

molecular	JJ

dynamics	NNS

,	,

slow-cooling	NN

torsion-angle	NN

molecular	JJ

dynamics	NNS

,	,

Cartesian	JJ

molecular	JJ

dynamics	NNS

,	,

and	CC

minimization	NN

Tests	NNS

were	VBD

carried	VBD

out	IN

using	VBG

experimental	JJ

NMR	NN

data	NNS

for	IN

protein	NN

G	NN

,	,

interleukin-8	NN

,	,

villin	NN

14T	NN

,	,

and	CC

a	DT

12	CD

base-pair	NN

duplex	NN

of	IN

DNA	NN

,	,

and	CC

simulated	JJ

NMR	NN

data	NNS

for	IN

bovine	JJ

pancreatic	JJ

trypsin	NN

inhibitor	NN

For	IN

villin	NN

14T	NN

,	,

a	DT

monomer	NN

consisting	VBG

of	IN

126	CD

residues	NNS

,	,

structure	NN

determination	NN

by	IN

torsion-angle	NN

molecular	JJ

dynamics	NNS

has	VBZ

a	DT

success	NN

rate	NN

of	IN

85	CD

%	NN

,	,

a	DT

more	RBR

than	IN

twofold	RB

improvement	NN

over	IN

other	JJ

methods	NNS

In	IN

the	DT

case	NN

of	IN

the	DT

12	CD

base-pair	NN

DNA	NN

duplex	NN

,	,

torsion-angle	NN

molecular	JJ

dynamics	NNS

had	VBD

a	DT

success	NN

rate	NN

of	IN

52	CD

%	NN

while	IN

Cartesian	JJ

molecular	JJ

dynamics	NNS

and	CC

metric-matrix	NN

distance	NN

geometry	NN

always	RB

failed	VBD

The	DT

wavelet-transform	NN

method	NN

is	VBZ

used	VBN

to	TO

quantify	VB

the	DT

magnetic	JJ

resonance	NN

spectroscopy	NN

(	NN

MRS	NNP

)	NN

parameters	NNS

:	:

chemical	NN

shift	NN

,	,

apparent	JJ

relaxation	NN

time	NN

T2	NN

,	,

resonance	NN

amplitude	NN

,	,

and	CC

phase	NN

Wavelet	NNP

transformation	NN

is	VBZ

a	DT

time-frequency	NN

representation	NN

which	WDT

separates	VBZ

each	DT

component	NN

from	IN

the	DT

FID	SYM

,	,

then	RB

successively	RB

quantifies	VBZ

it	PRP

and	CC

subtracts	NNS

it	PRP

from	IN

the	DT

raw	JJ

signal	NN

Two	CD

iterative	JJ

procedures	NNS

have	VB

been	VBN

developed	VBN

They	PRP

have	VB

been	VBN

combined	VBN

with	IN

a	DT

nonlinear	JJ

regression	NN

analysis	NN

method	NN

and	CC

tested	VBN

on	IN

both	DT

simulated	JJ

and	CC

real	RB

sets	NNS

of	IN

biomedical	JJ

MRS	NNP

data	NNS

selected	VBN

with	IN

respect	NN

to	TO

the	DT

main	JJ

problems	NNS

usually	RB

encountered	VBN

in	IN

quantifying	VBG

biomedical	JJ

MRS	NNP

,	,

specifically	RB

``	``

chemical	NN

noise	NN

,	,

''	''

resulting	VBG

from	IN

overlapping	VBG

resonances	NNS

,	,

and	CC

baseline	NN

distortion	NN

The	DT

results	NNS

indicate	VBP

that	IN

the	DT

wavelet-transform	NN

method	NN

can	MD

provide	VB

efficient	JJ

and	CC

accurate	JJ

quantification	NN

of	IN

MRS	NNP

data	NNS

BACKGROUND	NN

:	:

Antiplatelet	JJ

therapy	NN

with	IN

aspirin	NN

and	CC

systematic	JJ

anticoagulation	NN

with	IN

warfarin	NN

reduce	VB

cardiovascular	JJ

morbidity	NN

and	CC

mortality	NN

after	IN

myocardial	JJ

infarction	NN

when	WRB

given	VBN

alone	RB

In	IN

the	DT

Coumadin	NNP

Aspirin	NN

Reinfarction	NN

Study	NN

(	NN

CARS	NNS

)	NN

,	,

we	PRP

aimed	VBN

to	TO

find	VB

out	IN

whether	IN

a	DT

combination	NN

of	IN

low-dose	JJ

warfarin	NN

and	CC

low-dose	JJ

aspirin	NN

would	MD

give	VB

superior	JJ

results	NNS

to	TO

standard	NN

aspirin	NN

monotherapy	NN

without	IN

excessive	JJ

bleeding	VBG

risk	NN

METHODS	NNS

:	:

We	PRP

used	VBN

a	DT

randomised	VBN

double-blind	JJ

study	NN

design	NN

At	IN

293	CD

sites	NNS

,	,

we	PRP

randomly	RB

assigned	VBN

8803	CD

patients	NNS

who	WP

had	VBD

had	VBD

myocardial	JJ

infarction	NN

,	,

treatment	NN

with	IN

160	CD

mg	NN

aspirin	NN

,	,

3	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

,	,

or	CC

1	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

Patients	NNS

took	VBD

a	DT

single	JJ

tablet	NN

daily	RB

,	,

and	CC

attended	VBD

for	IN

prothrombin	NN

time	NN

(	NN

PT	NN

)	NN

measurements	NNS

at	IN

weeks	NNS

1	CD

,	,

2	CD

,	,

3	CD

,	,

4	CD

,	,

6	CD

,	,

and	CC

12	CD

,	,

and	CC

then	RB

every	DT

3	CD

months	NNS

Patients	NNS

were	VBD

followed	VBN

up	RB

for	IN

a	DT

maximum	NN

of	IN

33	CD

months	NNS

(	NN

median	NN

14	CD

months	NNS

)	NN

FINDINGS	NNS

:	:

The	DT

primary	JJ

event	NN

was	VBD

first	RB

occurrence	NN

of	IN

reinfarction	NN

,	,

non-fatal	JJ

ischaemic	JJ

stroke	NN

,	,

or	CC

cardiovascular	JJ

death	NN

1-year	JJ

life-table	JJ

estimates	NNS

for	IN

the	DT

primary	JJ

event	NN

were	VBD

8.6	CD

%	NN

(	NN

95	CD

%	NN

CI	NN

7.6-9.6	CD

)	NN

for	IN

160	CD

mg	NN

aspirin	NN

,	,

8.4	CD

%	NN

(	NN

7.4-9.4	CD

)	NN

for	IN

3	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

,	,

and	CC

8.8	CD

%	NN

(	NN

7.6-10	CD

)	NN

for	IN

1	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

Primary	JJ

comparisons	NNS

were	VBD

done	VBN

with	IN

all	DT

follow-up	NN

data	NNS

The	DT

relative	JJ

risk	NN

of	IN

the	DT

primary	JJ

event	NN

for	IN

the	DT

160	CD

mg	NN

aspirin	NN

group	NN

compared	VBN

with	IN

the	DT

3	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

group	NN

was	VBD

0.95	CD

(	NN

0.81-1.12	CD

,	,

p	NN

=	JJ

0.57	CD

)	NN

For	IN

spontaneous	JJ

major	JJ

haemorrhage	NN

(	NN

not	RB

procedure	NN

related	JJ

)	NN

,	,

1-year	JJ

life-table	JJ

estimates	NNS

were	VBD

0.74	CD

%	NN

(	NN

0.43-1.1	CD

)	NN

in	IN

the	DT

160	CD

mg	NN

aspirin	NN

group	NN

and	CC

1.4	CD

%	NN

(	NN

0.94-1.8	CD

)	NN

in	IN

the	DT

3	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

group	NN

(	NN

p	NN

=	JJ

0.014	CD

log	NN

rank	NN

on	IN

follow-up	NN

)	NN

For	IN

the	DT

3382	CD

patients	NNS

assigned	VBN

3	CD

mg	NN

warfarin	NN

with	IN

80	CD

mg	NN

aspirin	NN

,	,

the	DT

INR	NN

results	NNS

were	VBD

:	:

at	IN

week	NN

1	CD

(	NN

n	NN

=	JJ

2985	CD

)	NN

median	NN

1.51	CD

(	NN

IQR	NN

1.23-2.13	CD

)	NN

;	:

at	IN

week	NN

4	CD

(	NN

n	NN

=	JJ

2701	CD

)	NN

1.27	CD

(	NN

1.13-1.64	CD

)	NN

;	:

at	IN

month	NN

6	CD

(	NN

n	NN

=	JJ

2145	CD

)	NN

1.19	CD

(	NN

1.08-1.44	CD

)	NN

INTERPRETATION	NN

:	:

Low	JJ

,	,

fixed-dose	JJ

warfarin	NN

(	NN

1	CD

mg	NN

or	CC

3	CD

mg	NN

)	NN

combined	VBN

with	IN

low-dose	JJ

aspirin	NN

(	NN

80	CD

mg	NN

)	NN

in	IN

patients	NNS

who	WP

have	VB

had	VBD

myocardial	JJ

infarction	NN

does	VBZ

not	RB

provide	VB

clinical	JJ

benefit	NN

beyond	IN

that	IN

achievable	JJ

with	IN

160	CD

mg	NN

aspirin	NN

monotherapy	NN

BACKGROUND	NN

:	:

There	EX

is	VBZ

serological	JJ

evidence	NN

for	IN

an	DT

association	NN

between	IN

Chlamydia	NN

pneumoniae	FW

and	CC

coronary	JJ

heart	NN

disease	NN

We	PRP

investigated	VBN

the	DT

hypothesis	NN

that	IN

an	DT

antichlamydial	JJ

macrolide	NN

antibiotic	JJ

,	,

roxithromycin	NN

,	,

can	MD

prevent	VB

or	CC

reduce	VB

recurrent	JJ

major	JJ

ischaemic	JJ

events	NNS

in	IN

patients	NNS

with	IN

unstable	JJ

angina	NN

METHODS	NNS

:	:

The	DT

effect	NN

of	IN

roxithromycin	NN

was	VBD

assessed	VBN

in	IN

a	DT

double-blind	JJ

,	,

randomised	VBN

,	,

prospective	JJ

,	,

multicentre	JJ

,	,

parallel-group	NN

,	,

placebo-controlled	JJ

pilot	NN

study	NN

of	IN

202	CD

patients	NNS

with	IN

unstable	JJ

angina	NN

or	CC

non-Q-wave	JJ

myocardial	JJ

infarction	NN

Patients	NNS

were	VBD

randomly	RB

assigned	VBN

either	DT

roxithromycin	NN

150	CD

mg	NN

orally	RB

twice	RB

a	DT

day	NN

(	NN

n	NN

=	JJ

102	CD

)	NN

or	CC

placebo	NN

orally	RB

twice	RB

a	DT

day	NN

(	NN

n	NN

=	JJ

100	CD

)	NN

The	DT

treatment	NN

was	VBD

for	IN

30	CD

days	NNS

Patients	NNS

were	VBD

followed	VBN

up	RB

for	IN

6	CD

months	NNS

We	PRP

report	NN

the	DT

primary	JJ

clinical	JJ

endpoints	NNS

(	NN

cardiac	JJ

ischaemic	JJ

death	NN

,	,

myocardial	JJ

infarction	NN

,	,

and	CC

severe	JJ

recurrent	JJ

ischaemia	NN

)	NN

,	,

assessed	VBN

at	IN

day	NN

31	CD

,	,

in	IN

202	CD

patients	NNS

on	IN

an	DT

intention-to-treat	NN

basis	NN

FINDINGS	NNS

:	:

A	DT

statistically	RB

significant	JJ

reduction	NN

in	IN

the	DT

primary	JJ

composite	JJ

triple	RB

endpoint	NN

rates	NNS

was	VBD

observed	VBN

in	IN

the	DT

roxithromycin	NN

group	NN

:	:

p	NN

=	JJ

0.032	CD

The	DT

rate	NN

of	IN

severe	JJ

recurrent	JJ

ischaemia	NN

,	,

myocardial	JJ

infarction	NN

,	,

and	CC

ischaemic	JJ

death	NN

was	VBD

5.4	CD

%	NN

,	,

2.2	CD

%	NN

,	,

and	CC

2.2	CD

%	NN

in	IN

the	DT

placebo	NN

group	NN

and	CC

1.1	CD

%	NN

,	,

0	CD

%	NN

,	,

and	CC

0	CD

%	NN

,	,

in	IN

the	DT

roxithromycin	NN

group	NN

,	,

respectively	RB

No	DT

major	JJ

drug-related	JJ

adverse	JJ

effects	NNS

were	VBD

observed	VBN

INTERPRETATION	NN

:	:

Antichlamydial	JJ

antibiotics	NNS

may	MD

be	VB

useful	JJ

in	IN

therapeutic	JJ

intervention	NN

in	IN

addition	NN

to	TO

standard	NN

medication	NN

in	IN

patients	NNS

with	IN

coronary-artery	NN

disease	NN

Large-scale	JJ

trials	NNS

are	VBP

needed	VBN

to	TO

confirm	VB

these	DT

preliminary	JJ

observations	NNS

BACKGROUND	NN

:	:

Stage	NN

Ib	NN

and	CC

IIa	NN

cervical	JJ

carcinoma	NN

can	MD

be	VB

cured	VBN

by	IN

radical	NN

surgery	NN

or	CC

radiotherapy	NN

These	DT

two	CD

procedures	NNS

are	VBP

equally	RB

effective	JJ

,	,

but	CC

differ	VB

in	IN

associated	VBN

morbidity	NN

and	CC

type	NN

of	IN

complications	NNS

In	IN

this	DT

prospective	JJ

randomised	VBN

trial	NN

of	IN

radiotherapy	NN

versus	CC

surgery	NN

,	,

our	PRP$

aim	NN

was	VBD

to	TO

assess	VB

the	DT

5-year	JJ

survival	NN

and	CC

the	DT

rate	NN

and	CC

pattern	NN

of	IN

complications	NNS

and	CC

recurrences	NNS

associated	VBN

with	IN

each	DT

treatment	NN

METHODS	NNS

:	:

Between	IN

September	NNP

,	,

1986	CD

,	,

and	CC

December	NNP

,	,

1991	CD

,	,

469	CD

women	NNS

with	IN

newly	RB

diagnosed	VBN

stage	NN

Ib	NN

and	CC

IIa	NN

cervical	JJ

carcinoma	NN

were	VBD

referred	VBN

to	TO

our	PRP$

institute	NN

343	CD

eligible	NN

patients	NNS

were	VBD

randomised	VBN

:	:

172	CD

to	TO

surgery	NN

and	CC

171	CD

to	TO

radical	NN

radiotherapy	NN

Adjuvant	JJ

radiotherapy	NN

was	VBD

delivered	VBN

after	IN

surgery	NN

for	IN

women	NNS

with	IN

surgical	JJ

stage	NN

pT2b	NN

or	CC

greater	JJR

,	,

less	JJR

than	IN

3	CD

mm	NN

of	IN

safe	JJ

cervical	JJ

stroma	NN

,	,

cut-through	JJ

,	,

or	CC

positive	JJ

nodes	NNS

The	DT

primary	JJ

outcome	NN

measures	NNS

were	VBD

5-year	JJ

survival	NN

and	CC

the	DT

rate	NN

of	IN

complications	NNS

The	DT

analysis	NN

of	IN

survival	NN

and	CC

recurrence	NN

was	VBD

by	IN

intention	NN

to	TO

treat	NN

and	CC

analysis	NN

of	IN

complications	NNS

was	VBD

by	IN

treatment	NN

delivered	VBN

FINDINGS	NNS

:	:

170	CD

patients	NNS

in	IN

the	DT

surgery	NN

group	NN

and	CC

167	CD

in	IN

the	DT

radiotherapy	NN

group	NN

were	VBD

included	VBN

in	IN

the	DT

intention-to-treat	NN

analysis	NN

;	:

scheduled	VBN

treatment	NN

was	VBD

delivered	VBN

to	TO

169	CD

and	CC

158	CD

women	NNS

,	,

respectively	RB

,	,

62	CD

of	IN

114	CD

women	NNS

with	IN

cervical	JJ

diameters	NNS

of	IN

4	CD

cm	NN

or	CC

smaller	JJR

and	CC

46	CD

of	IN

55	CD

with	IN

diameters	NNS

larger	JJR

than	IN

4	CD

cm	NN

received	VBN

adjuvant	JJ

therapy	NN

After	IN

a	DT

median	NN

follow-up	NN

of	IN

87	CD

(	NN

range	NN

57-120	JJ

)	NN

months	NNS

,	,

5-year	JJ

overall	RB

and	CC

disease-free	JJ

survival	NN

were	VBD

identical	JJ

in	IN

the	DT

surgery	NN

and	CC

radiotherapy	NN

groups	NNS

(	NN

83	CD

%	NN

and	CC

74	CD

%	NN

,	,

respectively	RB

,	,

for	IN

both	DT

groups	NNS

)	NN

,	,

86	CD

women	NNS

developed	VBN

recurrent	JJ

disease	NN

:	:

42	CD

(	NN

25	CD

%	NN

)	NN

in	IN

the	DT

surgery	NN

group	NN

and	CC

44	CD

(	NN

26	CD

%	NN

)	NN

in	IN

the	DT

radiotherapy	NN

group	NN

Significant	JJ

factors	NNS

for	IN

survival	NN

in	IN

univariate	JJ

and	CC

multivariate	JJ

analyses	NNS

were	VBD

:	:

cervical	JJ

diameter	NN

,	,

positive	JJ

lymphangiography	NN

,	,

and	CC

adeno-carcinomatous	JJ

histotype	NN

48	CD

(	NN

28	CD

%	NN

)	NN

surgery-group	NN

patients	NNS

had	VBD

severe	JJ

morbidity	NN

compared	VBN

with	IN

19	CD

(	NN

12	CD

%	NN

)	NN

radiotherapy-group	NN

patients	NNS

(	NN

p	NN

=	JJ

0.0004	CD

)	NN

INTERPRETATION	NN

:	:

There	EX

is	VBZ

no	DT

treatment	NN

of	IN

choice	NN

for	IN

early-stage	JJ

cervical	JJ

carcinoma	NN

in	IN

terms	NNS

of	IN

overall	RB

or	CC

disease-free	JJ

survival	NN

The	DT

combination	NN

of	IN

surgery	NN

and	CC

radiotherapy	NN

has	VBZ

the	DT

worst	JJS

morbidity	NN

,	,

especially	RB

urological	NN

complications	NNS

The	DT

optimum	NN

therapy	NN

for	IN

each	DT

patient	NN

should	MD

take	VB

account	NN

of	IN

clinical	JJ

factors	NNS

such	JJ

as	IN

menopausal	JJ

status	NN

,	,

age	NN

,	,

medical	JJ

illness	NN

,	,

histological	JJ

type	NN

,	,

and	CC

cervical	JJ

diameter	NN

to	TO

yield	NN

the	DT

best	RB

cure	NN

with	IN

minimum	NN

complications	NNS

Today	NN

's	POS

technology	NN

links	NNS

health	NN

care	NN

providers	NNS

and	CC

patients	NNS

across	IN

town	NN

,	,

in	IN

the	DT

next	IN

state	NN

or	CC

even	RB

another	DT

country	NN

Nursing	NNP

across	IN

state	NN

lines	NNS

poses	VBZ

complications	NNS

:	:

state-bound	JJ

regulatory	JJ

and	CC

licensure	NN

issues	NNS

This	DT

article	NN

discusses	VBZ

many	JJ

of	IN

the	DT

nutritional	JJ

topics	NNS

important	JJ

to	TO

the	DT

intensivist	NN

Nutritional	NNP

assessment	NN

,	,

substrate	NN

immunonutrition	NN

,	,

and	CC

disease	NN

specific	JJ

issues	NNS

are	VBP

presented	VBN

Early	RB

introduction	NN

of	IN

enteral	NN

feeds	VBZ

and	CC

the	DT

use	NN

of	IN

nutritional	JJ

modulation	NN

are	VBP

emphasized	VBN

PROBLEM	NN

:	:

To	TO

compare	VB

the	DT

expression	NN

by	IN

T-lymphocytes	NNS

of	IN

an	DT

immunomodulatory	JJ

protein	NN

known	VBN

as	IN

progesterone-induced	JJ

blocking	VBG

factor	NN

(	NN

PIBF	NN

)	NN

in	IN

conception	NN

versus	CC

non-conception	JJ

cycles	NNS

even	RB

when	WRB

there	RB

has	VBZ

been	VBN

definite	JJ

fertilization	NN

and	CC

embryo	NN

formation	NN

METHOD	NN

:	:

PIBF	NN

expression	NN

on	IN

T	NN

lymphocytes	NNS

was	VBD

measured	VBN

using	VBG

an	DT

immunohistochemical	JJ

method	NN

with	IN

a	DT

PIBF-specific	JJ

polyclonal	JJ

antibody	NN

These	DT

levels	NNS

were	VBD

determined	VBN

in	IN

patients	NNS

undergoing	VBG

three	CD

types	NNS

of	IN

therapy	NN

:	:

non-in	JJ

vitro	NN

fertilization	NN

(	NN

IVF	NN

)	NN

,	,

IVF-embryo	NN

transfer	NN

(	NN

ET	NNP

)	NN

,	,

and	CC

frozen	JJ

ET	NNP

Sera	NNP

were	VBD

drawn	VBN

12	CD

days	NNS

from	IN

ovulation	NN

in	IN

non-IVF	JJ

cycles	NNS

or	CC

9	CD

days	NNS

after	IN

ET	NNP

and	CC

were	VBD

assayed	VBN

for	IN

PIBF	NN

and	CC

beta	NN

human	JJ

chorionic	JJ

gondotropin	NN

Comparison	NN

of	IN

the	DT

frequency	NN

of	IN

lymphocyte	NN

expression	NN

of	IN

PIBF	NN

in	IN

pregnant	JJ

versus	CC

non-pregnant	JJ

women	NNS

were	VBD

made	VBN

RESULTS	NNS

:	:

PIBF	NN

was	VBD

detected	VBN

in	IN

29.5	CD

%	NN

of	IN

non-pregnant	JJ

women	NNS

and	CC

52.5	CD

%	NN

of	IN

pregnant	JJ

women	NNS

There	EX

were	VBD

no	DT

differences	NNS

in	IN

PIBF	NN

levels	NNS

by	IN

therapy	NN

used	VBN

in	IN

non-pregnant	JJ

cases	NNS

or	CC

in	IN

the	DT

pregnant	JJ

group	NN

CONCLUSION	NN

:	:

These	DT

data	NNS

are	VBP

consistent	JJ

with	IN

the	DT

hypothesis	NN

that	IN

maternal	JJ

expression	NN

of	IN

PIBF	NN

in	IN

T-lymphocytes	NNS

soon	RB

after	IN

trophoblast	NN

invasion	NN

may	MD

depend	VB

on	IN

successful	JJ

implantation	NN

Many	JJ

amino	NN

acids	NNS

contain	VB

an	DT

asymmetric	JJ

centre	NN

,	,

occurring	VBG

as	IN

laevorotatory	JJ

,	,

L	NN

,	,

or	CC

dextrorotatory	JJ

,	,

D	NN

,	,

compounds	NNS

It	PRP

is	VBZ

generally	RB

assumed	VBN

that	IN

abiotic	JJ

synthesis	NN

of	IN

amino	NN

acids	NNS

on	IN

the	DT

early	RB

Earth	NNP

resulted	VBD

in	IN

racemic	JJ

mixtures	NNS

(	NN

L-	NN

and	CC

D-enantiomers	NNS

in	IN

equal	JJ

abundance	NN

)	NN

But	CC

the	DT

origin	NN

of	IN

life	NN

required	VBN

,	,

owing	VBG

to	TO

conformational	JJ

constraints	NNS

,	,

the	DT

almost	RB

exclusive	JJ

selection	NN

of	IN

either	DT

L-	NN

or	CC

D-enantiomers	NNS

,	,

and	CC

the	DT

question	NN

of	IN

why	WRB

living	VBG

systems	NNS

on	IN

the	DT

Earth	NNP

consist	VBP

of	IN

L-enantiomers	NNS

rather	RB

than	IN

D-enantiomers	NNS

is	VBZ

unresolved	JJ

A	DT

substantial	JJ

fraction	NN

of	IN

the	DT

organic	JJ

compounds	NNS

on	IN

the	DT

early	RB

Earth	NNP

may	MD

have	VB

been	VBN

derived	VBN

from	IN

comet	NN

and	CC

meteorite	NN

impacts	NNS

It	PRP

has	VBZ

been	VBN

reported	VBN

previously	RB

that	IN

amino	NN

acids	NNS

in	IN

the	DT

Murchison	NNP

meteorite	NN

exhibit	NN

an	DT

excess	NN

of	IN

L-enantiomers	NNS

,	,

raising	VBG

the	DT

possibility	NN

that	IN

a	DT

similar	JJ

excess	NN

was	VBD

present	JJ

in	IN

the	DT

initial	JJ

inventory	NN

of	IN

organic	JJ

compounds	NNS

on	IN

the	DT

Earth	NNP

The	DT

stable	JJ

carbon	NN

isotope	NN

compositions	NNS

of	IN

individual	JJ

amino	NN

acids	NNS

in	IN

Murchison	NNP

support	NN

an	DT

extraterrestrial	JJ

origin	NN

--	:

rather	RB

than	IN

a	DT

terrestrial	NN

overprint	NN

of	IN

biological	JJ

amino	NN

acids-although	JJ

reservations	NNS

have	VB

persisted	VBD

Here	RB

we	PRP

show	NN

that	IN

individual	JJ

amino-acid	JJ

enantiomers	NNS

from	IN

Murchison	NNP

are	VBP

enriched	JJ

in	IN

15N	NN

relative	JJ

to	TO

their	PRP$

terrestrial	NN

counterparts	NNS

,	,

so	RB

confirming	VBG

an	DT

extraterrestrial	JJ

source	NN

for	IN

an	DT

L-enantiomer	NN

excess	NN

in	IN

the	DT

Solar	NNP

System	NNP

that	IN

may	MD

predate	VB

the	DT

origin	NN

of	IN

life	NN

on	IN

the	DT

Earth	NNP

Home	NN

care	NN

workers	NNS

face	NN

an	DT

increasing	VBG

risk	NN

for	IN

workplace	NN

violence	NN

A	DT

proactive	JJ

preventive	JJ

approach	NN

is	VBZ

presented	VBN

that	IN

suggests	VBZ

strategies	NNS

to	TO

use	NN

during	IN

the	DT

previsit	NN

phase	NN

,	,

the	DT

visit	NN

experience	NN

,	,

and	CC

on	IN

an	DT

ongoing	JJ

basis	NN

The	DT

miracidia	NN

of	IN

Fasciola	NN

hepatica	NN

and	CC

Trichobilharzia	FW

ocellata	NN

approach	NN

their	PRP$

host	NN

snails	NNS

Lymnaea	NNP

truncatula	NN

and	CC

L.	NNP

stagnalis	NN

by	IN

increasing	VBG

their	PRP$

rate	NN

of	IN

change	NN

of	IN

direction	NN

(	NN

RCD	NN

)	NN

in	IN

increasing	VBG

gradients	NNS

of	IN

snail-conditioned	JJ

water	NN

(	NN

SCW	NN

)	NN

,	,

and	CC

they	PRP

perform	VB

a	DT

turnback	NN

swimming	VBG

in	IN

decreasing	VBG

gradients	NNS

Both	DT

hostfinding	VBG

responses	NNS

in	IN

both	DT

species	NNS

were	VBD

induced	VBN

by	IN

glycoconjugates	NNS

with	IN

a	DT

molecular	JJ

weight	NN

of	IN

>	JJR

30	CD

kDa	NN

that	IN

were	VBD

sensitive	JJ

to	TO

hydrolysis	NN

with	IN

pronase	NN

E	NN

and	CC

oxidation	NN

with	IN

NaIO4	NN

Alkaline	NN

cleavage	NN

revealed	VBD

that	IN

they	PRP

contained	VBN

carbohydrates	NNS

linked	VBN

O-glycosidically	RB

via	IN

serine	NN

and	CC

N-acetylgalactosamine	NN

Miracidia	NNP

clearly	RB

preferred	VBN

SCW	NN

from	IN

their	PRP$

specific	JJ

host	NN

snail	NN

versus	CC

other	JJ

sympatric	JJ

snail	NN

species	NNS

and	CC

did	VBD

not	RB

respond	NN

to	TO

water	NN

conditioned	VBN

with	IN

fish	NN

,	,

tadpoles	NNS

,	,

or	CC

leeches	NNS

Differences	NNS

in	IN

the	DT

chemical	NN

characteristics	NNS

of	IN

SCW	NN

from	IN

the	DT

intermediate	JJ

hosts	NNS

L.	NNP

truncatula	NN

and	CC

L.	NNP

stagnalis	NN

could	MD

be	VB

shown	VBN

by	IN

sodium	NN

dodecyl	NN

sulfate-polyacrylamide	JJ

gel	NN

electrophoresis	NN

,	,

blotting	NN

,	,

and	CC

subsequent	JJ

carbohydrate	NN

detection	NN

The	DT

first	RB

step	NN

of	IN

purification	NN

of	IN

the	DT

effective	JJ

signaling	NN

SCW	NN

components	NNS

from	IN

both	DT

snail	NN

species	NNS

was	VBD

achieved	VBN

by	IN

ion-exchange	NN

chromatography	NN

Black	NNP

patients	NNS

with	IN

colon	NN

cancer	NN

in	IN

the	DT

Black/White	NN

Cancer	NN

Survival	NN

Study	NN

were	VBD

found	VBN

to	TO

have	VB

a	DT

poorer	JJR

survival	NN

than	IN

white	JJ

patients	NNS

More	RBR

advanced-stage	NN

disease	NN

at	IN

diagnosis	NN

was	VBD

the	DT

primary	JJ

determinant	NN

,	,

accounting	NN

for	IN

60	CD

%	NN

of	IN

the	DT

excess	NN

mortality	NN

After	IN

adjusting	VBG

for	IN

stage	NN

,	,

factors	NNS

such	JJ

as	IN

poverty	NN

,	,

other	JJ

socioeconomic	JJ

conditions	NNS

,	,

and	CC

treatment	NN

did	VBD

not	RB

further	RB

explain	VB

the	DT

remaining	VBG

survival	NN

deficit	NN

This	DT

study	NN

examined	VBN

the	DT

aggressiveness	NN

of	IN

colon	NN

tumors	NNS

in	IN

blacks	NNS

and	CC

whites	NNS

to	TO

explore	VB

its	PRP$

role	NN

in	IN

the	DT

racial	JJ

survival	NN

differences	NNS

Tumor	NN

characteristics	NNS

of	IN

703	CD

cases	NNS

of	IN

newly	RB

diagnosed	VBN

invasive	JJ

colon	NN

adenocarcinoma	NN

were	VBD

centrally	RB

evaluated	VBN

by	IN

a	DT

gastrointestinal	JJ

pathologist	NN

,	,

blinded	VBN

in	IN

regard	NN

to	TO

the	DT

age	NN

,	,

race	NN

,	,

and	CC

sex	NN

of	IN

the	DT

patients	NNS

Blacks	NNPS

were	VBD

less	JJR

likely	RB

to	TO

have	VB

poorly	RB

differentiated	VBN

(	NN

grade	NN

3	CD

)	NN

tumors	NNS

(	NN

odds	NNS

ratio	NN

(	NN

OR	NN

)	NN

,	,

0.44	CD

;	:

95	CD

%	NN

confidence	NN

interval	NN

,	,

0.22-0.88	CD

)	NN

and	CC

lymphoid	JJ

reaction	NN

(	NN

OR	NN

,	,

0.49	CD

;	:

95	CD

%	NN

confidence	NN

interval	NN

,	,

0.26-0.90	CD

)	NN

when	WRB

compared	VBN

with	IN

whites	NNS

These	DT

black/white	NN

(	NN

B/W	NN

)	NN

differences	NNS

remained	VBD

statistically	RB

significant	JJ

after	IN

adjusting	VBG

for	IN

age	NN

,	,

sex	NN

,	,

metropolitan	JJ

area	NN

,	,

summary	NN

stage	NN

,	,

socioeconomic	JJ

status	NN

,	,

body	NN

mass	NN

index	NN

,	,

and	CC

health	NN

care	NN

access	NN

and	CC

utilization	NN

In	IN

addition	NN

,	,

blacks	NNS

were	VBD

less	JJR

likely	RB

to	TO

have	VB

high-grade	JJ

(	NN

grade	NN

3	CD

)	NN

nuclear	JJ

atypia	NN

,	,

mitotic	JJ

activity	NN

,	,

and	CC

tubule	NN

formation	NN

,	,

although	IN

these	DT

ORs	NNS

did	VBD

not	RB

reach	NN

a	DT

statistical	JJ

significance	NN

level	NN

of	IN

0.05	CD

Similar	JJ

B/W	NN

differences	NNS

were	VBD

observed	VBN

for	IN

patients	NNS

with	IN

advanced	VBN

disease	NN

but	CC

not	RB

with	IN

early	RB

stage	NN

Comparison	NN

by	IN

anatomical	JJ

subsite	NN

showed	VBD

that	IN

blacks	NNS

had	VBD

statistically	RB

significantly	RB

better	RB

differentiated	VBN

tumors	NNS

for	IN

cancers	NNS

of	IN

the	DT

proximal	JJ

and	CC

transverse	NN

colon	NN

but	CC

not	RB

for	IN

the	DT

distal	JJ

No	DT

racial	JJ

differences	NNS

were	VBD

found	VBN

for	IN

blood	NN

vessel	NN

and	CC

lymphatic	JJ

invasion	NN

,	,

necrosis	NN

,	,

fibrosis	NN

,	,

and	CC

mucinous	JJ

type	NN

of	IN

histology	NN

The	DT

findings	NNS

,	,

therefore	RB

,	,

are	VBP

the	DT

opposite	JJ

of	IN

those	DT

hypothesized	VBN

After	IN

adjusting	VBG

for	IN

stage	NN

,	,

more	RBR

aggressive	JJ

tumor	NN

characteristics	NNS

do	VB

not	RB

explain	VB

the	DT

adverse	JJ

survival	NN

differential	JJ

in	IN

blacks	NNS

This	DT

suggests	VBZ

that	IN

there	RB

may	MD

be	VB

racial	JJ

differences	NNS

in	IN

environmental	JJ

exposure	NN

,	,

and	CC

that	IN

the	DT

intensity	NN

and	CC

mode	NN

of	IN

delivery	NN

of	IN

carcinogen	NN

insult	NN

as	IN

well	RB

as	IN

host	NN

susceptibility	NN

may	MD

differ	VB

by	IN

race	NN

and	CC

anatomical	JJ

subsite	NN

Future	JJ

studies	NNS

should	MD

explore	VB

the	DT

B/W	NN

differences	NNS

in	IN

tumor	NN

biology	NN

using	VBG

molecular	JJ

markers	NNS

that	IN

precede	VB

the	DT

conventional	JJ

histological	JJ

parameters	NNS

evaluated	VBN

here	RB

A	DT

new	JJ

method	NN

is	VBZ

described	VBN

for	IN

detection	NN

of	IN

mutations	NNS

in	IN

the	DT

lysosomal	JJ

alpha-glucosidase	NN

gene	NN

(	NN

GAA	NN

)	NN

leading	VBG

to	TO

Glycogen	NN

Storage	NNP

Disease	NN

type	NN

II	NNP

(	NN

GSDII	CD

)	NN

A	DT

key	NN

feature	NN

of	IN

the	DT

method	NN

is	VBZ

isolation	NN

and	CC

reverse	NN

transcription	NN

of	IN

mRNA	NN

followed	VBN

by	IN

PCR	NN

amplification	NN

of	IN

lysosomal	JJ

alpha-glucosidase	NN

cDNA	NN

with	IN

M13-extended	JJ

primers	NNS

Dye	VB

labeled	VBN

primers	NNS

are	VBP

used	VBN

for	IN

cycle	NN

sequencing	NN

and	CC

an	DT

ABI	NN

PRISM	NN

377	CD

DNA	NN

sequencing	NN

system	NN

for	IN

analysis	NN

The	DT

method	NN

is	VBZ

rapid	JJ

and	CC

complementary	JJ

to	TO

the	DT

automated	VBN

sequencing	NN

of	IN

all	DT

the	DT

19	CD

,	,

PCR	NN

amplified	VBN

,	,

coding	VBG

exons	NNS

of	IN

the	DT

GAA	NN

gene	NN

The	DT

advantages	NNS

and	CC

pitfalls	NNS

of	IN

this	DT

new	JJ

method	NN

are	VBP

discussed	VBN

in	IN

the	DT

light	NN

of	IN

the	DT

results	NNS

obtained	VBN

with	IN

an	DT

infantile	JJ

GSDII	CD

patient	NN

A	DT

new	JJ

splice	NN

site	NN

mutation	NN

in	IN

the	DT

GAA	NN

gene	NN

of	IN

this	DT

patient	NN

was	VBD

identified	VBN

,	,

IVS16	NN

(	NN

+2T	NN

--	:

>	JJR

C	NN

)	NN

,	,

resulting	VBG

in	IN

the	DT

deletion	NN

of	IN

16	CD

base	NN

pairs	NNS

of	IN

exon	NN

16	CD

The	DT

presence	NN

of	IN

clinical	JJ

autonomic	JJ

dysfunction	NN

in	IN

patients	NNS

with	IN

neurologic	JJ

diseases	NNS

,	,

such	JJ

as	IN

multiple	JJ

sclerosis	NN

,	,

Parkinson	NNP

's	POS

disease	NN

,	,

and	CC

cerebrovascular	JJ

accident	NN

,	,

has	VBZ

become	VB

increasingly	RB

recognized	VBN

in	IN

the	DT

past	IN

decade	NN

Very	RB

few	JJ

autonomic	JJ

tests	NNS

have	VB

been	VBN

done	VBN

on	IN

pediatric	JJ

patients	NNS

thus	RB

far	RB

The	DT

purpose	NN

of	IN

this	DT

study	NN

was	VBD

to	TO

investigate	VB

the	DT

autonomic	JJ

function	NN

in	IN

patients	NNS

with	IN

cerebral	JJ

palsy	NN

using	VBG

two	CD

noninvasive	JJ

tests	NNS

:	:

sympathetic	JJ

skin	NN

response	NN

(	NN

SSR	NN

)	NN

and	CC

R-R	NN

interval	NN

variation	NN

(	NN

RRIV	NN

)	NN

Twenty-four	CD

patients	NNS

with	IN

cerebral	JJ

palsy	NN

and	CC

24	CD

control	NN

subjects	NNS

between	IN

the	DT

ages	NNS

of	IN

4	CD

and	CC

12	CD

yr	NN

were	VBD

enrolled	VBN

in	IN

this	DT

study	NN

There	EX

was	VBD

no	DT

significant	JJ

difference	NN

of	IN

mean	VB

latency	NN

,	,

amplitude	NN

,	,

or	CC

amplitude	NN

ratio	NN

of	IN

SSR	NN

between	IN

the	DT

two	CD

groups	NNS

under	IN

electric	JJ

stimulus	NN

,	,

startling	JJ

stimulus	NN

,	,

and	CC

deep	RB

breathing	NN

conditions	NNS

No	DT

significant	JJ

difference	NN

in	IN

frequency	NN

of	IN

absent	JJ

response	NN

and	CC

asymmetric	JJ

response	NN

was	VBD

also	RB

noted	VBN

Mean	NN

heart	NN

rate	NN

under	IN

relaxed	VBN

sitting	VBG

condition	NN

was	VBD

significantly	RB

higher	JJR

in	IN

the	DT

study	NN

group	NN

Significant	JJ

negative	JJ

correlation	NN

between	IN

heart	NN

rate	NN

and	CC

age	NN

was	VBD

noted	VBN

in	IN

the	DT

control	NN

group	NN

but	CC

was	VBD

not	RB

present	JJ

in	IN

the	DT

study	NN

group	NN

Also	RB

,	,

there	RB

was	VBD

no	DT

statistical	JJ

difference	NN

of	IN

mean	VB

RRIV	NN

between	IN

the	DT

two	CD

groups	NNS

No	DT

objective	NN

evidence	NN

of	IN

autonomic	JJ

disturbance	NN

in	IN

patients	NNS

with	IN

cerebral	JJ

palsy	NN

was	VBD

found	VBN

in	IN

this	DT

study	NN

A	DT

two-credits	NNS

per	IN

semester	NN

clinical	JJ

medicine	NN

course	NN

was	VBD

established	VBN

in	IN

the	DT

Department	NNP

of	IN

Physical	JJ

Medicine	NN

and	CC

Rehabilitation	NNP

(	NN

PM	NN

&	CC

#	#

38	CD

;	:

R	NN

)	NN

in	IN

cooperation	NN

with	IN

the	DT

Johns	NNP

Hopkins	NNP

University	NNP

undergraduate	JJ

Human	JJ

Biology	NN

faculty	NN

to	TO

present	JJ

the	DT

variety	NN

of	IN

inpatient	NN

consultation	NN

personnel	NNS

,	,

units	NNS

,	,

patient	NN

diagnostic	JJ

groups	NNS

,	,

and	CC

functional	JJ

problems	NNS

College	NNP

students	NNS

spend	VB

4	CD

hr	NN

weekly	RB

on	IN

the	DT

PM	NN

&	CC

#	#

38	CD

;	:

R	NN

consultation	NN

service	NN

as	IN

team	NN

members	NNS

under	IN

resident	NN

supervision	NN

The	DT

curriculum	NN

emphasizes	VBZ

student	NN

understanding	VBG

of	IN

the	DT

roles	NNS

of	IN

rehabilitation	NN

team	NN

members	NNS

Objectives	NNS

include	VB

demonstration	NN

of	IN

working	VBG

knowledge	NN

of	IN

the	DT

Biopsychosocial	NNP

Model	NNP

,	,

the	DT

World	NNP

Health	NNP

Organization	NNP

Model	NNP

of	IN

disablement	NN

and	CC

interdisciplinary	JJ

rehabilitation	NN

intervention	NN

The	DT

course	NN

includes	VBZ

simulations	NNS

of	IN

physical	JJ

impairments	NNS

,	,

demonstrations	NNS

of	IN

adaptive	JJ

equipment	NN

,	,

interactive	JJ

chart	NN

reviews	NNS

,	,

readings	NNS

,	,

and	CC

audio	NN

lectures	VBZ

A	DT

retrospective	NN

sequential	JJ

review	NN

was	VBD

made	VBN

of	IN

the	DT

last	JJ

100	CD

physical	JJ

medicine	NN

and	CC

rehabilitation	NN

consultations	NNS

with	IN

student	NN

attendance	NN

The	DT

results	NNS

confirm	VB

student	NN

exposure	NN

to	TO

many	JJ

ward	NN

settings	NNS

(	NN

surgery	NN

,	,

30	CD

%	NN

;	:

neurology/neurosurgery	NN

,	,

28	CD

%	NN

;	:

medicine	NN

,	,

24	CD

%	NN

;	:

intensive	JJ

care	NN

,	,

15	CD

%	NN

;	:

oncology	NN

,	,

2	CD

%	NN

;	:

and	CC

psychiatry	NN

,	,

1	CD

%	NN

)	NN

,	,

patient	NN

complexity	NN

(	NN

averaging	VBG

10	CD

problems	NNS

)	NN

,	,

and	CC

multiple	JJ

ICD-9	NN

diagnosis	NN

categories	NNS

(	NN

circulatory	JJ

,	,

36	CD

%	NN

;	:

neurologic	JJ

,	,

22	CD

%	NN

;	:

musculoskeletal	JJ

,	,

17	CD

%	NN

;	:

neoplasms	NNS

,	,

10	CD

%	NN

;	:

injury	NN

,	,

5	CD

%	NN

;	:

endocrine	NN

,	,

4	CD

%	NN

;	:

infections	NNS

,	,

3	CD

%	NN

;	:

and	CC

others	NNS

,	,

3	CD

%	NN

)	NN

The	DT

rehabilitation	NN

consultation	NN

service	NN

is	VBZ

particularly	RB

effective	JJ

as	IN

an	DT

introduction	NN

to	TO

hospital-based	JJ

medical	JJ

practice	NN

due	JJ

to	TO

the	DT

diagnostic	JJ

variety	NN

of	IN

the	DT

patients	NNS

,	,

the	DT

functional	JJ

approach	NN

of	IN

rehabilitation	NN

,	,

and	CC

student	NN

exposure	NN

to	TO

multiple	JJ

hospital	NN

settings	NNS

The	DT

Biopsychosocial	NNP

Model	NNP

of	IN

medical	JJ

practice	NN

is	VBZ

demonstrated	VBN

through	IN

multiple	JJ

interdisciplinary	JJ

perspectives	NNS

of	IN

needs	NNS

and	CC

interventions	NNS

for	IN

patients	NNS

with	IN

obvious	JJ

functional	JJ

deficits	NNS

This	DT

process	NN

develops	VBZ

a	DT

rudimentary	JJ

understanding	VBG

of	IN

the	DT

effect	NN

of	IN

illness	NN

on	IN

the	DT

person	NN

and	CC

the	DT

variety	NN

of	IN

medically	RB

effective	JJ

therapeutic	JJ

modalities	NNS

This	DT

study	NN

is	VBZ

designed	VBN

to	TO

investigate	VB

the	DT

immediate	JJ

effectiveness	NN

of	IN

electrotherapy	NN

on	IN

myofascial	JJ

trigger	NN

points	NNS

of	IN

upper	JJ

trapezius	NN

muscle	NN

Sixty	CD

patients	NNS

(	NN

25	CD

males	NNS

and	CC

35	CD

females	NNS

)	NN

who	WP

had	VBD

myofascial	JJ

trigger	NN

points	NNS

in	IN

one	CD

side	NN

of	IN

the	DT

upper	JJ

trapezius	NN

muscles	NNS

were	VBD

studied	VBN

The	DT

involved	VBN

upper	JJ

trapezius	NN

muscles	NNS

were	VBD

treated	VBN

with	IN

three	CD

different	JJ

methods	NNS

according	VBG

to	TO

a	DT

random	JJ

assignment	NN

:	:

group	NN

A	DT

muscles	NNS

(	NN

n	NN

=	JJ

18	CD

)	NN

were	VBD

given	VBN

placebo	NN

treatment	NN

(	NN

control	NN

group	NN

)	NN

;	:

group	NN

B	NN

muscles	NNS

(	NN

n	NN

=	JJ

20	CD

)	NN

were	VBD

treated	VBN

with	IN

electrical	JJ

nerve	NN

stimulation	NN

(	NN

ENS	NN

)	NN

therapy	NN

;	:

and	CC

group	NN

C	NN

muscles	NNS

(	NN

n	NN

=	JJ

22	CD

)	NN

were	VBD

given	VBN

electrical	JJ

muscle	NN

stimulation	NN

(	NN

EMS	NNP

)	NN

therapy	NN

The	DT

effectiveness	NN

of	IN

treatment	NN

was	VBD

assessed	VBN

by	IN

conducting	VBG

three	CD

measurements	NNS

on	IN

each	DT

muscle	NN

before	IN

and	CC

immediately	RB

after	IN

treatment	NN

:	:

subjective	JJ

pain	NN

intensity	NN

(	NN

(	NN

PI	NN

)	NN

with	IN

a	DT

visual	JJ

analog	NN

scale	NN

)	NN

,	,

pressure	NN

pain	NN

threshold	NN

(	NN

(	NN

PT	NN

)	NN

with	IN

algometry	NN

)	NN

,	,

and	CC

range	NN

of	IN

motion	NN

(	NN

(	NN

ROM	NN

)	NN

with	IN

a	DT

goniometer	NN

)	NN

of	IN

upper	JJ

trapezius	NN

muscle	NN

(	NN

lateral	JJ

bending	VBG

of	IN

cervical	JJ

spine	NN

to	TO

the	DT

opposite	JJ

side	NN

)	NN

When	WRB

the	DT

effectiveness	NN

of	IN

treatment	NN

was	VBD

compared	VBN

with	IN

that	IN

of	IN

the	DT

placebo	NN

group	NN

(	NN

group	NN

A	DT

)	NN

,	,

there	RB

was	VBD

significant	JJ

improvement	NN

in	IN

PI	NN

and	CC

PT	NN

in	IN

group	NN

B	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.01	CD

)	NN

but	CC

not	RB

in	IN

group	NN

C	NN

(	NN

P	NN

>	JJR

0.05	CD

)	NN

The	DT

improvement	NN

of	IN

ROM	NN

was	VBD

significantly	RB

more	RBR

in	IN

group	NN

C	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.01	CD

)	NN

as	IN

compared	VBN

with	IN

that	IN

in	IN

group	NN

A	DT

or	CC

group	NN

B	NN

When	WRB

each	DT

group	NN

was	VBD

divided	VBN

into	IN

two	CD

additional	JJ

subgroups	NNS

based	VBN

on	IN

the	DT

initial	JJ

PI	NN

,	,

it	PRP

was	VBD

found	VBN

that	IN

ENS	NN

could	MD

reduce	VB

PI	NN

and	CC

increase	NN

PT	NN

significantly	RB

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

,	,

but	CC

did	VBD

not	RB

significantly	RB

(	NN

P	NN

>	JJR

0.05	CD

)	NN

improve	VB

ROM	NN

,	,

as	IN

compared	VBN

with	IN

the	DT

placebo	NN

group	NN

for	IN

both	DT

subgroups	NNS

EMS	NNP

could	MD

significantly	RB

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

improve	VB

ROM	NN

,	,

but	CC

not	RB

PT	NN

,	,

better	RB

than	IN

the	DT

placebo	NN

groups	NNS

,	,

for	IN

either	DT

subgroup	NN

It	PRP

could	MD

reduce	VB

PI	NN

significantly	RB

more	RBR

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

than	IN

placebo	NN

controls	NNS

only	RB

for	IN

the	DT

subgroup	NN

with	IN

mild	JJ

to	TO

moderate	JJ

pain	NN

,	,

but	CC

not	RB

with	IN

severe	JJ

pain	NN

For	IN

pain	NN

relief	NN

,	,

ENS	NN

was	VBD

significantly	RB

better	RB

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

than	IN

EMS	NNP

;	:

but	CC

for	IN

the	DT

improvement	NN

of	IN

ROM	NN

,	,

EMS	NNP

was	VBD

significantly	RB

better	RB

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

than	IN

ENS	NN

It	PRP

is	VBZ

concluded	VBD

that	IN

ENS	NN

is	VBZ

more	RBR

effective	JJ

for	IN

immediate	JJ

relief	NN

of	IN

myofascial	JJ

trigger	NN

point	NN

pain	NN

than	IN

EMS	NNP

,	,

and	CC

EMS	NNP

has	VBZ

a	DT

better	RB

effect	NN

on	IN

immediate	JJ

release	NN

of	IN

muscle	NN

tightness	NN

than	IN

ENS	NN

Because	IN

activity	NN

and	CC

regular	JJ

exercise	NN

are	VBP

important	JJ

factors	NNS

to	TO

maintain	VB

general	JJ

good	JJ

health	NN

in	IN

senior	JJ

citizens	NNS

,	,

we	PRP

investigated	VBN

whether	IN

senior	JJ

dancing	NN

has	VBZ

any	DT

effect	NN

on	IN

peripheral	JJ

or	CC

lumbar	NN

bone	NN

density	NN

We	PRP

performed	VBN

a	DT

prospective	JJ

study	NN

over	IN

a12-mo	NN

period	NN

on	IN

bone	NN

density	NN

at	IN

a	DT

spinal	JJ

and	CC

peripheral	JJ

measuring	VBG

site	NN

in	IN

28	CD

female	NN

senior	JJ

members	NNS

(	NN

mean	VB

age	NN

:	:

67	CD

+/-	CC

2	CD

yr	NN

)	NN

of	IN

a	DT

dancing	NN

group	NN

in	IN

Vienna	NNP

Lumbar	NNP

bone	NN

mineral	NN

density	NN

was	VBD

assessed	VBN

by	IN

quantitative	JJ

computed	VBN

tomography	NN

(	NN

qCT	NN

)	NN

and	CC

radial	JJ

bone	NN

density	NN

by	IN

single	JJ

photon	NN

absorptiometry	NN

of	IN

the	DT

distal	JJ

forearm	NN

The	DT

mean	VB

training	NN

time	NN

per	IN

week	NN

was	VBD

3.2	CD

+/-	CC

0.8	CD

h.	NN

In	IN

the	DT

entire	JJ

group	NN

of	IN

female	NN

dancers	NNS

,	,

no	DT

significant	JJ

effects	NNS

of	IN

dancing	NN

on	IN

radial	JJ

or	CC

lumbar	NN

bone	NN

density	NN

could	MD

be	VB

observed	VBN

Linear	JJ

regression	NN

analysis	NN

showed	VBD

that	IN

the	DT

lower	JJR

the	DT

qCT	NN

at	IN

the	DT

beginning	VBG

of	IN

the	DT

observation	NN

period	NN

,	,

the	DT

higher	JJR

was	VBD

the	DT

percentage	NN

increase	NN

of	IN

spinal	JJ

qCT	NN

in	IN

the	DT

entire	JJ

group	NN

during	IN

12	CD

mo	NN

of	IN

dancing	NN

(	NN

r	NN

=	JJ

0.52	CD

,	,

P	NN

&	CC

#	#

60	CD

;	:

0.0001	CD

)	NN

For	IN

additional	JJ

evaluation	NN

,	,

females	NNS

were	VBD

divided	VBN

into	IN

two	CD

subgroups	NNS

,	,

osteoporotic	JJ

or	CC

nonosteoporotic	JJ

,	,

based	VBN

on	IN

x-rays	NNPS

and	CC

lumbar	NN

bone	NN

mineral	NN

density	NN

(	NN

BMD	NN

)	NN

as	IN

measured	VBN

by	IN

qCT	NN

The	DT

group	NN

classified	VBN

as	IN

dancers	NNS

with	IN

osteoporosis	NN

(	NN

group	NN

I	PRP

)	NN

showed	VBD

a	DT

significant	JJ

increase	NN

in	IN

lumbar	NN

bone	NN

density	NN

,	,

whereas	IN

in	IN

the	DT

group	NN

of	IN

dancers	NNS

without	IN

signs	NNS

of	IN

osteoporosis	NN

(	NN

group	NN

II	NNP

)	NN

,	,

BMD	NN

remained	VBD

unchanged	JJ

Additionally	RB

,	,

radial	JJ

bone	NN

density	NN

did	VBD

not	RB

show	NN

any	DT

changes	NNS

in	IN

either	DT

group	NN

Group	NNP

I	PRP

showed	VBD

a	DT

significant	JJ

correlation	NN

between	IN

basal	JJ

spinal	JJ

BMD	NN

and	CC

the	DT

percentage	NN

change	NN

of	IN

BMD	NN

during	IN

the	DT

observation	NN

period	NN

(	NN

r	NN

=	JJ

0.7	CD

,	,

P	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

Changes	NNS

of	IN

the	DT

biochemical	JJ

parameters	NNS

were	VBD

observed	VBN

in	IN

the	DT

bone-specific	JJ

isoenzyme	NN

of	IN

alkaline	NN

phosphatase	NN

,	,

a	DT

marker	NN

of	IN

osteoblastic	JJ

activity	NN

,	,

in	IN

group	NN

I	PRP

giving	VBG

additional	JJ

evidence	NN

of	IN

increased	VBN

bone	NN

formation	NN

OBJECTIVES	NNS

:	:

To	TO

estimate	NN

the	DT

prevalence	NN

of	IN

Chlamydia	NN

trachomatis	NN

in	IN

asymptomatic	JJ

women	NNS

attending	VBG

general	JJ

practice	NN

:	:

to	TO

assess	VB

the	DT

potential	NN

of	IN

the	DT

ligase	NN

chain	NN

reaction	NN

as	IN

a	DT

screening	NN

tool	NN

;	:

and	CC

to	TO

evaluate	VB

selective	JJ

screening	NN

criteria	NNS

DESIGN	NN

:	:

Cross	NN

sectional	JJ

survey	NN

SETTING	VBG

:	:

Four	CD

general	JJ

practices	NNS

in	IN

northeast	RB

London	NNP

SUBJECTS	NNS

:	:

890	CD

women	NNS

aged	JJ

18-35	CD

years	NNS

attending	VBG

general	JJ

practice	NN

for	IN

a	DT

cervical	JJ

smear	NN

or	CC

a	DT

``	``

young	JJ

well	RB

woman	NN

''	''

check	NN

between	IN

October	NNP

1994	CD

and	CC

January	NNP

1996	CD

The	DT

women	NNS

were	VBD

tested	VBN

for	IN

C	NN

trachomatis	NN

with	IN

confirmed	VBN

enzyme	NN

immunoassay	NN

(	NN

endocervical	JJ

specimens	NNS

)	NN

and	CC

ligase	NN

chain	NN

reaction	NN

assay	NN

on	IN

urine	NN

specimens	NNS

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

Prevalence	NN

of	IN

C	NN

trachomatis	NN

infection	NN

in	IN

women	NNS

aged	JJ

18-35	CD

on	IN

the	DT

basis	NN

of	IN

each	DT

test	NN

;	:

sensitivity	NN

and	CC

specificity	NN

of	IN

both	DT

tests	NNS

in	IN

this	DT

population	NN

RESULTS	NNS

:	:

Prevalence	NN

of	IN

confirmed	VBN

infection	NN

was	VBD

2.6	CD

%	NN

(	NN

95	CD

%	NN

confidence	NN

interval	NN

1.6	CD

%	NN

to	TO

3.6	CD

%	NN

)	NN

in	IN

all	DT

women	NNS

Prevalence	NN

on	IN

the	DT

basis	NN

of	IN

enzyme	NN

immunoassay	NN

was	VBD

1.6	CD

%	NN

(	NN

0.8	CD

%	NN

to	TO

2.7	CD

%	NN

)	NN

,	,

with	IN

a	DT

sensitivity	NN

of	IN

60	CD

%	NN

and	CC

a	DT

specificity	NN

of	IN

100	CD

%	NN

Prevalence	NN

on	IN

the	DT

basis	NN

of	IN

ligase	NN

chain	NN

reaction	NN

was	VBD

2.5	CD

%	NN

(	NN

1.5	CD

%	NN

to	TO

3.9	CD

%	NN

)	NN

,	,

with	IN

90	CD

%	NN

sensitivity	NN

and	CC

99.8	CD

%	NN

specificity	NN

Screening	VBG

all	DT

women	NNS

aged	JJ

&	CC

#	#

60	CD

;	:

or	CC

=	JJ

25	CD

and	CC

all	DT

women	NNS

who	WP

had	VBD

had	VBD

two	CD

or	CC

more	RBR

partners	NNS

in	IN

the	DT

past	IN

year	NN

would	MD

have	VB

detected	VBN

87	CD

%	NN

(	NN

20/23	CD

)	NN

of	IN

infections	NNS

CONCLUSION	NN

:	:

Ligase	NN

chain	NN

reaction	NN

on	IN

urine	NN

samples	NNS

performs	VBZ

at	IN

least	JJS

as	IN

well	RB

as	IN

enzyme	NN

immunoassay	NN

on	IN

cervical	JJ

specimens	NNS

in	IN

this	DT

low	JJ

prevalence	NN

population	NN

It	PRP

offers	NNS

potential	NN

as	IN

a	DT

non-invasive	JJ

screening	NN

tool	NN

A	DT

simple	JJ

selective	JJ

screening	NN

strategy	NN

might	MD

be	VB

appropriate	JJ

and	CC

would	MD

be	VB

able	JJ

to	TO

detect	VB

most	RBS

cases	NNS

of	IN

infection	NN

However	RB

,	,

a	DT

rigorous	JJ

economic	JJ

evaluation	NN

of	IN

possible	JJ

screening	NN

strategies	NNS

is	VBZ

needed	VBN

first	RB

Recently	RB

,	,

many	JJ

advances	NNS

have	VB

been	VBN

made	VBN

in	IN

the	DT

study	NN

of	IN

sexual	JJ

differentiation	NN

,	,

including	VBG

the	DT

discoveries	NNS

of	IN

the	DT

gene	NN

for	IN

antim1/4llerian	JJ

hormone	NN

as	IN

well	RB

as	IN

the	DT

gene	NN

for	IN

its	PRP$

receptor	NN

However	RB

,	,

the	DT

etiology	NN

of	IN

the	DT

clinical	JJ

syndrome	NN

of	IN

m1/4llerian	NN

agenesis	NN

remains	NNS

elusive	JJ

We	PRP

hypothesize	VB

that	IN

activating	VBG

mutations	NNS

of	IN

either	DT

the	DT

antim1/4llerian	JJ

hormone	NN

gene	NN

or	CC

its	PRP$

receptor	NN

gene	NN

may	MD

cause	NN

m1/4llerian	NN

duct	NN

regression	NN

in	IN

a	DT

genetic	JJ

female	NN

during	IN

embryogenesis	NN

This	DT

clinical	JJ

commentary	NN

discusses	VBZ

the	DT

current	JJ

management	NN

of	IN

the	DT

syndrome	NN

including	VBG

the	DT

Abbe-McIndoe	NNP

procedure	NN

,	,

the	DT

most	RBS

commonly	RB

used	VBN

method	NN

of	IN

surgical	JJ

correction	NN

,	,

and	CC

the	DT

Frank	NNP

vaginal	JJ

dilation	NN

method	NN

,	,

the	DT

most	RBS

common	JJ

nonsurgical	JJ

method	NN

of	IN

correction	NN

OBJECTIVES	NNS

:	:

Obesity	NN

is	VBZ

an	DT

important	JJ

clinical	JJ

problem	NN

,	,

and	CC

the	DT

use	NN

of	IN

dexfenfluramine	NN

hydrochloride	NN

for	IN

weight	NN

reduction	NN

has	VBZ

been	VBN

widely	RB

publicized	VBN

since	IN

its	PRP$

approval	NN

by	IN

the	DT

Food	NNP

and	CC

Drug	NN

Administration	NN

However	RB

,	,

animal	NN

and	CC

human	JJ

studies	NNS

have	VB

demonstrated	VBN

toxic	JJ

effects	NNS

of	IN

fenfluramines	NNS

that	IN

clinicians	NNS

should	MD

be	VB

aware	JJ

of	IN

when	WRB

considering	VBG

prescribing	VBG

the	DT

drugs	NNS

Our	PRP$

purpose	NN

was	VBD

to	TO

systematically	RB

review	NN

data	NNS

on	IN

brain	NN

serotonin	NN

neurotoxicity	NN

in	IN

animals	NNS

treated	VBN

with	IN

fenfluramines	NNS

and	CC

the	DT

evidence	NN

linking	VBG

fenfluramines	NNS

to	TO

primary	JJ

pulmonary	JJ

hypertension	NN

(	NN

PPH	NN

)	NN

DATA	NNP

SOURCES	NNS

:	:

Archival	JJ

articles	NNS

and	CC

reviews	NNS

identified	VBN

through	IN

a	DT

computerized	NN

search	NN

of	IN

MEDLINE	NN

from	IN

1966	CD

to	TO

April	NNP

1997	CD

using	VBG

``	``

fenfluramine	NN

(	NN

s	NNS

)	NN

,	,

''	''

``	``

serotonin	NN

,	,

''	''

``	``

neurotoxicity	NN

,	,

''	''

``	``

behavior	NN

,	,

''	''

``	``

anorexigens	NNS

,	,

''	''

``	``

weight	NN

loss	NN

,	,

''	''

and	CC

``	``

primary	JJ

pulmonary	JJ

hypertension	NN

''	''

as	IN

index	NN

terms	NNS

STUDY	NN

SELECTION	NN

:	:

Reports	NNS

dealing	VBG

with	IN

long-term	JJ

effects	NNS

of	IN

fenfluramines	NNS

on	IN

brain	NN

serotonin	NN

neurons	NNS

,	,

body	NN

weight	NN

,	,

and	CC

pulmonary	JJ

function	NN

in	IN

animals	NNS

and	CC

humans	NNS

DATA	NNP

EXTRACTION	NN

:	:

Reports	NNS

were	VBD

reviewed	VBN

by	IN

individuals	NNS

with	IN

expertise	NN

in	IN

serotonin	NN

neurobiology	NN

,	,

neurotoxicity	NN

,	,

neuropsychiatry	NN

,	,

and	CC

pulmonary	JJ

medicine	NN

and	CC

evaluated	VBN

for	IN

appropriateness	NN

for	IN

inclusion	NN

in	IN

this	DT

review	NN

DATA	NNP

SYNTHESIS	NN

:	:

Fenfluramines	NNS

cause	NN

dose-related	JJ

,	,

long-lasting	JJ

reductions	NNS

in	IN

serotonin	NN

axonal	IN

markers	NNS

in	IN

all	DT

the	DT

animal	NN

species	NNS

tested	VBN

and	CC

with	IN

all	DT

the	DT

routes	NNS

of	IN

drug	NN

administration	NN

used	VBN

Doses	NNS

of	IN

fenfluramines	NNS

that	IN

produce	VB

signs	NNS

of	IN

brain	NN

serotonin	NN

neurotoxicity	NN

in	IN

animals	NNS

are	VBP

on	IN

the	DT

same	JJ

order	NN

as	IN

those	DT

used	VBN

to	TO

treat	NN

humans	NNS

for	IN

weight	NN

loss	NN

when	WRB

one	CD

takes	VBZ

into	IN

account	NN

known	VBN

relations	NNS

between	IN

body	NN

mass	NN

and	CC

drug	NN

clearance	NN

However	RB

,	,

no	DT

human	JJ

studies	NNS

have	VB

been	VBN

conducted	VBN

,	,

and	CC

the	DT

pathological	JJ

and	CC

clinical	JJ

potential	NN

for	IN

neurotoxicity	NN

in	IN

humans	NNS

is	VBZ

unknown	JJ

Appetite	NN

suppressants-most	JJ

commonly	RB

fenfluramines	NNS

-increase	NN

the	DT

risk	NN

of	IN

developing	VBG

PPH	NN

(	NN

odds	NNS

ratio	NN

,	,

6.3	CD

)	NN

,	,

particularly	RB

when	WRB

used	VBN

for	IN

more	RBR

than	IN

3	CD

months	NNS

(	NN

odds	NNS

ratio	NN

,	,

>	JJR

20	CD

)	NN

CONCLUSIONS	NNS

:	:

Fenfluramine	NN

and	CC

dexfenfluramine	NN

have	VB

been	VBN

demonstrated	VBN

to	TO

damage	NN

brain	NN

serotonin	NN

neurons	NNS

in	IN

animal	NN

studies	NNS

It	PRP

is	VBZ

not	RB

known	VBN

if	IN

such	JJ

damage	NN

occurs	VBZ

in	IN

humans	NNS

or	CC

if	IN

there	RB

are	VBP

clinical	JJ

consequences	NNS

Use	NN

of	IN

fenfluramines	NNS

is	VBZ

associated	VBN

with	IN

an	DT

increased	VBN

risk	NN

of	IN

PPH	NN

Future	JJ

studies	NNS

should	MD

address	NN

the	DT

long-term	JJ

consequences	NNS

of	IN

prolonged	JJ

use	NN

of	IN

fenfluramines	NNS

Moxonidine	NN

(	NN

Physiotens-Solvay	NNP

)	NN

was	VBD

introduced	VBN

last	JJ

year	NN

as	IN

the	DT

first	RB

of	IN

a	DT

new	JJ

class	NN

of	IN

centrally-acting	JJ

antihypertensive	JJ

agents	NNS

,	,

the	DT

selective	JJ

imidazoline	NN

receptor	NN

agonists	NNS

The	DT

manufacturer	NN

claims	NNS

that	IN

moxonidine	NN

``	``

accurately	RB

targets	NNS

imidazoline	NN

receptors	NNS

at	IN

the	DT

cardiovascular	JJ

control	NN

centre	NN

in	IN

the	DT

brainstem	NN

''	''

and	CC

is	VBZ

``	``

as	IN

effective	JJ

as	IN

current	JJ

first-line	NN

therapies	NNS

for	IN

essential	JJ

hypertension	NN

``	``

Other	JJ

claims	NNS

suggest	VB

that	IN

it	PRP

causes	NNS

fewer	JJR

unwanted	JJ

effects	NNS

than	IN

older	JJR

centrally-acting	JJ

antihypertensive	JJ

drugs	NNS

such	JJ

as	IN

clonidine	NN

and	CC

methyldopa	NN

Is	VBZ

moxonidine	NN

a	DT

useful	JJ

addition	NN

to	TO

the	DT

growing	VBG

number	NN

of	IN

antihypertensives	NNS

on	IN

the	DT

market	NN

?	.

This	DT

article	NN

discusses	VBZ

dental	JJ

anxiety	NN

and	CC

phobia	NN

The	DT

author	NN

presents	NNS

background	NN

information	NN

,	,

including	VBG

incidence	NN

and	CC

etiology	NN

A	DT

discussion	NN

of	IN

evaluative	JJ

techniques	NNS

for	IN

assessing	VBG

anxiety	NN

levels	NNS

follows	VBZ

Examination	NN

and	CC

treatment	NN

planning	VBG

are	VBP

considered	VBN

in	IN

relation	NN

to	TO

this	DT

patient	NN

's	POS

special	JJ

needs	NNS

The	DT

article	NN

stresses	NNS

behavioral	JJ

treatment	NN

modalities	NNS

that	IN

eliminate	VB

the	DT

debilitating	VBG

phobia	NN

In	IN

closing	VBG

,	,

the	DT

author	NN

presents	NNS

practical	JJ

information	NN

regarding	VBG

prevention	NN

of	IN

dental	JJ

phobia	NN

and	CC

the	DT

merits	NNS

of	IN

incorporating	VBG

this	DT

type	NN

of	IN

patient	NN

into	IN

a	DT

dental	JJ

practice	NN

In	IN

order	NN

to	TO

evaluate	VB

the	DT

applicability	NN

of	IN

anthelminthic	JJ

treatment	NN

of	IN

wild	JJ

foxes	NNS

(	NN

Vulpes	NNP

vulpes	NNS

)	NN

to	TO

limit	NN

their	PRP$

infection	NN

with	IN

Echinococcus	NN

multilocularis	NNS

,	,

bait	NN

pellets	NNS

,	,

each	DT

containing	VBG

50	CD

mg	NN

praziquantel	NN

,	,

were	VBD

repeatedly	RB

distributed	VBN

in	IN

an	DT

area	NN

of	IN

566	CD

km2	NN

where	WRB

many	JJ

foxes	NNS

are	VBP

infected	JJ

,	,

in	IN

southern	JJ

Germany	NNP

After	IN

six	CD

baiting	VBG

campaigns	NNS

(	NN

15-20	CD

baits/km2	NN

)	NN

over	IN

a	DT

period	NN

of	IN

14	CD

months	NNS

,	,

the	DT

prevalence	NN

of	IN

the	DT

cestode	NN

in	IN

foxes	NNS

,	,

initially	RB

32	CD

%	NN

,	,

had	VBD

fallen	VBN

to	TO

4	CD

%	NN

The	DT

effect	NN

was	VBD

most	RBS

pronounced	JJ

in	IN

the	DT

central	JJ

part	NN

of	IN

the	DT

treated	VBN

area	NN

,	,

where	WRB

no	DT

positive	JJ

fox	NN

was	VBD

found	VBN

in	IN

the	DT

2	CD

months	NNS

before	IN

the	DT

end	NN

of	IN

the	DT

trial	NN

The	DT

study	NN

was	VBD

controlled	VBN

for	IN

other	JJ

factors	NNS

that	IN

could	MD

influence	NN

the	DT

parasite	NN

's	POS

prevalence	NN

,	,

such	JJ

as	IN

the	DT

availability	NN

of	IN

intermediate	JJ

hosts	NNS

While	IN

the	DT

potential	NN

of	IN

this	DT

baiting	VBG

method	NN

to	TO

remove	VB

E	NN

multilocularis	NNS

from	IN

wild	JJ

hosts	NNS

has	VBZ

been	VBN

demonstrated	VBN

,	,

the	DT

question	NN

of	IN

its	PRP$

long-term	JJ

efficacy	NN

and	CC

other	JJ

unresolved	JJ

problems	NNS

have	VB

to	TO

be	VB

addressed	VBD

by	IN

consecutive	JJ

studies	NNS

before	IN

routine	JJ

application	NN

can	MD

be	VB

recommended	VBN

In	IN

patients	NNS

with	IN

chronic	JJ

myeloid	JJ

leukemia	NN

(	NN

CML	NN

)	NN

,	,

the	DT

neoplastic	JJ

(	NN

BCR-ABL+	JJ

)	NN

progenitor	NN

cells	NNS

are	VBP

characterized	VBN

by	IN

an	DT

increased	VBN

proliferative	JJ

activity	NN

Whether	IN

these	DT

cells	NNS

are	VBP

also	RB

resistant	JJ

to	TO

apoptosis	NN

and	CC

if	IN

so	RB

,	,

under	IN

what	WDT

conditions	NNS

remains	NNS

controversial	JJ

We	PRP

now	RB

show	NN

that	IN

highly	RB

purified	VBN

populations	NNS

of	IN

very	RB

primitive	JJ

neoplastic	JJ

progenitor	NN

cells	NNS

obtained	VBN

directly	RB

from	IN

CML	NN

patients	NNS

survive	VB

and	CC

proliferate	VB

in	IN

vitro	NN

for	IN

several	JJ

weeks	NNS

in	IN

the	DT

absence	NN

of	IN

any	DT

added	VBN

growth	NN

factors	NNS

(	NN

except	IN

insulin	NN

)	NN

In	IN

contrast	NN

,	,

purified	VBN

primary	JJ

normal	JJ

progenitors	NNS

maintained	VBN

under	IN

the	DT

same	JJ

conditions	NNS

die	VB

rapidly	RB

Nevertheless	RB

,	,

both	DT

primary	JJ

CML	NN

cells	NNS

and	CC

BCR-ABL+	JJ

BAF3	NN

cells	NNS

show	NN

the	DT

same	JJ

dose-dependent	JJ

sensitivity	NN

to	TO

TNF-alpha	NN

or	CC

ceramide-induced	JJ

apoptosis	NN

as	IN

their	PRP$

respective	JJ

normal	JJ

counterparts	NNS

In	IN

fact	NN

,	,

time	NN

course	NN

studies	NNS

demonstrated	VBN

an	DT

even	RB

faster	RBR

onset	NN

of	IN

apoptosis	NN

in	IN

ceramide-treated	JJ

BCR-ABL+	JJ

BAF3	NN

cells	NNS

as	IN

compared	VBN

to	TO

normal	JJ

controls	NNS

BCR-ABL+	JJ

cells	NNS

treated	VBN

with	IN

ceramide	NN

also	RB

showed	VBD

a	DT

rapid	JJ

and	CC

sequential	JJ

increase	NN

in	IN

the	DT

tyrosine	NN

phosphorylation	NN

of	IN

p210	NN

(	NN

BCR-ABL	NN

)	NN

,	,

p46-56SHC	NN

and	CC

p120Cbl	NN

These	DT

findings	NNS

suggest	VB

growth	NN

factor	NN

deprivation	NN

and	CC

treatment	NN

with	IN

TNF-alpha	NN

or	CC

ceramide	NN

trigger	NN

different	JJ

initial	JJ

events	NNS

both	DT

of	IN

which	WDT

can	MD

lead	NN

to	TO

apoptosis	NN

in	IN

factor-dependent	JJ

hematopoietic	JJ

cells	NNS

However	RB

,	,

in	IN

the	DT

first	RB

case	NN

,	,

activation	NN

of	IN

apoptosis	NN

is	VBZ

blocked	VBN

by	IN

the	DT

basal	JJ

activity	NN

of	IN

p210	NN

(	NN

BCR-ABL	NN

)	NN

,	,

whereas	IN

in	IN

the	DT

second	JJ

,	,

the	DT

presence	NN

of	IN

p210	NN

(	NN

BCR-ABL	NN

)	NN

appears	VBZ

to	TO

accelerate	VB

the	DT

onset	NN

of	IN

apoptosis	NN

by	IN

a	DT

mechanism	NN

that	IN

may	MD

involve	VB

an	DT

activation	NN

of	IN

its	PRP$

kinase	NN

function	NN

Clinically	RB

,	,

the	DT

hallmark	NN

of	IN

the	DT

human	JJ

amnesic	JJ

syndrome	NN

is	VBZ

an	DT

impaired	JJ

ability	NN

to	TO

consciously	RB

recollect	NN

or	CC

remember	VB

daily	RB

events	NNS

If	IN

the	DT

medial	JJ

region	NN

of	IN

the	DT

temporal	JJ

lobes	NNS

,	,

including	VBG

the	DT

hippocampus	NN

and	CC

related	JJ

structures	NNS

,	,

is	VBZ

critical	JJ

for	IN

establishing	VBG

these	DT

new	JJ

memories	NNS

,	,

then	RB

this	DT

brain	NN

region	NN

should	MD

be	VB

active	JJ

whenever	WRB

events	NNS

are	VBP

experienced	JJ

,	,

regardless	RB

of	IN

whether	IN

subjects	NNS

are	VBP

asked	VBD

explicitly	RB

to	TO

learn	VB

and	CC

remember	VB

Here	RB

we	PRP

show	NN

that	IN

the	DT

medial	JJ

temporal	JJ

region	NN

is	VBZ

active	JJ

during	IN

encoding	VBG

and	CC

that	IN

the	DT

hemisphere	NN

activated	VBN

and	CC

the	DT

amount	NN

of	IN

activation	NN

depend	VB

on	IN

the	DT

type	NN

of	IN

stimulus	NN

presented	VBN

(	NN

objects	NNS

or	CC

words	NNS

)	NN

,	,

whether	IN

the	DT

stimulus	NN

can	MD

be	VB

encoded	VBN

for	IN

meaning	VBG

(	NN

real	RB

objects	NNS

and	CC

words	NNS

versus	CC

nonsense	NN

objects	NNS

and	CC

words	NNS

)	NN

,	,

and	CC

task	NN

experience	NN

(	NN

first	RB

versus	CC

the	DT

second	JJ

time	NN

a	DT

task	NN

is	VBZ

performed	VBN

)	NN

These	DT

findings	NNS

demonstrate	VB

that	IN

the	DT

medial	JJ

temporal	JJ

lobe	NN

memory	NN

system	NN

is	VBZ

engaged	VBN

automatically	RB

when	WRB

we	PRP

attend	VB

to	TO

a	DT

perceptual	JJ

event	NN

and	CC

that	IN

the	DT

location	NN

and	CC

amount	NN

of	IN

activation	NN

depend	VB

on	IN

stimulus	NN

characteristics	NNS

(	NN

physical	JJ

form	NN

,	,

meaning	VBG

)	NN

and	CC

experience	NN

The	DT

involvement	NN

of	IN

structures	NNS

in	IN

the	DT

medial	JJ

temporal	JJ

lobe	NN

during	IN

the	DT

encoding	VBG

of	IN

visual	JJ

associations	NNS

was	VBD

studied	VBN

with	IN

functional	JJ

magnetic	JJ

resonance	NN

imaging	NN

In	IN

11	CD

out	IN

of	IN

12	CD

normal	JJ

healthy	JJ

volunteers	NNS

this	DT

task	NN

resulted	VBD

in	IN

activation	NN

in	IN

posterior	NN

portions	NNS

of	IN

the	DT

parahippocampal	NN

region	NN

,	,

close	RB

to	TO

the	DT

collateral	NN

sulcus	NN

In	IN

seven	CD

subjects	NNS

activation	NN

was	VBD

encountered	VBN

in	IN

the	DT

hippocampal	NN

formation	NN

The	DT

visual	JJ

association	NN

task	NN

as	IN

adapted	VBN

for	IN

this	DT

study	NN

may	MD

provide	VB

a	DT

sensitive	JJ

measure	NN

to	TO

study	NN

anterograde	NN

amnesia	NN

prevalent	JJ

in	IN

Alzheimer	NN

's	POS

disease	NN

Therefore	RB

,	,

the	DT

present	JJ

paradigm	NN

enables	VBZ

the	DT

study	NN

of	IN

individual	JJ

changes	NNS

in	IN

learning	VBG

and	CC

memory	NN

capacities	NNS

over	IN

time	NN

Altered	JJ

calcium	NN

(	NN

Ca2+	NN

)	NN

homeostasis	NN

is	VBZ

thought	NN

to	TO

play	NN

a	DT

key	NN

role	NN

in	IN

aging	VBG

and	CC

neuropathology	NN

resulting	VBG

in	IN

memory	NN

deficits	NNS

Several	JJ

forms	NNS

of	IN

hippocampal	NN

synaptic	JJ

plasticity	NN

are	VBP

dependent	JJ

on	IN

Ca2+	NN

,	,

providing	VBG

a	DT

potential	NN

link	NN

between	IN

altered	JJ

Ca2+	NN

homeostasis	NN

and	CC

memory	NN

deficits	NNS

associated	VBN

with	IN

aging	VBG

The	DT

current	JJ

study	NN

reviews	NNS

evidence	NN

for	IN

Ca2+	NN

dysregulation	NN

during	IN

aging	VBG

which	WDT

could	MD

interact	NN

with	IN

Ca	NN

(	NN

2+	JJ

)	NN

-dependent	JJ

synaptic	JJ

plasticity	NN

The	DT

authors	NNS

suggest	VB

that	IN

changes	NNS

in	IN

Ca2+	NN

regulation	NN

could	MD

adjust	VBP

the	DT

thresholds	NNS

for	IN

synaptic	JJ

modification	NN

,	,

favoring	VBG

processes	NNS

for	IN

depression	NN

of	IN

synaptic	JJ

strength	NN

during	IN

aging	VBG

Transiently	RB

evolked	VBN

otoacoustic	JJ

emissions	NNS

(	NN

TEOAE	NN

)	NN

have	VB

been	VBN

reported	VBN

in	IN

several	JJ

studies	NNS

as	IN

absent	JJ

in	IN

a	DT

small	JJ

minority	NN

of	IN

normal	JJ

ears	NNS

Other	JJ

studies	NNS

have	VB

reported	VBN

TEOAEs	NNS

in	IN

all	DT

normal	JJ

ears	NNS

Differences	NNS

between	IN

studies	NNS

may	MD

arise	VB

directly	RB

from	IN

criteria	NNS

for	IN

TEOAE	NN

identification	NN

,	,

criteria	NNS

for	IN

selection	NN

of	IN

normals	NNS

,	,

or	CC

statistically	RB

due	JJ

to	TO

limited	JJ

sample	NN

sizes	NNS

In	IN

order	NN

to	TO

understand	VB

and	CC

model	NN

cochlear	NN

processes	NNS

involved	VBN

in	IN

TEOAE	NN

generation	NN

,	,

it	PRP

needs	NNS

to	TO

be	VB

known	VBN

whether	IN

the	DT

presence	NN

of	IN

normal	JJ

hearing	NN

leads	NNS

automatically	RB

to	TO

generation	NN

of	IN

TEOAEs	NNS

The	DT

present	JJ

study	NN

set	NN

out	IN

to	TO

establish	VB

in	IN

a	DT

large	JJ

sample	NN

if	IN

any	DT

ears	NNS

could	MD

be	VB

found	VBN

that	IN

lacked	VBD

TEOAEs	NNS

despite	IN

normal	JJ

hearing	NN

threshold	NN

levels	NNS

(	NN

HTL	NN

)	NN

A	DT

total	NN

of	IN

397	CD

ears	NNS

from	IN

highly	RB

cooperative	JJ

adult	JJ

subjects	NNS

were	VBD

examined	VBN

under	IN

laboratory	NN

conditions	NNS

Using	VBG

cross	NN

correlation	NN

between	IN

replicate	VB

nonlinear	JJ

waveforms	NNS

as	IN

the	DT

criterion	NN

,	,

TEOAEs	NNS

were	VBD

present	JJ

in	IN

99.2	CD

%	NN

of	IN

the	DT

sample	NN

(	NN

lower	JJR

CI	NN

98.1	CD

%	NN

)	NN

However	RB

,	,

careful	JJ

visual	JJ

assessment	NN

of	IN

the	DT

recorded	VBN

waveforms	NNS

for	IN

the	DT

remaining	VBG

ears	NNS

did	VBD

not	RB

unequivocally	RB

show	NN

absence	NN

of	IN

TEOAE	NN

characteristics	NNS

in	IN

any	DT

ear	NN

with	IN

normal	JJ

HTLs	NNS

While	IN

TEOAE	NN

strength	NN

varies	VBZ

widely	RB

among	IN

ears	NNS

,	,

no	DT

clear	JJ

evidence	NN

was	VBD

found	VBN

to	TO

show	NN

that	IN

TEOAEs	NNS

can	MD

be	VB

absent	JJ

when	WRB

HTLs	NNS

are	VBP

normal	JJ

In	IN

addition	NN

to	TO

a	DT

long	RB

form	NN

of	IN

591	CD

amino	NN

acids	NNS

(	NN

aa	NN

)	NN

,	,

two	CD

other	JJ

forms	NNS

of	IN

PRL	NN

receptor	NN

(	NN

PRLR	NN

)	NN

,	,

differing	VBG

in	IN

the	DT

length	NN

of	IN

their	PRP$

cytoplasmic	JJ

domains	NNS

,	,

have	VB

been	VBN

identified	VBN

in	IN

the	DT

rat	NN

The	DT

Nb2	NN

form	NN

,	,

lacking	VBG

198	CD

aa	NN

in	IN

the	DT

cytoplasmic	JJ

domain	NN

,	,

is	VBZ

able	JJ

to	TO

transmit	VB

a	DT

lactogenic	JJ

signal	NN

similar	JJ

to	TO

the	DT

long	RB

form	NN

,	,

whereas	IN

the	DT

short	RB

form	NN

of	IN

291	CD

aa	NN

is	VBZ

inactive	JJ

The	DT

ability	NN

of	IN

PRL	NN

to	TO

activate	VB

the	DT

promoter	NN

of	IN

the	DT

beta-casein	NN

gene	NN

or	CC

the	DT

lactogenic	JJ

hormone	NN

responsive	JJ

element	NN

fused	VBN

to	TO

the	DT

luciferase	NN

reporter	NN

was	VBD

assessed	VBN

in	IN

Chinese	JJ

hamster	NN

ovary	NN

cells	NNS

or	CC

293	CD

fibroblasts	NNS

transiently	RB

transfected	VBN

with	IN

PRLR	NN

cDNAs	NNS

The	DT

function	NN

of	IN

the	DT

short	RB

form	NN

was	VBD

examined	VBN

after	IN

cotransfection	NN

of	IN

both	DT

the	DT

long	RB

and	CC

short	RB

forms	NNS

These	DT

results	NNS

clearly	RB

show	NN

that	IN

the	DT

short	RB

form	NN

acts	NNS

as	IN

a	DT

dominant	JJ

negative	JJ

inhibitor	NN

through	IN

the	DT

formation	NN

of	IN

inactive	JJ

heterodimers	NNS

,	,

resulting	VBG

in	IN

an	DT

inhibition	NN

of	IN

Janus	NN

kinase	NN

2	CD

(	NN

JAK2	NN

)	NN

activation	NN

The	DT

present	JJ

study	NN

also	RB

investigates	VBZ

the	DT

possible	JJ

participation	NN

of	IN

cytoplasmic	JJ

receptors	NNS

in	IN

the	DT

signal	NN

transduction	NN

pathway	NN

,	,

using	VBG

cotransfection	NN

experiments	NNS

and	CC

a	DT

new	JJ

approach	NN

that	IN

selectively	RB

determines	VBZ

the	DT

contribution	NN

of	IN

cytoplasmic	JJ

receptors	NNS

in	IN

the	DT

process	NN

of	IN

signal	NN

transduction	NN

We	PRP

cotransfected	VBN

Chinese	JJ

hamster	NN

ovary	NN

cells	NNS

with	IN

two	CD

cDNA	NN

constructs	NNS

:	:

a	DT

cytoplasmic	JJ

(	NN

soluble	JJ

)	NN

form	NN

of	IN

the	DT

receptor	NN

with	IN

a	DT

deleted	VBN

signal	NN

peptide	NN

(	NN

delta-19	NN

)	NN

,	,

which	WDT

is	VBZ

unable	JJ

to	TO

bind	NN

PRL	NN

,	,

and	CC

a	DT

functionally	RB

inactive	JJ

receptor	NN

mutant	NN

(	NN

lacking	VBG

box	NN

1	CD

)	NN

,	,

which	WDT

is	VBZ

anchored	VBN

in	IN

the	DT

plasma	NN

membrane	NN

and	CC

able	JJ

to	TO

bind	NN

PRL	NN

This	DT

approach	NN

has	VBZ

allowed	VBN

us	PRP

to	TO

show	NN

that	IN

delta-19	NN

,	,

lacking	VBG

expression	NN

at	IN

the	DT

plasma	NN

membrane	NN

,	,

can	MD

transduce	VB

the	DT

hormonal	JJ

message	NN

,	,

at	IN

least	JJS

to	TO

a	DT

limited	JJ

extent	NN

(	NN

up	RB

to	TO

30	CD

%	NN

of	IN

wild	JJ

type	NN

efficiency	NN

)	NN

,	,

providing	VBG

that	IN

association/activation	NN

occurs	VBZ

with	IN

a	DT

PRL-PRLR	NN

complex	NN

initiated	VBN

at	IN

the	DT

cell	NN

surface	NN

level	NN

;	:

box	NN

1	CD

of	IN

the	DT

cytoplasmic	JJ

form	NN

is	VBZ

necessary	JJ

to	TO

rescue	NN

this	DT

partial	JJ

transcriptional	JJ

activity	NN

of	IN

the	DT

inactive	JJ

mutant	NN

This	DT

partial	JJ

recovery	NN

is	VBZ

also	RB

parallel	NN

to	TO

the	DT

partial	JJ

activation	NN

of	IN

JAK2	NN

,	,

indicating	VBG

that	IN

the	DT

signal	NN

transduction	NN

pathway	NN

implicated	VBN

JAK2	NN

Our	PRP$

results	NNS

provide	VB

evidence	NN

that	IN

heterodimerization	NN

of	IN

receptors	NNS

can	MD

be	VB

implicated	VBN

either	DT

in	IN

the	DT

positive	JJ

or	CC

in	IN

negative	JJ

activation	NN

of	IN

gene	NN

transcription	NN

BACKGROUND	NN

:	:

Inadequate	JJ

dietary	JJ

intake	NN

of	IN

calcium	NN

and	CC

vitamin	NN

D	NN

may	MD

contribute	VB

to	TO

the	DT

high	JJ

prevalence	NN

of	IN

osteoporosis	NN

among	IN

older	JJR

persons	NNS

METHODS	NNS

:	:

We	PRP

studied	VBN

the	DT

effects	NNS

of	IN

three	CD

years	NNS

of	IN

dietary	JJ

supplementation	NN

with	IN

calcium	NN

and	CC

vitamin	NN

D	NN

on	IN

bone	NN

mineral	NN

density	NN

,	,

biochemical	JJ

measures	NNS

of	IN

bone	NN

metabolism	NN

,	,

and	CC

the	DT

incidence	NN

of	IN

nonvertebral	JJ

fractures	NNS

in	IN

176	CD

men	NNS

and	CC

213	CD

women	NNS

65	CD

years	NNS

of	IN

age	NN

or	CC

older	JJR

who	WP

were	VBD

living	VBG

at	IN

home	NN

They	PRP

received	VBN

either	DT

500	CD

mg	NN

of	IN

calcium	NN

plus	CC

700	CD

IU	NN

of	IN

vitamin	NN

D3	NN

(	NN

cholecalciferol	NN

)	NN

per	IN

day	NN

or	CC

placebo	NN

Bone	NN

mineral	NN

density	NN

was	VBD

measured	VBN

by	IN

dual-energy	NN

x-ray	NN

absorptiometry	NN

,	,

blood	NN

and	CC

urine	NN

were	VBD

analyzed	VBN

every	DT

six	CD

months	NNS

,	,

and	CC

cases	NNS

of	IN

nonvertebral	JJ

fracture	NN

were	VBD

ascertained	VBN

by	IN

means	NNS

of	IN

interviews	NNS

and	CC

verified	VBN

with	IN

use	NN

of	IN

hospital	NN

records	NNS

RESULTS	NNS

:	:

The	DT

mean	VB

(	NN

+/-SD	NN

)	NN

changes	NNS

in	IN

bone	NN

mineral	NN

density	NN

in	IN

the	DT

calcium-vitamin	JJ

D	NN

and	CC

placebo	NN

groups	NNS

were	VBD

as	IN

follows	VBZ

:	:

femoral	JJ

neck	NN

,	,

+0.50+/-4.80	NN

and	CC

-0.70+/-5.03	CD

percent	NN

,	,

respectively	RB

(	NN

P=0.02	NN

)	NN

;	:

spine	NN

,	,

+2.12+/-4.06	CD

and	CC

+1.22+/-4.25	CD

percent	NN

(	NN

P=0.04	NN

)	NN

;	:

and	CC

total	NN

body	NN

,	,

+0.06+/-1.83	NN

and	CC

-1.09+/-1.71	CD

percent	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

The	DT

difference	NN

between	IN

the	DT

calcium-vitamin	JJ

D	NN

and	CC

placebo	NN

groups	NNS

was	VBD

significant	JJ

at	IN

all	DT

skeletal	JJ

sites	NNS

after	IN

one	CD

year	NN

,	,

but	CC

it	PRP

was	VBD

significant	JJ

only	RB

for	IN

total-body	NN

bone	NN

mineral	NN

density	NN

in	IN

the	DT

second	JJ

and	CC

third	JJ

years	NNS

Of	IN

37	CD

subjects	NNS

who	WP

had	VBD

nonvertebral	JJ

fractures	NNS

,	,

26	CD

were	VBD

in	IN

the	DT

placebo	NN

group	NN

and	CC

11	CD

were	VBD

in	IN

the	DT

calcium-vitamin	JJ

D	NN

group	NN

(	NN

P=0.02	NN

)	NN

CONCLUSIONS	NNS

:	:

In	IN

men	NNS

and	CC

women	NNS

65	CD

years	NNS

of	IN

age	NN

or	CC

older	JJR

who	WP

are	VBP

living	VBG

in	IN

the	DT

community	NN

,	,

dietary	JJ

supplementation	NN

with	IN

calcium	NN

and	CC

vitamin	NN

D	NN

moderately	RB

reduced	VBN

bone	NN

loss	NN

measured	VBN

in	IN

the	DT

femoral	JJ

neck	NN

,	,

spine	NN

,	,

and	CC

total	NN

body	NN

over	IN

the	DT

three-year	JJ

study	NN

period	NN

and	CC

reduced	VBN

the	DT

incidence	NN

of	IN

nonvertebral	JJ

fractures	NNS

The	DT

sterilization	NN

and	CC

contaminated	VBN

waste	NN

disposal	NN

practices	NNS

in	IN

all	DT

14	CD

dental	JJ

clinics	NNS

operated	VBN

by	IN

the	DT

Southern	NNP

Sydney	NNP

Area	NN

Health	NNP

Service	NNP

were	VBD

surveyed	VBN

All	DT

of	IN

the	DT

clinics	NNS

used	VBN

autoclaves	NNS

for	IN

sterilization	NN

All	DT

hand	NN

instruments	NNS

,	,

handpieces	NNS

and	CC

triplex	IN

syringes	NNS

were	VBD

autoclaved	VBN

between	IN

patients	NNS

Chemical	NNP

disinfection	NN

solutions	NNS

were	VBD

used	VBN

in	IN

12	CD

of	IN

the	DT

14	CD

dental	JJ

clinics	NNS

,	,

mainly	RB

for	IN

surface	NN

decontamination	NN

Five	CD

dental	JJ

clinics	NNS

had	VBD

separate	JJ

storage	NN

areas	NNS

for	IN

contaminated	VBN

waste	NN

which	WDT

compiled	VBN

with	IN

contaminated	VBN

waste	NN

separation	NN

and	CC

disposal	NN

guidelines	NNS

The	DT

practice	NN

of	IN

recapping	VBG

needles	NNS

with	IN

fingers	NNS

and	CC

some	DT

inadequate	JJ

washing	VBG

facilities	NNS

are	VBP

areas	NNS

that	IN

require	VB

particular	JJ

attention	NN

Safety	NN

and	CC

efficacy	NN

are	VBP

crucial	JJ

but	CC

separate	JJ

issues	NNS

for	IN

vitamin	NN

and	CC

mineral	NN

supplements	NNS

Misinterpretation	NNP

of	IN

``	``

safe	JJ

and	CC

adequate	JJ

''	''

to	TO

mean	VB

``	``

safety	NN

limit	NN

''	''

would	MD

impose	VB

restrictions	NNS

on	IN

vitamin	NN

and	CC

mineral	NN

intakes	NN

that	IN

are	VBP

not	RB

needed	VBN

to	TO

ensure	VB

safety	NN

Substantial	JJ

evidence	NN

indicates	VBZ

that	IN

intakes	NN

greater	JJR

than	IN

the	DT

recommended	VBN

dietary	JJ

allowances	NNS

(	NN

RDAs	NNS

)	NN

of	IN

certain	JJ

vitamins	NNS

and	CC

minerals	NNS

such	JJ

as	IN

calcium	NN

,	,

folic	NN

acid	NN

,	,

vitamin	NN

E	NN

,	,

selenium	NN

,	,

and	CC

chromium	NN

reduce	VB

the	DT

risk	NN

of	IN

certain	JJ

diseases	NNS

for	IN

some	DT

people	NNS

Limitation	NN

of	IN

intakes	NN

to	TO

the	DT

RDAs	NNS

would	MD

preclude	VB

reductions	NNS

in	IN

disease	NN

risk	NN

from	IN

these	DT

nutrients	NNS

The	DT

margin	NN

of	IN

safety	NN

between	IN

the	DT

usual	JJ

dietary	JJ

intake	NN

and	CC

the	DT

intake	NN

that	IN

would	MD

produce	VB

adverse	JJ

effects	NNS

varies	VBZ

greatly	RB

among	IN

the	DT

different	JJ

nutrients	NNS

Very	RB

high	JJ

intakes	NN

of	IN

vitamins	NNS

A	DT

and	CC

D	NN

,	,

niacin	NN

,	,

pyridoxine	NN

,	,

and	CC

selenium	NN

have	VB

produced	VBN

adverse	JJ

effects	NNS

Many	JJ

widely	RB

discussed	VBN

putative	JJ

adverse	JJ

effects	NNS

of	IN

vitamin	NN

C	NN

,	,

vitamin	NN

E	NN

,	,

and	CC

trivalent	JJ

chromium	NN

have	VB

little	RB

factual	JJ

basis	NN

There	EX

is	VBZ

no	DT

evidence	NN

of	IN

adverse	JJ

effects	NNS

from	IN

beta-carotene	NN

supplements	NNS

except	IN

in	IN

current	JJ

heavy	JJ

smokers	NNS

The	DT

mutator	NN

hypothesis	NN

of	IN

tumorigenesis	NN

suggests	VBZ

that	IN

loss	NN

of	IN

chromosomal	JJ

stability	NN

or	CC

maintenance	NN

functions	NNS

results	NNS

in	IN

elevated	JJ

mutation	NN

rates	NNS

,	,

leading	VBG

to	TO

the	DT

accumulation	NN

of	IN

the	DT

numerous	JJ

mutations	NNS

required	VBN

for	IN

multistep	JJ

carcinogenesis	NN

The	DT

human	JJ

DNA	NN

mismatch	NN

repair	NN

(	NN

MMR	NN

)	NN

genes	NNS

are	VBP

highly	RB

conserved	VBN

homologues	NNS

of	IN

the	DT

Escherichia	FW

coli	NN

MutHLS	NN

system	NN

,	,

which	WDT

contribute	VB

to	TO

genomic	JJ

stability	NN

by	IN

surveillance	NN

and	CC

repair	NN

of	IN

replication	NN

misincorporation	NN

errors	NNS

and	CC

exogenous	JJ

DNA	NN

damage	NN

Mutations	NNS

in	IN

one	CD

of	IN

these	DT

MMR	NN

genes	NNS

,	,

hMSH2	NN

,	,

account	NN

for	IN

about	IN

half	NN

of	IN

all	DT

cases	NNS

of	IN

genetically	RB

linked	VBN

hereditary	JJ

non-polyposis	JJ

colorectal	JJ

cancer	NN

Loss	NN

of	IN

function	NN

of	IN

p53	NN

has	VBZ

also	RB

been	VBN

proposed	VBN

to	TO

increase	NN

cellular	JJ

hypermutability	NN

,	,

thereby	RB

accelerating	VBG

carcinogenesis	NN

,	,

although	IN

a	DT

clear	JJ

role	NN

for	IN

p53	NN

in	IN

genomic	JJ

instability	NN

remains	NNS

controversial	JJ

p53	NN

is	VBZ

mutated	VBN

frequently	RB

in	IN

a	DT

wide	JJ

range	NN

of	IN

human	JJ

cancers	NNS

,	,

including	VBG

colonic	JJ

tumours	NNS

Both	DT

Msh2-	NN

and	CC

p53-targeted	JJ

knockout	NN

mice	NNS

are	VBP

viable	JJ

and	CC

susceptible	JJ

to	TO

cancer	NN

Here	RB

we	PRP

demonstrate	VB

that	IN

combined	VBN

Msh2	NN

and	CC

p53	NN

ablation	NN

(	NN

Msh2-/-p53-/-	NN

)	NN

results	NNS

in	IN

developmental	JJ

arrest	NN

of	IN

all	DT

female	NN

embryos	NNS

at	IN

9.5	CD

days	NNS

In	IN

contrast	NN

,	,

male	NN

Msh2-/-p53-/-	NN

mice	NNS

are	VBP

viable	JJ

,	,

but	CC

succumb	VB

to	TO

tumours	NNS

significantly	RB

earlier	RB

(	NN

t1-2	NN

is	VBZ

73	CD

days	NNS

)	NN

than	IN

either	DT

Msh2-/-	NN

or	CC

p53-/-	JJ

littermates	NNS

Furthermore	RB

,	,

the	DT

frequency	NN

of	IN

microsatellite	NN

instability	NN

(	NN

MSI	NNP

)	NN

in	IN

tumours	NNS

from	IN

Msh2-/-p53-/-	NN

mice	NNS

is	VBZ

not	RB

significantly	RB

different	JJ

than	IN

in	IN

Msh2-/-	NN

mice	NNS

Synergism	NN

in	IN

tumorigenesis	NN

and	CC

independent	JJ

segregation	NN

of	IN

the	DT

MSI	NNP

phenotype	NN

suggest	VB

that	IN

Msh2	NN

and	CC

p53	NN

are	VBP

not	RB

genetically	RB

epistatic	JJ

Our	PRP$

data	NNS

(	NN

Reddy	NNP

et	FW

al	NNP

.	.

,	,

Radiat	NN

Res	NNP

141	CD

,	,

252-258	CD

,	,

1995	CD

)	NN

on	IN

the	DT

kinetics	NNS

of	IN

the	DT

repair	NN

of	IN

potentially	RB

lethal	JJ

damage	NN

in	IN

log-phase	NN

Chinese	JJ

hamster	NN

V79	NN

cells	NNS

are	VBP

used	VBN

to	TO

test	NN

some	DT

predictions	NNS

which	WDT

arise	VB

from	IN

the	DT

different	JJ

assumptions	NNS

of	IN

the	DT

repair-misrepair	NN

(	NN

RMR	NN

)	NN

(	NN

C	NN

A	DT

Tobias	NNP

,	,

Radiat	NN

Res	NNP

104	CD

,	,

S77-S95	NN

,	,

1985	CD

)	NN

,	,

lethal-potentially	RB

lethal	JJ

(	NN

LPL	NNP

)	NN

(	NN

S.	NNP

B	NN

Curtis	NNP

,	,

Radiat	NN

Res	NNP

106	CD

,	,

252-270	CD

,	,

1986	CD

)	NN

and	CC

double-strand	NN

break	NN

(	NN

DSB	NN

)	NN

(	NN

J	NN

Y	NN

Ostashevsky	NNP

,	,

Radiat	NN

Res	NNP

118	CD

,	,

437-466	CD

,	,

1989	CD

)	NN

models	NNS

The	DT

LPL	NNP

model	NN

defines	VBZ

the	DT

time	NN

available	JJ

for	IN

repair	NN

of	IN

PLD	NN

(	NN

t	NN

(	NN

rep	NN

)	NN

)	NN

as	IN

the	DT

time	NN

taken	VBN

to	TO

reach	NN

maximal	JJ

survival	NN

in	IN

a	DT

delayed-plating	JJ

recovery	NN

experiment	NN

Those	DT

data	NNS

show	NN

that	IN

after	IN

this	DT

time	NN

has	VBZ

elapsed	VBN

,	,

contrary	NN

to	TO

the	DT

expectation	NN

of	IN

the	DT

LPL	NNP

model	NN

,	,

survival	NN

can	MD

be	VB

increased	VBN

by	IN

changing	VBG

the	DT

medium	NN

used	VBN

for	IN

delayed	VBN

plating	VBG

from	IN

fresh	JJ

growth	NN

medium	NN

to	TO

conditioned	VBN

medium	NN

According	VBG

to	TO

the	DT

RMR	NN

model	NN

,	,

all	DT

potentially	RB

lethal	JJ

lesions	NNS

should	MD

also	RB

be	VB

committed	VBN

by	IN

that	IN

time	NN

and	CC

be	VB

unavailable	JJ

for	IN

repair	NN

in	IN

the	DT

new	JJ

medium	NN

Only	RB

the	DT

DSB	NN

model	NN

correctly	RB

predicted	VBN

that	IN

PLD	NN

(	NN

=	JJ

DSBs	NNS

)	NN

would	MD

still	RB

be	VB

available	JJ

for	IN

repair	NN

after	IN

that	IN

time	NN

Second	JJ

,	,

data	NNS

for	IN

split-dose	NN

recovery	NN

are	VBP

used	VBN

to	TO

predict	VB

the	DT

first-order	NN

kinetics	NNS

time	NN

constant	JJ

for	IN

DSB	NN

repair	NN

(	NN

tau	IN

(	NN

DSBR	NN

)	NN

)	NN

using	VBG

the	DT

DSB	NN

model	NN

(	NN

24	CD

+/-	CC

1.5	CD

min	NN

)	NN

This	DT

value	NN

is	VBZ

nearly	RB

identical	JJ

to	TO

the	DT

value	NN

of	IN

27	CD

+/-	CC

1	CD

min	NN

determined	VBN

from	IN

the	DT

data	NNS

obtained	VBN

by	IN

Cheong	NNP

et	FW

al	NNP

.	.

using	VBG

pulsed-field	JJ

gel	NN

electrophoresis	NN

(	NN

PFGE	NN

)	NN

(	NN

Mutat	NN

Res	NNP

274	CD

,	,

111-122	CD

,	,

1992	CD

)	NN

The	DT

value	NN

based	VBN

on	IN

PFGE	NN

is	VBZ

used	VBN

to	TO

calculate	VB

the	DT

value	NN

of	IN

t	NN

(	NN

rep	NN

)	NN

predicted	VBN

by	IN

the	DT

DSB	NN

model	NN

(	NN

2.6	CD

+/-	CC

0.1	CD

h	NN

)	NN

,	,

which	WDT

agrees	VBZ

with	IN

the	DT

value	NN

determined	VBN

experimentally	RB

as	IN

the	DT

time	NN

when	WRB

changing	VBG

the	DT

delayed-plating	JJ

medium	NN

from	IN

growth	NN

medium	NN

to	TO

conditioned	VBN

medium	NN

no	DT

longer	RB

gives	VBZ

the	DT

full	JJ

recovery	NN

seen	VBN

with	IN

delayed	VBN

plating	VBG

in	IN

conditioned	VBN

medium	NN

(	NN

2.5	CD

h	NN

)	NN

However	RB

,	,

some	DT

recovery	NN

was	VBD

seen	VBN

for	IN

a	DT

change	NN

in	IN

the	DT

medium	NN

(	NN

growth	NN

medium	NN

to	TO

conditioned	VBN

medium	NN

)	NN

up	RB

to	TO

5-6	CD

h	NN

postirradiation	NN

Reanalysis	NNP

of	IN

the	DT

original	JJ

data	NNS

on	IN

DSB	NN

repair	NN

shows	NNS

that	IN

they	PRP

are	VBP

consistent	JJ

with	IN

two	CD

first-order	NN

repair	NN

rates	NNS

(	NN

18	CD

+/-	CC

7	CD

min	NN

and	CC

about	IN

52	CD

min	NN

)	NN

These	DT

results	NNS

are	VBP

consistent	JJ

with	IN

two	CD

pools	NNS

of	IN

DSBs	NNS

(	NN

or	CC

cells	NNS

)	NN

,	,

each	DT

with	IN

their	PRP$

own	JJ

t	NN

(	NN

rep	NN

)	NN

The	DT

early	RB

t	NN

(	NN

rep	NN

)	NN

,	,

associated	VBN

with	IN

tau	IN

(	NN

fast	RB

)	NN

,	,

is	VBZ

predicted	VBN

to	TO

be	VB

1.7	CD

+/-	CC

0.7	CD

h	NN

,	,

and	CC

the	DT

late	RB

t	NN

(	NN

rep	NN

)	NN

,	,

associated	VBN

with	IN

tau	IN

(	NN

slow	JJ

)	NN

,	,

is	VBZ

predicted	VBN

to	TO

be	VB

about	IN

5	CD

h.	NN

Both	DT

values	NNS

are	VBP

in	IN

excellent	JJ

agreement	NN

with	IN

the	DT

times	NNS

at	IN

which	WDT

changing	VBG

from	IN

growth	NN

medium	NN

to	TO

conditioned	VBN

medium	NN

no	DT

longer	RB

gives	VBZ

the	DT

full	JJ

recovery	NN

seen	VBN

in	IN

conditioned	VBN

medium	NN

only	RB

(	NN

the	DT

early	RB

t	NN

(	NN

rep	NN

)	NN

)	NN

,	,

and	CC

the	DT

time	NN

when	WRB

changing	VBG

from	IN

growth	NN

medium	NN

to	TO

conditioned	VBN

medium	NN

produces	VBZ

no	DT

further	RB

increase	NN

in	IN

survival	NN

(	NN

the	DT

late	RB

t	NN

(	NN

rep	NN

)	NN

)	NN

,	,

respectively	RB

It	PRP

is	VBZ

noted	VBN

that	IN

attempts	NNS

to	TO

correlate	NN

radiosensitivity	NN

with	IN

the	DT

rates	NNS

of	IN

DSB	NN

repair	NN

,	,

rather	RB

than	IN

using	VBG

an	DT

explicit	JJ

model	NN

such	JJ

as	IN

the	DT

DSB	NN

model	NN

,	,

are	VBP

unlikely	JJ

to	TO

be	VB

productive	JJ

since	IN

survival	NN

depends	VBZ

on	IN

both	DT

tau	IN

(	NN

DSBR	NN

)	NN

and	CC

t	NN

(	NN

rep	NN

)	NN

(	NN

as	IN

defined	VBN

in	IN

the	DT

DSB	NN

model	NN

)	NN

and	CC

the	DT

latter	JJ

may	MD

be	VB

the	DT

more	RBR

important	JJ

determinant	NN

of	IN

radiosensitivity	NN

(	NN

as	IN

it	PRP

appears	VBZ

to	TO

be	VB

for	IN

ataxia	NN

telangiectasia	NN

cells	NNS

compared	VBN

to	TO

normal	JJ

fibroblasts	NNS

and	CC

for	IN

irs	NNS

compared	VBN

to	TO

V79	NN

cells	NNS

)	NN

CONTEXT	NN

:	:

Adolescents	NNS

'	''

concerns	NNS

about	IN

privacy	NN

in	IN

clinical	JJ

settings	NNS

decrease	NN

their	PRP$

willingness	NN

to	TO

seek	VB

health	NN

care	NN

for	IN

sensitive	JJ

problems	NNS

and	CC

may	MD

inhibit	VB

their	PRP$

communication	NN

with	IN

physicians	NNS

OBJECTIVE	NN

:	:

To	TO

investigate	VB

the	DT

influence	NN

of	IN

physicians	NNS

'	''

assurances	NNS

of	IN

confidentiality	NN

on	IN

adolescents	NNS

'	''

willingness	NN

to	TO

disclose	VB

information	NN

and	CC

seek	VB

future	NN

health	NN

care	NN

DESIGN	NN

:	:

Randomized	VBN

controlled	VBN

trial	NN

SETTING	VBG

:	:

Three	CD

suburban	JJ

public	NN

high	JJ

schools	NNS

in	IN

California	NNP

PARTICIPANTS	NNS

:	:

The	DT

562	CD

participating	VBG

adolescents	NNS

represented	VBN

92	CD

%	NN

of	IN

students	NNS

in	IN

mandatory	JJ

classes	NNS

INTERVENTION	NN

:	:

After	IN

random	JJ

assignment	NN

to	TO

1	CD

of	IN

3	CD

groups	NNS

,	,

the	DT

adolescents	NNS

listened	VBD

to	TO

a	DT

standardized	JJ

audiotape	NN

depiction	NN

of	IN

an	DT

office	NN

visit	NN

during	IN

which	WDT

they	PRP

heard	VBN

a	DT

physician	NN

who	WP

assured	VBN

unconditional	JJ

confidentiality	NN

,	,

a	DT

physician	NN

who	WP

assured	VBN

conditional	JJ

confidentiality	NN

,	,

or	CC

a	DT

physician	NN

who	WP

did	VBD

not	RB

mention	NN

confidentiality	NN

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

Adolescents	NNS

'	''

willingness	NN

to	TO

disclose	VB

general	JJ

information	NN

,	,

willingness	NN

to	TO

disclose	VB

information	NN

about	IN

sensitive	JJ

topics	NNS

,	,

intended	VBN

honesty	NN

,	,

and	CC

likelihood	NN

of	IN

return	NN

visits	NNS

to	TO

the	DT

physician	NN

depicted	VBN

in	IN

the	DT

scenario	NN

were	VBD

assessed	VBN

by	IN

anonymous	JJ

written	VBN

questionnaire	NN

RESULTS	NNS

:	:

Assurances	NNP

of	IN

confidentiality	NN

increased	VBN

the	DT

number	NN

of	IN

adolescents	NNS

willing	JJ

to	TO

disclose	VB

sensitive	JJ

information	NN

about	IN

sexuality	NN

,	,

substance	NN

use	NN

,	,

and	CC

mental	JJ

health	NN

from	IN

39	CD

%	NN

(	NN

68/175	CD

)	NN

to	TO

46.5	CD

%	NN

(	NN

178/383	CD

)	NN

(	NN

beta=.10	NN

,	,

P=.02	NN

)	NN

and	CC

increased	VBN

the	DT

number	NN

willing	JJ

to	TO

seek	VB

future	NN

health	NN

care	NN

from	IN

53	CD

%	NN

(	NN

93/175	CD

)	NN

to	TO

67	CD

%	NN

(	NN

259/386	CD

)	NN

(	NN

beta=.17	NN

,	,

P	NN

&	CC

#	#

60	CD

;	:

.001	CD

)	NN

When	WRB

comparing	VBG

the	DT

unconditional	JJ

with	IN

the	DT

conditional	JJ

groups	NNS

,	,

assurances	NNS

of	IN

unconditional	JJ

confidentiality	NN

increased	VBN

the	DT

number	NN

of	IN

adolescents	NNS

willing	JJ

to	TO

return	NN

for	IN

a	DT

future	NN

visit	NN

by	IN

10	CD

percentage	NN

points	NNS

,	,

from	IN

62	CD

%	NN

(	NN

122/196	CD

)	NN

to	TO

72	CD

%	NN

(	NN

137/190	CD

)	NN

(	NN

beta=.14	NN

,	,

P=.001	NN

)	NN

CONCLUSIONS	NNS

:	:

Adolescents	NNS

are	VBP

more	RBR

willing	JJ

to	TO

communicate	VBP

with	IN

and	CC

seek	VB

health	NN

care	NN

from	IN

physicians	NNS

who	WP

assure	VB

confidentiality	NN

Further	RB

investigation	NN

is	VBZ

needed	VBN

to	TO

identify	VB

a	DT

confidentiality	NN

assurance	NN

statement	NN

that	IN

explains	VBZ

the	DT

legal	JJ

and	CC

ethical	JJ

limitations	NNS

of	IN

confidentiality	NN

without	IN

decreasing	VBG

adolescents	NNS

'	''

likelihood	NN

of	IN

seeking	VBG

future	NN

health	NN

care	NN

for	IN

routine	JJ

and	CC

nonreportable	JJ

sensitive	JJ

health	NN

concerns	NNS

BACKGROUND	NN

:	:

Diabetic	NNP

foot	NN

infections	NNS

cause	NN

substantial	JJ

morbidity	NN

and	CC

mortality	NN

Neutrophil	NN

superoxide	NN

generation	NN

,	,

a	DT

crucial	JJ

part	NN

of	IN

neutrophil	NN

bactericidal	JJ

activity	NN

,	,

is	VBZ

impaired	JJ

in	IN

diabetes	NN

Granulocyte-colony	NN

stimulating	VBG

factor	NN

(	NN

G-CSF	NN

)	NN

increases	NNS

the	DT

release	NN

of	IN

neutrophils	NNS

from	IN

the	DT

bone	NN

marrow	NN

and	CC

improves	VBZ

neutrophil	NN

function	NN

We	PRP

assessed	VBN

G-CSF	NN

as	IN

adjuvant	JJ

therapy	NN

for	IN

the	DT

treatment	NN

of	IN

severe	JJ

foot	NN

infections	NNS

in	IN

diabetic	JJ

patients	NNS

METHODS	NNS

:	:

40	CD

diabetic	JJ

patients	NNS

with	IN

foot	NN

infections	NNS

were	VBD

enrolled	VBN

in	IN

a	DT

double-blind	JJ

placebo-controlled	JJ

study	NN

On	IN

admission	NN

,	,

patients	NNS

were	VBD

randomly	RB

assigned	VBN

G-CSF	NN

(	NN

filgrastim	NN

)	NN

therapy	NN

(	NN

n	NN

=	JJ

20	CD

)	NN

or	CC

placebo	NN

(	NN

n	NN

=	JJ

20	CD

)	NN

for	IN

7	CD

days	NNS

Both	DT

groups	NNS

received	VBN

similar	JJ

antibiotic	JJ

and	CC

insulin	NN

treatment	NN

Neutrophils	NNS

from	IN

the	DT

peripheral	JJ

blood	NN

of	IN

these	DT

participants	NNS

and	CC

from	IN

healthy	JJ

controls	NNS

were	VBD

stimulated	VBN

with	IN

opsonised	VBN

zymosan	NN

,	,

and	CC

superoxide	NN

production	NN

was	VBD

measured	VBN

by	IN

a	DT

spectrophotometric	JJ

assay	NN

(	NN

reduction	NN

of	IN

ferricytochrome	NN

C	NN

)	NN

<	JJR

TO_SEE	NN

>	JJR

FINDINGS	NNS

:	:

G-CSF	NN

therapy	NN

was	VBD

associated	VBN

with	IN

earlier	RB

eradication	NN

of	IN

pathogens	NNS

from	IN

the	DT

infected	JJ

ulcer	NN

(	NN

median	NN

4	CD

(	NN

range	NN

2-10	CD

)	NN

vs	CC

8	CD

(	NN

2-79	CD

)	NN

days	NNS

in	IN

the	DT

placebo	NN

group	NN

;	:

p	NN

=	JJ

0.02	CD

)	NN

,	,

quicker	JJR

resolution	NN

of	IN

cellulitis	NNS

<	JJR

(	NN

7	CD

(	NN

5-20	CD

)	NN

vs	CC

12	CD

(	NN

5-93	NN

)	NN

days	NNS

;	:

p	NN

=	JJ

0.03	CD

)	NN

,	,

shorter	JJR

hospital	NN

stay	NN

(	NN

10	CD

(	NN

7-31	CD

)	NN

vs	CC

17.5	CD

(	NN

9-100	CD

)	NN

days	NNS

;	:

p	NN

=	JJ

0.02	CD

)	NN

,	,

and	CC

a	DT

shorter	JJR

duration	NN

of	IN

intravenous	JJ

antibiotic	JJ

treatment	NN

(	NN

8.5	CD

(	NN

5-30	CD

)	NN

vs	CC

14.5	CD

(	NN

8-63	CD

)	NN

days	NNS

;	:

p	NN

=	JJ

0.02	CD

)	NN

No	DT

G-CSF-treated	JJ

patient	NN

needed	VBN

surgery	NN

,	,

whereas	IN

two	CD

placebo	NN

recipients	NNS

underwent	VBD

to	TO

amputation	NN

and	CC

two	CD

had	VBD

extensive	JJ

debridement	NN

under	IN

anaesthesia	NN

After	IN

7	CD

days	NNS

'	''

treatment	NN

,	,

neutrophil	NN

superoxide	NN

production	NN

was	VBD

significantly	RB

higher	JJR

in	IN

the	DT

G-CSF	NN

group	NN

than	IN

in	IN

the	DT

placebo	NN

group	NN

(	NN

16.1	CD

(	NN

4.2-24.2	CD

)	NN

vs	CC

7.3	CD

(	NN

2.1-11.5	CD

)	NN

nmol	NN

per	IN

10	CD

(	NN

6	CD

)	NN

neutrophils	NNS

in	IN

30	CD

min	NN

;	:

p	NN

&	CC

#	#

60	CD

;	:

0.0001	CD

)	NN

G-CSF	NN

therapy	NN

was	VBD

generally	RB

well	RB

tolerated	VBN

INTERPRETATION	NN

:	:

G-CSF	NN

treatment	NN

was	VBD

associated	VBN

with	IN

improved	VBN

clinical	JJ

outcome	NN

of	IN

foot	NN

infection	NN

in	IN

diabetic	JJ

patients	NNS

This	DT

improvement	NN

may	MD

be	VB

related	JJ

to	TO

an	DT

increase	NN

in	IN

neutrophil	NN

superoxide	NN

production	NN

BACKGROUND	NN

:	:

Accelerated	VBN

infusion	NN

of	IN

alteplase	RB

(	NN

tissue	NN

plasminogen	NN

activator	NN

)	NN

over	IN

a	DT

period	NN

of	IN

90	CD

minutes	NNS

induces	VBZ

more	RBR

rapid	JJ

lysis	NN

of	IN

coronary-artery	NN

thrombi	NN

than	IN

a	DT

3-hour	JJ

infusion	NN

With	IN

two	CD

bolus	NN

doses	NNS

of	IN

alteplase	RB

,	,

further	RB

shortening	VBG

the	DT

duration	NN

of	IN

administration	NN

,	,

complete	JJ

reperfusion	NN

was	VBD

achieved	VBN

in	IN

more	RBR

than	IN

85	CD

percent	NN

of	IN

the	DT

patients	NNS

in	IN

initial	JJ

angiographic	JJ

studies	NNS

We	PRP

tested	VBN

the	DT

hypothesis	NN

that	IN

double-bolus	JJ

alteplase	RB

is	VBZ

at	IN

least	JJS

as	IN

effective	JJ

as	IN

accelerated	VBN

infusion	NN

METHODS	NNS

:	:

In	IN

398	CD

hospitals	NNS

,	,

7169	CD

patients	NNS

with	IN

acute	JJ

myocardial	JJ

infarction	NN

were	VBD

randomly	RB

assigned	VBN

to	TO

weight-adjusted	JJ

,	,

accelerated	VBN

infusion	NN

of	IN

100	CD

mg	NN

of	IN

alteplase	RB

or	CC

to	TO

a	DT

bolus	NN

of	IN

50	CD

mg	NN

of	IN

alteplase	RB

over	IN

a	DT

period	NN

of	IN

1	CD

to	TO

3	CD

minutes	NNS

followed	VBN

30	CD

minutes	NNS

later	RB

by	IN

a	DT

second	JJ

bolus	NN

of	IN

50	CD

mg	NN

(	NN

or	CC

40	CD

mg	NN

for	IN

patients	NNS

who	WP

weighed	VBD

less	JJR

than	IN

60	CD

kg	NN

)	NN

The	DT

primary	JJ

end	NN

point	NN

was	VBD

death	NN

from	IN

any	DT

cause	NN

at	IN

30	CD

days	NNS

The	DT

trial	NN

was	VBD

stopped	VBD

prematurely	RB

because	IN

of	IN

concern	NN

about	IN

the	DT

safety	NN

of	IN

the	DT

double-bolus	JJ

injection	NN

RESULTS	NNS

:	:

Thirty-day	JJ

mortality	NN

was	VBD

higher	JJR

in	IN

the	DT

double-bolus	JJ

group	NN

than	IN

in	IN

the	DT

accelerated-infusion	NN

group	NN

:	:

7.98	CD

percent	NN

as	IN

compared	VBN

with	IN

7.53	CD

percent	NN

The	DT

absolute	JJ

difference	NN

was	VBD

0.44	CD

percent	NN

,	,

with	IN

a	DT

one-sided	JJ

95	CD

percent	NN

upper	JJ

boundary	NN

of	IN

1.49	CD

percent	NN

,	,

which	WDT

exceeded	VBN

the	DT

prespecified	VBD

upper	JJ

limit	NN

of	IN

0.40	CD

percent	NN

to	TO

indicate	VBP

equivalence	JJ

in	IN

30-day	JJ

mortality	NN

between	IN

the	DT

two	CD

regimens	NNS

The	DT

respective	JJ

rates	NNS

of	IN

any	DT

stroke	NN

and	CC

of	IN

hemorrhagic	JJ

stroke	NN

were	VBD

1.92	CD

and	CC

1.12	CD

percent	NN

after	IN

double-bolus	JJ

alteplase	RB

,	,

as	IN

compared	VBN

with	IN

1.53	CD

and	CC

0.81	CD

percent	NN

after	IN

an	DT

accelerated	VBN

infusion	NN

of	IN

alteplase	RB

(	NN

P=0.24	NN

and	CC

P=0.23	NN

,	,

respectively	RB

)	NN

CONCLUSIONS	NNS

:	:

Double-bolus	JJ

alteplase	RB

was	VBD

not	RB

shown	VBN

to	TO

be	VB

equivalent	JJ

,	,

according	VBG

to	TO

the	DT

prespecified	VBD

criteria	NNS

,	,

to	TO

accelerated	VBN

infusion	NN

with	IN

regard	NN

to	TO

30-day	JJ

mortality	NN

There	EX

was	VBD

also	RB

a	DT

slightly	RB

higher	JJR

rate	NN

of	IN

intracranial	JJ

hemorrhage	NN

with	IN

the	DT

double-bolus	JJ

method	NN

Therefore	RB

,	,

accelerated	VBN

infusion	NN

of	IN

alteplase	RB

over	IN

a	DT

period	NN

of	IN

90	CD

minutes	NNS

remains	NNS

the	DT

preferred	VBN

regimen	NNS

BACKGROUND	NN

:	:

Fenfluramine	NN

and	CC

phentermine	NN

have	VB

been	VBN

individually	RB

approved	VBN

as	IN

anorectic	NN

agents	NNS

by	IN

the	DT

Food	NNP

and	CC

Drug	NN

Administration	NN

(	NN

FDA	NNP

)	NN

When	WRB

used	VBN

in	IN

combination	NN

the	DT

drugs	NNS

may	MD

be	VB

just	RB

as	IN

effective	JJ

as	IN

either	DT

drug	NN

alone	RB

,	,

with	IN

the	DT

added	VBN

advantages	NNS

of	IN

the	DT

need	NN

for	IN

lower	JJR

doses	NNS

of	IN

each	DT

agent	NN

and	CC

perhaps	RB

fewer	JJR

side	NN

effects	NNS

Although	IN

the	DT

combination	NN

has	VBZ

not	RB

been	VBN

approved	VBN

by	IN

the	DT

FDA	NNP

,	,

in	IN

1996	CD

the	DT

total	NN

number	NN

of	IN

prescriptions	NNS

in	IN

the	DT

United	NNP

States	NNPS

for	IN

fenfluramine	NN

and	CC

phentermine	NN

exceeded	VBN

18	CD

million	CD

<	JJR

TO_SEE	NN

>	JJR

METHODS	NNS

:	:

We	PRP

identified	VBN

valvular	JJ

heart	NN

diseasein	NN

24	CD

women	NNS

treated	VBN

with	IN

fenfluramine-phentermine	NN

who	WP

had	VBD

no	DT

history	NN

of	IN

cardiac	JJ

disease	NN

The	DT

women	NNS

presented	VBN

with	IN

cardiovascular	JJ

symptoms	NNS

or	CC

a	DT

heart	NN

murmur	NN

As	IN

increasing	VBG

numbers	NNS

of	IN

these	DT

patients	NNS

with	IN

similar	JJ

clinical	JJ

features	NNS

were	VBD

identified	VBN

,	,

there	RB

appeared	VBD

to	TO

be	VB

an	DT

association	NN

between	IN

these	DT

features	NNS

and	CC

fenfluramine-phentermine	NN

therapy	NN

RESULTS	NNS

:	:

Twenty-four	CD

women	NNS

(	NN

mean	VB

(	NN

+/-SD	NN

)	NN

age	NN

,	,

44+/-8	CD

years	NNS

)	NN

were	VBD

evaluated	VBN

12.3+/-7.1	CD

months	NNS

after	IN

the	DT

initiation	NN

of	IN

fenfluramine-phentermine	NN

therapy	NN

Echocardiography	NN

demonstrated	VBN

unusual	JJ

valvular	JJ

morphology	NN

and	CC

regurgitation	NN

in	IN

all	DT

patients	NNS

Both	DT

right-sided	JJ

and	CC

left-sided	JJ

heart	NN

valves	NNS

were	VBD

involved	VBN

Eight	CD

women	NNS

also	RB

had	VBD

newly	RB

documented	VBN

pulmonary	JJ

hypertension	NN

To	TO

date	NN

,	,

cardiac	JJ

surgical	JJ

intervention	NN

has	VBZ

been	VBN

required	VBN

in	IN

five	CD

patients	NNS

The	DT

heart	NN

valves	NNS

had	VBD

a	DT

glistening	VBG

white	JJ

appearance	NN

Histopathological	JJ

findings	NNS

included	VBN

plaque-like	JJ

encasement	NN

of	IN

the	DT

leaflets	NNS

and	CC

chordal	JJ

structures	NNS

with	IN

intact	JJ

valve	NN

architecture	NN

The	DT

histopathological	JJ

features	NNS

were	VBD

identical	JJ

to	TO

those	DT

seen	VBN

in	IN

carcinoid	NN

or	CC

ergotamine-induced	JJ

valve	NN

disease	NN

CONCLUSIONS	NNS

:	:

These	DT

cases	NNS

arouse	VB

concern	NN

that	IN

fenfluramine-phentermine	NN

therapy	NN

may	MD

be	VB

associated	VBN

with	IN

valvular	JJ

heart	NN

disease	NN

Candidates	NNS

for	IN

fenfluramine-phentermine	NN

therapy	NN

should	MD

be	VB

informed	VBN

about	IN

serious	JJ

potential	NN

adverse	JJ

effects	NNS

,	,

including	VBG

pulmonary	JJ

hypertension	NN

and	CC

valvular	JJ

heart	NN

disease	NN

<	JJR

TO_SEE	NN

>	JJR

Between	IN

1987	CD

and	CC

1992	CD

,	,

all	DT

patients	NNS

presenting	VBG

to	TO

the	DT

senior	JJ

author	NN

with	IN

a	DT

symptomatic	JJ

failed	VBD

silicone	NN

implant	VB

arthroplasty	NN

refractory	JJ

to	TO

conservative	JJ

treatment	NN

were	VBD

converted	VBN

to	TO

a	DT

metatarsophalangeal	NN

joint	NN

arthrodesis	NN

Internal	JJ

fixation	NN

was	VBD

achieved	VBN

with	IN

either	DT

dual	JJ

intrameduilary	JJ

threaded	VBN

Steinmann	NNP

pins	NNS

or	CC

an	DT

obliquely	RB

placed	VBN

AO	JJ

compression	NN

screw	VB

and	CC

a	DT

three-	CD

or	CC

four-hole	JJ

one-third	NN

tubular	JJ

dorsal	NN

neutralization	NN

plate	NN

Bone	NN

grafting	VBG

was	VBD

used	VBN

to	TO

maintain	VB

hallux	NN

length	NN

Successful	JJ

arthrodesis	NN

was	VBD

achieved	VBN

in	IN

all	DT

five	CD

feet	NNS

in	IN

patients	NNS

with	IN

rheumatoid	JJ

arthritis	NN

Subjectively	RB

,	,

patients	NNS

improved	VBN

from	IN

an	DT

average	NN

of	IN

0.69	CD

before	IN

arthrodesis	NN

to	TO

4.89	CD

after	IN

arthrodesis	NN

The	DT

average	NN

walking	VBG

tolerance	NN

improved	VBN

from	IN

1.11	CD

to	TO

4.80	CD

,	,

and	CC

the	DT

overall	RB

level	NN

of	IN

satisfaction	NN

improved	VBN

from	IN

0.0	CD

to	TO

4.79	CD

The	DT

patient	NN

's	POS

ability	NN

to	TO

wear	NN

shoes	NNS

improved	VBN

from	IN

0.87	CD

to	TO

3.1	CD

Successful	JJ

arthrodesis	NN

produces	VBZ

a	DT

foot	NN

that	IN

is	VBZ

more	RBR

functional	JJ

and	CC

durable	JJ

than	IN

excisional	JJ

arthroplasty	NN

Subjectively	RB

,	,

these	DT

patients	NNS

stated	VBN

that	IN

their	PRP$

level	NN

of	IN

pain	NN

,	,

walking	VBG

tolerance	NN

,	,

and	CC

overall	RB

satisfaction	NN

improved	VBN

significantly	RB

after	IN

the	DT

arthrodesis	NN

Clinically	RB

,	,

there	RB

was	VBD

no	DT

evidence	NN

of	IN

transfer	NN

lesions	NNS

,	,

tenderness	NN

,	,

or	CC

hallux	NN

subluxation	NN

Hallux	NNP

length	NN

was	VBD

well	RB

maintained	VBN

after	IN

surgery	NN

with	IN

bone	NN

grafting	VBG

,	,

but	CC

it	PRP

was	VBD

more	RBR

difficult	JJ

to	TO

obtain	VB

the	DT

alignment	NN

goals	NNS

The	DT

average	NN

postoperative	JJ

metatarsophalangeal	NN

dorsiflexion	NN

angle	NN

was	VBD

15.6	CD

degrees	NNS

and	CC

the	DT

first	RB

metatarsophalangeal	NN

angle	NN

was	VBD

3.1	CD

degrees	NNS

Despite	IN

this	DT

,	,

patient	NN

satisfaction	NN

was	VBD

high	JJ

Arthrodesis	FW

of	IN

the	DT

first	RB

metatarsophalangeal	NN

joint	NN

using	VBG

a	DT

bone	NN

graft	NN

to	TO

salvage	NN

failed	VBD

silicone	NN

implant	VB

arthroplasty	NN

produces	VBZ

acceptable	JJ

subjective	JJ

and	CC

radiographic	JJ

results	NNS

Although	IN

technically	RB

demanding	VBG

,	,

it	PRP

provides	VBZ

long-term	JJ

stability	NN

to	TO

the	DT

hallux	NN

,	,

restores	VBZ

weightbearing	VBG

,	,

and	CC

allows	VBZ

for	IN

maintenance	NN

of	IN

a	DT

propulsive	JJ

gait	NN

We	PRP

recommend	VB

this	DT

procedure	NN

instead	RB

of	IN

an	DT

excisional	JJ

arthroplasty	NN

to	TO

maintain	VB

high	JJ

level	NN

of	IN

function	NN

and	CC

overall	RB

patient	NN

satisfaction	NN

OBJECTIVE	NN

:	:

To	TO

estimate	NN

the	DT

crude	NN

incidence	NN

rates	NNS

of	IN

cerebrovascular	JJ

accidents	NNS

among	IN

the	DT

black	JJ

residents	NNS

of	IN

Harare	NNP

DESIGN	NN

:	:

Prospective	JJ

community-based	JJ

study	NN

SETTING	VBG

:	:

Black	NNP

residents	NNS

of	IN

Harare	NNP

,	,

Zimbabwe	NNP

PARTICIPANTS	NNS

:	:

Two	CD

hundred	CD

and	CC

seventy-three	CD

'first-ever	NN

'	''

strokes	NNS

prospectively	RB

identified	VBN

over	IN

a	DT

12-month	JJ

period	NN

MAIN	NN

OUTCOME	NN

STUDY	NN

FACTORS	NNS

:	:

Cerebrovascular	JJ

accident	NN

first-week	JJ

fatality	NN

rate	NN

;	:

age-	NN

and	CC

sex-related	JJ

incidence	NN

RESULTS	NNS

:	:

The	DT

crude	NN

incidence	NN

rate	NN

was	VBD

estimated	VBN

to	TO

be	VB

30.7	CD

per	IN

100000	CD

(	NN

95	CD

%	NN

confidence	NN

interval	NN

27.1-34.4	CD

)	NN

and	CC

the	DT

standardised	VBN

rate	NN

was	VBD

68	CD

per	IN

100000	CD

Fifty-one	CD

per	IN

cent	NN

of	IN

stroke	NN

victims	NNS

were	VBD

below	IN

the	DT

age	NN

of	IN

54	CD

years	NNS

Thirty-five	CD

per	IN

cent	NN

of	IN

patients	NNS

died	VBD

within	IN

1	CD

week	NN

of	IN

the	DT

stroke	NN

Overall	RB

,	,

the	DT

age-specific	JJ

rates	NNS

for	IN

both	DT

sexes	NNS

rose	VBD

with	IN

age	NN

,	,

with	IN

the	DT

rates	NNS

for	IN

women	NNS

being	VBG

higher	JJR

at	IN

all	DT

age	NN

strata	NN

except	IN

for	IN

the	DT

group	NN

45-54	CD

years	NNS

CONCLUSION	NN

:	:

With	IN

a	DT

standardised	VBN

rate	NN

of	IN

68	CD

per	IN

100000	CD

and	CC

a	DT

first-week	JJ

mortality	NN

rate	NN

of	IN

35	CD

%	NN

,	,

stroke	NN

must	MD

now	RB

be	VB

considered	VBN

an	DT

important	JJ

cause	NN

of	IN

morbidity	NN

and	CC

mortality	NN

in	IN

the	DT

population	NN

OBJECTIVE	NN

:	:

To	TO

explore	VB

the	DT

long-term	JJ

effect	NN

of	IN

calcium	NN

supplementation	NN

during	IN

pregnancy	NN

on	IN

the	DT

offspring	NN

's	POS

blood	NN

pressure	NN

during	IN

childhood	NN

DESIGN	NN

:	:

Follow	VB

up	RB

of	IN

a	DT

population	NN

enrolled	VBN

in	IN

a	DT

double	RB

blind	JJ

,	,

randomised	VBN

,	,

placebo	NN

controlled	VBN

trial	NN

SETTING	VBG

:	:

Perinatal	JJ

research	NN

unit	NN

,	,

World	NNP

Health	NNP

Organisation	NNP

's	POS

collaborative	JJ

research	NN

centre	NN

SUBJECTS	NNS

:	:

591	CD

children	NNS

at	IN

a	DT

mean	VB

age	NN

of	IN

7	CD

years	NNS

whose	WP$

mothers	NNS

were	VBD

randomly	RB

assigned	VBN

during	IN

pregnancy	NN

to	TO

receive	VB

2	CD

g/day	NN

of	IN

elemental	JJ

calcium	NN

(	NN

n	NN

=	JJ

298	CD

)	NN

or	CC

placebo	NN

(	NN

n	NN

=	JJ

293	CD

)	NN

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

Mean	NN

blood	NN

pressure	NN

and	CC

rate	NN

of	IN

high	JJ

blood	NN

pressure	NN

of	IN

children	NNS

RESULTS	NNS

:	:

Overall	RB

,	,

systolic	JJ

blood	NN

pressure	NN

was	VBD

lower	JJR

in	IN

the	DT

calcium	NN

group	NN

(	NN

mean	VB

difference	NN

-1.4	CD

mm	NN

Hg	NN

;	:

95	CD

%	NN

confidence	NN

interval	NN

-3.2	CD

to	TO

0.5	CD

)	NN

than	IN

in	IN

the	DT

placebo	NN

group	NN

The	DT

effect	NN

was	VBD

found	VBN

predominantly	RB

among	IN

children	NNS

whose	WP$

body	NN

mass	NN

index	NN

at	IN

assessment	NN

was	VBD

above	IN

the	DT

median	NN

for	IN

this	DT

population	NN

(	NN

mean	VB

difference	NN

in	IN

systolic	JJ

blood	NN

pressure	NN

-5.8	CD

mm	NN

Hg	NN

(	NN

-9.8	CD

mm	NN

Hg	NN

to	TO

-1.7	CD

mm	NN

Hg	NN

)	NN

for	IN

children	NNS

with	IN

an	DT

index	NN

>	JJR

17.5	CD

and	CC

-3.2	CD

mm	NN

Hg	NN

(	NN

-6.3	CD

mm	NN

Hg	NN

to	TO

-0.1	CD

mm	NN

Hg	NN

)	NN

for	IN

those	DT

with	IN

an	DT

index	NN

of	IN

>	JJR

15.7	CD

to	TO

17.5	CD

)	NN

The	DT

risk	NN

of	IN

high	JJ

systolic	JJ

blood	NN

pressure	NN

was	VBD

also	RB

lower	JJR

in	IN

the	DT

calcium	NN

group	NN

than	IN

in	IN

the	DT

placebo	NN

group	NN

(	NN

relative	JJ

risk	NN

0.59	CD

;	:

0.39	CD

to	TO

0.90	CD

)	NN

and	CC

particularly	RB

among	IN

children	NNS

in	IN

the	DT

highest	JJS

fourth	JJ

of	IN

body	NN

mass	NN

index	NN

(	NN

0.43	CD

;	:

0.26	CD

to	TO

0.71	CD

)	NN

CONCLUSION	NN

:	:

Calcium	NN

supplementation	NN

during	IN

pregnancy	NN

is	VBZ

associated	VBN

with	IN

lower	JJR

systolic	JJ

blood	NN

pressure	NN

in	IN

the	DT

offspring	NN

,	,

particularly	RB

among	IN

overweight	JJ

children	NNS

The	DT

fast	RB

reaction	NN

of	IN

peroxynitrite	NN

with	IN

CO2	NN

and	CC

the	DT

high	JJ

concentration	NN

of	IN

dissolved	VBN

CO2	NN

in	IN

vivo	FW

(	NN

ca	MD

1	CD

mM	NN

)	NN

suggest	VB

that	IN

CO2	NN

modulates	VBZ

most	RBS

of	IN

the	DT

reactions	NNS

of	IN

peroxynitrite	NN

in	IN

biological	JJ

systems	NNS

The	DT

addition	NN

of	IN

peroxynitrite	NN

to	TO

CO2	NN

produces	VBZ

of	IN

the	DT

adduct	NN

ONOO-CO2-	NN

(	NN

1	CD

)	NN

The	DT

production	NN

of	IN

1	CD

greatly	RB

accelerates	VBZ

the	DT

decomposition	NN

of	IN

peroxynitrite	NN

to	TO

give	VB

nitrate	VB

We	PRP

now	RB

show	NN

that	IN

the	DT

formation	NN

of	IN

1	CD

is	VBZ

followed	VBN

by	IN

reformation	NN

of	IN

CO2	NN

(	NN

rather	RB

than	IN

another	DT

carbonate	NN

species	NNS

such	JJ

as	IN

CO3	NN

=	JJ

or	CC

HCO3-	JJ

)	NN

To	TO

show	NN

this	DT

,	,

it	PRP

is	VBZ

necessary	JJ

to	TO

study	NN

systems	NNS

with	IN

limiting	VBG

concentrations	NNS

of	IN

CO2	NN

(	NN

When	WRB

CO2	NN

is	VBZ

present	JJ

in	IN

excess	NN

,	,

its	PRP$

concentration	NN

remains	NNS

nearly	RB

constant	JJ

during	IN

the	DT

decomposition	NN

of	IN

peroxynitrite	NN

,	,

and	CC

the	DT

recycling	VBG

of	IN

CO2	NN

,	,

although	IN

it	PRP

occurs	VBZ

,	,

can	MD

not	RB

be	VB

detected	VBN

kinetically	RB

)	NN

We	PRP

find	VB

that	IN

CO2	NN

is	VBZ

a	DT

true	JJ

catalyst	NN

of	IN

the	DT

decomposition	NN

of	IN

peroxynitrite	NN

,	,

and	CC

this	DT

fundamental	JJ

insight	NN

into	IN

its	PRP$

action	NN

must	MD

be	VB

rationalized	VBN

by	IN

any	DT

in	IN

vivo	FW

or	CC

in	IN

vitro	NN

reaction	NN

mechanism	NN

that	IN

is	VBZ

proposed	VBN

When	WRB

the	DT

concentration	NN

of	IN

CO2	NN

is	VBZ

lower	JJR

than	IN

that	IN

of	IN

peroxynitrite	NN

,	,

the	DT

reformation	NN

of	IN

CO2	NN

amplifies	VBZ

the	DT

fraction	NN

of	IN

peroxynitrite	NN

that	IN

reacts	VBZ

with	IN

CO2	NN

Even	RB

low	JJ

concentrations	NNS

of	IN

CO2	NN

that	IN

result	NN

from	IN

the	DT

dissolution	NN

of	IN

ambient	JJ

CO2	NN

can	MD

have	VB

pronounced	JJ

catalytic	JJ

effects	NNS

These	DT

effects	NNS

can	MD

cause	NN

deviations	NNS

from	IN

predicted	VBN

kinetic	JJ

behavior	NN

in	IN

studies	NNS

of	IN

peroxynitrite	NN

in	IN

noncarbonate	JJ

buffers	NNS

in	IN

vitro	NN

,	,

and	CC

since	IN

1	CD

and	CC

other	JJ

intermediates	NNS

derived	VBN

from	IN

it	PRP

are	VBP

oxidants	NNS

and/or	CC

nitrating	VBG

agents	NNS

,	,

some	DT

of	IN

the	DT

reactions	NNS

attributed	VBN

to	TO

peroxynitrite	NN

may	MD

depend	VB

on	IN

the	DT

availability	NN

of	IN

CO2	NN

A	DT

prospective	JJ

,	,

randomized	VBN

,	,

placebo-controlled	JJ

,	,

double-blind	JJ

,	,

parallel-group	NN

,	,

6-month	JJ

study	NN

assessed	VBN

the	DT

efficacy	NN

and	CC

safety	NN

of	IN

ropinirole	NN

,	,

a	DT

nonergoline	NN

D2-dopamine	NN

agonist	NN

,	,

in	IN

patients	NNS

with	IN

early	RB

Parkinson	NNP

's	POS

disease	NN

(	NN

n	NN

=	JJ

241	CD

;	:

Hoehn	NNP

&	CC

#	#

38	CD

;	:

Yahr	NN

stages	NNS

I	PRP

to	TO

III	NNP

)	NN

with	IN

limited	JJ

or	CC

no	DT

prior	RB

dopaminergic	JJ

therapy	NN

Patients	NNS

(	NN

mean	VB

age	NN

,	,

62.8	CD

years	NNS

)	NN

,	,

stratified	VBN

by	IN

concomitant	JJ

use	NN

of	IN

selegiline	NN

,	,

were	VBD

randomized	VBN

to	TO

ropinirole	NN

(	NN

n	NN

=	JJ

116	CD

)	NN

or	CC

placebo	NN

(	NN

n	NN

=	JJ

125	CD

)	NN

The	DT

starting	VBG

dose	NN

of	IN

ropinirole	NN

was	VBD

0.25	CD

mg	NN

tid	NN

with	IN

titration	NN

to	TO

at	IN

least	JJS

1.5	CD

mg	NN

tid	NN

(	NN

maximum	NN

dose	NN

,	,

8	CD

mg	NN

tid	NN

)	NN

Primary	JJ

efficacy	NN

endpoint	NN

was	VBD

the	DT

percentage	NN

improvement	NN

in	IN

Unified	JJ

Parkinson	NNP

's	POS

Disease	NN

Rating	NNP

Scale	NNP

(	NN

UPDRS	NNS

)	NN

motor	NN

score	NN

Ropinirole-treated	JJ

patients	NNS

had	VBD

a	DT

significantly	RB

greater	JJR

percentage	NN

improvement	NN

in	IN

UPDRS	NNS

motor	NN

score	NN

than	IN

patients	NNS

who	WP

received	VBN

placebo	NN

(	NN

+24	CD

%	NN

vs	CC

-3	CD

%	NN

;	:

p	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

Ropinirole	NNP

was	VBD

well	RB

tolerated	VBN

and	CC

patient	NN

withdrawals	NNS

were	VBD

infrequent	JJ

Most	JJS

adverse	JJ

experiences	NNS

were	VBD

related	JJ

to	TO

peripheral	JJ

dopaminergic	JJ

activity	NN

Ropinirole	NNP

monotherapy	NN

is	VBZ

an	DT

effective	JJ

and	CC

well-tolerated	JJ

therapeutic	JJ

option	NN

for	IN

treatment	NN

of	IN

early	RB

Parkinson	NNP

's	POS

disease	NN

Starfish	NNP

oocytes	NNS

can	MD

be	VB

fertilized	VBN

after	IN

germinal	JJ

vesicle	NN

breakdown	NN

(	NN

GVBD	NN

)	NN

and	CC

artificial	JJ

parthenogenesis	NN

can	MD

be	VB

induced	VBN

by	IN

activating	VBG

the	DT

oocytes	NNS

after	IN

GVBD	NN

(	NN

post-GVBD	JJ

activation	NN

)	NN

In	IN

the	DT

present	JJ

study	NN

,	,

parthenogenotes	NNS

were	VBD

obtained	VBN

by	IN

the	DT

activation	NN

of	IN

immature	JJ

oocytes	NNS

with	IN

caffeine	NN

before	IN

treatment	NN

with	IN

1-methyladenine	NN

(	NN

1-MeAde	NN

)	NN

to	TO

induce	VB

oocyte	NN

maturation	NN

Most	JJS

of	IN

the	DT

caffeine-treated	JJ

eggs	NNS

developed	VBN

as	IN

tetraploids	NNS

,	,

as	IN

parthenogenotes	NNS

produced	VBN

by	IN

the	DT

post-GVBD	JJ

activation	NN

The	DT

parthengenotes	NNS

were	VBD

derived	VBN

only	RB

from	IN

eggs	NNS

that	IN

failed	VBD

to	TO

extrude	VB

polar	JJ

bodies	NNS

,	,

mostly	RB

from	IN

eggs	NNS

failing	VBG

to	TO

extrude	VB

a	DT

second	JJ

polar	JJ

body	NN

Eggs	NNP

derived	VBN

from	IN

immature	JJ

oocytes	NNS

activated	VBN

by	IN

A23187	NN

,	,

treated	VBN

with	IN

1-MeAde	NN

and	CC

post-treated	JJ

with	IN

cytochalasin	NN

B	NN

failed	VBD

to	TO

extrude	VB

polar	JJ

bodies	NNS

,	,

and	CC

eventually	RB

developed	VBN

into	IN

parthenogenetic	JJ

embryos	NNS

These	DT

results	NNS

indicate	VBP

that	IN

the	DT

present	JJ

parthenogenesis	NN

mechanism	NN

shares	NNS

the	DT

same	JJ

characteristics	NNS

as	IN

that	IN

achieved	VBN

by	IN

post-GVBD	JJ

activation	NN

in	IN

the	DT

suppression	NN

of	IN

polar	JJ

body	NN

formation	NN

as	IN

a	DT

key	NN

means	NNS

for	IN

successful	JJ

starfish	NN

parthenogenesis	NN

We	PRP

hypothesized	VBN

that	IN

fluoride	NN

partly	RB

acts	NNS

by	IN

changing	VBG

the	DT

levels	NNS

of	IN

circulating	VBG

calcium-regulating	JJ

hormones	NNS

and	CC

skeletal	JJ

growth	NN

factors	NNS

The	DT

effects	NNS

of	IN

oral	JJ

fluoride	NN

on	IN

24	CD

female	NN

,	,

Dutch-Belted	JJ

,	,

young	JJ

adult	JJ

rabbits	NNS

were	VBD

studied	VBN

The	DT

rabbits	NNS

were	VBD

divided	VBN

into	IN

two	CD

study	NN

groups	NNS

,	,

one	CD

control	NN

and	CC

the	DT

other	JJ

receiving	VBG

about	IN

16	CD

mg	NN

fluoride/rabbit/day	NN

in	IN

their	PRP$

drinking	NN

water	NN

After	IN

6	CD

months	NNS

of	IN

fluoride	NN

dosing	NN

,	,

all	DT

rabbits	NNS

were	VBD

euthanized	VBN

and	CC

bone	NN

and	CC

blood	NN

samples	NNS

were	VBD

taken	VBN

for	IN

analyses	NNS

Fluoride	NN

treatment	NN

increased	VBN

serum	NN

and	CC

bone	NN

fluoride	NN

levels	NNS

by	IN

over	IN

an	DT

order	NN

of	IN

magnitude	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

,	,

but	CC

did	VBD

not	RB

affect	VB

body	NN

weight	NN

or	CC

the	DT

following	VBG

serum	NN

biochemical	JJ

variables	NNS

:	:

urea	NN

,	,

creatinine	NN

,	,

phosphorus	NN

,	,

total	NN

protein	NN

,	,

albumin	NN

,	,

bilirubin	NN

,	,

SGOT	NN

,	,

or	CC

total	NN

alkaline	NN

phosphatase	NN

<	JJR

TO_SEE	NN

>	JJR

No	DT

skeletal	JJ

fluorosis	NN

or	CC

osteomalacia	NN

was	VBD

observed	VBN

histologically	RB

,	,

nor	CC

did	VBD

fluoride	NN

affect	VB

serum	NN

PTH	NN

or	CC

Vitamin	NN

D	NN

metabolites	NNS

(	NN

P	NN

>	JJR

0.4	CD

)	NN

BAP	NN

was	VBD

increased	VBN

37	CD

%	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

by	IN

fluoride	NN

;	:

serum	NN

TRAP	NN

was	VBD

increased	VBN

42	CD

%	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

;	:

serum	NN

IGF-1	NN

was	VBD

increased	VBN

40	CD

%	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

Fluoride	NN

increased	VBN

the	DT

vertebral	NN

BV/TV	NN

by	IN

35	CD

%	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

and	CC

tibial	JJ

ash	JJ

weight	NN

by	IN

10	CD

%	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

However	RB

,	,

the	DT

increases	NNS

in	IN

bone	NN

mass	NN

and	CC

bone	NN

formation	NN

were	VBD

not	RB

reflected	VBN

in	IN

improved	VBN

bone	NN

strength	NN

Fluoride	NN

decreased	VBN

bone	NN

strength	NN

by	IN

about	IN

19	CD

%	NN

in	IN

the	DT

L5	NN

vertebra	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.01	CD

)	NN

and	CC

25	CD

%	NN

in	IN

the	DT

femoral	JJ

neck	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0	CD

05	NN

)	NN

X-ray	NN

diffraction	NN

showed	VBD

altered	JJ

mineral	NN

crystal	NN

thickness	NN

in	IN

fluoride-treated	JJ

bones	NNS

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.001	CD

)	NN

,	,

and	CC

there	RB

was	VBD

a	DT

negative	JJ

association	NN

between	IN

crystal	NN

width	NN

and	CC

fracture	NN

stress	NN

of	IN

the	DT

femur	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.02	CD

)	NN

In	IN

conclusion	NN

,	,

fluoride	NN

's	POS

effects	NNS

on	IN

bone	NN

mass	NN

and	CC

bone	NN

turnover	NN

were	VBD

not	RB

mediated	VBN

by	IN

PTH	NN

IGF-1	NN

was	VBD

increased	VBN

by	IN

fluoride	NN

and	CC

was	VBD

associated	VBN

with	IN

increased	VBN

bone	NN

turnover	NN

,	,

but	CC

was	VBD

not	RB

correlated	VBD

with	IN

bone	NN

formation	NN

markers	NNS

High-dose	JJ

fluoride	NN

treatment	NN

did	VBD

not	RB

improve	VB

,	,

but	CC

decreased	VBN

,	,

bone	NN

strength	NN

in	IN

rabbits	NNS

,	,

even	RB

in	IN

the	DT

absence	NN

of	IN

impaired	JJ

mineralization	NN

PURPOSE	NN

:	:

To	TO

determine	VB

the	DT

effect	NN

of	IN

various	JJ

methods	NNS

of	IN

managing	VBG

the	DT

posterior	NN

capsule	NN

and	CC

anterior	JJ

vitreous	JJ

on	IN

the	DT

rate	NN

of	IN

posterior	NN

capsule	NN

opacification	NN

in	IN

pediatric	JJ

eyes	NNS

implanted	VBN

with	IN

posterior	NN

chamber	NN

intraocular	JJ

lenses	NNS

(	NN

PC	NN

IOLs	NNS

)	NN

SETTING	VBG

:	:

Cullen	NNP

Eye	NNP

Institute	NNP

,	,

Baylor	NNP

College	NNP

of	IN

Medicine	NN

,	,

Houston	NNP

,	,

Texas	NNP

,	,

USA	NNP

METHODS	NNS

:	:

We	PRP

reviewed	VBN

the	DT

charts	NNS

of	IN

20	CD

eyes	NNS

of	IN

15	CD

children	NNS

(	NN

aged	JJ

1.5	CD

to	TO

2	CD

years	NNS

)	NN

who	WP

had	VBD

primary	JJ

cataract	NN

surgery	NN

with	IN

PC	NN

IOL	NNP

implantation	NN

during	IN

the	DT

past	IN

5	CD

years	NNS

The	DT

posterior	NN

capsule	NN

and	CC

anterior	JJ

vitreous	JJ

were	VBD

managed	VBN

in	IN

a	DT

variety	NN

of	IN

ways	NNS

:	:

In	IN

5	CD

eyes	NNS

,	,

the	DT

posterior	NN

capsule	NN

was	VBD

left	RB

intact	JJ

;	:

in	IN

15	CD

eyes	NNS

,	,

a	DT

posterior	NN

continuous	JJ

curvilinear	NN

capsulorhexis	NN

(	NN

PCCC	NN

)	NN

was	VBD

performed	VBN

-	:

6	CD

with	IN

and	CC

9	CD

without	IN

anterior	JJ

vitrectomy	NN

;	:

in	IN

8	CD

eyes	NNS

,	,

posterior	NN

optic	JJ

capture	NN

was	VBD

performed	VBN

-	:

3	CD

with	IN

and	CC

5	CD

without	IN

vitrectomy	NN

The	DT

follow-up	NN

ranged	VBD

from	IN

1	CD

to	TO

4.5	CD

years	NNS

(	NN

mean	VB

2	CD

years	NNS

)	NN

RESULTS	NNS

:	:

Visually	RB

significant	JJ

secondary	JJ

cataract	NN

developed	VBN

in	IN

the	DT

five	CD

eyes	NNS

with	IN

intact	JJ

posterior	NN

capsules	NNS

and	CC

in	IN

the	DT

four	CD

eyes	NNS

that	IN

had	VBD

PCCC	NN

without	IN

vitrectomy	NN

and	CC

without	IN

posterior	NN

optic	JJ

capture	NN

(	NN

i.e	NN

.	.

,	,

the	DT

optic	JJ

was	VBD

left	RB

in	IN

the	DT

capsular	JJ

bag	NN

)	NN

The	DT

optical	JJ

axis	NN

remained	VBD

clear	JJ

in	IN

the	DT

six	CD

eyes	NNS

that	IN

had	VBD

PC	NN

IOL	NNP

implantation	NN

with	IN

vitrectomy	NN

(	NN

with	IN

or	CC

without	IN

posterior	NN

optic	JJ

capture	NN

)	NN

Initially	RB

,	,

all	DT

eyes	NNS

that	IN

had	VBD

optic	JJ

capture	NN

without	IN

vitrectomy	NN

also	RB

remained	VBD

clear	JJ

,	,

but	CC

after	IN

6	CD

months	NNS

,	,

four	CD

of	IN

five	CD

developed	VBN

opacification	NN

CONCLUSION	NN

:	:

In	IN

this	DT

series	NN

,	,

PCCC	NN

with	IN

anterior	JJ

vitrectomy	NN

was	VBD

the	DT

only	RB

effective	JJ

method	NN

of	IN

preventing	VBG

or	CC

delaying	VBG

secondary	JJ

cataract	NN

formation	NN

in	IN

infants	NNS

and	CC

children	NNS

Evidence	NN

for	IN

the	DT

presence	NN

of	IN

a	DT

serotonin1A	NN

(	NN

5-HT1A	NN

)	NN

receptor	NN

subtype	NN

in	IN

the	DT

salmonid	NN

fish	NN

brain	NN

has	VBZ

recently	RB

been	VBN

presented	VBN

In	IN

the	DT

present	JJ

study	NN

the	DT

potent	JJ

5-HT1A	NN

receptor	NN

agonist	NN

,	,

8-hydroxy-2-	NN

(	NN

di-n-propylamino	NN

)	NN

-tetralin	NN

(	NN

8-OH-DPAT	NN

)	NN

was	VBD

tested	VBN

for	IN

its	PRP$

effect	NN

on	IN

plasma	NN

cortisol	NN

concentrations	NNS

in	IN

rainbow	NN

trout	NNS

(	NN

Oncorhynchus	NNP

mykiss	NN

)	NN

Blood	NN

was	VBD

sampled	VBN

and	CC

8-OH-DPAT	NN

administered	VBN

through	IN

a	DT

catheter	NN

in	IN

the	DT

dorsal	NN

aorta	NN

Thirty	CD

minutes	NNS

after	IN

the	DT

injection	NN

of	IN

40	CD

microg	NN

of	IN

8-OH-DPAT/kg	NN

,	,

plasma	NN

cortisol	NN

levels	NNS

had	VBD

increased	VBN

from	IN

12	CD

to	TO

149	CD

ng/ml	NN

,	,

whereupon	NN

they	PRP

fell	VBD

,	,

reaching	VBG

baseline	NN

levels	NNS

after	IN

4	CD

h.	NN

The	DT

effect	NN

of	IN

1-40	CD

microg	NN

8-OH-DPAT/kg	NN

on	IN

plasma	NN

cortisol	NN

concentrations	NNS

was	VBD

dose-dependent	JJ

The	DT

results	NNS

lends	VBZ

further	RB

support	NN

to	TO

the	DT

hypothesis	NN

that	IN

the	DT

brain	NN

serotonergic	JJ

system	NN

plays	NNS

a	DT

key	NN

role	NN

in	IN

integrating	VBG

autonomic	JJ

,	,

behavioral	JJ

and	CC

neuroendocrine	NN

stress-responses	NNS

in	IN

fish	NN

as	IN

well	RB

as	IN

mammals	NNS

,	,

suggesting	VBG

that	IN

not	RB

only	RB

the	DT

structural	JJ

and	CC

biochemical	JJ

organization	NN

,	,

but	CC

also	RB

the	DT

function	NN

of	IN

the	DT

serotonergic	JJ

system	NN

has	VBZ

been	VBN

conserved	VBN

during	IN

vertebrate	NN

evolution	NN

OBJECTIVE	NN

:	:

To	TO

assess	VB

the	DT

medicalising	VBG

effect	NN

of	IN

prescribing	VBG

antibiotics	NNS

for	IN

sore	JJ

throat	NN

SETTING	VBG

:	:

11	CD

general	JJ

practices	NNS

in	IN

England	NNP

DESIGN	NN

:	:

Randomised	VBN

trial	NN

of	IN

three	CD

approaches	NNS

to	TO

sore	JJ

throat	NN

:	:

a	DT

10	CD

day	NN

prescription	NN

of	IN

antibiotics	NNS

,	,

no	DT

antibiotics	NNS

,	,

or	CC

a	DT

delayed	VBN

prescription	NN

if	IN

the	DT

sore	JJ

throat	NN

had	VBD

not	RB

started	VBD

to	TO

settle	VB

after	IN

three	CD

days	NNS

PATIENTS	NNS

:	:

716	CD

patients	NNS

aged	JJ

4	CD

and	CC

over	IN

with	IN

sore	JJ

throat	NN

and	CC

an	DT

abnormal	JJ

physical	JJ

sign	NN

:	:

84	CD

%	NN

had	VBD

tonsillitis	NN

or	CC

pharyngitis	NN

OUTCOME	NN

MEASURES	NNS

:	:

Number	NN

and	CC

rate	NN

of	IN

patients	NNS

making	VBG

a	DT

first	RB

return	NN

with	IN

sore	JJ

throat	NN

,	,

pharyngitis	NN

,	,

or	CC

tonsillitis	NN

Early	RB

returns	NNS

(	NN

within	IN

two	CD

weeks	NNS

)	NN

and	CC

complications	NNS

(	NN

otitis	NN

media	NNS

,	,

sinusitis	NN

,	,

quinsy	NN

)	NN

Outcomes	NNS

were	VBD

documented	VBN

in	IN

675	CD

subjects	NNS

(	NN

94	CD

%	NN

)	NN

RESULTS	NNS

:	:

Mean	NN

follow	VB

up	RB

time	NN

was	VBD

similar	JJ

(	NN

antibiotic	JJ

group	NN

1.07	CD

years	NNS

,	,

other	JJ

two	CD

groups	NNS

1.03	CD

years	NNS

)	NN

More	RBR

of	IN

those	DT

initially	RB

prescribed	VBN

antibiotics	NNS

initially	RB

returned	VBN

to	TO

the	DT

surgery	NN

with	IN

sore	JJ

throat	NN

(	NN

38	CD

%	NN

v	LS

27	CD

%	NN

,	,

adjusted	VBN

hazard	NN

ratio	NN

for	IN

return	NN

1.39	CD

%	NN

,	,

95	CD

%	NN

confidence	NN

interval	NN

1.03	CD

to	TO

1.89	CD

)	NN

Antibiotics	NNS

prescribed	VBN

for	IN

sore	JJ

throat	NN

during	IN

the	DT

previous	JJ

year	NN

had	VBD

an	DT

additional	JJ

effect	NN

(	NN

hazard	NN

ratio	NN

1.69	CD

,	,

1.20	CD

to	TO

2.37	CD

)	NN

Longer	JJR

duration	NN

of	IN

illness	NN

(	NN

>	JJR

5	CD

days	NNS

)	NN

was	VBD

associated	VBN

with	IN

increased	VBN

return	NN

within	IN

six	CD

weeks	NNS

(	NN

hazard	NN

ratio	NN

2.90	CD

,	,

1.70	CD

to	TO

4.92	CD

)	NN

Prior	RB

attendance	NN

with	IN

upper	JJ

respiratory	JJ

conditions	NNS

was	VBD

also	RB

associated	VBN

with	IN

increased	VBN

reattendance	NN

There	EX

was	VBD

no	DT

difference	NN

between	IN

groups	NNS

in	IN

early	RB

return	NN

(	NN

13/238	CD

(	NN

5.5	CD

%	NN

)	NN

v	LS

27/437	CD

(	NN

6	CD

%	NN

)	NN

)	NN

,	,

or	CC

complications	NNS

(	NN

2/236	CD

(	NN

0.8	CD

%	NN

)	NN

v	LS

3/434	CD

(	NN

0.7	CD

%	NN

)	NN

)	NN

CONCLUSIONS	NNS

:	:

Complications	NNS

and	CC

early	RB

return	NN

resulting	VBG

from	IN

no	DT

or	CC

delayed	VBN

prescribing	VBG

of	IN

antibiotics	NNS

for	IN

sore	JJ

throat	NN

are	VBP

rare	JJ

Both	DT

current	JJ

and	CC

previous	JJ

prescribing	VBG

for	IN

sore	JJ

throat	NN

increase	NN

reattendance	NN

To	TO

avoid	VB

medicalising	VBG

a	DT

self	NN

limiting	VBG

illness	NN

doctors	NNS

should	MD

avoid	VB

antibiotics	NNS

or	CC

offer	NN

a	DT

delayed	VBN

prescription	NN

for	IN

most	RBS

patients	NNS

with	IN

sore	JJ

throat	NN

This	DT

study	NN

was	VBD

designed	VBN

to	TO

determine	VB

and	CC

compare	VB

the	DT

dose-response	NN

characteristics	NNS

,	,

speed	NN

of	IN

onset	NN

,	,

and	CC

relative	JJ

potency	NN

of	IN

single-dose	JJ

epidural	JJ

fentanyl	NN

(	NN

F	NN

)	NN

and	CC

sufentanil	NN

(	NN

S	NN

)	NN

for	IN

postoperative	JJ

pain	NN

relief	NN

<	JJR

TO_SEE	NN

>	JJR

Eighty	CD

women	NNS

undergoing	VBG

cesarean	NN

section	NN

(	NN

C/S	NN

)	NN

with	IN

epidural	JJ

2	CD

%	NN

lidocaine	NN

with	IN

epinephrine	NN

(	NN

1	CD

:	:

200	CD

,	,

000	CD

)	NN

were	VBD

randomly	RB

assigned	VBN

to	TO

receive	VB

double-blind	JJ

epidural	JJ

administration	NN

of	IN

F	NN

(	NN

25	CD

,	,

50	CD

,	,

100	CD

,	,

or	CC

200	CD

microg	NN

)	NN

or	CC

S	NN

(	NN

5	CD

,	,

10	CD

,	,

20	CD

,	,

or	CC

30	CD

microg	NN

)	NN

(	NN

n	NN

=	JJ

10	CD

per	IN

group	NN

)	NN

upon	IN

complaint	NN

of	IN

pain	NN

postoperatively	RB

Visual	JJ

analog	NN

scales	NNS

(	NN

VAS	NNP

,	,

0-100	CD

mm	NN

)	NN

were	VBD

used	VBN

to	TO

assess	VB

pain	NN

and	CC

sedation	NN

at	IN

baseline	NN

;	:

at	IN

3	CD

,	,

6	CD

,	,

9	CD

,	,

12	CD

,	,

15	CD

,	,

20	CD

,	,

25	CD

,	,

30	CD

,	,

45	CD

,	,

and	CC

60	CD

min	NN

;	:

and	CC

every	DT

30	CD

min	NN

until	IN

further	RB

analgesia	NN

was	VBD

requested	VBN

The	DT

study	NN

was	VBD

terminated	VBN

at	IN

30	CD

min	NN

if	IN

satisfactory	JJ

analgesia	NN

was	VBD

not	RB

achieved	VBN

Side	NN

effects	NNS

were	VBD

recorded	VBN

A	DT

dose-response	NN

was	VBD

demonstrated	VBN

for	IN

both	DT

opioids	NNS

F	NN

25	CD

microg	NN

and	CC

S	NN

5	CD

microg	NN

were	VBD

ineffective	JJ

,	,

with	IN

significantly	RB

fewer	JJR

women	NNS

achieving	VBG

VAS	NNP

scores	NNS

&	CC

#	#

60	CD

;	:

10	CD

mm	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

compared	VBN

with	IN

F	NN

100	CD

or	CC

200	CD

microg	NN

and	CC

S	NN

20	CD

or	CC

30	CD

microg	NN

)	NN

F	NN

100	CD

and	CC

200	CD

microg	NN

and	CC

S	NN

20	CD

and	CC

30	CD

microg	NN

all	DT

achieved	VBN

VAS	NNP

scores	NNS

&	CC

#	#

60	CD

;	:

10	CD

mm	NN

in	IN

all	DT

women	NNS

with	IN

no	DT

differences	NNS

in	IN

time	NN

to	TO

50	CD

%	NN

reduction	NN

in	IN

VAS	NNP

(	NN

mean	VB

11-16	CD

min	NN

)	NN

and	CC

no	DT

differences	NNS

in	IN

duration	NN

of	IN

analgesia	NN

(	NN

mean	VB

117-138	CD

min	NN

)	NN

The	DT

50	CD

%	NN

and	CC

95	CD

%	NN

effective	JJ

dose	NN

values	NNS

for	IN

each	DT

opioid	NN

to	TO

achieve	VB

a	DT

VAS	NNP

score	NN

&	CC

#	#

60	CD

;	:

10	CD

mm	NN

were	VBD

F	NN

33	CD

microg	NN

and	CC

92	CD

microg	NN

and	CC

S	NN

6.7	CD

microg	NN

and	CC

17.5	CD

microg	NN

There	EX

were	VBD

no	DT

differences	NNS

among	IN

groups	NNS

in	IN

sedation	NN

scores	NNS

or	CC

side	NN

effects	NNS

Our	PRP$

data	NNS

suggest	VB

that	IN

the	DT

relative	JJ

analgesic	JJ

potency	NN

of	IN

epidural	JJ

S	NN

:	:

F	NN

is	VBZ

approximately	RB

5	CD

and	CC

that	IN

there	RB

are	VBP

no	DT

differences	NNS

between	IN

the	DT

opioids	NNS

in	IN

the	DT

onset	NN

,	,

duration	NN

,	,

and	CC

effectiveness	NN

of	IN

analgesia	NN

when	WRB

equianalgesic	JJ

doses	NNS

are	VBP

administered	VBN

postoperatively	RB

after	IN

lidocaine	NN

anesthesia	NN

for	IN

C/S	NN

We	PRP

describe	VBP

2	CD

cases	NNS

in	IN

which	WDT

intraoperative	JJ

transesophageal	NN

echocardiography	NN

detected	VBN

complications	NNS

related	JJ

to	TO

the	DT

proximal	JJ

coronary	JJ

arteries	NNS

during	IN

homograft	NN

aortic	JJ

valve	NN

and	CC

root	NN

replacement	NN

In	IN

both	DT

cases	NNS

,	,

cardiopulmonary	JJ

bypass	NN

could	MD

not	RB

be	VB

discontinued	VBN

despite	IN

the	DT

use	NN

of	IN

large	JJ

doses	NNS

of	IN

inotropic	JJ

drugs	NNS

Transesophageal	NN

echocardiography	NN

demonstrated	VBN

aliasing	VBG

on	IN

color	NN

flow	NN

mapping	NN

in	IN

the	DT

left	RB

main	JJ

coronary	JJ

artery	NN

in	IN

1	CD

case	NN

and	CC

proximal	JJ

right	RB

coronary	JJ

artery	NN

in	IN

the	DT

other	JJ

,	,

along	IN

with	IN

severely	RB

depressed	JJ

left	RB

ventricular	JJ

anterior	JJ

wall	NN

and	CC

right	RB

ventricular	JJ

function	NN

,	,

respectively	RB

Coronary	JJ

artery	NN

bypass	NN

grafting	VBG

was	VBD

performed	VBN

in	IN

both	DT

cases	NNS

,	,

and	CC

the	DT

outcome	NN

was	VBD

successful	JJ

<	JJR

TO_SEE	NN

>	JJR

Granulocyte	NN

colony-stimulating	JJ

factor	NN

(	NN

G-CSF	NN

)	NN

has	VBZ

been	VBN

used	VBN

to	TO

improve	VB

granulocyte	NN

count	NN

in	IN

chronic	JJ

neutropenia	NN

and	CC

myelodysplasia	NN

,	,

to	TO

minimize	VB

the	DT

incidence	NN

and	CC

duration	NN

of	IN

neutropenia	NN

during	IN

conventional	JJ

chemotherapy	NN

,	,

and	CC

to	TO

mobilize	VB

peripheral	JJ

blood	NN

stem	NN

cells	NNS

prior	RB

to	TO

leukapheresis	NN

for	IN

use	NN

in	IN

autologous	JJ

and	CC

allogeneic	JJ

marrow	NN

transplantation	NN

The	DT

most	RBS

common	JJ

toxicity	NN

is	VBZ

bone	NN

pain	NN

,	,

and	CC

other	JJ

reactions	NNS

such	JJ

as	IN

inflammation	NN

at	IN

the	DT

site	NN

of	IN

injection	NN

have	VB

also	RB

occurred	VBD

In	IN

patients	NNS

with	IN

chronic	JJ

neutropenia	NN

,	,

splenomegaly	NN

has	VBZ

been	VBN

described	VBN

with	IN

long-term	JJ

use	NN

,	,

and	CC

extramedullary	JJ

hematopoiesis	NN

has	VBZ

also	RB

been	VBN

reported	VBN

However	RB

,	,

thus	RB

far	RB

,	,

no	DT

life-threatening	JJ

sequelae	NN

of	IN

these	DT

effects	NNS

are	VBP

found	VBN

in	IN

the	DT

literature	NN

We	PRP

now	RB

describe	VBP

a	DT

case	NN

of	IN

spontaneous	JJ

splenic	JJ

rupture	NN

four	CD

days	NNS

following	VBG

a	DT

six-day	JJ

course	NN

of	IN

G-CSF	NN

therapy	NN

in	IN

an	DT

allogeneic	JJ

donor	NN

of	IN

peripheral	JJ

blood	NN

stem	NN

cells	NNS

Evidence-based	JJ

medicine	NN

(	NN

EBM	NN

)	NN

aids	NNS

clinical	JJ

decision	NN

making	VBG

in	IN

all	DT

fields	NNS

of	IN

medicine	NN

,	,

including	VBG

primary	JJ

care	NN

General	NNP

practice	NN

is	VBZ

characterized	VBN

by	IN

particular	JJ

emphasis	NN

on	IN

the	DT

doctor-patient	JJ

relationship	NN

and	CC

on	IN

biomedical	JJ

,	,

personal	JJ

and	CC

contextual	JJ

perspectives	NNS

in	IN

diagnosis	NN

Most	JJS

evidence	NN

available	JJ

to	TO

general	JJ

practitioners	NNS

(	NN

GPs	NNS

)	NN

addresses	NNS

only	RB

the	DT

bio-medical	JJ

perspective	NN

and	CC

is	VBZ

often	RB

not	RB

directly	RB

applicable	JJ

to	TO

primary	JJ

care	NN

,	,

as	IN

it	PRP

derives	VBZ

from	IN

secondary	JJ

or	CC

tertiary	JJ

care	NN

Emphasis	NN

on	IN

the	DT

biomedical	JJ

domain	NN

and	CC

the	DT

randomized	VBN

controlled	VBN

trial	NN

(	NN

RCT	NN

)	NN

alone	RB

reflects	VBZ

a	DT

reductionist	JJ

approach	NN

that	IN

fails	VBZ

to	TO

do	VB

justice	NN

to	TO

the	DT

philosophy	NN

of	IN

general	JJ

practice	NN

The	DT

art	NN

of	IN

medicine	NN

is	VBZ

founded	VBN

on	IN

context	NN

,	,

anecdote	NN

,	,

patient	NN

stories	NNS

of	IN

illness	NN

and	CC

personal	JJ

experience	NN

,	,

and	CC

we	PRP

should	MD

continue	VB

to	TO

blend	VB

this	DT

with	IN

good	JJ

quality	NN

and	CC

appropriate	JJ

research	NN

findings	NNS

in	IN

patient	NN

care	NN

Abdominal	JJ

tuberculosis	NN

is	VBZ

not	RB

uncommon	JJ

in	IN

the	DT

UK	NNP

,	,

especially	RB

in	IN

Asian	JJ

immigrants	NNS

It	PRP

resembles	VBZ

Crohn	NN

's	POS

disease	NN

clinically	RB

and	CC

radiologically	RB

,	,

and	CC

it	PRP

may	MD

be	VB

difficult	JJ

to	TO

differentiate	VB

between	IN

them	PRP

,	,

even	RB

at	IN

laparotomy	NN

or	CC

histology	NN

The	DT

distinction	NN

is	VBZ

important	JJ

,	,

however	RB

,	,

for	IN

proper	JJ

management	NN

of	IN

the	DT

two	CD

conditions	NNS

<	JJR

TO_SEE	NN

>	JJR

Every	DT

effort	NN

must	MD

be	VB

made	VBN

to	TO

exclude	VB

abdominal	JJ

tuberculosis	NN

before	IN

the	DT

patient	NN

is	VBZ

diagnosed	VBN

as	IN

having	VBG

Crohn	NN

's	POS

disease	NN

and	CC

is	VBZ

treated	VBN

with	IN

steroids	NNS

PURPOSE	NN

:	:

The	DT

American	NNP

Urological	JJ

Association	NNP

convened	VBN

the	DT

Female	JJ

Stress	NN

Urinary	JJ

Incontinence	NN

Clinical	JJ

Guidelines	NNS

Panel	NN

to	TO

analyze	VB

the	DT

literature	NN

regarding	VBG

surgical	JJ

procedures	NNS

for	IN

treating	VBG

stress	NN

urinary	JJ

incontinence	NN

in	IN

the	DT

otherwise	RB

healthy	JJ

female	NN

subject	NN

and	CC

to	TO

make	VB

practice	NN

recommendations	NNS

based	VBN

on	IN

the	DT

treatment	NN

outcomes	NNS

data	NNS

MATERIALS	NNS

AND	CC

METHODS	NNS

:	:

The	DT

panel	NN

searched	VBD

the	DT

MEDLINE	NN

data	NNS

base	NN

for	IN

all	DT

articles	NNS

through	IN

1993	CD

on	IN

surgical	JJ

treatment	NN

of	IN

female	NN

stress	NN

urinary	JJ

incontinence	NN

Outcomes	NNS

data	NNS

were	VBD

extracted	VBN

from	IN

articles	NNS

accepted	VBN

after	IN

panel	NN

review	NN

The	DT

data	NNS

were	VBD

then	RB

meta-analyzed	JJ

to	TO

produce	VB

outcome	NN

estimates	NNS

for	IN

alternative	NN

surgical	JJ

procedures	NNS

RESULTS	NNS

:	:

The	DT

data	NNS

indicate	VBP

that	IN

after	IN

48	CD

months	NNS

retropubic	NN

suspensions	NNS

and	CC

slings	NNS

appear	VB

to	TO

be	VB

more	RBR

efficacious	JJ

than	IN

transvaginal	JJ

suspensions	NNS

,	,

and	CC

also	RB

more	RBR

efficacious	JJ

than	IN

anterior	JJ

repairs	NNS

The	DT

literature	NN

suggests	VBZ

higher	JJR

complication	NN

rates	NNS

when	WRB

synthetic	JJ

materials	NNS

are	VBP

used	VBN

for	IN

slings	NNS

CONCLUSIONS	NNS

:	:

The	DT

panel	NN

found	VBN

sufficient	JJ

acceptable	JJ

long-term	JJ

outcomes	NNS

data	NNS

(	NN

longer	RB

than	IN

48	CD

months	NNS

)	NN

to	TO

conclude	VBP

that	IN

surgical	JJ

treatment	NN

of	IN

female	NN

stress	NN

urinary	JJ

incontinence	NN

is	VBZ

effective	JJ

,	,

offering	NN

a	DT

long-term	JJ

cure	NN

in	IN

a	DT

significant	JJ

percentage	NN

of	IN

women	NNS

The	DT

evidence	NN

supports	NNS

surgery	NN

as	IN

initial	JJ

therapy	NN

and	CC

as	IN

a	DT

secondary	JJ

form	NN

of	IN

therapy	NN

after	IN

failure	NN

of	IN

other	JJ

treatments	NNS

for	IN

stress	NN

urinary	JJ

incontinence	NN

Retropubic	JJ

suspensions	NNS

and	CC

slings	NNS

are	VBP

the	DT

most	RBS

efficacious	JJ

procedures	NNS

for	IN

long-term	JJ

success	NN

(	NN

based	VBN

on	IN

cure/dry	NN

rates	NNS

)	NN

However	RB

,	,

in	IN

the	DT

panel	NN

's	POS

opinion	NN

retropubic	NN

suspensions	NNS

and	CC

sling	NN

procedures	NNS

are	VBP

associated	VBN

with	IN

slightly	RB

higher	JJR

complication	NN

rates	NNS

,	,

including	VBG

longer	RB

convalescence	NN

and	CC

postoperative	JJ

voiding	VBG

dysfunction	NN

A	DT

55-year-old	JJ

lady	NN

underwent	VBD

repeat	NN

aortic	JJ

valve	NN

replacement	NN

using	VBG

a	DT

16-mm	NN

Carbomedics	NNS

prosthesis	NN

She	PRP

made	VBN

an	DT

uneventful	JJ

postoperative	JJ

recovery	NN

and	CC

now	RB

leads	NNS

an	DT

unrestricted	JJ

life	NN

Doppler	NNP

echocardiography	NN

reveals	VBZ

a	DT

21-mm	NN

Hg	NN

gradient	NN

across	IN

the	DT

valve	NN

at	IN

rest	NN

This	DT

did	VBD

not	RB

increase	NN

with	IN

an	DT

infusion	NN

of	IN

30	CD

mcg/kg	NN

per	IN

min	NN

of	IN

dobutamine	NN

,	,

which	WDT

resulted	VBD

in	IN

an	DT

increase	NN

in	IN

the	DT

cardiac	JJ

output	NN

from	IN

1.96	CD

to	TO

5.46	CD

l/min	NN

BACKGROUND	NN

:	:

For	IN

more	RBR

than	IN

30	CD

years	NNS

it	PRP

has	VBZ

been	VBN

known	VBN

that	IN

gastric	JJ

acid	NN

secretion	NN

is	VBZ

inversely	RB

related	JJ

to	TO

the	DT

extent	NN

and	CC

severity	NN

of	IN

corpal	NN

gastritis	NN

We	PRP

therefore	RB

evaluated	VBN

the	DT

effect	NN

of	IN

cure	NN

of	IN

Helicobacter	NNP

pylori	NN

infection	NN

on	IN

basal	JJ

and	CC

pentagastrin-stimulated	JJ

acid	NN

secretion	NN

METHODS	NNS

:	:

Basal	JJ

acid	NN

output	NN

(	NN

BAO	NNP

)	NN

and	CC

maximal	JJ

acid	NN

output	NN

(	NN

MAO	NNP

)	NN

were	VBD

assessed	VBN

in	IN

11	CD

H.	NNP

pylori-infected	JJ

dyspeptic	JJ

patients	NNS

(	NN

8	CD

women	NNS

and	CC

3	CD

men	NNS

;	:

mean	VB

age	NN

,	,

28	CD

years	NNS

)	NN

before	IN

and	CC

after	IN

successful	JJ

anti-H	JJ

pylori	NN

therapy	NN

RESULTS	NNS

:	:

The	DT

gastritis	NN

index	NN

was	VBD

significantly	RB

lower	JJR

after	IN

therapy	NN

and	CC

was	VBD

associated	VBN

with	IN

an	DT

increase	NN

in	IN

both	DT

BAO	NNP

and	CC

MAO	NNP

after	IN

cure	NN

of	IN

the	DT

H.	NNP

pylori	NN

infection	NN

(	NN

BAO	NNP

from	IN

0.3	CD

mmol/h	NN

and	CC

MAO	NNP

from	IN

4.8	CD

mmol/h	NN

to	TO

19	CD

mmol/	NN

h	NN

)	NN

Basal	JJ

and	CC

stimulated	VBN

acid	NN

concentrations	NNS

also	RB

increased	VBN

(	NN

29.1	CD

+/-	CC

36.6	CD

to	TO

54	CD

+/-	CC

31	CD

mmol/l	NN

and	CC

72.5	CD

+/-	CC

46	CD

to	TO

120.1	CD

+/-	CC

30	CD

mmol/l	NN

,	,

respectively	RB

,	,

for	IN

basal	JJ

and	CC

stimulated	VBN

acid	NN

concentrations	NNS

;	:

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

for	IN

peak	NN

and	CC

MAO	NNP

,	,

P	NN

=	JJ

0.07	CD

for	IN

BAO	NNP

)	NN

CONCLUSION	NN

:	:

Gastric	JJ

acid	NN

secretion	NN

increased	VBN

into	IN

the	DT

normal	JJ

range	NN

after	IN

successful	JJ

treatment	NN

of	IN

H.	NNP

pylori	NN

infection	NN

,	,

suggesting	VBG

that	IN

gastric	JJ

function	NN

can	MD

recover	VB

to	TO

normal	JJ

or	CC

almost	RB

normal	JJ

after	IN

cure	NN

of	IN

H.	NNP

pylori	NN

infection	NN

OBJECTIVE	NN

:	:

Reports	NNS

suggest	VB

that	IN

there	RB

is	VBZ

an	DT

increased	VBN

incidence	NN

of	IN

preeclampsia	NN

after	IN

a	DT

previously	RB

normal	JJ

pregnancy	NN

if	IN

there	RB

is	VBZ

a	DT

change	NN

in	IN

paternity	NN

We	PRP

hypothesize	VB

that	IN

there	RB

is	VBZ

a	DT

higher	JJR

incidence	NN

of	IN

preeclampsia	NN

(	NN

proteinuric	JJ

hypertension	NN

)	NN

in	IN

women	NNS

conceiving	VBG

by	IN

intrauterine	JJ

insemination	NN

with	IN

donor	NN

sperm	NN

versus	CC

intrauterine	JJ

insemination	NN

with	IN

partner	NN

sperm	NN

STUDY	NN

DESIGN	NN

:	:

This	DT

was	VBD

a	DT

retrospective	NN

cohort	NN

study	NN

In	IN

women	NNS

with	IN

primary	JJ

infertility	NN

all	DT

pregnancies	NNS

achieved	VBN

by	IN

either	DT

partner	NN

or	CC

donor	NN

intrauterine	JJ

insemination	NN

carried	VBD

to	TO

birth	NN

of	IN

a	DT

fetus	NN

(	NN

>	JJR

20	CD

weeks	NNS

)	NN

were	VBD

identified	VBN

The	DT

medical	JJ

records	NNS

were	VBD

examined	VBN

for	IN

the	DT

maternal	JJ

and	CC

pregnancy	NN

outcome	NN

data	NNS

The	DT

relative	JJ

risk	NN

and	CC

95	CD

%	NN

confidence	NN

interval	NN

were	VBD

calculated	VBN

for	IN

the	DT

risk	NN

of	IN

preeclampsia	NN

The	DT

baseline	NN

data	NNS

were	VBD

compared	VBN

with	IN

t	NN

tests	NNS

,	,

chi	NN

2	CD

analysis	NN

and	CC

Fisher	NNP

's	POS

exact	JJ

test	NN

where	WRB

appropriate	JJ

RESULTS	NNS

:	:

Forty-four	CD

patients	NNS

in	IN

the	DT

partner	NN

intrauterine	JJ

insemination	NN

group	NN

and	CC

37	CD

in	IN

the	DT

donor	NN

insemination	NN

group	NN

were	VBD

identified	VBN

as	IN

having	VBG

primary	JJ

infertility	NN

Three	CD

cases	NNS

of	IN

mild	JJ

preeclampsia	NN

were	VBD

found	VBN

in	IN

the	DT

partner	NN

insemination	NN

program	NN

and	CC

nine	CD

cases	NNS

of	IN

preeclampsia	NN

(	NN

five	CD

severe	JJ

,	,

four	CD

mild	JJ

)	NN

in	IN

the	DT

donor	NN

insemination	NN

program	NN

(	NN

relative	JJ

risk	NN

1.85	CD

,	,

95	CD

%	NN

confidence	NN

interval	NN

1.20	CD

to	TO

2.85	CD

)	NN

.	.

CONCLUSIONS	NNS

:	:

There	EX

is	VBZ

a	DT

higher	JJR

incidence	NN

of	IN

preeclampsia	NN

in	IN

women	NNS

conceiving	VBG

by	IN

intrauterine	JJ

insemination	NN

with	IN

washed	VBN

donor	NN

sperm	NN

compared	VBN

with	IN

intrauterine	JJ

insemination	NN

with	IN

washed	VBN

partner	NN

sperm	NN

.	.

CONCLUSIONS	NNS

:	:

There	EX

is	VBZ

a	DT

higher	JJR

incidence	NN

of	IN

preeclampsia	NN

in	IN

women	NNS

conceiving	VBG

by	IN

intrauterine	JJ

insemination	NN

with	IN

washed	VBN

donor	NN

sperm	NN

compared	VBN

with	IN

intrauterine	JJ

insemination	NN

with	IN

washed	VBN

partner	NN

sperm	NN

.	.

This	DT

supports	NNS

,	,

indirectly	RB

,	,

an	DT

immunologic	JJ

basis	NN

for	IN

preeclampsia	NN

The	DT

antigenic	JJ

factor	NN

would	MD

appear	VB

to	TO

be	VB

located	JJ

on	IN

the	DT

sperm	NN

as	IN

opposed	VBN

to	TO

the	DT

seminal	JJ

fluid	NN

itself	PRP

After	IN

a	DT

rapid	JJ

examination	NN

of	IN

a	DT

few	JJ

basic	JJ

concepts	NNS

concerning	VBG

cellular	JJ

aging	VBG

and	CC

programmed	VBN

cell	NN

death	NN

,	,

the	DT

aging	VBG

of	IN

the	DT

tissues	NNS

and	CC

organs	NNS

,	,

the	DT

authors	NNS

discuss	VB

the	DT

principal	NN

theories	NNS

on	IN

senescence	NN

They	PRP

underline	VB

that	IN

it	PRP

is	VBZ

necessary	JJ

to	TO

agree	VB

in	IN

considering	VBG

the	DT

various	JJ

genetic	JJ

and	CC

epigenetic	JJ

,	,

endogenous	JJ

and	CC

exogenous	JJ

mechanisms	NNS

that	IN

lead	NN

to	TO

the	DT

complex	NN

aging	VBG

phenomenon	NN

multiple	JJ

and	CC

interrelated	VBN

In	IN

particular	JJ

they	PRP

stress	NN

the	DT

hypothesis	NN

that	IN

senescence	NN

can	MD

be	VB

due	JJ

to	TO

a	DT

sum	NN

of	IN

molecular	JJ

damages	NNS

caused	VBN

by	IN

free	JJ

radicals	NNS

,	,

and	CC

to	TO

the	DT

loss	NN

of	IN

telomeric	JJ

DNA	NN

Radical	NNP

reactions	NNS

can	MD

cause	NN

mutations	NNS

,	,

inactivation	NN

or	CC

a	DT

decrease	NN

in	IN

the	DT

turnover	NN

of	IN

mitochondrial	JJ

DNA	NN

which	WDT

is	VBZ

more	RBR

vulnerable	JJ

than	IN

the	DT

nuclear	JJ

genoma	NN

to	TO

the	DT

attack	NN

of	IN

mutagenic	JJ

agents	NNS

,	,

acting	VBG

also	RB

as	IN

a	DT

continuous	JJ

source	NN

of	IN

initial	JJ

and/or	CC

promoting	VBG

factors	NNS

of	IN

the	DT

carcinogenetic	JJ

process	NN

The	DT

somatic	JJ

cells	NNS

become	VB

senescent	JJ

because	IN

during	IN

cell	NN

division	NN

,	,

they	PRP

lose	VB

the	DT

mechanisms	NNS

for	IN

the	DT

lengthening	VBG

of	IN

the	DT

telomere	NN

The	DT

telomerase	NN

prevents	VBZ

the	DT

shortening	VBG

of	IN

telomeres	NNS

in	IN

neoplastic	JJ

cells	NNS

and	CC

therefore	RB

renders	VBZ

them	PRP

immortal	JJ

Paradoxically	RB

the	DT

protection	NN

of	IN

the	DT

telomere	NN

is	VBZ

exactly	RB

what	WDT

must	MD

be	VB

avoided	VBN

in	IN

the	DT

case	NN

of	IN

tumor	NN

cells	NNS

Recently	RB

the	DT

demonstration	NN

that	IN

telomerase	NN

is	VBZ

not	RB

always	RB

involved	VBN

in	IN

the	DT

restoration	NN

of	IN

telomere	NN

length	NN

shows	NNS

the	DT

complexity	NN

of	IN

the	DT

problems	NNS

connected	VBN

to	TO

the	DT

cause	NN

of	IN

senescence	NN

Chromosomally	RB

integrated	VBN

retroviral	JJ

switch	NN

(	NN

S	NN

)	NN

substrates	NNS

have	VB

been	VBN

developed	VBN

to	TO

reveal	VB

switch	NN

recombinase-like	JJ

activities	NNS

(	NN

SRLA	NN

)	NN

in	IN

pre-B	JJ

and	CC

mature	JJ

B	NN

cell	NN

lines	NNS

Switch	VB

substrate	NN

retrovectors	NNS

(	NN

SSR	NN

)	NN

contain	VB

a	DT

long-terminal	JJ

repeat-driven	JJ

neomycin	NN

(	NN

Neo	NN

)	NN

gene	NN

for	IN

proviral	JJ

chromosomal	JJ

maintenance	NN

(	NN

pre-	JJ

and	CC

post-S	JJ

recombination	NN

)	NN

and	CC

a	DT

CMV	NN

promoter-driven	JJ

,	,

chimeric	JJ

hygromycin-thymidine	NN

kinase	NN

(	NN

Hytk	NN

)	NN

gene	NN

(	NN

flanked	VBN

by	IN

S	NN

mu	NN

and	CC

S	NN

gamma	NN

2b	NN

recombination	NN

targets	NNS

)	NN

to	TO

select	JJ

for	IN

(	NN

ganciclovir	NN

)	NN

and	CC

against	IN

(	NN

hygromycin	NN

B	NN

)	NN

S	NN

region	NN

recombination	NN

The	DT

retro-substrates	NNS

'	''

strong	JJ

,	,

constitutive	JJ

promoters	NNS

ensure	VB

that	IN

variations	NNS

in	IN

cellular	JJ

switch	NN

recombinase	NN

activities	NNS

are	VBP

independent	JJ

of	IN

S	NN

region	NN

accessibility	NN

control	NN

By	IN

initially	RB

selecting	VBG

for	IN

proviral	JJ

integrants	NNS

in	IN

hygromycin	NN

followed	VBN

by	IN

shifting	VBG

into	IN

neomycin	NN

+	CC

ganciclovir	NN

to	TO

select	JJ

for	IN

S	NN

sequence-mediated	JJ

deletions	NNS

,	,

switch	NN

recombinations	NNS

can	MD

be	VB

specifically	RB

forestalled	VBN

in	IN

B	NN

cell	NN

lines	NNS

whilst	IN

most	RBS

switch-incompetent	JJ

cells	NNS

do	VB

not	RB

survive	VB

secondary	JJ

selection	NN

A	DT

qualitative	JJ

,	,

direct	JJ

PCR	NN

assay	NN

reveals	VBZ

that	IN

SSR	NN

recombinations	NNS

are	VBP

stochastic	JJ

in	IN

B	NN

cell	NN

lines	NNS

generating	VBG

a	DT

product	NN

array	NN

akin	JJ

to	TO

natural	JJ

GH	NN

class	NN

switching	NN

A	DT

semi-quantitative	JJ

DC-PCR	NN

assay	NN

detects	VBZ

a	DT

significant	JJ

recombinase	NN

activity	NN

only	RB

in	IN

a	DT

restricted	JJ

set	NN

of	IN

late	RB

stage	NN

pre-B	JJ

and	CC

mature	JJ

B	NN

cell	NN

lines	NNS

BCL1B1	NN

mature	JJ

B	NN

cells	NNS

have	VB

the	DT

highest	JJS

level	NN

of	IN

recombinase	NN

activity	NN

with	IN

25	CD

%	NN

or	CC

more	RBR

of	IN

proviral	JJ

integrants	NNS

accumulating	VBG

S	NN

mu/S	NN

gamma	NN

2b	NN

substrate	NN

recombinations	NNS

within	IN

10-14	CD

cell	NN

generations	NNS

The	DT

SSR	NN

recombinase	NN

assay	NN

can	MD

be	VB

performed	VBN

in	IN

a	DT

transient	JJ

fashion	NN

wherein	WRB

extensive	JJ

,	,

B	NN

cell-specific	JJ

recombination	NN

can	MD

be	VB

visualized	VBN

within	IN

only	RB

a	DT

few	JJ

cell	NN

divisions	NNS

post	NN

proviral	JJ

integration	NN

We	PRP

propose	VBP

that	IN

switch	NN

recombinase	NN

activity	NN

becomes	VBZ

activated	VBN

during	IN

B	NN

cell	NN

ontogeny	NN

independent	JJ

of	IN

or	CC

prior	RB

to	TO

the	DT

acquisition	NN

of	IN

CH	NN

locus	NN

accessibility	NN

and	CC

that	IN

endogenous	JJ

S	NN

segment	NN

targeting	VBG

to	TO

pre-existing	JJ

recombinase	NN

requires	VBZ

a	DT

level	NN

of	IN

accessibility	NN

beyond	IN

transcriptional	JJ

activation	NN

OBJECTIVE	NN

:	:

To	TO

determine	VB

the	DT

prevalence	NN

of	IN

illicit	JJ

drug	NN

abuse	NN

and	CC

alcohol	NN

use	NN

in	IN

an	DT

obstetric	NN

population	NN

based	VBN

in	IN

an	DT

urban	JJ

maternity	NN

hospital	NN

SETTING	VBG

:	:

A	DT

collaborative	JJ

study	NN

between	IN

the	DT

Rotunda	NNP

Hospital	NN

,	,

Dublin	NNP

and	CC

the	DT

Irish	JJ

National	NNP

Drug	NN

Advisory	NNP

&	CC

#	#

38	CD

;	:

Treatment	NN

Centre	NNP

DESIGN	NN

:	:

A	DT

prospective	JJ

study	NN

consisting	VBG

of	IN

anonymous	JJ

,	,

unlinked	JJ

urine	NN

testing	NN

of	IN

504	CD

'first	IN

visit	NN

'	''

antenatal	JJ

patients	NNS

and	CC

a	DT

separate	JJ

group	NN

of	IN

515	CD

patients	NNS

six	CD

weeks	NNS

after	IN

delivery	NN

METHODS	NNS

&	CC

#	#

38	CD

;	:

OUTCOME	NN

MEASURES	NNS

:	:

Toxicological	JJ

screening	NN

using	VBG

enzyme-linked	JJ

immunoassay	NN

techniques	NNS

,	,

with	IN

all	DT

positive	JJ

samples	NNS

being	VBG

reanalysed	VBN

Drug	NN

histories	NNS

were	VBD

taken	VBN

and	CC

samples	NNS

were	VBD

tested	VBN

for	IN

alcohol	NN

and	CC

six	CD

of	IN

the	DT

most	RBS

commonly	RB

abused	JJ

drugs	NNS

The	DT

pre-	JJ

and	CC

postnatal	JJ

prevalence	NN

of	IN

abuse	NN

was	VBD

matched	VBN

with	IN

demographic	JJ

data	NNS

RESULTS	NNS

:	:

The	DT

prevalence	NN

of	IN

chemical	NN

substance	NN

misuse	NN

in	IN

the	DT

antenatal	JJ

population	NN

was	VBD

2.8	CD

%	NN

and	CC

5.6	CD

%	NN

in	IN

the	DT

postnatal	JJ

population	NN

Substances	NNS

identified	VBN

included	VBN

benzodiazepines	NNS

,	,

cannabis	NN

,	,

amphetamines	NNS

,	,

opiates	NNS

and	CC

cocaine	NN

Less	RBR

than	IN

2	CD

%	NN

of	IN

samples	NNS

tested	VBN

positive	JJ

for	IN

alcohol	NN

None	NN

of	IN

the	DT

women	NNS

yielding	VBG

positive	JJ

samples	NNS

had	VBD

been	VBN

pre-identified	JJ

on	IN

the	DT

basis	NN

of	IN

history	NN

A	DT

significant	JJ

proportion	NN

of	IN

the	DT

women	NNS

were	VBD

in	IN

the	DT

high	JJ

risk	NN

categories	NNS

with	IN

regard	NN

to	TO

age	NN

and	CC

socio-economic	JJ

status	NN

CONCLUSION	NN

:	:

The	DT

prevalence	NN

of	IN

drug	NN

misuse	NN

antenatally	RB

was	VBD

nearly	RB

3	CD

%	NN

and	CC

postnatally	RB

almost	RB

6	CD

%	NN

Substance	NN

abusers	NNS

in	IN

pregnancy	NN

are	VBP

more	RBR

likely	RB

to	TO

be	VB

single	JJ

,	,

unemployed	JJ

,	,

and	CC

to	TO

have	VB

had	VBD

a	DT

previous	JJ

pregnancy	NN

Schizophrenic	JJ

illnesses	NNS

occur	VB

with	IN

approximately	RB

the	DT

same	JJ

incidence	NN

in	IN

all	DT

human	JJ

populations	NNS

with	IN

a	DT

characteristic	JJ

distribution	NN

(	NN

slightly	RB

earlier	RB

in	IN

males	NNS

)	NN

of	IN

ages	NNS

of	IN

onset	NN

Given	VBN

that	IN

the	DT

predisposition	NN

(	NN

which	WDT

presumably	RB

is	VBZ

genetic	JJ

)	NN

is	VBZ

associated	VBN

with	IN

a	DT

procreative	JJ

disadvantage	NN

why	WRB

do	VB

such	JJ

illnesses	NNS

persist	VB

?	.

Here	RB

it	PRP

is	VBZ

suggested	VBN

that	IN

these	DT

conditions	NNS

are	VBP

a	DT

manifestation	NN

of	IN

genetic	JJ

diversity	NN

in	IN

the	DT

evolution	NN

of	IN

the	DT

specifically	RB

human	JJ

characteristic	JJ

of	IN

language	NN

,	,

an	DT

innovation	NN

that	IN

has	VBZ

occurred	VBD

by	IN

a	DT

process	NN

of	IN

progressive	JJ

hemispheric	JJ

specialization-the	NN

establishment	NN

of	IN

dominance	NN

for	IN

some	DT

critical	JJ

component	NN

of	IN

language	NN

in	IN

one	CD

or	CC

the	DT

other	JJ

hemisphere	NN

Individuals	NNS

who	WP

develop	VB

schizophrenic	JJ

symptoms	NNS

show	NN

lesser	JJR

anatomical	JJ

and	CC

functional	JJ

asymmetries	NNS

than	IN

the	DT

population	NN

as	IN

a	DT

whole	JJ

;	:

such	JJ

symptoms	NNS

may	MD

reflect	VB

'dominance	NN

failure	NN

'	''

for	IN

language	NN

Cloacal	JJ

anomalies	NNS

are	VBP

extremely	RB

rare	JJ

and	CC

have	VB

variable	JJ

presentations	NNS

Prenatal	JJ

diagnosis	NN

can	MD

be	VB

difficult	JJ

especially	RB

if	IN

they	PRP

present	JJ

in	IN

late	RB

gestation	NN

Here	RB

we	PRP

present	JJ

two	CD

cases	NNS

diagnosed	VBN

in	IN

the	DT

late	RB

third	JJ

trimester	NN

and	CC

review	NN

the	DT

literature	NN

regarding	VBG

prenatal	JJ

diagnosis	NN

of	IN

cloacal	JJ

anomalies	NNS

OBJECTIVE	NN

:	:

To	TO

determine	VB

whether	IN

patients	NNS

with	IN

myocardial	JJ

amyloidosis	NN

due	JJ

either	DT

to	TO

AL	NNP

(	NN

primary	JJ

)	NN

amyloid	NN

or	CC

familial	JJ

amyloid	NN

have	VB

distinguishing	VBG

echocardiographic	JJ

or	CC

electrocardiographic	JJ

features	NNS

;	:

and	CC

to	TO

compare	VB

the	DT

prevalence	NN

of	IN

heart	NN

failure	NN

and	CC

survival	NN

in	IN

the	DT

two	CD

types	NNS

of	IN

amyloidosis	NN

in	IN

relation	NN

to	TO

echocardiographic	JJ

findings	NNS

DESIGN	NN

:	:

Blinded	VBN

group	NN

comparison	NN

of	IN

randomly	RB

selected	VBN

cases	NNS

of	IN

cardiac	JJ

amyloidosis	NN

SETTING	VBG

:	:

International	NNP

referral	NN

centre	NN

for	IN

amyloid	NN

research	NN

and	CC

treatment	NN

PATIENTS	NNS

:	:

36	CD

patients	NNS

with	IN

cardiac	JJ

amyloid	NN

heart	NN

disease	NN

,	,

of	IN

whom	WP

12	CD

had	VBD

familial	JJ

and	CC

24	CD

had	VBD

primary	JJ

AL	NNP

amyloidosis	NN

RESULTS	NNS

:	:

Familial	JJ

and	CC

AL	NNP

echocardiograms	NNS

were	VBD

morphologically	RB

indistinguishable	JJ

,	,

with	IN

similar	JJ

left	RB

ventricular	JJ

wall	NN

thickness	NN

,	,

mean	VB

(	NN

SD	NN

)	NN

15.4	CD

(	NN

2.3	CD

)	NN

nu	NN

15.8	CD

(	NN

2.5	CD

)	NN

mm	NN

,	,

respectively	RB

;	:

right	RB

ventricular	JJ

wall	NN

thickness	NN

was	VBD

also	RB

similar	JJ

between	IN

amyloid	NN

types	NNS

:	:

9.6	CD

(	NN

2.8	CD

)	NN

nu	NN

9.7	CD

(	NN

6.5	CD

)	NN

mm	NN

,	,

respectively	RB

Doppler	NNP

indices	NNS

of	IN

left	RB

and	CC

right	RB

ventricular	JJ

function	NN

,	,

left	RB

ventricular	JJ

volume	NN

,	,

and	CC

ejection	NN

fraction	NN

were	VBD

also	RB

similar	JJ

Low	JJ

voltage	NN

electrocardiograms	NNS

(	NN

&	CC

#	#

60	CD

;	:

0.5	CD

mV	NN

)	NN

were	VBD

more	RBR

common	JJ

in	IN

the	DT

AL	NNP

(	NN

16/24	CD

,	,

67	CD

%	NN

)	NN

than	IN

in	IN

the	DT

familial	JJ

group	NN

(	NN

4/12	CD

,	,

25	CD

%	NN

)	NN

,	,

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

The	DT

one	CD

year	NN

survival	NN

for	IN

familial	JJ

and	CC

AL	NNP

forms	NNS

was	VBD

92	CD

%	NN

(	NN

11/12	CD

)	NN

nu	NN

38	CD

%	NN

(	NN

6/24	CD

)	NN

,	,

respectively	RB

,	,

with	IN

virtually	RB

all	DT

deaths	NNS

due	JJ

to	TO

cardiac	JJ

causes	NNS

CONCLUSIONS	NNS

:	:

Although	IN

cardiac	JJ

involvement	NN

is	VBZ

echocardiographically	RB

indistinguishable	JJ

,	,

cardiac	JJ

mortality	NN

is	VBZ

very	RB

different	JJ

between	IN

the	DT

two	CD

forms	NNS

of	IN

amyloidosis	NN

Preservation	NN

of	IN

electrocardiographic	JJ

voltage	NN

in	IN

familial	JJ

amyloidosis	NN

suggests	VBZ

that	IN

the	DT

particular	JJ

biochemical	JJ

characteristics	NNS

of	IN

distinct	JJ

types	NNS

of	IN

amyloid	NN

fibril	NN

have	VB

different	JJ

pathological	JJ

effects	NNS

on	IN

the	DT

myocardium	NN

This	DT

distinction	NN

becomes	VBZ

critical	JJ

in	IN

the	DT

evaluation	NN

,	,

treatment	NN

,	,

and	CC

management	NN

of	IN

patients	NNS

who	WP

have	VB

a	DT

diagnosis	NN

within	IN

the	DT

spectrum	NN

of	IN

the	DT

protein	NN

deposition	NN

diseases	NNS

OBJECTIVE	NN

:	:

To	TO

examine	VB

the	DT

relationship	NN

between	IN

plasma	NN

plasminogen	NN

activator	NN

inhibitor	NN

1	CD

(	NN

PAI-1	NN

)	NN

activity	NN

and	CC

PAI-1	NN

gene	NN

(	NN

4G/5G	NN

)	NN

polymorphism	NN

and	CC

diabetic	JJ

retinopathy	NN

in	IN

Pima	NNP

Indians	NNPS

with	IN

type	NN

2	CD

diabetes	NN

RESEARCH	NN

DESIGN	NN

AND	CC

METHODS	NNS

:	:

We	PRP

studied	VBN

171	CD

Pima	NNP

Indians	NNPS

with	IN

type	NN

2	CD

diabetes	NN

between	IN

the	DT

ages	NNS

of	IN

30-70	CD

years	NNS

in	IN

a	DT

population-based	JJ

epidemiological	JJ

survey	NN

Plasma	NN

PAI-1	NN

activity	NN

was	VBD

measured	VBN

by	IN

a	DT

spectrophotometric	JJ

assay	NN

and	CC

PAI-1	NN

4G/5G	NN

promoter	NN

genotype	NN

by	IN

the	DT

polymerase	NN

chain	NN

reaction	NN

(	NN

PCR	NN

)	NN

using	VBG

allele-specific	JJ

primers	NNS

Retinopathy	NNP

was	VBD

assessed	VBN

by	IN

ophthalmoscopy	NN

after	IN

pupillary	NN

dilation	NN

and	CC

classified	VBN

as	IN

any	DT

retinopathy	NN

or	CC

as	IN

nonproliferative	JJ

and	CC

proliferative	JJ

RESULTS	NNS

:	:

Retinopathy	NNP

was	VBD

present	JJ

in	IN

70	CD

(	NN

41	CD

%	NN

)	NN

subjects	NNS

,	,

and	CC

4	CD

(	NN

2.3	CD

%	NN

)	NN

subjects	NNS

had	VBD

proliferative	JJ

retinopathy	NN

Plasma	NN

PAI-1	NN

activity	NN

was	VBD

not	RB

significantly	RB

different	JJ

among	IN

subjects	NNS

with	IN

and	CC

without	IN

retinopathy	NN

(	NN

17.1	CD

+/-	CC

vs.	CC

19.7	CD

+/-	CC

9.1	CD

arbitrary	JJ

units	NNS

(	NN

AU	NN

)	NN

/ml	NN

,	,

P	NN

=	JJ

0.09	CD

)	NN

PAI-1	NN

activity	NN

was	VBD

negatively	RB

correlated	VBD

with	IN

duration	NN

of	IN

diabetes	NN

(	NN

rs	NNS

=	JJ

-0.18	CD

,	,

P	NN

=	JJ

0.02	CD

)	NN

In	IN

a	DT

logistic	JJ

regression	NN

analysis	NN

controlled	VBN

for	IN

age	NN

,	,

sex	NN

,	,

BMI	NN

,	,

and	CC

duration	NN

of	IN

diabetes	NN

,	,

any	DT

retinopathy	NN

was	VBD

significantly	RB

associated	VBN

with	IN

fasting	VBG

plasma	NN

glucose	NN

concentrations	NNS

(	NN

P	NN

&	CC

#	#

60	CD

;	:

0.05	CD

)	NN

,	,

2-h	JJ

postload	NN

glucose	NN

(	NN

P	NN

=	JJ

0.02	CD

)	NN

,	,

and	CC

HbA1c	NN

(	NN

P	NN

=	JJ

0.008	CD

)	NN

,	,

but	CC

not	RB

with	IN

PAI-1	NN

activity	NN

(	NN

P	NN

=	JJ

0.48	CD

)	NN

The	DT

prevalence	NN

of	IN

retinopathy	NN

in	IN

the	DT

three	CD

genotype	NN

groups	NNS

differed	VBN

significantly	RB

(	NN

4G/4G	NN

,	,

4G/5G	NN

,	,

and	CC

5G/5G	NN

were	VBD

44	CD

,	,

49	CD

,	,

and	CC

24	CD

%	NN

,	,

respectively	RB

;	:

chi	NN

2	CD

=	JJ

8.22	CD

,	,

df	NN

=	JJ

2	CD

,	,

P	NN

=	JJ

0.016	CD

)	NN

and	CC

remained	VBD

significant	JJ

after	IN

controlling	VBG

for	IN

age	NN

,	,

sex	NN

,	,

BMI	NN

,	,

duration	NN

of	IN

diabetes	NN

,	,

glycated	VBN

hemoglobin	NN

,	,

and	CC

urine	NN

albumin-to-creatine	NN

ratio	NN

in	IN

a	DT

logistic	JJ

regression	NN

analysis	NN

The	DT

odds	NNS

ratios	NNS

for	IN

retinopathy	NN

in	IN

subjects	NNS

with	IN

4G/4G	NN

and	CC

4G/5G	NN

,	,

compared	VBN

with	IN

the	DT

5G/5G	NN

genotype	NN

,	,

were	VBD

2.0	CD

and	CC

3.1	CD

,	,

respectively	RB

CONCLUSIONS	NNS

:	:

Although	IN

diabetic	JJ

retinopathy	NN

in	IN

Pima	NNP

Indians	NNPS

with	IN

type	NN

2	CD

diabetes	NN

is	VBZ

not	RB

associated	VBN

with	IN

PAI-1	NN

activity	NN

,	,

subjects	NNS

with	IN

the	DT

4G/4G	NN

and	CC

4G/5G	NN

genotype	NN

had	VBD

a	DT

higher	JJR

prevalence	NN

of	IN

retinopathy	NN

compared	VBN

with	IN

5G/5G	NN

PAI-1genotype	NN

These	DT

preliminary	JJ

findings	NNS

indicate	VBP

that	IN

in	IN

Pima	NNP

Indians	NNPS

with	IN

type	NN

2	CD

diabetes	NN

,	,

presence	NN

of	IN

the	DT

4G	NN

allele	NN

of	IN

the	DT

PAI-1	NN

gene	NN

was	VBD

associated	VBN

with	IN

a	DT

higher	JJR

risk	NN

of	IN

diabetic	JJ

retinopathy	NN

BACKGROUND	NN

:	:

Diagnostic	JJ

peritoneal	NN

lavage	NN

(	NN

DPL	NNP

)	NN

is	VBZ

used	VBN

to	TO

diagnose	VB

intra-abdominal	JJ

injury	NN

in	IN

patients	NNS

with	IN

stab	NN

wounds	NNS

and	CC

blunt	JJ

trauma	NN

Because	IN

exploratory	NN

celiotomy	NN

is	VBZ

routinely	RB

performed	VBN

on	IN

patients	NNS

with	IN

gunshot	NN

wounds	NNS

to	TO

the	DT

abdomen	NN

,	,

DPL	NNP

is	VBZ

rarely	RB

employed	VBN

However	RB

,	,

several	JJ

studies	NNS

have	VB

questioned	VBD

routine	JJ

exploration	NN

and	CC

have	VB

drawn	VBN

attention	NN

to	TO

the	DT

associated	VBN

morbidity	NN

of	IN

negative	JJ

celiotomy	NN

Diagnostic	JJ

peritoneal	NN

lavage	NN

is	VBZ

an	DT

easily	RB

performed	VBN

and	CC

inexpensive	JJ

test	NN

that	IN

may	MD

be	VB

useful	JJ

in	IN

this	DT

situation	NN

OBJECTIVE	NN

:	:

To	TO

evaluate	VB

the	DT

performance	NN

of	IN

DPL	NNP

in	IN

the	DT

diagnosis	NN

of	IN

intra-abdominal	JJ

injury	NN

in	IN

hemodynamically	RB

stable	JJ

patients	NNS

with	IN

gunshot	NN

wounds	NNS

to	TO

the	DT

abdomen	NN

DESIGN	NN

:	:

A	DT

prospective	JJ

clinical	JJ

trial	NN

SETTING	VBG

:	:

Two	CD

urban	JJ

trauma	NN

centers	NNS

PATIENTS	NNS

:	:

Patients	NNS

with	IN

gunshot	NN

wounds	NNS

to	TO

the	DT

abdomen	NN

and	CC

a	DT

systolic	JJ

blood	NN

pressure	NN

of	IN

at	IN

least	JJS

90	CD

mm	NN

Hg	NN

INTERVENTIONS	NNS

:	:

Clinical	JJ

predication	NN

of	IN

intra-abdominal	JJ

injury	NN

in	IN

the	DT

emergency	NN

department	NN

and	CC

DPL	NNP

performed	VBN

in	IN

the	DT

operating	VBG

room	NN

before	IN

the	DT

initiation	NN

of	IN

celiotomy	NN

Injuries	NNS

found	VBN

during	IN

the	DT

celiotomy	NN

were	VBD

recorded	VBN

MAIN	NN

OUTCOME	NN

MEASURES	NNS

:	:

The	DT

results	NNS

of	IN

the	DT

clinical	JJ

evaluation	NN

and	CC

DPL	NNP

were	VBD

compared	VBN

with	IN

the	DT

findings	NNS

of	IN

the	DT

celiotomy	NN

RESULTS	NNS

:	:

Forty-four	CD

patients	NNS

were	VBD

enrolled	VBN

into	IN

the	DT

study	NN

Intra-abdominal	JJ

injury	NN

was	VBD

present	JJ

in	IN

32	CD

(	NN

73	CD

%	NN

)	NN

of	IN

these	DT

patients	NNS

The	DT

senior	JJ

surgery	NN

resident	NN

correctly	RB

predicted	VBN

the	DT

presence	NN

of	IN

intra-abdominal	JJ

injury	NN

in	IN

36	CD

(	NN

82	CD

%	NN

)	NN

of	IN

the	DT

patients	NNS

(	NN

sensitivity	NN

=	JJ

90.0	CD

%	NN

,	,

specificity	NN

=	JJ

58.3	CD

%	NN

,	,

positive	JJ

predictive	JJ

value	NN

=	JJ

85.3	CD

%	NN

,	,

negative	JJ

predictive	JJ

value	NN

=	JJ

63.6	CD

%	NN

,	,

phi	NN

=	JJ

0.52	CD

,	,

P	NN

&	CC

#	#

60	CD

;	:

.01	CD

)	NN

in	IN

the	DT

emergency	NN

department	NN

before	IN

DPL	NNP

and	CC

celiotomy	NN

were	VBD

performed	VBN

Diagnostic	JJ

peritoneal	NN

lavage	NN

correctly	RB

identified	VBN

the	DT

presence	NN

or	CC

absence	NN

of	IN

intra-abdominal	JJ

injury	NN

in	IN

40	CD

(	NN

91	CD

%	NN

)	NN

of	IN

the	DT

patients	NNS

(	NN

positive	JJ

predictive	JJ

value	NN

=	JJ

96.7	NN

%	NN

,	,

negative	JJ

predictive	JJ

value	NN

=	JJ

78.6	CD

%	NN

,	,

phi	NN

=	JJ

0.79	CD

,	,

P	NN

&	CC

#	#

60	CD

;	:

.01	CD

)	NN

CONCLUSIONS	NNS

:	:

Clinical	JJ

judgment	NN

is	VBZ

highly	RB

accurate	JJ

in	IN

separating	VBG

patients	NNS

with	IN

tangential	JJ

gunshot	NN

wounds	NNS

to	TO

the	DT

abdomen	NN

from	IN

those	DT

with	IN

intra-abdominal	JJ

injury	NN

but	CC

may	MD

miss	VB

patients	NNS

with	IN

intra-abdominal	JJ

hemorrhage	NN

Diagnostic	JJ

peritoneal	NN

lavage	NN

is	VBZ

highly	RB

predictive	JJ

of	IN

the	DT

presence	NN

of	IN

intra-abdominal	JJ

injury	NN

The	DT

return	NN

of	IN

gross	JJ

blood	NN

on	IN

aspiration	NN

or	CC

a	DT

lavage	NN

red	JJ

blood	NN

cell	NN

count	NN

greater	JJR

than	IN

10	CD

x	NN

10	CD

(	NN

9	CD

)	NN

/L	NN

should	MD

prompt	JJ

an	DT

urgent	JJ

celiotomy	NN

Missed	VBN

injuries	NNS

are	VBP

rare	JJ

and	CC

most	RBS

likely	RB

to	TO

be	VB

bowel	NN

perforations	NNS

Diagnostic	JJ

peritoneal	NN

lavage	NN

is	VBZ

an	DT

objective	NN

test	NN

that	IN

may	MD

augment	VBP

clinical	JJ

judgment	NN

in	IN

selecting	VBG

hemodynamically	RB

stable	JJ

patients	NNS

with	IN

potential	NN

tangential	JJ

gunshot	NN

wounds	NNS

for	IN

observation	NN

and	CC

is	VBZ

especially	RB

useful	JJ

in	IN

identifying	VBG

intra-abdominal	JJ

hemorrhage	NN

BACKGROUND	NN

:	:

To	TO

evaluate	VB

the	DT

frequency	NN

of	IN

Blastocystis	NNP

hominis	NNS

parasitation	NN

and	CC

to	TO

ascertain	VB

its	PRP$

role	NN

as	IN

an	DT

intestinal	JJ

a	DT

prospective	JJ

study	NN

during	IN

18	CD

months	NNS

pathogen	NN

has	VBZ

been	VBN

carried	VBD

out	IN

SUBJECTS	NNS

AND	CC

METHODS	NNS

:	:

The	DT

study	NN

included	VBN

2	CD

,	,

039	CD

patients	NNS

,	,

which	WDT

were	VBD

classified	VBN

in	IN

three	CD

groups	NNS

(	NN

asymptomatic	JJ

(	NN

group	NN

A	DT

)	NN

,	,

with	IN

suspicion	NN

of	IN

parasitosis	NN

(	NN

group	NN

B	NN

)	NN

,	,

with	IN

diarrhoea	NN

(	NN

group	NN

C	NN

)	NN

)	NN

In	IN

all	DT

cases	NNS

a	DT

coproparasitological	JJ

study	NN

was	VBD

performed	VBN

In	IN

the	DT

group	NN

C	NN

the	DT

presence	NN

of	IN

non-parasitic	JJ

enteropathogens	NNS

was	VBD

also	RB

investigated	VBN

In	IN

patients	NNS

with	IN

B	NN

hominis	NNS

in	IN

the	DT

absence	NN

of	IN

other	JJ

pathogens	NNS

clinical	JJ

and	CC

epidemiological	JJ

characteristics	NNS

were	VBD

evaluated	VBN

Also	RB

,	,

its	PRP$

was	VBD

determined	VBN

the	DT

morphology	NN

and	CC

quantification	NN

of	IN

parasites	NNS

RESULTS	NNS

:	:

Parasites	NNS

were	VBD

identified	VBN

in	IN

26.2	CD

%	NN

of	IN

population	NN

B	NN

hominis	NNS

was	VBD

identified	VBN

in	IN

336	CD

patients	NNS

(	NN

16.5	CD

%	NN

)	NN

The	DT

frequency	NN

of	IN

parasitation	NN

was	VBD

superior	JJ

in	IN

adults	NNS

(	NN

p	NN

&	CC

#	#

60	CD

;	:

0.0001	CD

)	NN

,	,

with	IN

a	DT

slight	JJ

predominance	NN

in	IN

the	DT

female	NN

sex	NN

The	DT

rate	NN

of	IN

asymptomatic	JJ

carriers	NNS

was	VBD

3.3	CD

%	NN

In	IN

21	CD

patients	NNS

B	NN

hominis	NNS

(	NN

group	NN

C	NN

)	NN

was	VBD

observed	VBN

in	IN

absence	NN

of	IN

other	JJ

enteropathogens	NNS

Statistical	JJ

significant	JJ

association	NN

was	VBD

found	VBN

between	IN

B	NN

hominis	NNS

,	,

in	IN

absence	NN

of	IN

other	JJ

pathogens	NNS

and	CC

the	DT

presence	NN

of	IN

clinical	JJ

manifestations	NNS

(	NN

p	NN

&	CC

#	#

60	CD

;	:

0.0001	CD

)	NN

,	,

the	DT

most	RBS

common	JJ

of	IN

which	WDT

were	VBD

diarrhoea	NN

and	CC

abdominal	JJ

pain	NN

We	PRP

did	VBD

not	RB

find	VB

a	DT

statistically	RB

significant	JJ

association	NN

between	IN

the	DT

number	NN

of	IN

B	NN

hominis	NNS

present	JJ

and	CC

stool	NN

characteristics	NNS

The	DT

vacuolar	NN

form	NN

was	VBD

the	DT

predominant	JJ

morphological	JJ

type	NN

The	DT

ameboid	NN

form	NN

was	VBD

observed	VBN

only	RB

in	IN

diarrhoeal	NN

stools	NNS

CONCLUSIONS	NNS

:	:

B	NN

hominis	NNS

is	VBZ

the	DT

most	RBS

frequent	JJ

parasite	NN

found	VBN

in	IN

faecal	JJ

parasitological	JJ

investigation	NN

In	IN

absence	NN

of	IN

other	JJ

causes	NNS

,	,

B	NN

hominis	NNS

must	MD

be	VB

considered	VBN

as	IN

a	DT

pathogen	NN

<	JJR

TO_SEE	NN

>	JJR

BACKGROUND	NN

:	:

The	DT

cause	NN

of	IN

severe	JJ

acquired	VBN

hyperammonemia	NN

,	,

an	DT

uncommon	JJ

but	CC

often	RB

fatal	JJ

complication	NN

of	IN

organ	NN

transplantation	NN

and	CC

chemotherapy	NN

for	IN

cancer	NN

,	,

is	VBZ

obscure	JJ

<	JJR

/TO_SEES	NN

>	JJR

OBJECTIVE	NN

:	:

To	TO

test	NN

the	DT

hypothesis	NN

that	IN

liver	NN

glutamine	NN

synthetase	NN

deficiency	NN

may	MD

explain	VB

hyperammonemia	NN

in	IN

patients	NNS

who	WP

have	VB

had	VBD

organ	NN

transplantation	NN

or	CC

are	VBP

receiving	VBG

chemotherapy	NN

DESIGN	NN

:	:

Case	NN

report	NN

PATIENTS	NNS

:	:

Two	CD

patients	NNS

who	WP

had	VBD

fatal	JJ

hyperammonemia	NN

after	IN

orthotopic	JJ

lung	NN

transplantation	NN

.	.

MEASUREMENTS	NNS

:	:

Liver	NN

tissue	NN

was	VBD

analyzed	VBN

to	TO

determine	VB

the	DT

activities	NNS

of	IN

two	CD

urea	NN

cycle	NN

enzymes	NNS

and	CC

glutamine	NN

synthetase	NN

Western	NNP

blot	NN

assays	NNS

for	IN

hepatic	JJ

glutamine	NN

synthetase	NN

were	VBD

performed	VBN

to	TO

determine	VB

whether	IN

glutamine	NN

synthetase	NN

deficiency	NN

resulted	VBD

from	IN

reduced	VBN

enzyme	NN

levels	NNS

RESULTS	NNS

:	:

Activities	NNS

of	IN

carbamoyl	NN

phosphate	NN

synthetase	NN

I	PRP

and	CC

ornithine	NN

carbamoyltransferase	NN

in	IN

the	DT

liver	NN

were	VBD

normal	JJ

The	DT

activity	NN

of	IN

hepatic	JJ

glutamine	NN

synthetase	NN

was	VBD

markedly	RB

reduced	VBN

(	NN

in	IN

patient	NN

1	CD

,	,

12	CD

%	NN

of	IN

the	DT

mean	VB

value	NN

in	IN

controls	NNS

;	:

in	IN

patient	NN

2	CD

,	,

28	CD

%	NN

of	IN

the	DT

mean	VB

value	NN

in	IN

controls	NNS

)	NN

,	,

and	CC

a	DT

concomitant	JJ

reduction	NN

in	IN

the	DT

amount	NN

of	IN

glutamine	NN

synthetase	NN

protein	NN

was	VBD

observed	VBN

<	JJR

TO_SEE	NN

>	JJR

CONCLUSION	NN

:	:

Hyperammonemia	NN

after	IN

transplantation	NN

was	VBD

associated	VBN

with	IN

hepatic	JJ

glutamine	NN

synthetase	NN

deficiency	NN

in	IN

two	CD

patients	NNS

,	,

but	CC

the	DT

causal	JJ

relation	NN

between	IN

these	DT

two	CD

conditions	NNS

must	MD

be	VB

further	RB

studied	VBN

Postnatal	JJ

growth	NN

was	VBD

prospectively	RB

measured	VBN

from	IN

birth	NN

to	TO

1	CD

y	NN

in	IN

54	CD

term	NN

infants	NNS

born	VBN

small	JJ

for	IN

gestational	JJ

age	NN

(	NN

SGA	NNP

)	NN

,	,

fed	NN

either	DT

breast	NN

milk	NN

or	CC

a	DT

standard	NN

term	NN

infant	NN

formula	NN

Breastfeeding	VBG

was	VBD

associated	VBN

with	IN

a	DT

0.36	CD

and	CC

0.64	CD

standard	NN

deviation	NN

(	NN

SD	NN

)	NN

increase	NN

in	IN

weight	NN

at	IN

2	CD

weeks	NNS

and	CC

3	CD

months	NNS

of	IN

age	NN

,	,

respectively	RB

,	,

which	WDT

persisted	VBD

beyond	IN

the	DT

breastfeeding	VBG

period	NN

(	NN

0.64	CD

SD	NN

at	IN

1	CD

y	NN

)	NN

Breastfed	VBN

infants	NNS

also	RB

showed	VBD

greater	JJR

catch-up	NN

growth	NN

in	IN

head	NN

circumference	NN

(	NN

SD	NN

score	NN

(	NN

SDS	NN

)	NN

0.53	CD

higher	JJR

at	IN

3	CD

months	NNS

)	NN

,	,

and	CC

greater	JJR

body	NN

length	NN

gain	NN

(	NN

SDS	NN

0.68	CD

higher	JJR

at	IN

6	CD

months	NNS

)	NN

This	DT

increased	VBN

growth	NN

was	VBD

independent	JJ

of	IN

potentially	RB

confounding	VBG

obstetric	NN

,	,

social	JJ

and	CC

demographic	JJ

factors	NNS

Our	PRP$

findings	NNS

suggest	VB

that	IN

breastfeeding	VBG

may	MD

promote	VB

faster	RBR

growth	NN

in	IN

infants	NNS

compromised	VBN

by	IN

poor	JJ

growth	NN

in	IN

utero	NN

SGA	NNP

infants	NNS

may	MD

be	VB

programmed	VBN

for	IN

a	DT

number	NN

of	IN

adverse	JJ

outcomes	NNS

;	:

the	DT

possibility	NN

that	IN

such	JJ

events	NNS

are	VBP

altered	JJ

by	IN

choice	NN

of	IN

postnatal	JJ

diet	NN

is	VBZ

a	DT

key	NN

issue	NN

for	IN

future	NN

research	NN

BACKGROUND	NN

:	:

Few	JJ

studies	NNS

have	VB

explored	VBN

the	DT

health	NN

practices	NNS

of	IN

critical	JJ

care	NN

nurses	NNS

Critical	JJ

care	NN

nurses	NNS

routinely	RB

teach	VB

patients	NNS

about	IN

using	VBG

healthy	JJ

practices	NNS

such	JJ

as	IN

low-fat	JJ

diets	NNS

,	,

exercise	NN

,	,

and	CC

routine	JJ

screening	NN

examinations	NNS

However	RB

,	,

it	PRP

may	MD

be	VB

even	RB

more	RBR

important	JJ

that	IN

the	DT

nurses	NNS

themselves	PRP

have	VB

a	DT

healthy	JJ

lifestyle	NN

,	,

thus	RB

serving	VBG

as	IN

role	NN

models	NNS

for	IN

patients	NNS

Nurses	NNS

are	VBP

selling	VBG

a	DT

product	NN

,	,

and	CC

that	IN

product	NN

is	VBZ

health	NN

The	DT

best	RB

salespersons	NNS

are	VBP

those	DT

who	WP

are	VBP

genuinely	RB

committed	VBN

to	TO

their	PRP$

product	NN

and	CC

model	NN

its	PRP$

benefits	NNS

Therefore	RB

,	,

critical	JJ

care	NN

nurses	NNS

'	''

healthful	JJ

practices	NNS

can	MD

have	VB

a	DT

profound	JJ

effect	NN

on	IN

their	PRP$

patients	NNS

OBJECTIVES	NNS

:	:

The	DT

purpose	NN

of	IN

this	DT

descriptive	JJ

exploratory	NN

study	NN

was	VBD

to	TO

examine	VB

critical	JJ

care	NN

nurses	NNS

'	''

responses	NNS

to	TO

three	CD

questions	NNS

about	IN

health	NN

practices	NNS

in	IN

their	PRP$

daily	RB

lives	NNS

:	:

(	NN

1	CD

)	NN

What	WDT

are	VBP

critical	JJ

care	NN

nurses	NNS

doing	VBG

currently	RB

to	TO

stay	NN

healthy	JJ

?	.

(	NN

2	CD

)	NN

Do	VB

they	PRP

anticipate	VB

making	VBG

any	DT

changes	NNS

in	IN

their	PRP$

lifestyle	NN

in	IN

the	DT

future	NN

?	.

(	NN

3	CD

)	NN

Would	MD

they	PRP

recommend	VB

their	PRP$

lifestyle	NN

to	TO

their	PRP$

patients	NNS

?	.

METHODS	NNS

:	:

One	CD

hundred	CD

twenty-seven	CD

critical	JJ

care	NN

nurses	NNS

attending	VBG

a	DT

midwestern	JJ

critical	JJ

care	NN

conference	NN

completed	VBN

a	DT

two-part	JJ

questionnaire	NN

designed	VBN

to	TO

produce	VB

a	DT

health	NN

profile	NN

In	IN

a	DT

man-on-the-street	NN

approach	NN

,	,

23	CD

nurses	NNS

participated	VBD

in	IN

an	DT

interview	NN

via	IN

video	NN

camera	NN

Descriptive	JJ

statistics	NNS

were	VBD

used	VBN

to	TO

analyze	VB

the	DT

data	NNS

retrieved	VBN

from	IN

the	DT

questionnaires	NNS

Interviews	NNS

were	VBD

transcribed	VBN

verbatim	JJ

and	CC

analyzed	VBN

for	IN

themes	NNS

with	IN

a	DT

constant	JJ

comparative	JJ

method	NN

RESULTS	NNS

:	:

More	RBR

than	IN

70	CD

%	NN

of	IN

the	DT

critical	JJ

care	NN

nurses	NNS

who	WP

responded	VBD

engage	VB

in	IN

exercise	NN

and	CC

follow	VB

a	DT

healthy	JJ

,	,

low-fat	JJ

diet	NN

Seventy-one	CD

percent	NN

said	VBD

that	IN

they	PRP

anticipate	VB

making	VBG

a	DT

change	NN

in	IN

their	PRP$

lifestyle	NN

in	IN

the	DT

future	NN

,	,

and	CC

70	CD

%	NN

said	VBD

that	IN

they	PRP

would	MD

recommend	VB

their	PRP$

lifestyle	NN

to	TO

their	PRP$

patients	NNS

Five	CD

themes	NNS

emerged	VBD

from	IN

the	DT

videotaped	JJ

interviews	NNS

:	:

(	NN

1	CD

)	NN

Heart-healthy	JJ

practices	NNS

predominated	VBD

the	DT

responses	NNS

(	NN

2	CD

)	NN

Incorporating	VBG

a	DT

healthy	JJ

lifestyle	NN

was	VBD

easy	JJ

for	IN

some	DT

and	CC

a	DT

struggle	NN

for	IN

others	NNS

(	NN

3	CD

)	NN

Critical	JJ

care	NN

nurses	NNS

readily	RB

listed	VBN

barriers	NNS

to	TO

healthy	JJ

living	VBG

(	NN

4	CD

)	NN

The	DT

nurses	NNS

had	VBD

a	DT

positive	JJ

attitude	NN

about	IN

their	PRP$

healthy	JJ

lifestyles	NNS

and	CC

felt	VBD

optimistic	JJ

about	IN

being	VBG

role	NN

models	NNS

for	IN

their	PRP$

patients	NNS

(	NN

5	CD

)	NN

Future	JJ

plans	NNS

were	VBD

either	DT

singular	JJ

in	IN

focus	NN

or	CC

limited	JJ

to	TO

maintenance	NN

of	IN

current	JJ

health	NN

habits	NNS

CONCLUSIONS	NNS

:	:

The	DT

majority	NN

of	IN

the	DT

nurses	NNS

reported	VBN

practicing	VBG

a	DT

healthy	JJ

lifestyle	NN

and	CC

thought	NN

that	IN

they	PRP

were	VBD

good	JJ

role	NN

models	NNS

for	IN

patients	NNS

Cytochrome	NN

P450	NN

1A1	NN

(	NN

CYP1A1	NN

)	NN

and	CC

glutathione	NN

S-transferase	NN

M1	NN

(	NN

GSTM1	NN

)	NN

genetic	JJ

polymorphisms	NNS

are	VBP

involved	VBN

in	IN

the	DT

activation	NN

and	CC

detoxification	NN

of	IN

chemical	NN

carcinogens	NNS

found	VBN

in	IN

tobacco	NN

smoke	NN

;	:

thus	RB

they	PRP

may	MD

influence	NN

host	NN

susceptibility	NN

to	TO

lung	NN

cancer	NN

In	IN

this	DT

study	NN

at	IN

Massachusetts	NNP

General	NNP

Hospital	NN

(	NN

Boston	NNP

,	,

MA	NNP

,	,

USA	NNP

)	NN

of	IN

416	CD

cases	NNS

and	CC

446	CD

controls	NNS

(	NN

mostly	RB

White	NNP

)	NN

we	PRP

evaluated	VBN

the	DT

association	NN

between	IN

the	DT

CYP1A1	NN

MspI	NN

and	CC

GSTM1	NN

polymorphisms	NNS

and	CC

lung	NN

cancer	NN

risk	NN

,	,

and	CC

their	PRP$

interaction	NN

with	IN

cigarette	NN

smoke	NN

The	DT

CYP1A1	NN

MspI	NN

heterozygous	JJ

genotype	NN

was	VBD

present	JJ

in	IN

18	CD

percent	NN

of	IN

cases	NNS

and	CC

16	CD

percent	NN

of	IN

controls	NNS

,	,

and	CC

one	CD

percent	NN

of	IN

cases	NNS

and	CC

controls	NNS

were	VBD

CYP1A1	NN

MspI	NN

homozygous	JJ

variant	NN

The	DT

GSTM1	NN

null	JJ

genotype	NN

was	VBD

detected	VBN

in	IN

54	CD

percent	NN

of	IN

cases	NNS

and	CC

52	CD

percent	NN

of	IN

controls	NNS

After	IN

adjusting	VBG

for	IN

age	NN

,	,

gender	NN

,	,

pack-years	NNS

of	IN

smoking	NN

,	,

and	CC

years	NNS

since	IN

quitting	VBG

smoking	NN

,	,

while	IN

neither	DT

the	DT

CYP1A1	NN

MspI	NN

heterozygous	JJ

genotype	NN

alone	RB

nor	CC

the	DT

GSTM1	NN

null	JJ

genotype	NN

alone	RB

were	VBD

associated	VBN

with	IN

a	DT

significant	JJ

increase	NN

in	IN

lung	NN

cancer	NN

risk	NN

,	,

having	VBG

both	DT

genetic	JJ

traits	NNS

was	VBD

associated	VBN

with	IN

a	DT

twofold	RB

increase	NN

in	IN

risk	NN

(	NN

95	CD

percent	NN

confidence	NN

interval	NN

(	NN

CI	NN

)	NN

=	JJ

1.0-3.4	CD

)	NN

Our	PRP$

data	NNS

did	VBD

not	RB

provide	VB

enough	RB

evidence	NN

for	IN

a	DT

substantial	JJ

modification	NN

of	IN

the	DT

effect	NN

of	IN

pack-years	NNS

on	IN

lung	NN

cancer	NN

risk	NN

by	IN

the	DT

CYP1A1	NN

MspI	NN

and	CC

GSTM1	NN

genotypes	NNS

However	RB

,	,

limitations	NNS

of	IN

our	PRP$

study	NN

preclude	VB

a	DT

conclusion	NN

about	IN

this	DT

potential	NN

interaction	NN

BACKGROUND	NN

:	:

Thrombolytic	JJ

treatment	NN

has	VBZ

been	VBN

shown	VBN

to	TO

accelerate	VB

resolution	NN

of	IN

major	JJ

pulmonary	JJ

embolism	NN

and	CC

lead	NN

to	TO

a	DT

rapid	JJ

improvement	NN

of	IN

right-side	JJ

hemodynamics	NNS

However	RB

,	,

the	DT

association	NN

between	IN

these	DT

favorable	JJ

effects	NNS

and	CC

the	DT

clinical	JJ

outcome	NN

of	IN

patients	NNS

who	WP

have	VB

no	DT

severe	JJ

hemodynamic	JJ

compromise	NN

at	IN

presentation	NN

remains	NNS

unknown	JJ

METHODS	NNS

AND	CC

RESULTS	NNS

:	:

The	DT

present	JJ

multicenter	NN

registry	NN

included	VBN

719	CD

consecutive	JJ

patients	NNS

with	IN

major	JJ

pulmonary	JJ

embolism	NN

according	VBG

to	TO

clinical	JJ

,	,

echocardiographic	JJ

,	,

scintigraphic	JJ

,	,

and	CC

cardiac	JJ

catheterization	NN

criteria	NNS

Symptom	NN

onset	NN

was	VBD

acute	JJ

(	NN

&	CC

#	#

60	CD

;	:

48	CD

hours	NNS

)	NN

in	IN

63	CD

%	NN

of	IN

patients	NNS

All	DT

patients	NNS

were	VBD

hemodynamically	RB

stable	JJ

(	NN

ie	FW

,	,

without	IN

evidence	NN

of	IN

cardiogenic	JJ

shock	NN

)	NN

at	IN

presentation	NN

treatment	NN

(	NN

within	IN

24	CD

hours	NNS

of	IN

diagnosis	NN

)	NN

was	VBD

given	VBN

to	TO

169	CD

patients	NNS

(	NN

23.5	CD

%	NN

)	NN

,	,

whereas	IN

the	DT

remaining	VBG

550	CD

patients	NNS

were	VBD

initially	RB

treated	VBN

with	IN

heparin	NN

alone	RB

Overall	RB

30-day	JJ

mortality	NN

was	VBD

significantly	RB

lower	JJR

in	IN

the	DT

patients	NNS

who	WP

received	VBN

thrombolytic	JJ

agents	NNS

(	NN

4.7	CD

versus	CC

11.1	CD

%	NN

,	,

P=.016	NN

)	NN

Clinical	JJ

factors	NNS

associated	VBN

with	IN

a	DT

higher	JJR

death	NN

rate	NN

were	VBD

syncope	NN

(	NN

P=.012	NN

)	NN

,	,

arterial	JJ

hypotension	NN

(	NN

P=.021	NN

)	NN

,	,

history	NN

of	IN

congestive	JJ

heart	NN

failure	NN

(	NN

P=.013	NN

)	NN

,	,

and	CC

chronic	JJ

pulmonary	JJ

disease	NN

(	NN

P=.032	NN

)	NN

However	RB

,	,

only	RB

primary	JJ

thrombolysis	NN

was	VBD

found	VBN

by	IN

multivariate	JJ

analysis	NN

to	TO

be	VB

an	DT

independent	JJ

predictor	NN

of	IN

survival	NN

(	NN

odds	NNS

ratio	NN

for	IN

in-hospital	JJ

death	NN

,	,

0.46	CD

;	:

95	CD

%	NN

confidence	NN

interval	NN

,	,

0.21	CD

to	TO

1.00	CD

)	NN

<	JJR

TO_SEE	NN

>	JJR

Patients	NNS

who	WP

underwent	VBD

early	RB

thrombolytic	JJ

treatment	NN

had	VBD

a	DT

reduced	VBN

rate	NN

of	IN

recurrent	JJ

pulmonary	JJ

embolism	NN

(	NN

7.7	CD

versus	CC

18.7	CD

%	NN

,	,

P	NN

&	CC

#	#

60	CD

;	:

.001	CD

)	NN

but	CC

also	RB

a	DT

higher	JJR

frequency	NN

of	IN

major	JJ

bleeding	VBG

episodes	NNS

(	NN

21.9	CD

%	NN

versus	CC

7.8	CD

%	NN

,	,

P	NN

&	CC

#	#

60	CD

;	:

.001	CD

)	NN

Cerebral	JJ

bleeding	VBG

occurred	VBD

in	IN

2	CD

patients	NNS

in	IN

each	DT

treatment	NN

group	NN

,	,

and	CC

1	CD

patient	NN

in	IN

each	DT

group	NN

died	VBD

of	IN

a	DT

bleeding	VBG

complication	NN

CONCLUSIONS	NNS

:	:

The	DT

results	NNS

of	IN

our	PRP$

study	NN

suggest	VB

that	IN

thrombolysis	NN

may	MD

favorably	RB

affect	VB

the	DT

clinical	JJ

outcome	NN

of	IN

hemodynamically	RB

stable	JJ

patients	NNS

with	IN

major	JJ

pulmonary	JJ

embolism	NN

A	DT

66-year-old	JJ

male	NN

engineer	NN

diagnosed	VBN

with	IN

malignant	JJ

pleural	JJ

mesothelioma	NN

4	CD

years	NNS

previously	RB

had	VBD

thoracotomy	NN

,	,

radiotherapy	NN

,	,

and	CC

chemotherapy	NN

He	PRP

was	VBD

followed	VBN

regularly	RB

with	IN

chest	NN

computed	VBN

tomography	NN

(	NN

CT	NN

)	NN

scan	VB

and	CC

had	VBD

been	VBN

asymptomatic	JJ

During	IN

one	CD

of	IN

his	PRP$

physical	JJ

examinations	NNS

,	,

routine	JJ

sigmoidoscopy	NN

showed	VBD

incidental	JJ

colonic	JJ

polyps	NNS

which	WDT

were	VBD

biopsied	VBN

Subsequently	RB

,	,

recurrence	NN

of	IN

pleural	JJ

mesothelioma	NN

and	CC

peritoneal	NN

involvement	NN

by	IN

mesothelioma	NN

was	VBD

documented	VBN

Two	CD

of	IN

the	DT

polyps	NNS

showed	VBD

metastatic	JJ

malignant	JJ

mesothelioma	NN

in	IN

the	DT

lamina	NN

propia	NN

which	WDT

strongly	RB

resembled	VBD

adenocarcinoma	NN

histologically	RB

causing	VBG

difficulty	NN

in	IN

making	VBG

definitive	JJ

diagnosis	NN

Review	NN

of	IN

the	DT

literature	NN

disclosed	VBN

no	DT

previously	RB

documented	VBN

similar	JJ

occurrence	NN

This	DT

case	NN

shows	NNS

the	DT

importance	NN

of	IN

clinical	JJ

history	NN

and	CC

ancillary	NN

laboratory	NN

procedures	NNS

such	JJ

as	IN

immunohistochemistry	NN

and	CC

electron	NN

microscopy	NN

to	TO

avoid	VB

diagnostic	JJ

pitfalls	NNS

The	DT

authors	NNS

report	NN

the	DT

postoperative	JJ

magnetic	JJ

resonance	NN

(	NN

MR	NN

)	NN

imaging	NN

findings	NNS

in	IN

36	CD

patients	NNS

with	IN

advanced	VBN

Parkinson	NNP

's	POS

disease	NN

who	WP

underwent	VBD

unilateral	JJ

microelectrode-guided	JJ

posteroventral	JJ

pallidotomy	NN

The	DT

lesions	NNS

were	VBD

placed	VBN

within	IN

1	CD

mm	NN

of	IN

the	DT

ventral	JJ

border	NN

of	IN

the	DT

globus	NN

pallidus	NN

internus	NN

(	NN

GPi	SYM

)	NN

to	TO

include	VB

pallidothalamic	JJ

outflow	NN

pathways	NNS

Sequential	JJ

MR	NN

studies	NNS

were	VBD

obtained	VBN

within	IN

1	CD

to	TO

3	CD

days	NNS

postoperatively	RB

and	CC

at	IN

6-month	JJ

follow-up	NN

examination	NN

Thirty-four	CD

(	NN

94	CD

%	NN

)	NN

of	IN

the	DT

36	CD

patients	NNS

enjoyed	VBN

sustained	JJ

moderate	JJ

or	CC

marked	JJ

improvement	NN

of	IN

their	PRP$

parkinsonian	NN

symptoms	NNS

6	CD

months	NNS

postoperatively	RB

Transient	JJ

side	NN

effects	NNS

occurred	VBD

in	IN

five	CD

patients	NNS

(	NN

14	CD

%	NN

)	NN

,	,

but	CC

there	RB

were	VBD

no	DT

persistent	JJ

complications	NNS

The	DT

pallidal	NN

radiofrequency	NN

lesions	NNS

were	VBD

prolate	VB

spheroid	NN

shaped	VBN

and	CC

were	VBD

composed	VBN

of	IN

three	CD

concentric	JJ

zones	NNS

in	IN

the	DT

early	RB

postoperative	JJ

studies	NNS

The	DT

mean	VB

volume	NN

of	IN

the	DT

middle	JJ

zone	NN

,	,

corresponding	VBG

to	TO

the	DT

area	NN

of	IN

hemorrhagic	JJ

coagulation	NN

necrosis	NN

,	,

was	VBD

44.4	CD

+/-	CC

17.6	CD

mm3	NN

;	:

the	DT

mean	VB

lesion	NN

volume	NN

as	IN

defined	VBN

by	IN

the	DT

outer	JJ

zone	NN

,	,

corresponding	VBG

to	TO

perilesional	JJ

edema	NN

,	,

was	VBD

262.2	CD

+/-	CC

111.6	CD

mm3	NN

Additional	JJ

edema	NN

spreading	VBG

to	TO

the	DT

internal	JJ

capsule	NN

was	VBD

noted	VBN

in	IN

32	CD

of	IN

34	CD

cases	NNS

and	CC

to	TO

the	DT

optic	JJ

tract	NN

in	IN

11	CD

of	IN

34	CD

cases	NNS

In	IN

two	CD

patients	NNS

small	JJ

ischemic	JJ

infarctions	NNS

involving	VBG

the	DT

corona	NN

radiata	NN

were	VBD

found	VBN

,	,

and	CC

in	IN

one	CD

a	DT

venous	JJ

infarction	NN

was	VBD

detected	VBN

Ischemic	JJ

infarction	NN

resulted	VBD

in	IN

mild	JJ

transient	JJ

Broca	NNP

's	POS

aphasia	NN

in	IN

one	CD

patient	NN

,	,

but	CC

there	RB

was	VBD

no	DT

detectable	JJ

neurological	JJ

deficit	NN

in	IN

the	DT

other	JJ

two	CD

The	DT

mean	VB

volume	NN

of	IN

late-phase	NN

(	NN

6	CD

months	NNS

)	NN

lesions	NNS

was	VBD

22	CD

+/-	CC

28.8	CD

mm3	NN

In	IN

three	CD

patients	NNS

no	DT

lesion	NN

was	VBD

identified	VBN

despite	IN

sustained	JJ

clinical	JJ

improvement	NN

The	DT

lesion	NN

was	VBD

located	JJ

in	IN

the	DT

posteroventral	JJ

GPi	SYM

in	IN

all	DT

cases	NNS

except	IN

in	IN

one	CD

patient	NN

in	IN

whom	WP

it	PRP

was	VBD

confined	VBN

to	TO

the	DT

GP	NN

externus	NN

(	NN

GPe	SYM

)	NN

This	DT

49-year-old	JJ

woman	NN

did	VBD

not	RB

experience	NN

sustained	JJ

benefit	NN

The	DT

authors	NNS

found	VBN

no	DT

consistent	JJ

correlations	NNS

between	IN

lesion	NN

size	NN

and	CC

location	NN

and	CC

clinical	JJ

outcome	NN

as	IN

measured	VBN

by	IN

a	DT

global	JJ

outcome	NN

score	NN

,	,

the	DT

Unified	JJ

Parkinson	NNP

's	POS

Disease	NN

Rating	NNP

Scale	NNP

motor	NN

,	,

activities	NNS

of	IN

daily	RB

living	VBG

,	,

and	CC

bradykinesia	NN

``	``

off	IN

''	''

scores	NNS

or	CC

rating	NN

of	IN

dyskinesias	NNS

Lesioning	VBG

of	IN

pallidal	NN

and	CC

subpallidal	JJ

pathways	NNS

may	MD

contribute	VB

to	TO

the	DT

sustained	JJ

clinical	JJ

benefit	NN

in	IN

this	DT

series	NN

Magnetic	JJ

resonance	NN

imaging	NN

analysis	NN

showed	VBD

that	IN

intraoperative	JJ

microelectrode	NN

recording	VBG

facilitated	VBN

accurate	JJ

placement	NN

of	IN

the	DT

lesion	NN

in	IN

this	DT

critical	JJ

area	NN

A	DT

commercially	RB

available	JJ

health	NN

food	NN

product	NN

of	IN

cold-pressed	JJ

hemp	NN

seed	NN

oil	NN

ingested	VBN

by	IN

one	CD

volunteer	NN

twice	RB

a	DT

day	NN

for	IN

4	CD

1/2	CD

days	NNS

(	NN

135	CD

mL	NN

total	NN

)	NN

Urine	NN

specimens	NNS

collected	VBN

from	IN

the	DT

volunteer	NN

were	VBD

subjected	VBN

to	TO

standard	NN

workplace	NN

urine	NN

drug	NN

testing	NN

procedures	NNS

,	,

and	CC

the	DT

following	VBG

concentrations	NNS

of	IN

11-nor-delta9-	JJ

tetrahydrocannabinol	NN

carboxylic	JJ

acid	NN

(	NN

9-THCA	NN

)	NN

were	VBD

detected	VBN

:	:

41	CD

ng/mL	NN

9-THCA	NN

at	IN

45	CD

h	NN

,	,

49	CD

ng/mL	NN

at	IN

69	CD

h	NN

,	,

and	CC

55	CD

ng/mL	NN

at	IN

93	CD

h.	NN

Ingestion	NN

was	VBD

discontinued	VBN

after	IN

93	CD

h	NN

,	,

and	CC

the	DT

following	VBG

concentrations	NNS

were	VBD

detected	VBN

:	:

68	CD

ng/mL	NN

at	IN

108	CD

h	NN

,	,

57	CD

ng/mL	NN

at	IN

117	CD

h	NN

,	,

31	CD

ng/mL	NN

at	IN

126	CD

h	NN

,	,

and	CC

20	CD

ng/mL	NN

at	IN

142	CD

h.	NN

The	DT

first	RB

specimen	NN

that	IN

tested	VBN

negative	JJ

(	NN

50	CD

ng/mL	NN

initial	JJ

immunoassay	NN

test	NN

,	,

15	CD

ng/mL	NN

confirmatory	JJ

gas	NN

chromatographic-mass	NN

spectrometric	JJ

test	NN

)	NN

was	VBD

at	IN

146	CD

h	NN

,	,

which	WDT

was	VBD

53	CD

h	NN

after	IN

the	DT

last	JJ

hemp	NN

seed	NN

oil	NN

ingestion	NN

Four	CD

subsequent	JJ

specimens	NNS

taken	VBN

to	TO

177	CD

h	NN

were	VBD

also	RB

negative	JJ

This	DT

study	NN

indicates	VBZ

that	IN

a	DT

workplace	NN

urine	NN

drug	NN

test	NN

positive	JJ

for	IN

cannabinoids	NNS

may	MD

arise	VB

from	IN

the	DT

consumption	NN

of	IN

commercially	RB

available	JJ

cold-pressed	JJ

hemp	NN

seed	NN

oil	NN

OBJECTIVE	NN

:	:

We	PRP

determined	VBN

the	DT

sensitivity	NN

and	CC

specificity	NN

of	IN

neonatal	JJ

brain-stem	NN

auditory	NN

evoked	VBN

potentials	NNS

(	NN

BAEP	NN

)	NN

as	IN

markers	NNS

for	IN

subsequent	JJ

hearing	NN

impairment	NN

and	CC

for	IN

developmental	JJ

problems	NNS

found	VBN

later	RB

in	IN

infancy	NN

and	CC

childhood	NN

METHODS	NNS

:	:

BAEP	NN

studies	NNS

were	VBD

performed	VBN

before	IN

discharge	NN

in	IN

infants	NNS

treated	VBN

with	IN

extracorporeal	JJ

membrane	NN

oxygenation	NN

(	NN

ECMO	NN

)	NN

,	,

and	CC

two	CD

specific	JJ

abnormalities	NNS

were	VBD

analyzed	VBN

:	:

elevated	JJ

threshold	NN

and	CC

delayed	VBN

central	JJ

auditory	NN

conduction	NN

Behavioral	JJ

audiometry	NN

was	VBD

repeated	VBN

during	IN

periodic	JJ

follow-up	NN

until	IN

reliable	JJ

responses	NNS

were	VBD

obtained	VBN

for	IN

all	DT

frequencies	NNS

,	,

and	CC

standardized	JJ

developmental	JJ

testing	NN

was	VBD

also	RB

conducted	VBN

The	DT

sensitivity	NN

and	CC

specificity	NN

of	IN

an	DT

elevated	JJ

threshold	NN

on	IN

the	DT

neonatal	JJ

BAEP	NN

for	IN

detecting	VBG

subsequent	JJ

hearing	NN

loss	NN

,	,

and	CC

the	DT

relationship	NN

of	IN

any	DT

neonatal	JJ

BAEP	NN

abnormality	NN

to	TO

language	NN

or	CC

developmental	JJ

disorders	NNS

in	IN

infancy	NN

,	,

were	VBD

calculated	VBN

RESULTS	NNS

:	:

Test	NN

results	NNS

for	IN

46	CD

ECMO-treated	JJ

infants	NNS

(	NN

57.5	CD

%	NN

)	NN

were	VBD

normal	JJ

,	,

and	CC

those	DT

for	IN

34	CD

infants	NNS

(	NN

42.5	CD

%	NN

)	NN

were	VBD

abnormal	JJ

,	,

with	IN

either	DT

elevated	JJ

wave	NN

V	NN

threshold	NN

,	,

prolonged	JJ

wave	NN

I-V	NN

interval	NN

,	,

or	CC

both	DT

on	IN

neonatal	JJ

BAEP	NN

recordings	NNS

Most	JJS

significantly	RB

,	,

7	CD

(	NN

58	CD

%	NN

)	NN

of	IN

the	DT

12	CD

children	NNS

with	IN

subsequent	JJ

sensorineural	NN

hearing	NN

loss	NN

had	VBD

left	RB

the	DT

hospital	NN

after	IN

showing	VBG

normal	JJ

results	NNS

on	IN

threshold	NN

tests	NNS

There	EX

was	VBD

no	DT

significant	JJ

difference	NN

in	IN

the	DT

frequency	NN

of	IN

hearing	NN

loss	NN

between	IN

subjects	NNS

with	IN

abnormal	JJ

(	NN

5/21	NN

,	,

or	CC

24	CD

%	NN

)	NN

and	CC

those	DT

with	IN

normal	JJ

BAEP	NN

thresholds	NNS

(	NN

7/59	CD

,	,

or	CC

12	CD

%	NN

;	:

Fisher	NNP

Exact	JJ

Test	NN

,	,

p	NN

=	JJ

0.28	CD

)	NN

Therefore	RB

the	DT

sensitivity	NN

of	IN

neonatal	JJ

BAEP	NN

testing	NN

for	IN

predicting	VBG

subsequent	JJ

hearing	NN

loss	NN

was	VBD

only	RB

42	CD

%	NN

Neonatal	JJ

BAEP	NN

specificity	NN

for	IN

excluding	VBG

subsequent	JJ

hearing	NN

loss	NN

was	VBD

76	CD

%	NN

In	IN

contrast	NN

,	,

on	IN

language	NN

development	NN

testing	NN

,	,

19	CD

children	NNS

demonstrated	VBN

receptive	JJ

language	NN

delay	NN

Of	IN

these	DT

children	NNS

,	,

12	CD

(	NN

63	CD

%	NN

)	NN

had	VBD

abnormal	JJ

neonatal	JJ

BAEP	NN

recordings	NNS

and	CC

7	CD

(	NN

37	CD

%	NN

)	NN

had	VBD

a	DT

normal	JJ

BAEP	NN

threshold	NN

,	,

normal	JJ

central	JJ

auditory	NN

conduction	NN

test	NN

results	NNS

,	,

or	CC

both	DT

(	NN

p	NN

=	JJ

0.04	CD

)	NN

CONCLUSIONS	NNS

:	:

Neonatal	JJ

BAEP	NN

threshold	NN

recordings	NNS

were	VBD

of	IN

limited	JJ

value	NN

for	IN

predicting	VBG

subsequent	JJ

hearing	NN

loss	NN

common	JJ

in	IN

ECMO	NN

-treated	JJ

survivors	NNS

However	RB

,	,

an	DT

abnormal	JJ

neonatal	JJ

BAEP	NN

significantly	RB

increased	VBN

the	DT

probability	NN

of	IN

finding	NN

a	DT

receptive	JJ

language	NN

delay	NN

during	IN

early	RB

childhood	NN

,	,

even	RB

in	IN

those	DT

with	IN

subsequently	RB

normal	JJ

audiometry	NN

findings	NNS

Because	IN

neonatal	JJ

ECMO	NN

is	VBZ

associated	VBN

with	IN

a	DT

high	JJ

risk	NN

of	IN

hearing	NN

and	CC

receptive	JJ

language	NN

disorders	NNS

,	,

parents	NNS

should	MD

be	VB

counseled	VBN

that	IN

audiologic	JJ

and	CC

developmental	JJ

follow-up	NN

evaluations	NNS

in	IN

surviving	VBG

children	NNS

are	VBP

essential	JJ

regardless	RB

of	IN

the	DT

results	NNS

of	IN

neonatal	JJ

BAEP	NN

testing	NN

The	DT

Federated	NNP

Council	NNP

of	IN

Internal	JJ

Medicine	NN

has	VBZ

developed	VBN

a	DT

resource	NN

guide	NN

to	TO

help	NN

internal	JJ

medicine	NN

residency	NN

programs	NNS

produce	VB

internists	NNS

who	WP

are	VBP

prepared	JJ

for	IN

today	NN

's	POS

practice	NN

of	IN

internal	JJ

medicine	NN

and	CC

the	DT

challenges	NNS

of	IN

practice	NN

in	IN

the	DT

future	NN

The	DT

guide	NN

situates	VBZ

general	JJ

internal	JJ

medicine	NN

as	IN

the	DT

primary	JJ

care	NN

profession	NN

that	IN

focuses	VBZ

on	IN

preventive	JJ

,	,

short-term	JJ

,	,

and	CC

long-term	JJ

care	NN

of	IN

adult	JJ

patients	NNS

It	PRP

assumes	VBZ

that	IN

a	DT

single	JJ

pathway	NN

is	VBZ

sufficient	JJ

for	IN

educating	VBG

general	JJ

internists	NNS

and	CC

subspecialty-bound	JJ

trainees	NNS

It	PRP

identifies	VBZ

the	DT

learning	VBG

experiences	NNS

that	IN

should	MD

be	VB

part	NN

of	IN

general	JJ

internal	JJ

medicine	NN

residency	NN

training	NN

,	,

lists	NNS

the	DT

clinical	JJ

competencies	NNS

that	IN

are	VBP

important	JJ

for	IN

primary	JJ

care	NN

practice	NN

,	,

and	CC

describes	VBZ

the	DT

role	NN

of	IN

the	DT

integrative	JJ

disciplines	NNS

that	IN

should	MD

inform	VB

the	DT

care	NN

of	IN

every	DT

patient	NN

It	PRP

also	RB

describes	VBZ

a	DT

process	NN

that	IN

program	NN

directors	NNS

and	CC

local	JJ

program	NN

committees	NNS

can	MD

use	NN

to	TO

develop	VB

competency-based	JJ

curricula	NN

BACKGROUND	NN

:	:

Darier	NNP

disease	NN

is	VBZ

an	DT

uncommon	JJ

genodermatosis	NN

characterized	VBN

by	IN

the	DT

symmetrical	JJ

eruption	NN

of	IN

keratotic	JJ

reddish-brown	JJ

papules	NNS

occurring	VBG

in	IN

the	DT

seborrheic	JJ

areas	NNS

of	IN

the	DT

body	NN

A	DT

unilateral	JJ

,	,

or	CC

localized	JJ

,	,

variant	NN

has	VBZ

been	VBN

identified	VBN

We	PRP

report	NN

4	CD

new	JJ

cases	NNS

of	IN

localized	JJ

Darier	NNP

disease	NN

and	CC

review	NN

the	DT

English-language	NN

literature	NN

The	DT

implications	NNS

of	IN

these	DT

cases	NNS

on	IN

future	NN

genetic	JJ

studies	NNS

are	VBP

also	RB

discussed	VBN

OBSERVATIONS	NNS

:	:

Localized	JJ

Darier	NNP

disease	NN

occurred	VBD

with	IN

equal	JJ

frequency	NN

in	IN

males	NNS

and	CC

females	NNS

The	DT

average	NN

age	NN

at	IN

onset	NN

was	VBD

27	CD

years	NNS

The	DT

most	RBS

frequent	JJ

site	NN

of	IN

involvement	NN

was	VBD

the	DT

trunk	NN

(	NN

40	CD

%	NN

(	NN

16/40	CD

)	NN

)	NN

This	DT

condition	NN

was	VBD

aggravated	VBN

by	IN

sunlight	NN

,	,

heat	NN

,	,

or	CC

sweating	NN

in	IN

42	CD

%	NN

(	NN

19/40	CD

)	NN

of	IN

reported	VBN

cases	NNS

,	,

and	CC

38	CD

%	NN

(	NN

15/40	CD

)	NN

of	IN

the	DT

patients	NNS

responded	VBD

to	TO

treatment	NN

with	IN

topical	JJ

tretinoin	NN

CONCLUSIONS	NNS

:	:

Many	JJ

of	IN

the	DT

clinical	JJ

features	NNS

of	IN

localized	JJ

Darier	NNP

disease	NN

suggest	VB

that	IN

it	PRP

is	VBZ

a	DT

genetic	JJ

mosaic	NN

of	IN

generalized	VBN

Darier	NNP

disease	NN

Further	RB

studies	NNS

of	IN

localized	JJ

Darier	NNP

disease	NN

may	MD

therefore	RB

prove	VB

to	TO

be	VB

instrumental	JJ

in	IN

the	DT

search	NN

for	IN

the	DT

Darier	NNP

disease	NN

gene	NN

UV	NN

radiation	NN

induces	VBZ

two	CD

major	JJ

DNA	NN

damage	NN

products	NNS

,	,

the	DT

cyclobutane	NN

pyrimidine	NN

dimer	NN

(	NN

CPD	NN

)	NN

and	CC

,	,

at	IN

a	DT

lower	JJR

frequency	NN

,	,

the	DT

pyrimidine	NN

(	NN

6-4	CD

)	NN

pyrimidinone	NN

dimer	NN

(	NN

6-4	CD

product	NN

)	NN

Although	IN

Escherichia	FW

coli	NN

and	CC

Saccharomyes	NNS

cerevisiae	FW

produce	VB

a	DT

CPD-specific	JJ

photolyase	NN

that	IN

eliminates	VBZ

only	RB

this	DT

class	NN

of	IN

dimer	NN

,	,

Arabidopsis	NNP

thaliana	NN

,	,

Drosphila	NN

melanogaster	FW

,	,

Crotalus	NNP

atrox	NN

,	,

and	CC

Xenopus	NN

laevis	NN

have	VB

recently	RB

been	VBN

shown	VBN

to	TO

photoreactivate	NN

both	DT

CPDs	NNS

and	CC

6-4	CD

products	NNS

We	PRP

describe	VBP

the	DT

isolation	NN

and	CC

characterization	NN

of	IN

two	CD

new	JJ

classes	NNS

of	IN

mutants	NNS

of	IN

Arabidopsis	NNP

,	,

termed	VBN

uvr2	NN

and	CC

uvr3	NN

,	,

that	IN

are	VBP

defective	JJ

in	IN

the	DT

photoreactivation	NN

of	IN

CPDs	NNS

and	CC

6-4	CD

products	NNS

,	,

respectively	RB

We	PRP

demonstrate	VB

that	IN

the	DT

CPD	NN

photolyase	NN

mutation	NN

is	VBZ

genetically	RB

linked	VBN

to	TO

a	DT

DNA	NN

sequence	NN

encoding	VBG

a	DT

type	NN

II	NNP

(	NN

metazoan	NN

)	NN

CPD	NN

photolyase	NN

In	IN

addition	NN

,	,

we	PRP

are	VBP

able	JJ

to	TO

generate	VB

plants	NNS

in	IN

which	WDT

only	RB

CPDs	NNS

or	CC

6-4	CD

products	NNS

are	VBP

photoreactivated	VBN

in	IN

the	DT

nuclear	JJ

genome	NN

by	IN

exposing	VBG

these	DT

mutants	NNS

to	TO

UV	NN

light	NN

and	CC

then	RB

allowing	VBG

them	PRP

to	TO

repair	NN

one	CD

or	CC

the	DT

other	JJ

class	NN

of	IN

dimers	NNS

This	DT

provides	VBZ

us	PRP

with	IN

a	DT

unique	JJ

opportunity	NN

to	TO

study	NN

the	DT

biological	JJ

consequences	NNS

of	IN

each	DT

of	IN

these	DT

two	CD

major	JJ

UV-induced	JJ

photoproducts	NNS

in	IN

an	DT

intact	JJ

living	VBG

system	NN

A	DT

diffuse	NN

macular	JJ

erythroderma	NN

and	CC

subsequent	JJ

desquamation	NN

after	IN

1	CD

to	TO

2	CD

weeks	NNS

are	VBP

two	CD

of	IN

the	DT

five	CD

major	JJ

diagnostic	JJ

criteria	NNS

of	IN

toxic	JJ

shock	NN

syndrome	NN

(	NN

TSS	NN

)	NN

We	PRP

present	JJ

the	DT

case	NN

of	IN

a	DT

15-month-old	JJ

girl	NN

with	IN

TSS	NN

,	,

but	CC

without	IN

erythroderma	NN

or	CC

desquamation	NN

She	PRP

was	VBD

admitted	VBN

with	IN

high	JJ

fever	NN

,	,

shock	NN

,	,

and	CC

multiorgan	JJ

involvement	NN

Minimal	JJ

or	CC

no	DT

cutaneous	JJ

signs	NNS

were	VBD

present	JJ

Initially	RB

the	DT

diagnosis	NN

of	IN

the	DT

syndrome	NN

of	IN

hemorrhagic	JJ

shock	NN

and	CC

encephalopathy	NN

was	VBD

made	VBN

After	IN

7	CD

days	NNS

,	,

a	DT

TSS	NN

toxin	NN

1-producing	JJ

strain	NN

of	IN

Staphylococcus	FW

aureus	NN

was	VBD

cultured	VBN

from	IN

an	DT

inguinal	JJ

lymph	NN

node	NN

,	,

where	WRB

inflammation	NN

had	VBD

already	RB

been	VBN

noticed	VBN

on	IN

admission	NN

Moreover	RB

,	,

the	DT

girl	NN

had	VBD

no	DT

antibodies	NNS

against	IN

this	DT

toxin	NN

The	DT

serum	NN

cytokine	NN

profile	NN

during	IN

the	DT

acute	JJ

phase	NN

of	IN

her	PRP$

illness	NN

showed	VBD

high	JJ

levels	NNS

of	IN

tumor	NN

necrosis	NN

factor-alpha	NN

,	,

interleukin-6	NN

and	CC

interferon-gamma	NN

,	,

as	IN

is	VBZ

seen	VBN

during	IN

activation	NN

of	IN

the	DT

immune	JJ

system	NN

by	IN

TSS	NN

toxin	NN

1	CD

Other	JJ

possible	JJ

causes	NNS

for	IN

the	DT

patient	NN

's	POS

illness	NN

were	VBD

excluded	VBN

We	PRP

conclude	VBP

that	IN

the	DT

patient	NN

had	VBD

TSS	NN

without	IN

rash	NN

Without	IN

the	DT

evidence	NN

implicating	VBG

a	DT

TSS	NN

toxin	NN

1-producing	JJ

strain	NN

of	IN

S.	NNP

aureus	NN

as	IN

the	DT

cause	NN

of	IN

her	PRP$

disease	NN

,	,

a	DT

diagnosis	NN

of	IN

syndrome	NN

of	IN

hemorrhagic	JJ

shock	NN

and	CC

encephalopathy	NN

would	MD

have	VB

been	VBN

made	VBN

It	PRP

is	VBZ

possible	JJ

that	IN

some	DT

cases	NNS

of	IN

syndrome	NN

of	IN

hemorrhagic	JJ

shock	NN

and	CC

encephalopathy	NN

represent	VB

a	DT

variant	NN

of	IN

TSS	NN

in	IN

small	JJ

children	NNS

<	JJR

TO_SEE	NN

>	JJR

BACKGROUND	NN

:	:

The	DT

growing	VBG

teratoma	NN

syndrome	NN

refers	VBZ

to	TO

the	DT

phenomenon	NN

whereby	WRB

germ	NN

cell	NN

tumors	NNS

enlarge	VB

after	IN

chemotherapy	NN

despite	IN

complete	JJ

eradication	NN

of	IN

malignant	JJ

cells	NNS

and	CC

normalization	NN

of	IN

serum	NN

tumor	NN

markers	NNS

This	DT

clinical	JJ

scenario	NN

must	MD

be	VB

differentiated	VBN

from	IN

that	IN

in	IN

which	WDT

germ	NN

cell	NN

tumors	NNS

maintain	VB

their	PRP$

malignant	JJ

characteristics	NNS

with	IN

elevated	JJ

levels	NNS

of	IN

serum	NN

tumor	NN

markers	NNS

METHODS	NNS

:	:

Hospital	NN

record	NN

review	NN

was	VBD

conducted	VBN

of	IN

2	CD

cases	NNS

RESULTS	NNS

:	:

Two	CD

male	NN

patients	NNS

are	VBP

presented	VBN

,	,

1	CD

with	IN

a	DT

metastatic	JJ

germ	NN

cell	NN

tumor	NN

of	IN

both	DT

the	DT

retroperitoneum	NN

and	CC

mediastinum	NN

(	NN

with	IN

elevated	JJ

alpha-fetoprotein	NN

level	NN

)	NN

and	CC

1	CD

with	IN

a	DT

primary	JJ

germ	NN

cell	NN

tumor	NN

of	IN

the	DT

mediastinum	NN

(	NN

with	IN

elevated	JJ

alpha-fetoprotein	NN

and	CC

beta-human	NN

chorionic	JJ

gonadotropin	NN

levels	NNS

)	NN

After	IN

completion	NN

of	IN

chemotherapy	NN

and	CC

normalization	NN

of	IN

tumor	NN

markers	NNS

,	,

both	DT

patients	NNS

presented	VBN

with	IN

pulmonary	JJ

symptoms	NNS

attributable	JJ

to	TO

their	PRP$

massively	RB

enlarging	VBG

mediastinal	JJ

teratomas	NNS

.	.

The	DT

clinical	JJ

and	CC

roentgenographic	JJ

features	NNS

of	IN

patients	NNS

with	IN

thoracic	JJ

manifestations	NNS

of	IN

the	DT

growing	VBG

teratoma	NN

syndrome	NN

,	,

as	IN

well	RB

as	IN

its	PRP$

management	NN

,	,

are	VBP

reviewed	VBN

<	JJR

TO_SEE	NN

>	JJR

CONCLUSIONS	NNS

:	:

After	IN

chemotherapy	NN

in	IN

patients	NNS

with	IN

primary	JJ

or	CC

metastatic	JJ

mediastinal	JJ

germ	NN

cell	NN

tumors	NNS

whose	WP$

tumor	NN

markers	NNS

normalize	VB

,	,

a	DT

growing	VBG

mass	NN

in	IN

the	DT

mediastinum	NN

may	MD

represent	VB

the	DT

growing	VBG

teratoma	NN

syndrome	NN

The	DT

chicken	NN

calmodulin	NN

I	PRP

(	NN

CaMI	NN

)	NN

gene	NN

has	VBZ

been	VBN

isolated	VBN

and	CC

characterized	VBN

on	IN

the	DT

level	NN

of	IN

cDNA	NN

and	CC

genomic	JJ

DNA	NN

The	DT

deduced	VBN

amino	NN

acid	NN

(	NN

aa	NN

)	NN

sequence	NN

is	VBZ

identical	JJ

to	TO

the	DT

one	CD

of	IN

chicken	NN

CaMII	NN

which	WDT

consists	VBZ

of	IN

148	CD

aa	NN

The	DT

CaMI	NN

gene	NN

contains	VBZ

six	CD

exons	NNS

Its	PRP$

intron/exon	NN

organization	NN

is	VBZ

identical	JJ

to	TO

that	IN

of	IN

the	DT

chicken	NN

CaMII	NN

and	CC

the	DT

CaMI	NN

and	CC

CaMIII	NN

genes	NNS

of	IN

rat	NN

and	CC

human	JJ

Expression	NN

of	IN

the	DT

CaMI	NN

gene	NN

was	VBD

detected	VBN

in	IN

all	DT

chicken	NN

tissues	NNS

examined	VBN

,	,

although	IN

at	IN

varying	VBG

levels	NNS

The	DT

gene	NN

is	VBZ

transcribed	VBN

into	IN

four	CD

mRNAs	NNS

of	IN

0.8	CD

,	,

1.4	CD

,	,

1.7	CD

and	CC

4.4	CD

kb	NN

as	IN

determined	VBN

by	IN

Northern	NN

blot	NN

analysis	NN

Our	PRP$

results	NNS

demonstrate	VB

that	IN

the	DT

``	``

multigene-one-protein	JJ

''	''

principle	NN

of	IN

CaM	NN

synthesis	NN

is	VBZ

not	RB

only	RB

applicable	JJ

to	TO

mammals	NNS

whose	WP$

CaM	NN

is	VBZ

encoded	VBN

by	IN

three	CD

different	JJ

genes	NNS

,	,

but	CC

also	RB

to	TO

chickens	NNS

BACKGROUND	NN

:	:

We	PRP

assessed	VBN

the	DT

accuracy	NN

of	IN

two	CD

electron	NN

beam	NN

computed	VBN

tomography	NN

(	NN

EBCT	NN

)	NN

protocols	NNS

for	IN

predicting	VBG

coronary	JJ

events	NNS

METHODS	NNS

AND	CC

RESULTS	NNS

:	:

In	IN

1994	CD

,	,

24	CD

months	NNS

after	IN

enrollment	NN

in	IN

a	DT

longitudinal	JJ

study	NN

,	,

326	CD

high-risk	JJ

adults	NNS

underwent	VBD

both	DT

3-	CD

and	CC

6-mm	JJ

image-slice	NN

thickness	NN

EBCT	NN

scanning	NN

and	CC

were	VBD

followed	VBN

up	RB

for	IN

32.0+/-4.0	CD

additional	JJ

months	NNS

Events	NNS

were	VBD

defined	VBN

as	IN

either	DT

coronary	JJ

death	NN

,	,

myocardial	JJ

infarction	NN

,	,

or	CC

revascularization	NN

We	PRP

monitored	VBN

these	DT

subjects	NNS

for	IN

the	DT

32-month	JJ

postscanning	VBG

period	NN

with	IN

yearly	JJ

phone	NN

calls	NNS

and	CC

acquisition	NN

of	IN

records	NNS

for	IN

all	DT

hospital	NN

admissions	NNS

At	IN

the	DT

time	NN

of	IN

scanning	NN

,	,

11	CD

subjects	NNS

(	NN

3	CD

%	NN

)	NN

had	VBD

already	RB

suffered	VBN

12	CD

events	NNS

(	NN

5	CD

infarctions	NNS

and	CC

7	CD

revascularizations	NNS

)	NN

during	IN

the	DT

24-month	JJ

prescanning	VBG

period	NN

During	IN

the	DT

postscanning	VBG

period	NN

,	,

18	CD

subjects	NNS

(	NN

6	CD

%	NN

)	NN

suffered	VBN

23	CD

events	NNS

(	NN

5	CD

coronary	JJ

deaths	NNS

,	,

6	CD

infarctions	NNS

,	,

and	CC

12	CD

revascularizations	NNS

)	NN

Thus	RB

,	,

28	CD

subjects	NNS

(	NN

9	CD

%	NN

)	NN

suffered	VBN

35	CD

events	NNS

Calcium	NN

quantities	NNS

calculated	VBN

for	IN

both	DT

protocols	NNS

,	,

performed	VBN

on	IN

the	DT

same	JJ

subjects	NNS

,	,

were	VBD

sorted	VBN

in	IN

ascending	VBG

order	NN

and	CC

divided	VBN

into	IN

equal	JJ

quartiles	NNS

When	WRB

revascularizations	NNS

were	VBD

included	VBN

,	,

there	RB

was	VBD

a	DT

significant	JJ

trend	NN

toward	IN

higher	JJR

frequencies	NNS

of	IN

events	NNS

with	IN

increasing	VBG

calcium	NN

quantity	NN

(	NN

P	NN

&	CC

#	#

60	CD

;	:

.01	CD

)	NN

However	RB

,	,

coronary	JJ

death	NN

and	CC

infarction	NN

were	VBD

not	RB

significantly	RB

more	RBR

frequent	JJ

in	IN

higher	JJR

quartiles	NNS

These	DT

relationships	NNS

were	VBD

preserved	JJ

in	IN

the	DT

subjects	NNS

without	IN

prior	RB

events	NNS

at	IN

the	DT

time	NN

of	IN

scanning	NN

CONCLUSIONS	NNS

:	:

Calcium	NN

quantities	NNS

from	IN

the	DT

3-mm	NN

and	CC

the	DT

more	RBR

reproducible	JJ

6-mm	JJ

scanning	NN

are	VBP

equally	RB

accurate	JJ

for	IN

predicting	VBG

events	NNS

Coronary	JJ

calcium	NN

amount	NN

appears	VBZ

to	TO

be	VB

a	DT

weak	JJ

predictor	NN

of	IN

coronary	JJ

death	NN

and	CC

infarction	NN

Its	PRP$

predictive	JJ

accuracy	NN

is	VBZ

superior	JJ

for	IN

predicting	VBG

revascularization	NN

Research	NNP

into	IN

the	DT

genetic	JJ

component	NN

of	IN

some	DT

complex	NN

behaviors	NNS

often	RB

causes	NNS

controversy	NN

,	,

depending	VBG

on	IN

the	DT

social	JJ

meaning	VBG

and	CC

significance	NN

of	IN

the	DT

behavior	NN

under	IN

study	NN

Research	NNP

into	IN

sexual	JJ

orientation-simplistically	RB

referred	VBN

to	TO

as	IN

``	``

gay	JJ

gene	NN

''	''

research-is	JJ

an	DT

example	NN

of	IN

research	NN

that	IN

provokes	VBZ

intense	JJ

controversy	NN

This	DT

research	NN

is	VBZ

worrisome	JJ

for	IN

many	JJ

reasons	NNS

,	,

including	VBG

the	DT

fact	NN

that	IN

it	PRP

has	VBZ

been	VBN

used	VBN

to	TO

harm	NN

lesbians	NNS

and	CC

gay	JJ

men	NNS

Many	JJ

homosexual	NN

people	NNS

have	VB

been	VBN

forced	VBN

to	TO

undergo	VB

``	``

treatments	NNS

''	''

to	TO

change	NN

their	PRP$

sexual	JJ

orientation	NN

Other	JJ

chose	VBD

to	TO

undergo	VB

them	PRP

to	TO

escape	NN

discrimination	NN

and	CC

social	JJ

disapprobation	NN

But	CC

there	RB

are	VBP

other	JJ

reasons	NNS

to	TO

worry	NN

about	IN

such	JJ

research	NN

The	DT

very	RB

motivation	NN

for	IN

seeking	VBG

an	DT

``	``

origin	NN

''	''

of	IN

homosexuality	NN

reveals	VBZ

homophobia	NN

Moreover	RB

,	,

such	JJ

research	NN

may	MD

lead	NN

to	TO

prenatal	JJ

tests	NNS

that	IN

claim	NN

to	TO

predict	VB

for	IN

homosexuality	NN

For	IN

homosexual	NN

people	NNS

who	WP

live	VB

in	IN

countries	NNS

with	IN

no	DT

legal	JJ

protections	NNS

these	DT

dangers	NNS

are	VBP

particularly	RB

serious	JJ

The	DT

efficiency	NN

of	IN

testicular	JJ

sperm	NN

retrieval	NN

by	IN

testicular	JJ

fine	NN

needle	NN

aspiration	NN

(	NN

TEFNA	NN

)	NN

was	VBD

compared	VBN

with	IN

open	JJ

biopsy	NN

and	CC

testicular	JJ

sperm	NN

extraction	NN

(	NN

TESE	NN

)	NN

,	,

in	IN

37	CD

rigorously	RB

selected	VBN

patients	NNS

with	IN

non-obstructive	JJ

azoospermia	NN

All	DT

patients	NNS

underwent	VBD

TEFNA	NN

and	CC

TESE	NN

consecutively	RB

Thus	RB

,	,

each	DT

patient	NN

served	VBD

as	IN

his	PRP$

own	JJ

control	NN

The	DT

case	NN

was	VBD

regarded	VBN

as	IN

successful	JJ

if	IN

at	IN

least	JJS

one	CD

testicular	JJ

spermatozoon	NN

was	VBD

found	VBN

allowing	VBG

intracytoplasmic	JJ

sperm	NN

injection	NN

(	NN

ICSI	NN

)	NN

of	IN

at	IN

least	JJS

one	CD

oocyte	NN

The	DT

mean	VB

age	NN

of	IN

the	DT

male	NN

patients	NNS

was	VBD

32.7	CD

years	NNS

(	NN

range	NN

24-47	CD

)	NN

Whereas	IN

by	IN

TEFNA	NN

spermatozoa	NN

enabling	VBG

performance	NN

of	IN

ICSI	NN

were	VBD

found	VBN

in	IN

only	RB

four	CD

patients	NNS

out	IN

of	IN

37	CD

(	NN

11	CD

%	NN

)	NN

,	,

open	JJ

biopsy	NN

and	CC

TESE	NN

yielded	VBD

spermatozoa	NN

in	IN

16	CD

cases	NNS

(	NN

43	CD

%	NN

)	NN

The	DT

negative	JJ

predictive	JJ

value	NN

of	IN

high	JJ

serum	NN

follicle	NN

stimulating	VBG

hormone	NN

(	NN

FSH	NN

)	NN

concentrations	NNS

(	NN

>	JJR

or	CC

=10	CD

IU/l	NN

)	NN

(	NN

predicting	VBG

failure	NN

to	TO

find	VB

spermatozoa	NN

for	IN

ICSI	NN

)	NN

was	VBD

low	JJ

(	NN

38.4	CD

%	NN

)	NN

The	DT

positive	JJ

predictive	JJ

value	NN

(	NN

predicting	VBG

the	DT

chance	NN

to	TO

find	VB

spermatozoa	NN

for	IN

ICSI	NN

)	NN

of	IN

normal-sized	JJ

testicle	NN

was	VBD

not	RB

different	JJ

from	IN

that	IN

of	IN

small-sized	JJ

(	NN

&	CC

#	#

60	CD

;	:

15	CD

ml	NN

)	NN

testicle	NN

(	NN

50	CD

%	NN

)	NN

Complications	NNS

included	VBN

one	CD

case	NN

of	IN

testicular	JJ

bleeding	VBG

following	VBG

fine	NN

needle	NN

aspiration	NN

,	,

treated	VBN

locally	RB

,	,

and	CC

two	CD

cases	NNS

of	IN

extratunical	JJ

haematomata	NN

following	VBG

TESE	NN

requiring	VBG

no	DT

intervention	NN

<	JJR

TO_SEE	NN

>	JJR

In	IN

patients	NNS

with	IN

non-obstructive	JJ

azoospermia	NN

,	,

TEFNA	NN

has	VBZ

a	DT

significantly	RB

lower	JJR

yield	NN

compared	VBN

to	TO

TESE	NN

Performance	NNP

of	IN

ICSI	NN

with	IN

testicular	JJ

sperm	NN

in	IN

these	DT

cases	NNS

resulted	VBD

in	IN

satisfactory	JJ

fertilization	NN

and	CC

high	JJ

embryo	NN

transfer	NN

rates	NNS

The	DT

implantation	NN

and	CC

pregnancy	NN

rates	NNS

per	IN

embryo	NN

transfer	NN

were	VBD

13	CD

and	CC

29	CD

%	NN

respectively	RB

Neither	DT

serum	NN

FSH	NN

values	NNS

nor	CC

testicular	JJ

size	NN

were	VBD

predictive	JJ

of	IN

the	DT

chances	NNS

to	TO

find	VB

spermatozoa	NN

for	IN

ICSI	NN

Some	DT

complications	NNS

may	MD

occur	VB

even	RB

following	VBG

TEFNA	NN

Cyclin	NN

D1	NN

,	,

the	DT

regulatory	JJ

subunit	NN

of	IN

certain	JJ

protein	NN

kinases	NNS

thought	NN

to	TO

advance	NN

the	DT

G1	NN

phase	NN

of	IN

the	DT

cell	NN

cycle	NN

,	,

is	VBZ

now	RB

established	VBN

as	IN

a	DT

proto-oncogene	NN

,	,

with	IN

evidence	NN

indicating	VBG

that	IN

its	PRP$

derangement	NN

may	MD

contribute	VB

to	TO

the	DT

uncontrolled	JJ

cell	NN

growth	NN

characteristic	JJ

of	IN

tumors	NNS

The	DT

chromosomal	JJ

translocation	NN

t	NN

(	NN

11	CD

;	:

14	CD

)	NN

(	NN

q13	NN

:	:

q32	NN

)	NN

,	,

involving	VBG

rearrangement	NN

of	IN

the	DT

BCL-1	NN

locus	NN

,	,

is	VBZ

closely	RB

associated	VBN

with	IN

human	JJ

lymphoid	JJ

neoplasia	NN

affecting	VBG

mantle	NN

cell	NN

lymphomas	NNS

(	NN

MCL	NN

)	NN

Recently	RB

,	,

the	DT

putative	JJ

BCL-1	NN

proto-oncogene	NN

turned	VBD

out	IN

to	TO

be	VB

none	NN

other	JJ

than	IN

the	DT

cyclin	NN

D1	NN

gene	NN

Although	IN

the	DT

observed	VBN

break	NN

points	NNS

in	IN

the	DT

BCL-1	NN

locus	NN

are	VBP

not	RB

tightly	RB

clustered	VBN

,	,

its	PRP$

rearrangement	NN

has	VBZ

been	VBN

documented	VBN

in	IN

40-70	CD

%	NN

of	IN

cases	NNS

of	IN

mantle	NN

cell	NN

lymphoma	NN

,	,

whereas	IN

it	PRP

only	RB

rarely	RB

occurs	VBZ

in	IN

other	JJ

B	NN

cell	NN

lymphomas	NNS

Of	IN

note	NN

,	,

all	DT

of	IN

the	DT

known	VBN

break	NN

points	NNS

leave	NN

the	DT

cyclin	NN

D1	NN

coding	VBG

region	NN

structurally	RB

intact	JJ

and	CC

result	NN

in	IN

increased	VBN

protein	NN

expression	NN

,	,

implying	VBG

that	IN

this	DT

may	MD

provide	VB

a	DT

highly	RB

sensitive	JJ

and	CC

specific	JJ

marker	NN

for	IN

MCL	NN

Recent	JJ

studies	NNS

demonstrated	VBN

that	IN

immunohistochemical	JJ

detection	NN

in	IN

paraffin-embedded	JJ

material	NN

,	,

using	VBG

a	DT

monoclonal	JJ

antibody	NN

,	,

is	VBZ

very	RB

useful	JJ

for	IN

routine	JJ

diagnosis	NN

Current	JJ

knowledge	NN

of	IN

cyclin	NN

D1	NN

overexpression	NN

in	IN

malignant	JJ

lymphomas	NNS

,	,

with	IN

emphasis	NN

on	IN

its	PRP$

clinicopathologic	JJ

significance	NN

,	,

is	VBZ

reviewed	VBN

In	IN

the	DT

mammalian	JJ

central	JJ

nervous	JJ

system	NN

,	,

a	DT

diverse	JJ

group	NN

of	IN

basic	JJ

helix-loop-helix	JJ

(	NN

bHLH	JJ

)	NN

proteins	NNS

is	VBZ

involved	VBN

in	IN

the	DT

determination	NN

of	IN

progenitor	NN

cells	NNS

and	CC

,	,

subsequently	RB

,	,

in	IN

regulating	VBG

neuronal	JJ

differentiation	NN

Here	RB

we	PRP

report	NN

the	DT

identification	NN

of	IN

a	DT

novel	JJ

subfamily	NN

of	IN

bHLH	JJ

proteins	NNS

,	,

defined	VBN

by	IN

two	CD

mammalian	JJ

enhancer-of-split-	JJ

and	CC

hairy-related	JJ

proteins	NNS

,	,

termed	VBN

SHARP-1	NN

and	CC

SHARP-2	NN

In	IN

contrast	NN

to	TO

known	VBN

bHLH	JJ

genes	NNS

,	,

detectable	JJ

transcription	NN

of	IN

SHARP	JJ

genes	NNS

begins	VBZ

at	IN

the	DT

end	NN

of	IN

embryonic	JJ

development	NN

marking	VBG

differentiated	VBN

neurons	NNS

that	IN

have	VB

reached	VBN

a	DT

final	JJ

position	NN

,	,

and	CC

increases	NNS

as	IN

postnatal	JJ

development	NN

proceeds	NNS

In	IN

the	DT

adult	JJ

,	,

SHARP	JJ

genes	NNS

are	VBP

expressed	VBN

in	IN

subregions	NNS

of	IN

the	DT

CNS	NNS

that	IN

have	VB

been	VBN

associated	VBN

with	IN

adult	JJ

plasticity	NN

In	IN

PC12	NN

cells	NNS

,	,

a	DT

model	NN

system	NN

to	TO

study	NN

neurite	NN

outgrowth	NN

,	,

SHARP	JJ

genes	NNS

can	MD

be	VB

induced	VBN

by	IN

NGF	NN

with	IN

the	DT

kinetics	NNS

of	IN

an	DT

immediate-early	JJ

gene	NN

Similarly	RB

,	,

within	IN

1	CD

h	NN

after	IN

the	DT

administration	NN

of	IN

kainic	JJ

acid	NN

in	IN

vivo	FW

,	,

SHARP-2	NN

is	VBZ

induced	VBN

in	IN

neurons	NNS

throughout	IN

the	DT

rat	NN

cerebral	JJ

cortex	NN

This	DT

suggests	VBZ

that	IN

neuronal	JJ

bHLH	JJ

proteins	NNS

are	VBP

also	RB

involved	VBN

in	IN

the	DT

``	``

adaptive	JJ

''	''

changes	NNS

of	IN

mature	JJ

CNS	NNS

neurons	NNS

which	WDT

are	VBP

coupled	VBN

to	TO

glutamatergic	JJ

stimulation	NN

The	DT

embryonic	JJ

development	NN

of	IN

the	DT

face	NN

has	VBZ

been	VBN

studied	VBN

in	IN

many	JJ

reviews	NNS

,	,

this	DT

work	NN

purposes	NNS

only	RB

to	TO

clear	JJ

up	RB

some	DT

points	NNS

which	WDT

remain	VB

obscure	JJ

concerning	VBG

cervico-facial	JJ

morphogenesis	NN

In	IN

the	DT

first	RB

part	NN

of	IN

this	DT

study	NN

only	RB

the	DT

facial	JJ

development	NN

,	,

properly	RB

speaking	VBG

,	,

is	VBZ

considered	VBN

,	,

although	IN

it	PRP

can	MD

not	RB

be	VB

separate	JJ

of	IN

cervical	JJ

development	NN

to	TO

which	WDT

a	DT

second	JJ

study	NN

will	MD

be	VB

reserved	VBN

In	IN

the	DT

present	JJ

study	NN

we	PRP

recall	NN

the	DT

particular	JJ

aspects	NNS

of	IN

the	DT

neurulation	NN

in	IN

the	DT

cephalic	JJ

area	NN

,	,

then	RB

the	DT

establishment	NN

of	IN

the	DT

facial	JJ

processes	NNS

Then	RB

we	PRP

approach	NN

among	IN

other	JJ

things	NNS

the	DT

way	NN

to	TO

consider	VB

the	DT

maxillary	JJ

process	NN

with	IN

regard	NN

to	TO

the	DT

other	JJ

facial	JJ

processes	NNS

After	IN

is	VBZ

considered	VBN

constitution	NN

and	CC

natured	JJ

of	IN

the	DT

prechordal	JJ

plate	NN

which	WDT

has	VBZ

been	VBN

diversely	RB

explained	VBN

Finally	RB

,	,

the	DT

modelling	NN

of	IN

the	DT

face	NN

is	VBZ

evocated	VBN

,	,

in	IN

which	WDT

the	DT

dissociation	NN

between	IN

the	DT

olfactive	JJ

and	CC

buccal	JJ

spheres	NNS

is	VBZ

pointed	JJ

out	IN

,	,

with	IN

the	DT

disparition	NN

of	IN

the	DT

muzzle	NN

,	,

as	IN

it	PRP

is	VBZ

established	VBN

in	IN

the	DT

haplorhinae	NN

,	,

a	DT

class	NN

of	IN

primates	NNS

in	IN

which	WDT

the	DT

human	JJ

being	VBG

is	VBZ

involved	VBN

This	DT

phenomenon	NN

raises	VBZ

different	JJ

questions	NNS

,	,

in	IN

particular	JJ

about	IN

the	DT

relation	NN

of	IN

this	DT

disposition	NN

with	IN

the	DT

nasoseptal	JJ

center	NN

,	,

the	DT

medial	JJ

part	NN

of	IN

the	DT

nasodorsal	NN

center	NN

A	DT

case-control	JJ

study	NN

was	VBD

performed	VBN

in	IN

eight	CD

pairs	NNS

of	IN

women	NNS

to	TO

determine	VB

whether	IN

preeclamptic	JJ

women	NNS

developed	VBN

abnormalities	NNS

in	IN

minor	JJ

hemoglobins	NNS

,	,

glycolytic	JJ

enzymes	NNS

,	,

or	CC

other	JJ

blood	NN

components	NNS

that	IN

might	MD

provide	VB

insight	NN

into	IN

the	DT

pathophysiology	NN

of	IN

preeclampsia	NN

,	,

or	CC

that	IN

in	IN

combination	NN

might	MD

be	VB

used	VBN

as	IN

a	DT

marker	NN

for	IN

the	DT

condition	NN

These	DT

variables	NNS

and	CC

standard	NN

clinical	JJ

tests	NNS

were	VBD

analyzed	VBN

as	IN

discriminators	NNS

between	IN

preeclamptic	JJ

and	CC

control	NN

women	NNS

The	DT

subjects	NNS

were	VBD

matched	VBN

for	IN

age	NN

,	,

ethnicity	NN

,	,

parity	NN

,	,

and	CC

gestational	JJ

age	NN

Blood	NN

samples	NNS

were	VBD

taken	VBN

at	IN

the	DT

time	NN

of	IN

diagnosis	NN

of	IN

preeclampsia	NN

and	CC

at	IN

comparable	JJ

gestational	JJ

ages	NNS

for	IN

matched	VBN

normal	JJ

controls	NNS

Variables	NNS

differing	VBG

significantly	RB

between	IN

groups	NNS

included	VBN

increases	NNS

in	IN

uric	JJ

acid	NN

(	NN

UA	NNP

)	NN

,	,

low-density	NN

lipoproteins	NNS

(	NN

LDL	NN

)	NN

,	,

phosphoglycerate	NN

kinase	NN

(	NN

PGK	NN

)	NN

,	,

and	CC

mean	VB

platelet	NN

volume	NN

(	NN

MPV	NN

)	NN

,	,

and	CC

decreases	NNS

in	IN

glyceraldehyde	NN

phosphate	NN

dehydrogenase	NN

(	NN

G3PD	NN

)	NN

in	IN

preeclamptic	JJ

women	NNS

compared	VBN

to	TO

normal	JJ

controls	NNS

Discriminant	JJ

analysis	NN

revealed	VBD

the	DT

following	VBG

function	NN

to	TO

separate	JJ

the	DT

groups	NNS

:	:

0.7764	CD

(	NN

UA	NNP

)	NN

+	CC

0.8086	CD

(	NN

PGK	NN

)	NN

-0.7032	CD

(	NN

G3PD	NN

)	NN

+	CC

0.1399	CD

(	NN

LDL	NN

)	NN

-0.2386	CD

(	NN

MPV	NN

)	NN

A	DT

discriminant	JJ

score	NN

of	IN

>	JJR

or	CC

=	JJ

275	CD

indicated	VBD

a	DT

>	JJR

or	CC

=	JJ

90	CD

%	NN

probability	NN

of	IN

preeclampsia	NN

The	DT

results	NNS

are	VBP

consistent	JJ

with	IN

perturbations	NNS

in	IN

red	JJ

cell	NN

glycolysis	NN

in	IN

preeclampsia	NN

Further	RB

prospective	JJ

studies	NNS

are	VBP

warranted	VBN

to	TO

test	NN

the	DT

efficacy	NN

of	IN

this	DT

discriminant	JJ

function	NN

in	IN

predicting	VBG

preeclampsia	NN

A	DT

novel	JJ

technique	NN

for	IN

patterning	NN

immobilized	VBN

antibody	NN

layers	NNS

based	VBN

upon	IN

photolithography	NN

and	CC

oxygen	NN

plasma	NN

exposure	NN

has	VBZ

been	VBN

developed	VBN

Mouse	NN

monoclonal	JJ

antibodies	NNS

specific	JJ

for	IN

thiabendazole	NN

(	NN

a	DT

post-harvest	JJ

fungicide	NN

and	CC

veterinary	JJ

anthelmintic	JJ

)	NN

were	VBD

covalently	RB

linked	VBN

through	IN

free	JJ

amine	NN

groups	NNS

to	TO

aminosilanized	VBN

silicon	NN

dioxide	NN

films	NNS

using	VBG

glutaraldehyde	NN

Immobilized	VBN

antibody	NN

layers	NNS

were	VBD

stabilized	VBN

with	IN

sucrose	NN

,	,

dehydrated	VBN

,	,

and	CC

stored	VBN

refrigerated	VBN

with	IN

desiccant	NN

Photolithographic	JJ

patterning	NN

was	VBD

performed	VBN

with	IN

a	DT

positive	JJ

photoresist	NN

with	IN

modified	VBN

bake	VB

temperatures	NNS

and	CC

times	NNS

,	,

selective	JJ

UV	NN

exposure	NN

with	IN

a	DT

contact	NN

mask	NN

,	,

and	CC

aqueous	JJ

alkaline	NN

solubilization	NN

of	IN

exposed	VBN

resist	VB

Exposed	VBN

regions	NNS

of	IN

immobilized	VBN

antibody	NN

were	VBD

then	RB

removed	VBN

by	IN

exposure	NN

to	TO

a	DT

low	JJ

power	NN

,	,

radio	NN

frequency	NN

oxygen	NN

discharge	NN

Residual	JJ

resist	VB

was	VBD

stripped	VBN

with	IN

acetone	NN

Successful	JJ

patterning	NN

was	VBD

demonstrated	VBN

by	IN

challenging	VBG

surfaces	NNS

with	IN

goat	NN

anti-mouse	JJ

antibody	NN

conjugated	VBN

to	TO

tetramethylrhodamine	NN

isothiocyanate	NN

Sucrose	NN

stabilization	NN

was	VBD

necessary	JJ

for	IN

antibody	NN

to	TO

undergo	VB

photoresist	NN

processing	NN

without	IN

loss	NN

of	IN

binding	NN

activity	NN

Challenge	NN

with	IN

enzyme	NN

linked	VBN

antigen	NN

of	IN

oxygen	NN

plasma	NN

exposed	VBN

antibody	NN

layers	NNS

demonstrated	VBN

that	IN

plasma	NN

treatment	NN

completely	RB

neutralized	VBN

antibody	NN

capture	NN

ability	NN

Ellipsometry	NN

measurements	NNS

of	IN

oxygen	NN

plasma	NN

exposed	VBN

antibody	NN

layers	NNS

indicated	VBD

complete	JJ

removal	NN

of	IN

immobilized	VBN

antibodies	NNS

Fluorescent	JJ

imaging	NN

demonstrated	VBN

smallest	JJS

line	NN

widths	NNS

of	IN

2-3	CD

microns	NNS

Immune	NNP

cells	NNS

in	IN

vivo	FW

routinely	RB

perform	VB

highly	RB

selective	JJ

immunosensing	NN

in	IN

blood	NN

and	CC

tissues	NNS

as	IN

part	NN

of	IN

their	PRP$

normal	JJ

immune	JJ

surveillance	NN

functions	NNS

We	PRP

have	VB

been	VBN

investigating	VBG

the	DT

potential	NN

of	IN

exploiting	VBG

the	DT

immunosensing	NN

detection	NN

abilities	NNS

of	IN

excitable	JJ

immune	JJ

cells	NNS

(	NN

i.e	NN

.	.

the	DT

mast	NN

cell	NN

)	NN

for	IN

the	DT

development	NN

of	IN

whole	JJ

cell	NN

immunobiosensors	NNS

A	DT

key	NN

feature	NN

is	VBZ

that	IN

these	DT

immune	JJ

cells	NNS

can	MD

be	VB

selectively	RB

engineered	VBN

to	TO

recognize	VB

specific	JJ

antigens	NNS

in	IN

vitro	NN

In	IN

the	DT

presence	NN

of	IN

antigen	NN

,	,

these	DT

cells	NNS

undergo	VB

excitable	JJ

activation	NN

responses	NNS

which	WDT

result	NN

in	IN

increased	VBN

metabolism	NN

and	CC

the	DT

exocytosis	NN

of	IN

stored	VBN

intracellular	JJ

mediators	NNS

We	PRP

have	VB

previously	RB

determined	VBN

that	IN

mast	NN

cell	NN

metabolic	JJ

responses	NNS

can	MD

be	VB

thermally	RB

transduced	VBN

in	IN

real	RB

time	NN

,	,

thus	RB

indicating	VBG

the	DT

possibility	NN

of	IN

whole	JJ

cell	NN

thermoelectric	IN

immunobiosensing	NN

In	IN

this	DT

work	NN

we	PRP

investigated	VBN

the	DT

use	NN

of	IN

enzyme	NN

amplification	NN

systems	NNS

to	TO

enhance	VB

the	DT

direct	JJ

transduction	NN

of	IN

immune	JJ

cell	NN

responses	NNS

to	TO

analyte	NN

It	PRP

was	VBD

found	VBN

that	IN

with	IN

appropriate	JJ

enzymes	NNS

,	,

peak	NN

outputs	NNS

occurred	VBD

within	IN

approximately	RB

5	CD

min	NN

(	NN

4-20	CD

times	NNS

faster	RBR

than	IN

without	IN

enzymes	NNS

)	NN

and	CC

peak	NN

response	NN

magnitudes	NNS

were	VBD

up	RB

to	TO

nine-fold	RB

greater	JJR

than	IN

without	IN

enzymes	NNS

An	DT

easy-to-use	JJ

technique	NN

for	IN

detection	NN

of	IN

antibodies	NNS

specific	JJ

for	IN

the	DT

parasite	NN

L.	NNP

donovani	NNS

in	IN

human	JJ

serum	NN

sample	NN

has	VBZ

been	VBN

developed	VBN

The	DT

method	NN

is	VBZ

based	VBN

on	IN

an	DT

evanescent	JJ

wave	NN

generated	VBN

from	IN

a	DT

tapered	VBN

configuration	NN

of	IN

decladded	VBN

optical	JJ

fibre	NN

and	CC

does	VBZ

not	RB

require	VB

any	DT

volumetric	JJ

measurement	NN

Tapered	VBN

fibres	NNS

are	VBP

immobilized	VBN

with	IN

the	DT

purified	VBN

cell	NN

surface	NN

protein	NN

of	IN

L.	NNP

donovani	NNS

by	IN

covalent	JJ

bonding	NN

Treated	VBN

fibres	NNS

are	VBP

incubated	VBN

with	IN

the	DT

patient	NN

serum	NN

for	IN

10	CD

min	NN

followed	VBN

by	IN

incubation	NN

with	IN

goat	NN

anti	JJ

human	JJ

IgG	NN

tagged	VBN

FITC	NN

Fluorescent	JJ

intensity	NN

from	IN

the	DT

fibre	NN

has	VBZ

been	VBN

shown	VBN

to	TO

be	VB

proportional	JJ

to	TO

L.	NNP

donovani	NNS

specific	JJ

antibodies	NNS

present	JJ

in	IN

the	DT

test	NN

sera	NNS

Direct	JJ

readings	NNS

can	MD

be	VB

obtained	VBN

after	IN

signal	NN

enhancement	NN

through	IN

a	DT

photomultiplier	NN

tube	NN

within	IN

5	CD

min	NN

The	DT

system	NN

,	,

when	WRB

tested	VBN

on	IN

12	CD

positive	JJ

sera	NNS

,	,

did	VBD

not	RB

show	NN

any	DT

false	JJ

negative	JJ

result	NN

Also	RB

,	,

no	DT

false	JJ

positive	JJ

result	NN

was	VBD

obtained	VBN

with	IN

serum	NN

samples	NNS

of	IN

patients	NNS

infected	JJ

with	IN

leprosy	NNP

,	,

tuberculosis	NN

,	,

typhoid	NN

and	CC

malaria	NN

,	,

showing	VBG

the	DT

specificity	NN

of	IN

the	DT

sensor	NN

and	CC

efficacy	NN

of	IN

the	DT

technique	NN

We	PRP

present	JJ

an	DT

optical	JJ

biosensor	NN

design	NN

that	IN

expands	NNS

the	DT

utility	NN

of	IN

enzyme	NN

biosensors	NNS

These	DT

biosensors	NNS

are	VBP

fabricated	VBN

by	IN

site-selective	JJ

photodeposition	NN

of	IN

analyte-sensitive	JJ

polymer	NN

matrices	NNS

on	IN

optical	JJ

imaging	NN

fibres	NNS

These	DT

dual-analyte	NN

arrays	NNS

allow	VB

for	IN

the	DT

simultaneous	JJ

,	,

independent	JJ

measurement	NN

of	IN

the	DT

analyte	NN

of	IN

interest	NN

and	CC

the	DT

transducing	VBG

analyte	NN

The	DT

first	RB

integrated	VBN

optical-biosensors	NNS

using	VBG

this	DT

design	NN

have	VB

been	VBN

prepared	JJ

that	IN

allow	VB

both	DT

the	DT

dependent	JJ

and	CC

independent	JJ

analytes	NNS

to	TO

be	VB

measured	VBN

simultaneously	RB

,	,

for	IN

example	NN

penicillin	NN

and	CC

pH	NN

(	NN

Healey	NNP

&	CC

#	#

38	CD

;	:

Walt	NNP

,	,

1995	CD

)	NN

or	CC

glucose	NN

and	CC

O2	CD

(	NN

Li	NNP

&	CC

#	#

38	CD

;	:

Walt	NNP

,	,

1995	CD

)	NN

Independent	NNP

measurement	NN

of	IN

the	DT

transducing	VBG

analyte	NN

allows	VBZ

penicillin	NN

or	CC

glucose	NN

to	TO

be	VB

quantitated	VBN

in	IN

the	DT

presence	NN

of	IN

a	DT

concurrent	JJ

pH	NN

or	CC

O2	CD

change	NN

,	,

respectively	RB

Penicillin	NN

can	MD

be	VB

measured	VBN

in	IN

the	DT

range	NN

0.25-10.0	CD

mM	NN

in	IN

the	DT

pH	NN

range	NN

6.2-7.5	CD

Glucose	NN

can	MD

be	VB

measured	VBN

in	IN

the	DT

range	NN

0.6-20.0	CD

mM	NN

in	IN

the	DT

O2	CD

range	NN

20-100	CD

%	NN

The	DT

utility	NN

of	IN

the	DT

sensor	NN

design	NN

was	VBD

demonstrated	VBN

by	IN

using	VBG

the	DT

penicillin-dual-analyte	NN

biosensor	NN

to	TO

quantitate	VB

penicillin	NN

produced	VBN

during	IN

a	DT

Penicillium	NNP

chrysogenum	NN

fermentation	NN

The	DT

characterization	NN

of	IN

low	JJ

molecular	JJ

weight	NN

ligand	NN

interaction	NN

with	IN

receptor	NN

molecules	NNS

is	VBZ

of	IN

importance	NN

for	IN

the	DT

investigation	NN

of	IN

biological	JJ

processes	NNS

and	CC

for	IN

drug	NN

research	NN

We	PRP

report	NN

on	IN

the	DT

investigation	NN

of	IN

the	DT

binding	NN

of	IN

low	JJ

molecular	JJ

weight	NN

ligands	NNS

to	TO

immobilized	VBN

receptors	NNS

by	IN

label-free	JJ

detection	NN

Reflectometric	JJ

interference	NN

spectroscopy	NN

,	,

an	DT

optical	JJ

transducer	NN

which	WDT

allows	VBZ

the	DT

monitoring	VBG

of	IN

a	DT

few	JJ

picograms	NNS

per	IN

square	NN

millimetre	JJ

changes	NNS

in	IN

surface	NN

coverage	NN

,	,

was	VBD

used	VBN

to	TO

study	NN

two	CD

model	NN

systems	NNS

In	IN

both	DT

cases	NNS

detection	NN

of	IN

the	DT

binding	NN

event	NN

was	VBD

successful	JJ

High	JJ

affinity	NN

binding	NN

of	IN

biotin	NN

to	TO

immobilized	VBN

streptavidin	NN

was	VBD

clearly	RB

detectable	JJ

at	IN

receptor	NN

surface	NN

concentrations	NNS

as	IN

low	JJ

as	IN

1-2	CD

x	NN

10	CD

(	NN

10	CD

)	NN

binding	NN

sites/mm2	NN

Linear	JJ

correlation	NN

between	IN

the	DT

receptor	NN

surface	NN

concentration	NN

and	CC

the	DT

response	NN

to	TO

biotin	NN

binding	NN

was	VBD

observed	VBN

Using	VBG

immobilized	VBN

DNA	NN

,	,

we	PRP

investigated	VBN

the	DT

binding	NN

of	IN

common	JJ

intercalators	NNS

with	IN

respect	NN

to	TO

kinetics	NNS

and	CC

thermodynamics	NNS

by	IN

evaluation	NN

of	IN

the	DT

association	NN

and	CC

the	DT

dissociation	NN

part	NN

of	IN

the	DT

binding	NN

curve	NN

Bi-exponential	JJ

increase	NN

and	CC

decrease	NN

of	IN

intercalator	NN

loading	VBG

was	VBD

observed	VBN

,	,

indicating	VBG

complex	NN

interaction	NN

kinetics	NNS

The	DT

four	CD

structurally	RB

different	JJ

intercalators	NNS

showed	VBD

significant	JJ

distinction	NN

in	IN

binding	NN

kinetics	NNS

and	CC

equilibrium	NN

signals	NNS

Improvement	NN

of	IN

experimental	JJ

parameters	NNS

is	VBZ

required	VBN

to	TO

obtain	VB

more	RBR

reliable	JJ

kinetic	JJ

data	NNS

An	DT

amperometric	JJ

lactate	NN

oxidase	NN

catheter	NN

has	VBZ

been	VBN

developed	VBN

for	IN

in	IN

vivo	FW

application	NN

to	TO

real-time	JJ

lactate	NN

monitoring	VBG

The	DT

electrochemical	JJ

behaviour	NN

of	IN

the	DT

1	CD

x	NN

3	CD

mm	NN

Pt-Ag/AgCl	NN

thin	JJ

film	NN

electrode	NN

is	VBZ

not	RB

significantly	RB

influenced	VBN

by	IN

lactate	NN

oxidase-polyurethane	NN

covering	VBG

Gamma-irradiation	NN

(	NN

25	CD

kGy	NN

)	NN

is	VBZ

suitable	JJ

for	IN

the	DT

sterilization	NN

procedure	NN

The	DT

final	JJ

lactate	NN

catheter	NN

is	VBZ

characterized	VBN

by	IN

a	DT

linear	JJ

concentration	NN

range	NN

between	IN

0.5	CD

and	CC

20	CD

mmol/l	NN

lactate	NN

with	IN

a	DT

sensitivity	NN

around	IN

2	CD

nA	NN

mmol-1	NN

l-1	NN

lactate	NN

The	DT

accuracy	NN

is	VBZ

demonstrated	VBN

by	IN

the	DT

measurement	NN

of	IN

control	NN

sera	NNS

Both	DT

physiological	JJ

and	CC

pathological	JJ

materials	NNS

correlate	NN

well	RB

with	IN

the	DT

declared	VBN

values	NNS

The	DT

dry	JJ

stored	VBN

lactate	NN

catheter	NN

needs	NNS

about	IN

10	CD

min	NN

for	IN

hydration	NN

and	CC

is	VBZ

characterized	VBN

by	IN

response	NN

times	NNS

t98	NN

%	NN

of	IN

less	JJR

than	IN

2	CD

min	NN

Ex	FW

vivo	FW

whole	JJ

blood	NN

measurements	NNS

using	VBG

the	DT

lactate	NN

catheter	NN

(	NN

y	NN

)	NN

give	VB

a	DT

correlation	NN

with	IN

the	DT

BIOSEN	NNP

Med	VBN

L	NN

(	NN

x	NN

)	NN

of	IN

y	NN

=	JJ

(	NN

1.010x	NN

+	CC

0.513	CD

)	NN

mmol/l	NN

(	NN

r	NN

=	JJ

0.9748	CD

)	NN

Lactate	NN

values	NNS

obtained	VBN

by	IN

continuous	JJ

catheter	NN

operation	NN

ex	FW

vivo	FW

correlate	NN

well	RB

with	IN

those	DT

obtained	VBN

by	IN

BIOSEN	NNP

Med	VBN

L.	NNP

First	NNP

subcutaneous	JJ

implantation	NN

(	NN

dog	NN

)	NN

underlines	NNS

the	DT

characteristics	NNS

obtained	VBN

ex	FW

vivo	FW

:	:

after	IN

30	CD

min	NN

hydration	NN

the	DT

lactate	NN

catheter	NN

follows	VBZ

the	DT

lactate	NN

concentration	NN

measured	VBN

ex	FW

vivo	FW

with	IN

samples	NNS

from	IN

the	DT

leg	NN

vein	NN

by	IN

BIOSEN	NNP

Med	VBN

L.	NNP

The	DT

diffusion-limited	JJ

binding	NN

kinetics	NNS

of	IN

antigen	NN

(	NN

or	CC

antibody	NN

)	NN

in	IN

solution	NN

to	TO

antibody	NN

(	NN

or	CC

antigen	NN

)	NN

immobilized	VBN

on	IN

a	DT

biosensor	NN

and	CC

other	JJ

surfaces	NNS

is	VBZ

analyzed	VBN

within	IN

a	DT

fractal	JJ

framework	NN

Often	RB

,	,

the	DT

binding	NN

kinetics	NNS

may	MD

be	VB

described	VBN

by	IN

a	DT

single-fractal	JJ

analysis	NN

In	IN

some	DT

cases	NNS

,	,

the	DT

binding	NN

curve	NN

exhibits	NNS

complexities	NNS

Then	RB

,	,

for	IN

these	DT

cases	NNS

,	,

the	DT

dual-fractal	JJ

analysis	NN

provides	VBZ

an	DT

improved	VBN

fit	NN

when	WRB

compared	VBN

with	IN

a	DT

single-fractal	JJ

analysis	NN

This	DT

indicates	VBZ

a	DT

change	NN

in	IN

the	DT

reaction	NN

mechanism	NN

on	IN

the	DT

surface	NN

It	PRP

is	VBZ

of	IN

interest	NN

to	TO

note	NN

that	IN

the	DT

state	NN

of	IN

disorder	NN

(	NN

or	CC

the	DT

fractal	JJ

dimension	NN

)	NN

and	CC

the	DT

binding	NN

rate	NN

coefficient	NN

both	DT

increase	NN

as	IN

the	DT

reaction	NN

progresses	VBZ

on	IN

the	DT

biosensor	NN

surface	NN

For	IN

example	NN

,	,

for	IN

the	DT

binding	NN

of	IN

10	CD

nM	NN

insulin	NN

growth	NN

factor-1	NN

in	IN

solution	NN

to	TO

insulin	NN

growth	NN

factor	NN

binding	NN

protein-1	NN

immobilized	VBN

on	IN

a	DT

biosensor	NN

surface	NN

,	,

a	DT

64	CD

%	NN

increase	NN

in	IN

the	DT

fractal	JJ

dimension	NN

from	IN

1.73	CD

(	NN

Df1	NN

)	NN

to	TO

2.85	CD

(	NN

Df2	NN

)	NN

leads	NNS

to	TO

an	DT

increase	NN

in	IN

the	DT

binding	NN

rate	NN

coefficient	NN

by	IN

a	DT

factor	NN

of	IN

31.8	CD

from	IN

3.92	CD

(	NN

k1	NN

)	NN

to	TO

125	CD

(	NN

k2	NN

)	NN

Furthermore	RB

,	,

as	IN

the	DT

IGF-1	NN

concentration	NN

in	IN

solution	NN

increases	NNS

from	IN

10	CD

to	TO

80	CD

nM	NN

in	IN

solution	NN

,	,

k2	NN

and	CC

Df2	NN

exhibit	NN

a	DT

linear	JJ

increase	NN

k1	NN

and	CC

Df1	NN

exhibit	NN

a	DT

linear	JJ

increase	NN

with	IN

the	DT

reciprocal	JJ

of	IN

the	DT

IGF-1	NN

concentration	NN

in	IN

solution	NN

The	DT

different	JJ

examples	NNS

analyzed	VBN

and	CC

presented	VBN

together	RB

provide	VB

a	DT

means	NNS

by	IN

which	WDT

the	DT

antigen-antibody	JJ

reactions	NNS

may	MD

be	VB

better	RB

controlled	VBN

by	IN

noting	VBG

the	DT

magnitude	NN

of	IN

the	DT

changes	NNS

in	IN

the	DT

fractal	JJ

dimension	NN

and	CC

in	IN

the	DT

binding	NN

rate	NN

coefficient	NN

as	IN

the	DT

reaction	NN

progresses	VBZ

on	IN

the	DT

biosensor	NN

surface	NN

Also	RB

,	,

the	DT

magnitude	NN

of	IN

the	DT

changes	NNS

in	IN

the	DT

binding	NN

rate	NN

coefficients	NNS

(	NN

k1	NN

and	CC

k2	NN

)	NN

and	CC

in	IN

the	DT

fractal	JJ

dimensions	NNS

(	NN

Df1	NN

and	CC

Df2	NN

)	NN

as	IN

different	JJ

parameters	NNS

are	VBP

changed	VBN

for	IN

the	DT

different	JJ

biosensor	NN

applications	NNS

are	VBP

of	IN

particular	JJ

value	NN

,	,

since	IN

they	PRP

provide	VB

us	PRP

with	IN

a	DT

measure	NN

or	CC

extent	NN

of	IN

changes	NNS

in	IN

the	DT

binding	NN

rate	NN

coefficient	NN

on	IN

changing	VBG

different	JJ

experimental	JJ

parameter	NN

values	NNS

It	PRP

is	VBZ

of	IN

interest	NN

to	TO

note	NN

the	DT

effect	NN

of	IN

different	JJ

parameters	NNS

on	IN

the	DT

extent	NN

or	CC

heterogeneity	NN

that	IN

exists	VBZ

on	IN

the	DT

surface	NN

and	CC

how	WRB

this	DT

influences	NNS

the	DT

binding	NN

rate	NN

coefficients	NNS

This	DT

may	MD

be	VB

one	CD

method	NN

to	TO

help	NN

manipulate	VB

or	CC

control	NN

the	DT

binding	NN

rate	NN

coefficients	NNS

on	IN

the	DT

reaction	NN

surface	NN

To	TO

determine	VB

if	IN

microscopic	JJ

urinalysis	NN

is	VBZ

needed	VBN

in	IN

all	DT

pediatric	JJ

emergency	NN

room	NN

patients	NNS

screened	VBN

for	IN

urinary	JJ

tract	NN

infections	NNS

(	NN

UTI	NN

)	NN

,	,

we	PRP

compared	VBN

the	DT

dipstick	NN

urinalysis	NN

and	CC

complete	JJ

urinalysis	NN

(	NN

dipstick	NN

and	CC

microscopy	NN

)	NN

with	IN

urine	NN

cultures	NNS

in	IN

236	CD

children	NNS

,	,

aged	JJ

3	CD

weeks	NNS

to	TO

21	CD

years	NNS

The	DT

ability	NN

to	TO

detect	VB

UTI	NN

by	IN

dipstick	NN

only	RB

and	CC

by	IN

complete	JJ

urinalysis	NN

was	VBD

the	DT

same	JJ

,	,

however	RB

microscopic	JJ

evaluation	NN

added	VBN

many	JJ

false-positive	JJ

results	NNS

without	IN

detecting	VBG

additional	JJ

UTIs	NNS

Because	IN

the	DT

ability	NN

to	TO

detect	VB

UTI	NN

(	NN

sensitivity	NN

)	NN

is	VBZ

maintained	VBN

,	,

we	PRP

now	RB

offer	NN

a	DT

dipstick	NN

only	RB

urinalysis	NN

to	TO

our	PRP$

emergency	NN

room	NN

for	IN

children	NNS

2	CD

years	NNS

of	IN

age	NN

or	CC

older	JJR

,	,

with	IN

a	DT

microscopic	JJ

analysis	NN

performed	VBN

automatically	RB

if	IN

dipstick	NN

results	NNS

are	VBP

positive	JJ

If	IN

no	DT

microscopic	JJ

urinalysis	NN

is	VBZ

required	VBN

,	,

testing	NN

turn-around	NN

time	NN

is	VBZ

reduced	VBN

by	IN

12.3	CD

min/test	JJS

and	CC

the	DT

hospital	NN

charge	NN

is	VBZ

reduced	VBN

from	IN

U.S	NNP

$	$

32	CD

to	TO

U.S	NNP

$	$

12	CD

Using	VBG

video-intensified	JJ

fluorescence	NN

microscopy	NN

and	CC

a	DT

pseudocolor	NN

display	NN

of	IN

fluorescence	NN

intensity	NN

,	,

we	PRP

analyzed	VBN

the	DT

distribution	NN

of	IN

microinjected	VBN

molecules	NNS

within	IN

the	DT

nurse-cell/oocyte	NN

syncytium	NN

of	IN

Drosophila	FW

ovarian	JJ

follicles	NNS

We	PRP

varied	VBD

the	DT

composition	NN

and	CC

the	DT

osmolarity	NN

of	IN

the	DT

culture	NN

solution	NN

as	IN

well	RB

as	IN

the	DT

electrical	JJ

charge	NN

and	CC

the	DT

molecular	JJ

mass	NN

of	IN

the	DT

microinjected	VBN

fluorescent	JJ

probe	NN

As	IN

culture	NN

solutions	NNS

,	,

we	PRP

used	VBN

four	CD

simple	JJ

salines	NNS

(	NN

IMADS	NN

)	NN

and	CC

a	DT

complex	NN

tissue-culture	NN

medium	NN

(	NN

R-14	NN

)	NN

that	IN

matched	VBN

the	DT

osmolarity	NN

of	IN

adult	JJ

hemolymph	NN

Small	JJ

amounts	NNS

of	IN

two	CD

anionic	JJ

dyes	NNS

(	NN

Lucifer	NNP

Yellow	JJ

CH	NN

and	CC

Lucifer	NNP

Yellow	JJ

dextran	NN

)	NN

as	IN

well	RB

as	IN

of	IN

two	CD

cationic	NN

dyes	NNS

(	NN

rhodamine	NN

6G	NN

and	CC

tetramethylrhodamine	NN

dextran-lysine	NN

)	NN

were	VBD

iontophoretically	RB

microinjected	VBN

either	DT

into	IN

a	DT

nurse	NN

cell	NN

or	CC

into	IN

the	DT

oocyte	NN

of	IN

stage-10	NN

follicles	NNS

In	IN

the	DT

tissue-culture	NN

medium	NN

,	,

within	IN

a	DT

few	JJ

seconds	NNS

following	VBG

microinjection	NN

,	,

all	DT

tested	VBN

dyes	NNS

passed	VBN

through	IN

the	DT

intercellular	JJ

bridges	NNS

in	IN

both	DT

the	DT

anterior	JJ

direction	NN

(	NN

to	TO

the	DT

nurse	NN

cells	NNS

)	NN

and	CC

the	DT

posterior	NN

direction	NN

(	NN

to	TO

the	DT

oocyte	NN

)	NN

,	,

independent	JJ

of	IN

their	PRP$

electrical	JJ

charge	NN

or	CC

molecular	JJ

mass	NN

In	IN

all	DT

simple	JJ

salines	NNS

,	,

irrespective	RB

of	IN

their	PRP$

osmolarity	NN

,	,

Lucifer	NNP

Yellow	JJ

CH	NN

was	VBD

found	VBN

to	TO

preferentially	RB

migrate	VB

in	IN

the	DT

posterior	NN

direction	NN

and	CC

to	TO

accumulate	VB

in	IN

the	DT

oocyte	NN

due	JJ

to	TO

progressive	JJ

binding	NN

to	TO

yolk	NN

spheres	NNS

Thus	RB

,	,

with	IN

this	DT

sensitive	JJ

method	NN

,	,

no	DT

correlation	NN

was	VBD

detectable	JJ

between	IN

the	DT

external	JJ

osmolarity	NN

,	,

the	DT

electrical	JJ

charge	NN

and	CC

the	DT

preferential	JJ

direction	NN

of	IN

migration	NN

of	IN

a	DT

microinjected	VBN

probe	NN

Our	PRP$

results	NNS

indicate	VBP

that	IN

the	DT

electrical	JJ

gradient	NN

described	VBN

by	IN

other	JJ

authors	NNS

does	VBZ

not	RB

exert	VB

significant	JJ

influence	NN

on	IN

the	DT

migration	NN

of	IN

charged	VBN

molecules	NNS

through	IN

intercellular	JJ

bridges	NNS

in	IN

situ	FW

The	DT

AF-4	NN

gene	NN

on	IN

human	JJ

chromosome	NN

4q21	NN

is	VBZ

involved	VBN

in	IN

reciprocal	JJ

translocations	NNS

to	TO

the	DT

ALL-1	NN

gene	NN

on	IN

chromosome	NN

11q23	NN

,	,

which	WDT

are	VBP

associated	VBN

with	IN

acute	JJ

lymphoblastic	JJ

leukaemias	NNS

A	DT

set	NN

of	IN

recombinant	JJ

phage	NN

carrying	VBG

genomic	JJ

fragments	NNS

for	IN

the	DT

coding	VBG

region	NN

and	CC

flanking	VBG

sequences	NNS

of	IN

the	DT

AF-4	NN

gene	NN

were	VBD

isolated	VBN

Phage	NN

inserts	NNS

were	VBD

assembled	VBN

into	IN

four	CD

contigs	NNS

with	IN

21	CD

exons	NNS

,	,

and	CC

an	DT

intron	NN

phase	NN

map	NN

was	VBD

produced	VBN

enabling	VBG

the	DT

interpretation	NN

of	IN

translocation-generated	JJ

fusion	NN

proteins	NNS

The	DT

gene	NN

contains	VBZ

two	CD

alternative	NN

first	RB

exons	NNS

,	,

1a	NN

and	CC

1b	NN

,	,

both	DT

including	VBG

a	DT

translation	NN

initiation	NN

codon	NN

The	DT

translocation	NN

breakpoint	NN

cluster	NN

region	NN

is	VBZ

flanked	VBN

by	IN

exons	NNS

3	CD

and	CC

6	CD

and	CC

two	CD

different	JJ

polyadenylation	NN

signals	NNS

were	VBD

identified	VBN

Polyclonal	JJ

antisera	NNS

directed	VBN

against	IN

three	CD

different	JJ

portions	NNS

of	IN

the	DT

AF-4	NN

protein	NN

were	VBD

produced	VBN

and	CC

used	VBN

to	TO

detect	VB

a	DT

116	CD

kD	NN

protein	NN

in	IN

cellular	JJ

extracts	NNS

of	IN

human	JJ

B-lymphoblastoid	JJ

and	CC

proB	NN

cell	NN

lines	NNS

In	IN

mitogen-stimulated	JJ

human	JJ

peripheral	JJ

blood	NN

mononuclear	JJ

cells	NNS

the	DT

AF-4	NN

antigen	NN

was	VBD

predominantly	RB

located	JJ

in	IN

the	DT

nucleus	NN

The	DT

AF-4	NN

gene	NN

is	VBZ

a	DT

member	NN

of	IN

the	DT

AF-4	NN

,	,

LAF-4	NN

and	CC

FMR-2	NN

gene	NN

family	NN

The	DT

members	NNS

of	IN

this	DT

family	NN

encode	VBP

serine-proline-rich	JJ

proteins	NNS

with	IN

properties	NNS

of	IN

nuclear	JJ

transcription	NN

factors	NNS

Comparison	NN

of	IN

AF-4	NN

protein	NN

coding	VBG

sequences	NNS

with	IN

the	DT

LAF-4	NN

and	CC

FMR-2	NN

sequences	NNS

revealed	VBD

five	CD

highly	RB

conserved	VBN

domains	NNS

of	IN

potential	NN

functional	JJ

relevance	NN

Immunoglobulin	NN

superfamily	NN

molecules	NNS

in	IN

the	DT

brain	NN

are	VBP

involved	VBN

in	IN

distinct	JJ

aspects	NNS

of	IN

nervous	JJ

system	NN

histogenesis	NN

,	,

for	IN

example	NN

neuronal	JJ

migration	NN

and	CC

axonal	IN

growth	NN

To	TO

identify	VB

novel	JJ

members	NNS

of	IN

this	DT

superfamily	NN

in	IN

the	DT

chick	NN

nervous	JJ

system	NN

,	,

we	PRP

developed	VBN

a	DT

polymerase	NN

chain	NN

reaction-based	JJ

approach	NN

making	VBG

use	NN

of	IN

sequence	NN

motifs	NNS

of	IN

immunoglobulin-like	JJ

domains	NNS

In	IN

the	DT

present	JJ

study	NN

,	,

we	PRP

report	NN

the	DT

molecular	JJ

cloning	VBG

of	IN

three	CD

isoforms	NNS

,	,

the	DT

biochemical	JJ

analysis	NN

and	CC

the	DT

immunohistochemical	JJ

characterization	NN

of	IN

one	CD

of	IN

the	DT

proteins	NNS

identified	VBN

in	IN

this	DT

screen	NN

This	DT

molecule	NN

has	VBZ

91	CD

%	NN

sequence	NN

identity	NN

with	IN

the	DT

limbic	JJ

system-associated	JJ

membrane	NN

protein	NN

(	NN

LAMP	NN

)	NN

characterized	VBN

in	IN

the	DT

rat	NN

and	CC

is	VBZ

therefore	RB

referred	VBN

to	TO

as	IN

the	DT

chicken	NN

homologue	NN

of	IN

the	DT

latter	JJ

(	NN

chLAMP	NN

)	NN

The	DT

molecule	NN

is	VBZ

a	DT

glycosylphosphatidyl-inositol-anchored	JJ

60	CD

kDa	NN

protein	NN

with	IN

three	CD

immunoglobulin-like	JJ

domains	NNS

and	CC

contains	VBZ

40	CD

%	NN

N-linked	JJ

carbohydrate	NN

We	PRP

identify	VB

three	CD

different	JJ

mRNA	NN

forms	NNS

of	IN

chLAMP	NN

and	CC

show	NN

that	IN

two	CD

forms	NNS

with	IN

distinct	JJ

5'-termini	JJ

are	VBP

differentially	RB

transcribed	VBN

in	IN

neural	JJ

development	NN

In	IN

addition	NN

,	,

we	PRP

demonstrate	VB

using	VBG

a	DT

fusion	NN

protein	NN

expressed	VBN

in	IN

eukaryotic	JJ

cells	NNS

that	IN

chLAMP	NN

has	VBZ

homophilic	JJ

binding	NN

activity	NN

The	DT

protein	NN

was	VBD

found	VBN

on	IN

a	DT

subset	NN

of	IN

axons	NNS

in	IN

the	DT

central	JJ

and	CC

peripheral	JJ

nervous	JJ

system	NN

and	CC

is	VBZ

likely	RB

to	TO

be	VB

involved	VBN

in	IN

specific	JJ

cell-cell	JJ

interactions	NNS

in	IN

neurohistogenesis	NN

Two	CD

novel	JJ

cDNAs	NNS

,	,

DNAS1L2	NN

and	CC

DNAS1L3	NN

,	,

are	VBP

predicted	VBN

to	TO

encode	VBP

proteins	NNS

of	IN

299	CD

and	CC

305	CD

amino	NN

acids	NNS

with	IN

56	CD

and	CC

46	CD

%	NN

residue	NN

identity	NN

(	NN

71	CD

and	CC

63	CD

%	NN

similarity	NN

)	NN

,	,

respectively	RB

,	,

to	TO

deoxyribonuclease	NN

I	PRP

(	NN

DNase	NN

I	PRP

)	NN

DNAS1L2	NN

is	VBZ

located	JJ

on	IN

a	DT

16p13.3	NN

cosmid	NN

,	,

while	IN

DNAS1L3	NN

maps	NNS

to	TO

3p14.3-p21.1	NN

by	IN

fluorescence	NN

in	IN

situ	FW

hybridization	NN

and	CC

by	IN

PCR	NN

analysis	NN

of	IN

a	DT

radiation	NN

hybrid	NN

panel	NN

Northern	NN

analysis	NN

revealed	VBD

DNAS1L3	NN

expression	NN

nearly	RB

exclusively	RB

in	IN

liver	NN

,	,

while	IN

DNAS1L2	NN

expression	NN

was	VBD

detected	VBN

in	IN

brain	NN

by	IN

RT-PCR	NN

The	DT

previously	RB

defined	VBN

DNL1L	NN

or	CC

DNAS1L1	NN

is	VBZ

expressed	VBN

highest	JJS

in	IN

heart	NN

and	CC

skeletal	JJ

muscle	NN

,	,

while	IN

DNase	NN

I	PRP

is	VBZ

expressed	VBN

in	IN

the	DT

pancreas	NN

,	,

parotid	NN

gland	NN

,	,

and	CC

kidney	NN

Thus	RB

,	,

to	TO

date	NN

,	,

four	CD

DNase	NN

I-like	JJ

genes	NNS

that	IN

show	NN

different	JJ

tissue	NN

expression	NN

patterns	NNS

are	VBP

known	VBN

A	DT

comparison	NN

of	IN

DNAS1L1	NN

,	,

DNAS1L2	NN

,	,

and	CC

DNAS1L3	NN

with	IN

the	DT

well-characterized	JJ

DNase	NN

I	PRP

suggests	VBZ

that	IN

the	DT

DNAS1L	NN

proteins	NNS

are	VBP

unlikely	JJ

to	TO

be	VB

glycosylated	VBN

or	CC

bind	NN

actin	NN

;	:

however	RB

,	,

catalytic	JJ

and	CC

calcium-	NN

and	CC

DNA-binding	JJ

residues	NNS

are	VBP

conserved	VBN

,	,

and	CC

potentially	RB

cleavable	JJ

signal	NN

peptides	NNS

are	VBP

present	JJ

among	IN

all	DT

these	DT

proteins	NNS

This	DT

analysis	NN

also	RB

identifies	VBZ

regions	NNS

of	IN

high	JJ

conservation	NN

among	IN

these	DT

proteins	NNS

with	IN

no	DT

currently	RB

assigned	VBN

function	NN

Two	CD

different	JJ

responses	NNS

to	TO

the	DT

therapy	NN

were	VBD

observed	VBN

in	IN

a	DT

group	NN

of	IN

patients	NNS

receiving	VBG

the	DT

protease	NN

inhibitor	NN

indinavir	NN

In	IN

one	CD

,	,

suppression	NN

of	IN

virus	NN

replication	NN

occurred	VBD

and	CC

has	VBZ

persisted	VBD

for	IN

90	CD

weeks	NNS

(	NN

bDNA	NN

,	,

&	CC

#	#

60	CD

;	:

500	CD

human	JJ

immunodeficiency	NN

virus	NN

type	NN

1	CD

(	NN

HIV-1	NN

)	NN

RNA	NN

copies/ml	NN

)	NN

In	IN

the	DT

second	JJ

group	NN

,	,

a	DT

rebound	NN

in	IN

virus	NN

levels	NNS

in	IN

plasma	NN

followed	VBN

the	DT

initial	JJ

sharp	JJ

decline	NN

observed	VBN

at	IN

the	DT

start	NN

of	IN

therapy	NN

This	DT

was	VBD

associated	VBN

with	IN

the	DT

emergence	NN

of	IN

drug-resistant	JJ

variants	NNS

Sequence	NN

analysis	NN

of	IN

the	DT

protease	NN

gene	NN

during	IN

the	DT

course	NN

of	IN

therapy	NN

revealed	VBD

that	IN

in	IN

this	DT

second	JJ

group	NN

there	RB

was	VBD

a	DT

sequential	JJ

acquisition	NN

of	IN

protease	NN

mutations	NNS

at	IN

amino	NN

acids	NNS

46	CD

,	,

82	CD

,	,

54	CD

,	,

71	CD

,	,

89	CD

,	,

and	CC

90	CD

In	IN

the	DT

six	CD

patients	NNS

in	IN

this	DT

group	NN

,	,

there	RB

was	VBD

also	RB

an	DT

identical	JJ

mutation	NN

in	IN

the	DT

gag	NN

p7/p1	NN

gag	NN

protease	NN

cleavage	NN

site	NN

In	IN

three	CD

of	IN

the	DT

patients	NNS

,	,

this	DT

change	NN

was	VBD

seen	VBN

as	IN

early	RB

as	IN

6	CD

to	TO

10	CD

weeks	NNS

after	IN

the	DT

start	NN

of	IN

therapy	NN

In	IN

one	CD

patient	NN

,	,

a	DT

second	JJ

mutation	NN

occurred	VBD

at	IN

the	DT

gag	NN

p1/p6	NN

cleavage	NN

site	NN

,	,

but	CC

it	PRP

appeared	VBD

18	CD

weeks	NNS

after	IN

the	DT

time	NN

of	IN

appearance	NN

of	IN

the	DT

p7/p1	NN

mutation	NN

Recombinant	JJ

HIV-1	NN

variants	NNS

containing	VBG

two	CD

or	CC

three	CD

mutations	NNS

in	IN

the	DT

protease	NN

gene	NN

were	VBD

constructed	VBN

either	DT

with	IN

mutations	NNS

at	IN

the	DT

p7/p1	NN

cleavage	NN

site	NN

or	CC

with	IN

wild-type	JJ

(	NN

WT	JJ

)	NN

gag	NN

sequences	NNS

When	WRB

recombinant	JJ

HIV-1-containing	JJ

protease	NN

mutations	NNS

at	IN

46	CD

and	CC

82	CD

was	VBD

grown	VBN

in	IN

MT2	NN

cells	NNS

,	,

there	RB

was	VBD

a	DT

68	CD

%	NN

reduction	NN

in	IN

its	PRP$

rate	NN

of	IN

replication	NN

compared	VBN

to	TO

the	DT

WT	JJ

virus	NN

Introduction	NN

of	IN

an	DT

additional	JJ

mutation	NN

at	IN

the	DT

gag	NN

p7/p1	NN

protease	NN

cleavage	NN

site	NN

compensated	VBN

for	IN

the	DT

partially	RB

defective	JJ

protease	NN

gene	NN

Similarly	RB

,	,

rates	NNS

of	IN

replication	NN

of	IN

viruses	NNS

with	IN

mutations	NNS

M46L/I	NN

,	,

I54V	NN

,	,

and	CC

V82A	NN

in	IN

protease	NN

were	VBD

enhanced	VBN

both	DT

in	IN

the	DT

presence	NN

and	CC

in	IN

the	DT

absence	NN

of	IN

Indinavir	NNP

when	WRB

combined	VBN

with	IN

mutations	NNS

in	IN

the	DT

gag	NN

p7/p1	NN

and	CC

the	DT

gag	NN

p1/p6	NN

cleavage	NN

sites	NNS

Optimal	JJ

rates	NNS

of	IN

virus	NN

replication	NN

require	VB

protease	NN

cleavage	NN

of	IN

precursor	NN

polyproteins	NNS

A	DT

mutation	NN

in	IN

the	DT

cleavage	NN

site	NN

that	IN

enhanced	VBN

the	DT

availability	NN

of	IN

a	DT

protein	NN

that	IN

was	VBD

rate	NN

limiting	VBG

for	IN

virus	NN

maturation	NN

would	MD

confer	VB

on	IN

that	IN

virus	NN

a	DT

significant	JJ

growth	NN

advantage	NN

and	CC

may	MD

explain	VB

the	DT

uniform	NN

emergence	NN

of	IN

viruses	NNS

with	IN

alterations	NNS

at	IN

the	DT

p7/p1	NN

cleavage	NN

site	NN

This	DT

is	VBZ

the	DT

first	RB

report	NN

of	IN

the	DT

emergence	NN

of	IN

mutations	NNS

in	IN

the	DT

gag	NN

p7/p1	NN

protease	NN

cleavage	NN

sites	NNS

in	IN

patients	NNS

receiving	VBG

protease	NN

therapy	NN

and	CC

identifies	VBZ

this	DT

change	NN

as	IN

an	DT

important	JJ

determinant	NN

of	IN

HIV-1	NN

resistance	NN

to	TO

protease	NN

inhibitors	NNS

in	IN

patient	NN

populations	NNS

A	DT

novel	JJ

intracellular	JJ

calcium-binding	JJ

protein	NN

from	IN

Echinococcus	NN

granulosus	NN

is	VBZ

described	VBN

in	IN

this	DT

work	NN

A	DT

cDNA	NN

was	VBD

isolated	VBN

from	IN

a	DT

lambdagt11	NN

protoscolex	NN

expression	NN

library	NN

and	CC

the	DT

deduced	VBN

amino	NN

acid	NN

sequence	NN

has	VBZ

at	IN

least	JJS

fifteen	CD

sequentially	RB

repeated	VBN

twelve-residue	JJ

repeats	NNS

that	IN

resemble	VB

the	DT

calcium-binding	JJ

loop	NN

of	IN

EF-hands	NNS

;	:

however	RB

,	,

the	DT

dodecamer	NN

motif	NN

has	VBZ

no	DT

flanking	VBG

helices	NNS

The	DT

cDNA	NN

was	VBD

expressed	VBN

in	IN

Escherichia	FW

coli	NN

using	VBG

the	DT

pGEX	NN

vector	NN

,	,

and	CC

a	DT

recombinant	JJ

fusion	NN

protein	NN

(	NN

EgCaBP1-GST	NN

)	NN

was	VBD

obtained	VBN

The	DT

recombinant	JJ

fusion	NN

protein	NN

binds	VBZ

calcium	NN

when	WRB

assayed	VBN

with	IN

45Ca	NN

It	PRP

is	VBZ

possible	JJ

that	IN

the	DT

calcium-binding	JJ

motifs	NNS

present	JJ

a	DT

secondary	JJ

structure	NN

similar	JJ

to	TO

the	DT

parallel	NN

beta	NN

roll	NN

structure	NN

described	VBN

for	IN

an	DT

alkaline	NN

protease	NN

from	IN

Pseudomonas	FW

aeruginosa	FW

A	DT

native	JJ

protein	NN

of	IN

more	RBR

than	IN

300	CD

kDa	NN

was	VBD

recognized	VBN

by	IN

an	DT

anti-EgCaBP1	JJ

monoclonal	JJ

antibody	NN

by	IN

Western-blot	JJ

analysis	NN

Immunohistochemistry	NN

using	VBG

a	DT

pool	NN

of	IN

anti-EgCaBP1-GST	JJ

mouse	NN

sera	NNS

demonstrated	VBN

a	DT

strong	JJ

association	NN

of	IN

the	DT

protein	NN

with	IN

calcareous	JJ

corpuscles	NNS

The	DT

possible	JJ

role	NN

of	IN

this	DT

protein	NN

and	CC

that	IN

of	IN

the	DT

calcareous	JJ

corpuscles	NNS

in	IN

the	DT

protoscolex	NN

are	VBP

discussed	VBN

The	DT

enzyme	NN

activity	NN

of	IN

mitogen-activated	JJ

protein	NN

kinase	NN

(	NN

MAP	NN

kinase	NN

)	NN

increases	NNS

in	IN

response	NN

to	TO

agents	NNS

acting	VBG

on	IN

a	DT

variety	NN

of	IN

cell	NN

surface	NN

receptors	NNS

,	,

including	VBG

receptors	NNS

linked	VBN

to	TO

heterotrimeric	JJ

G	NN

proteins	NNS

In	IN

this	DT

report	NN

,	,

we	PRP

demonstrated	VBN

that	IN

Raf-1	NN

protein	NN

kinase	NN

activity	NN

in	IN

the	DT

mouse	NN

parotid	NN

glands	NNS

was	VBD

induced	VBN

by	IN

chronic	JJ

isoproterenol	NN

administration	NN

in	IN

whole	JJ

animals	NNS

To	TO

investigate	VB

the	DT

molecular	JJ

nature	NN

underlying	VBG

cellular	JJ

responses	NNS

to	TO

Raf-1	NN

activation	NN

,	,

we	PRP

have	VB

stably	RB

transfected	VBN

rat	NN

salivary	JJ

epithelial	JJ

Pa-4	NN

cells	NNS

with	IN

human	JJ

Raf-1-estrogen	NN

receptor	NN

fusion	NN

gene	NN

(	NN

DeltaRaf-1	NN

:	:

ER	NN

)	NN

and	CC

used	VBN

mRNA	NN

differential	JJ

display	NN

in	IN

search	NN

of	IN

messages	NNS

induced	VBN

by	IN

DeltaRaf-1	NN

:	:

ER	NN

activation	NN

Through	IN

this	DT

approach	NN

,	,

the	DT

gene	NN

encoding	VBG

non-histone	JJ

chromosomal	JJ

protein	NN

HMGI-C	NN

was	VBD

identified	VBN

as	IN

one	CD

of	IN

the	DT

target	NN

genes	NNS

activated	VBN

by	IN

oncogenic	JJ

Raf-1	NN

kinase	NN

Activation	NN

of	IN

Raf-1	NN

kinase	NN

resulted	VBD

in	IN

a	DT

delayed	VBN

and	CC

sustained	JJ

increase	NN

of	IN

HMGI-C	NN

expression	NN

in	IN

the	DT

Pa-4	NN

cells	NNS

The	DT

induction	NN

of	IN

HMGI-C	NN

mRNA	NN

level	NN

is	VBZ

sensitive	JJ

to	TO

both	DT

the	DT

protein	NN

synthesis	NN

inhibitor	NN

cycloheximide	NN

and	CC

transcription	NN

inhibitor	NN

actinomycin	NN

D	NN

The	DT

role	NN

of	IN

the	DT

extracellular	JJ

signal-related	JJ

kinase	NN

(	NN

ERK	NN

)	NN

signaling	NN

pathway	NN

in	IN

the	DT

HMGI-C	NN

induction	NN

was	VBD

highlighted	VBN

by	IN

the	DT

result	NN

that	IN

the	DT

MAP	NN

kinase	NN

kinase	NN

(	NN

MEK	NN

)	NN

inhibitor	NN

,	,

PD	NN

98059	CD

,	,

blocked	VBN

DeltaRaf-1	NN

:	:

ER-	JJ

and	CC

12-O-tetradecanoylphorbol-13-acetate-stimulated	JJ

HMGI-C	NN

induction	NN

Altogether	RB

,	,

these	DT

findings	NNS

support	NN

the	DT

notion	NN

that	IN

the	DT

Raf/MEK/ERK	NN

signaling	NN

module	NN

,	,

at	IN

least	JJS

in	IN

part	NN

,	,

regulates	VBZ

transcriptional	JJ

activation	NN

of	IN

the	DT

chromosomal	JJ

architectural	JJ

protein	NN

HMGI-C	NN

Pendred	NNP

syndrome	NN

is	VBZ

a	DT

recessively	RB

inherited	VBN

disorder	NN

with	IN

the	DT

hallmark	NN

features	NNS

of	IN

congenital	JJ

deafness	NN

and	CC

thyroid	NN

goitre	NN

By	IN

some	DT

estimates	NNS

,	,

the	DT

disorder	NN

may	MD

account	NN

for	IN

upwards	NNS

of	IN

10	CD

%	NN

of	IN

hereditary	JJ

deafness	NN

Previous	JJ

genetic	JJ

linkage	NN

studies	NNS

localized	JJ

the	DT

gene	NN

to	TO

a	DT

broad	JJ

interval	NN

on	IN

human	JJ

chromosome	NN

7q22-31.1	NN

Using	VBG

a	DT

positional	JJ

cloning	VBG

strategy	NN

,	,

we	PRP

have	VB

identified	VBN

the	DT

gene	NN

(	NN

PDS	NN

)	NN

mutated	VBN

in	IN

Pendred	NNP

syndrome	NN

and	CC

found	VBN

three	CD

apparently	RB

deleterious	JJ

mutations	NNS

,	,

each	DT

segregating	VBG

with	IN

the	DT

disease	NN

in	IN

the	DT

respective	JJ

families	NNS

in	IN

which	WDT

they	PRP

occur	VB

PDS	NN

produces	VBZ

a	DT

transcript	NN

of	IN

approximately	RB

5	CD

kb	NN

that	IN

was	VBD

found	VBN

to	TO

be	VB

expressed	VBN

at	IN

significant	JJ

levels	NNS

only	RB

in	IN

the	DT

thyroid	NN

The	DT

predicted	VBN

protein	NN

,	,

pendrin	NN

,	,

is	VBZ

closely	RB

related	JJ

to	TO

a	DT

number	NN

of	IN

known	VBN

sulphate	NN

transporters	NNS

These	DT

studies	NNS

provide	VB

compelling	JJ

evidence	NN

that	IN

defects	NNS

in	IN

pendrin	NN

cause	NN

Pendred	NNP

syndrome	NN

thereby	RB

launching	VBG

a	DT

new	JJ

area	NN

of	IN

investigation	NN

into	IN

thyroid	NN

physiology	NN

,	,

the	DT

pathogenesis	NN

of	IN

congenital	JJ

deafness	NN

and	CC

the	DT

role	NN

of	IN

altered	JJ

sulphate	NN

transport	NN

in	IN

human	JJ

disease	NN

We	PRP

report	NN

the	DT

cDNA	NN

cloning	VBG

,	,

partial	JJ

genomic	JJ

organization	NN

,	,

and	CC

expression	NN

pattern	NN

of	IN

Stra10	NN

,	,

a	DT

novel	JJ

retinoic	JJ

acid-inducible	JJ

gene	NN

in	IN

P19	NN

embryonal	JJ

carcinoma	NN

cells	NNS

Four	CD

murine	JJ

cDNA	NN

isoforms	NNS

have	VB

been	VBN

isolated	VBN

,	,

which	WDT

are	VBP

likely	RB

to	TO

result	NN

from	IN

alternative	NN

splicing	NN

The	DT

predicted	VBN

protein	NN

sequences	NNS

exhibit	NN

approximately	RB

85	CD

%	NN

identity	NN

with	IN

the	DT

Pbx-related	JJ

Meis1	NN

homeobox	NN

gene	NN

products	NNS

,	,

which	WDT

are	VBP

involved	VBN

in	IN

myeloid	JJ

leukemia	NN

in	IN

BXH-2	NN

mice	NNS

,	,

and	CC

one	CD

of	IN

the	DT

Stra10	NN

isoforms	NNS

corresponds	VBZ

to	TO

the	DT

recently	RB

published	VBN

Meis2	NN

sequence	NN

(	NN

Nakamura	NNP

et	FW

al	NNP

.	.

(	NN

1996	CD

)	NN

Oncogene	NN

13	CD

:	:

2235-2242	CD

)	NN

The	DT

Meis2	NN

homeodomain	NN

is	VBZ

identical	JJ

to	TO

that	IN

of	IN

Meis1	NN

,	,

and	CC

is	VBZ

most	RBS

closely	RB

related	JJ

to	TO

those	DT

of	IN

the	DT

Pbx/TGIF	NN

homeobox	NN

gene	NN

products	NNS

By	IN

in	IN

situ	FW

hybridization	NN

analysis	NN

,	,

we	PRP

show	NN

that	IN

the	DT

Meis2	NN

gene	NN

displays	NNS

spatially	RB

restricted	JJ

expression	NN

patterns	NNS

in	IN

the	DT

developing	VBG

nervous	JJ

system	NN

,	,

limbs	NNS

,	,

face	NN

,	,

and	CC

in	IN

various	JJ

viscera	NN

In	IN

adult	JJ

mice	NNS

,	,

Meis2	NN

is	VBZ

mainly	RB

expressed	VBN

in	IN

the	DT

brain	NN

and	CC

female	NN

genital	JJ

tract	NN

,	,

with	IN

a	DT

different	JJ

distribution	NN

of	IN

the	DT

alternative	NN

splice	NN

forms	NNS

in	IN

these	DT

organs	NNS

A	DT

methodical	JJ

strategy	NN

for	IN

the	DT

isolation	NN

of	IN

microsatellite	NN

markers	NNS

specific	JJ

for	IN

targeted	VBN

regions	NNS

of	IN

bovine	JJ

chromosomes	NNS

is	VBZ

presented	VBN

The	DT

procedure	NN

involves	VBZ

directed	VBN

microdissection	NN

of	IN

one	CD

defined	VBN

subchromosomal	JJ

area	NN

,	,

its	PRP$

DOP-PCR-amplification	NN

and	CC

cloning	VBG

With	IN

this	DT

approach	NN

,	,

a	DT

library	NN

specific	JJ

to	TO

the	DT

BTA	NN

6q21-31	NN

chromosomal	JJ

region	NN

was	VBD

constructed	VBN

Eleven	CD

unique	JJ

microsatellite-containing	JJ

sequences	NNS

were	VBD

isolated	VBN

,	,

converted	VBN

into	IN

sequence-tagged	JJ

microsatellite	NN

sites	NNS

,	,

and	CC

characterized	VBN

concerning	VBG

their	PRP$

species-specific	JJ

origin	NN

Seven	CD

primer	NN

pairs	NNS

generated	VBN

bovine-specific	JJ

PCR	NN

products	NNS

and	CC

provided	VBN

a	DT

set	NN

of	IN

microsatellite	NN

markers	NNS

that	IN

generally	RB

revealed	VBD

high	JJ

informativity	NN

in	IN

the	DT

HF	NN

breed	NN

Linkage	NN

analysis	NN

assigned	VBN

six	CD

of	IN

them	PRP

to	TO

their	PRP$

predefined	VBN

subchromosomal	JJ

origin	NN

on	IN

BTA	NN

6	CD

corresponding	VBG

to	TO

the	DT

specific	JJ

rehybridization	NN

signal	NN

of	IN

the	DT

DOP-PCR	NN

product	NN

generated	VBN

from	IN

the	DT

microdissected	VBN

chromosome	NN

area	NN

6q21-31	NN

The	DT

results	NNS

underline	VB

the	DT

usefulness	NN

of	IN

the	DT

BTA	NN

6q21-31	NN

library	NN

for	IN

targeted	VBN

isolation	NN

of	IN

unique	JJ

sequences	NNS

that	IN

are	VBP

specific	JJ

for	IN

the	DT

dissected	VBN

chromosomal	JJ

region	NN

as	IN

demonstrated	VBN

here	RB

by	IN

the	DT

isolation	NN

of	IN

microsatellite	NN

markers	NNS

Phylogeographic	JJ

structure	NN

was	VBD

determined	VBN

for	IN

the	DT

yellow	JJ

mongoose	NN

,	,

Cynictis	NNP

penicillata	NN

,	,

using	VBG

mtDNA	NN

RFLPs	NNS

and	CC

control	NN

region	NN

sequences	NNS

The	DT

RFLP	NN

analysis	NN

revealed	VBD

13	CD

haplotypes	NNS

which	WDT

showed	VBD

weak	JJ

geographical	JJ

patterning	NN

consistent	JJ

with	IN

a	DT

recent	JJ

range	NN

expansion	NN

from	IN

a	DT

refugial	JJ

population	NN

(	NN

s	NNS

)	NN

An	DT

analysis	NN

of	IN

molecular	JJ

variance	NN

(	NN

AMOVA	NNP

)	NN

revealed	VBD

no	DT

correspondence	NN

between	IN

mtDNA	NN

phylogeography	NN

and	CC

subspecies	NNS

delimitation	NN

,	,

nor	CC

between	IN

matrilines	NNS

and	CC

areas	NNS

characterized	VBN

by	IN

a	DT

high	JJ

incidence	NN

of	IN

the	DT

viverrid-type	JJ

rabies	NNP

,	,

of	IN

which	WDT

the	DT

yellow	JJ

mongoose	NN

is	VBZ

the	DT

principal	NN

vector	NN

The	DT

lack	NN

of	IN

structure	NN

was	VBD

also	RB

shown	VBN

by	IN

control	NN

region	NN

sequences	NNS

although	IN

four	CD

of	IN

the	DT

maternal	JJ

lineages	NNS

shared	VBN

a	DT

near-perfect	JJ

81	CD

bp	NN

repeat	NN

We	PRP

speculate	VB

that	IN

regional	JJ

hot	JJ

spots	NNS

of	IN

the	DT

viverrid	NN

rabies	NNP

biotype	NN

reflect	VB

population	NN

density	NN

differences	NNS

in	IN

the	DT

yellow	JJ

mongoose	NN

that	IN

are	VBP

not	RB

underscored	VBN

by	IN

genetic	JJ

partitioning	VBG

,	,

at	IN

least	JJS

at	IN

the	DT

level	NN

of	IN

resolution	NN

provided	VBN

by	IN

our	PRP$

analyses	NNS

The	DT

indoor	JJ

pollution	NN

,	,

where	WRB

the	DT

patients	NNS

pass	NN

in	IN

general	JJ

close	RB

to	TO

90	CD

%	NN

of	IN

their	PRP$

time	NN

,	,

is	VBZ

an	DT

important	JJ

factor	NN

to	TO

take	VB

in	IN

consideration	NN

if	IN

one	CD

wants	VBZ

to	TO

evaluate	VB

suitably	RB

the	DT

effects	NNS

of	IN

the	DT

air	NN

pollution	NN

on	IN

the	DT

health	NN

Causes	NNS

of	IN

this	DT

kind	NN

of	IN

pollution	NN

are	VBP

partially	RB

linked	VBN

to	TO

the	DT

external	JJ

pollution	NN

and	CC

the	DT

outdoor	JJ

environment	NN

and	CC

also	RB

are	VBP

function	NN

of	IN

human	JJ

activities	NNS

and	CC

introduced	VBN

products	NNS

in	IN

the	DT

habitat	NN

(	NN

heating	NN

,	,

tabagisme	NN

,	,

handywork	NN

,	,

products	NNS

of	IN

maintenance	NN

,	,

coatings	NNS

,	,

materials	NNS

of	IN

construction	NN

,	,

etc	FW

)	NN

The	DT

effects	NNS

on	IN

health	NN

are	VBP

as	IN

various	JJ

as	IN

the	DT

pollutants	NNS

,	,

going	VBG

from	IN

sharp	JJ

intoxication	NN

to	TO

irritations	NNS

or	CC

simply	RB

desagreements	NNS

In	IN

this	DT

problem	NN

of	IN

public	NN

health	NN

we	PRP

may	MD

not	RB

underestimated	VBD

sensitive	JJ

persons	NNS

and	CC

risky	JJ

group	NN

as	IN

well	RB

as	IN

long	RB

terme	IN

effects	NNS

,	,

and	CC

chronic	JJ

exposition	NN

effects	NNS

The	DT

search	NN

of	IN

solutions	NNS

needs	NNS

multiple	JJ

competences	NNS

from	IN

the	DT

physician	NN

,	,

who	WP

has	VBZ

to	TO

play	NN

an	DT

essential	JJ

role	NN

Dioxins	NNS

are	VBP

a	DT

family	NN

of	IN

chlorinated	VBN

aromatic	JJ

hydrocarbons	NNS

that	IN

are	VBP

produced	VBN

during	IN

combustion	NN

processes	NNS

in	IN

the	DT

presence	NN

of	IN

a	DT

chlorine	NN

donor	NN

and	CC

as	IN

by-products	NNS

of	IN

the	DT

chlorine-processing	NN

chemical	NN

industries	NNS

Several	JJ

dioxins	NNS

are	VBP

extremely	RB

stable	JJ

compounds	NNS

and	CC

persist	VB

for	IN

years	NNS

in	IN

the	DT

environment	NN

Exposure	NN

to	TO

dioxins	NNS

occurs	VBZ

mainly	RB

via	IN

the	DT

ingestion	NN

of	IN

contaminated	VBN

food	NN

The	DT

lipophilic	JJ

character	NN

of	IN

dioxins	NNS

prevents	VBZ

their	PRP$

excretion	NN

in	IN

the	DT

urine	NN

and	CC

causes	NNS

their	PRP$

accumulation	NN

in	IN

body	NN

fat	NN

The	DT

mechanisms	NNS

of	IN

dioxin	NN

action	NN

are	VBP

similar	JJ

to	TO

those	DT

of	IN

a	DT

hormone	NN

Dioxins	NNS

bind	NN

to	TO

a	DT

specific	JJ

intracellular	JJ

receptor	NN

and	CC

the	DT

complex	NN

acts	NNS

as	IN

a	DT

transcription	NN

factor	NN

that	IN

induces	VBZ

the	DT

production	NN

of	IN

a	DT

great	JJ

number	NN

of	IN

proteins	NNS

Certain	JJ

dioxins	NNS

,	,

particularly	RB

2	CD

,	,

3	CD

,	,

7	CD

,	,

8-tetrachlorodibenzo-p-dioxin	NN

,	,

are	VBP

very	RB

toxic	JJ

and	CC

able	JJ

to	TO

induce	VB

numerous	JJ

clinical	JJ

conditions	NNS

The	DT

carcinogenicity	NN

of	IN

dioxins	NNS

is	VBZ

well	RB

documented	VBN

in	IN

animal	NN

models	NNS

and	CC

has	VBZ

been	VBN

described	VBN

in	IN

humans	NNS

after	IN

professional	JJ

and	CC

accidental	JJ

exposures	NNS

Recent	JJ

experimental	JJ

data	NNS

also	RB

indicate	VBP

that	IN

dioxins	NNS

can	MD

cause	NN

dysfunction	NN

of	IN

the	DT

sexual	JJ

and	CC

thyroid	NN

hormone	NN

systems	NNS

and	CC

that	IN

the	DT

administration	NN

of	IN

dioxins	NNS

induces	VBZ

several	JJ

conditions	NNS

related	JJ

to	TO

hormonal	JJ

dysfunction	NN

Chronic	JJ

exposure	NN

of	IN

female	NN

Rhesus	NN

monkeys	NNS

increases	NNS

the	DT

incidence	NN

and	CC

severity	NN

of	IN

endometriosis	NN

The	DT

administration	NN

of	IN

dioxins	NNS

during	IN

pregnancy	NN

and	CC

nursing	NN

causes	NNS

altered	JJ

development	NN

of	IN

the	DT

reproductive	JJ

system	NN

,	,

decreased	VBN

spermatogenesis	NN

,	,

hypothyroidism	NN

and	CC

disturbed	JJ

psychomotor	NN

development	NN

in	IN

the	DT

offspring	NN

The	DT

particular	JJ

sensibility	NN

of	IN

the	DT

fetus	NN

and	CC

newborn	JJ

is	VBZ

of	IN

concern	NN

because	IN

the	DT

exposition	NN

to	TO

dioxins	NNS

is	VBZ

particularly	RB

important	JJ

during	IN

those	DT

periods	NNS

of	IN

life	NN

In	IN

humans	NNS

a	DT

series	NN

of	IN

conditions	NNS

related	JJ

to	TO

hormonal	JJ

dysfunction	NN

as	IN

undescended	JJ

testis	NN

,	,

decreased	VBN

spermatogenesis	NN

,	,

testicular	JJ

cancer	NN

and	CC

endometriosis	NN

have	VB

increased	VBN

in	IN

incidence	NN

during	IN

the	DT

last	JJ

decades	NNS

The	DT

chronological	JJ

parallelism	NN

with	IN

the	DT

appearance	NN

of	IN

dioxins	NNS

in	IN

the	DT

environment	NN

suggests	VBZ

that	IN

these	DT

might	MD

exert	VB

biological	JJ

effects	NNS

at	IN

the	DT

prevailing	VBG

level	NN

of	IN

exposure	NN

Nevertheless	RB

this	DT

hypothesis	NN

is	VBZ

currently	RB

unconfirmed	JJ

by	IN

epidemiological	JJ

studies	NNS

The	DT

implications	NNS

of	IN

this	DT

scientific	JJ

incertitude	NN

for	IN

the	DT

implementation	NN

of	IN

preventive	JJ

measures	NNS

are	VBP

briefly	NN

discussed	VBN

This	DT

presentation	NN

summarizes	VBZ

the	DT

debate	NN

on	IN

the	DT

suggested	VBN

progressive	JJ

impairment	NN

of	IN

semen	NN

quality	NN

(	NN

the	DT

``	``

sperm	NN

fall	NN

''	''

)	NN

in	IN

the	DT

last	JJ

forty	CD

years	NNS

in	IN

the	DT

developed	VBN

countries	NNS

The	DT

various	JJ

available	JJ

data	NNS

strongly	RB

suggesting	VBG

an	DT

environmental	JJ

toxic	JJ

origin	NN

for	IN

the	DT

``	``

sperm	NN

fall	NN

''	''

will	MD

be	VB

presented	VBN

as	IN

well	RB

as	IN

the	DT

most	RBS

frequently	RB

suspected	VBN

class	NN

of	IN

substances	NNS

,	,

the	DT

xenoestrogens	NNS

Diabetes	NNP

mellitus	NN

is	VBZ

a	DT

still	RB

growing	VBG

disease	NN

New	NNP

diagnostic	JJ

criteria	NNS

lowered	VBN

the	DT

cut	NN

off	IN

value	NN

to	TO

126	CD

mg/dl	NN

,	,

in	IN

order	NN

to	TO

detect	VB

more	RBR

rapidly	RB

diabetes	NN

and	CC

its	PRP$

complications	NNS

The	DT

treatment	NN

of	IN

diabetes	NN

2	CD

by	IN

the	DT

classic	JJ

oral	JJ

antidiabetic	JJ

drugs	NNS

(	NN

sulfamides	NNS

and	CC

biguanides	NNS

)	NN

is	VBZ

completed	VBN

by	IN

intestinal	JJ

glycosidases	NNS

inhibitors	NNS

and	CC

thiazolidendiones	NNS

These	DT

last	JJ

drugs	NNS

seem	VB

very	RB

attractive	JJ

because	IN

they	PRP

decrease	NN

insulin	NN

resistance	NN

in	IN

obese	JJ

,	,

diabetics	NNS

Their	PRP$

hepatic	JJ

side	NN

effects	NNS

must	MD

be	VB

however	RB

under	IN

control	NN

Better	RBR

knowledge	NN

of	IN

non	JJ

lipidic	JJ

effects	NNS

of	IN

statins	NNS

on	IN

the	DT

arterial	JJ

wall	NN

and	CC

the	DT

discovery	NN

of	IN

the	DT

action	NN

of	IN

fibrates	NNS

on	IN

PPAR	NN

(	NN

Peroxisome	NN

Proliferator	NN

Activated	VBN

Receptors	NNS

)	NN

improved	VBN

strongly	RB

the	DT

therapeutic	JJ

management	NN

of	IN

hyperlipidemias	NNS

Recent	JJ

intervention	NN

studies	NNS

have	VB

demonstrated	VBN

the	DT

necessity	NN

to	TO

treat	NN

vigorously	RB

dysipidemias	NNS

<	JJR

TO_SEE	NN

>	JJR

Despite	IN

Beta-blockade	NN

therapy	NN

has	VBZ

been	VBN

considered	VBN

as	IN

an	DT

absolute	JJ

contraindication	NN

in	IN

the	DT

treatment	NN

of	IN

heart	NN

failure	NN

,	,

it	PRP

has	VBZ

been	VBN

shown	VBN

that	IN

they	PRP

could	MD

have	VB

a	DT

beneficial	JJ

effect	NN

,	,

provided	VBN

that	IN

they	PRP

were	VBD

introduced	VBN

at	IN

very	RB

low	JJ

dose	NN

,	,

and	CC

very	RB

progressively	RB

in	IN

addition	NN

of	IN

the	DT

traditional	JJ

treatment	NN

The	DT

advances	NNS

in	IN

the	DT

understanding	VBG

of	IN

the	DT

neuro-hormonal	JJ

mechanisms	NNS

of	IN

heart	NN

failure	NN

have	VB

modified	VBN

the	DT

therapeutic	JJ

strategy	NN

:	:

the	DT

deleterious	JJ

effect	NN

of	IN

the	DT

activation	NN

of	IN

the	DT

sympathetic	JJ

nervous	JJ

system	NN

on	IN

the	DT

myocardium	NN

has	VBZ

served	VBD

as	IN

the	DT

rationale	NN

for	IN

randomized	VBN

clinical	JJ

trials	NNS

comparing	VBG

beta-blockade	NN

to	TO

placebo	NN

:	:

the	DT

current	JJ

data	NNS

are	VBP

promising	VBG

,	,

suggesting	VBG

a	DT

beneficial	JJ

effect	NN

on	IN

survival	NN

as	IN

well	RB

as	IN

on	IN

quality	NN

of	IN

life	NN

However	RB

,	,

these	DT

results	NNS

have	VB

to	TO

be	VB

confirmed	VBN

by	IN

larger	JJR

trials	NNS

,	,

currently	RB

underway	NN

,	,

before	IN

to	TO

consider	VB

that	IN

beta-blockade	NN

should	MD

definitely	RB

be	VB

incorporated	VBN

in	IN

the	DT

treatment	NN

of	IN

heart	NN

failure	NN

Calcium	NN

antagonists	NNS

have	VB

been	VBN

used	VBN

for	IN

treatment	NN

of	IN

cardiovascular	JJ

diseases	NNS

for	IN

more	RBR

than	IN

25	CD

years	NNS

Several	JJ

recent	JJ

retrospective	NN

studies	NNS

have	VB

suggested	VBN

that	IN

chronic	JJ

treatment	NN

with	IN

short-acting	JJ

dihydropyridines	NNS

increased	VBN

the	DT

incidence	NN

of	IN

cardiac	JJ

events	NNS

,	,

cancer	NN

and	CC

gastrointestinal	JJ

bleedings	NNS

Randomized	VBN

prospective	JJ

studies	NNS

have	VB

,	,

however	RB

,	,

never	RB

been	VBN

able	JJ

to	TO

confirm	VB

these	DT

observations	NNS

In	IN

addition	NN

,	,

well-conducted	JJ

studies	NNS

using	VBG

verapamil	NN

and	CC

diltiazem	NN

have	VB

suggested	VBN

that	IN

these	DT

calcium	NN

antagonists	NNS

may	MD

even	RB

improve	VB

cardiovascular	JJ

mortality	NN

and	CC

morbidity	NN

of	IN

the	DT

hypertensive	JJ

patient	NN

<	JJR

TO_SEE	NN

>	JJR

There	EX

is	VBZ

therefore	RB

no	DT

reason	NN

to	TO

believe	VB

that	IN

the	DT

questionable	JJ

results	NNS

derived	VBN

from	IN

retrospective	NN

studies	NNS

of	IN

the	DT

effects	NNS

of	IN

short-acting	JJ

calcium	NN

antagonists	NNS

on	IN

cardiac	JJ

and	CC

noncardiac	JJ

events	NNS

may	MD

apply	VB

to	TO

the	DT

newer	JJR

generation	NN

of	IN

long-acting	JJ

calcium	NN

antagonists	NNS

Sumatriptan	NNP

and	CC

other	JJ

selective	JJ

serotonin	NN

agonists	NNS

represent	VB

a	DT

major	JJ

breakthrough	NN

in	IN

acute	JJ

migraine	NN

treatment	NN

These	DT

drugs	NNS

are	VBP

very	RB

efficacious	JJ

and	CC

generally	RB

devoided	VBN

of	IN

important	JJ

side	NN

effects	NNS

,	,

but	CC

they	PRP

are	VBP

expensive	JJ

and	CC

therefore	RB

have	VB

to	TO

be	VB

compared	VBN

with	IN

other	JJ

,	,

more	RBR

conventional	JJ

drugs	NNS

with	IN

established	VBN

or	CC

assumed	VBN

efficacy	NN

We	PRP

summarize	VB

the	DT

pharmacologic	JJ

characteristics	NNS

of	IN

Sumatriptan	NNP

and	CC

give	VB

recommendations	NNS

about	IN

its	PRP$

use	NN

in	IN

clinical	JJ

practice	NN

Fiercer	JJR

competition	NN

between	IN

athletes	NNS

and	CC

a	DT

wider	JJR

knowledge	NN

of	IN

optimal	JJ

training	NN

regimens	NNS

dramatically	RB

influence	NN

current	JJ

training	NN

methods	NNS

A	DT

single	JJ

training	NN

bout	NN

per	IN

day	NN

was	VBD

previously	RB

considered	VBN

sufficient	JJ

,	,

whereas	IN

today	NN

athletes	NNS

regularly	RB

train	NN

twice	RB

a	DT

day	NN

or	CC

more	RBR

Consequently	RB

,	,

the	DT

number	NN

of	IN

athletes	NNS

who	WP

are	VBP

overtraining	VBG

and	CC

have	VB

insufficient	JJ

rest	NN

is	VBZ

increasing	VBG

Positive	JJ

overtraining	VBG

can	MD

be	VB

regarded	VBN

as	IN

a	DT

natural	JJ

process	NN

when	WRB

the	DT

end	NN

result	NN

is	VBZ

adaptation	NN

and	CC

improved	VBN

performance	NN

:	:

the	DT

supercompensation	NN

principle	NN

--	:

which	WDT

includes	VBZ

the	DT

breakdown	NN

process	NN

(	NN

training	NN

)	NN

followed	VBN

by	IN

the	DT

recovery	NN

process	NN

(	NN

rest	NN

)	NN

--	:

is	VBZ

well	RB

known	VBN

in	IN

sports	NNS

However	RB

,	,

negative	JJ

overtraining	VBG

,	,

causing	VBG

maladaptation	NN

and	CC

other	JJ

negative	JJ

consequences	NNS

such	JJ

as	IN

staleness	NN

,	,

can	MD

occur	VB

Physiological	JJ

,	,

psychological	JJ

,	,

biochemical	JJ

and	CC

immunological	JJ

symptoms	NNS

must	MD

be	VB

considered	VBN

,	,

both	DT

independently	RB

and	CC

together	RB

,	,

to	TO

fully	RB

understand	VB

the	DT

'staleness	NN

'	''

syndrome	NN

However	RB

,	,

psychological	JJ

testing	NN

may	MD

reveal	VB

early-warning	JJ

signs	NNS

more	RBR

readily	RB

than	IN

the	DT

various	JJ

physiological	JJ

or	CC

immunological	JJ

markers	NNS

The	DT

time	NN

frame	NN

of	IN

training	NN

and	CC

recovery	NN

is	VBZ

also	RB

important	JJ

since	IN

the	DT

consequences	NNS

of	IN

negative	JJ

overtraining	VBG

comprise	VBP

an	DT

overtraining-response	NN

continuum	NN

from	IN

short	RB

to	TO

long	RB

term	NN

effects	NNS

An	DT

athlete	NN

failing	VBG

to	TO

recover	VB

within	IN

72	CD

hours	NNS

has	VBZ

presumably	RB

negatively	RB

overtrained	VBN

and	CC

is	VBZ

in	IN

an	DT

overreached	VBD

state	NN

For	IN

an	DT

elite	NN

athlete	NN

to	TO

refrain	NN

from	IN

training	NN

for	IN

>	JJR

72	CD

hours	NNS

is	VBZ

extremely	RB

undesirable	JJ

,	,

highlighting	VBG

the	DT

importance	NN

of	IN

a	DT

carefully	RB

monitored	VBN

recovery	NN

process	NN

There	EX

are	VBP

many	JJ

methods	NNS

used	VBN

to	TO

measure	NN

the	DT

training	NN

process	NN

but	CC

few	JJ

with	IN

which	WDT

to	TO

match	NN

the	DT

recovery	NN

process	NN

against	IN

it	PRP

One	CD

such	JJ

framework	NN

for	IN

this	DT

is	VBZ

referred	VBN

to	TO

as	IN

the	DT

total	NN

quality	NN

recovery	NN

(	NN

TQR	NN

)	NN

process	NN

By	IN

using	VBG

a	DT

TQR	NN

scale	NN

,	,

structured	VBN

around	IN

the	DT

scale	NN

developed	VBN

for	IN

ratings	NNS

of	IN

perceived	VBN

exertion	NN

(	NN

RPE	NN

)	NN

,	,

the	DT

recovery	NN

process	NN

can	MD

be	VB

monitored	VBN

and	CC

matched	VBN

against	IN

the	DT

breakdown	NN

(	NN

training	NN

)	NN

process	NN

(	NN

TQR	NN

versus	CC

RPE	NN

)	NN

The	DT

TQR	NN

scale	NN

emphasises	VBZ

both	DT

the	DT

athlete	NN

's	POS

perception	NN

of	IN

recovery	NN

and	CC

the	DT

importance	NN

of	IN

active	JJ

measures	NNS

to	TO

improve	VB

the	DT

recovery	NN

process	NN

Furthermore	RB

,	,

directing	VBG

attention	NN

to	TO

psychophysiological	JJ

cues	NNS

serves	VBZ

the	DT

same	JJ

purpose	NN

as	IN

in	IN

RPE	NN

,	,

i.e	NN

.	.

increasing	VBG

self-awareness	NN

This	DT

article	NN

reviews	NNS

and	CC

conceptualises	NNS

the	DT

whole	JJ

overtraining	VBG

process	NN

In	IN

doing	VBG

so	RB

,	,

it	PRP

(	NN

i	LS

)	NN

aims	NNS

to	TO

differentiate	VB

between	IN

the	DT

types	NNS

of	IN

stress	NN

affecting	VBG

an	DT

athlete	NN

's	POS

performance	NN

:	:

(	NN

ii	LS

)	NN

identifies	VBZ

factors	NNS

influencing	VBG

an	DT

athlete	NN

's	POS

ability	NN

to	TO

adapt	VB

to	TO

physical	JJ

training	NN

:	:

(	NN

iii	LS

)	NN

structures	NNS

the	DT

recovery	NN

process	NN

The	DT

TQR	NN

method	NN

to	TO

facilitate	VB

monitoring	VBG

of	IN

the	DT

recovery	NN

process	NN

is	VBZ

then	RB

suggested	VBN

and	CC

a	DT

conceptual	JJ

model	NN

that	IN

incorporates	VBZ

all	DT

of	IN

the	DT

important	JJ

parameters	NNS

for	IN

performance	NN

gain	NN

(	NN

adaptation	NN

)	NN

and	CC

loss	NN

(	NN

maladaptation	NN

)	NN

Little	JJ

attention	NN

has	VBZ

been	VBN

directed	VBN

toward	IN

identifying	VBG

the	DT

changes	NNS

which	WDT

occur	VB

in	IN

salivary	JJ

composition	NN

in	IN

response	NN

to	TO

exercise	NN

To	TO

address	NN

this	DT

,	,

our	PRP$

article	NN

first	RB

refers	VBZ

to	TO

the	DT

main	JJ

aspects	NNS

of	IN

salivary	JJ

gland	NN

physiology	NN

A	DT

knowledge	NN

of	IN

the	DT

neural	JJ

control	NN

of	IN

salivary	JJ

secretion	NN

is	VBZ

especially	RB

important	JJ

for	IN

the	DT

understanding	VBG

of	IN

the	DT

effects	NNS

of	IN

exertion	NN

on	IN

salivary	JJ

secretion	NN

Both	DT

salivary	JJ

output	NN

and	CC

composition	NN

depend	VB

on	IN

the	DT

activity	NN

of	IN

the	DT

autonomic	JJ

nervous	JJ

system	NN

and	CC

any	DT

modification	NN

of	IN

this	DT

activity	NN

can	MD

be	VB

observed	VBN

indirectly	RB

by	IN

alternations	NNS

in	IN

the	DT

salivary	JJ

excretion	NN

The	DT

effects	NNS

of	IN

physical	JJ

activity	NN

(	NN

with	IN

reference	NN

to	TO

factors	NNS

such	JJ

as	IN

exercise	NN

intensity	NN

and	CC

duration	NN

,	,

or	CC

type	NN

of	IN

exercise	NN

protocol	NN

)	NN

on	IN

salivary	JJ

composition	NN

are	VBP

then	RB

considered	VBN

Exercise	NN

might	MD

indeed	RB

induce	VB

changes	NNS

in	IN

several	JJ

salivary	JJ

components	NNS

such	JJ

as	IN

immunoglobulins	NNS

,	,

hormones	NNS

,	,

lactate	NN

,	,

proteins	NNS

and	CC

electrolytes	NNS

Saliva	FW

composition	NN

might	MD

therefore	RB

be	VB

used	VBN

as	IN

an	DT

alternative	NN

noninvasive	JJ

indicator	NN

of	IN

the	DT

response	NN

of	IN

the	DT

different	JJ

body	NN

tissues	NNS

and	CC

systems	NNS

to	TO

physical	JJ

exertion	NN

In	IN

this	DT

respect	NN

,	,

the	DT

response	NN

of	IN

salivary	JJ

amylase	NN

and	CC

salivary	JJ

electrolytes	NNS

to	TO

incremental	JJ

levels	NNS

of	IN

exercise	NN

is	VBZ

of	IN

particular	JJ

interest	NN

Beyond	IN

a	DT

certain	JJ

intensity	NN

of	IN

exercise	NN

,	,

and	CC

coinciding	VBG

with	IN

the	DT

accumulation	NN

of	IN

blood	NN

lactate	NN

(	NN

anaerobic	JJ

threshold	NN

or	CC

AT	IN

)	NN

,	,

a	DT

'saliva	NN

threshold	NN

'	''

(	NN

Tsa	NN

)	NN

does	VBZ

indeed	RB

exist	VB

Tsa	NN

is	VBZ

the	DT

point	NN

during	IN

exercise	NN

at	IN

which	WDT

the	DT

levels	NNS

of	IN

salivary	JJ

alpha-amylase	NN

and	CC

electrolytes	NNS

(	NN

especially	RB

Na+	NN

)	NN

also	RB

begin	VB

to	TO

rise	NN

above	IN

baseline	NN

levels	NNS

The	DT

occurrence	NN

of	IN

the	DT

2	CD

thresholds	NNS

(	NN

AT	IN

and	CC

Tsa	NN

)	NN

might	MD

,	,

in	IN

turn	NN

,	,

be	VB

attributable	JJ

to	TO

the	DT

same	JJ

underlying	VBG

mechanism	NN

,	,

that	IN

of	IN

increased	VBN

adrenal	JJ

sympathetic	JJ

activity	NN

at	IN

high	JJ

exercise	NN

intensities	NNS

Fat	NNP

is	VBZ

an	DT

extremely	RB

important	JJ

substrate	NN

for	IN

muscle	NN

contraction	NN

,	,

both	DT

at	IN

rest	NN

and	CC

during	IN

exercise	NN

Triglycerides	NNS

(	NN

TGs	NNS

)	NN

,	,

stored	VBN

in	IN

adipose	NN

tissue	NN

and	CC

within	IN

muscle	NN

fibres	NNS

,	,

are	VBP

considered	VBN

to	TO

be	VB

the	DT

main	JJ

source	NN

of	IN

the	DT

free	JJ

fatty	NN

acids	NNS

(	NN

FFAs	NNS

)	NN

oxidised	VBN

during	IN

exercise	NN

It	PRP

is	VBZ

still	RB

unclear	JJ

,	,

however	RB

,	,

how	WRB

the	DT

use	NN

of	IN

these	DT

substrates	NNS

is	VBZ

regulated	VBN

during	IN

exercise	NN

The	DT

regulation	NN

seems	VBZ

to	TO

be	VB

multifactorial	JJ

and	CC

includes	VBZ

:	:

(	NN

i	LS

)	NN

dietary	JJ

and	CC

nutritional	JJ

status	NN

;	:

(	NN

ii	LS

)	NN

hormonal	JJ

milieu	NN

;	:

(	NN

iii	LS

)	NN

exercise	NN

mode	NN

,	,

intensity	NN

and	CC

duration	NN

;	:

and	CC

(	NN

iv	NN

)	NN

training	NN

status	NN

On	IN

the	DT

other	JJ

hand	NN

,	,

the	DT

mechanism	NN

for	IN

FFA	SYM

transport	NN

from	IN

its	PRP$

storage	NN

as	IN

triglycerides	NNS

in	IN

adipose	NN

tissue	NN

and	CC

muscle	NN

to	TO

its	PRP$

place	NN

of	IN

utilisation	NN

in	IN

heart	NN

,	,

skeletal	JJ

muscle	NN

,	,

kidney	NN

and	CC

liver	NN

is	VBZ

more	RBR

clearly	RB

understood	VBN

It	PRP

has	VBZ

been	VBN

determined	VBN

that	IN

the	DT

plasma	NN

FFA	SYM

turnover	NN

rate	NN

is	VBZ

sufficiently	RB

rapid	JJ

to	TO

account	NN

for	IN

most	RBS

of	IN

the	DT

fat	NN

metabolised	VBN

during	IN

low	JJ

intensity	NN

exercise	NN

(	NN

25	CD

to	TO

40	CD

%	NN

VO2max	NN

)	NN

However	RB

,	,

an	DT

exercise	NN

intensity	NN

of	IN

65	CD

%	NN

VO2max	NN

results	NNS

in	IN

a	DT

slight	JJ

decrease	NN

in	IN

the	DT

amount	NN

of	IN

plasma	NN

FFA	SYM

uptake	NN

by	IN

muscle	NN

tissue	NN

Other	JJ

studies	NNS

have	VB

found	VBN

that	IN

during	IN

prolonged	JJ

exercise	NN

,	,

muscle	NN

TGs	NNS

become	VB

the	DT

predominant	JJ

source	NN

of	IN

energy	NN

obtained	VBN

from	IN

fat	NN

Furthermore	RB

,	,

it	PRP

is	VBZ

widely	RB

documented	VBN

that	IN

endurance	JJ

activities	NNS

increase	NN

the	DT

energy	NN

utilisation	NN

from	IN

fat	NN

while	IN

sparing	VBG

carbohydrate	NN

sources	NNS

For	IN

example	NN

,	,

during	IN

exercise	NN

on	IN

a	DT

cycle	NN

ergometer	NN

,	,

nonplasma	NN

FFAs	NNS

and	CC

plasma	NN

FFAs	NNS

contribute	VB

40	CD

%	NN

,	,

and	CC

carbohydrates	NNS

60	CD

%	NN

,	,

of	IN

the	DT

total	NN

calculated	VBN

amount	NN

of	IN

energy	NN

expenditure	NN

before	IN

exercise	NN

and	CC

vice	NN

versa	RB

after	IN

exercise	NN

(	NN

60	CD

%	NN

nonplasma	NN

and	CC

plasma	NN

FFAs	NNS

and	CC

40	CD

%	NN

carbohydrates	NNS

)	NN

Although	IN

it	PRP

was	VBD

many	JJ

years	NNS

before	IN

it	PRP

was	VBD

fully	RB

demonstrated	VBN

,	,

fat	NN

is	VBZ

now	RB

known	VBN

to	TO

be	VB

transported	VBN

in	IN

the	DT

blood	NN

as	IN

FFA	SYM

bound	VBN

to	TO

the	DT

protein	NN

carrier	NN

albumin	NN

The	DT

mobilisation	NN

of	IN

FFA	SYM

is	VBZ

primarily	RB

a	DT

function	NN

of	IN

sympathetic	JJ

nervous	JJ

activity	NN

directed	VBN

towards	IN

the	DT

adipocytes	NNS

,	,

or	CC

the	DT

'fat	NN

pad	NN

'	''

.	.

This	DT

nervous	JJ

activity	NN

can	MD

be	VB

direct	JJ

or	CC

may	MD

be	VB

an	DT

effect	NN

of	IN

circulating	VBG

catecholamines	NNS

such	JJ

as	IN

adrenaline	NN

(	NN

epinephrine	NN

)	NN

This	DT

article	NN

summarises	VBZ

the	DT

role	NN

of	IN

fat	NN

metabolism	NN

during	IN

exercise	NN

As	IN

the	DT

clinical	JJ

availability	NN

of	IN

glycohaemoglobin/GHb	NN

measurement	NN

increases	NNS

,	,

so	RB

does	VBZ

the	DT

need	NN

for	IN

comparable	JJ

and	CC

accurate	JJ

values	NNS

among	IN

different	JJ

laboratories	NNS

and	CC

different	JJ

methods	NNS

At	IN

least	JJS

there	RB

should	MD

be	VB

comparability	NN

,	,

i.e	NN

.	.

,	,

commutability	NN

or	CC

feasibility	NN

of	IN

providing	VBG

comparable	JJ

results	NNS

from	IN

different	JJ

assays	NNS

in	IN

different	JJ

laboratories	NNS

A	DT

clinical	JJ

joint	NN

study	NN

on	IN

insulin	NN

therapy	NN

,	,

a	DT

survey	NN

of	IN

the	DT

actual	JJ

inter-laboratory	JJ

differences	NNS

in	IN

GHb	NN

measurement	NN

among	IN

41	CD

institutions	NNS

and	CC

an	DT

assessment	NN

of	IN

11	CD

assay	NN

methods	NNS

for	IN

the	DT

determination	NN

of	IN

GHb	NN

were	VBD

performed	VBN

using	VBG

commercial	JJ

calibrators	NNS

and	CC

fresh	JJ

blood	NN

samples	NNS

Data	NNS

on	IN

the	DT

actual	JJ

state	NN

of	IN

inter-laboratory	JJ

and	CC

inter-assay	NN

differences	NNS

of	IN

observed	VBN

values	NNS

were	VBD

useful	JJ

for	IN

comparing	VBG

results	NNS

among	IN

facilities	NNS

The	DT

recommendation	NN

of	IN

the	DT

Japan	NNP

Diabetes	NNP

Society	NNP

to	TO

measure	NN

only	RB

the	DT

stable	JJ

GHb	NN

component	NN

and	CC

to	TO

correct	JJ

the	DT

GHb	NN

percentage	NN

by	IN

two-point	JJ

calibration	NN

with	IN

assigned	VBN

values	NNS

,	,

was	VBD

effective	JJ

but	CC

not	RB

sufficient	JJ

Even	RB

after	IN

correction	NN

,	,

8	CD

out	IN

of	IN

11	CD

methods	NNS

still	RB

remained	VBD

of	IN

little	RB

practical	JJ

use	NN

because	IN

of	IN

their	PRP$

large	JJ

relative	JJ

errors	NNS

Inter-method	NN

differences	NNS

among	IN

11	CD

available	JJ

assay	NN

methods	NNS

were	VBD

great	JJ

even	RB

after	IN

correction	NN

and	CC

depended	VBD

on	IN

not	RB

only	RB

the	DT

methods	NNS

but	CC

the	DT

samples	NNS

used	VBN

for	IN

the	DT

determination	NN

The	DT

performance	NN

of	IN

some	DT

methods	NNS

or	CC

instruments	NNS

used	VBN

are	VBP

only	RB

poor	JJ

at	IN

distinguishing	VBG

the	DT

stable	JJ

glycated	VBN

haemoglobin	NN

itself	PRP

Some	DT

alternative	NN

measurement	NN

system	NN

with	IN

comparability	NN

,	,

commutability	NN

and	CC

precision	NN

should	MD

be	VB

established	VBN

An	DT

urgent	JJ

and	CC

worldwide	RB

problem	NN

to	TO

remove	VB

inter-laboratory	JJ

differences	NNS

in	IN

the	DT

measurement	NN

of	IN

GHb	NN

needs	NNS

to	TO

be	VB

solved	VBD

Users	NNS

in	IN

clinical	JJ

practice	NN

must	MD

recognize	VB

these	DT

problems	NNS

,	,

and	CC

,	,

before	IN

supply	NN

,	,

the	DT

providers	NNS

should	MD

check	NN

their	PRP$

method	NN

and	CC

keep	VB

records	NNS

that	IN

are	VBP

readily	RB

traceable	JJ

A	DT

postal	JJ

survey	NN

was	VBD

performed	VBN

to	TO

determine	VB

the	DT

current	JJ

practices	NNS

and	CC

attitudes	NNS

of	IN

radiologists	NNS

towards	IN

the	DT

imaging	NN

of	IN

suspected	VBN

lower	JJR

limb	NN

deep	RB

vein	NN

thrombosis	NN

(	NN

DVT	NN

)	NN

One	CD

hundred	CD

and	CC

twenty-seven	CD

departments	NNS

responded	VBD

to	TO

a	DT

questionnaire	NN

sent	VBN

in	IN

March	NNP

1996	CD

The	DT

results	NNS

show	NN

that	IN

87	CD

%	NN

of	IN

hospitals	NNS

possess	VB

colour	NN

Doppler	NNP

ultrasound	NN

(	NN

CDUS	NN

)	NN

machines	NNS

and	CC

that	IN

46	CD

%	NN

of	IN

departments	NNS

perform	VB

ultrasound	NN

as	IN

the	DT

first	RB

line	NN

investigation	NN

in	IN

over	IN

90	CD

%	NN

of	IN

cases	NNS

Thirty	CD

per	IN

cent	NN

of	IN

departments	NNS

considered	VBN

calf	NN

vein	NN

visualization	NN

to	TO

be	VB

generally	RB

adequate	JJ

and	CC

34	CD

%	NN

thought	NN

that	IN

clinicians	NNS

in	IN

their	PRP$

hospitals	NNS

invariably	RB

anticoagulated	JJ

patients	NNS

with	IN

isolated	VBN

calf	NN

thrombus	NN

In	IN

hospitals	NNS

where	WRB

venography	NN

was	VBD

routinely	RB

used	VBN

as	IN

the	DT

first	RB

line	NN

investigation	NN

,	,

the	DT

most	RBS

common	JJ

reasons	NNS

were	VBD

:	:

the	DT

perceived	VBN

inferiority	NN

of	IN

ultrasound	NN

(	NN

US	NNP

)	NN

in	IN

demonstrating	VBG

below-knee	NN

clot	NNS

,	,

its	PRP$

time-consuming	JJ

nature	NN

and	CC

the	DT

limited	JJ

access	NN

to	TO

suitable	JJ

ultrasound	NN

machines	NNS

The	DT

widespread	JJ

use	NN

of	IN

ultrasound	NN

is	VBZ

encouraging	VBG

,	,

however	RB

,	,

there	RB

are	VBP

clearly	RB

diverse	JJ

views	NNS

A	DT

significant	JJ

minority	NN

of	IN

departments	NNS

depend	VB

principally	RB

upon	IN

venography	NN

in	IN

the	DT

diagnosis	NN

of	IN

DVT	NN

Existential	JJ

phenomenology	NN

and	CC

the	DT

sociological	JJ

tradition	NN

Dual	JJ

leadership	NN

in	IN

complex	NN

organizations	NNS

Scientists	NNS

at	IN

major	JJ

and	CC

minor	JJ

universities	NNS

:	:

a	DT

study	NN

of	IN

productivity	NN

and	CC

recognition	NN

Demotion	NN

in	IN

industrial	JJ

management	NN

Career	NNP

anchorage	NN

:	:

managerial	JJ

mobility	NN

motivations	NNS

Social	NNP

class	NN

and	CC

premarital	JJ

sexual	JJ

permissiveness	NN

:	:

a	DT

re-examination	NN

A	DT

comment	NN

on	IN

``	``

anomy	NN

''	''

A	DT

factor	NN

analytic	JJ

exploration	NN

of	IN

the	DT

alienation	NN

,	,

anomia	NN

and	CC

authoritarianism	NN

domain	NN

Technical	NNP

note	NN

on	IN

two	CD

rates	NNS

of	IN

mixed	JJ

marriage	NN

Some	DT

comments	NNS

on	IN

awareness	NN

On	IN

experimental	JJ

design	NN

Observations	NNS

on	IN

the	DT

incidence	NN

of	IN

following	VBG

of	IN

visual	JJ

and	CC

auditory	NN

stimuli	NNS

in	IN

naive	JJ

mallard	NN

ducklings	NNS

(	NN

Anas	NNP

platyrhynchos	NNS

)	NN

The	DT

comfort	NN

movements	NNS

of	IN

Anatidae	NNP

Potential	JJ

ethological	JJ

isolating	VBG

mechanisms	NNS

and	CC

assortative	JJ

mating	NN

in	IN

the	DT

domestic	JJ

fowl	NN

An	DT

experimental	JJ

study	NN

of	IN

conflict	NN

and	CC

fear	NN

:	:

an	DT

analysis	NN

of	IN

behavior	NN

of	IN

young	JJ

chicks	NNS

toward	IN

a	DT

mealworm	NN

I	PRP

.	.

The	DT

behavior	NN

of	IN

chicks	NNS

which	WDT

do	VB

not	RB

eat	VB

the	DT

mealworm	NN

The	DT

measuring	VBG

function	NN

of	IN

the	DT

first	RB

legs	NNS

of	IN

Araneus	NNP

diadematus	NN

Cl	NN

The	DT

transport	NN

of	IN

prey	NN

by	IN

ants	NNS

Courtship	NN

behaviour	NN

in	IN

the	DT

Drosophila	FW

obscura	NN

group	NN

II	NNP

Comparative	JJ

studies	NNS

Vision	NNP

versus	CC

touch	NN

in	IN

form	NN

discrimination	NN

Short-term	JJ

retention	NN

as	IN

a	DT

function	NN

of	IN

method	NN

of	IN

measurement	NN

,	,

recording	VBG

time	NN

,	,

and	CC

meaningfulness	NN

of	IN

the	DT

material	NN

The	DT

conservation	NN

of	IN

a	DT

shape	NN

property	NN

and	CC

a	DT

proposal	NN

about	IN

the	DT

origin	NN

of	IN

the	DT

conservations	NNS

Persisting	VBG

odours	NNS

as	IN

a	DT

biasing	VBG

factor	NN

in	IN

open-field	JJ

research	NN

with	IN

mice	NNS

The	DT

display	NN

of	IN

information	NN

and	CC

the	DT

judgment	NN

of	IN

contingency	NN

Vividness	NN

of	IN

words	NNS

and	CC

learning	VBG

to	TO

learn	VB

in	IN

free-recall	NN

learning	VBG

Genetic	JJ

study	NN

of	IN

the	DT

memorization	NN

of	IN

words	NNS

and	CC

pictures	NNS

Amylase	NN

production	NN

by	IN

Streptomyces	NNS

species	NNS

Physico-chemical	JJ

studies	NNS

on	IN

the	DT

stability	NN

of	IN

penicillin	NN

salts	NNS

IV	CD

A	DT

statistical	JJ

evaluation	NN

Studies	NNS

on	IN

nitrogen	NN

metabolism	NN

of	IN

Penicillium	NNP

chrysogenum	NN

Thom	NNP

.	.

I	PRP

.	.

Effects	NNS

of	IN

lactose	NN

and	CC

sucrose	NN

additions	NNS

on	IN

nitrogen	NN

metabolism	NN

Studies	NNS

on	IN

nitrogen	NN

metabolism	NN

of	IN

Penicillium	NNP

chrysogenum	NN

Thom	NNP

.	.

II	NNP

Amino	NN

acid	NN

metabolism	NN

and	CC

its	PRP$

relation	NN

to	TO

the	DT

biosynthesis	NN

of	IN

penicillin	NN

The	DT

contribution	NN

of	IN

thoracic	JJ

surgery	NN

to	TO

our	PRP$

discipline	NN

Research	NNP

past	IN

and	CC

present	JJ

,	,

with	IN

particular	JJ

reference	NN

to	TO

the	DT

application	NN

of	IN

the	DT

techniques	NNS

of	IN

basic	JJ

science	NN

to	TO

the	DT

problems	NNS

of	IN

adrenal	JJ

pathology	NN

Some	DT

inflammatory	JJ

disorders	NNS

of	IN

the	DT

large	JJ

intestine	NN

Coexistence	NN

of	IN

subdural	JJ

and	CC

archnoidal	JJ

collections	NNS

of	IN

fluid	NN

:	:

an	DT

unusual	JJ

case	NN

The	DT

scope	NN

of	IN

sphincterotomy	NN

in	IN

biliary	JJ

and	CC

pancreatic	JJ

surgery	NN

Sarcoidosis	NN

involving	VBG

the	DT

veriform	NN

appendix	NN

``	``

Chronic	JJ

pancreatitis	NN

``	``

and	CC

carcinoma	NN

of	IN

the	DT

pancreas	NN

A	DT

method	NN

to	TO

aid	NN

correct	JJ

diagnosis	NN

Control	NN

of	IN

post-haemorrhoidectomy	JJ

bleeding	VBG

with	IN

a	DT

Foley	NNP

catheter	NN

and	CC

a	DT

pack	NN

Diagnosis	NN

and	CC

therapy	NN

of	IN

chronic	JJ

aspecific	JJ

pancreatitis	NN

Behavior	NN

of	IN

the	DT

tetanus	NN

patient	NN

subjected	VBN

to	TO

resuscitation	NN

treatment	NN

Further	RB

data	NNS

on	IN

mediastinal	JJ

and	CC

pulmonary	JJ

tumors	NNS

of	IN

the	DT

child	NN

Review	NN

and	CC

personal	JJ

cases	NNS

Dextran	NN

of	IN

low	JJ

molecular	JJ

weight	NN

in	IN

peripheral	JJ

arterial	JJ

insufficiency	NN

Clinico-statistical	JJ

considerations	NNS

on	IN

vescicular	JJ

mole	NN

On	IN

the	DT

significance	NN

of	IN

histologic	JJ

findings	NNS

in	IN

neoplasms	NNS

of	IN

the	DT

trophoblast	NN

(	NN

case	NN

contributions	NNS

)	NN

Diagnostic	JJ

evaluation	NN

of	IN

the	DT

patient	NN

with	IN

high	JJ

blood	NN

pressure	NN

Epidemiology	NNP

of	IN

hypertension	NN

Renal	JJ

vascular	JJ

hypertension	NN

;	:

diagnosis	NN

and	CC

treatment	NN

The	DT

use	NN

of	IN

radioactive	JJ

isotopes	NNS

in	IN

the	DT

diagnosis	NN

of	IN

hypertension	NN

The	DT

angiogram	NN

in	IN

the	DT

study	NN

of	IN

hypertension	NN

Guanethidine	NN

Hepatocerebral	JJ

degeneration	NN

(	NN

portal	NN

systemic	JJ

encephalopathy	NN

)	NN

The	DT

relationship	NN

to	TO

fatty	NN

acids	NNS

Oviposition	NN

and	CC

its	PRP$

regulation	NN

in	IN

the	DT

polygynous	JJ

society	NN

of	IN

Polistes	NNS

gallicus	NN

L.	NNP

Interaction	NN

of	IN

aggressive	JJ

and	CC

sexual	JJ

behavior	NN

in	IN

male	NN

mice	NNS

Conflict	NN

and	CC

conditioned	VBN

aversive	JJ

stimuli	NNS

in	IN

the	DT

development	NN

of	IN

experimental	JJ

neuroses	NNS

Study	NN

of	IN

the	DT

effect	NN

of	IN

newer	JJR

analeptic	JJ

(	NN

Micoren	NNP

)	NN

in	IN

hypoventilation	NN

syndrome	NN

Treatment	NN

of	IN

a	DT

disorder	NN

of	IN

perception	NN

and	CC

concept	NN

formation	NN

in	IN

a	DT

case	NN

of	IN

school	NN

failure	NN

Rorschach	NNP

correlates	VBZ

of	IN

time	NN

estimation	NN

Use	NN

of	IN

food	NN

in	IN

child	NN

psychotherapy	NN

About	IN

genital	JJ

discharge	NN

with	IN

special	JJ

consideration	NN

of	IN

its	PRP$

cervical	JJ

manifestation	NN

Auto-uro	NN

therapy	NN

:	:

status	NN

and	CC

future	NN

prospects	NNS

Clinical	JJ

experience	NN

with	IN

the	DT

surface	NN

anesthetic	NN

xylocaine	NN

in	IN

obstetrics	NNS

The	DT

problem	NN

of	IN

medicinal	JJ

management	NN

of	IN

labor	NN

Conglutination	NN

of	IN

the	DT

labia	NN

minora	NN

The	DT

fight	NN

against	IN

hemolytic	JJ

disease	NN

of	IN

the	DT

newborn	JJ

in	IN

general	JJ

practice	NN

Long	NNP

term	NN

results	NNS

in	IN

the	DT

300	CD

most	RBS

grave	NN

cases	NNS

out	IN

of	IN

4000	CD

hyperthyroid	JJ

patients	NNS

treated	VBN

with	IN

iodine	NN

I-131	NN

at	IN

the	DT

center	NN

of	IN

Ancona	NNP

On	IN

socalled	JJ

nervous	JJ

exhaustion	NN

Examination	NN

of	IN

neonatal	JJ

archaic	JJ

(	NN

primitive	JJ

)	NN

reflexes	NNS

in	IN

icterus	NN

gravis	NN

Urologic	JJ

complications	NNS

in	IN

non-recurrent	JJ

cancer	NN

of	IN

the	DT

cervix	NN

Prolonged	JJ

cortisone	NN

therapy	NN

in	IN

treatment	NN

of	IN

allergic	JJ

diseases	NNS

The	DT

complexing	VBG

of	IN

calcium	NN

by	IN

citrate	NN

,	,

ortho-	JJ

and	CC

polyphosphates	NNS

A	DT

method	NN

of	IN

determining	VBG

the	DT

patency	NN

of	IN

the	DT

nasolacrimal	NN

apparatus	NN

Intra-arterial	JJ

infusion	NN

of	IN

the	DT

head	NN

and	CC

neck	NN

Anatomic	JJ

and	CC

distributional	JJ

problems	NNS

Lymphatics	NNS

of	IN

the	DT

mouth	NN

and	CC

neck	NN

Effect	NN

of	IN

sodium	NN

ions	NNS

on	IN

the	DT

behavior	NN

of	IN

rest	NN

and	CC

action	NN

potentials	NNS

of	IN

the	DT

cell	NN

membrane	NN

of	IN

the	DT

rat	NN

myometrium	NN

Studies	NNS

on	IN

contractile	NN

properties	NNS

of	IN

the	DT

blood	NN

serum	NN

Twin	JJ

pregnancy	NN

and	CC

fetal	JJ

and	CC

infantile	JJ

perinatal	JJ

mortality	NN

Fate	NNP

of	IN

the	DT

2d	NN

twin	NN

Differential	JJ

diagnosis	NN

of	IN

infectious	JJ

hepatitis	NN

in	IN

pregnancy	NN

Epithelial	JJ

metaplasia	NN

of	IN

the	DT

endometrium	NN

Leukoplakia	NN

of	IN

the	DT

vaginal	JJ

portion	NN

of	IN

the	DT

uterus	NN

and	CC

its	PRP$

clinical	JJ

evaluation	NN

Blood	NN

loss	NN

in	IN

artificial	JJ

interruption	NN

of	IN

pregnancy	NN

Modified	VBN

bra	NN

in	IN

the	DT

prevention	NN

of	IN

mastitis	NN

in	IN

nursing	NN

mothers	NNS

Hormonal	JJ

phenomenon	NN

after	IN

the	DT

excision	NN

of	IN

hydatiform	NN

mole	NN

Fetal	JJ

chondrodystrophy	NN

Malignant	JJ

mesodermal	JJ

mixed	JJ

tumor	NN

of	IN

the	DT

uterus	NN

following	VBG

irradiation	NN

Supportive	JJ

role	NN

of	IN

nurse	NN

in	IN

first	RB

stage	NN

of	IN

labor	NN

``	``

can	MD

not	RB

be	VB

emphasized	VBN

enough	RB

''	''

,	,

according	VBG

to	TO

patient	NN

Toxemia	NNP

of	IN

pregnancy	NN

Outpatient	NN

care	NN

--	:

the	DT

role	NN

of	IN

the	DT

nurse	NN

Abandonment	NNP

:	:

deepest	JJS

fear	NN

of	IN

hospitalized	VBN

children	NNS

Support	NN

in	IN

first	RB

stage	NN

of	IN

labor	NN

The	DT

family	NN

physician	NN

and	CC

cervical	JJ

carcinoma	NN

--	:

challenge	NN

and	CC

opportunity	NN

Purposeful	JJ

``	``

heroic	JJ

''	''

heart	NN

treatment	NN

Skilled	JJ

workers	NNS

are	VBP

vital	JJ

to	TO

maintenance	NN

cost	NN

cuts	NNS

Karen	NNP

:	:

the	DT

other	JJ

side	NN

of	IN

the	DT

picture	NN

Rhesus	NN

haemolytic	JJ

disease	NN

;	:

an	DT

approach	NN

to	TO

prevention	NN

Tumours	NNP

of	IN

the	DT

uterus	NN

2	CD

Malignancy	NN

Cancer	NN

of	IN

the	DT

vulva	NN

Effects	NNS

of	IN

smoking	NN

on	IN

selected	VBN

clinical	JJ

obstetric	NN

factors	NNS

Amniotic	JJ

fluid	NN

embolism	NN

A	DT

review	NN

of	IN

the	DT

syndrome	NN

with	IN

a	DT

report	NN

of	IN

4	CD

cases	NNS

Chronic	JJ

histiocytosis	NN

X	NN

associated	VBN

with	IN

pregnancy	NN

Disseminated	VBN

lupus	NN

erythematosus	NN

in	IN

pregnancy	NN

Intralesional	JJ

therapy	NN

with	IN

betamethasone	NN

Strucutre	NNP

of	IN

the	DT

influenza	NN

virus	NN

2	CD

students	NNS

at	IN

Quo	NN

Vadis	NNP

Double	JJ

aortic	JJ

arch	NN

associated	VBN

with	IN

tetralogy	NN

of	IN

Fallot	NNP

in	IN

infants	NNS

;	:

report	NN

of	IN

two	CD

cases	NNS

Tested	VBN

questionnaires	NNS

help	NN

administration	NN

learn	VB

if	IN

programs	NNS

are	VBP

a	DT

success	NN

,	,

and	CC

why	WRB

Dumping	VBG

syndrome	NN

following	VBG

pyloroplasty	NN

.	.

Measured	VBN

subtotal	JJ

gastrectomy	NN

for	IN

duodenal	JJ

ulcer	NN

The	DT

lesions	NNS

in	IN

bovine	JJ

udders	NNS

shedding	VBG

nonhemolytic	JJ

coagulase-negative	JJ

staphylococci	NNS

Repository	JJ

vitamin	NN

B	NN

12	CD

preparations	NNS

Mass	NNP

spectrometry	NN

in	IN

structural	JJ

and	CC

stereochemical	JJ

problems	NNS

93	CD

Further	RB

observations	NNS

on	IN

the	DT

importance	NN

of	IN

interatomic	JJ

distance	NN

in	IN

the	DT

McLafferty	NN

rearrangement	NN

Synthesis	NN

and	CC

fragmentation	NN

behavior	NN

of	IN

deuterium-labeled	JJ

12-keto	JJ

steroids	NNS

Treatment	NN

of	IN

childhood	NN

schizophrenia	NN

A	DT

three-year	JJ

comparison	NN

of	IN

day	NN

and	CC

residental	JJ

treatment	NN

Polycystic	JJ

ovaries	NNS

associated	VBN

with	IN

congenital	JJ

adrenal	JJ

hyperplasia	NN

Beta-propiolactone	NN

as	IN

used	VBN

in	IN

sterilization	NN

of	IN

homografts	NNS

not	RB

carcinogenic	JJ

for	IN

mice	NNS

New	NNP

operations	NNS

in	IN

children	NNS

's	POS

cardiac	JJ

disease	NN

Effect	NN

of	IN

diabetes	NN

and	CC

starvation	NN

on	IN

myocardial	JJ

triglyceride	NN

and	CC

free	JJ

fatty	NN

acid	NN

utilization	NN

Effect	NN

of	IN

epinephrine	NN

on	IN

myocardial	JJ

triglyceride	NN

and	CC

free	JJ

fatty	NN

acid	NN

utilization	NN

Diurnal	JJ

periodicity	NN

in	IN

the	DT

metabolic	JJ

activity	NN

of	IN

bone	NN

tissue	NN

Fine	NNP

structure	NN

of	IN

desmosomes	NNS

,	,

hemidesmosomes	NNS

,	,

and	CC

an	DT

adepidermal	JJ

globular	JJ

layer	NN

in	IN

developing	VBG

newt	NN

epidermis	NN

Redundant	JJ

myelin	JJ

sheaths	NNS

and	CC

other	JJ

ultrastructural	JJ

features	NNS

of	IN

the	DT

toad	NN

cerebellum	NN

A	DT

radioautographic	JJ

study	NN

with	IN

H3-thymidine	NN

on	IN

adrenal	JJ

medulla	NN

nuclei	NNS

of	IN

rats	NNS

intermittently	RB

exposed	VBN

to	TO

cold	JJ

A	DT

fine	NN

structural	JJ

analysis	NN

of	IN

the	DT

epidermis	NN

of	IN

the	DT

earthworm	NN

,	,

Lumbricus	NN

terrestris	NN

L.	NNP

Effect	NN

of	IN

thoracic	JJ

cava	NN

obstruction	NN

on	IN

response	NN

of	IN

proximal	JJ

tubule	NN

sodium	NN

reabsorption	NN

to	TO

saline	NN

infusion	NN

The	DT

metabolism	NN

of	IN

intravenously	RB

injected	VBN

isotopic	JJ

cholic	JJ

acid	NN

in	IN

Laennec	NNP

's	POS

cirrhosis	NN

The	DT

origin	NN

and	CC

glyceride	NN

distribution	NN

of	IN

fatty	NN

acids	NNS

in	IN

rat	NN

adipose	NN

tissue	NN

Absorption	NN

of	IN

medium	NN

and	CC

long	RB

chain	NN

triglycerides	NNS

:	:

factors	NNS

influencing	VBG

their	PRP$

hydrolysis	NN

and	CC

transport	NN

The	DT

effect	NN

of	IN

epinephrine	NN

on	IN

immunoreactive	JJ

insulin	NN

levels	NNS

in	IN

man	NN

The	DT

role	NN

of	IN

the	DT

liver	NN

in	IN

serum-induced	JJ

hypercoagulability	NN

Comparative	JJ

fates	NNS

of	IN

intravenously	RB

and	CC

orally	RB

administered	VBN

aldosterone	NN

:	:

evidence	NN

for	IN

extrahepatic	JJ

formation	NN

of	IN

acid-hydrolyzable	JJ

conjugate	NN

in	IN

man	NN

Binding	NN

of	IN

sulfobromophthalein	NN

(	NN

BSP	NN

)	NN

sodium	NN

by	IN

plasma	NN

albumin	NN

Its	PRP$

role	NN

in	IN

hepatic	JJ

BSP	NN

extraction	NN

The	DT

rationale	NN

of	IN

extended	VBN

resection	NN

for	IN

complicated	VBN

cancer	NN

of	IN

the	DT

large	JJ

bowel	NN

Etiology	NN

and	CC

incidence	NN

of	IN

renal	JJ

stones	NNS

Diagnosis	NN

of	IN

stone	NN

disease	NN

Medical	NNP

treatment	NN

of	IN

stone	NN

disease	NN

Surgical	NNP

treatment	NN

of	IN

urinary	JJ

stones	NNS

Prevention	NNP

of	IN

stone	NN

formation	NN

Urinary	JJ

calculi	NNS

Is	VBZ

the	DT

task	NN

hopeless	JJ

?	.

The	DT

family	NN

medicine	NN

program	NN

of	IN

the	DT

University	NNP

of	IN

Miami	NNP

Electron	NN

microscopic	JJ

studies	NNS

of	IN

Mycoplasma	NN

(	NN

PPLO	NN

strain	NN

880	CD

)	NN

in	IN

artificial	JJ

medium	NN

and	CC

in	IN

tissue	NN

culture	NN

Chemotherapeutic	JJ

effects	NNS

on	IN

mammalian	JJ

tumor	NN

cells	NNS

3	CD

Modification	NN

of	IN

leukemia	NN

L1210	NN

growth	NN

kinetics	NNS

with	IN

an	DT

antimetabolite	JJ

Comparison	NN

of	IN

the	DT

sensitivity	NN

of	IN

normal	JJ

hematopoietic	JJ

and	CC

transplanted	VBN

lymphoma	NN

colony-forming	JJ

cells	NNS

of	IN

mice	NNS

to	TO

vinblastine	NN

administered	VBN

in	IN

vivo	FW

Evidence	NN

for	IN

an	DT

immunological	JJ

reaction	NN

of	IN

the	DT

host	NN

directed	VBN

against	IN

its	PRP$

own	JJ

actively	RB

growing	VBG

primary	JJ

tumor	NN

Hyperbaric	JJ

oxygen	NN

,	,

whole-body	JJ

X	NN

irradiation	NN

,	,

and	CC

cyclophosphamide	NN

combination	NN

therapy	NN

in	IN

mouse	NN

leukemia	NN

L1210	NN

Clinical	JJ

staging	NN

in	IN

cancer	NN

of	IN

the	DT

larynx	NN

:	:

a	DT

report	NN

on	IN

788	CD

cases	NNS

using	VBG

the	DT

American	NNP

Joint	NNP

Committee	NNP

's	POS

method	NN

of	IN

stage	NN

classification	NN

Comparison	NN

of	IN

the	DT

international	JJ

and	CC

American	NNP

systems	NNS

for	IN

the	DT

staging	NN

of	IN

breast	NN

cancer	NN

Effects	NNS

of	IN

tryptophan	NN

mustard	NN

on	IN

incorporation	NN

of	IN

amino	NN

acids	NNS

into	IN

proteins	NNS

in	IN

tumor-bearing	JJ

rats	NNS

An	DT

electron	NN

microscope	NN

study	NN

of	IN

plant	NN

neoplasia	NN

induced	VBN

by	IN

wound	NN

tumor	NN

virus	NN

Possibilities	NNS

of	IN

surgical	JJ

correction	NN

of	IN

malformations	NNS

of	IN

the	DT

bones	NNS

of	IN

the	DT

foot	NN

The	DT

postprandial	JJ

period	NN

of	IN

the	DT

gastrectomized	VBN

patient	NN

Radiocinematographic	JJ

and	CC

clinical	JJ

correlation	NN

Muscle	NN

pathology	NN

;	:

contribution	NN

of	IN

experimentation	NN

Origin	NN

of	IN

milk	NN

cholesterol	NN

in	IN

the	DT

rat	NN

:	:

dietary	JJ

versus	CC

endogenous	JJ

sources	NNS

Comparative	JJ

effects	NNS

of	IN

two	CD

benzodiazepine	NN

compounds	NNS

on	IN

isolated	VBN

human	JJ

myometrium	NN

Histochemistry	NN

of	IN

hydrolytic	JJ

and	CC

oxidative	JJ

enzymes	NNS

in	IN

the	DT

human	JJ

and	CC

experimentally	RB

induced	VBN

adenocarcinoma	NN

of	IN

the	DT

endometrium	NN

Cardiac	JJ

monitors	NNS

work	NN

--	:

but	CC

they	PRP

should	MD

report	NN

more	RBR

than	IN

they	PRP

do	VB

Delivery	NN

room	NN

pediatrics	NNS

The	DT

responsibilities	NNS

of	IN

the	DT

obstetrician	NN

A	DT

pediatrician	NN

's	POS

checklist	NN

for	IN

adolescents	NNS

Community	NN

clinic	NN

treatment	NN

for	IN

back-ward	JJ

patients	NNS

Studies	NNS

in	IN

infantile	JJ

malnutrition	NN

V	NN

The	DT

effect	NN

of	IN

dietary	JJ

protein	NN

source	NN

on	IN

serum	NN

proteins	NNS

Fish	NN

protein	NN

concentrates	VBZ

in	IN

the	DT

treatment	NN

of	IN

kwashiorkor	NN

athyrism	NN

in	IN

the	DT

fetal	JJ

rat	NN

Evidence	NN

for	IN

impairment	NN

of	IN

elastin	NN

formation	NN

Familial	JJ

vitamin	NN

D	NN

resistant	JJ

rickets	NN

in	IN

untreated	JJ

adult	JJ

Bony	NNP

proliferation	NN

of	IN

neural	JJ

arches	NNS

with	IN

cord	NN

compression	NN

Amyloidosis	NNP

of	IN

the	DT

cornea	NN

Report	NNP

of	IN

a	DT

case	NN

without	IN

conjunctival	NN

involvement	NN

Effect	NN

of	IN

tranquilizing	VBG

drugs	NNS

on	IN

postnatal	JJ

behavior	NN

Fathers	NNS

in	IN

the	DT

delivery	NN

room	NN

--	:

an	DT

opposition	NN

standpoint	NN

Fathers	NNS

in	IN

the	DT

delivery	NN

--	:

''	''

helpful	JJ

and	CC

supportive	JJ

''	''

``	``

Return	NN

the	DT

joy	NN

of	IN

home	NN

delivery	NN

''	''

with	IN

fathers	NNS

in	IN

the	DT

delivery	NN

room	NN

Fathers	NNS

in	IN

the	DT

delivery	NN

room	NN

--	:

long	RB

experience	NN

molds	NNS

one	CD

viewpoint	NN

Doctors	NNS

--	:

we	PRP

need	NN

you	PRP

Pharmacological	JJ

blockade	NN

of	IN

ovulation	NN

in	IN

the	DT

ewe	NN

Some	DT

factors	NNS

affecting	VBG

the	DT

response	NN

of	IN

the	DT

immature	JJ

mouse	NN

to	TO

pregnant	JJ

mare	NN

serum	NN

gonadotrophin	NN

and	CC

human	JJ

chorionic	JJ

gonadotrophin	NN

The	DT

metabolism	NN

of	IN

cortisol	NN

by	IN

human	JJ

extra-hepatic	JJ

tissues	NNS

Aromatization	NN

of	IN

7-alpha-hydroxydehydroepiandrosterone	NN

and	CC

of	IN

its	PRP$

3-sulphate	NN

by	IN

ovarian	JJ

and	CC

placental	JJ

tissue	NN

cultures	NNS

Metabolic	JJ

and	CC

endocrine	NN

effects	NNS

of	IN

lysergic	JJ

acid	NN

diethylamide	NN

(	NN

LSD-25	CD

)	NN

on	IN

male	NN

rats	NNS

Mutation	NN

frequencies	NNS

detected	VBN

following	VBG

irradiation	NN

of	IN

virgin	JJ

and	CC

inseminated	VBN

Drosophila	FW

melanogaster	FW

females	NNS

Relationship	NN

of	IN

fractons	NNS

of	IN

soybeans	NNS

and	CC

a	DT

crystalline	JJ

soybean	NN

trypsin	NN

inhibitor	NN

to	TO

the	DT

effects	NNS

of	IN

feeding	VBG

unheated	JJ

soybean	NN

meal	NN

to	TO

chicks	NNS

Metabolism	NN

of	IN

polyunsaturated	JJ

fatty	NN

acids	NNS

and	CC

serum	NN

cholesterol	NN

levels	NNS

in	IN

the	DT

rat	NN

Comparison	NN

of	IN

neutral	JJ

fat	NN

and	CC

free	JJ

fatty	NN

acids	NNS

in	IN

high	JJ

lipid-low	NN

carbohydrate	NN

diets	NNS

for	IN

the	DT

growing	VBG

chicken	NN

An	DT

approach	NN

to	TO

quantitative	JJ

analysis	NN

of	IN

intrauterine	JJ

pressure	NN

data	NNS

Intracranial	JJ

teratomas	NNS

in	IN

fetal	JJ

life	NN

and	CC

infancy	NN

Twinning	VBG

in	IN

relation	NN

to	TO

birth	NN

weight	NN

,	,

mortality	NN

,	,

and	CC

congenital	JJ

anomalies	NNS

Breast	NN

engorgement	NN

and	CC

postpartum	NN

fever	NN

Evolution	NN

of	IN

a	DT

placenta	NN

circumvallata	NN

Sequential	JJ

estrogen-progestogen	NN

therapy	NN

in	IN

gynecology	NN

Ovarian	JJ

carcinoma	NN

The	DT

problems	NNS

of	IN

staging	NN

and	CC

grading	VBG

Oxytocin	NN

induction	NN

in	IN

pregnant	JJ

rabbits	NNS

,	,

with	IN

special	JJ

reference	NN

to	TO

the	DT

stillbirth	NN

rate	NN

Significance	NN

of	IN

a	DT

single	JJ

umbilical	JJ

artery	NN

Report	NNP

from	IN

the	DT

collaborative	JJ

study	NN

of	IN

cerebral	JJ

palsy	NN

Perforated	JJ

peptic	JJ

ulcer	NN

in	IN

pregnancy	NN

Poverty	NN

as	IN

an	DT

isolated	VBN

factor	NN

in	IN

relation	NN

to	TO

perinatal	JJ

asphyxia	NN

Perforation	NN

of	IN

the	DT

postpartum	NN

uterus	NN

with	IN

an	DT

intrauterine	JJ

contraceptive	NN

device	NN

Congenital	JJ

heart	NN

disease	NN

,	,

deaf-mutism	NN

and	CC

associated	VBN

somatic	JJ

malformations	NNS

occurring	VBG

in	IN

several	JJ

members	NNS

of	IN

one	CD

family	NN

Toward	IN

a	DT

community	NN

alcoholism	NN

program	NN

Cases	NNS

8	CD

and	CC

9	CD

Anesthesia	NNP

accidents	NNS

Gynaecological	JJ

pain	NN

Profileplasty	NNP

Hypertrophic	JJ

obstructive	JJ

cardiomyopathy	NN

Oral	JJ

contraceptives	NNS

,	,

thrombosis	NN

,	,

and	CC

cyclical	JJ

factors	NNS

affecting	VBG

veins	NNS

.	.

On	IN

the	DT

influence	NN

of	IN

cytostatic	JJ

agents	NNS

and	CC

immune	JJ

bodies	NNS

on	IN

choriocarcinoma	NN

cells	NNS

in	IN

tissue	NN

culture	NN

Fat	NNP

absorption	NN

:	:

a	DT

transport	NN

problem	NN

Corpora	NNP

lutea	NN

in	IN

proven	VBN

mules	NNS

Reconstructive	JJ

tubal	JJ

surgery	NN

Studies	NNS

on	IN

the	DT

natural	JJ

posterior	NN

pituitary	NN

hormones	NNS

II	NNP

On	IN

the	DT

official	NN

inspection	NN

of	IN

coal-tar	NN

dyes	NNS

in	IN

1969	CD

3	CD

Analysis	NN

of	IN

Cr	NN

,	,

Zn	NN

,	,

Fe	NNP

and	CC

Pb	NN

contaminants	NNS

in	IN

food	NN

coal-tar	NN

dyes	NNS

and	CC

their	PRP$

aluminium	NN

lakes	NNS

by	IN

atomic	JJ

absorption	NN

spectrophotometry	NN

Radiosterilization	NN

of	IN

medical	JJ

products	NNS

I	PRP

.	.

Effects	NNS

of	IN

radiation	NN

on	IN

physical	JJ

and	CC

chemical	NN

properties	NNS

of	IN

injection	NN

needles	NNS

Screening	VBG

tests	NNS

of	IN

microorganisms	NNS

for	IN

the	DT

microbial	JJ

transformation	NN

of	IN

griseophenone	NN

A	DT

,	,

N-methylcoclaurine	NN

and	CC

sparteine	NN

Gas	NN

chromatographic	JJ

studies	NNS

on	IN

organic	JJ

mercurials	NNS

Application	NN

of	IN

infra-red	JJ

absorption	NN

spectroscopy	NN

to	TO

examination	NN

of	IN

drugs	NNS

and	CC

their	PRP$

preparation	NN

XIX	NNP

Determination	NN

of	IN

silicone	NN

oil	NN

in	IN

disposable	JJ

plastic	NN

syringes	NNS

Observation	NN

of	IN

air	NN

pollution	NN

with	IN

the	DT

aid	NN

of	IN

continuous	JJ

analysers	NNS

3	CD

Correlation	NN

between	IN

the	DT

concentration	NN

of	IN

various	JJ

kinds	NNS

of	IN

pollutants	NNS

in	IN

atmosphere	NN

and	CC

wind	NN

direction	NN

and	CC

velocity	NN

at	IN

Kasumigaseki	NNP

,	,

central	JJ

district	NN

of	IN

Tokyo	NNP

Ultramicro-analysis	NN

of	IN

cyclohexylamine	NN

and	CC

low	JJ

fatty	NN

amines	NNS

by	IN

gas	NN

chromatography	NN

Some	DT

knowledges	NNS

on	IN

the	DT

potency	NN

of	IN

heparin	NN

fractions	NNS

obtained	VBN

by	IN

gel	NN

filtration	NN

On	IN

the	DT

peripheral	JJ

effects	NNS

of	IN

endotoxin	NN

and	CC

leucocyte	NN

pyrogen	NN

in	IN

rabbit	NN

A	DT

tentative	NN

draft	NN

of	IN

qualitative	JJ

test	NN

of	IN

fluoride	NN

for	IN

adoption	NN

to	TO

the	DT

general	JJ

tests	NNS

of	IN

eighth	JJ

revised	VBN

edition	NN

of	IN

the	DT

Pharmacopoeia	NNP

of	IN

Japan	NNP

Identification	NN

of	IN

tranquillizers	NNS

by	IN

thin-layer	JJ

chromatography	NN

Analysis	NN

of	IN

steroids	NNS

II	NNP

A	DT

note	NN

on	IN

the	DT

assay	NN

of	IN

corticoid	NN

preparations	NNS

by	IN

tetrazolium	NN

salt	NN

Analysis	NN

of	IN

steroids	NNS

3	CD

Colorimetric	NNP

assay	NN

of	IN

thiomesterone	NN

Studies	NNS

on	IN

the	DT

radioimmunoassay	NN

of	IN

insulin	NN

I	PRP

.	.

The	DT

production	NN

and	CC

detection	NN

of	IN

anti-insulin	JJ

serum	NN

and	CC

anti-guinea-pig	JJ

globulin	NN

rabbit	NN

serum	NN

Synthesis	NN

of	IN

lysergic	JJ

acid	NN

diethylamide	NN

(	NN

LSD	NN

)	NN

Studies	NNS

on	IN

the	DT

anti-microbial	JJ

activity	NN

of	IN

nonionic	JJ

and	CC

anionic	JJ

surfactants	NNS

On	IN

the	DT

National	NNP

Institute	NNP

of	IN

Hygienic	JJ

Sciences	NNPS

Standard	NNP

``	``

lysozyme	NN

standard	NN

''	''

On	IN

the	DT

examination	NN

of	IN

ginseng	NN

and	CC

powdered	JJ

ginseng	NN

in	IN

1969	CD

On	IN

the	DT

standardization	NN

of	IN

plastic	NN

suture	NN

Undergraduate	JJ

research	NN

assistants	NNS

in	IN

the	DT

Faculty	NN

of	IN

Medicine	NN

University	NNP

College	NNP

of	IN

Rhodesia	NNP

Congenital	JJ

aortic	JJ

stenosis	NN

Sodium	NN

in	IN

heart	NN

failure	NN

Potassium	NN

in	IN

heart	NN

failure	NN

Hydrogen	NN

ion	NN

equilibrium	NN

in	IN

heart	NN

failure	NN

Various	JJ

aspects	NNS

of	IN

water-salt	NN

metabolism	NN

in	IN

heart	NN

congestive	JJ

failure	NN

Clinical	JJ

physiopathology	NN

of	IN

the	DT

patency	NN

of	IN

the	DT

interatrial	JJ

septum	NN

Various	JJ

aspects	NNS

of	IN

diuresis	NN

in	IN

heart	NN

congestive	JJ

failure	NN

Changes	NNS

in	IN

the	DT

mechanism	NN

of	IN

renal	JJ

acidification	NN

in	IN

congestive	JJ

heart	NN

failure	NN

:	:

effects	NNS

of	IN

diuretic	JJ

treatment	NN

on	IN

the	DT

acid-base	NN

equilibrium	NN

Defects	NNS

of	IN

the	DT

interventricular	JJ

septum	NN

not	RB

associated	VBN

with	IN

other	JJ

malformations	NNS

Clinical	JJ

physiopathology	NN

of	IN

the	DT

patency	NN

of	IN

Botallo	NNP

's	POS

ductus	NN

arteriosus	NN

Clinical	JJ

physiopathology	NN

of	IN

congenital	JJ

cyanogenic	JJ

cardiopathies	NNS

Electronic	JJ

computers	NNS

in	IN

medical	JJ

education	NN

of	IN

the	DT

future	NN

Anesthesiology	NNP

and	CC

computers	NNS

Immediate	NNP

outcome	NN

and	CC

long-term	JJ

results	NNS

of	IN

108	CD

sphincterotomies	NNS

of	IN

Oddi	NNP

's	POS

sphincter	NN

of	IN

biliary	JJ

indication	NN

Neuraminic	JJ

acid-containing	JJ

oligosaccharides	NNS

of	IN

human	JJ

urine	NN

:	:

isolation	NN

and	CC

identification	NN

of	IN

di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine	NN

,	,

6-2-Nacetylneuraminyl-lactose	NN

,	,

6-2-N-acetylneuraminyl-N-acetyllactosamine	NN

and	CC

3-2-N-acetylneuraminyl-lactose	NN

Determination	NN

of	IN

serum	NN

oxytocinase	NN

(	NN

1-cystine-aminopeptidase	NN

)	NN

activity	NN

Intolerance	NN

to	TO

milk	NN

in	IN

ulcerative	JJ

colitis	NN

A	DT

preliminary	JJ

report	NN

Rhinitis	NN

in	IN

herds	NNS

with	IN

piglet	NN

influenza	NN

Research	NNP

on	IN

breeding	VBG

hygiene	NN

in	IN

pigs	NNS

and	CC

piglets	NNS

free	JJ

from	IN

epidemic	JJ

diseases	NNS

The	DT

stimulatory	JJ

effect	NN

of	IN

luteinizing	VBG

hormone	NN

on	IN

adenosine	NN

3	CD

'	''

,	,

5'-monophosphate	JJ

accumulation	NN

in	IN

corpus	NN

luteum	NN

slices	NNS

Electrolyte	NN

and	CC

acid-base	NN

balance	NN

in	IN

fetal	JJ

and	CC

maternal	JJ

blood	NN

An	DT

experimental	JJ

and	CC

a	DT

clinical	JJ

study	NN

Q	NNP

fever	NN

at	IN

a	DT

combined	VBN

meat	NN

and	CC

poultry	NN

abattoir	NN

Some	DT

functional	JJ

and	CC

morphological	JJ

alterations	NNS

occurring	VBG

during	IN

and	CC

after	IN

the	DT

adaptation	NN

of	IN

BHK	NNP

21	CD

clone	NN

13	CD

cells	NNS

to	TO

suspension	NN

culture	NN

Asbestos	NN

as	IN

an	DT

urban	JJ

air	NN

contaminant	NN

Gas	NN

permeability	NN

of	IN

plastic	NN

membranes	NNS

for	IN

artificial	JJ

lungs	NNS

Technoogy	NNP

,	,

automation	NN

and	CC

human	JJ

welfare	NN

A	DT

radium	NN

accident	NN

in	IN

a	DT

hospital	NN

High	JJ

energy	NN

roentgen	NN

ray	NN

contamination	NN

of	IN

the	DT

electron	NN

beam	NN

from	IN

a	DT

medical	JJ

betatron	NN

The	DT

genetically	RB

significant	JJ

dose	NN

from	IN

roentgen	NN

examinations	NNS

in	IN

Finland	NNP

in	IN

1963	CD

Differential	JJ

expression	NN

of	IN

fibroblast	NN

growth	NN

factor-2	NN

and	CC

receptor	NN

by	IN

glial	JJ

cells	NNS

in	IN

experimental	JJ

autoimmune	JJ

encephalomelitis	NN

(	NN

EAE	NNP

)	NN

Cesarean	NNP

deliveries	NNS

at	IN

a	DT

university	NN

hospital	NN

:	:

analysis	NN

of	IN

rates	NNS

and	CC

indications	NNS

Increase	NN

in	IN

ambient	JJ

temperature	NN

may	MD

explain	VB

decrease	NN

in	IN

amniotic	JJ

fluid	NN

index	NN

Early	RB

treatment	NN

of	IN

gestational	JJ

diabetes	NN

reduces	VBZ

the	DT

rate	NN

of	IN

fetal	JJ

macrosomia	NN

Antenatally	RB

detectable	JJ

markers	NNS

for	IN

the	DT

diagnosis	NN

of	IN

autosomally	RB

trisomic	JJ

fetuses	NNS

in	IN

at-risk	NN

pregnancies	NNS

The	DT

rate	NN

of	IN

severe	JJ

preeclampsia	NN

is	VBZ

increased	VBN

in	IN

triplet	NN

as	IN

compared	VBN

to	TO

twin	NN

gestations	NNS

Thermal	JJ

equipment	NN

usage	NN

patterns	NNS

in	IN

neonatal	JJ

intensive	JJ

care	NN

units	NNS

:	:

interunit	NN

variability	NN

and	CC

intraunit	NN

consistency	NN

Massive	JJ

fetomaternal	JJ

hemorrhage	NN

Perinatal	JJ

features	NNS

of	IN

omphalocele-exstrophy-imperforate	JJ

anus-spinal	JJ

defects	NNS

(	NN

OEIS	NNS

complex	NN

)	NN

associated	VBN

with	IN

large	JJ

meningomyeloceles	NNS

and	CC

severe	JJ

limb	NN

defects	NNS

Subchorial	JJ

hematoma	NN

:	:

a	DT

probable	JJ

cause	NN

of	IN

reversible	JJ

nonimmune	JJ

hydrops	NNS

fetalis	NN

Pregnancy	NN

in	IN

chronic	JJ

progressive	JJ

external	JJ

ophthalmoplegia	NN

:	:

a	DT

case	NN

report	NN

Effect	NN

of	IN

magnesium	NN

sulfate	NN

on	IN

the	DT

development	NN

of	IN

cystic	JJ

periventricular	JJ

leukomalacia	NN

in	IN

preterm	NN

infants	NNS

<	JJR

TO_SEE	NN

>	JJR

Repeated	VBN

courses	NNS

of	IN

steroids	NNS

in	IN

preterm	NN

membrane	NN

rupture	NN

do	VB

not	RB

increase	NN

the	DT

risk	NN

of	IN

histologic	JJ

chorioamnionitis	NN

Intrapartum	NNP

sonography	NN

of	IN

the	DT

lower	JJR

uterine	NN

segment	NN

in	IN

patients	NNS

with	IN

breech-presenting	NN

fetuses	NNS

Isolated	VBN

persistent	JJ

fetal	JJ

bradycardia	NN

in	IN

complete	JJ

A-V	NN

block	NN

:	:

a	DT

conservative	JJ

approach	NN

is	VBZ

appropriate	JJ

A	DT

case	NN

report	NN

and	CC

a	DT

review	NN

of	IN

the	DT

literature	NN

Spontaneous	JJ

rectus	NN

sheath	NN

hematoma	NN

during	IN

pregnancy	NN

mimicking	VBG

abruptio	NN

placenta	NN

Amnioinfusion	NNP

for	IN

prevention	NN

of	IN

pulmonary	JJ

hypoplasia	NN

in	IN

second-trimester	NN

rupture	NN

of	IN

membranes	NNS

Trauma	NN

and	CC

pregnancy	NN

Fetal	JJ

breathing	NN

movements	NNS

within	IN

24	CD

hours	NNS

of	IN

delivery	NN

in	IN

prematurity	NN

are	VBP

related	JJ

to	TO

histologic	JJ

and	CC

clinical	JJ

evidence	NN

of	IN

amnionitis	NN

Laerdal	NNP

infant	NN

resuscitators	NNS

are	VBP

unreliable	JJ

as	IN

free-flow	JJ

oxygen	NN

delivery	NN

devices	NNS

Laryngeal	NN

obstruction	NN

caused	VBN

by	IN

lingual	NN

thyroglossal	NN

duct	NN

cyst	NN

presenting	VBG

at	IN

birth	NN

Oligohydramnios	NNS

and	CC

the	DT

appropriately	RB

grown	VBN

fetus	NN

Ultrastructure	NN

of	IN

human	JJ

colostral	NN

cells	NNS

Dubowitz	NNP

assessment	NN

of	IN

gestational	JJ

age	NN

and	CC

agreement	NN

with	IN

prenatal	JJ

methods	NNS

Low	JJ

prenatal	JJ

weight	NN

gain	NN

among	IN

low-income	JJ

women	NNS

:	:

what	WDT

are	VBP

the	DT

risk	NN

factors	NNS

?	.

Depression	NN

after	IN

childbirth	NN

:	:

the	DT

views	NNS

of	IN

medical	JJ

students	NNS

and	CC

women	NNS

compared	VBN

Breastfeeding	VBG

and	CC

the	DT

use	NN

of	IN

pacifiers	NNS

Care	NNP

in	IN

normal	JJ

birth	NN

:	:

a	DT

practical	JJ

guide	NN

Technical	NNP

Working	VBG

Group	NNP

,	,

World	NNP

Health	NNP

Organization	NNP

Cesarean	NNP

sections	NNS

:	:

women	NNS

's	POS

choice	NN

for	IN

giving	VBG

birth	NN

?	.

Epidurals	NNS

and	CC

breastfeeding	VBG

Lamaze	NN

and	CC

Bradley	NNP

childbirth	NN

classes	NNS

Concerns	NNS

about	IN

the	DT

institutionalization	NN

of	IN

childbirth	NN

education	NN

Index	NN

to	TO

current	JJ

literature	NN

A	DT

randomized	VBN

trial	NN

of	IN

one-to-one	JJ

nurse	NN

support	NN

of	IN

women	NNS

in	IN

labor	NN

Commentary	NN

:	:

are	VBP

nurses	NNS

effective	JJ

providers	NNS

of	IN

labor	NN

support	NN

?	.

Should	MD

they	PRP

be	VB

?	.

Can	MD

they	PRP

be	VB

?	.

Women	NNS

's	POS

views	NNS

of	IN

different	JJ

models	NNS

of	IN

antenatal	JJ

care	NN

in	IN

Victoria	NNP

,	,

Australia	NNP

The	DT

effect	NN

of	IN

discharge	NN

pack	NN

formula	NN

and	CC

breast	NN

pumps	NNS

on	IN

breastfeeding	VBG

duration	NN

and	CC

choice	NN

of	IN

infant	NN

feeding	VBG

method	NN

Commentary	NN

:	:

discharge	NN

packs	NNS

:	:

how	WRB

much	RB

do	VB

they	PRP

matter	NN

?	.

Quality	JJ

framework	NN

for	IN

force	NN

plate	NN

testing	NN

Bone	NN

registration	NN

method	NN

for	IN

robot	NN

assisted	VBN

surgery	NN

:	:

pedicle	NN

screw	VB

insertion	NN

Parameter	NN

sensitivity	NN

of	IN

a	DT

mathematical	JJ

model	NN

of	IN

the	DT

anterior	JJ

cruciate	NN

ligament	NN

Simultaneous	JJ

measurement	NN

of	IN

stiffness	NN

and	CC

energy	NN

absorptive	JJ

properties	NNS

of	IN

articular	JJ

cartilage	NN

and	CC

subchondral	NN

trabecular	JJ

bone	NN

Estimation	NN

of	IN

loads	NNS

and	CC

stresses	NNS

in	IN

abdominal	JJ

muscles	NNS

during	IN

slow	JJ

lifts	NNS

Contralateral	JJ

modification	NN

of	IN

transitory	JJ

evoked	VBN

otoacoustic	JJ

emissions	NNS

Treatment	NN

of	IN

cavernous	JJ

hemangiomas	NNS

with	IN

the	DT

neodymium	NN

:	:

YAG	NN

laser	NN

Mucous	JJ

membrane	NN

melanomas	NNS

of	IN

the	DT

upper	JJ

aerodigestive	JJ

tract	NN

An	DT

analysis	NN

of	IN

34	CD

cases	NNS

Are	VBP

the	DT

products	NNS

of	IN

CD44	NN

exons	NNS

v5	NN

and	CC

v6	NN

markers	NNS

for	IN

metastasis	NN

of	IN

laryngeal	NN

carcinomas	NNS

?	.

Detection	NN

of	IN

differentially	RB

expressed	VBN

genes	NNS

in	IN

head-neck	NN

carcinomas	NNS

Tuberculosis	NN

of	IN

the	DT

parotid	NN

gland	NN

:	:

a	DT

rare	JJ

differential	JJ

diagnosis	NN

of	IN

parotid	NN

tumor	NN

A	DT

case	NN

of	IN

sarcoidosis	NN

of	IN

the	DT

mastoid	NN

Genomic	JJ

medicine	NN

Internet	NN

resources	NNS

for	IN

medical	JJ

genetics	NNS

Genetics	NNP

A	DT

piece	NN

of	IN

my	PRP$

mind	NN

A	DT

'normal	JJ

'	''

practice	NN

Predisposition	NN

genetic	JJ

testing	NN

for	IN

late-onset	NN

disorders	NNS

in	IN

adults	NNS

A	DT

position	NN

paper	NN

of	IN

the	DT

National	NNP

Society	NNP

of	IN

Genetic	JJ

Counselors	NNS

Scientists	NNS

revel	VB

in	IN

new	JJ

research	NN

tool	NN

:	:

an	DT

online	NN

index	NN

of	IN

cancer	NN

genes	NNS

Center	NNP

for	IN

genetic	JJ

research	NN

on	IN

scleroderma	NN

As	IN

discoveries	NNS

unfold	VB

,	,

a	DT

new	JJ

urgency	NN

to	TO

bring	VB

genetic	JJ

literacy	NN

to	TO

physicians	NNS

>	JJR

From	IN

the	DT

Centers	NNPS

for	IN

Disease	NN

Control	NN

and	CC

Prevention	NNP

Gonorrhea	NNP

among	IN

men	NNS

who	WP

have	VB

sex	NN

with	IN

men	NNS

--	:

selected	VBN

sexually	RB

transmitted	VBN

diseases	NNS

clinics	NNS

,	,

1993-1996	CD

>	JJR

From	IN

the	DT

Centers	NNPS

for	IN

Disease	NN

Control	NN

and	CC

Prevention	NNP

Chlamydia	NN

screening	NN

practices	NNS

of	IN

primary-care	JJ

providers	NNS

--	:

Wake	VB

County	NNP

,	,

North	NNP

Carolina	NNP

,	,

1996	CD

Social	NNP

ties	NNS

and	CC

susceptibility	NN

to	TO

the	DT

common	JJ

cold	JJ

Prevention	NNP

of	IN

bacterial	JJ

endocarditis	NN

:	:

American	NNP

Heart	NNP

Association	NNP

recommendations	NNS

Issues	NNS

regarding	VBG

antiretroviral	JJ

treatment	NN

for	IN

patients	NNS

with	IN

HIV-1	NN

infection	NN

Prescribing	VBG

protease	NN

inhibitors	NNS

for	IN

the	DT

homeless	NN

Treatment	NN

of	IN

verruca	NN

vulgaris	NN

with	IN

topical	JJ

cidofovir	NN

Complete	JJ

genomic	JJ

screen	NN

in	IN

late-onset	NN

familial	JJ

Alzheimer	NN

disease	NN

Evidence	NN

for	IN

a	DT

new	JJ

locus	NN

on	IN

chromosome	NN

12	CD

BRCA1	NN

sequence	NN

analysis	NN

in	IN

women	NNS

at	IN

high	JJ

risk	NN

for	IN

susceptibility	NN

mutations	NNS

Risk	NN

factor	NN

analysis	NN

and	CC

implications	NNS

for	IN

genetic	JJ

testing	NN

Characteristics	NNS

of	IN

prostate	NN

cancer	NN

in	IN

families	NNS

potentially	RB

linked	VBN

to	TO

the	DT

hereditary	JJ

prostate	NN

cancer	NN

1	CD

(	NN

HPC1	NN

)	NN

locus	NN

Chromosome	NN

19	CD

single-locus	NN

and	CC

multilocus	NN

haplotype	NN

associations	NNS

with	IN

multiple	JJ

sclerosis	NN

Evidence	NN

of	IN

a	DT

new	JJ

susceptibility	NN

locus	NN

in	IN

Caucasian	JJ

and	CC

Chinese	JJ

patients	NNS

Cancer	NN

incidence	NN

after	IN

retinoblastoma	NN

Radiation	NNP

dose	NN

and	CC

sarcoma	NN

risk	NN

Genetic	JJ

testing	NN

in	IN

hereditary	JJ

colorectal	JJ

cancer	NN

Molecular	JJ

neurogenetics	NNS

:	:

the	DT

genome	NN

is	VBZ

settling	VBG

the	DT

issue	NN

Family	NNP

history	NN

and	CC

genetic	JJ

risk	NN

factors	NNS

:	:

forward	RB

to	TO

the	DT

future	NN

Preparing	VBG

health	NN

professionals	NNS

for	IN

the	DT

genetic	JJ

revolution	NN

Preterm	NNP

premature	JJ

rupture	NN

of	IN

the	DT

membranes	NNS

associated	VBN

with	IN

recent	JJ

cocaine	NN

use	NN

Attitudes	NNS

toward	IN

health-care	NN

,	,

HIV	NN

infection	NN

,	,

and	CC

perinatal	JJ

transmission	NN

interventions	NNS

in	IN

a	DT

cohort	NN

of	IN

inner-city	NN

,	,

pregnant	JJ

women	NNS

Association	NNP

of	IN

parvovirus	NN

infection	NN

with	IN

isolated	VBN

fetal	JJ

effusions	NNS

Early	RB

and	CC

long-term	JJ

results	NNS

of	IN

rehabilitation	NN

of	IN

cochlear	NN

implant	VB

patients	NNS

)	NN

Principles	NNS

of	IN

signal	NN

detection	NN

in	IN

pharmacovigilance	NN

Homology	NN

modeling	NN

of	IN

adenylosuccinate	JJ

synthetase	NN

from	IN

Saccharomyces	FW

cerevisiae	FW

reveals	VBZ

a	DT

possible	JJ

binding	NN

region	NN

for	IN

single-stranded	JJ

ARS	NN

sequences	NNS

Deletion	NN

analysis	NN

of	IN

the	DT

p16/CDKN2	NN

gene	NN

in	IN

head	NN

and	CC

neck	NN

squamous	JJ

cell	NN

carcinoma	NN

using	VBG

quantitative	JJ

polymerase	NN

chain	NN

reaction	NN

method	NN

Ribosomal	JJ

S6	NN

kinase	NN

p90rsk	NN

and	CC

mRNA	NN

cap-binding	JJ

protein	NN

eIF4E	NN

phosphorylations	NNS

correlate	NN

with	IN

MAP	NN

kinase	NN

activation	NN

during	IN

meiotic	JJ

reinitiation	NN

of	IN

mouse	NN

oocytes	NNS

Hyaluronidase	NN

activity	NN

of	IN

macaque	JJ

sperm	NN

assessed	VBN

by	IN

an	DT

in	IN

vitro	NN

cumulus	NN

penetration	NN

assay	NN

The	DT

comparison	NN

of	IN

the	DT

responsiveness	NN

of	IN

human	JJ

isolated	VBN

internal	JJ

mammary	JJ

and	CC

gastroepiploic	JJ

arteries	NNS

to	TO

levcromakalim	NN

:	:

an	DT

alternative	NN

approach	NN

to	TO

the	DT

management	NN

of	IN

graft	NN

spasm	NN

Single-dose	JJ

pharmacokinetics	NNS

of	IN

felbamate	NN

in	IN

patients	NNS

with	IN

renal	JJ

dysfunction	NN

Reporting	NNP

of	IN

adverse	JJ

drug	NN

reactions	NNS

by	IN

hospital	NN

doctors	NNS

and	CC

the	DT

response	NN

to	TO

intervention	NN

Glutamate	NNP

receptors	NNS

and	CC

gene	NN

induction	NN

:	:

signalling	NN

from	IN

receptor	NN

to	TO

nucleus	NN

Role	NN

of	IN

phosphatidylinositol	NN

3-kinase	NN

in	IN

degranulation	NN

induced	VBN

by	IN

IgE-dependent	JJ

and	CC

-independent	JJ

mechanisms	NNS

in	IN

rat	NN

basophilic	JJ

RBL-2H3	NN

(	NN

ml	NN

)	NN

cells	NNS

Platelet-derived	JJ

growth	NN

factor	NN

activates	VBZ

a	DT

mammalian	JJ

Ste20	NN

coupled	VBN

mitogen-activated	JJ

protein	NN

kinase	NN

in	IN

airway	NN

smooth	NN

muscle	NN

Cyclic	JJ

AMP	NN

inhibitors	NNS

inhibits	VBZ

PDGF-stimulated	JJ

mitogen-activated	JJ

protein	NN

kinase	NN

activity	NN

in	IN

rat	NN

aortic	JJ

smooth	NN

muscle	NN

cells	NNS

via	IN

inactivation	NN

of	IN

c-Raf-1	NN

kinase	NN

and	CC

induction	NN

of	IN

MAP	NN

kinase	NN

phosphatase-1	NN

Mitochondrial	JJ

cytopathies	NNS

and	CC

renal	JJ

tubular	JJ

acidosis	NN

Elective	JJ

surgery	NN

for	IN

colorectal	JJ

cancer	NN

in	IN

the	DT

aged	JJ

:	:

a	DT

clinical-economical	JJ

evaluation	NN

Leukaemia	NN

and	CC

non-Hodgkin	JJ

's	POS

lymphoma	NN

in	IN

children	NNS

and	CC

young	JJ

adults	NNS

:	:

are	VBP

prenatal	JJ

and	CC

neonatal	JJ

factors	NNS

important	JJ

determinants	NNS

of	IN

disease	NN

?	.

Inverse	JJ

correlation	NN

between	IN

loss	NN

of	IN

heterozygosity	NN

of	IN

the	DT

short	RB

arm	NN

of	IN

chromosome	NN

12	CD

and	CC

p15ink4B/p16ink4	NN

gene	NN

inactivation	NN

in	IN

childhood	NN

acute	JJ

lymphoblastic	JJ

leukaemia	NN

Drug	NN

resistance	NN

markers	NNS

:	:

are	VBP

they	PRP

bad	JJ

or	CC

good	JJ

?	.

Elective	JJ

surgery	NN

for	IN

gastrointestinal	JJ

tumours	NNS

in	IN

the	DT

elderly	JJ

Folate	NNP

and	CC

heart	NN

disease	NN

:	:

theoretical	JJ

link	NN

needs	NNS

study	NN

.	.

A	DT

call	NN

for	IN

stepped-up	JJ

melanoma	NN

screening	NN

New	NNP

approaches	NNS

to	TO

stroke	NN

require	VB

immediate	JJ

action	NN

The	DT

focus	NN

is	VBZ

now	RB

on	IN

standards	NNS

and	CC

privacy	NN

in	IN

electronic	JJ

patient	NN

records	NNS

Osteopathic	JJ

manifesto	NN

I	PRP

.	.

Introduction	NN

II	NNP

The	DT

roots	NNS

1981	CD

Treatment	NN

uncertainties	NNS

surround	VB

early	RB

diagnosis	NN

of	IN

breast	NN

cancer	NN

Depression	NN

in	IN

the	DT

chronically	RB

ill	RB

needs	NNS

separate	JJ

treatment	NN

Medical	NNP

centers	NNS

tackle	VB

delays	NNS

,	,

reduce	VB

wait	NN

times	NNS

Epilepsy	NNP

and	CC

attention	NN

deficit	NN

hyperactivity	NN

disorder	NN

:	:

is	VBZ

methylphenidate	NN

safe	JJ

and	CC

effective	JJ

?	.

Applying	VBG

the	DT

AIDS	NN

paradigm	NN

to	TO

hepatitis	NN

New	NNP

asthma	NN

guidelines	NNS

emphasize	VB

better	RB

diagnosis	NN

,	,

stricter	JJR

control	NN

Osteopathic	JJ

manifesto	NN

IV	CD

The	DT

search	NN

1981	CD

Researchers	NNS

puzzle	NN

over	IN

origin	NN

of	IN

type	NN

2	CD

diabetes	NN

Ovarian	JJ

cancer	NN

:	:

diagnostic	JJ

limitations	NNS

,	,

treatment	NN

obstacles	NNS

Osteopathic	JJ

manifesto	NN

V	NN

Legislative	JJ

and	CC

legal	JJ

vigilance	NN

1981	CD

Osteopathic	JJ

manifesto	NN

VI	NNP

The	DT

light	NN

of	IN

the	DT

profession	NN

1981	CD

Electrophysiological	JJ

evidence	NN

on	IN

the	DT

time	NN

course	NN

of	IN

semantic	JJ

and	CC

phonological	JJ

processes	NNS

in	IN

speech	NN

production	NN

Effects	NNS

of	IN

alanine	NN

and	CC

glycine	NN

substitution	NN

for	IN

tryptophan	NN

on	IN

the	DT

heterogeneity	NN

of	IN

gramicidin	NN

A	DT

analogs	NNS

in	IN

micelles	NNS

Torsion-angle	JJ

molecular	JJ

dynamics	NNS

as	IN

a	DT

new	JJ

efficient	JJ

tool	NN

for	IN

NMR	NN

structure	NN

calculation	NN

Time-domain	NN

quanification	NN

of	IN

amplitude	NN

,	,

chemical	NN

shift	NN

,	,

apparent	JJ

relaxation	NN

time	NN

T2	NN

,	,

and	CC

phase	NN

by	IN

wavelet-transform	NN

analysis	NN

Application	NN

to	TO

biomedical	JJ

magnetic	JJ

resonance	NN

spectroscopy	NN

Investigation	NN

of	IN

uncertainties	NNS

in	IN

relaxation	NN

analysis	NN

of	IN

2D	NN

NOE	NNP

which	WDT

arise	VB

from	IN

spectral	JJ

noise	NN

An	DT

efficient	JJ

HN	NN

(	NN

CA	NNP

)	NN

NH	NNP

pluse	NN

scheme	NN

for	IN

triple-resonance	NN

4D	NN

correlation	NN

of	IN

sequential	JJ

amide	NN

protons	NNS

and	CC

nitrogens-15	NN

in	IN

deuterated	VBN

proteins	NNS

Optimal	JJ

detection	NN

of	IN

weak	JJ

nJ	NN

(	NN

1H-	CD

119Sn	NN

)	NN

couplings	NNS

by	IN

gradient-enhanced	JJ

1D	NN

and	CC

2D	NN

heteronuclear	NN

multiple-quantum	JJ

correlation	NN

spectroscopy	NN

Application	NN

to	TO

a	DT

novel	JJ

tin	NN

derivative	NN

of	IN

erythromycin	NN

A	DT

Thermoelectric	NNP

cooling	VBG

for	IN

NMR	NN

sample	NN

temperature	NN

control	NN

H2NCO-E.COSY	NN

,	,

a	DT

simple	JJ

method	NN

for	IN

the	DT

sterospecific	JJ

assignment	NN

of	IN

side-chain	NN

amide	NN

protons	NNS

in	IN

proteins	NNS

Applying	VBG

excitation	NN

sculpting	VBG

to	TO

construct	NN

singly	RB

and	CC

doubly	RB

selective	JJ

1D	NN

NMR	NN

experiments	NNS

Radiation	NNP

dosimetry	NN

by	IN

localized	JJ

magnetic	JJ

resonance	NN

spectroscopy	NN

The	DT

2D	NN

NMR	NN

experiments	NNS

H	NN

(	NN

C	NN

)	NN

CO2	NN

and	CC

HCCO2	NN

for	IN

assignment	NN

and	CC

pH	NN

titration	NN

of	IN

carboxylate	NN

groups	NNS

in	IN

uniformly	RB

15N/13C-labeled	JJ

proteins	NNS

Post-acquisition	NN

solvent	JJ

suppression	NN

by	IN

singular-value	JJ

decomposition	NN

Osteopathic	JJ

manifesto	NN

IX	CD

What	WDT

about	IN

our	PRP$

distinctiveness	NN

?	.

1981	CD

Preparing	VBG

for	IN

thalidomide	IN

's	POS

comeback	NN

Heart	NNP

disease	NN

:	:

women	NNS

's	POS

unique	JJ

risks	NNS

demand	NN

attention	NN

Resolution	NN

due	JJ

in	IN

medical	JJ

software	NN

regulation	NN

Osteopathic	JJ

manifesto	NN

VII	NN

Shadows	NNS

and	CC

images	NNS

1981	CD

The	DT

practical	JJ

use	NN

of	IN

PCR	NN

for	IN

rapid	JJ

detection	NN

of	IN

methicillin	NN

resistance	NN

among	IN

staphylococcal	NN

clinical	JJ

isolates	NNS

from	IN

Turkish	JJ

hospitals	NNS

Randomised	VBN

double-blind	JJ

trial	NN

of	IN

fixed	VBN

low-dose	JJ

warfarin	NN

with	IN

aspirin	NN

after	IN

myocardial	JJ

infarction	NN

Coumadin	NNP

Aspirin	NN

Reinfarction	NN

Study	NN

(	NN

CARS	NNS

)	NN

Investigators	NNS

Randomised	VBN

trial	NN

of	IN

roxithromycin	NN

in	IN

non-Q-wave	JJ

coronary	JJ

syndromes	NNS

:	:

ROXIS	NNS

Pilot	NN

Study	NN

ROXIS	NNS

Study	NN

Group	NNP

Association	NNP

between	IN

5-HT2A	NN

gene	NN

promoter	NN

polymorphism	NN

and	CC

anorexia	NN

nervosa	NN

Randomised	VBN

study	NN

of	IN

radical	NN

surgery	NN

versus	CC

radiotherapy	NN

for	IN

stage	NN

Ib-IIa	NN

cervical	JJ

cancer	NN

State	NN

regulation	NN

in	IN

a	DT

world	NN

of	IN

``	``

boundary-less	JJ

''	''

technology	NN

Screening	VBG

for	IN

Chlamydia	NN

trachomatis	NN

?	.

Physician-assisted	JJ

suicide	NN

in	IN

Oregon	NNP

Common	JJ

nutritional	JJ

issues	NNS

in	IN

pediatric	JJ

and	CC

adult	JJ

critical	JJ

care	NN

medicine	NN

A	DT

multifactorial	JJ

analysis	NN

of	IN

facial	JJ

nerve	NN

results	NNS

in	IN

surgery	NN

for	IN

cerebellopontine	NN

angle	NN

tumors	NNS

Osteopathic	JJ

manifesto	NN

VIII	CD

Our	PRP$

distinct	JJ

image	NN

1981	CD

Quality	JJ

in	IN

general	JJ

practice	NN

Winning	VBG

the	DT

war	NN

on	IN

cancer	NN

Clinical	JJ

problem-solving	JJ

--	:

where	WRB

did	VBD

good	JJ

old	JJ

clinical	JJ

diagnosis	NN

go	VB

?	.

The	DT

named	VBN

nurse	NN

:	:

patient	NN

and	CC

nurse	NN

expectations	NNS

Genetic	JJ

testing	NN

opens	VBZ

brave	VB

new	JJ

world	NN

Heterologous	JJ

vaccines	NNS

:	:

proponent	NN

sparks	VBZ

some	DT

interest	NN

Steps	NNS

still	RB

being	VBG

taken	VBN

to	TO

undo	VB

damage	NN

of	IN

``	``

America	NNP

's	POS

Nuremberg	NNP

''	''

Patient-centered	JJ

ethics	NNS

reclaiming	VBG

center	NN

stage	NN

Social	NNP

ties	NNS

and	CC

susceptibility	NN

to	TO

the	DT

common	JJ

cold	JJ

Connecting	VBG

peptide	NN

,	,

correcting	VBG

peptide	NN

?	.

Winning	VBG

health	NN

victories	NNS

with	IN

community	NN

commitment	NN

Telemedicine	NNP

gets	VBZ

a	DT

chance	NN

to	TO

prove	VB

itself	PRP

Additional	JJ

opinions	NNS

on	IN

the	DT

mortality	NN

of	IN

animal	NN

research	NN

Recurrent	JJ

strokes	NNS

in	IN

a	DT

34-year-old	JJ

man	NN

A	DT

plan	NN

for	IN

improving	VBG

outcomes	NNS

for	IN

patients	NNS

with	IN

chronic	JJ

renal	JJ

failure	NN

Scientific	NNP

evidence	NN

in	IN

family	NN

and	CC

community	NN

medicine	NN

Evidence	NN

that	IN

the	DT

expression	NN

of	IN

progesterone-induced	JJ

blocking	VBG

factor	NN

by	IN

maternal	JJ

T-lymphocytes	NNS

is	VBZ

positively	RB

correlated	VBD

with	IN

conception	NN

Another	DT

use	NN

of	IN

androgens	NNS

:	:

treatment	NN

of	IN

anemia	NN

of	IN

end-stage	NN

renal	JJ

disease	NN

Isotopic	JJ

evidence	NN

for	IN

extraterrestrial	JJ

non-racemic	JJ

amino	NN

acids	NNS

in	IN

the	DT

Murchison	NNP

meteorite	NN

The	DT

American	NNP

Medical	NNP

Association	NNP

Guidelines	NNS

for	IN

Adolescent	JJ

Preventive	JJ

Services	NNPS

Classification	NN

of	IN

malignant	JJ

lymphomas	NNS

:	:

the	DT

updated	VBN

Kiel	NNP

classification	NN

Rethink	VB

on	IN

screening	NN

for	IN

breast	NN

cancer	NN

Sports-related	JJ

ocular	JJ

injuries	NNS

Fruit	NNP

juice	NN

consumption	NN

The	DT

case	NN

of	IN

the	DT

missing	VBG

methylphenidate	NN

<	JJR

TO_SEE	NN

>	JJR

Intensive	JJ

insulin	NN

treatment	NN

after	IN

acute	JJ

myocardial	JJ

infarction	NN

in	IN

diabetes	NN

mellitus	NN

Intensive	JJ

insulin	NN

regimens	NNS

in	IN

primary	JJ

prevention	NN

should	MD

be	VB

assessed	VBN

GPs	NNS

'	''

perceptions	NNS

of	IN

tolerability	NN

of	IN

selective	JJ

serotonin	NN

reuptake	NN

inhibitors	NNS

and	CC

tricyclic	JJ

antidepressants	NNS

Research	NNP

into	IN

long	RB

term	NN

use	NN

is	VBZ

needed	VBN

Diagnosing	VBG

and	CC

managing	VBG

polymyalgia	NN

rheumatica	NN

and	CC

temporal	JJ

arteritis	NN

Sensitivity	NN

of	IN

temporal	JJ

artery	NN

biopsy	NN

varies	VBZ

with	IN

biopsy	NN

length	NN

and	CC

sectioning	NN

strategy	NN

Obstructive	JJ

sleep	NN

apnoea	NN

Authors	NNS

'	''

reply	NN

Impact	NN

of	IN

postmenopausal	JJ

hormone	NN

therapy	NN

on	IN

cardiovascular	JJ

events	NNS

and	CC

cancer	NN

.	.

Search	VB

for	IN

studies	NNS

was	VBD

limited	JJ

Treating	VBG

shoulder	NN

complaints	NNS

in	IN

general	JJ

practice	NN

Diagnostic	JJ

criteria	NNS

must	MD

be	VB

used	VBN

and	CC

therapeutic	JJ

regimens	NNS

standardised	VBN

Authorship	NN

System	NNP

acknowledging	VBG

roles	NNS

of	IN

contributors	NNS

is	VBZ

best	RB

Authorship	NN

New	NNP

authorship	NN

practices	NNS

are	VBP

needed	VBN

in	IN

developing	VBG

countries	NNS

Authorship	NN

Researchers	NNS

'	''

objective	NN

is	VBZ

to	TO

get	VB

the	DT

job	NN

done	VBN

Quality	JJ

and	CC

clinical	JJ

audit	NN

Transurethral	JJ

microwave	NN

thermotherapy	NN

Management	NN

of	IN

ileosigmoid	NN

knotting	VBG

Epitome	NNP

of	IN

myocarditis	NN

Producing	NNP

consistent	JJ

estimates	NNS

of	IN

the	DT

power	NN

spectral	JJ

density	NN

of	IN

NN	NNP

sequences	NNS

Environmental	NNP

tobacco	NN

smoke	NN

and	CC

coronary	JJ

heart	NN

disease	NN

Long-term	JJ

benefit	NN

of	IN

one	CD

thrombolytic	JJ

over	IN

another	DT

Coupling	NN

of	IN

hemodynamic	JJ

measurements	NNS

with	IN

oxygen	NN

during	IN

exercise	NN

does	VBZ

not	RB

improve	VB

risk	NN

stratification	NN

in	IN

patients	NNS

with	IN

heart	NN

failure	NN

Smoking	NN

--	:

good	JJ

or	CC

bad	JJ

for	IN

semen	NN

?	.

The	DT

pruning	NN

of	IN

Doctor	NN

McDonough	NNP

and	CC

the	DT

``	``

humanizing	VBG

''	''

of	IN

statistics	NNS

Violence	NN

Prevention	NNP

in	IN

the	DT

home	NN

health	NN

setting	VBG

Contempo	NNP

1997	CD

:	:

obstetrics	NNS

and	CC

gynecology	NN

Mortality	NN

and	CC

refusal	NN

of	IN

ICU	NN

admission	NN

Extracorporeal	NNP

photopheresis	NN

in	IN

S	NN

(	NN

c	NN

)	NN

zary	NN

syndrome	NN

Attacks	NNS

on	IN

tobacco	NN

industry	NN

Does	VBZ

blinding	VBG

of	IN

readers	NNS

affect	VB

results	NNS

of	IN

meta-analyses	NNS

?	.

Consumption	NN

of	IN

alcohol	NN

and	CC

mortality	NN

in	IN

Russia	NNP

Presenilin	NNP

polymorphisms	NNS

in	IN

Alzheimer	NN

's	POS

disease	NN

Autoimmune	NN

enteropathy	NN

in	IN

adults	NNS

Cyclosporiasis	NNP

and	CC

raspberries	NNS

Protean	JJ

agonists	NNS

Keys	NNP

to	TO

receptor	NN

active	JJ

states	NNS

?	.

Kinetic	JJ

models	NNS

of	IN

ion	NN

channels	NNS

Agonist	NN

efficacy	NN

and	CC

allosteric	JJ

models	NNS

of	IN

receptor	NN

action	NN

Receptor	NN

Classification	NN

:	:

The	DT

Integration	NN

of	IN

Operational	JJ

,	,

Structural	NNP

,	,

and	CC

Transductional	JJ

Information	NN

Conference	NN

proceedings	NNS

Verona	NNP

,	,

Italy	NNP

,	,

September	NNP

21-22	CD

,	,

1995	CD

Policies	NNS

for	IN

posting	VBG

biomedical	JJ

journal	NN

information	NN

on	IN

the	DT

Internet	NN

International	NNP

Committee	NNP

of	IN

Medical	NNP

Journal	NNP

Editors	NNS

Who	WP

understands	VBZ

the	DT

menopause	NN

?	.

Comparison	NN

of	IN

two	CD

methods	NNS

of	IN

screening	NN

for	IN

genital	JJ

chlamydial	JJ

infection	NN

in	IN

women	NNS

attending	VBG

in	IN

general	JJ

practice	NN

:	:

cross	NN

sectional	JJ

survey	NN

Antimicrobial	JJ

therapy	NN

in	IN

neutropenia	NN

M1/4llerian	NN

agenesis	NN

:	:

an	DT

update	VB

The	DT

US	NNP

attack	NN

on	IN

Cuba	NNP

's	POS

health	NN

Patient	NN

consent	NN

for	IN

publication	NN

and	CC

the	DT

health	NN

of	IN

the	DT

public	NN

Brain	NN

serotonin	NN

neurotoxicity	NN

and	CC

primary	JJ

pulmonary	JJ

hypertension	NN

from	IN

fenfluramine	NN

and	CC

dexfenfluramine	NN

Battling	VBG

HI	NN

on	IN

many	JJ

fronts	NNS

Medical	NNP

Injury	NNP

Compensation	NNP

Reform	NN

Act	NNP

:	:

good	JJ

or	CC

bad	JJ

?	.

Fever	NN

of	IN

unknown	JJ

origin	NN

Moxonidine	NN

for	IN

hypertension	NN

Researchers	NNS

make	VB

slow	JJ

headway	NN

in	IN

managing	VBG

dry	JJ

mouth	NN

A	DT

kinder	JJR

,	,

gentler	JJR

approach	NN

Putting	VBG

patients	NNS

first	RB

?	.

Managing	VBG

the	DT

anxious	JJ

and	CC

phobic	JJ

dental	JJ

patient	NN

Do	VB

it	PRP

or	CC

lose	VB

it	PRP

Assessment	NNP

of	IN

fetal	JJ

nuchal	JJ

translucency	NN

test	NN

for	IN

Down	NN

's	POS

syndrome	NN

Amiodarone	NNP

and	CC

thyroid	NN

function	NN

Chemotherapy	NN

with	IN

praziquantel	NN

has	VBZ

the	DT

potential	NN

to	TO

reduce	VB

the	DT

prevalence	NN

of	IN

Echinococcus	NN

multilocularis	NNS

in	IN

wild	JJ

foxes	NNS

(	NN

Vulpes	NNP

vulpes	NNS

)	NN

Death	NN

rates	NNS

from	IN

childhood	NN

leukaemia	NN

near	IN

nuclear	JJ

sites	NNS

Other	JJ

studies	NNS

showed	VBD

that	IN

radiation	NN

levels	NNS

in	IN

Newbury	NNP

area	NN

were	VBD

low	JJ

Haemoptysis	NNP

:	:

a	DT

rare	JJ

cause	NN

Human	JJ

papillomavirus	NN

types	NNS

52	CD

and	CC

58	CD

are	VBP

prevalent	JJ

in	IN

cervical	JJ

cancer	NN

from	IN

Chinese	JJ

women	NNS

Breastfeeding	VBG

after	IN

early	RB

discharge	NN

Malnutrition	NN

and	CC

microcephaly	NN

in	IN

Australian	JJ

aboriginal	NN

children	NNS

<	JJR

TO_SEE	NN

>	JJR

Probucol	NN

and	CC

multivitamins	NNS

in	IN

the	DT

prevention	NN

of	IN

restenosis	NN

after	IN

coronary	JJ

angioplasty	NN

Generalised	VBN

caseous	JJ

lymphadenitis	NN

Public	NNP

health	NN

approach	NN

to	TO

activated	VBN

protein	NN

C	NN

resistance	NN

assay	NN

Hormone	NN

replacement	NN

therapy	NN

Dose-volume	NN

histograms	NNS

can	MD

be	VB

interpreted	VBN

in	IN

different	JJ

ways	NNS

Addressing	VBG

needle-stick	NN

concerns	NNS

Cervical	JJ

cancer	NN

screening	NN

CyberCHEST	NN

An	DT

open	JJ

future	NN

Keeping	VBG

us	PRP

on	IN

our	PRP$

toes	NNS

!	.

Thalidomide	NNP

in	IN

oral	JJ

Crohn	NN

's	POS

disease	NN

refractory	JJ

to	TO

conventional	JJ

medical	JJ

treatment	NN

Mortality	NN

and	CC

length	NN

of	IN

stay	NN

in	IN

teaching	NN

vs	CC

nonteaching	VBG

hospitals	NNS

Early	RB

discharge	NN

of	IN

newborns	NNS

Patient	NN

consent	NN

for	IN

publication	NN

Flucticasone	NN

propionate	NN

is	VBZ

safe	JJ

in	IN

recommended	VBN

doses	NNS

Fetal	JJ

nuchal	JJ

translucency	NN

test	NN

for	IN

Down	NN

's	POS

syndrome	NN

Treatment	NN

of	IN

hypertension	NN

in	IN

elderly	JJ

patients	NNS

Meta-analyses	NNS

and	CC

large	JJ

randomized	VBN

,	,

controlled	VBN

trials	NNS

Low-fat	NN

diets	NNS

Ultrasonographic	JJ

evaluation	NN

of	IN

parathyroid	JJ

hyperplasia	NN

Misconceptions	NNS

about	IN

mosaicism	NN

Are	VBP

normal	JJ

hearing	NN

thresholds	NNS

a	DT

sufficient	JJ

condition	NN

for	IN

click-evoked	JJ

otoacoustic	JJ

emissions	NNS

?	.

Structure	NN

and	CC

in	IN

vitro	NN

substrate	NN

specificity	NN

of	IN

the	DT

murine	JJ

multidrug	JJ

resistance-associated	JJ

protein	NN

ATP-dependent	JJ

transport	NN

of	IN

lipophilic	JJ

cytotoxic	JJ

drugs	NNS

by	IN

membrane	NN

vesicles	NNS

prepared	JJ

from	IN

MRP-overexpressing	JJ

HL60/ADR	NN

cells	NNS

Cellular	JJ

and	CC

in	IN

vitro	NN

transport	NN

of	IN

glutathione	NN

conjugates	NNS

by	IN

MRP	NN

Dominant	JJ

negative	JJ

and	CC

cooperative	JJ

effects	NNS

of	IN

mutant	NN

forms	NNS

of	IN

prolactin	NN

receptor	NN

Effect	NN

of	IN

calcium	NN

and	CC

vitamin	NN

D	NN

supplementation	NN

on	IN

bone	NN

density	NN

in	IN

men	NNS

and	CC

women	NNS

65	CD

years	NNS

of	IN

age	NN

or	CC

older	JJR

Infection	NN

control	NN

and	CC

contaminated	VBN

waste	NN

disposal	NN

practices	NNS

in	IN

Southern	NNP

Sydney	NNP

Area	NN

Health	NNP

Service	NNP

Dental	JJ

Clinics	NNS

Vitamins	NNS

and	CC

minerals	NNS

:	:

efficacy	NN

and	CC

safety	NN

Joint	NNP

Commission	NNP

on	IN

Accreditation	NN

of	IN

Healthcare	NNP

Organizations	NNP

'	''

infection	NN

control	NN

requirements	NNS

:	:

fact	NN

or	CC

fiction	NN

?	.

Poppy	NNP

tea	NN

and	CC

the	DT

baker	NN

's	POS

first	RB

seizure	NN

ABC	NNP

of	IN

mental	JJ

health	NN

Mental	JJ

health	NN

and	CC

the	DT

law	NN

Female	JJ

embryonic	JJ

lethality	NN

in	IN

mice	NNS

nullizygous	JJ

for	IN

both	DT

Msh2	NN

and	CC

p53	NN

Tests	NNS

of	IN

the	DT

double-strand	NN

break	NN

,	,

lethal-potentially	RB

lethal	JJ

and	CC

repair-misrepair	NN

models	NNS

for	IN

mammalian	JJ

cell	NN

survival	NN

using	VBG

data	NNS

for	IN

survival	NN

as	IN

a	DT

function	NN

of	IN

delayed-plating	JJ

interval	NN

for	IN

log-phase	NN

Chinese	JJ

hamster	NN

V79	NN

cells	NNS

Influence	NN

of	IN

physician	NN

confidentiality	NN

assurances	NNS

on	IN

adolescents	NNS

'	''

willingness	NN

to	TO

disclose	VB

information	NN

and	CC

seek	VB

future	NN

health	NN

care	NN

A	DT

randomized	VBN

controlled	VBN

trial	NN

Fever	NN

in	IN

Africa	NNP

:	:

do	VB

patients	NNS

know	VB

when	WRB

they	PRP

are	VBP

hot	JJ

?	.

Randomised	VBN

placebo-controlled	JJ

trial	NN

of	IN

granulocyte-colony	JJ

stimulating	VBG

factor	NN

in	IN

diabetic	JJ

foot	NN

infection	NN

Systemic	JJ

absorption	NN

of	IN

sunscreen	NN

after	IN

topical	JJ

application	NN

A	DT

comparison	NN

of	IN

continuous	JJ

infusion	NN

of	IN

alteplase	RB

with	IN

double-bolus	JJ

administration	NN

for	IN

acute	JJ

myocardial	JJ

infarction	NN

The	DT

Continuous	JJ

Infusion	NN

versus	CC

Double-Bolus	JJ

Administration	NN

of	IN

Alteplase	RB

(	NN

COBALT	NNP

)	NN

Investigators	NNS

Evaluation	NN

and	CC

management	NN

of	IN

traumatic	JJ

lacerations	NNS

Atrial	NNP

fibrillation	NN

begets	VBZ

trouble	NN

Ethics	NNS

of	IN

HIV	NN

trials	NNS

The	DT

ethics	NNS

industry	NN

Fever	NN

in	IN

Africa	NNP

and	CC

WHO	WP

recommendation	NN

``	``

Whiplash	NN

''	''

injury	NN

of	IN

the	DT

cervical	JJ

spine	NN

:	:

value	NN

of	IN

modern	JJ

diagnostic	JJ

imaging	NN

Guidelines	NNS

and	CC

cardiac	JJ

anaesthetists	NNS

Antibiotic	JJ

management	NN

of	IN

sore	JJ

throat	NN

Lansoprazole	NN

,	,

H.	NNP

pylori	NN

,	,

and	CC

atrophic	JJ

gastritis	NN

.	.

Help	VB

wanted	VBD

:	:

ultrasonographers	NNS

``	``

Children	NNS

are	VBP

not	RB

supposed	VBN

to	TO

die	VB

''	''

Combined	VBN

pediatric	JJ

and	CC

radiation	NN

oncology	NN

grand	JJ

rounds	NNS

addresses	NNS

severe	JJ

illness	NN

and	CC

death	NN

Structure-activity	JJ

and	CC

mechanism	NN

studies	NNS

on	IN

silicon	NN

phthalocyanines	NNS

with	IN

Plasmodium	NN

falciparum	NN

in	IN

the	DT

dark	JJ

and	CC

under	IN

red	JJ

light	NN

The	DT

importance	NN

of	IN

being	VBG

where	WRB

?	.

Balancing	VBG

the	DT

perspective	NN

on	IN

practice	NN

coverage	NN

Effects	NNS

of	IN

dobutamine	NN

at	IN

maximally	RB

tolerated	VBN

dose	NN

on	IN

myocardial	JJ

blood	NN

flow	NN

in	IN

humans	NNS

with	IN

ischemic	JJ

heart	NN

disease	NN

.	.

Cholesterol-lowering	JJ

therapy	NN

Ion	NN

composition	NN

of	IN

airway	NN

surface	NN

liquid	NN

of	IN

patients	NNS

with	IN

cystic	JJ

fibrosis	NN

as	IN

compared	VBN

with	IN

normal	JJ

and	CC

disease-control	JJ

subjects	NNS

Research	NNP

in	IN

Copenhagen	NNP

hospitals	NNS

--	:

a	DT

bibliometric	JJ

evaluation	NN

More	RBR

on	IN

infertility	NN

Dermatobia	NNP

--	:

tropical	JJ

myiasis	NN

Progressive	JJ

sensorineural	NN

hearing	NN

loss	NN

,	,

subjective	JJ

tinnitus	NN

and	CC

vertigo	NN

caused	VBN

by	IN

elevated	JJ

blood	NN

lipids	NNS

Chronic	JJ

telogen	NN

effluvium	NN

:	:

potential	NN

complication	NN

for	IN

clinical	JJ

trials	NNS

in	IN

female	NN

androgenetic	JJ

alopecia	NN

?	.

<	JJR

TO_SEE	NN

>	JJR

Measles	NNP

vaccination	NN

and	CC

inflammatory	JJ

bowel	NN

disease	NN

Treatment	NN

of	IN

suicidal	JJ

patients	NNS

The	DT

systemic	JJ

amyloidoses	NNS

Cancer	NN

therapy	NN

and	CC

tumor	NN

physiology	NN

Mutual	JJ

relationships	NNS

based	VBN

on	IN

equality	NN

Specialists	NNS

and	CC

nurses	NNS

:	:

the	DT

pillars	NNS

of	IN

hospital	NN

care	NN

Disability	NN

models	NNS

in	IN

geriatrics	NNS

:	:

comprehensive	JJ

rather	RB

than	IN

competing	VBG

models	NNS

should	MD

be	VB

promoted	VBN

Ethical	JJ

issues	NNS

in	IN

interventional	JJ

radiology	NN

Taking	VBG

issue	NN

with	IN

UK	NNP

funding	NN

priorities	NNS

Phototherapeutic	JJ

keratectomy	NN

in	IN

recurrent	JJ

corneal	NN

erosions	NNS

refractory	JJ

to	TO

other	JJ

forms	NNS

of	IN

treatment	NN

Wegener	NNP

's	POS

granulomatosis	NN

from	IN

infancy	NN

to	TO

adolescence	NN

Hormonal	JJ

responses	NNS

to	TO

restraint	NN

in	IN

rhesus	NN

monkeys	NNS

Planned	NNP

parenthood	NN

and	CC

artifical	JJ

selection	NN

Valvular	JJ

heart	NN

disease	NN

associated	VBN

with	IN

fenfluramine-phentermine	NN

The	DT

role	NN

of	IN

procedures	NNS

in	IN

family	NN

practice	NN

:	:

is	VBZ

there	RB

a	DT

right	RB

answer	NN

?	.

Arthrodesis	FW

of	IN

the	DT

first	RB

metatarsophalangeal	NN

joint	NN

to	TO

salvage	NN

failed	VBD

silicone	NN

implant	VB

arthroplasty	NN

Methadone	NNP

maintenance	NN

treatment	NN

:	:

a	DT

Canadian	JJ

perspective	NN

Survey	NN

on	IN

rotavirus	NN

infections	NNS

in	IN

a	DT

German	JJ

pediatric	JJ

hospital	NN

Stroke	NN

incidence	NN

rates	NNS

among	IN

black	JJ

residents	NNS

of	IN

Harare	NNP

--	:

a	DT

prospective	JJ

community-based	JJ

study	NN

Long-term	JJ

effect	NN

of	IN

calcium	NN

supplementation	NN

during	IN

pregnancy	NN

on	IN

the	DT

blood	NN

pressure	NN

of	IN

offspring	NN

:	:

follow	VB

up	RB

of	IN

a	DT

randomised	VBN

controlled	VBN

trial	NN

The	DT

catalytic	JJ

role	NN

of	IN

carbon	NN

dioxide	NN

in	IN

the	DT

decomposition	NN

of	IN

peroxynitrite	NN

Unethical	JJ

trials	NNS

of	IN

interventions	NNS

to	TO

reduce	VB

perinatal	JJ

transmission	NN

of	IN

the	DT

human	JJ

immunodeficiency	NN

virus	NN

in	IN

developing	VBG

countries	NNS

Ropinirole	NNP

for	IN

the	DT

treatment	NN

of	IN

early	RB

Parkinson	NNP

's	POS

disease	NN

The	DT

Ropinirole	NNP

Study	NN

Group	NNP

DOTS	NNS

--	:

are	VBP

we	PRP

over-optimistic	JJ

?	.

Activation	NN

at	IN

the	DT

germinal	JJ

vesicle	NN

stage	NN

of	IN

starfish	NN

oocytes	NNS

produces	VBZ

parthenogenetic	JJ

development	NN

through	IN

the	DT

failure	NN

of	IN

polar	JJ

body	NN

extrusion	NN

Female	JJ

genital	JJ

mutilation	NN

:	:

a	DT

contemporary	JJ

issue	NN

,	,

and	CC

a	DT

Victorian	JJ

obsession	NN

Early	RB

death	NN

amongst	IN

anaesthetists	NNS

Fluoride	NN

treatment	NN

increased	VBN

serum	NN

IGF-1	NN

,	,

bone	NN

turnover	NN

,	,

and	CC

bone	NN

mass	NN

,	,

but	CC

not	RB

bone	NN

strength	NN

,	,

in	IN

rabbits	NNS

Retrospective	JJ

comparison	NN

of	IN

techniques	NNS

to	TO

prevent	VB

secondary	JJ

cataract	NN

formation	NN

after	IN

posterior	NN

chamber	NN

intraocular	JJ

lens	NN

implantation	NN

in	IN

infants	NNS

and	CC

children	NNS

Serotonin	NN

as	IN

a	DT

regulator	NN

of	IN

hypothalamic-pituitary-interrenal	JJ

activity	NN

in	IN

teleost	IN

fish	NN

Predicting	VBG

functional	JJ

appliance	NN

treatment	NN

outcome	NN

in	IN

Class	NN

II	NNP

malocclusions	NNS

--	:

a	DT

review	NN

Effect	NN

of	IN

cereal	NN

fibre	NN

source	NN

and	CC

processing	NN

on	IN

rectal	JJ

epithelial	JJ

cell	NN

proliferation	NN

Update	NNP

:	:

influenza	NN

activity	NN

--	:

worldwide	RB

,	,

March-August	NNP

1997	CD

A	DT

drop	NN

in	IN

pediatric	JJ

subject	NN

examination	NN

scores	NNS

after	IN

curriculum	NN

changes	NNS

that	IN

emphasize	VB

general	JJ

pediatric	JJ

topics	NNS

Paradigms	NNS

and	CC

the	DT

rise	NN

(	NN

or	CC

fall	NN

?	.

)	NN

of	IN

molecular	JJ

biology	NN

Water	NN

fluoridation	NN

,	,

tooth	NN

decay	NN

in	IN

5	CD

year	NN

olds	NNS

,	,

and	CC

social	JJ

deprivation	NN

measured	VBN

by	IN

the	DT

Jarman	NNP

score	NN

:	:

analysis	NN

of	IN

data	NNS

from	IN

British	JJ

dental	JJ

surveys	NNS

The	DT

diabetes	NN

audit	NN

and	CC

research	NN

in	IN

Tayside	NNP

Scotland	NNP

(	NN

DARTS	NN

)	NN

study	NN

:	:

electronic	JJ

record	NN

linkage	NN

to	TO

create	VB

a	DT

diabetes	NN

register	NN

DARTS/MEMO	NN

Collaboration	NN

Pharmaceutical	NNP

industry	NN

is	VBZ

invited	VBN

to	TO

respond	NN

to	TO

amnesty	NN

for	IN

unreported	JJ

trials	NNS

Should	MD

we	PRP

screen	NN

for	IN

gestational	JJ

diabetes	NN

?	.

Vesico-uterine	JJ

fistula	NN

--	:

a	DT

rare	JJ

complication	NN

of	IN

vacuum	NN

extraction	NN

in	IN

a	DT

patient	NN

with	IN

previous	JJ

caesarean	NN

section	NN

Managing	VBG

endophthalmitis	NN

The	DT

plug	NN

and	CC

patch	NN

repair	NN

for	IN

managing	VBG

the	DT

inguinal	JJ

hernia	NN

of	IN

the	DT

adult	JJ

Human	JJ

herpesvirus	NN

8	CD

variants	NNS

in	IN

sarcoid	NN

tissues	NNS

Practice	NN

parameters	NNS

for	IN

the	DT

assessment	NN

and	CC

treatment	NN

of	IN

children	NNS

and	CC

adolescents	NNS

with	IN

schizophrenia	NN

American	NNP

Academy	NNP

of	IN

Child	NN

and	CC

Adolescent	JJ

Psychiatry	NNP

Practice	NN

parameters	NNS

for	IN

the	DT

psychiatric	JJ

assessment	NN

of	IN

infants	NNS

and	CC

toddlers	NNS

(	NN

0-36	CD

months	NNS

)	NN

American	NNP

Academy	NNP

of	IN

Child	NN

and	CC

Adolescent	JJ

Psychiatry	NNP

Practice	NN

parameters	NNS

for	IN

the	DT

forensic	JJ

evaluation	NN

of	IN

children	NNS

and	CC

adolescents	NNS

who	WP

may	MD

have	VB

been	VBN

physically	RB

or	CC

sexually	RB

abused	JJ

American	NNP

Academy	NNP

of	IN

Child	NN

and	CC

Adolescent	JJ

Psychiatry	NNP

Practice	NN

parameters	NNS

for	IN

the	DT

psychiatric	JJ

assessment	NN

of	IN

children	NNS

and	CC

adolescents	NNS

American	NNP

Academy	NNP

of	IN

Child	NN

and	CC

Adolescent	JJ

Psychiatry	NNP

Alternative	NNP

medicine	NN

Leprosy	NNP

beyond	IN

the	DT

year	NN

2000	CD

Effect	NN

of	IN

danaparoid	JJ

sodium	NN

on	IN

hard	RB

exudates	NNS

in	IN

diabetic	JJ

retinopathy	NN

.	.

Lead	JJ

based	VBN

paint	NN

hazards	NNS

in	IN

early	RB

childhood	NN

centres	NNS

in	IN

the	DT

Wellington	NNP

region	NN

Gene	NN

technology	NN

and	CC

democracy	NN

Use	NN

of	IN

statins	NNS

Adequacy	NN

of	IN

SMAC	NN

's	POS

statement	NN

should	MD

be	VB

judged	VBN

by	IN

clinicians	NNS

,	,

not	RB

health	NN

economists	NNS

Glasgow	NNP

has	VBZ

already	RB

produced	VBN

strategy	NN

for	IN

treatment	NN

Evidence	NN

on	IN

effectiveness	NN

is	VBZ

stronger	JJR

for	IN

statins	NNS

than	IN

for	IN

other	JJ

treatments	NNS

Evidence	NN

based	VBN

advertising	NN

?	.

Half	NN

of	IN

drug	NN

advertisements	NNS

in	IN

BMJ	NNP

over	IN

six	CD

months	NNS

cited	VBN

no	DT

supporting	VBG

evidence	NN

Non-steroidal	JJ

anti-inflammatory	JJ

therapy	NN

for	IN

bronchial	JJ

asthma	NN

Drugs	NNS

for	IN

the	DT

Third	NNP

World	NNP

Getting	VBG

a	DT

handle	VB

on	IN

the	DT

molecules	NNS

that	IN

guide	NN

axons	NNS

The	DT

functional	JJ

neuroanatomy	NN

of	IN

episodic	JJ

memory	NN

retrieval	NN

Re	NNP

:	:

``	``

Biologic	JJ

synergism	NN

and	CC

parallelism	NN

''	''

Shifting	VBG

medical	JJ

education	NN

from	IN

the	DT

icebox	NN

to	TO

the	DT

refrigerator	NN

Reattendance	NN

and	CC

complications	NNS

in	IN

a	DT

randomised	VBN

trial	NN

of	IN

prescribing	VBG

strategies	NNS

for	IN

sore	JJ

throat	NN

:	:

the	DT

medicalising	VBG

effect	NN

of	IN

prescribing	VBG

antibiotics	NNS

Pure	JJ

alexia	IN

could	MD

not	RB

be	VB

a	DT

disconnection	NN

syndrome	NN

A	DT

randomized	VBN

,	,

double-blind	JJ

,	,

dose-response	NN

comparison	NN

of	IN

epidural	JJ

fentanyl	NN

versus	CC

sufentanil	NN

analgesia	NN

after	IN

cesarean	NN

section	NN

<	JJR

TO_SEE	NN

>	JJR

Coronary	JJ

artery	NN

problems	NNS

during	IN

homograft	NN

aortic	JJ

valve	NN

replacement	NN

:	:

role	NN

of	IN

transesophageal	NN

echocardiography	NN

Spontaneous	JJ

splenic	JJ

rupture	NN

following	VBG

administration	NN

of	IN

granulocyte	NN

colony-stimulating	JJ

factor	NN

(	NN

G-CSF	NN

)	NN

:	:

occurrence	NN

in	IN

an	DT

allogeneic	JJ

donor	NN

of	IN

peripheral	JJ

blood	NN

stem	NN

cells	NNS

Evidence-based	JJ

medicine	NN

and	CC

general	JJ

practice	NN

Koch	NNP

's	POS

or	CC

Crohn	NN

's	POS

?	.

Female	JJ

Stress	NN

Urinary	JJ

Incontinence	NN

Clinical	JJ

Guidelines	NNS

Panel	NN

summary	NN

report	NN

on	IN

surgical	JJ

management	NN

of	IN

female	NN

stress	NN

urinary	JJ

incontinence	NN

The	DT

American	NNP

Urological	JJ

Association	NNP

Haemodynamic	JJ

performance	NN

of	IN

a	DT

16-mm	NN

Carbomedics	NNS

aortic	JJ

prosthesis	NN

Case	NN

records	NNS

of	IN

the	DT

Massachusetts	NNP

General	NNP

Hospital	NN

Weekly	NNP

clinicopathological	JJ

exercises	NNS

Case	NN

30-1997	CD

A	DT

preterm	NN

newborn	JJ

female	NN

triplet	NN

with	IN

diffuse	NN

cystic	JJ

changes	NNS

in	IN

the	DT

left	RB

lung	NN

Cure	VB

of	IN

Helicobacter	NNP

pylori	NN

infection	NN

improves	VBZ

gastric	JJ

acid	NN

secretion	NN

in	IN

patients	NNS

with	IN

corpus	NN

gastritis	NN

<	JJR

TO_SEE	NN

>	JJR

Increased	VBN

incidence	NN

of	IN

preeclampsia	NN

in	IN

women	NNS

conceiving	VBG

by	IN

intrauterine	JJ

insemination	NN

with	IN

donor	NN

versus	CC

partner	NN

sperm	NN

for	IN

treatment	NN

of	IN

primary	JJ

infertility	NN

Pediatric	NNP

cervical	JJ

spine	NN

injury	NN

sustained	JJ

in	IN

falls	VBZ

from	IN

low	JJ

heights	NNS

Prophylaxis	NNP

after	IN

occupational	JJ

exposure	NN

to	TO

HIV	NN

How	WRB

critical	JJ

are	VBP

critical	JJ

values	NNS

?	.

Back	RB

from	IN

the	DT

dead	JJ

:	:

extracorporeal	JJ

rewarming	VBG

of	IN

severe	JJ

accidental	JJ

hypothermia	NN

victims	NNS

in	IN

accident	NN

and	CC

emergency	NN

A	DT

classification	NN

of	IN

nucleotide-diphospho-sugar	JJ

glycosyltransferases	NNS

based	VBN

on	IN

amino	NN

acid	NN

sequence	NN

similarities	NNS

EU	NNP

directive	NN

on	IN

bovine	JJ

spongiform	NN

encephalopathy	NN

will	MD

not	RB

affect	VB

drugs	NNS

Management	NN

of	IN

patients	NNS

with	IN

HIV/AIDS	NN

Who	WP

should	MD

care	NN

?	.

Anesthesiology	NNP

Second	JJ

of	IN

two	CD

parts	NNS

Overdrugging	VBG

and	CC

undertreatment	NN

in	IN

primary	JJ

health	NN

care	NN

Transesophageal	NN

echocardiography	NN

probe	NN

holder	NN

Pregnancy	NN

outcomes	NNS

in	IN

women	NNS

with	IN

gestational	JJ

diabetes	NN

compared	VBN

with	IN

the	DT

general	JJ

obstetric	NN

population	NN

Confidentiality	NN

as	IN

a	DT

barrier	NN

to	TO

treatment	NN

Recombinant	JJ

human	JJ

DNase	NN

(	NN

rhDNase	NN

)	NN

influences	NNS

phospholipid	NN

composition	NN

,	,

surface	NN

activity	NN

,	,

rheology	NN

and	CC

consecutively	RB

clearance	NN

indices	NNS

of	IN

cystic	JJ

fibrosis	NN

sputum	NN

Palliative	NN

options	NNS

of	IN

last	JJ

resort	NN

:	:

a	DT

comparison	NN

of	IN

voluntarily	RB

stopping	VBG

eating	VBG

and	CC

drinking	NN

,	,

terminal	JJ

sedation	NN

,	,

physician-assisted	JJ

suicide	NN

,	,

and	CC

voluntary	JJ

active	JJ

euthanasia	NN

Automation	NN

in	IN

cervical	JJ

cytology	NN

:	:

whose	WP$

cost	NN

and	CC

whose	WP$

benefit	NN

?	.

Losing	VBG

weight	NN

--	:

an	DT

ill-fated	JJ

New	NNP

Year	NN

's	POS

resolution	NN

Lumbar	NNP

puncture	NN

need	NN

n't	RB

be	VB

a	DT

headache	NN

Profiting	VBG

from	IN

closure	NN

:	:

the	DT

private	JJ

finance	NN

initiative	NN

and	CC

the	DT

NHS	NNS

Incidence	NN

of	IN

dog	NN

bite	VB

injuries	NNS

treated	VBN

in	IN

emergency	NN

departments	NNS

Use	NN

of	IN

rotational	JJ

movements	NNS

to	TO

remove	VB

mandibular	JJ

molars	NNS

Comparison	NN

of	IN

three	CD

methods	NNS

used	VBN

for	IN

assessment	NN

of	IN

pain	NN

in	IN

dogs	NNS

Randomised	VBN

controlled	VBN

trial	NN

of	IN

magnetic-resonance	NN

pelvimetry	NN

in	IN

breech	NN

presentation	NN

at	IN

term	NN

Single-breath	JJ

diffusing	VBG

capacities	NNS

for	IN

NO	NN

,	,

CO	NNP

and	CC

C18O2	NN

in	IN

rabbits	NNS

Improved	VBN

control	NN

will	MD

provide	VB

better	RB

quality	NN

Interview	NN

by	IN

Tom	NNP

Heinemann	NNP

Case	NN

of	IN

the	DT

month	NN

Autopsy	NN

Committee	NNP

of	IN

the	DT

College	NNP

of	IN

American	NNP

Pathologists	NNS

Cor	NNP

pulmonale	NN

Human	JJ

papillomavirus	NN

in	IN

the	DT

woman	NN

with	IN

HIV	NN

Reducing	VBG

risk	NN

is	VBZ

best	RB

strategy	NN

The	DT

realpolitik	NN

of	IN

a	DT

new	JJ

National	NNP

Health	NNP

Service	NNP

for	IN

the	DT

UK	NNP

What	WDT

is	VBZ

your	PRP$

diagnosis	NN

?	.

Foreign	NNP

body	NN

in	IN

the	DT

abdomen	NN

Septic	JJ

arthritis	NN

Brain	NN

tumours	NNS

and	CC

mobile	JJ

phones	NNS

?	.

Lung	NN

cancer	NN

,	,

tobacco	NN

smoking	NN

and	CC

environmental	JJ

factors	NNS

in	IN

Denmark	NNP

Emergency	NN

department	NN

use	NN

as	IN

a	DT

component	NN

of	IN

total	NN

ambulatory	JJ

care	NN

:	:

a	DT

population	NN

perspective	NN

Occupational	JJ

therapy	NN

and	CC

outcomes	NNS

for	IN

older	JJR

adults	NNS

Anesthesiology	NNP

Low-molecular-weight	JJ

heparins	NNS

Case	NN

30-1997	CD

:	:

pulmonary	JJ

interstitial	JJ

emphysema	NN

in	IN

infancy	NN

The	DT

tobacco	NN

settlement	NN

Two	CD

actions	NNS

are	VBP

possible	JJ

for	IN

doctors	NNS

wanting	VBG

to	TO

promote	VB

human	JJ

welfare	NN

in	IN

Africa	NNP

Carcinogenesis	NN

in	IN

transgenic	JJ

mouse	NN

models	NNS

Trouble	NN

in	IN

paradise	NN

Atomic	JJ

legacy	NN

in	IN

the	DT

Marshall	NNP

Islands	NNPS

The	DT

road	NN

to	TO

justice	NN

Solvent	JJ

solution	NN

Role	NN

of	IN

free	JJ

radicals	NNS

,	,

telomeres	NNS

,	,

and	CC

telomerases	NNS

in	IN

aging	VBG

and	CC

cancerogenesis	NN

The	DT

effect	NN

of	IN

ephedrine	NN

on	IN

the	DT

onset	NN

time	NN

of	IN

rocuronium	NN

Antibody	NN

class	NN

switch	NN

recombinase	NN

activity	NN

is	VBZ

B	NN

cell	NN

stage	NN

specific	JJ

and	CC

functions	NNS

stochastically	RB

in	IN

the	DT

absence	NN

of	IN

'targeted	VBN

accessibility	NN

'	''

control	NN

Systematic	JJ

review	NN

of	IN

prophylactic	NN

vs	CC

rescue	NN

surfactant	NN

The	DT

safety-net	NN

role	NN

of	IN

international	JJ

medical	JJ

graduates	NNS

The	DT

prevalence	NN

of	IN

chemical	NN

substance	NN

and	CC

alcohol	NN

abuse	NN

in	IN

an	DT

obstetric	NN

population	NN

in	IN

Dublin	NNP

schizophrenia	NN

as	IN

failure	NN

of	IN

hemispheric	JJ

dominance	NN

for	IN

language	NN

Late	RB

prenatal	JJ

ultrasound	NN

features	NNS

of	IN

hydrometrocolpos	NNS

secondary	JJ

to	TO

cloacal	JJ

anomaly	RB

:	:

case	NN

reports	NNS

and	CC

review	NN

of	IN

the	DT

literature	NN

Familial	JJ

and	CC

primary	JJ

(	NN

AL	NNP

)	NN

cardiac	JJ

amyloidosis	NN

:	:

echocardiographically	RB

similar	JJ

diseases	NNS

with	IN

distinctly	RB

different	JJ

clinical	JJ

outcomes	NNS

Diabetic	NNP

retinopathy	NN

,	,

promoter	NN

(	NN

4G/5G	NN

)	NN

polymorphism	NN

of	IN

PAI-1	NN

gene	NN

,	,

and	CC

PAI-1	NN

activity	NN

in	IN

Pima	NNP

Indians	NNPS

with	IN

type	NN

2	CD

diabetes	NN

Evaluation	NN

of	IN

diagnostic	JJ

peritoneal	NN

lavage	NN

in	IN

stable	JJ

patients	NNS

with	IN

gunshot	NN

wounds	NNS

to	TO

the	DT

abdomen	NN

Cerebral	JJ

abscesses	NNS

in	IN

a	DT

patient	NN

with	IN

AIDS	NN

caused	VBN

by	IN

methicillin-resistant	JJ

Staphylococcus	FW

aureus	NN

(	NN

MRSA	NNP

)	NN

A	DT

randomised	VBN

comparison	NN

of	IN

the	DT

EuroQol	NNP

and	CC

Short	JJ

Form-36	NN

after	IN

stroke	NN

United	NNP

Kingdom	NNP

collaborators	NNS

in	IN

the	DT

International	NNP

Stroke	NN

Trial	NN

Clinical	JJ

significance	NN

of	IN

Blastocystis	NNP

hominis	NNS

infection	NN

:	:

epidemiologic	JJ

study	NN

Karolinska	NNP

Institute	NNP

rocked	VBD

by	IN

research	NN

misconduct	NN

<	JJR

TO_SEE	NN

>	JJR

Hepatic	JJ

glutamine	NN

synthetase	NN

deficiency	NN

in	IN

fatal	JJ

hyperammonemia	NN

after	IN

lung	NN

transplantation	NN

Where	WRB

next	IN

in	IN

the	DT

treatment	NN

of	IN

rectal	JJ

cancer	NN

?	.

GAPS	NNS

(	NN

AMA	NNP

Guidelines	NNS

for	IN

Adolescent	JJ

Preventive	JJ

Services	NNPS

)	NN

Protocols	NNS

for	IN

wound	NN

management	NN

Chronic	JJ

leg	NN

ulcers	NNS

:	:

beware	NN

the	DT

'wolf	NN

in	IN

sheep	NN

's	POS

clothing	NN

!	.

'	''

.	.

Role	NN

of	IN

fine	NN

needle	NN

aspiration	NN

cytology	NN

in	IN

the	DT

management	NN

of	IN

the	DT

discrete	JJ

parotid	NN

lump	NN

More	RBR

than	IN

20	CD

years	NNS

second-look	NN

surgery	NN

in	IN

advanced	VBN

epithelial	JJ

ovarian	JJ

cancer	NN

:	:

what	WDT

did	VBD

we	PRP

learn	VB

?	.

Evaluating	VBG

prostate	NN

needle	NN

biopsy	NN

:	:

therapeutic	JJ

and	CC

prognostic	JJ

importance	NN

Sudden	JJ

cryptococcal	JJ

deafness	NN

Methicillin-resistant	JJ

Staphylococcus	FW

aureus	NN

clinical	JJ

strain	NN

with	IN

reduced	VBN

vancomycin	NN

susceptibility	NN

HIV	NN

and	CC

AIDS	NN

awareness	NN

:	:

an	DT

evaluation	NN

of	IN

a	DT

short	RB

training	NN

programme	NN

for	IN

midwives	NNS

What	WDT

investigations	NNS

and	CC

procedures	NNS

do	VB

patients	NNS

in	IN

hospices	NNS

want	VB

?	.

Interview	NN

based	VBN

survey	NN

of	IN

patients	NNS

and	CC

their	PRP$

nurses	NNS

Occupational	JJ

asthma	NN

due	JJ

to	TO

porcine	NN

pancreatic	JJ

amylase	NN

Double-blind	JJ

study	NN

of	IN

pulsing	VBG

magnetic	JJ

field	NN

effects	NNS

on	IN

multiple	JJ

sclerosis	NN

.	.

CDA	NNP

opposes	VBZ

proposed	VBN

HBV	NN

recommendations	NNS

The	DT

influence	NN

of	IN

allergy	NN

and	CC

smoking	NN

on	IN

the	DT

sulphation	NN

of	IN

nasal	JJ

mucins	NNS

Clinical	JJ

problem-solving	JJ

A	DT

hidden	VBN

agenda	NN

A	DT

comparison	NN

of	IN

the	DT

early	RB

outcome	NN

of	IN

acute	JJ

myocardial	JJ

infarction	NN

in	IN

women	NNS

and	CC

men	NNS

The	DT

Third	NNP

International	NNP

Study	NN

of	IN

Infarct	NNP

Survival	NN

Collaborative	JJ

Group	NNP

Management	NN

of	IN

life-threatening	JJ

acid-base	NN

disorders	NNS

Second	JJ

of	IN

two	CD

parts	NNS

<	JJR

TO_SEE	NN

>	JJR

Freeze-dried	JJ

cortical	JJ

allograft	NN

in	IN

posterior	NN

spinal	JJ

arthrodesis	NN

:	:

use	NN

with	IN

segmental	JJ

instrumentation	NN

for	IN

idiopathic	JJ

adolescent	JJ

scoliosis	NN

Removal	NN

of	IN

a	DT

broken	VBN

solid-core	NN

intramedullary	JJ

femoral	JJ

nail	NN

using	VBG

both	DT

antegrade	NN

and	CC

retrograde	NN

starting	VBG

points	NNS

Do	VB

no	DT

harm	NN

Thalidomide	NNP

,	,

laser	NN

cavity	NN

preparation	NN

and	CC

oral	JJ

hydrogen	NN

peroxide	NN

Emergency	NN

!	.

Meningococcal	JJ

disease	NN

First	NNP

the	DT

bad	JJ

news	NN

...	:

Does	VBZ

hyperglycemia	NN

really	RB

cause	NN

coronary	JJ

heart	NN

disease	NN

?	.

Diagnosis	NN

and	CC

therapy	NN

of	IN

primary	JJ

stomach	NN

lymphoma	NN

Consensus	NN

of	IN

the	DT

Surgical	NNP

Working	VBG

Group	NNP

for	IN

Oncology	NNP

,	,

the	DT

Working	VBG

Group	NNP

for	IN

Medical	NNP

Oncology	NNP

and	CC

the	DT

Working	VBG

Group	NNP

for	IN

Radiologic	JJ

Oncology	NNP

Rate	NN

of	IN

RhD	NN

sensitisation	NN

before	IN

and	CC

after	IN

implementation	NN

of	IN

a	DT

community	NN

based	VBN

antenatal	JJ

prophylaxis	NN

programme	NN

Ovine	NNP

Johne	NNP

's	POS

disease	NN

Effect	NN

of	IN

HAART	NNP

on	IN

natural	JJ

history	NN

of	IN

AIDS-related	JJ

opportunistic	JJ

disorders	NNS

Psoas	NNS

abscess	NN

Diagnosed	VBN

if	IN

suspected	VBN

Breastfeeding	VBG

and	CC

catch-up	NN

growth	NN

in	IN

infants	NNS

born	VBN

small	JJ

for	IN

gestational	JJ

age	NN

Health	NNP

practices	NNS

of	IN

critical	JJ

care	NN

nurses	NNS

:	:

are	VBP

these	DT

nurses	NNS

good	JJ

role	NN

models	NNS

for	IN

patients	NNS

?	.

Testing	VBG

for	IN

Helicobacter	NNP

pylori	NN

infection	NN

after	IN

antibiotic	JJ

treatment	NN

.	.

Bullous	JJ

eruption	NN

in	IN

a	DT

patient	NN

with	IN

systemic	JJ

lupus	NN

erythematosus	NN

:	:

mite	JJ

dermatitis	NN

caused	VBN

by	IN

Cheyletiella	NNP

blakei	FW

A	DT

case-control	JJ

study	NN

of	IN

cytochrome	NN

P450	NN

1A1	NN

,	,

glutathione	NN

S-transferase	NN

M1	NN

,	,

cigarette	NN

smoking	NN

and	CC

lung	NN

cancer	NN

susceptibility	NN

(	NN

Massachusetts	NNP

,	,

United	NNP

States	NNPS

)	NN

Association	NNP

between	IN

thrombolytic	JJ

treatment	NN

and	CC

the	DT

prognosis	NN

of	IN

hemodynamically	RB

stable	JJ

patients	NNS

with	IN

major	JJ

pulmonary	JJ

embolism	NN

:	:

results	NNS

of	IN

a	DT

multicenter	NN

registry	NN

.	.

Metastatic	JJ

malignant	JJ

mesothelioma	NN

presenting	VBG

as	IN

colonic	JJ

polyps	NNS

Microelectrode-guided	JJ

posteroventral	JJ

pallidotomy	NN

for	IN

treatment	NN

of	IN

Parkinson	NNP

's	POS

disease	NN

:	:

postoperative	JJ

magnetic	JJ

resonance	NN

imaging	NN

analysis	NN

A	DT

positive	JJ

cannabinoids	NNS

workplace	NN

drug	NN

test	NN

following	VBG

the	DT

ingestion	NN

of	IN

commercially	RB

available	JJ

hemp	NN

seed	NN

oil	NN

Congenital	JJ

diaphragmatic	NN

hernia	NN

:	:

what	WDT

happens	VBZ

after	IN

discharge	NN

?	.

Goldilocks	NNP

and	CC

Mrs	NNP

Ilych	NNP

:	:

a	DT

critical	JJ

look	NN

at	IN

the	DT

``	``

philosophy	NN

of	IN

hospice	NN

''	''

Sensitivity	NN

and	CC

specificity	NN

of	IN

the	DT

neonatal	JJ

brain-stem	NN

auditory	NN

evoked	VBN

potential	NN

for	IN

hearing	NN

and	CC

language	NN

deficits	NNS

in	IN

survivors	NNS

of	IN

extracorporeal	JJ

membrane	NN

oxygenation	NN

The	DT

Federated	NNP

Council	NNP

of	IN

Internal	JJ

Medicine	NN

's	POS

resource	NN

guide	NN

for	IN

residency	NN

education	NN

:	:

an	DT

instrument	NN

for	IN

curricular	JJ

change	NN

A	DT

reluctant	JJ

doctor	NN

shopper	NN

Frequent	JJ

users	NNS

of	IN

emergency	NN

services	NNS

Localized	JJ

Darier	NNP

disease	NN

Implications	NNS

for	IN

genetic	JJ

studies	NNS

Follow	VB

up	RB

after	IN

potential	NN

curative	JJ

surgery	NN

of	IN

colorectal	JJ

cancer	NN

Guidelines	NNS

from	IN

the	DT

Norwegian	JJ

Gastrointestinal	JJ

Cancer	NN

Group	NNP

The	DT

prison	NN

patient	NN

Fulminant	JJ

hepatic	JJ

failure	NN

in	IN

murine	JJ

hepatitis	NN

virus	NN

strain	NN

3	CD

infection	NN

:	:

tissue-specific	JJ

expression	NN

of	IN

a	DT

novel	JJ

fgl2	NN

prothrombinase	NN

Lung	NN

volume	NN

reduction	NN

surgery	NN

for	IN

emphysema	NN

The	DT

use	NN

and	CC

effects	NNS

of	IN

postcoital	JJ

contraception	NN

Vancomycin-resistant	JJ

Staphylococcus	FW

aureus	NN

:	:

apocalypse	NN

now	RB

?	.

Reflex	NN

sympathetic	JJ

dystrophy	NN

:	:

fact	NN

and	CC

fiction	NN

Acute	JJ

hydrocephalus	NN

and	CC

brain	NN

abscess	NN

in	IN

Listeria	NN

monocytogenes	NNS

meningitis	NN

Antisense	JJ

suppression	NN

of	IN

4-coumarate	JJ

:	:

coenzyme	NN

A	DT

ligase	NN

activity	NN

in	IN

Arabidopsis	NNP

leads	NNS

to	TO

altered	JJ

lignin	NN

subunit	NN

composition	NN

<	JJR

TO_SEE	NN

>	JJR

Alopecia	NNP

as	IN

a	DT

consequence	NN

of	IN

tacrolimus	NN

therapy	NN

in	IN

renal	JJ

transplantation	NN

?	.

Implementation	NN

of	IN

pharmaceutical	JJ

practice	NN

guidelines	NNS

In	IN

vitro	NN

interactions	NNS

of	IN

oxidatively	RB

modified	VBN

LDL	NN

with	IN

type	NN

I	PRP

,	,

II	NNP

,	,

III	NNP

,	,

IV	CD

,	,

and	CC

V	NN

collagen	NN

,	,

laminin	NN

,	,

fibronectin	NN

,	,

and	CC

poly-D-lysine	NN

Factors	NNS

influencing	VBG

blood	NN

flow	NN

in	IN

the	DT

optic	JJ

nerve	NN

head	NN

Mutations	NNS

of	IN

the	DT

Drosophila	FW

dDP	NN

,	,

dE2F	NN

,	,

and	CC

cyclin	NN

E	NN

genes	NNS

reveal	VB

distinct	JJ

roles	NNS

for	IN

the	DT

E2F-DP	NN

transcription	NN

factor	NN

and	CC

cyclin	NN

E	NN

during	IN

the	DT

G1-S	NN

transition	NN

SYT-SSX	NN

gene	NN

fusion	NN

as	IN

a	DT

determinant	NN

of	IN

morphology	NN

and	CC

prognosis	NN

in	IN

synovial	JJ

sarcoma	NN

A	DT

rapid	JJ

molecular	JJ

method	NN

(	NN

polymerase	NN

chain	NN

reaction	NN

with	IN

sequence-specific	JJ

primers	NNS

)	NN

to	TO

genotype	NN

for	IN

ABO	NN

blood	NN

group	NN

and	CC

secretor	NN

status	NN

and	CC

its	PRP$

potential	NN

for	IN

organ	NN

transplants	NNS

A	DT

population-based	JJ

registry	NN

on	IN

paraproteinaemia	NN

in	IN

The	DT

Netherlands	NNP

Comprehensive	NNP

Cancer	NN

Centre	NNP

West	NNP

,	,

Leiden	NNP

,	,

The	DT

Netherlands	NNP

Intra-	JJ

and	CC

inter-individual	JJ

biological	JJ

variability	NN

data	NNS

bank	NN

Genetic	JJ

testing	NN

for	IN

cancer	NN

risk	NN

:	:

how	WRB

to	TO

reconcile	VB

the	DT

conflicts	NNS

Run-in	NN

periods	NNS

in	IN

randomized	VBN

trials	NNS

:	:

implications	NNS

for	IN

the	DT

application	NN

of	IN

results	NNS

in	IN

clinical	JJ

practice	NN

Rapid	JJ

and	CC

ultrarapid	NN

opioid	NN

detoxification	NN

techniques	NNS

Fulminant	JJ

hepatitis	NN

associated	VBN

with	IN

hepatitis	NN

A	DT

virus	NN

superinfection	NN

in	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

The	DT

Overactive	JJ

Bladder	NN

:	:

From	IN

Basic	JJ

Science	NN

to	TO

Clinical	JJ

Management	NN

Consensus	NN

Conference	NN

Proceedings	NNP

London	NNP

,	,

England	NNP

,	,

June	NNP

29	CD

,	,

1997	CD

Techniques	NNS

for	IN

erbium	NN

:	:

YAG	NN

laser	NN

skin	NN

resurfacing	VBG

:	:

initial	JJ

pearls	NNS

from	IN

the	DT

first	RB

100	CD

patients	NNS

Predicting	VBG

changes	NNS

in	IN

the	DT

distribution	NN

of	IN

sweating	NN

following	VBG

thoracoscopic	JJ

sympathectomy	NN

.	.

The	DT

AACC	NN

Lectureship	NN

Award	NN

Address	NN

The	DT

market	NN

for	IN

health	NN

care	NN

:	:

where	WRB

is	VBZ

the	DT

patient	NN

?	.

Human	JJ

fetal	JJ

pituitary	NN

expresses	VBZ

functional	JJ

growth	NN

hormone-releasing	NN

peptide	NN

receptors	NNS

The	DT

Bizarro	NNP

world	NN

of	IN

osteodistraction	NN

A	DT

piece	NN

of	IN

my	PRP$

mind	NN

Leaders	NNS

or	CC

lemmings	NNS

?	.

Sales	NNS

of	IN

food	NN

aid	NN

as	IN

sign	NN

of	IN

distress	NN

,	,

not	RB

excess	NN

Gastrointestinal	JJ

absorption	NN

of	IN

metals	NNS

Embryonic	JJ

stem	NN

cells	NNS

and	CC

hematopoietic	JJ

stem	NN

cell	NN

biology	NN

Shark	NN

cartilage	NN

for	IN

cancer	NN

?	.

The	DT

role	NN

of	IN

the	DT

school	NN

in	IN

the	DT

management	NN

of	IN

attention	NN

deficit	NN

hyperactivity	NN

disorder	NN

Photorepair	NNP

mutants	NNS

of	IN

Arabidopsis	NNP

Toxic	JJ

shock	NN

syndrome	NN

without	IN

rash	NN

in	IN

a	DT

young	JJ

child	NN

:	:

link	NN

with	IN

syndrome	NN

of	IN

hemorrhagic	JJ

shock	NN

and	CC

encephalopathy	NN

?	.

Mediastinal	JJ

growing	VBG

teratoma	NN

syndrome	NN

Structure	NN

and	CC

expression	NN

of	IN

the	DT

chicken	NN

calmodulin	NN

I	PRP

gene	NN

Fibromyalgia	NNP

--	:

out	IN

of	IN

control	NN

?	.

Fibromyalgia	NNP

:	:

La	NNP

Maladie	NNP

est	IN

Morte	NNP

Vive	NNP

le	DT

Malade	NNP

!	.

Electron	NN

beam	NN

computed	VBN

tomographic	NN

coronary	JJ

calcium	NN

as	IN

a	DT

predictor	NN

of	IN

coronary	JJ

events	NNS

:	:

comparison	NN

of	IN

two	CD

protocols	NNS

The	DT

ethics	NNS

of	IN

genetic	JJ

research	NN

on	IN

sexual	JJ

orientation	NN

Testicular	JJ

sperm	NN

retrieval	NN

by	IN

percutaneous	JJ

fine	NN

needle	NN

sperm	NN

aspiration	NN

compared	VBN

with	IN

testicular	JJ

sperm	NN

extraction	NN

by	IN

open	JJ

biopsy	NN

in	IN

men	NNS

with	IN

non-obstructive	JJ

azoospermia	NN

Cyclin	NN

D1	NN

overexpression	NN

in	IN

malignant	JJ

lymphomas	NNS

Patient	NN

safety	NN

and	CC

scented	JJ

pediatric	JJ

anesthesia	NN

facemasks	NNS

Ion	NN

channels	NNS

SHARPs	NNS

:	:

mammalian	JJ

enhancer-of-split-	JJ

and	CC

hairy-related	JJ

proteins	NNS

coupled	VBN

to	TO

neuronal	JJ

stimulation	NN

Complementary	JJ

and	CC

alternative	NN

medicine	NN

:	:

friend	NN

,	,

foe	NN

,	,

or	CC

OWA	NNP

?	.

Ondansetron	NNP

is	VBZ

not	RB

a	DT

panacea	NN

Masking	VBG

,	,

blinding	VBG

,	,

and	CC

peer	VB

review	NN

:	:

the	DT

blind	JJ

leading	VBG

the	DT

blinded	VBN

Human	JJ

cervico-facial	JJ

morphogenesis	NN

Evaluation	NN

of	IN

acquired	VBN

data	NNS

and	CC

current	JJ

outlook	NN

(	NN

Part	NN

1	CD

:	:

facial	JJ

morphogenesis	NN

)	NN

The	DT

effect	NN

of	IN

TRK-530	NN

on	IN

experimental	JJ

arthritis	NN

in	IN

mice	NNS

Spontaneous	JJ

exfoliation	NN

of	IN

teeth	NNS

following	VBG

severe	JJ

elemental	JJ

mercury	NN

poisoning	NN

:	:

case	NN

report	NN

and	CC

histological	JJ

investigation	NN

for	IN

mechanism	NN

Small	JJ

cell	NN

lung	NN

cancer	NN

can	MD

express	VB

CD34	NN

antigen	NN

X	NN

inactivation	NN

in	IN

females	NNS

with	IN

X-linked	JJ

disease	NN

Report	NNP

of	IN

spores	NNS

of	IN

Henneguya	NN

salminicola	NN

(	NN

Myxozoa	NN

)	NN

in	IN

human	JJ

stool	NN

specimens	NNS

:	:

possible	JJ

source	NN

of	IN

confusion	NN

with	IN

human	JJ

spermatozoa	NN

Evaluation	NN

of	IN

a	DT

ventilation	NN

strategy	NN

to	TO

prevent	VB

barotrauma	NN

in	IN

patients	NNS

at	IN

high	JJ

risk	NN

for	IN

acute	JJ

respiratory	JJ

distress	NN

syndrome	NN

Pressure-	NN

and	CC

Volume-Limited	JJ

Ventilation	NN

Strategy	NN

Group	NNP

Audit	NNP

commission	NN

tackles	VBZ

anaesthetic	NN

services	NNS

Abdominal	JJ

tuberculosis	NN

involving	VBG

hepatic	JJ

hilar	JJ

lymph	NN

nodes	NNS

A	DT

cause	NN

of	IN

portal	NN

vein	NN

thrombosis	NN

and	CC

portal	NN

hypertension	NN

Treatment	NN

of	IN

men	NNS

with	IN

paraphilia	NN

with	IN

a	DT

long-acting	JJ

analogue	NN

of	IN

gonadotropin-releasing	NN

hormone	NN

Analgesic	JJ

nephropathy	NN

Translocations	NNS

of	IN

11q13	NN

in	IN

mantle	NN

cell	NN

lymphoma	NN

fail	VB

to	TO

disrupt	VB

the	DT

S	NN

mu	NN

bp-2	NN

gene	NN

Variation	NN

in	IN

proficiency	NN

testing	NN

performance	NN

by	IN

testing	NN

site	NN

The	DT

``	``

H	NN

''	''

graft	NN

:	:

an	DT

alternative	NN

approach	NN

for	IN

performing	VBG

minimally	RB

invasive	JJ

direct	JJ

coronary	JJ

artery	NN

bypass	NN

Effect	NN

of	IN

interferon	NN

on	IN

hepatitis	NN

B	NN

.	.

Health	NNP

insurance	NN

for	IN

children	NNS

--	:

a	DT

model	NN

for	IN

incremental	JJ

health	NN

reform	NN

?	.

Distinction	NN

awards	NNS

and	CC

racial	JJ

discrimination	NN

Potential	JJ

biases	NNS

were	VBD

not	RB

taken	VBN

into	IN

account	NN

in	IN

study	NN

of	IN

waiting	VBG

times	NNS

Factors	NNS

affecting	VBG

uptake	NN

of	IN

antenatal	JJ

HIV	NN

testing	NN

in	IN

London	NNP

:	:

results	NNS

of	IN

a	DT

multicentre	JJ

study	NN

Coronary	JJ

arterioluminal	JJ

communications	NNS

in	IN

routine	JJ

angiography	NN

Peptide	NN

nucleic	JJ

acid	NN

(	NN

PNA	NN

)	NN

from	IN

DNA	NN

recognition	NN

to	TO

antisense	JJ

and	CC

DNA	NN

structure	NN

Homeopathy	NNP

for	IN

postoperative	JJ

ileus	NN

?	.

A	DT

meta-analysis	NN

Treatment	NN

of	IN

postmenopausal	JJ

osteoporosis	NN

Fascioloidiasis	NN

in	IN

game-ranched	JJ

elk	NN

from	IN

Montana	NNP

Connexin-26	NN

mutations	NNS

in	IN

sporadic	JJ

non-syndromal	JJ

sensorineural	NN

deafness	NN

Lyme	NN

disease	NN

presenting	VBG

as	IN

Tourette	NNP

's	POS

syndrome	NN

The	DT

screening	NN

muddle	VB

Treatment	NN

of	IN

hypertensive	JJ

patients	NNS

with	IN

diabetes	NN

China	NNP

's	POS

human-organ	JJ

trade	NN

highlighted	VBN

by	IN

US	NNP

arrest	NN

of	IN

``	``

salesman	NN

''	''

Dimension	NN

in	IN

defining	VBG

tumor	NN

response	NN

Administration	NN

of	IN

dexamethasone	NN

induces	VBZ

proteinuria	NN

of	IN

glomerular	JJ

origin	NN

in	IN

mice	NNS

Preoperative	JJ

thromboxane	NN

A2/prostaglandin	NN

H2	NN

receptor	NN

activity	NN

predicts	VBZ

early	RB

graft	NN

thrombosis	NN

Hypertension	NN

treatment	NN

and	CC

control	NN

in	IN

sub-Saharan	JJ

Africa	NNP

:	:

the	DT

epidemiological	JJ

basis	NN

for	IN

policy	NN

Needle-exchange	NN

programmes	NNS

in	IN

the	DT

USA	NNP

A	DT

discriminant	JJ

function	NN

for	IN

preeclampsia	NN

:	:

case-control	JJ

study	NN

of	IN

minor	JJ

hemoglobins	NNS

,	,

red	JJ

cell	NN

enzymes	NNS

,	,

and	CC

clinical	JJ

laboratory	NN

values	NNS

Patterning	NN

of	IN

immobilized	VBN

antibody	NN

layers	NNS

via	IN

photolithography	NN

and	CC

oxygen	NN

plasma	NN

exposure	NN

A	DT

cell-based	JJ

immunobiosensor	NN

with	IN

engineered	VBN

molecular	JJ

recognition	NN

--	:

Part	NN

II	NNP

:	:

Enzyme	NN

amplification	NN

systems	NNS

Evanescent	JJ

wave	NN

fibre	NN

optic	JJ

sensor	NN

for	IN

detection	NN

of	IN

L.	NNP

donovani	NNS

specific	JJ

antibodies	NNS

in	IN

sera	NNS

of	IN

kala	NN

azar	IN

patients	NNS

Multianalyte	JJ

biosensors	NNS

on	IN

optical	JJ

imaging	NN

bundles	NNS

Specific	JJ

binding	NN

of	IN

low	JJ

molecular	JJ

weight	NN

ligands	NNS

with	IN

direct	JJ

optical	JJ

detection	NN

Amperometric	JJ

lactate	NN

oxidase	NN

catheter	NN

for	IN

real-time	JJ

lactate	NN

monitoring	VBG

based	VBN

on	IN

thin	JJ

film	NN

technology	NN

Dual-fractal	JJ

analysis	NN

for	IN

antigen	NN

--	:

antibody	NN

binding	NN

kinetics	NNS

for	IN

biosensor	NN

applications	NNS

Dipstick	NNP

only	RB

urinalysis	NN

screen	NN

for	IN

the	DT

pediatric	JJ

emergency	NN

room	NN

Cytoplasmic	JJ

transport	NN

in	IN

Drosophila	FW

ovarian	JJ

follicles	NNS

:	:

the	DT

migration	NN

of	IN

microinjected	VBN

fluorescent	JJ

probes	NNS

through	IN

intercellular	JJ

bridges	NNS

depends	VBZ

neither	DT

on	IN

electrical	JJ

charge	NN

nor	CC

on	IN

external	JJ

osmolarity	NN

Further	RB

evidence	NN

for	IN

the	DT

importance	NN

of	IN

an	DT

androgen	NN

response	NN

element	NN

in	IN

the	DT

factor	NN

IX	CD

promoter	NN

The	DT

obstetric	NN

experience	NN

of	IN

carriers	NNS

of	IN

haemophilia	NN

Acquired	VBN

haemophilia	NN

,	,

an	DT

unusual	JJ

cause	NN

of	IN

severe	JJ

postpartum	NN

haemorrhage	NN

Zoonotic	JJ

and	CC

viral	JJ

infection	NN

in	IN

fetal	JJ

loss	NN

after	IN

12	CD

weeks	NNS

High-affinity	JJ

binding	NN

of	IN

the	DT

neonatal	JJ

Fc	NN

receptor	NN

to	TO

its	PRP$

IgG	NN

ligand	NN

requires	VBZ

receptor	NN

immobilization	NN

Molecular	JJ

distances	NNS

from	IN

dipolar	NN

coupled	VBN

spin-labels	NNS

:	:

the	DT

global	JJ

analysis	NN

of	IN

multifrequency	NN

continuous	JJ

wave	NN

electron	NN

paramagnetic	JJ

resonance	NN

data	NNS

Computer	NN

science	NN

and	CC

biology	NN

--	:

the	DT

German	JJ

Conference	NN

on	IN

Bioinformatics	NNS

(	NN

GCB'96	NN

)	NN

Surface	NN

plasmon	NNS

resonance	NN

analysis	NN

of	IN

topoisomerase	NN

I-DNA	NN

binding	NN

:	:

effect	NN

of	IN

Mg2+	NN

and	CC

DNA	NN

sequence	NN

The	DT

1996	CD

list	NN

Proposed	VBN

new	JJ

bacterial	JJ

taxa	NN

and	CC

proposed	VBN

changes	NNS

of	IN

bacterial	JJ

names	NNS

published	VBN

during	IN

1996	CD

and	CC

considered	VBN

to	TO

be	VB

of	IN

interest	NN

to	TO

medical	JJ

or	CC

veterinary	JJ

bacteriology	NN

An	DT

informational	JJ

note	NN

The	DT

1995	CD

list	NN

Proposed	VBN

new	JJ

bacterial	JJ

taxa	NN

and	CC

proposed	VBN

changes	NNS

of	IN

bacterial	JJ

names	NNS

published	VBN

during	IN

1995	CD

and	CC

considered	VBN

to	TO

be	VB

of	IN

interest	NN

to	TO

medical	JJ

or	CC

veterinary	JJ

bacteriology	NN

An	DT

informational	JJ

note	NN

Biobehavioral	NNP

pain	NN

research	NN

:	:

a	DT

multi-institute	JJ

assessment	NN

of	IN

cross-cutting	NN

issues	NNS

and	CC

research	NN

needs	NNS

Use	NN

of	IN

surface	NN

plasmon	NNS

resonance	NN

to	TO

probe	NN

the	DT

equilibrium	NN

and	CC

dynamic	JJ

aspects	NNS

of	IN

interactions	NNS

between	IN

biological	JJ

macromolecules	NNS

ABC	NNP

of	IN

mental	JJ

health	NN

Psychosexual	JJ

problems	NNS

Hazards	NNS

of	IN

running	VBG

a	DT

marathon	NN

Troponin-T	NN

concentrations	NNS

should	MD

be	VB

measured	VBN

Second	JJ

Strang	NNP

International	NNP

Cancer	NN

Conference	NN

:	:

genetics	NNS

and	CC

the	DT

environment	NN

New	NNP

York	NNP

,	,

USA	NNP

,	,

15-16	CD

November	NNP

1996	CD

Use	NN

of	IN

a	DT

modified	VBN

version	NN

of	IN

the	DT

Overt	JJ

Aggression	NNP

Scale	NNP

in	IN

the	DT

measurement	NN

and	CC

assessment	NN

of	IN

aggressive	JJ

behaviours	NNS

following	VBG

brain	NN

injury	NN

Ectopic	JJ

pregnancy	NN

recurrence	NN

:	:

role	NN

of	IN

gynecologic	JJ

,	,

obstetric	NN

,	,

contraceptive	NN

and	CC

smoking	NN

history	NN

AIDS	NN

:	:

a	DT

world	NN

,	,

a	DT

desire	NN

Urogynaecology	NNP

proceedings	NNS

of	IN

the	DT

joint	NN

RCOG/BAUS	NN

urogynaecology	NN

meeting	NN

19	CD

September	NNP

1996	CD

The	DT

naming	VBG

of	IN

a	DT

syndrome	NN

The	DT

use	NN

of	IN

implantable	JJ

venous	JJ

access	NN

devices	NNS

(	NN

IVADs	NNS

)	NN

in	IN

children	NNS

with	IN

hemophilia	NN

Nephrotic	JJ

syndrome	NN

associated	VBN

with	IN

hypocomplementemia	NN

in	IN

a	DT

4-year-old	JJ

boy	NN

with	IN

hemophilia	NN

B	NN

Growth	NN

hormone	NN

secretion	NN

in	IN

HIV-positive	JJ

versus	CC

HIV-negative	JJ

hemophilic	JJ

males	NNS

with	IN

abnormal	JJ

growth	NN

and	CC

pubertal	JJ

development	NN

The	DT

Hemophilia	NNP

Growth	NN

and	CC

Development	NNP

Study	NN

Trends	NNS

in	IN

HIV	NN

counseling	NN

and	CC

testing	NN

of	IN

clients	NNS

attending	VBG

a	DT

public	NN

sexually	RB

transmitted	VBN

disease	NN

clinic	NN

in	IN

Portland	NNP

,	,

Oregon	NNP

,	,

1989-1995	CD

Risk	NN

factors	NNS

for	IN

HIV-1	NN

infection	NN

among	IN

pregnant	JJ

women	NNS

in	IN

French	JJ

Guiana	NNP

Angiogenesis	NN

in	IN

inflammatory	JJ

disease	NN

Epidemiology	NNP

and	CC

association	NN

with	IN

extra-gastrointestinal	JJ

diseases	NNS

Extra-gastrointestinal	JJ

diseases	NNS

and	CC

Helicobacter	NNP

pylori	NN

Update	NNP

on	IN

Helicobacter	NNP

pylori	NN

research	NN

Diagnosis	NN

Uptake	NN

on	IN

Helicobacter	NNP

pylori	NN

research	NN

Pathogenesis	NN

and	CC

host	NN

response	NN

Update	NNP

on	IN

Helicobacter	NNP

pylori	NN

research	NN

Malignancies	NNS

Update	NNP

on	IN

Helicobacter	NNP

pylori	NN

research	NN

Dyspepsia	NN

Update	NNP

on	IN

Helicobacter	NNP

pylori	NN

research	NN

Eradication	NN

Sequence	NN

analysis	NN

of	IN

the	DT

36-kb	JJ

region	NN

between	IN

gntZ	NN

and	CC

trnY	NN

genes	NNS

of	IN

Bacillus	NN

subtilis	NNS

genome	NN

A	DT

review	NN

of	IN

interferon	NN

immunogenicity	NN

Based	VBN

on	IN

a	DT

roundtable	NN

workshop	NN

held	VBN

in	IN

London	NNP

,	,

United	NNP

Kingdom	NNP

,	,

9	CD

February	NNP

1996	CD

Histologic	JJ

diagnosis	NN

of	IN

chronic	JJ

hepatitis	NN

,	,

grading	VBG

and	CC

staging	NN

Inositol	NN

treatment	NN

of	IN

autism	NN

Current	JJ

progress	NN

in	IN

early	RB

pregnancy	NN

investigation	NN

Truncated-gene	JJ

reporter	NN

system	NN

for	IN

studying	VBG

the	DT

regulation	NN

of	IN

manganese	NN

peroxidase	NN

expression	NN

Disparate	JJ

sequence	NN

characteristics	NNS

of	IN

the	DT

Erysiphe	NNP

graminis	NN

f.sp	NN

hordei	NN

glyceraldehyde-3-phosphate	NN

dehydrogenase	NN

gene	NN

The	DT

Integrative	JJ

Neurobiology	NNP

of	IN

Affiliation	NN

Proceedings	NNP

of	IN

a	DT

conference	NN

Washington	NNP

,	,

DC	NN

,	,

USA	NNP

March	NNP

14-17	CD

,	,

1996	CD

Proceedings	NNP

of	IN

the	DT

10th	JJ

International	NNP

Symposium	NNP

on	IN

the	DT

Pharmacology	NN

of	IN

Thermoregulation	NN

Memphis	NNP

,	,

Tennessee	NNP

,	,

USA	NNP

August	NNP

17-22	CD

,	,

1996	CD

Neuropeptides	NNS

in	IN

Development	NNP

and	CC

Aging	NN

Proceedings	NNP

of	IN

a	DT

conference	NN

Breckenridge	NNP

,	,

Colorado	NNP

,	,

USA	NNP

February	NNP

3-6	CD

,	,

1996	CD

Receptor	NN

Classification	NN

:	:

The	DT

Integration	NN

of	IN

Operational	JJ

,	,

Structural	NNP

,	,

and	CC

Transductional	JJ

Information	NN

Proceedings	NNP

of	IN

a	DT

conference	NN

Verona	NNP

,	,

Italy	NNP

,	,

September	NNP

21-22	CD

,	,

1995	CD

Psychobiology	NN

of	IN

Postraumatic	JJ

Stress	NN

Disorder	NN

Proceedings	NNP

of	IN

a	DT

conference	NN

New	NNP

York	NNP

,	,

New	NNP

York	NNP

,	,

USA	NNP

September	NNP

7-10	CD

,	,

1996	CD

Adolescent	JJ

Gynecology	NNP

and	CC

Endocrinology	NNP

:	:

Basic	JJ

and	CC

Clinical	JJ

Aspects	NNS

Proceedings	NNP

of	IN

the	DT

3rd	JJ

International	NNP

Congress	NNP

Athens	NNP

,	,

Greece	NNP

,	,

December	NNP

6-9	CD

,	,

1995	CD

Proceedings	NNP

of	IN

the	DT

3rd	JJ

International	NNP

Conference	NN

on	IN

Neuroprotective	JJ

Agents	NNS

:	:

Clinical	JJ

and	CC

Experimental	JJ

Aspects	NNS

Lake	NNP

Como	NNP

,	,

Italy	NNP

,	,

September	NNP

9-12	CD

,	,

1996	CD

Exon/intron	NN

structure	NN

of	IN

the	DT

human	JJ

AF-4	NN

gene	NN

,	,

a	DT

member	NN

of	IN

the	DT

AF-4/LAF-4/FMR-2	NN

gene	NN

family	NN

coding	VBG

for	IN

a	DT

nuclear	JJ

protein	NN

with	IN

structural	JJ

alterations	NNS

in	IN

acute	JJ

leukaemia	NN

Cloning	NN

and	CC

characterization	NN

of	IN

a	DT

neural	JJ

cell	NN

recognition	NN

molecule	NN

on	IN

axons	NNS

of	IN

the	DT

retinotectal	JJ

system	NN

and	CC

spinal	JJ

cord	NN

Identification	NN

,	,

localization	NN

,	,

and	CC

expression	NN

of	IN

two	CD

novel	JJ

human	JJ

genes	NNS

similar	JJ

to	TO

deoxyribonuclease	NN

I	PRP

.	.

Drug	NN

resistance	NN

during	IN

indinavir	NN

therapy	NN

is	VBZ

caused	VBN

by	IN

mutations	NNS

in	IN

the	DT

protease	NN

gene	NN

and	CC

in	IN

its	PRP$

Gag	NN

substrate	NN

cleavage	NN

sites	NNS

A	DT

protein	NN

with	IN

a	DT

novel	JJ

calcium-binding	JJ

domain	NN

associated	VBN

with	IN

calcareous	JJ

corpuscles	NNS

in	IN

Echinococcus	NN

granulosus	NN

Oncogenic	JJ

raf-1	NN

induces	VBZ

the	DT

expression	NN

of	IN

non-histone	JJ

chromosomal	JJ

architectural	JJ

protein	NN

HMGI-C	NN

via	IN

a	DT

p44/p42	NN

mitogen-activated	JJ

protein	NN

kinase-dependent	JJ

pathway	NN

in	IN

salivary	JJ

epithelial	JJ

cells	NNS

Pendred	NNP

syndrome	NN

is	VBZ

caused	VBN

by	IN

mutations	NNS

in	IN

a	DT

putative	JJ

sulphate	NN

transporter	NN

gene	NN

(	NN

PDS	NN

)	NN

Meis2	NN

,	,

a	DT

novel	JJ

mouse	NN

Pbx-related	JJ

homeobox	NN

gene	NN

induced	VBN

by	IN

retinoic	JJ

acid	NN

during	IN

differentiation	NN

of	IN

P19	NN

embryonal	JJ

carcinoma	NN

cells	NNS

Proceedings	NNP

of	IN

the	DT

VIIIth	NN

International	NNP

Conference	NN

on	IN

the	DT

Na/K-ATPase	NN

and	CC

Related	VBN

Transport	NN

ATPases	NNS

Mar	NNP

del	DT

Plata	NNP

,	,

Argentina	NNP

,	,

August	NNP

26-30	CD

,	,

1996	CD

Targeted	VBN

development	NN

of	IN

microsatellite	NN

markers	NNS

from	IN

the	DT

defined	VBN

region	NN

of	IN

bovine	JJ

chromosome	NN

6q21-31	NN

Genetic	JJ

population	NN

structure	NN

in	IN

the	DT

yellow	JJ

mongoose	NN

,	,

Cynictis	NNP

penicillata	NN

ETTIN	NN

patterns	NNS

the	DT

Arabidopsis	NNP

floral	JJ

meristem	NN

and	CC

reproductive	JJ

organs	NNS

Ancient	JJ

DNA	NN

from	IN

amber	NN

fossil	NN

bees	NNS

?	.

The	DT

histone	NN

H1	NN

genes	NNS

of	IN

the	DT

dipteran	NN

insect	NN

,	,

Chironomus	NNP

thummi	IN

,	,

fall	NN

under	IN

two	CD

divergent	JJ

classes	NNS

and	CC

encode	VBP

proteins	NNS

with	IN

distinct	JJ

intranuclear	JJ

distribution	NN

and	CC

potentially	RB

different	JJ

functions	NNS

Characterization	NN

of	IN

the	DT

orf31-petG	NN

gene	NN

cluster	NN

from	IN

the	DT

plastid	NN

genome	NN

of	IN

Populus	NN

deltoides	NNS

Xenopus	NN

Pax-2	NN

displays	NNS

multiple	JJ

splice	NN

forms	NNS

during	IN

embryogenesis	NN

and	CC

pronephric	JJ

kidney	NN

development	NN

International	NNP

Workshop	NNP

on	IN

Bone	NN

Research	NNP

in	IN

Space	NN

Tokyo	NNP

,	,

Japan	NNP

,	,

November	NNP

11-13	CD

,	,

1996	CD

Proceedings	NNP

Joint	NNP

meeting	NN

of	IN

the	DT

Benelux	NNP

Society	NNP

for	IN

Microcirculation	NN

and	CC

the	DT

Gesellschaft	NN

f1/4r	NN

Mikrozirkulation	NN

e.V	NN

Mainz	NNP

,	,

Germany	NNP

,	,

October	NNP

23-25	CD

,	,

1997	CD

Abstracts	NNS

3rd	JJ

Congress	NNP

of	IN

the	DT

French	JJ

Society	NNP

of	IN

Blood	NN

Transfusion	NN

Marseille	NNP

,	,

France	NNP

,	,

28-30	CD

April	NNP

1998	CD

Central	NNP

and	CC

East	NNP

European	JJ

Regional	NNP

INTERASMA	NN

Conference	NN

Budapest	NNP

,	,

Hungary	NNP

,	,

August	NNP

24-27	CD

,	,

1997	CD

Summary	NN

of	IN

symposium	NN

,	,

antisense	JJ

oligonucleotides	NNS

:	:

strategies	NNS

and	CC

successes	NNS

Sarasota	NNP

,	,

Florida	NNP

,	,

USA	NNP

April	NNP

21	CD

,	,

1995	CD

International	NNP

forensic	JJ

science	NN

and	CC

justice	NN

Proceedings	NNP

of	IN

the	DT

6th	JJ

Congress	NNP

of	IN

the	DT

Soci	NN

(	NN

c	NN

)	NN

t	NN

(	NN

c	NN

)	NN

de	IN

Pharmaco-Toxicologie	NN

Cellulaire	NNP

and	CC

the	DT

Soci	NN

(	NN

c	NN

)	NN

t	NN

(	NN

c	NN

)	NN

Franaise	NN

de	IN

Toxicologie	NN

G	NN

(	NN

c	NN

)	NN

n	NN

(	NN

c	NN

)	NN

tique	NN

Paris	NNP

,	,

France	NNP

,	,

March	NNP

6-7	CD

,	,

1997	CD

The	DT

Italian	JJ

Association	NNP

for	IN

the	DT

Study	NN

of	IN

Glaucoma	FW

Proceedings	NNP

of	IN

the	DT

12th	JJ

annual	JJ

general	JJ

meeting	NN

Rapallo	NNP

,	,

Italy	NNP

,	,

14-15	CD

March	NNP

1997	CD

Report	NNP

of	IN

the	DT

61st	IN

National	NNP

Scientific	NNP

Meeting	VBG

of	IN

the	DT

American	NNP

College	NNP

of	IN

Rheumatology	NNP

,	,

Washington	NNP

DC	NN

,	,

8-12	CD

November	NNP

1997	CD

Topical	JJ

dictionary	NN

USAN	NNP

Council	NNP

List	NN

No	DT

404	CD

New	NNP

names	NNS

Nagrestipen	NN

Proposed	VBN

genetic	JJ

nomenclature	NN

rules	NNS

for	IN

Tetrahymena	NNP

thermophila	NN

,	,

Paramecium	NN

primaurelia	NN

and	CC

Paramecium	NN

tetraurelia	NN

The	DT

Seventh	NNP

International	NNP

Meeting	VBG

on	IN

Ciliate	NNP

Molecular	JJ

Biology	NN

Genetics	NNP

Nomenclature	NNP

Joint	NNP

annual	JJ

session	NN

of	IN

the	DT

North	NNP

German	JJ

Society	NNP

of	IN

Radiology	NNP

and	CC

the	DT

Radiology	NNP

Society	NNP

of	IN

Lower	JJR

Saxony	NNP

and	CC

Sachsen	NNP

Anhalt	NNP

Kiel	NNP

,	,

20-21	NN

February	NNP

1998	CD

Abstracts	NNS

Neurone	NN

development	NN

and	CC

death	NN

,	,

from	IN

a	DT

cell	NN

biologist	NN

's	POS

perspective	NN

3rd	JJ

Neurotrauma/Polytrauma	NN

Symposium	NNP

Cologne	NNP

,	,

Germany	NNP

,	,

March	NNP

14-15	CD

,	,

1998	CD

Abstracts	NNS

Neuroimmunomodulation	NN

:	:

Molecular	JJ

Aspects	NNS

,	,

Integrative	JJ

Systems	NNPS

,	,

and	CC

Clinical	JJ

Advances	NNS

Proceedings	NNP

of	IN

the	DT

3rd	JJ

Congress	NNP

of	IN

the	DT

International	NNP

Society	NNP

of	IN

NeuroImmunoModulation	NN

(	NN

ISNIM	NNP

)	NN

Bethesda	NNP

,	,

Maryland	NNP

,	,

USA	NNP

November	NNP

13-15	CD

,	,

1996	CD

8th	JJ

European	JJ

Meeting	VBG

on	IN

Dysmorphology	NNP

Strasbourg	NNP

,	,

France	NNP

,	,

3-6	CD

September	NNP

1997	CD

Abstracts	NNS

EU	NNP

Working	VBG

Group	NNP

on	IN

Tobacco	NN

and	CC

Oral	JJ

Health	NNP

Consensus	NN

Meeting	VBG

Copenhagen	NNP

,	,

23-26	CD

October	NNP

1997	CD

Abstracts	NNS

Presentations	NNS

from	IN

the	DT

2nd	JJ

NIH	NNP

Symposium	NNP

on	IN

Therapeutic	JJ

Oligonucleotides	NNS

:	:

Targeting	NN

Transcription	NN

Factors	NNS

and	CC

Signaling	NN

Pathways	NNS

Bethesda	NNP

,	,

Maryland	NNP

,	,

USA	NNP

December	NNP

5	CD

,	,

1997	CD

Infectious	JJ

diseases	NNS

:	:

their	PRP$

impact	NN

on	IN

dentistry	NN

What	WDT

's	POS

new	JJ

in	IN

protein	NN

folding	JJ

?	.

EMBO	NNP

workshop	NN

:	:

protein	NN

folding	JJ

and	CC

misfolding	NN

inside	IN

and	CC

outside	IN

the	DT

cell	NN

Meeting	VBG

of	IN

the	DT

European	JJ

forum	NN

of	IN

nurses	NNS

17th	JJ

European	JJ

Workshop	NNP

on	IN

the	DT

Cell	NN

Biology	NN

of	IN

Phagocytes	NNS

Catania	NNP

,	,

Italy	NNP

,	,

May	NNP

27-31	CD

,	,

1998	CD

Abstracts	NNS

Onset	NN

of	IN

the	DT

preovulatory	JJ

luteinizing	VBG

hormone	NN

surge	NN

:	:

diurnal	JJ

timing	NN

and	CC

critical	JJ

follicular	JJ

prerequisites	NNS

Municipal	JJ

animal	NN

control	NN

ordinances	NNS

--	:

some	DT

legal	JJ

issues	NNS

Psychosexual	JJ

care	NN

in	IN

a	DT

multi-ethnic	JJ

society	NN

Serologic	JJ

evidence	NN

for	IN

mother-to-child	JJ

transmission	NN

of	IN

Kaposi	NN

sarcoma-associated	JJ

herpesvirus	NN

infection	NN

Brandon/Hill	NNP

selected	VBN

list	NN

of	IN

nursing	NN

books	NNS

and	CC

journals	NNS

Retraction	NN

The	DT

TSG101	NN

tumor	NN

susceptibility	NN

gene	NN

is	VBZ

located	JJ

in	IN

chromosome	NN

11	CD

band	NN

p15	NN

and	CC

is	VBZ

mutated	VBN

in	IN

human	JJ

breast	NN

cancer	NN

An	DT

omission	NN

Indoor	JJ

pollution	NN

and	CC

health	NN

Dioxins	NNS

:	:

current	JJ

knowledge	NN

about	IN

health	NN

effects	NNS

Influence	NN

of	IN

environmental	JJ

factors	NNS

on	IN

fertility	NN

:	:

example	NN

of	IN

the	DT

diminution	NN

of	IN

sperm	NN

quality	NN

New	NNP

developments	NNS

in	IN

the	DT

treatment	NN

of	IN

diabetes	NN

and	CC

hyperlipidemias	NNS

Role	NN

of	IN

beta-blockers	NNS

in	IN

the	DT

treatment	NN

of	IN

cardiac	JJ

insufficiency	NN

Which	WDT

calcium	NN

antagonists	NNS

for	IN

hypertension	NN

?	.

Correct	JJ

use	NN

of	IN

serotonin	NN

agonists	NNS

in	IN

migraine	NN

:	:

oral	JJ

or	CC

injectable	JJ

form	NN

?	.

Overtraining	VBG

and	CC

recovery	NN

A	DT

conceptual	JJ

model	NN

Saliva	FW

composition	NN

and	CC

exercise	NN

Lipid	NN

metabolism	NN

during	IN

exercise	NN

Golf	NNP

injuries	NNS

An	DT

overview	NN

Prevention	NNP

of	IN

ankle	NN

injuries	NNS

Academic	NNP

medicine	NN

--	:

alternative	NN

medicine	NN

from	IN

the	DT

viewpoint	NN

of	IN

public	NN

health	NN

public	NN

health	NN

directors	NNS

Academic	NNP

medicine	NN

and	CC

complementary	JJ

medicine	NN

--	:

campaign	NN

for	IN

the	DT

truth	NN

in	IN

medical	JJ

theories	NNS

The	DT

academic	JJ

medicine	NN

--	:

alternative	NN

medicine	NN

tension	NN

field	NN

Are	VBP

academic	JJ

medicine-alternative	JJ

medicine	NN

incompatible	JJ

,	,

compatible	JJ

,	,

complementary	JJ

?	.

Research	NNP

in	IN

complementary	JJ

medicine	NN

:	:

results	NNS

and	CC

problems	NNS

Subcutaneous	NNP

hematomas	NNS

,	,

reduced	VBN

Quick	RB

value	NN

Factor	NN

VII	NN

deficiency	NN

Mononucleosis	NN

infectiosa	NN

(	NN

Epstein-Barr	JJ

virus	NN

infection	NN

Morphology	NN

and	CC

molecular	JJ

biology	NN

of	IN

malignant	JJ

soft	JJ

tissue	NN

sarcomas	NNS

Surgical	NNP

aspects	NNS

in	IN

the	DT

multidisciplinary	JJ

treatment	NN

of	IN

soft	JJ

tissue	NN

sarcomas	NNS

Surgical	NNP

management	NN

of	IN

soft	JJ

tissue	NN

sarcomas	NNS

:	:

principles	NNS

of	IN

resection	NN

and	CC

reconstructive	NN

plastic	NN

procedures	NNS

Adjuvant	JJ

chemotherapy	NN

in	IN

early	RB

soft	JJ

tissue	NN

sarcoma	NN

and	CC

palliative	NN

chemotherapy	NN

in	IN

advanced	VBN

soft	JJ

tissue	NN

sarcoma	NN

in	IN

adults	NNS

Radiotherapy	NN

of	IN

soft	JJ

tissue	NN

sarcomas	NNS

Spinal	JJ

muscular	JJ

atrophy	NN

:	:

where	WRB

are	VBP

we	PRP

in	IN

1998	CD

?	.

Diseases	NNS

transmitted	VBN

by	IN

non-conventional	JJ

agents	NNS

(	NN

``	``

prions	NNS

''	''

)	NN

:	:

nosology	NN

and	CC

diagnosis	NN

A	DT

note	NN

on	IN

the	DT

epidemiology	NN

of	IN

Creutzfeldt-Jakob	NN

syndrome	NN

Biology	NN

of	IN

non-conventional	JJ

transmissible	JJ

agents	NNS

or	CC

prions	NNS

Cerebral	JJ

hemosiderosis	NN

related	JJ

to	TO

hereditary	JJ

ceruloplasmin	NN

deficiency	NN

Clinical	JJ

familial	JJ

case	NN

study	NN

Intramedullary	JJ

metastases	NNS

of	IN

bronchogenic	JJ

carcinoma	NN

Two	CD

cases	NNS

Nervous	JJ

system	NN

borreliosis	NN

with	IN

pseudo-lymphoma	NN

cells	NNS

in	IN

cerebrospinal	JJ

fluid	NN

Epidural	JJ

and	CC

intramedullary	JJ

abscess	NN

of	IN

acute	JJ

onset	NN

Cranial	JJ

nerve	NN

injuries	NNS

during	IN

multifocal	JJ

neuropathies	NNS

with	IN

persistent	JJ

conduction	NN

blocks	NNS

Cytokines	NNS

and	CC

peripheral	JJ

neuropathies	NNS

Clinical	JJ

diagnosis	NN

of	IN

frontotemporal	NN

dementia	NN

Study	NN

of	IN

cortical	JJ

atrophy	NN

with	IN

magnetic	JJ

resonance	NN

imaging	NN

in	IN

corticobasal	NN

degeneration	NN

Autosomal	RB

dominant	JJ

nocturnal	JJ

frontal	JJ

lobe	NN

epilepsy	NN

Eosinophilic	JJ

meningitis	NN

due	JJ

to	TO

Angiostrongylus	JJ

cantonensis	NN

Case	NN

of	IN

superficial	JJ

hemosiderosis	NN

of	IN

the	DT

central	JJ

nervous	JJ

system	NN

treated	VBN

with	IN

trientine	NN

Germinal	JJ

tumor	NN

metastases	NNS

Case	NN

report	NN

Bradycardia	NN

:	:

an	DT

unrecognized	JJ

complication	NN

of	IN

some	DT

epileptic	JJ

crises	NNS

Facial	JJ

palsy	NN

relevant	JJ

to	TO

HIV	NN

seropositivity	NN

Pneumosinus	NN

dilatans	NNS

:	:

a	DT

little-known	JJ

diagnostic	JJ

tool	NN

Current	JJ

status	NN

of	IN

mitochondrial	JJ

diseases	NNS

Vascular	JJ

Parkinson	NNP

syndromes	NNS

:	:

a	DT

controversial	JJ

concept	NN

Epilepsy	NNP

and	CC

psychiatric	JJ

disorders	NNS

:	:

epidemiological	JJ

data	NNS

Auditory	NNP

perception	NN

disorders	NNS

due	JJ

to	TO

bilateral	JJ

cortical	JJ

lesions	NNS

An	DT

electrophysiology	NN

study	NN

Zinc	NN

gluconate	NN

lozenges	NNS

for	IN

treating	VBG

the	DT

common	JJ

cold	JJ

Body	NN

weight	NN

and	CC

mortality	NN

among	IN

women	NNS

Survey	NN

and	CC

assessment	NN

of	IN

the	DT

actual	JJ

state	NN

of	IN

routine	JJ

measurement	NN

of	IN

glycohaemoglobin/GHb	NN

by	IN

commercial	JJ

methods	NNS

:	:

warning	VBG

to	TO

the	DT

users	NNS

and	CC

the	DT

providers	NNS

The	DT

radiological	JJ

investigation	NN

of	IN

suspected	VBN

lower	JJR

limb	NN

deep	RB

vein	NN

thrombosis	NN

p53	NN

mutations	NNS

in	IN

BRCA1-associated	JJ

familial	JJ

breast	NN

cancer	NN

Metronidazole	NNP

(	NN

Flagyl	NNP

)	NN

The	DT

Preterm	NNP

Prediction	NN

Study	NN

:	:

association	NN

of	IN

cesarean	NN

delivery	NN

with	IN

increases	NNS

in	IN

maternal	JJ

weight	NN

and	CC

body	NN

mass	NN

index	NN

Controversies	NNS

in	IN

hydrating	VBG

the	DT

terminally	RB

ill	RB

patient	NN

Frequency	NN

and	CC

significance	NN

of	IN

antinuclear	JJ

antibodies	NNS

in	IN

multiple	JJ

sclerosis	NN

Magnetic	JJ

resonance	NN

imaging	NN

of	IN

the	DT

bone	NN

marrow	NN

in	IN

hematologic	JJ

malignancies	NNS

Generation	NN

of	IN

diversity	NN

in	IN

mammalian	JJ

gut-associated	JJ

lymphoid	JJ

tissues	NNS

:	:

restricted	JJ

V	NN

gene	NN

usage	NN

does	VBZ

not	RB

preclude	VB

complex	NN

V	NN

gene	NN

organization	NN

A	DT

major	JJ

non-LTR	JJ

retrotransposon	NN

of	IN

Bombyx	NNP

mori	NN

,	,

L1Bm	NN

Algae	NNP

or	CC

protozoa	NN

:	:

phylogenetic	JJ

position	NN

of	IN

euglenophytes	NNS

and	CC

dinoflagellates	NNS

as	IN

inferred	VBN

from	IN

mitochondrial	JJ

sequences	NNS

Structure	NN

and	CC

function	NN

of	IN

the	DT

long	RB

terminal	JJ

repeats	NNS

of	IN

feline	JJ

leukemia	NN

viruses	NNS

derived	VBN

from	IN

naturally	RB

occurring	VBG

acute	JJ

myeloid	JJ

leukemias	NNS

in	IN

cats	NNS

Use	NN

of	IN

protein-C	JJ

concentrate	NN

,	,

heparin	NN

,	,

and	CC

haemodiafiltration	NN

in	IN

meningococcus-induced	JJ

purpura	NN

fulminans	NNS

Satellite	NNP

DNA	NN

repeat	NN

sequence	NN

variation	NN

is	VBZ

low	JJ

in	IN

three	CD

species	NNS

of	IN

burying	VBG

beetles	NNS

in	IN

the	DT

genus	NN

Nicrophorus	NN

(	NN

Coleoptera	NNP

:	:

Silphidae	FW

)	NN

The	DT

importance	NN

of	IN

patient	NN

registration	NN

and	CC

processing	NN

Dose-dependent	JJ

effects	NNS

of	IN

recombinant	JJ

human	JJ

interleukin-6	NN

on	IN

glucose	NN

regulation	NN

Genomic	JJ

sequence	NN

of	IN

a	DT

Lyme	NN

disease	NN

spirochaete	NN

,	,

Borrelia	FW

burgdorferi	FW

Interaction	NN

between	IN

electronic	JJ

article	NN

surveillance	NN

systems	NNS

and	CC

implantable	JJ

defibrillators	NNS

:	:

insights	NNS

from	IN

a	DT

fourth	JJ

generation	NN

ICD	NN

Human	JJ

bodily	JJ

health	NN

and	CC

the	DT

common	JJ

good	JJ

Proposals	NNS

for	IN

action	NN

by	IN

individuals	NNS

and	CC

the	DT

Catholic	NNP

Church	NNP

Invited	VBN

commentary	NN

:	:

le	DT

mystre	NN

de	IN

Montr	NN

(	NN

c	NN

)	NN

al	NNP

.	.

Why	WRB

Oedipus	NNP

and	CC

not	RB

Christ	NNP

?	.

:	:

a	DT

psychoanalytic	JJ

inquiry	NN

into	IN

innocence	NN

,	,

human	JJ

sacrifice	NN

,	,

and	CC

the	DT

sacred	JJ

--	:

Part	NN

I	PRP

:	:

Innocence	NN

,	,

spirituality	NN

,	,

and	CC

human	JJ

sacrifice	NN

Equine	NN

dinucleotide	NN

repeat	NN

loci	NNS

LEX049-LEX063	NN

Molecular	JJ

systematics	NNS

of	IN

tanagers	NNS

(	NN

Thraupinae	FW

)	NN

:	:

evolution	NN

and	CC

biogeography	NN

of	IN

a	DT

diverse	JJ

radiation	NN

of	IN

neotropical	JJ

birds	NNS

Expression	NN

of	IN

cytokeratin	NN

20	CD

in	IN

urinary	JJ

cytology	NN

of	IN

patients	NNS

with	IN

bladder	NN

carcinoma	NN

A	DT

family	NN

of	IN

highly	RB

repetitive	JJ

DNAs	NNS

from	IN

``	``

ginbuna	NN

''	''

(	NN

Carassius	NNP

auratus	NN

langsdorfi	NN

)	NN

genome	NN

common	JJ

to	TO

Carassius	NNP

auratus	NN

populations	NNS

Characterization	NN

of	IN

cDNA	NN

clones	NNS

in	IN

size-fractionated	JJ

cDNA	NN

libraries	NNS

from	IN

human	JJ

brain	NN

<	JJR

TO_SEE	NN

>	JJR

Respiratory	JJ

arrest	NN

following	VBG

peribulbar	NN

anesthesia	NN

for	IN

cataract	NN

surgery	NN

:	:

case	NN

report	NN

and	CC

review	NN

of	IN

the	DT

literature	NN

Mouse	NN

LIM-kinase	NN

2	CD

gene	NN

:	:

cDNA	NN

cloning	VBG

,	,

genomic	JJ

organization	NN

,	,

and	CC

tissue-specific	JJ

expression	NN

of	IN

two	CD

alternatively	RB

initiated	VBN

transcripts	NNS

A	DT

gross	JJ

and	CC

microscopic	JJ

study	NN

of	IN

cerebral	JJ

injuries	NNS

accompanying	VBG

maxillofacial	JJ

high-velocity	NN

projectile	NN

wounding	VBG

in	IN

dogs	NNS

Does	VBZ

this	DT

patient	NN

have	VB

a	DT

mole	NN

or	CC

a	DT

melanoma	NN

?	.

Methotrexate	NNP

and	CC

trimethoprim	NN

:	:

a	DT

fatal	JJ

interaction	NN

Pellagra	NNP

and	CC

the	DT

origin	NN

of	IN

a	DT

myth	NN

:	:

evidence	NN

from	IN

European	JJ

literature	NN

and	CC

folklore	NN

Absorbable	JJ

suture	NN

technique	NN

:	:

solution	NN

to	TO

the	DT

growth	NN

problem	NN

in	IN

pediatric	JJ

pacing	NN

with	IN

endocardial	JJ

leads	NNS

Undergraduate	JJ

orthodontic	NN

education	NN

:	:

what	WDT

should	MD

we	PRP

teach	VB

rather	RB

than	IN

what	WDT

can	MD

we	PRP

teach	VB

?	.

Genetic	JJ

variation	NN

in	IN

the	DT

dimorphic	JJ

regions	NNS

of	IN

RAP-1	NN

genes	NNS

and	CC

rap-1	NN

loci	NNS

of	IN

Babesia	NNP

bigemina	NN

History	NN

--	:

a	DT

living	VBG

museum	NN

Interview	NN

by	IN

Grethe	NNP

Kjaergaard	NNP

Gastric	JJ

site	NN

of	IN

epidermoid	NN

carcinoma	NN

Hypodermic	JJ

needles	NNS

in	IN

the	DT

neuropathic	JJ

foot	NN

of	IN

a	DT

patient	NN

with	IN

diabetes	NN

Helicobacter	NNP

pylori	NN

--	:

more	RBR

light	NN

,	,

less	JJR

heat	NN

A	DT

national	JJ

survey	NN

of	IN

physician-assisted	JJ

suicide	NN

and	CC

euthanasia	NN

in	IN

the	DT

United	NNP

States	NNPS

Death	NN

is	VBZ

a	DT

journey	NN

to	TO

be	VB

undertaken	VBN

Replicated	VBN

declines	NNS

in	IN

assault	NN

rates	NNS

after	IN

implementation	NN

of	IN

the	DT

Assaulted	VBN

Staff	NN

Action	NNP

Program	NN

Positive	JJ

patch	NN

test	NN

to	TO

cocamidopropyl	NN

betaine	NN

in	IN

a	DT

hairdresser	NN

Management	NN

of	IN

dyslipidemia	NN

in	IN

adults	NNS

with	IN

diabetes	NN

American	NNP

Diabetes	NNP

Association	NNP

Acute	JJ

diverticulitis	NN

Investigation	NN

of	IN

the	DT

yeast	NN

mitochondrial	JJ

unselective	JJ

channel	NN

in	IN

intact	JJ

and	CC

permeabilized	JJ

spheroplasts	NNS

Acute	JJ

sciatica	NN

with	IN

an	DT

infective	JJ

cause	NN

An	DT

ecologic	JJ

analysis	NN

of	IN

psychosocial	JJ

stress	NN

and	CC

heart	NN

disease	NN

in	IN

British	JJ

Columbia	NNP

Human	JJ

leukocyte	NN

antigen	NN

frequencies	NNS

in	IN

a	DT

selected	VBN

group	NN

of	IN

Lebanese	JJ

Greek	JJ

Orthodox	NN

Alcohol	NN

and	CC

the	DT

heart	NN

Spontaneous	JJ

ovarian	JJ

hyperstimulation	NN

syndrome	NN

with	IN

pregnancy	NN

Will	MD

the	DT

real	RB

plastic	NN

surgeon	NN

please	VB

stand	VB

up	RB

?	.

Modulation	NN

of	IN

ultraviolet	NN

light-induced	JJ

epidermal	JJ

damage	NN

:	:

beneficial	JJ

effects	NNS

of	IN

tocopherol	NN

A	DT

survey	NN

of	IN

the	DT

attitudes	NNS

of	IN

chronic	JJ

psychiatric	JJ

patients	NNS

living	VBG

in	IN

the	DT

community	NN

toward	IN

their	PRP$

medication	NN

Alterations	NNS

in	IN

the	DT

developing	VBG

immune	JJ

system	NN

of	IN

the	DT

F344	NN

rat	NN

after	IN

perinatal	JJ

exposure	NN

to	TO

2	CD

,	,

3	CD

,	,

7	CD

,	,

8-tetrachlorodibenzo-p-dioxin	NN

:	:

II	NNP

Effects	NNS

on	IN

the	DT

pup	NN

and	CC

the	DT

adult	JJ

Renal	JJ

ultrasonography	NN

:	:

a	DT

procedure	NN

for	IN

nephrologists	NNS

Use	NN

of	IN

cisapride	NN

in	IN

treatment	NN

of	IN

constipation	NN

in	IN

children	NNS

Bilateral	JJ

sampling	NN

of	IN

the	DT

internal	JJ

jugular	JJ

vein	NN

to	TO

distinguish	VB

between	IN

mechanisms	NNS

of	IN

adrenocorticotropic	JJ

hormone-dependent	JJ

Cushing	NN

syndrome	NN

The	DT

influence	NN

of	IN

patients	NNS

'	''

hopes	NNS

of	IN

receiving	VBG

a	DT

prescription	NN

on	IN

doctors	NNS

'	''

perceptions	NNS

and	CC

the	DT

decision	NN

to	TO

prescribe	VB

:	:

a	DT

questionnaire	NN

survey	NN

Coronary	JJ

endothelial	JJ

dysfunction	NN

in	IN

humans	NNS

is	VBZ

associated	VBN

with	IN

myocardial	JJ

perfusion	NN

defects	NNS

Medical	NNP

devices	NNS

and	CC

the	DT

year	NN

2000	CD

problem	NN

Internists	NNS

'	''

and	CC

surgeons	NNS

'	''

attitudes	NNS

toward	IN

guns	NNS

and	CC

firearm	NN

injury	NN

prevention	NN

Firearm	NN

injury	NN

prevention	NN

American	NNP

College	NNP

of	IN

Physicians	NNP

Management	NN

of	IN

vaginal	JJ

vault	NN

prolapse	NN

Death	NN

rates	NNS

of	IN

characters	NNS

in	IN

soap	NN

operas	NNS

on	IN

British	JJ

television	NN

:	:

is	VBZ

a	DT

government	NN

health	NN

warning	VBG

required	VBN

?	.

Child	NN

sexual	JJ

abuse	NN

:	:

when	WRB

a	DT

doctor	NN

's	POS

duty	NN

to	TO

report	NN

abuse	NN

conflicts	NNS

with	IN

a	DT

duty	NN

of	IN

confidentiality	NN

to	TO

the	DT

victim	NN

Tissue	NN

adhesives	NNS

--	:

revisited	VBN

Racial	JJ

discrimination	NN

in	IN

the	DT

allocation	NN

of	IN

distinction	NN

awards	NNS

?	.

Analysis	NN

of	IN

list	NN

of	IN

award	NN

holders	NNS

by	IN

type	NN

of	IN

award	NN

,	,

specialty	NN

and	CC

region	NN

Multicenter	NNP

study	NN

of	IN

surfactant	NN

(	NN

beractant	NN

)	NN

use	NN

in	IN

the	DT

treatment	NN

of	IN

term	NN

infants	NNS

with	IN

severe	JJ

respiratory	JJ

failure	NN

Survanta	NN

in	IN

Term	NN

Infants	NNS

Study	NN

Group	NNP

Consultation	NN

section	NN

Cataract	NN

surgical	JJ

problem	NN

Changing	VBG

the	DT

law	NN

on	IN

decision	NN

making	VBG

for	IN

mentally	RB

incapacitated	VBN

adults	NNS

The	DT

coding	VBG

audit	NN

Providing	VBG

primary	JJ

care	NN

in	IN

the	DT

accident	NN

and	CC

emergency	NN

department	NN

Challenges	NNS

to	TO

Native	JJ

American	NNP

health	NN

care	NN

Federal	NNP

programs	NNS

and	CC

Indian	JJ

country	NN

:	:

a	DT

time	NN

for	IN

reinvention	NN

Chicago	NNP

report	NN

profiles	NNS

Big	NNP

city	NN

health	NN

College-age	JJ

drinking	NN

problems	NNS

Using	VBG

YPLL	NN

in	IN

health	NN

planning	VBG

WHO	WP

decides	VBZ

:	:

food	NN

irradiation	NN

safe	JJ

at	IN

any	DT

level	NN

Genetic	JJ

sampling	NN

:	:

big	JJ

brother	NN

or	CC

big	JJ

science	NN

?	.

Physician	NN

assistants	NNS

and	CC

nurse	NN

practitioners	NNS

in	IN

hospital	NN

outpatient	NN

departments	NNS

,	,

1993-1994	CD

Laying	VBG

the	DT

foundation	NN

for	IN

Healthy	JJ

People	NNS

2010	CD

The	DT

first	RB

year	NN

of	IN

consultation	NN

The	DT

veracious	JJ

etiology	NN

of	IN

ectopic	JJ

pregnancy	NN

Is	VBZ

dietary	JJ

fat	NN

a	DT

major	JJ

determinant	NN

of	IN

body	NN

fat	NN

?	.

Factors	NNS

involved	VBN

in	IN

the	DT

rate	NN

of	IN

fall	NN

of	IN

thyroid	NN

stimulating	VBG

hormone	NN

in	IN

treated	VBN

hypothyroidism	NN

Case	NN

complexity	NN

Imaging	NNP

pulmonary	JJ

embolism	NN

Early	RB

inpatient	NN

rehabilitation	NN

after	IN

elective	JJ

hip	NN

and	CC

knee	NN

arthroplasty	NN

Inpatient	JJ

rehabilitation	NN

after	IN

total	NN

joint	NN

replacement	NN

Delayed	VBN

healing	NN

of	IN

rhytidectomy	NN

flap	NN

resurfaced	VBD

with	IN

CO2	NN

laser	NN

The	DT

SAPHO	NNP

syndrome	NN

:	:

an	DT

evolving	VBG

concept	NN

for	IN

unifying	JJ

several	JJ

idiopathic	JJ

disorders	NNS

of	IN

bone	NN

and	CC

skin	NN

Beverage	NNP

use	NN

and	CC

risk	NN

for	IN

kidney	NN

stones	NNS

in	IN

women	NNS

Use	NN

of	IN

a	DT

Foley	NNP

catheter	NN

in	IN

the	DT

removal	NN

of	IN

a	DT

substernal	JJ

goiter	NN

Early	RB

identification	NN

of	IN

variant	NN

Creutzfeldt-Jakob	NN

disease	NN

Slater	NNP

revisited	VBN

:	:

6	CD

year	NN

follow	VB

up	RB

study	NN

of	IN

patients	NNS

with	IN

medically	RB

unexplained	JJ

motor	NN

symptoms	NNS

Re	NNP

:	:

Intermediate	NNP

term	NN

assessment	NN

of	IN

the	DT

reliability	NN

,	,

function	NN

and	CC

patient	NN

satisfaction	NN

with	IN

the	DT

AMS700	NN

ultrex	NN

penile	NN

prosthesis	NN

Reduced	VBN

ratio	NN

of	IN

male	NN

to	TO

female	NN

births	NNS

in	IN

several	JJ

industrial	JJ

countries	NNS

:	:

a	DT

sentinel	NN

health	NN

indicator	NN

?	.

Should	MD

we	PRP

accept	VB

mediocrity	NN

?	.

Resolution	NN

of	IN

recalcitrant	JJ

molluscum	NN

contagiosum	NN

virus	NN

lesions	NNS

in	IN

human	JJ

immunodeficiency	NN

virus-infected	JJ

patients	NNS

treated	VBN

with	IN

cidofovir	NN

Colonoscopic	NNP

removal	NN

of	IN

chicken	NN

bones	NNS

impacted	VBN

in	IN

the	DT

sigmoid	NN

in	IN

two	CD

patients	NNS

``	``

Pull	VB

''	''

or	CC

``	``

push	NN

''	''

PEG	NN

:	:

the	DT

reinsertion	NN

of	IN

the	DT

gastroscope	NN

is	VBZ

often	RB

unnecessary	JJ

Clear	JJ

cell	NN

papulosis	NN

:	:

case	NN

report	NN

and	CC

literature	NN

review	NN

Malignant	JJ

melanoma	NN

in	IN

situ	FW

:	:

an	DT

oxymoron	NN

whose	WP$

time	NN

has	VBZ

come	VBN

External	JJ

beam	NN

radiation	NN

therapy	NN

for	IN

choroidal	NN

neovascularization	NN

Somatic	JJ

mesoderm	NN

differentiation	NN

and	CC

the	DT

development	NN

of	IN

a	DT

subset	NN

of	IN

pericardial	JJ

cells	NNS

depend	VB

on	IN

the	DT

not	RB

enough	RB

muscles	NNS

(	NN

nem	NN

)	NN

locus	NN

,	,

which	WDT

contains	VBZ

the	DT

inscuteable	JJ

gene	NN

and	CC

the	DT

intron	NN

located	JJ

gene	NN

,	,

skittles	NNS

Hemodynamic	JJ

effects	NNS

of	IN

acute	JJ

tetrandrine	NN

and	CC

terlipressin	NN

administration	NN

on	IN

portal	NN

hypertensive	JJ

rats	NNS

Nonneoplastic	JJ

disorders	NNS

of	IN

the	DT

eccrine	NN

glands	NNS

Cerebrospinal	JJ

fluid	NN

and	CC

plasma	NN

insulin	NN

levels	NNS

in	IN

Alzheimer	NN

's	POS

disease	NN

:	:

relationship	NN

to	TO

severity	NN

of	IN

dementia	NN

and	CC

apolipoprotein	NN

E	NN

genotype	NN

Isolated	VBN

internal	JJ

ophthalmoplegia	NN

associated	VBN

with	IN

IgG	NN

anti-GQ1b	JJ

antibody	NN

Bolus	NN

thrombolytic	JJ

infusions	NNS

during	IN

CPR	NNP

for	IN

patients	NNS

with	IN

refractory	JJ

arrest	NN

rhythms	NNS

:	:

outcome	NN

of	IN

a	DT

case	NN

series	NN

Enthesopathy	NNP

in	IN

a	DT

case	NN

of	IN

primary	JJ

biliary	JJ

cirrhosis	NN

with	IN

positive	JJ

HLA-B27	NN

Remifentanil	NNP

in	IN

the	DT

critically	RB

ill	RB

Hyponatremia	NN

with	IN

venlafaxine	NN

.	.

Use	NN

of	IN

a	DT

nerve	NN

stimulator	NN

for	IN

phrenic	JJ

nerve	NN

block	NN

in	IN

treatment	NN

of	IN

hiccups	NNS

Anaesthesia	NNP

for	IN

laparoscopic	JJ

cholecystectomy	NN

in	IN

a	DT

patient	NN

with	IN

Eisenmenger	NNP

's	POS

syndrome	NN

Micronutrients	NNS

and	CC

human	JJ

cancer	NN

risks	NNS

--	:

prospects	NNS

for	IN

prevention	NN

Joint	NNP

International	NNP

Symposium	NNP

of	IN

the	DT

Danish	JJ

Cancer	NN

Society	NNP

,	,

European	JJ

Cancer	NN

Prevention	NNP

Organization	NNP

and	CC

National	NNP

Food	NNP

Agency	NNP

of	IN

Denmark	NNP

Aarhus	NNP

,	,

Denmark	NNP

,	,

21-24	CD

May	NNP

1997	CD

Abstracts	NNS

Vitamin	NN

K2	NN

and	CC

serum	NN

cholesterol	NN

in	IN

patients	NNS

on	IN

continuous	JJ

ambulatory	JJ

peritoneal	NN

dialysis	NN

Income	NN

inequality	NN

and	CC

population	NN

health	NN

Naloxone	NN

-precipitated	JJ

acute	JJ

opioid	NN

withdrawal	NN

syndrome	NN

after	IN

epidural	JJ

morphine	NN

Idiopathic	JJ

atrial	IN

flutter	NN

Munchausen	NN

's	POS

syndrome	NN

Clinical	JJ

evaluation	NN

of	IN

adjuvant	JJ

chemoradiotherapy	NN

with	IN

CDDP	NN

,	,

5-FU	NN

,	,

and	CC

VP-16	NN

for	IN

advanced	VBN

esophageal	NN

cancer	NN

New	NNP

drug	NN

treatment	NN

for	IN

Alzheimer	NN

's	POS

disease	NN

:	:

lessons	NNS

for	IN

healthcare	NN

policy	NN

Development	NNP

of	IN

neurosurgery	NN

in	IN

Greece	NNP

:	:

past	IN

,	,

present	JJ

,	,

and	CC

future	NN

Intravascular-catheter-related	JJ

infections	NNS

The	DT

effect	NN

of	IN

a	DT

social	JJ

support	NN

boosting	VBG

intervention	NN

on	IN

stress	NN

,	,

coping	VBG

,	,

and	CC

social	JJ

support	NN

in	IN

caregivers	NNS

of	IN

children	NNS

with	IN

HIV/AIDS	NN

Point-counterpoint	NN

Mass	NNP

population	NN

skin	NN

cancer	NN

screening	NN

is	VBZ

not	RB

worthwhile	JJ

Persons	NNS

successful	JJ

at	IN

long-term	JJ

weight	NN

loss	NN

and	CC

maintenance	NN

continue	VB

to	TO

consume	VB

a	DT

low-energy	JJ

,	,

low-fat	JJ

diet	NN

Ultrasound	NN

measurements	NNS

of	IN

the	DT

newborn	JJ

hip	NN

Comparison	NN

of	IN

two	CD

methods	NNS

in	IN

657	CD

newborns	NNS

Inferences	NNS

from	IN

symphysiotomy	NN

experience	NN

1995	CD

coronary	JJ

artery	NN

bypass	NN

risk	NN

model	NN

:	:

The	DT

Society	NNP

of	IN

Thoracic	JJ

Surgeons	NNS

Adult	NN

Cardiac	JJ

National	NNP

Database	NN

Informed	VBN

consent	NN

:	:

edging	VBG

forwards	RB

(	NN

and	CC

backwards	RB

)	NN

Online	NN

medical	JJ

surveys	NNS

:	:

using	VBG

the	DT

Internet	NN

as	IN

a	DT

research	NN

tool	NN

US-guided	JJ

puncture	NN

of	IN

the	DT

internal	JJ

jugular	JJ

vein	NN

:	:

complications	NNS

and	CC

anatomic	JJ

considerations	NNS

Mouth	NN

care	NN

and	CC

skin	NN

care	NN

in	IN

palliative	NN

medicine	NN

Simple	JJ

antiseptic	JJ

mouthwashes	NNS

are	VBP

best	RB

for	IN

infection	NN

The	DT

effect	NN

of	IN

melatonin	NN

administration	NN

on	IN

ethanol-induced	JJ

lipid	NN

peroxidation	NN

in	IN

rats	NNS

A	DT

comparison	NN

of	IN

aspirin	NN

plus	CC

tirofiban	NN

with	IN

aspirin	NN

plus	CC

heparin	NN

for	IN

unstable	JJ

angina	NN

Platelet	NN

Receptor	NN

Inhibition	NN

in	IN

Ischemic	JJ

Syndrome	NN

Management	NN

(	NN

PRISM	NN

)	NN

Study	NN

Investigators	NNS

Mike	NNP

Grace	NNP

talks	NNS

to	TO

Mike	NNP

Joy	NNP

Interview	NN

by	IN

Mike	NNP

Grace	NNP

Multivalent	JJ

cations	NNS

depress	VB

ligand	NN

affinity	NN

of	IN

insulin-like	JJ

growth	NN

factor-binding	JJ

proteins-3	NN

and	CC

-5	CD

on	IN

human	JJ

GM-10	NN

fibroblast	NN

cell	NN

surfaces	NNS

Effect	NN

of	IN

continuous	JJ

spinal	JJ

remifentanil	NN

infusion	NN

on	IN

behaviour	NN

and	CC

spinal	JJ

glutamate	NN

release	NN

evoked	VBN

by	IN

subcutaneous	JJ

formalin	NN

in	IN

the	DT

rat	NN

How	WRB

long	RB

should	MD

suction	NN

drains	VBZ

stay	NN

in	IN

after	IN

breast	NN

surgery	NN

with	IN

axillary	JJ

dissection	NN

?	.

Physicians	NNP

disciplined	VBN

for	IN

sex-related	JJ

offenses	NNS

Something	NN

from	IN

nothing	NN

:	:

the	DT

evolution	NN

and	CC

utility	NN

of	IN

satellite	NN

repeats	NNS

Sudden	JJ

death	NN

in	IN

young	JJ

athletes	NNS

:	:

screening	NN

for	IN

the	DT

needle	NN

in	IN

a	DT

haystack	NN

Chemotherapy	NN

alone	RB

compared	VBN

with	IN

chemotherapy	NN

plus	CC

radiotherapy	NN

for	IN

localized	JJ

intermediate-	NN

and	CC

high-grade	JJ

non-Hodgkin	JJ

's	POS

lymphoma	NN

<	JJR

TO_SEE	NN

>	JJR

Prevention	NNP

of	IN

a	DT

first	RB

stroke	NN

by	IN

transfusions	NNS

in	IN

children	NNS

with	IN

sickle	NN

cell	NN

anemia	NN

and	CC

abnormal	JJ

results	NNS

on	IN

transcranial	JJ

Doppler	NNP

ultrasonography	NN

HIV	NN

vaccines	NNS

:	:

prospects	NNS

and	CC

challenges	NNS

Occupation	NN

:	:

the	DT

keystone	NN

of	IN

a	DT

curriculum	NN

for	IN

a	DT

self-defined	JJ

profession	NN

Touch	NN

sensibility	NN

in	IN

the	DT

breast	NN

after	IN

subcutaneous	JJ

mastectomy	NN

and	CC

immediate	JJ

reconstruction	NN

with	IN

a	DT

prosthesis	NN

Iatrogenic	JJ

ruptures	NNS

of	IN

the	DT

tracheobronchial	JJ

tree	NN

Endoscopic	JJ

hemostasis	NN

of	IN

bleeding	VBG

duodenal	JJ

ulcer	NN

in	IN

a	DT

child	NN

with	IN

Henoch-Schnlein	NN

purpura	NN

Classification	NN

of	IN

primary	JJ

gastric	JJ

lymphomas	NNS

according	VBG

to	TO

histologic	JJ

features	NNS

SCIM	NN

--	:

spinal	JJ

cord	NN

independence	NN

measure	NN

:	:

a	DT

new	JJ

disability	NN

scale	NN

for	IN

patients	NNS

with	IN

spinal	JJ

cord	NN

lesions	NNS

Molecular	JJ

analysis	NN

of	IN

cellulose	NN

biosynthesis	NN

in	IN

Arabidopsis	NNP

Users	NNS

'	''

guides	NNS

to	TO

the	DT

medical	JJ

literature	NN

:	:

XIV	NNP

How	WRB

to	TO

decide	VB

on	IN

the	DT

applicability	NN

of	IN

clinical	JJ

trial	NN

results	NNS

to	TO

your	PRP$

patient	NN

Evidence-Based	JJ

Medicine	NN

Working	VBG

Group	NNP

Hemispheric	NNP

difference	NN

in	IN

human	JJ

skin	NN

color	NN

Limitations	NNPS

of	IN

diagnostic	JJ

criteria	NNS

and	CC

assessment	NN

instruments	NNS

for	IN

mental	JJ

disorders	NNS

Implications	NNS

for	IN

research	NN

and	CC

policy	NN

Causing	VBG

death	NN

or	CC

allowing	VBG

to	TO

die	VB

?	.

Developments	NNS

in	IN

the	DT

law	NN

Albumin	NN

synthesis	NN

rates	NNS

are	VBP

not	RB

decreased	VBN

in	IN

hypoalbuminemic	JJ

cachectic	NN

cancer	NN

patients	NNS

with	IN

an	DT

ongoing	JJ

acute-phase	NN

protein	NN

response	NN

Brain-gut	NN

axis	NN

in	IN

health	NN

and	CC

disease	NN

Pins	NNS

and	CC

Rubbers	NNS

Traction	NNP

System	NNP

A	DT

specialist	NN

nurse	NN

can	MD

replace	VB

pre-registration	NN

house	NN

officers	NNS

in	IN

the	DT

surgical	JJ

pre-admission	JJ

clinic	NN

Voluntary	JJ

death	NN

:	:

a	DT

comparison	NN

of	IN

terminal	JJ

dehydration	NN

and	CC

physician-assisted	JJ

suicide	NN

Ionized	VBN

magnesium	NN

in	IN

serum	NN

and	CC

ultrafiltrate	NN

:	:

pH	NN

and	CC

bicarbonate	NN

effect	NN

on	IN

measurements	NNS

with	IN

the	DT

AVL	NN

988-4	CD

electrolyte	NN

analyzer	NN

Anterior	NNP

glenohumeral	NN

dislocations	NNS

:	:

what	WDT

to	TO

do	VB

and	CC

how	WRB

to	TO

do	VB

it	PRP

Relationship	NN

between	IN

topotecan	NN

systemic	JJ

exposure	NN

and	CC

tumor	NN

response	NN

in	IN

human	JJ

neuroblastoma	NN

xenografts	NNS

Cerebral	JJ

infarct	NN

following	VBG

central	JJ

venous	JJ

cannulation	NN

The	DT

Gram	NN

stain	VB

Heavy	NNP

caffeine	NN

intake	NN

in	IN

pregnancy	NN

and	CC

sudden	JJ

infant	NN

death	NN

syndrome	NN

New	NNP

Zealand	NNP

Cot	NN

Death	NN

Study	NN

Group	NNP

When	WRB

can	MD

odds	NNS

ratios	NNS

mislead	NN

?	.

Treatment	NN

of	IN

renal	JJ

failure	NN

in	IN

idiopathic	JJ

membranous	JJ

nephropathy	NN

with	IN

azathioprine	NN

and	CC

prednisolone	NN

Enzyme	NN

structure	NN

with	IN

two	CD

catalytic	JJ

sites	NNS

for	IN

double-sieve	JJ

selection	NN

of	IN

substrate	NN

Role	NN

of	IN

the	DT

ketogenic	JJ

diet	NN

in	IN

children	NNS

with	IN

intractable	JJ

seizures	NNS

.	.

Building-associated	JJ

pulmonary	JJ

disease	NN

from	IN

exposure	NN

to	TO

Stachybotrys	NNS

chartarum	NN

and	CC

Aspergillus	NN

versicolor	NN

Interleukin-8	NN

participates	VBZ

in	IN

angiogenesis	NN

in	IN

non-small	JJ

cell	NN

,	,

but	CC

not	RB

small	JJ

cell	NN

carcinoma	NN

of	IN

the	DT

lung	NN

Antenatal	JJ

indomethacin	NN

--	:

adverse	JJ

fetal	JJ

effects	NNS

confirmed	VBN

Evaluation	NN

of	IN

the	DT

microparticle	NN

enzyme	NN

immunoassay	NN

Abbott	NNP

IMx	NN

Select	NNP

Chlamydia	NN

and	CC

the	DT

importance	NN

of	IN

urethral	NN

site	NN

sampling	NN

to	TO

detect	VB

Chlamydia	NN

trachomatis	NN

in	IN

women	NNS

The	DT

persistent	JJ

vegetative	JJ

state	NN

after	IN

closed	VBN

head	NN

injury	NN

:	:

clinical	JJ

and	CC

magnetic	JJ

resonance	NN

imaging	NN

findings	NNS

in	IN

42	CD

patients	NNS

Wegener	NNP

's	POS

granulomatosis	NN

of	IN

the	DT

head	NN

and	CC

neck	NN

Chromosomal	JJ

abnormalities	NNS

of	IN

a	DT

new	JJ

nasopharyngeal	NN

carcinoma	NN

cell	NN

line	NN

(	NN

NPC-BM1	NN

)	NN

derived	VBN

from	IN

a	DT

bone	NN

marrow	NN

metastatic	JJ

lesion	NN

Relation	NN

between	IN

intellectual	JJ

dysfunctioning	VBG

and	CC

mortality	NN

in	IN

community-residing	NN

older	JJR

people	NNS

Anxiety	NN

and	CC

autonomic	JJ

flexibility	NN

:	:

a	DT

cardiovascular	JJ

approach	NN

Cross-reactivity	NN

of	IN

specific	JJ

antibodies	NNS

directed	VBN

to	TO

heat	NN

shock	NN

proteins	NNS

from	IN

periodontopathogenic	JJ

bacteria	NNS

and	CC

of	IN

human	JJ

origin	NN

(	NN

corrected	VBN

)	NN

Immunogenicity	NN

of	IN

hepatitis	NN

B	NN

vaccine	NN

in	IN

term	NN

and	CC

preterm	NN

infants	NNS

Secondary	JJ

prevention	NN

for	IN

stroke	NN

after	IN

CAPRIE	NNP

and	CC

ESPS-2	NN

<	JJR

TO_SEE	NN

>	JJR

New-onset	NN

angina	NN

preceding	VBG

acute	JJ

myocardial	JJ

infarction	NN

is	VBZ

associated	VBN

with	IN

improved	VBN

contractile	NN

recovery	NN

after	IN

thrombolysis	NN

Magnetic	JJ

resonance	NN

imaging	NN

in	IN

focal	JJ

myositis	NN

Concomitant	JJ

alveolitis	NN

and	CC

asthma	NN

following	VBG

exposure	NN

to	TO

triphenylmethane	NN

triisocyanate	NN

Gorlin	NNP

syndrome	NN

:	:

identification	NN

of	IN

4	CD

novel	JJ

germ-line	NN

mutations	NNS

of	IN

the	DT

human	JJ

patched	VBN

(	NN

PTCH	NN

)	NN

gene	NN

Mutations	NNS

in	IN

brief	NN

no	DT

137	CD

Online	NN

Genetic	JJ

findings	NNS

in	IN

congenital	JJ

bilateral	JJ

aplasia	NN

of	IN

vas	FW

deferens	NNS

patients	NNS

and	CC

identification	NN

of	IN

six	CD

novel	JJ

mutatations	NNS

Mutations	NNS

in	IN

brief	NN

no	DT

138	CD

Online	NN

A	DT

novel	JJ

point	NN

mutation	NN

in	IN

a	DT

splice	NN

acceptor	NN

site	NN

of	IN

intron	NN

1	CD

of	IN

the	DT

human	JJ

low	JJ

density	NN

lipoprotein	NN

receptor	NN

gene	NN

which	WDT

causes	NNS

severe	JJ

hypercholesterolemia	NN

:	:

an	DT

unexpected	JJ

absence	NN

of	IN

exon	NN

skipping	VBG

Mutations	NNS

in	IN

brief	NN

no	DT

139	CD

Online	NN

A	DT

de	IN

novo	FW

missense	NN

mutation	NN

(	NN

R1623Q	NN

)	NN

of	IN

the	DT

SCN5A	NN

gene	NN

in	IN

a	DT

Japanese	JJ

girl	NN

with	IN

sporadic	JJ

long	RB

QT	NN

sydrome	NN

Mutations	NNS

in	IN

brief	NN

no	DT

140	CD

Online	NN

Missense	NN

mutation	NN

in	IN

exon	NN

11	CD

(	NN

Codon	NNP

378	CD

)	NN

of	IN

the	DT

presenilin-1	NN

gene	NN

in	IN

a	DT

French	JJ

family	NN

with	IN

early-onset	JJ

Alzheimer	NN

's	POS

disease	NN

and	CC

transmission	NN

study	NN

by	IN

mismatch	NN

enhanced	VBN

allele	NN

specific	JJ

amplification	NN

Mutations	NNS

in	IN

brief	NN

no	DT

141	CD

Online	NN

besancon	NN

@	SYM

rockefeller1.univ.lyon1.fr	NN

Mutation	NN

sharing	VBG

,	,

predominant	JJ

involvement	NN

of	IN

the	DT

MLH1	NN

gene	NN

and	CC

description	NN

of	IN

four	CD

novel	JJ

mutations	NNS

in	IN

hereditary	JJ

nonpolyposis	NN

colorectal	JJ

cancer	NN

Mutations	NNS

in	IN

brief	NN

no	DT

144	CD

Online	NN

A	DT

new	JJ

informative	JJ

Alw	NN

26	CD

I	PRP

polymorphism	NN

in	IN

exon	NN

10	CD

of	IN

the	DT

human	JJ

low	JJ

density	NN

lipoprotein	NN

receptor	NN

gene	NN

Application	NN

to	TO

prenatal	JJ

diagnosis	NN

Mutations	NNS

in	IN

brief	NN

no	DT

145	CD

Online	NN

Novel	JJ

acceptor	NN

splice	NN

site	NN

mutation	NN

in	IN

the	DT

invariant	JJ

AG	NNP

of	IN

intron	NN

6	CD

of	IN

alpha-galactosidase	NN

A	DT

gene	NN

,	,

causing	VBG

Fabry	NN

disease	NN

Mutations	NNS

in	IN

brief	NN

no	DT

146	CD

Online	NN

Meta-analysis	NN

of	IN

trials	NNS

comparing	VBG

antidepressants	NNS

with	IN

active	JJ

placebos	NNS

Evidence-based	JJ

guidelines	NNS

for	IN

universal	JJ

counselling	VBG

and	CC

offering	NN

of	IN

HIV	NN

testing	NN

in	IN

pregnancy	NN

in	IN

Canada	NNP

Chelation	NN

therapy	NN

for	IN

peripheral	JJ

arterial	JJ

occlusive	NN

disease	NN

:	:

a	DT

systematic	JJ

review	NN

<	JJR

TO_SEE	NN

>	JJR

Sodium	NN

channel	NN

block	NN

with	IN

mexiletine	NN

is	VBZ

effective	JJ

in	IN

reducing	VBG

dispersion	NN

of	IN

repolarization	NN

and	CC

preventing	VBG

torsade	NN

des	FW

pointes	NNS

in	IN

LQT2	NN

and	CC

LQT3	NN

models	NNS

of	IN

the	DT

long-QT	JJ

syndrome	NN

Simultaneous	JJ

microsurgical	JJ

vasal	NN

reconstruction	NN

and	CC

varicocele	NN

ligation	NN

:	:

safety	NN

profile	NN

and	CC

outcomes	NNS

A	DT

predetermined	VBN

design	NN

for	IN

easier	JJR

aesthetic	JJ

abdominoplasty	NN

Significance	NN

of	IN

revision	NN

of	IN

the	DT

occupational	JJ

illness	NN

legislation	NN

for	IN

evaluating	VBG

intervertebral	NN

disk	NN

damage	NN

Serum	NN

urate	NN

during	IN

bouts	NNS

of	IN

acute	JJ

gouty	JJ

arthritis	NN

Isolated	VBN

axial	IN

lateral	JJ

pulse	NN

as	IN

a	DT

sign	NN

of	IN

latero-bulbar	JJ

ischemia	NN

:	:

clinical	JJ

topographic	JJ

correlation	NN

Microalbuminuria	NNP

is	VBZ

positively	RB

associated	VBN

with	IN

usual	JJ

dietary	JJ

saturated	VBN

fat	NN

intake	NN

and	CC

negatively	RB

associated	VBN

with	IN

usual	JJ

dietary	JJ

protein	NN

intake	NN

in	IN

people	NNS

with	IN

insulin-dependent	JJ

diabetes	NN

mellitus	NN

Endoscopic	JJ

ultrasound	NN

miniprobe-guided	JJ

steroid	NN

injection	NN

for	IN

treatment	NN

of	IN

refractory	JJ

esophageal	NN

strictures	NNS

Purification	NN

and	CC

characterization	NN

of	IN

an	DT

acetyl	NN

xylan	NN

esterase	NN

from	IN

Bacillus	NN

pumilus	NN

The	DT

Stresst'er	NN

ergometer	NN

as	IN

an	DT

alternative	NN

to	TO

treadmill	NN

testing	NN

in	IN

patients	NNS

with	IN

claudication	NN

Renal	JJ

trauma	NN

and	CC

the	DT

risk	NN

of	IN

long-term	JJ

complications	NNS

in	IN

shock	NN

wave	NN

lithotripsy	NN

Current	JJ

management	NN

of	IN

corneal	NN

abrasions	NNS

:	:

evidence	NN

based	VBN

practice	NN

?	.

Placebo	NN

in	IN

drug	NN

clinical	JJ

trials	NNS

Chromosome	NN

22qII	NN

deletions	NNS

An	DT

under-recognised	JJ

cause	NN

of	IN

idiopathic	JJ

learning	VBG

disability	NN

Serial	JJ

magnetic	JJ

resonance	NN

imaging	NN

findings	NNS

for	IN

a	DT

spontaneously	RB

resolving	VBG

spinal	JJ

subdural	JJ

hematoma	NN

:	:

case	NN

report	NN

A	DT

simple	JJ

technique	NN

for	IN

correction	NN

of	IN

mucosal	JJ

irregularities	NNS

of	IN

the	DT

lip	NN

Cancer	NN

risk	NN

in	IN

the	DT

rubber	NN

industry	NN

:	:

a	DT

review	NN

of	IN

the	DT

recent	JJ

epidemiological	JJ

evidence	NN

HIV	NN

treatment	NN

strategies	NNS

:	:

planning	VBG

for	IN

the	DT

long	RB

term	NN

The	DT

project	NN

of	IN

a	DT

national	JJ

control	NN

program	NN

for	IN

tuberculosis	NN

in	IN

Spain	NNP

Decrease	NN

in	IN

antibiotic	JJ

susceptibility	NN

or	CC

increase	NN

in	IN

resistance	NN

?	.

Helicobacter	NNP

pylori	NN

and	CC

abdominal	JJ

symptoms	NNS

:	:

a	DT

population-based	JJ

study	NN

among	IN

preschool	JJ

children	NNS

in	IN

southern	JJ

Germany	NNP

Have	VBP

we	PRP

treated	VBN

AIDS	NN

too	RB

well	RB

?	.

Rationing	VBG

and	CC

the	DT

future	NN

of	IN

AIDS	NN

exceptionalism	NN

Recommendations	NNS

on	IN

antiretroviral	JJ

treatment	NN

The	DT

AIDS	NN

Study	NN

Group	NNP

of	IN

the	DT

Spanish	JJ

Society	NNP

of	IN

Infectious	JJ

Diseases	NNS

and	CC

Clinical	JJ

Microbiology	NNP

Requirements	NNS

for	IN

training	NN

to	TO

ensure	VB

competence	NN

of	IN

endoscopists	NNS

performing	VBG

invasive	JJ

procedures	NNS

in	IN

children	NNS

Safe	NN

motherhood	NN

:	:

can	MD

we	PRP

make	VB

a	DT

difference	NN

?	.

Lumbar	NNP

spine	NN

stenosis	NN

:	:

a	DT

common	JJ

cause	NN

of	IN

back	RB

and	CC

leg	NN

pain	NN

Myoepithelial	JJ

carcinoma	NN

with	IN

predominance	NN

of	IN

plasmacytoid	NN

cells	NNS

arising	VBG

in	IN

a	DT

pleomorphic	JJ

adenoma	NN

of	IN

the	DT

parotid	NN

gland	NN

Lonomia	NNP

obliqua	NN

caterpillar	NN

spicules	NNS

trigger	NN

human	JJ

blood	NN

coagulation	NN

via	IN

activation	NN

of	IN

factor	NN

X	NN

and	CC

prothrombin	NN

Doing	VBG

everything	NN

Successful	JJ

replantation	NN

of	IN

an	DT

amputated	VBN

tongue	NN

Morbidity	NN

and	CC

healthcare	NN

utilisation	NN

of	IN

children	NNS

in	IN

households	NNS

with	IN

one	CD

adult	JJ

:	:

comparative	JJ

observational	JJ

study	NN

A	DT

novel	JJ

frameshift	NN

mutation	NN

840delA	NN

and	CC

a	DT

novel	JJ

polymorphism	NN

D203A	NN

in	IN

the	DT

steroidogenic	JJ

acute	JJ

regulatory	JJ

protein	NN

gene	NN

in	IN

a	DT

Japanese	JJ

patient	NN

with	IN

congenital	JJ

lipoid	NN

adrenal	JJ

hyperplasia	NN

Mutations	NNS

in	IN

brief	NN

no	DT

117	CD

Online	NN

Identification	NN

of	IN

five	CD

new	JJ

mutations	NNS

and	CC

three	CD

novel	JJ

polymorphisms	NNS

in	IN

the	DT

muscle	NN

chloride	NN

channel	NN

gene	NN

(	NN

CLCN1	NN

)	NN

in	IN

20	CD

Italian	JJ

patients	NNS

with	IN

dominant	JJ

and	CC

recessive	JJ

myotonia	NN

congenita	NN

Mutations	NNS

in	IN

brief	NN

no	DT

118	CD

Online	NN

Identification	NN

of	IN

a	DT

large	JJ

insertion	NN

and	CC

two	CD

novel	JJ

point	NN

mutations	NNS

(	NN

3671del8	NN

and	CC

S1221X	NN

)	NN

in	IN

tuberous	JJ

sclerosis	NN

complex	NN

(	NN

TSC	NNP

)	NN

patients	NNS

Mutations	NNS

in	IN

brief	NN

no	DT

119	CD

Online	NN

Mutational	JJ

analysis	NN

of	IN

the	DT

cystathionine	NN

beta-synthase	NN

gene	NN

:	:

a	DT

splicing	NN

mutation	NN

,	,

two	CD

missense	NN

mutations	NNS

and	CC

an	DT

insertion	NN

in	IN

patients	NNS

with	IN

homocystinuria	NN

Mutations	NNS

in	IN

brief	NN

no	DT

120	CD

Online	NN

Analysis	NN

of	IN

five	CD

mutations	NNS

in	IN

20	CD

mucopolysaccharidois	NN

type	NN

1	CD

patients	NNS

:	:

high	JJ

prevalence	NN

of	IN

the	DT

W402X	NN

mutation	NN

Mutations	NNS

in	IN

brief	NN

no	DT

121	CD

Online	NN

A	DT

novel	JJ

missense	NN

mutation	NN

Ile538Val	NN

in	IN

the	DT

fibroblast	NN

growth	NN

factor	NN

receptor	NN

3	CD

in	IN

hypochondroplasia	NN

Mutations	NNS

in	IN

brief	NN

no	DT

122	CD

Online	NN

Detection	NN

of	IN

four	CD

novel	JJ

mutations	NNS

in	IN

the	DT

iduronate-2-sulfatase	NN

gene	NN

Mutations	NNS

in	IN

brief	NN

no	DT

123	CD

Online	NN

Polymorphisms	NNS

in	IN

the	DT

coding	VBG

exons	NNS

of	IN

the	DT

human	JJ

luteinizing	VBG

hormone	NN

receptor	NN

gene	NN

Mutations	NNS

in	IN

brief	NN

no	DT

124	CD

Online	NN

Independent	NNP

occurrence	NN

of	IN

the	DT

novel	JJ

Arg2163	NN

to	TO

His	PRP$

mutation	NN

in	IN

the	DT

factor	NN

VIII	CD

gene	NN

in	IN

three	CD

unrelated	JJ

families	NNS

with	IN

haemophila	NN

A	DT

with	IN

different	JJ

phenotypes	NNS

Mutations	NNS

in	IN

brief	NN

no	DT

126	CD

Online	NN

Are	VBP

Japanese	JJ

researchers	NNS

exploiting	VBG

Thai	NNP

HIV	NN

patients	NNS

?	.

Underutilization	NN

of	IN

aspirin	NN

in	IN

older	JJR

patients	NNS

with	IN

prior	RB

myocardial	JJ

infarction	NN

at	IN

the	DT

time	NN

of	IN

admission	NN

to	TO

a	DT

nursing	NN

home	NN

.	.

Distinguishing	VBG

silent	JJ

lacunar	NN

infarction	NN

from	IN

enlarged	JJ

Virchow-Robin	NNP

spaces	NNS

:	:

a	DT

magnetic	JJ

resonance	NN

imaging	NN

and	CC

pathological	JJ

study	NN

Correlation	NN

is	VBZ

not	RB

causation	NN

Inhalation	NN

of	IN

ammonium	NN

nitrate	VB

fuel	NN

oil	NN

explosive	NN

(	NN

ANFO	NNP

)	NN

Management	NN

of	IN

polycythaemia	NN

in	IN

adults	NNS

with	IN

cyanotic	JJ

congenital	JJ

heart	NN

disease	NN

Bolstering	VBG

Sisyphus	NNP

Use	NN

of	IN

public	NN

performance	NN

reports	NNS

:	:

a	DT

survey	NN

of	IN

patients	NNS

undergoing	VBG

cardiac	JJ

surgery	NN

Role	NN

of	IN

a	DT

p53	NN

polymorphism	NN

in	IN

the	DT

development	NN

of	IN

human	JJ

papillomavirus-associated	JJ

cancer	NN

The	DT

use	NN

of	IN

nurses	NNS

in	IN

alternative	NN

dispute	NN

resolution	NN

Re	NNP

:	:

Friday	NNP

afternoon	NN

pulmonary	JJ

arteriography	NN

(	NN

FAPA	NN

)	NN

:	:

are	VBP

Fridays	NNS

good	JJ

for	IN

your	PRP$

health	NN

?	.

Hormone	NN

replacement	NN

therapy	NN

and	CC

breast	NN

cancer	NN

.	.

Physician	NN

heal	VB

thyself	IN

:	:

are	VBP

antibiotics	NNS

the	DT

cure	NN

or	CC

the	DT

disease	NN

?	.

Primary	JJ

biliary	JJ

cirrhosis	NN

Polymorphism	NN

in	IN

promoter	NN

region	NN

of	IN

inducible	JJ

nitric	JJ

oxide	NN

synthase	NN

gene	NN

and	CC

protection	NN

against	IN

malaria	NN

Ventilatory	JJ

responses	NNS

to	TO

acute	JJ

and	CC

sustained	JJ

hypoxia	NN

during	IN

isoflurane	NN

anesthesia	NN

Leprosy	NNP

type	NN

1	CD

reaction	NN

as	IN

the	DT

first	RB

manifestation	NN

of	IN

borderline	NN

lepromatous	JJ

leprosy	NNP

in	IN

a	DT

young	JJ

native	JJ

German	JJ

A	DT

systematic	JJ

review	NN

of	IN

five	CD

systemic	JJ

treatments	NNS

for	IN

severe	JJ

psoriasis	NN

Trisomy	NNP

10	CD

in	IN

leukemia	NN

Receptive	JJ

properties	NNS

of	IN

primary	JJ

afferent	JJ

fibres	NNS

from	IN

rabbit	NN

pleura	NN

,	,

in	IN

vitro	NN

Congenital	JJ

anomalies	NNS

of	IN

tracheobronchial	JJ

branching	VBG

patterns	NNS

:	:

spiral	NN

CT	NN

aspects	NNS

in	IN

adults	NNS

American	NNP

Heart	NNP

Association	NNP

urges	VBZ

caution	NN

on	IN

new	JJ

diet	NN

drug	NN

Absence	NN

of	IN

renal	JJ

and	CC

hepatic	JJ

toxicity	NN

after	IN

four	CD

hours	NNS

of	IN

1.25	CD

minimum	NN

alveolar	JJ

anesthetic	NN

concentration	NN

sevoflurane	NN

anesthesia	NN

in	IN

volunteers	NNS

Linear	JJ

lichen	NN

planopilaris	NN

of	IN

the	DT

face	NN

Electrolyte	NN

abnormalities	NNS

in	IN

patients	NNS

with	IN

chronic	JJ

renal	JJ

failure	NN

receiving	VBG

parenteral	JJ

nutrition	NN

Risk	NN

factors	NNS

for	IN

hemiretinal	JJ

vein	NN

occlusion	NN

:	:

comparison	NN

with	IN

risk	NN

factors	NNS

for	IN

central	JJ

and	CC

branch	NN

retinal	JJ

vein	NN

occlusion	NN

:	:

the	DT

eye	NN

disease	NN

case-control	JJ

study	NN

The	DT

psychological	JJ

profiles	NNS

of	IN

patients	NNS

with	IN

whiplash-associated	JJ

headache	NN

<	JJR

TO_SEE	NN

>	JJR

Fatal	JJ

spontaneous	JJ

spinal	JJ

epidural	JJ

hematoma	NN

following	VBG

thrombolysis	NN

for	IN

myocardial	JJ

infarction	NN

Bifid	NN

T	NN

waves	NNS

induced	VBN

by	IN

isoprenaline	NN

in	IN

a	DT

patient	NN

with	IN

Brugada	NNP

syndrome	NN

.	.

Quo	NN

vadis	NN

``	``

suprema	NN

lex	NN

''	''

?	.

Death	NN

in	IN

springtime	NN

Clinical	JJ

management	NN

and	CC

treatment	NN

outcomes	NNS

of	IN

Merkel	NNP

cell	NN

carcinoma	NN

Relatives	NNS

in	IN

the	DT

resuscitation	NN

room	NN

:	:

their	PRP$

point	NN

of	IN

view	NN

Large	JJ

airway	NN

disease	NN

associated	VBN

with	IN

inflammatory	JJ

bowel	NN

disease	NN

Autonomy	NN

in	IN

the	DT

face	NN

of	IN

a	DT

devastating	VBG

diagnosis	NN

Advanced	NNP

practice	NN

nursing	NN

:	:

is	VBZ

the	DT

physician	NN

's	POS

assistant	NN

an	DT

accident	NN

of	IN

history	NN

or	CC

a	DT

failure	NN

to	TO

act	NN

?	.

Acute	JJ

obstructive	JJ

hydrocephalus	NN

complicating	VBG

bacterial	JJ

meningitis	NN

in	IN

childhood	NN

Subcutaneous	NNP

autologous	JJ

ovarian	JJ

transplantation	NN

in	IN

Wistar	NNP

rats	NNS

maintains	VBZ

hormone	NN

secretion	NN

Teaching	NN

irritable	JJ

bowel	NN

syndrome	NN

patients	NNS

to	TO

care	NN

for	IN

themselves	PRP

Nonanesthetic	JJ

volatile	JJ

drugs	NNS

obey	VB

the	DT

Meyer-Overton	NNP

correlation	NN

in	IN

two	CD

molecular	JJ

protein	NN

site	NN

models	NNS

Inhaled	VBN

sodium	NN

cromoglycate	NN

in	IN

young	JJ

children	NNS

with	IN

moderate	JJ

asthma	NN

Directly	RB

observed	VBN

therapy	NN

and	CC

treatment	NN

completion	NN

for	IN

tuberculosis	NN

in	IN

the	DT

United	NNP

States	NNPS

:	:

is	VBZ

universal	JJ

supervised	VBN

therapy	NN

necessary	JJ

?	.

Investigation	NN

of	IN

antibiotic	JJ

prophylaxis	NN

usage	NN

for	IN

vascular	JJ

and	CC

nonvascular	JJ

interventional	JJ

procedures	NNS

Effect	NN

of	IN

protein	NN

kinase	NN

C	NN

inhibitors	NNS

on	IN

cardioprotection	NN

by	IN

ischemic	JJ

preconditioning	VBG

depends	VBZ

on	IN

the	DT

number	NN

of	IN

preconditioning	VBG

episodes	NNS

How	WRB

do	VB

you	PRP

treat	NN

refractory	JJ

pouchitis	NN

and	CC

when	WRB

do	VB

you	PRP

decide	VB

to	TO

remove	VB

the	DT

pouch	NN

?	.

Filter	NNP

paper	NN

blood	NN

spot	NN

assay	NN

of	IN

human	JJ

insulin-like	JJ

growth	NN

factor	NN

I	PRP

(	NN

IGF-I	NN

)	NN

and	CC

IGF-binding	JJ

protein-3	NN

and	CC

preliminary	JJ

application	NN

in	IN

the	DT

evaluation	NN

of	IN

growth	NN

hormone	NN

status	NN

Effect	NN

of	IN

iodixanol	NN

on	IN

renal	JJ

function	NN

immediately	RB

after	IN

abdominal	JJ

angiography	NN

.	.

Clinical	JJ

comparison	NN

with	IN

iomeprol	NN

and	CC

ioxaglate	NN

A	DT

new	JJ

modified	VBN

technique	NN

for	IN

harvest	NN

of	IN

calcaneal	NN

bone	NN

grafts	NNS

in	IN

surgery	NN

on	IN

the	DT

foot	NN

and	CC

ankle	NN

Is	VBZ

prevaccination	NN

screening	NN

for	IN

hepatitis	NN

B	NN

among	IN

sexually	RB

active	JJ

adolescents	NNS

cost-effective	JJ

?	.

Epilepsy	NNP

--	:

a	DT

guide	NN

to	TO

medical	JJ

treatment	NN

1	CD

:	:

Antiepileptic	JJ

drugs	NNS

Adolescent	JJ

pregnancy	NN

and	CC

sexual	JJ

abuse	NN

Normoxic	JJ

cardiopulmonary	JJ

bypass	NN

reduces	VBZ

oxidative	JJ

myocardial	JJ

damage	NN

and	CC

nitric	JJ

oxide	NN

during	IN

cardiac	JJ

operations	NNS

in	IN

the	DT

adult	JJ

A	DT

multidimensional	JJ

study	NN

of	IN

preference	NN

judgements	NNS

for	IN

excerpts	NNS

of	IN

music	NN

Extending	VBG

the	DT

benefits	NNS

of	IN

breast	NN

cancer	NN

screening	NN

Still	RB

hard	RB

to	TO

know	VB

how	WRB

large	JJ

the	DT

benefits	NNS

will	MD

really	RB

be	VB

Rhabdomyolysis	NNP

and	CC

carbon	NN

monoxide	NN

poisoning	NN

Effect	NN

of	IN

dental	JJ

treatment	NN

on	IN

the	DT

lung	NN

function	NN

of	IN

children	NNS

with	IN

asthma	NN

.	.

conclusions	NNS

:	:

apc	IN

is	VBZ

effective	JJ

for	IN

the	DT

treatment	NN

of	IN

endoluminal	JJ

hemoptysis	NN

and	CC

airway	NN

obstruction	NN

induction	NN

chemotherapy	NN

(	NN

cisplatin	NN

+	CC

vinorelbine	NN

)	NN

is	VBZ

found	VBN

to	TO

be	VB

markedly	RB

effective	JJ

for	IN

squamous	JJ

cell	NN

lung	NN

carcinoma	NN

with	IN

sarcoidosis	NN

--	:

a	DT

case	NN

report	NN

<	JJR

TO_SEE	NN

>	JJR

in	IN

conclusion	NN

,	,

3d	NN

computer-assisted	JJ

analysis	NN

of	IN

the	DT

internal	JJ

structure	NN

of	IN

small	JJ

pulmonary	JJ

nodules	NNS

using	VBG

contrast-enhanced	JJ

dh-ct	NN

was	VBD

found	VBN

to	TO

be	VB

effective	JJ

for	IN

differentiating	VBG

between	IN

benign	JJ

and	CC

malignant	JJ

nodules	NNS

the	DT

patient	NN

was	VBD

a	DT

62-year-old	JJ

man	NN

with	IN

squamous	JJ

cell	NN

lung	NN

cancer	NN

,	,

which	WDT

was	VBD

first	RB

successfully	RB

treated	VBN

by	IN

a	DT

combination	NN

of	IN

radiation	NN

therapy	NN

and	CC

chemotherapy	NN

,	,

but	CC

showed	VBD

local	JJ

recurrence	NN

after	IN

8	CD

months	NNS

the	DT

combination	NN

of	IN

txt	NN

,	,

gem	NN

and	CC

cddp	NN

may	MD

be	VB

effective	JJ

for	IN

recurrent	JJ

non-small-cell	JJ

lung	NN

carcinoma	NN

,	,

even	RB

in	IN

patients	NNS

that	IN

have	VB

failed	VBD

to	TO

respond	NN

to	TO

more	RBR

than	IN

one	CD

chemotherapy	NN

regimen	NNS

the	DT

aim	NN

of	IN

the	DT

current	JJ

study	NN

was	VBD

to	TO

compare	VB

the	DT

objective	NN

response	NN

and	CC

survival	NN

rates	NNS

of	IN

patients	NNS

with	IN

mrcc	NN

treated	VBN

with	IN

il-2	NN

administered	VBN

either	DT

systemically	RB

(	NN

syst	IN

,	,

subcutaneously	RB

)	NN

or	CC

via	IN

inhalation	NN

(	NN

inh	NN

)	NN

,	,

using	VBG

relatively	RB

large	JJ

sample	NN

sizes	NNS

to	TO

afford	VB

a	DT

more	RBR

meaningful	JJ

comparison	NN

conclusion	NN

:	:

as	IN

expected	VBN

,	,

the	DT

type	NN

of	IN

chemotherapy	NN

we	PRP

used	VBN

,	,

to	TO

treat	NN

non-seminomatous	JJ

germ-cell	NN

tumors	NNS

proved	VBN

to	TO

be	VB

highly	RB

effective	JJ

for	IN

seminomatous	JJ

types	NNS

,	,

as	IN

well	RB

carboplatin	NN

and	CC

ifosfamide	NN

performed	VBN

well	RB

and	CC

safe	JJ

,	,

in	IN

the	DT

treatment	NN

of	IN

non-bulky	JJ

metastatic	JJ

seminoma	NN

these	DT

results	NNS

suggested	VBN

that	IN

the	DT

sp1	NN

decoy	NN

strategy	NN

would	MD

be	VB

effective	JJ

for	IN

regulating	VBG

tumor	NN

growth	NN

by	IN

simultaneously	RB

reducing	VBG

cancer	NN

cell	NN

(	NN

a	DT

)	NN

angiogenic	JJ

growth	NN

factor	NN

expression	NN

,	,

(	NN

b	NN

)	NN

proliferation	NN

,	,

and	CC

(	NN

c	NN

)	NN

invasiveness	NN

considering	VBG

that	IN

hamsters	NNS

had	VBD

a	DT

lung	NN

metastasis	NN

rate	NN

of	IN

50	CD

%	NN

before	IN

mdp-lys	NNS

treatment	NN

,	,

liposomal	JJ

mdp-lys	NNS

given	VBN

at	IN

a	DT

dose	NN

of	IN

20	CD

microg	NN

twice/week	NN

was	VBD

effective	JJ

for	IN

inhibiting	VBG

lung	NN

metastasis	NN

at	IN

a	DT

far	RB

lower	JJR

dose	NN

of	IN

mdp-lys	NNS

than	IN

that	IN

given	VBN

as	IN

a	DT

solution	NN

(	NN

40	CD

microg	NN

vs.	CC

350	CD

microg	NN

per	IN

week	NN

)	NN

we	PRP

have	VB

documented	VBN

previously	RB

that	IN

adenovirus-mediated	JJ

interleukin	NN

12	CD

(	NN

il-12	NN

)	NN

gene	NN

therapy	NN

is	VBZ

effective	JJ

for	IN

orthotopic	JJ

tumor	NN

control	NN

and	CC

suppression	NN

of	IN

pre-established	JJ

metastases	NNS

in	IN

a	DT

preclinical	JJ

prostate	NN

cancer	NN

model	NN

(	NN

y.	IN

nasu	NN

et	FW

al	NNP

.	.

,	,

gene	NN

ther	IN

we	PRP

further	RB

developed	VBN

a	DT

vaccine	NN

model	NN

based	VBN

on	IN

s.c.injection	NN

of	IN

infected	JJ

,	,

irradiated	JJ

rm-9	NN

cells	NNS

and	CC

found	VBN

that	IN

both	DT

admil-12	NN

and	CC

admil-12/b7	NN

are	VBP

effective	JJ

at	IN

suppressing	VBG

the	DT

development	NN

and	CC

growth	NN

of	IN

challenge	NN

orthotopic	JJ

tumors	NNS

using	VBG

this	DT

protocol	NN

despite	IN

the	DT

marked	JJ

toxicity	NN

of	IN

the	DT

initial	JJ

intensive	JJ

chemotherapy	NN

,	,

the	DT

treatments	NNS

are	VBP

tolerable	JJ

and	CC

effective	JJ

in	IN

the	DT

control	NN

of	IN

extra-thoracic	JJ

micrometastases	NNS

,	,

whereas	IN

they	PRP

are	VBP

less	JJR

effective	JJ

for	IN

thoracic	JJ

primary	JJ

tumor	NN

radiotherapy	NN

is	VBZ

effective	JJ

for	IN

palliation	NN

of	IN

symptoms	NNS

associated	VBN

with	IN

sblc	NN

clinically	RB

,	,

oral	JJ

administration	NN

of	IN

uft	NN

has	VBZ

proved	VBN

to	TO

be	VB

effective	JJ

as	IN

an	DT

adjuvant	JJ

therapy	NN

after	IN

surgery	NN

for	IN

some	DT

malignant	JJ

tumors	NNS

such	JJ

as	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

moreover	RB

,	,

uft	NN

has	VBZ

proved	VBN

to	TO

be	VB

effective	JJ

for	IN

inoperable	JJ

advanced	VBN

malignancies	NNS

such	JJ

as	IN

colorectal	JJ

cancer	NN

,	,

especially	RB

in	IN

combination	NN

with	IN

leucovorin	NN

or	CC

cisplatin	NN

a	DT

phase	NN

ii	LS

study	NN

of	IN

fractionated	VBN

administration	NN

of	IN

irinotecan	NN

(	NN

cpt-11	NN

)	NN

and	CC

cisplatin	NN

(	NN

cddp	NN

)	NN

in	IN

patients	NNS

with	IN

non-small-cell	JJ

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

was	VBD

conducted	VBN

in	IN

conclusion	NN

,	,

fractionated	VBN

administration	NN

of	IN

cpt-11	NN

and	CC

cddp	NN

was	VBD

highly	RB

effective	JJ

for	IN

advanced	VBN

nsclc	NN

with	IN

manageable	JJ

toxicities	NNS

we	PRP

report	NN

the	DT

use	NN

of	IN

paclitaxel	NN

in	IN

the	DT

successful	JJ

treatment	NN

of	IN

a	DT

patient	NN

with	IN

recurrent	JJ

adenocarcinoma	NN

of	IN

the	DT

cervix	NN

weekly	RB

paclitaxel	NN

was	VBD

very	RB

well	RB

tolerated	VBN

,	,

yet	RB

was	VBD

effective	JJ

for	IN

recurrent	JJ

cervical	JJ

adenocarcinoma	NN

conclusion	NN

:	:

our	PRP$

results	NNS

suggest	VB

that	IN

pseudoephedrine	NN

plus	CC

acetaminophen	NN

is	VBZ

effective	JJ

for	IN

relief	NN

of	IN

symptoms	NNS

attributable	JJ

to	TO

the	DT

paranasal	NN

sinuses	NNS

that	IN

may	MD

develop	VB

early	RB

in	IN

the	DT

course	NN

of	IN

a	DT

cold	JJ

reviewer	NN

's	POS

conclusions	NNS

:	:

a	DT

single	JJ

dose	NN

of	IN

nasal	JJ

decongestant	NN

in	IN

the	DT

common	JJ

cold	JJ

is	VBZ

moderately	RB

effective	JJ

for	IN

the	DT

short	RB

term	NN

relief	NN

of	IN

congestion	NN

in	IN

adults	NNS

,	,

while	IN

there	RB

is	VBZ

no	DT

evidence	NN

available	JJ

to	TO

show	NN

benefit	NN

after	IN

repeated	VBN

use	NN

over	IN

several	JJ

days	NNS

conclusions	NNS

:	:

members	NNS

of	IN

an	DT

ethnically	RB

diverse	JJ

community	NN

believe	VB

antibiotics	NNS

are	VBP

effective	JJ

for	IN

colds	NNS

,	,

are	VBP

very	RB

likely	RB

to	TO

seek	VB

care	NN

for	IN

colds	NNS

,	,

and	CC

often	RB

obtain	VB

antibiotics	NNS

without	IN

a	DT

prescription	NN

the	DT

available	JJ

inactivated	VBN

vaccine	NN

is	VBZ

effective	JJ

for	IN

preventing	VBG

influenza	NN

and	CC

the	DT

serious	JJ

disease	NN

and	CC

death	NN

that	IN

can	MD

accompany	VB

it	PRP

<	JJR

TO_SEE	NN

>	JJR

amantadine	NN

,	,

rimantadine	NN

,	,

and	CC

the	DT

newly	RB

available	JJ

drugs	NNS

zanamivir	NN

and	CC

oseltamivir	NN

are	VBP

effective	JJ

for	IN

influenza	NN

prevention	NN

and	CC

treatment	NN

(	NN

the	DT

former	JJ

two	CD

for	IN

influenza	NN

a	DT

only	RB

)	NN

<	JJR

TO_SEE	NN

>	JJR

the	DT

availability	NN

of	IN

four	CD

antiviral	JJ

agents	NNS

that	IN

effectively	RB

prevent	VB

and	CC

treat	NN

influenza	NN

provides	VBZ

the	DT

physician	NN

with	IN

considerable	JJ

flexibility	NN

for	IN

their	PRP$

use	NN

in	IN

influenza	NN

control	NN

<	JJR

TO_SEE	NN

>	JJR

thus	RB

influenza	NN

vaccination	NN

is	VBZ

effective	JJ

for	IN

preventing	VBG

influenza	NN

disease	NN

in	IN

persons	NNS

aged	JJ

65	CD

years	NNS

and	CC

over	IN

,	,

and	CC

should	MD

be	VB

an	DT

integral	JJ

part	NN

of	IN

the	DT

care	NN

of	IN

this	DT

population	NN

residing	VBG

in	IN

nursing	NN

homes	NNS

intravenous	JJ

injection	NN

of	IN

pb2-as	NNS

,	,

as	IN

a	DT

complex	NN

with	IN

dmrie-c	NN

,	,

a	DT

cationic	NN

liposome	NN

,	,

was	VBD

most	RBS

effective	JJ

for	IN

prolonging	VBG

the	DT

mean	VB

survival	NN

time	NN

in	IN

days	NNS

(	NN

msds	NNS

)	NN

and	CC

increasing	VBG

the	DT

survival	NN

rates	NNS

of	IN

mice	NNS

infected	JJ

with	IN

the	DT

influenza	NN

a	DT

virus	NN

background	NN

and	CC

objectives	NNS

:	:

thoracic	JJ

paravertebral	NN

block	NN

(	NN

tpvb	NN

)	NN

is	VBZ

a	DT

unilateral	JJ

analgesic	JJ

technique	NN

that	IN

has	VBZ

been	VBN

advocated	VBN

in	IN

both	DT

acute	JJ

and	CC

chronic	JJ

thoracic	JJ

and	CC

abdominal	JJ

pain	NN

other	JJ

blocks	NNS

such	JJ

as	IN

interpleural	JJ

and	CC

epidural	JJ

can	MD

be	VB

effectively	RB

used	VBN

in	IN

pleuritic	JJ

pain	NN

this	DT

report	NN

illustrates	VBZ

that	IN

tpvb	NN

could	MD

also	RB

be	VB

effective	JJ

for	IN

this	DT

kind	NN

of	IN

pain	NN

conclusions	NNS

:	:

this	DT

case	NN

report	NN

supports	NNS

the	DT

notion	NN

that	IN

,	,

in	IN

practice	NN

,	,

the	DT

paravertebral	NN

block	NN

could	MD

be	VB

an	DT

effective	JJ

and	CC

safe	JJ

alternative	NN

to	TO

relief	NN

of	IN

pleuritic	JJ

pain	NN

conclusion	NN

:	:

mr-guided	JJ

rfa	NN

using	VBG

single	JJ

cooled	VBN

tip	NN

electrodes	NNS

is	VBZ

safe	JJ

and	CC

technically	RB

effective	JJ

for	IN

treatment	NN

of	IN

hepatic	JJ

neoplasms	NNS

up	RB

to	TO

3	CD

cm	NN

in	IN

size	NN

,	,

however	RB

further	RB

improvements	NNS

are	VBP

necessary	JJ

a	DT

68-year-old	JJ

man	NN

underwent	VBD

curative	JJ

pancreaticoduodenectomy	NN

for	IN

bile	NN

duct	NN

cancer	NN

one	CD

course	NN

of	IN

chronochemotherapy	NN

was	VBD

effective	JJ

for	IN

lymph	NN

node	NN

and	CC

peritoneum	NN

metastases	NNS

the	DT

only	RB

specific	JJ

antidote	NN

for	IN

dosage-dependent	JJ

hepatotoxicity	NN

is	VBZ

n-acetylcysteine	NN

(	NN

and	CC

some	DT

other	JJ

sulfhydryl	NN

donors	NNS

)	NN

,	,

which	WDT

is	VBZ

highly	RB

effective	JJ

for	IN

the	DT

prevention	NN

of	IN

significant	JJ

hepatotoxicity	NN

after	IN

acetaminophen	NN

overdose	NN

corticosteroids	NNS

can	MD

be	VB

considered	VBN

for	IN

cases	NNS

of	IN

drug-induced	JJ

hepatitis	NN

,	,

especially	RB

those	DT

with	IN

evidence	NN

of	IN

immune	JJ

hypersensitivity	NN

,	,

if	IN

no	DT

improvement	NN

is	VBZ

seen	VBN

in	IN

8	CD

to	TO

12	CD

weeks	NNS

our	PRP$

conclusion	NN

was	VBD

that	IN

the	DT

covered-ems	NNS

can	MD

be	VB

effective	JJ

for	IN

the	DT

palliation	NN

of	IN

esophagorespiratory	JJ

fistulas	NNS

the	DT

food	NN

and	CC

drug	NN

administration	NN

(	NN

fda	NN

)	NN

recently	RB

approved	VBN

the	DT

first	RB

protein-polysaccharide	JJ

conjugate	NN

vaccine	NN

to	TO

prevent	VB

invasive	JJ

pneumococcal	JJ

diseases	NNS

in	IN

infants	NNS

and	CC

toddlers	NNS

<	JJR

2	CD

years	NNS

of	IN

age	NN

this	DT

conjugated	VBN

vaccine	NN

against	IN

pneumococcus	NN

uses	NNS

the	DT

same	JJ

technology	NN

as	IN

the	DT

successful	JJ

vaccine	NN

against	IN

haemophilus	NN

influenzae	NNS

type	NN

b	NN

the	DT

most	RBS

recent	JJ

study	NN

,	,

involving	VBG

over	IN

37	CD

,	,

000	CD

young	JJ

children	NNS

,	,

also	RB

evaluated	VBN

the	DT

vaccine	NN

's	POS

efficacy	NN

,	,

and	CC

reported	VBN

that	IN

the	DT

vaccine	NN

is	VBZ

highly	RB

effective	JJ

in	IN

preventing	VBG

invasive	JJ

disease	NN

and	CC

has	VBZ

had	VBD

an	DT

impact	NN

on	IN

otitis	NN

media	NNS

conclusions	NNS

:	:

the	DT

heptavalent	NN

pneumococcal	JJ

conjugate	NN

vaccine	NN

is	VBZ

safe	JJ

and	CC

highly	RB

effective	JJ

in	IN

preventing	VBG

pneumococcal	JJ

meningitis	NN

and	CC

bacteremic	JJ

pneumonia	NN

in	IN

young	JJ

children	NNS

<	JJR

2	CD

years	NNS

of	IN

age	NN

;	:

it	PRP

is	VBZ

less	JJR

effective	JJ

in	IN

preventing	VBG

otitis	NN

media	NNS

based	VBN

on	IN

the	DT

results	NNS

of	IN

three	CD

well-designed	JJ

studies	NNS

demonstrating	VBG

the	DT

vaccine	NN

's	POS

safety	NN

,	,

immunogenicity	NN

,	,

and	CC

efficacy	NN

,	,

the	DT

vaccine	NN

is	VBZ

safe	JJ

and	CC

effective	JJ

for	IN

active	JJ

immunization	NN

of	IN

children	NNS

<	JJR

2	CD

years	NNS

of	IN

age	NN

against	IN

invasive	JJ

disease	NN

caused	VBN

by	IN

seven	CD

streptococcus	NN

pneumoniae	FW

serotypes	NNS

included	VBN

in	IN

the	DT

vaccine	NN

<	JJR

TO_SEE	NN

>	JJR

i	LS

concluded	VBD

that	IN

6-month	JJ

regimen	NNS

containing	VBG

pyrazinamide	NN

was	VBD

effective	JJ

for	IN

the	DT

patients	NNS

with	IN

isoniazid-rifampicin	NN

susceptible	JJ

tuberculosis	NN

patients	NNS

except	IN

the	DT

patients	NNS

complicated	VBN

with	IN

diabetes	NN

mellitus	NN

only	RB

the	DT

combination	NN

of	IN

a	DT

cell	NN

wall-active	JJ

antibiotic	JJ

to	TO

which	WDT

the	DT

enterococcus	NN

is	VBZ

susceptible	JJ

(	NN

ie	FW

,	,

certain	JJ

beta-lactams	NNS

or	CC

vancomycin	NN

)	NN

plus	CC

an	DT

aminoglycoside	IN

(	NN

ie	FW

,	,

gentamicin	NN

or	CC

streptomycin	NN

)	NN

is	VBZ

bactericidal	JJ

,	,

and	CC

is	VBZ

required	VBN

for	IN

cure	NN

of	IN

endocarditis	NN

,	,

meningitis	NN

and	CC

probably	RB

infection	NN

in	IN

neutropenic	NN

patients	NNS

;	:

bacteriostatic	JJ

activity	NN

is	VBZ

sufficient	JJ

to	TO

treat	NN

most	RBS

other	JJ

infections	NNS

two	CD

triazole	NN

antifungal	JJ

agents	NNS

,	,

fluconazole	NN

and	CC

itraconazole	NN

,	,

were	VBD

introduced	VBN

over	IN

a	DT

decade	NN

ago	IN

and	CC

since	IN

then	RB

have	VB

been	VBN

used	VBN

extensively	RB

for	IN

the	DT

prophylaxis	NN

and	CC

treatment	NN

of	IN

a	DT

variety	NN

of	IN

fungal	JJ

infections	NNS

the	DT

use	NN

of	IN

topical	JJ

corticosteroids	NNS

has	VBZ

revolutionised	VBN

the	DT

treatment	NN

of	IN

inflammatory	JJ

skin	NN

diseases	NNS

in	IN

particular	JJ

,	,

tacrolimus	NN

and	CC

ascomycin	NN

derivatives	NNS

have	VB

been	VBN

shown	VBN

to	TO

be	VB

effective	JJ

for	IN

treating	VBG

atopic	JJ

dermatitism	NN

with	IN

a	DT

surprising	JJ

lack	NN

of	IN

side	NN

effects	NNS

cyclophosphamide	NN

therapy	NN

is	VBZ

effective	JJ

for	IN

bronchiolitis	NN

obliterans	NNS

occurring	VBG

as	IN

a	DT

late	RB

manifestation	NN

of	IN

lupus	NN

erythematosus	NN

(	NN

letter	NN

)	NN

in	IN

summary	NN

,	,

gemifloxacin	NN

was	VBD

found	VBN

to	TO

be	VB

well	RB

tolerated	VBN

and	CC

effective	JJ

for	IN

the	DT

treatment	NN

of	IN

aecb	IN

,	,

suggesting	VBG

it	PRP

is	VBZ

well	RB

suited	VBN

for	IN

empirical	JJ

treatment	NN

of	IN

this	DT

common	JJ

respiratory	JJ

condition	NN

in	IN

the	DT

current	JJ

clinical	JJ

environment	NN

d-penicillamine	NN

(	NN

2-amino-3-mercapto-3-methylbutanoic	JJ

acid	NN

)	NN

,	,

a	DT

well-known	JJ

heavy	JJ

metal	NN

chelator	NN

,	,

is	VBZ

the	DT

drug	NN

of	IN

choice	NN

in	IN

the	DT

treatment	NN

of	IN

wilson	NN

's	POS

disease	NN

and	CC

is	VBZ

also	RB

effective	JJ

for	IN

the	DT

treatment	NN

of	IN

several	JJ

disorders	NNS

including	VBG

rheumatoid	JJ

arthritis	NN

,	,

primary	JJ

biliary	JJ

cirrhosis	NN

,	,

scleroderma	NN

,	,

fibrotic	JJ

lung	NN

diseases	NNS

and	CC

progressive	JJ

systemic	JJ

sclerosis	NN

stages	NNS

of	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

that	IN

are	VBP

potential	NN

candidates	NNS

for	IN

surgical	JJ

resection	NN

have	VB

been	VBN

treated	VBN

in	IN

several	JJ

ways	NNS

:	:

surgery	NN

alone	RB

is	VBZ

curative	JJ

in	IN

only	RB

two-thirds	NNS

of	IN

cases	NNS

and	CC

post-operative	JJ

radiotherapy	NN

(	NN

rt	NN

)	NN

provides	VBZ

only	RB

weak	JJ

control	NN

of	IN

advanced-stage	NN

disease	NN

among	IN

these	DT

,	,

the	DT

gemcitabine/cisplatin	NN

study	NN

protocol	NN

(	NN

gc	NN

)	NN

,	,

set	NN

up	RB

in	IN

a	DT

phase	NN

ii	LS

study	NN

for	IN

patients	NNS

with	IN

stage	NN

iiia	NN

n2	NN

nsclc	NN

,	,

was	VBD

very	RB

effective	JJ

(	NN

objective	NN

response	NN

(	NN

or	CC

)	NN

:	:

70.2	CD

%	NN

;	:

median	NN

survival	NN

:	:

19	CD

months	NNS

)	NN

and	CC

should	MD

be	VB

promising	VBG

for	IN

stages	NNS

ib	NN

and	CC

ii	LS

several	JJ

studies	NNS

have	VB

suggested	VBN

that	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

patients	NNS

whose	WP$

tumors	NNS

have	VB

neuroendocrine	NN

(	NN

ne	NN

)	NN

features	NNS

may	MD

be	VB

more	RBR

responsive	JJ

to	TO

chemotherapy	NN

in	IN

addition	NN

,	,

increased	VBN

expression	NN

of	IN

p53	NN

and	CC

her2	NN

may	MD

confer	VB

relative	JJ

chemotherapy	NN

resistance	NN

and	CC

shortened	VBD

survival	NN

the	DT

cancer	NN

and	CC

leukemia	NN

group	NN

b	NN

performed	VBN

a	DT

series	NN

of	IN

studies	NNS

involving	VBG

sequential	JJ

chemotherapy	NN

followed	VBN

by	IN

radiation	NN

for	IN

patients	NNS

with	IN

unresectable	JJ

stage	NN

iii	LS

nsclc	NN

this	DT

london	NN

lung	NN

cancer	NN

group	NN

trial	NN

of	IN

gemcitabine/carboplatin	NN

may	MD

define	VB

an	DT

active	JJ

,	,

safe	JJ

,	,

and	CC

acceptable	JJ

treatment	NN

for	IN

patients	NNS

with	IN

extensive-stage	NN

and	CC

poor-prognosis	NN

small	JJ

cell	NN

lung	NN

cancer	NN

gemcitabine	NN

and	CC

carboplatin	NN

for	IN

patients	NNS

with	IN

advanced	VBN

non-small	JJ

cell	NN

lung	NN

cancer	NN

an	DT

aggressive	JJ

surgical	JJ

approach	NN

is	VBZ

justified	JJ

in	IN

patients	NNS

with	IN

mplc	NN

and	CC

offers	NNS

the	DT

greatest	JJS

chance	NN

for	IN

long-term	JJ

survival	NN

even	RB

in	IN

the	DT

case	NN

of	IN

limited	JJ

resection	NN

methods	NNS

and	CC

materials	NNS

:	:

eleven	NNS

patients	NNS

with	IN

small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

,	,

who	WP

had	VBD

presented	VBN

complete	JJ

response	NN

of	IN

disease	NN

after	IN

chemotherapy	NN

and	CC

radical	NN

radiotherapy	NN

in	IN

the	DT

lung	NN

,	,

were	VBD

prescribed	VBN

to	TO

receive	VB

a	DT

prophylacting	VBG

cranial	JJ

irradiation	NN

(	NN

pci	NN

)	NN

with	IN

a	DT

6	CD

mev	NN

linear	JJ

accelerator	NN

only	RB

22	CD

patients	NNS

(	NN

10	CD

%	NN

)	NN

were	VBD

alive	JJ

at	IN

five	CD

years	NNS

:	:

19	CD

patients	NNS

with	IN

nsclc	NN

who	WP

had	VBD

got	VBD

surgical	JJ

treatment	NN

,	,

one	CD

patient	NN

with	IN

nsclc	NN

(	NN

stage	NN

iiib	NN

)	NN

who	WP

had	VBD

recieved	VBN

radiotherapy	NN

,	,

and	CC

two	CD

patients	NNS

with	IN

sclc	NN

,	,

limited	JJ

disease	NN

,	,

treated	VBN

with	IN

chemo-	JJ

and	CC

radiotherapy	NN

<	JJR

TO_SEE	NN

>	JJR

the	DT

standard	NN

care	NN

for	IN

patients	NNS

with	IN

non-small-cell	JJ

lung	NN

cancer	NN

is	VBZ

chemotherapy	NN

of	IN

supportive	JJ

care	NN

,	,

with	IN

surgery	NN

being	VBG

reserved	VBN

for	IN

palliation	NN

of	IN

symptoms	NNS

;	:

however	RB

,	,

there	RB

is	VBZ

a	DT

small	JJ

group	NN

of	IN

patients	NNS

with	IN

a	DT

finite	JJ

number	NN

of	IN

extrathoracic	JJ

metastases	NNS

(	NN

oligometastases	NNS

)	NN

who	WP

may	MD

experience	NN

improved	VBN

survival	NN

by	IN

resection	NN

of	IN

their	PRP$

metastases	NNS

and	CC

the	DT

primary	JJ

site	NN

,	,

with	IN

or	CC

without	IN

systemic	JJ

treatment	NN

five	CD

new	JJ

agents	NNS

,	,

paclitaxel	NN

,	,

docetaxel	NN

,	,

vinorelbine	NN

,	,

gemcitabine	NN

and	CC

irinotecan	NN

,	,

have	VB

been	VBN

introduced	VBN

for	IN

the	DT

treatment	NN

of	IN

nsclc	NN

and	CC

investigated	VBN

extensively	RB

both	DT

preclinically	RB

and	CC

clinically	RB

whether	IN

the	DT

era	NN

of	IN

platinum-based	JJ

chemotherapy	NN

in	IN

the	DT

treatment	NN

of	IN

nsclc	NN

should	MD

continue	VB

or	CC

not	RB

must	MD

be	VB

determined	VBN

by	IN

phase	NN

iii	LS

trials	NNS

,	,

evaluating	VBG

the	DT

use	NN

of	IN

a	DT

platinum	NN

agent	NN

with	IN

one	CD

of	IN

the	DT

new	JJ

agent	NN

combinations	NNS

these	DT

aggressive	JJ

chemotherapeutic	JJ

combinations	NNS

will	MD

hopefully	RB

improve	VB

survival	NN

and	CC

quality	NN

of	IN

life	NN

for	IN

patients	NNS

with	IN

advanced	VBN

nsclc	NN

results	NNS

:	:

we	PRP

have	VB

performed	VBN

60	CD

carinal	JJ

resections	NNS

for	IN

bronchogenic	JJ

carcinoma	NN

:	:

18	CD

isolated	VBN

carinal	JJ

resections	NNS

for	IN

tumor	NN

confined	VBN

to	TO

the	DT

carinal	JJ

or	CC

proximal	JJ

main	JJ

stem	NN

bronchus	NNS

;	:

35	CD

carinal	JJ

pneumonectomies	NNS

;	:

5	CD

carinal	JJ

plus	CC

lobar	NN

resections	NNS

,	,

and	CC

2	CD

carinal	JJ

resections	NNS

for	IN

stump	NN

recurrence	NN

after	IN

prior	RB

pneumonectomy	NN

conclusions	NNS

:	:

this	DT

constitutes	VBZ

one	CD

of	IN

the	DT

largest	JJS

single-institution	NN

reports	NNS

on	IN

carinal	JJ

resection	NN

for	IN

bronchogenic	JJ

carcinoma	NN

involving	VBG

the	DT

carina	NN

extracorporeal	JJ

photopheresis	NN

has	VBZ

evolved	VBD

as	IN

a	DT

possible	JJ

therapy	NN

for	IN

patients	NNS

with	IN

acute	JJ

nd	NN

chronic	JJ

lung	NN

allograft	NN

rejection	NN

methods	NNS

:	:

we	PRP

retrospectively	RB

reviewed	VBN

14	CD

patients	NNS

diagnosed	VBN

with	IN

bos	NNS

who	WP

underwent	VBD

therapy	NN

with	IN

extracorporeal	JJ

photopheresis	NN

in	IN

three	CD

patients	NNS

with	IN

bos	NNS

and	CC

concurrent	JJ

acute	JJ

rejection	NN

,	,

therapy	NN

with	IN

extracorporeal	JJ

photopheresis	NN

led	VBN

to	TO

the	DT

resolution	NN

of	IN

the	DT

acute	JJ

rejection	NN

episode	NN

conclusion	NN

:	:

extracorporeal	JJ

photopheresis	NN

appears	VBZ

to	TO

be	VB

a	DT

promising	VBG

therapy	NN

for	IN

patients	NNS

with	IN

early	RB

bos	NNS

purpose	NN

:	:

many	JJ

patients	NNS

with	IN

locally	RB

advanced	VBN

non-small-cell	JJ

lung	NN

cancer	NN

(	NN

la-nsclc	NN

)	NN

are	VBP

eligible	NN

for	IN

combined-modality	NN

therapy	NN

(	NN

cmt	NN

;	:

chemotherapy	NN

and	CC

radiotherapy	NN

)	NN

over	IN

the	DT

past	IN

twenty	CD

years	NNS

combination	NN

chemotherapy	NN

has	VBZ

continued	VBN

to	TO

produce	VB

small	JJ

survival	NN

gains	NNS

for	IN

patients	NNS

with	IN

sclc	NN

<	JJR

TO_SEE	NN

>	JJR

purpose	NN

:	:

the	DT

benefit	NN

of	IN

whole-lung	JJ

irradiation	NN

(	NN

wli	NNS

)	NN

for	IN

patients	NNS

who	WP

have	VB

pulmonary	JJ

metastases	NNS

(	NN

pm	NN

)	NN

of	IN

ewing	VBG

sarcoma	NN

family	NN

tumors	NNS

(	NN

esft	NN

)	NN

is	VBZ

unclear	JJ

extent	NN

of	IN

pulmonary	JJ

involvement	NN

at	IN

diagnosis	NN

,	,

response	NN

of	IN

pm	NN

after	IN

induction	NN

chemotherapy	NN

,	,

local	JJ

treatment	NN

of	IN

pm	NN

thereafter	RB

,	,

and	CC

clinical	JJ

outcome	NN

were	VBD

recorded	VBN

conclusions	NNS

:	:

the	DT

comparable	JJ

survival	NN

of	IN

patients	NNS

with	IN

poor	JJ

and	CC

good	JJ

response	NN

of	IN

pm	NN

to	TO

induction	NN

chemotherapy	NN

suggests	VBZ

that	IN

wli	NNS

may	MD

benefit	NN

poor	JJ

responders	NNS

objective	NN

:	:

to	TO

report	NN

the	DT

use	NN

of	IN

heparin	NN

and	CC

enoxaparin	NN

for	IN

radiation-induced	JJ

myelopathy	NN

therefore	RB

,	,

patients	NNS

with	IN

radiation-induced	JJ

spinal	JJ

cord	NN

injury	NN

may	MD

benefit	NN

from	IN

anticoagulant	NN

therapy	NN

conclusions	NNS

:	:

heparin	NN

and/or	CC

enoxaparin	NN

may	MD

be	VB

considered	VBN

as	IN

potential	NN

treatments	NNS

for	IN

patients	NNS

with	IN

radiation-induced	JJ

myelopathy	NN

<	JJR

TO_SEE	NN

>	JJR

tracheal	NN

stent	NN

insertion	NN

is	VBZ

a	DT

useful	JJ

method	NN

for	IN

patients	NNS

with	IN

malignant	JJ

tracheal	NN

stenosis	NN

expandable	JJ

metal	NN

stents	NNS

were	VBD

inserted	VBN

in	IN

two	CD

patients	NNS

with	IN

severe	JJ

dyspnea	NN

due	JJ

to	TO

tracheal	NN

stenosis	NN

caused	VBN

by	IN

lung	NN

cancer	NN

and	CC

esophageal	NN

cancer	NN

thus	RB

,	,

we	PRP

should	MD

recognize	VB

this	DT

immanent	JJ

risk	NN

and	CC

perform	VB

peri-	JJ

and	CC

postoperative	JJ

management	NN

for	IN

patients	NNS

with	IN

gh-producing	JJ

tumors	NNS

background	NN

:	:

at	IN

present	JJ

the	DT

addition	NN

of	IN

thoracic	JJ

irradiation	NN

to	TO

combination	NN

chemotherapy	NN

is	VBZ

a	DT

standard	NN

treatment	NN

for	IN

limited	JJ

staged	VBD

small	JJ

cell	NN

lung	NN

cancer	NN

we	PRP

conducted	VBN

a	DT

phase	NN

ii	LS

study	NN

of	IN

etoposide	NN

(	NN

vp-16	NN

)	NN

-ifosfamide-cisplatin	NN

(	NN

vip	NN

)	NN

combination	NN

chemotherapy	NN

plus	CC

early	RB

concurrent	JJ

thoracic	JJ

irradiation	NN

for	IN

the	DT

patients	NNS

with	IN

previously	RB

untreated	JJ

limited	JJ

small	JJ

cell	NN

lung	NN

cancer	NN

in	IN

order	NN

to	TO

assess	VB

if	IN

the	DT

treatment	NN

modality	NN

could	MD

improve	VB

the	DT

response	NN

rate	NN

and	CC

the	DT

toxicity	NN

methods	NNS

:	:

forty-four	CD

patients	NNS

with	IN

limited	JJ

small	JJ

cell	NN

lung	NN

cancer	NN

were	VBD

treated	VBN

with	IN

etoposide-ifosfamide-cisplatin	NN

and	CC

concurrent	JJ

thoracic	JJ

irradiation	NN

conclusion	NN

:	:

vip	NN

combination	NN

chemotherapy	NN

and	CC

early	RB

concurrent	JJ

thoracic	JJ

irradiation	NN

for	IN

patients	NNS

with	IN

limited	JJ

stage	NN

small	JJ

cell	NN

lung	NN

cancer	NN

revealed	VBD

excellent	JJ

antitumor	NN

response	NN

with	IN

tolerable	JJ

toxicity	NN

in	IN

this	DT

study	NN

we	PRP

analyzed	VBN

33	CD

cases	NNS

which	WDT

underwent	VBD

complete	JJ

surgical	JJ

resection	NN

to	TO

assess	VB

the	DT

role	NN

of	IN

surgery	NN

in	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

n	NN

2	CD

nsclc	NN

we	PRP

thereby	RB

recommend	VB

that	IN

surgery	NN

should	MD

only	RB

be	VB

performed	VBN

for	IN

those	DT

n	NN

2	CD

nsclc	NN

patients	NNS

diagnosed	VBN

as	IN

t	NN

1	CD

or	CC

t	NN

2	CD

with	IN

a	DT

classification	NN

of	IN

p1	NN

or	CC

less	JJR

inhaled	VBN

corticosteroid	NN

therapy	NN

is	VBZ

recommended	VBN

for	IN

patients	NNS

with	IN

persistent	JJ

disease	NN

,	,

and	CC

careful	JJ

instruction	NN

in	IN

the	DT

use	NN

of	IN

metered-dose	JJ

inhalers	NNS

is	VBZ

particularly	RB

important	JJ

for	IN

the	DT

elderly	JJ

background	NN

:	:

the	DT

role	NN

of	IN

surgical	JJ

staging	NN

of	IN

patients	NNS

with	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

continues	VBZ

to	TO

evolve	VB

<	JJR

TO_SEE	NN

>	JJR

this	DT

report	NN

describes	VBZ

our	PRP$

findings	NNS

utilizing	VBG

routine	JJ

cervical	JJ

mediastinoscopy	NN

in	IN

the	DT

evaluation	NN

of	IN

peripheral	JJ

t1	NN

(	NN

<	JJR

3	CD

cm	NN

)	NN

lung	NN

tumors	NNS

<	JJR

TO_SEE	NN

>	JJR

mediastinoscopy	NN

facilitates	NNS

identification	NN

of	IN

patients	NNS

with	IN

regionally	RB

advanced	VBN

disease	NN

prior	RB

to	TO

resection	NN

,	,

allowing	VBG

neoadjuvant	NN

therapy	NN

and	CC

avoiding	VBG

unnecessary	JJ

resections	NNS

purpose	NN

:	:

given	VBN

the	DT

cisplatin-related	JJ

myelotoxicity	NN

and	CC

nonhematologic	JJ

toxicities	NNS

,	,

we	PRP

were	VBD

prompted	VBD

to	TO

undertake	VB

a	DT

study	NN

of	IN

the	DT

noncisplatin	NN

combination	NN

of	IN

paclitaxel	NN

plus	CC

gemcitabine	NN

to	TO

evaluate	VB

the	DT

efficacy	NN

,	,

tolerance	NN

,	,

and	CC

survival	NN

of	IN

this	DT

combination	NN

in	IN

patients	NNS

with	IN

locally	RB

advanced	VBN

and	CC

metastatic	JJ

non-small-cell	JJ

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

we	PRP

evaluated	VBN

the	DT

role	NN

of	IN

systemic	JJ

chemotherapy	NN

for	IN

patients	NNS

with	IN

malignant	JJ

pleural	JJ

effusions	NNS

from	IN

nsclc	NN

methods	NNS

:	:

we	PRP

analyzed	VBN

34	CD

patients	NNS

who	WP

were	VBD

found	VBN

to	TO

have	VB

malignant	JJ

pleural	JJ

effusions	NNS

in	IN

the	DT

course	NN

of	IN

diagnosis	NN

of	IN

118	CD

patients	NNS

enrolled	VBN

in	IN

three	CD

consecutive	JJ

clinical	JJ

trials	NNS

on	IN

advanced	VBN

nsclc	NN

assessing	VBG

combination	NN

chemotherapy	NN

of	IN

cisplatin	NN

,	,

ifosfamide	NN

,	,

and	CC

irinotecan	NN

with	IN

recombinant	JJ

human	JJ

granulocyte	NN

colony-stimulating	JJ

factor	NN

support	NN

conclusions	NNS

:	:

both	DT

the	DT

response	NN

rate	NN

and	CC

survival	NN

data	NNS

in	IN

this	DT

retrospective	NN

study	NN

suggest	VB

a	DT

high	JJ

degree	NN

of	IN

activity	NN

of	IN

this	DT

combination	NN

chemotherapy	NN

in	IN

patients	NNS

with	IN

malignant	JJ

pleural	JJ

effusions	NNS

from	IN

nsclc	NN

in	IN

contrast	NN

,	,

the	DT

introduction	NN

and	CC

improvement	NN

of	IN

chemotherapy	NN

since	IN

the	DT

1970s	NNS

gave	VBD

rise	NN

to	TO

an	DT

improvement	NN

in	IN

-	:

only	RB

short-term	JJ

(	NN

<	JJR

2	CD

years	NNS

)	NN

-	:

survival	NN

for	IN

patients	NNS

with	IN

small-cell	NN

lung	NN

cancer	NN

between	IN

july	NNP

1992	CD

and	CC

december	NNP

1997	CD

,	,

1799	CD

patients	NNS

were	VBD

diagnosed	VBN

as	IN

having	VBG

lung	NN

cancer	NN

in	IN

our	PRP$

hospital	NN

and	CC

926	CD

patients	NNS

received	VBN

chemotherapy	NN

and/or	CC

thoracic	JJ

radiotherapy	NN

the	DT

administration	NN

of	IN

mitomycin	NN

c	NN

in	IN

addition	NN

to	TO

cisplatin-based	JJ

regimens	NNS

for	IN

patients	NNS

with	IN

lung	NN

cancer	NN

should	MD

be	VB

carefully	RB

considered	VBN

570	CD

patients	NNS

with	IN

osteosarcoma	NN

of	IN

the	DT

extremities	NNS

were	VBD

treated	VBN

with	IN

five	CD

different	JJ

protocols	NNS

of	IN

neoadjuvant	NN

chemotherapy	NN

at	IN

rizzoli	NNS

institute	NN

between	IN

1983	CD

and	CC

1995	CD

we	PRP

conclude	VBP

that	IN

for	IN

patients	NNS

with	IN

osteosarcoma	NN

of	IN

the	DT

extremities	NNS

treated	VBN

with	IN

neoadjuvant	NN

chemotherapy	NN

:	:

(	NN

a	DT

)	NN

the	DT

pattern	NN

of	IN

systemic	JJ

relapse	NN

changes	NNS

according	VBG

to	TO

the	DT

efficacy	NN

of	IN

the	DT

protocol	NN

of	IN

chemotherapy	NN

used	VBN

the	DT

degree	NN

of	IN

healing	NN

and	CC

damage	NN

of	IN

the	DT

bronchial	JJ

wall	NN

after	IN

photodynamic	JJ

therapy	NN

,	,

nd-yag	NN

laser	NN

and	CC

electrocautery	NN

for	IN

intraluminal	JJ

early-stage	JJ

cancer	NN

have	VB

been	VBN

analysed	VBN

to	TO

examine	VB

whether	IN

efficacy	NN

of	IN

postoperative	JJ

oral	JJ

administration	NN

of	IN

uft	NN

,	,

a	DT

5-fluorouracil	NN

derivative	NN

chemotherapeutic	JJ

agent	NN

,	,

may	MD

be	VB

influenced	VBN

by	IN

incidence	NN

of	IN

apoptosis	NN

(	NN

apoptosis	NN

index	NN

)	NN

or	CC

apoptosis-related	JJ

gene	NN

status	NN

(	NN

p53	NN

and	CC

bcl-2	NN

)	NN

of	IN

the	DT

tumour	NN

,	,

a	DT

total	NN

of	IN

162	CD

patients	NNS

with	IN

pathologic	JJ

stage	NN

i	LS

non-small	JJ

cell	NN

lung	NN

cancer	NN

were	VBD

retrospectively	RB

reviewed	VBN

objectives	NNS

:	:

the	DT

purpose	NN

of	IN

this	DT

study	NN

is	VBZ

to	TO

review	NN

our	PRP$

experience	NN

with	IN

the	DT

spectrum	NN

of	IN

neuroendocrine	NN

neoplasms	NNS

of	IN

the	DT

lung	NN

with	IN

emphasis	NN

on	IN

the	DT

histopathologic	JJ

classification	NN

and	CC

surgical	JJ

therapy	NN

of	IN

each	DT

class	NN

of	IN

neoplasm	NN

patients	NNS

:	:

during	IN

this	DT

period	NN

,	,

a	DT

total	NN

of	IN

77	CD

patients	NNS

underwent	VBD

lung	NN

resection	NN

for	IN

the	DT

following	VBG

neuroendocrine	NN

neoplasms	NNS

:	:

typical	JJ

carcinoid	NN

(	NN

tc	NN

)	NN

,	,

50	CD

patients	NNS

;	:

atypical	JJ

carcinoid	NN

(	NN

ac	NN

)	NN

,	,

5	CD

patients	NNS

;	:

large	JJ

cell	NN

neuroendocrine	NN

carcinoma	NN

(	NN

lcnec	NN

)	NN

,	,

9	CD

patients	NNS

;	:

mixed	JJ

large-small	NN

cell	NN

neuroendocrine	NN

carcinoma	NN

(	NN

lsnec	NN

)	NN

,	,

4	CD

patients	NNS

;	:

or	CC

small	JJ

cell	NN

neuroendocrine	NN

carcinoma	NN

(	NN

scc	NN

)	NN

,	,

9	CD

patients	NNS

despite	IN

the	DT

poor	JJ

overall	RB

prognosis	NN

in	IN

high-grade	JJ

neuroendocrine	NN

tumors	NNS

of	IN

the	DT

lung	NN

,	,

surgery	NN

remains	NNS

a	DT

viable	JJ

adjunct	NN

in	IN

the	DT

early	RB

stages	NNS

of	IN

this	DT

disease	NN

urpose	NN

:	:

to	TO

assess	VB

results	NNS

with	IN

twice-daily	JJ

high-dose	JJ

radiotherapy	NN

(	NN

rt	NN

)	NN

for	IN

non-small-cell	JJ

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

is	VBZ

prolonged	JJ

survival	NN

possible	JJ

for	IN

patients	NNS

with	IN

supraclavicular	JJ

node	NN

metastases	NNS

in	IN

nsclc	NN

treated	VBN

with	IN

chemoradiotherapy	NN

?	.

ijrobp	NN

1999	CD

;	:

44	CD

(	NN

4	CD

)	NN

:	:

847-853	CD

we	PRP

aimed	VBN

to	TO

investigate	VB

whether	IN

biological	JJ

factors	NNS

related	JJ

to	TO

radiosensitivity	NN

and	CC

chemosensitivity	NN

have	VB

prognostic	JJ

significance	NN

in	IN

non-small-cell-lung-cancer	JJ

(	NN

nsclc	NN

)	NN

patients	NNS

treated	VBN

with	IN

daily	RB

low	JJ

doses	NNS

of	IN

cisplatin	NN

and	CC

radiotherapy	NN

we	PRP

treated	VBN

27	CD

nsclcm	NN

patients	NNS

with	IN

concomitant	JJ

daily	RB

low-dose	JJ

cisplatin	NN

and	CC

radiotherapy	NN

between	IN

1993	CD

and	CC

1995	CD

background	NN

:	:

we	PRP

examined	VBN

the	DT

complications	NNS

and	CC

outcomes	NNS

of	IN

placing	VBG

stents	NNS

for	IN

both	DT

esophageal	NN

and	CC

tracheobronchial	JJ

stenoses	NNS

methods	NNS

:	:

we	PRP

placed	VBN

stents	NNS

for	IN

both	DT

esophageal	NN

and	CC

tracheobronchial	JJ

stenoses	NNS

in	IN

8	CD

patients	NNS

(	NN

7	CD

with	IN

esophageal	NN

cancer	NN

and	CC

1	CD

with	IN

lung	NN

cancer	NN

)	NN

covered	VBN

or	CC

noncovered	JJ

metallic	JJ

stents	NNS

were	VBD

used	VBN

for	IN

the	DT

esophageal	NN

stenoses	NNS

,	,

except	IN

in	IN

1	CD

patient	NN

treated	VBN

with	IN

a	DT

silicone	NN

stent	NN

silicone	NN

stents	NNS

were	VBD

used	VBN

for	IN

the	DT

tracheobronchial	JJ

stenoses	NNS

results	NNS

:	:

all	DT

patients	NNS

experienced	JJ

improvement	NN

of	IN

grades	NNS

of	IN

both	DT

dysphagia	NN

and	CC

respiratory	JJ

symptoms	NNS

after	IN

stent	NN

therapy	NN

conclusions	NNS

:	:

for	IN

patients	NNS

with	IN

both	DT

esophageal	NN

and	CC

tracheobronchial	JJ

stenoses	NNS

,	,

a	DT

stent	NN

should	MD

be	VB

introduced	VBN

into	IN

the	DT

tracheobronchus	NN

first	RB

because	IN

placement	NN

of	IN

stents	NNS

in	IN

both	DT

the	DT

esophagus	NN

and	CC

tracheobronchus	NN

has	VBZ

a	DT

high	JJ

risk	NN

of	IN

enlargement	NN

of	IN

the	DT

fistula	NN

,	,

a	DT

covered	VBN

metallic	JJ

stent	NN

is	VBZ

preferable	JJ

for	IN

esophageal	NN

cancer	NN

involving	VBG

the	DT

tracheobronchus	NN

a	DT

retrospective	NN

immunohistochemical	JJ

study	NN

was	VBD

performed	VBN

on	IN

material	NN

from	IN

patients	NNS

who	WP

were	VBD

newly	RB

diagnosed	VBN

with	IN

osteogenic	JJ

sarcoma	NN

who	WP

were	VBD

treated	VBN

according	VBG

to	TO

the	DT

t12	NN

protocol	NN

from	IN

the	DT

authors	NNS

'	''

institution	NN

between	IN

1986	CD

to	TO

1993	CD

these	DT

data	NNS

suggest	VB

that	IN

her2/erbb-2	NN

should	MD

be	VB

evaluated	VBN

prospectively	RB

as	IN

a	DT

prognostic	JJ

indicator	NN

and	CC

clinical	JJ

trials	NNS

using	VBG

antibodies	NNS

that	IN

target	NN

this	DT

receptor	NN

should	MD

be	VB

considered	VBN

for	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

osteogenic	JJ

sarcoma	NN

objective	NN

:	:

to	TO

examine	VB

the	DT

effectiveness	NN

of	IN

ninjin	NN

yoei	NN

to	TO

(	NN

nyt	NN

;	:

ren-shen-yang-rong-tang	NN

in	IN

chinese	JJ

medicine	NN

;	:

kotaro	NN

pharmaceutical	JJ

co.	IN

,	,

ltd.	IN

,	,

osaka	NN

,	,

japan	NN

)	NN

,	,

one	CD

of	IN

the	DT

traditional	JJ

herbal	JJ

medicines	NNS

,	,

against	IN

lung	NN

carcinoma	NN

setting	VBG

:	:

the	DT

nursing	NN

center	NN

himawari	NNS

design	NN

,	,

patient	NN

,	,

and	CC

preparation	NN

:	:

the	DT

regular	JJ

dosage	NN

of	IN

nyt	NN

(	NN

15	CD

g/d	NN

)	NN

was	VBD

prescribed	VBN

for	IN

7	CD

weeks	NNS

to	TO

one	CD

elderly	JJ

patient	NN

with	IN

lung	NN

carcinoma	NN

conclusion	NN

:	:

nyt	NN

has	VBZ

a	DT

positive	JJ

effect	NN

on	IN

life	NN

expectancy	NN

for	IN

patients	NNS

with	IN

malignancy	NN

background	NN

:	:

the	DT

costs	NNS

of	IN

videothoracoscopic	JJ

procedures	NNS

for	IN

patients	NNS

with	IN

lung	NN

carcinoma	NN

were	VBD

compared	VBN

with	IN

those	DT

of	IN

patients	NNS

who	WP

underwent	VBD

open	JJ

thoracotomy	NN

in	IN

japan	NN

methods	NNS

:	:

the	DT

cost	NN

of	IN

surgical	JJ

treatment	NN

in	IN

1997	CD

and	CC

1998	CD

for	IN

patients	NNS

with	IN

resectable	JJ

primary	JJ

or	CC

metastatic	JJ

lung	NN

carcinoma	NN

was	VBD

analyzed	VBN

from	IN

itemized	VBN

statements	NNS

of	IN

hospital	NN

charges	NNS

for	IN

patients	NNS

with	IN

lung	NN

carcinoma	NN

who	WP

are	VBP

in	IN

relatively	RB

poor	JJ

health	NN

,	,

the	DT

authors	NNS

chose	VBD

videothoracoscopic	JJ

lobectomy	NN

or	CC

partial	JJ

resection	NN

of	IN

the	DT

lung	NN

instead	RB

of	IN

an	DT

open	JJ

thoracotomy	NN

for	IN

patients	NNS

with	IN

solitary	JJ

pulmonary	JJ

metastasis	NN

,	,

the	DT

authors	NNS

routinely	RB

performed	VBN

thoracoscopic	JJ

partial	JJ

resection	NN

of	IN

the	DT

lung	NN

background	NN

:	:

curative	JJ

therapy	NN

is	VBZ

available	JJ

for	IN

patients	NNS

with	IN

stage	NN

0	CD

lung	NN

carcinoma	NN

,	,

with	IN

a	DT

>	JJR

90	CD

%	NN

5-year	JJ

survival	NN

rate	NN

promising	VBG

chemopreventive	JJ

agents	NNS

also	RB

are	VBP

under	IN

investigation	NN

currently	RB

to	TO

reduce	VB

the	DT

risk	NN

of	IN

lung	NN

carcinoma	NN

in	IN

high	JJ

risk	NN

populations	NNS

object	NN

:	:

the	DT

purpose	NN

of	IN

this	DT

retrospective	NN

study	NN

was	VBD

to	TO

compare	VB

the	DT

effectiveness	NN

of	IN

gamma	NN

knife	NN

radiosurgery	NN

(	NN

gks	NNS

)	NN

for	IN

multiple	JJ

cerebral	JJ

metastases	NNS

with	IN

that	IN

of	IN

whole-brain	NN

radiation	NN

therapy	NN

(	NN

wbrt	NN

)	NN

in	IN

the	DT

gks	NNS

group	NN

,	,

large	JJ

lesions	NNS

(	NN

>	JJR

30	CD

mm	NN

)	NN

were	VBD

removed	VBN

surgically	RB

and	CC

all	DT

other	JJ

small	JJ

lesions	NNS

(	NN

<	JJR

or	CC

=	JJ

30	CD

mm	NN

)	NN

were	VBD

treated	VBN

by	IN

gks	NNS

new	JJ

distant	JJ

lesions	NNS

were	VBD

treated	VBN

by	IN

repeated	VBN

gks	NNS

without	IN

prophylactic	NN

wbrt	NN

conclusions	NNS

:	:

gamma	NN

knife	NN

radiosurgery	NN

without	IN

prophylactic	NN

wbrt	NN

could	MD

be	VB

a	DT

primary	JJ

choice	NN

of	IN

treatment	NN

for	IN

patients	NNS

with	IN

as	IN

many	JJ

as	IN

10	CD

cerebral	JJ

metastases	NNS

from	IN

nonsmall	NN

cell	NN

cancer	NN

the	DT

notable	JJ

exception	NN

has	VBZ

been	VBN

docetaxel	NN

,	,

which	WDT

has	VBZ

been	VBN

extensively	RB

studied	VBN

as	IN

a	DT

second-line	NN

therapy	NN

for	IN

nsclc	NN

object	NN

:	:

the	DT

purpose	NN

of	IN

this	DT

retrospective	NN

study	NN

was	VBD

to	TO

compare	VB

the	DT

effectiveness	NN

of	IN

gamma	NN

knife	NN

radiosurgery	NN

(	NN

gks	NNS

)	NN

for	IN

multiple	JJ

cerebral	JJ

metastases	NNS

with	IN

that	IN

of	IN

whole-brain	NN

radiation	NN

therapy	NN

(	NN

wbrt	NN

)	NN

patients	NNS

with	IN

a	DT

single	JJ

non-sclc	JJ

,	,

breast	NN

,	,

melanoma	NN

,	,

renal	JJ

cell	NN

,	,

and	CC

ovarian	JJ

carcinoma	NN

brain	NN

metastasis	NN

have	VB

the	DT

best	RB

chance	NN

for	IN

long-term	JJ

survival	NN

if	IN

treated	VBN

with	IN

surgical	JJ

resection	NN

and	CC

wbrt	NN

objective	NN

:	:

careful	JJ

patient	NN

selection	NN

is	VBZ

vital	JJ

when	WRB

video-assisted	JJ

thoracoscopic	JJ

surgical	JJ

(	NN

vats	NNS

)	NN

therapeutic	JJ

pulmonary	JJ

metastasectomy	NN

of	IN

colorectal	JJ

carcinoma	NN

is	VBZ

considered	VBN

we	PRP

reviewed	VBN

our	PRP$

vats	NNS

experience	NN

for	IN

therapeutic	JJ

metastasectomy	NN

of	IN

peripheral	JJ

colorectal	JJ

pulmonary	JJ

metastases	NNS

methods	NNS

:	:

over	IN

90	CD

months	NNS

,	,

therapeutic	JJ

vats	NNS

metastasectomy	NN

was	VBD

accomplished	VBN

upon	IN

80	CD

patients	NNS

with	IN

colorectal	JJ

metastases	NNS

conclusions	NNS

:	:

therapeutic	JJ

vats	NNS

resection	NN

of	IN

colorectal	JJ

metastases	NNS

appears	VBZ

efficacious	JJ

objectives	NNS

:	:

to	TO

review	NN

the	DT

spectrum	NN

of	IN

presentation	NN

and	CC

the	DT

surgical	JJ

management	NN

of	IN

non	JJ

small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

and	CC

the	DT

role	NN

of	IN

various	JJ

diagnostic	JJ

modalities	NNS

in	IN

predicting	VBG

the	DT

post-operative	JJ

stage	NN

and	CC

the	DT

correlation	NN

of	IN

the	DT

post-operative	JJ

stage	NN

with	IN

the	DT

chances	NNS

of	IN

recurrence	NN

patients	NNS

with	IN

limited-stage	NN

small-cell	NN

carcinoma	NN

of	IN

the	DT

lung	NN

are	VBP

treated	VBN

with	IN

combined-modality	NN

therapy	NN

with	IN

the	DT

intent	NN

to	TO

cure	NN

in	IN

the	DT

past	IN

several	JJ

years	NNS

,	,

new	JJ

chemotherapeutic	JJ

agents	NNS

,	,

including	VBG

the	DT

taxanes	NNS

and	CC

the	DT

topoisomerase	NN

i	LS

inhibitors	NNS

,	,

have	VB

demonstrated	VBN

substantial	JJ

activity	NN

against	IN

small-cell	NN

carcinoma	NN

we	PRP

evaluated	VBN

the	DT

role	NN

of	IN

chemotherapy	NN

for	IN

patients	NNS

with	IN

brain	NN

metastases	NNS

from	IN

nsclc	NN

methods	NNS

:	:

we	PRP

analyzed	VBN

30	CD

patients	NNS

who	WP

were	VBD

discovered	VBN

to	TO

have	VB

brain	NN

metastases	NNS

during	IN

the	DT

diagnosis	NN

of	IN

121	CD

patients	NNS

enrolled	VBN

in	IN

three	CD

consecutive	JJ

clinical	JJ

trials	NNS

on	IN

advanced	VBN

nsclc	NN

assessing	VBG

combination	NN

chemotherapy	NN

of	IN

cisplatin	NN

,	,

ifosfamide	NN

and	CC

irinotecan	NN

with	IN

rhg-csf	NN

support	NN

conclusions	NNS

:	:

both	DT

the	DT

response	NN

rate	NN

and	CC

survival	NN

data	NNS

in	IN

this	DT

retrospective	NN

study	NN

suggest	VB

a	DT

high	JJ

degree	NN

of	IN

activity	NN

of	IN

this	DT

combination	NN

chemotherapy	NN

in	IN

patients	NNS

with	IN

brain	NN

metastases	NNS

from	IN

nsclc	NN

the	DT

aim	NN

of	IN

this	DT

study	NN

was	VBD

the	DT

evaluation	NN

of	IN

both	DT

the	DT

antitumour	NN

activity	NN

and	CC

toxicity	NN

of	IN

an	DT

immunochemotherapeutic	JJ

regimen	NNS

consisting	VBG

of	IN

interferon-alpha2b	NN

and	CC

interleukin-2	NN

in	IN

combination	NN

with	IN

fotemustine	NN

for	IN

patients	NNS

with	IN

metastatic	JJ

melanoma	NN

to	TO

explore	VB

the	DT

induction	NN

of	IN

chemotherapy	NN

(	NN

ct	NN

)	NN

dna	NN

damage	NN

and	CC

its	PRP$

correlation	NN

with	IN

tumor	NN

response	NN

and	CC

patient	NN

survival	NN

,	,

we	PRP

undertook	VBD

the	DT

present	JJ

study	NN

in	IN

20	CD

small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

patients	NNS

in	IN

patients	NNS

with	IN

metastatic	JJ

colorectal	JJ

cancer	NN

,	,

intravenous	JJ

oxaliplatin	NN

has	VBZ

been	VBN

trialled	VBN

as	IN

a	DT

monotherapy	NN

and	CC

in	IN

combination	NN

with	IN

other	JJ

agents	NNS

neoadjuvant	NN

therapy	NN

with	IN

oxaliplatin/fluorouracil/folinic	JJ

acid	NN

has	VBZ

proven	VBN

beneficial	JJ

in	IN

enabling	VBG

surgical	JJ

removal	NN

of	IN

previously	RB

unresectable	JJ

liver	NN

metastases	NNS

in	IN

2	CD

studies	NNS

,	,

surgery	NN

with	IN

curative	JJ

intent	NN

was	VBD

performed	VBN

in	IN

16	CD

and	CC

51	CD

%	NN

of	IN

patients	NNS

with	IN

initially	RB

unresectable	JJ

liver	NN

metastases	NNS

following	VBG

oxaliplatin/fluorouracil/folinic	JJ

acid	NN

therapy	NN

;	:

the	DT

5-year	JJ

survival	NN

rates	NNS

were	VBD

40	CD

and	CC

50	CD

%	NN

,	,

respectively	RB

in	IN

patients	NNS

with	IN

advanced	VBN

ovarian	JJ

cancer	NN

,	,

first-line	NN

therapy	NN

with	IN

oxaliplatin/cyclophosphamide	NN

achieved	VBN

an	DT

objective	NN

response	NN

rate	NN

which	WDT

did	VBD

not	RB

differ	VB

significantly	RB

from	IN

that	IN

of	IN

cisplatin/cyclophosphamide	NN

(	NN

33	CD

vs	CC

42	CD

%	NN

)	NN

in	IN

addition	NN

,	,

oxaliplatin	NN

has	VBZ

shown	VBN

efficacy	NN

in	IN

patients	NNS

with	IN

platinum-pretreated	JJ

ovarian	JJ

cancer	NN

and	CC

achieved	VBN

objective	NN

response	NN

rates	NNS

similar	JJ

to	TO

paclitaxel	NN

in	IN

this	DT

setting	VBG

(	NN

16	CD

vs	CC

17	CD

%	NN

)	NN

promising	VBG

results	NNS

have	VB

also	RB

been	VBN

found	VBN

with	IN

oxaliplatin	NN

in	IN

patients	NNS

with	IN

non-hodgkin	JJ

's	POS

lymphoma	NN

,	,

breast	NN

cancer	NN

,	,

mesothelioma	NN

and	CC

non-small	JJ

cell	NN

lung	NN

cancer	NN

conclusion	NN

:	:

oxaliplatin	NN

in	IN

combination	NN

with	IN

fluorouracil/folinic	JJ

acid	NN

is	VBZ

an	DT

effective	JJ

treatment	NN

option	NN

for	IN

patients	NNS

with	IN

metastatic	JJ

colorectal	JJ

cancer	NN

,	,

both	DT

as	IN

a	DT

first-line	NN

therapy	NN

and	CC

in	IN

patients	NNS

refractory	JJ

to	TO

previous	JJ

chemotherapy	NN

additional	JJ

clinical	JJ

investigation	NN

of	IN

oxaliplatin	NN

in	IN

patients	NNS

with	IN

other	JJ

cancers	NNS

is	VBZ

warranted	VBN

given	VBN

the	DT

promising	VBG

results	NNS

achieved	VBN

in	IN

early	RB

trials	NNS

,	,

most	RBS

notably	RB

in	IN

patients	NNS

with	IN

platinum-pretreated	JJ

ovarian	JJ

cancer	NN

combined	VBN

modality	NN

treatment	NN

has	VBZ

'come	NN

out	IN

of	IN

age	NN

'	''

and	CC

increasingly	RB

represents	VBZ

standard	NN

of	IN

care	NN

for	IN

a	DT

rapidly	RB

growing	VBG

number	NN

of	IN

patients	NNS

in	IN

locally	RB

advanced	VBN

stages	NNS

of	IN

nsclc	NN

the	DT

current	JJ

study	NN

was	VBD

designed	VBN

to	TO

assess	VB

the	DT

prognostic	JJ

value	NN

of	IN

immunomorphologic	JJ

changes	NNS

in	IN

locoregional	JJ

lymph	NN

nodes	NNS

and	CC

lymphocytic	JJ

infiltration	NN

of	IN

primary	JJ

tumor	NN

(	NN

li	NN

)	NN

in	IN

patients	NNS

who	WP

undergo	VB

resection	NN

for	IN

bronchogenic	JJ

carcinoma	NN

conclusions	NNS

:	:

lymph	NN

node	NN

immunoreactivity	NN

and	CC

li	NN

significantly	RB

influence	NN

long	RB

term	NN

survival	NN

after	IN

curative	JJ

surgery	NN

for	IN

patients	NNS

with	IN

carcinoma	NN

of	IN

the	DT

lung	NN

and	CC

may	MD

be	VB

useful	JJ

in	IN

stratifying	VBG

patients	NNS

for	IN

prospective	JJ

trials	NNS

of	IN

adjuvant	JJ

treatment	NN

,	,

including	VBG

immunotherapy	NN

the	DT

drug	NN

is	VBZ

currently	RB

in	IN

phase	NN

iii	LS

clinical	JJ

trials	NNS

for	IN

patients	NNS

with	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

in	IN

combination	NN

with	IN

paclitaxel	NN

and	CC

carboplatin	NN

,	,

as	IN

well	RB

as	IN

in	IN

advanced	VBN

hormone	NN

refractory	JJ

prostate	NN

cancer	NN

in	IN

combination	NN

with	IN

mitoxantrone	NN

standard	NN

treatment	NN

of	IN

sclc	NN

consists	VBZ

of	IN

platinum-based	JJ

combination	NN

chemotherapy	NN

,	,

with	IN

thoracic	JJ

irradiation	NN

added	VBN

for	IN

patients	NNS

with	IN

limited-stage	NN

disease	NN

several	JJ

newer	JJR

chemotherapeutic	JJ

drugs	NNS

have	VB

recently	RB

been	VBN

shown	VBN

to	TO

have	VB

significant	JJ

activity	NN

in	IN

patients	NNS

with	IN

untreated	JJ

or	CC

relapsed	VBD

sclc	NN

we	PRP

recently	RB

performed	VBN

completion	NN

pneumonectomy	NN

of	IN

the	DT

left	RB

lung	NN

in	IN

a	DT

70-year-old	JJ

man	NN

with	IN

hemophilia	NN

a	DT

,	,

for	IN

squamous	JJ

cell	NN

carcinoma	NN

in	IN

the	DT

residual	JJ

left	RB

lung	NN

objective	NN

:	:

several	JJ

reports	NNS

emphasize	VB

the	DT

importance	NN

of	IN

en-bloc	NN

resection	NN

as	IN

the	DT

optimal	JJ

surgical	JJ

treatment	NN

of	IN

lung	NN

cancer	NN

with	IN

chest	NN

wall	NN

invasion	NN

methods	NNS

:	:

between	IN

1981	CD

and	CC

1998	CD

,	,

100	CD

patients	NNS

(	NN

90	CD

male	NN

;	:

ten	CD

female	NN

)	NN

,	,

with	IN

a	DT

median	NN

age	NN

of	IN

60	CD

years	NNS

(	NN

36-84	NN

)	NN

,	,

underwent	VBD

radical	NN

en-bloc	NN

resection	NN

of	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

with	IN

chest	NN

wall	NN

involvement	NN

over	IN

the	DT

past	IN

17	CD

years	NNS

(	NN

1981	CD

to	TO

1997	CD

)	NN

,	,

29	CD

patients	NNS

underwent	VBD

complete	JJ

pulmonary	JJ

resection	NN

for	IN

primary	JJ

lung	NN

cancer	NN

accompanied	VBN

by	IN

satellite	NN

nodules	NNS

in	IN

the	DT

same	JJ

lobe	NN

as	IN

the	DT

primary	JJ

of	IN

1	CD

,	,

042	CD

patients	NNS

with	IN

primary	JJ

lung	NN

cancer	NN

who	WP

underwent	VBD

resection	NN

from	IN

1982	CD

to	TO

1995	CD

,	,

549	CD

patients	NNS

with	IN

adenocarcinoma	NN

(	NN

ad	NN

)	NN

and	CC

363	CD

with	IN

squamous	JJ

cell	NN

carcinoma	NN

(	NN

sq	NN

)	NN

were	VBD

included	VBN

in	IN

this	DT

study	NN

for	IN

small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

,	,

which	WDT

accounts	NNS

for	IN

approximately	RB

20	CD

%	NN

of	IN

cases	NNS

of	IN

lung	NN

cancer	NN

,	,

the	DT

primary	JJ

treatment	NN

is	VBZ

chemotherapy	NN

and	CC

in	IN

the	DT

majority	NN

of	IN

cases	NNS

the	DT

primary	JJ

aim	NN

is	VBZ

to	TO

control	NN

the	DT

disease	NN

which	WDT

generally	RB

would	MD

have	VB

spread	NN

beyond	IN

the	DT

lungs	NNS

at	IN

the	DT

time	NN

of	IN

presentation	NN

a	DT

growing	VBG

body	NN

of	IN

evidence	NN

suggests	VBZ

that	IN

postoperative	JJ

irradiation	NN

for	IN

non-small	JJ

cell	NN

lung	NN

cancer	NN

may	MD

cause	NN

life-threatening	JJ

toxicity	NN

and	CC

,	,

when	WRB

the	DT

risk	NN

of	IN

local-regional	JJ

recurrence	NN

is	VBZ

low	JJ

,	,

the	DT

toxicity	NN

of	IN

irradiation	NN

may	MD

outweight	VB

the	DT

benefit	NN

as	IN

a	DT

best-case	JJ

scenario	NN

,	,

postoperative	JJ

irradiation	NN

may	MD

improve	VB

the	DT

chance	NN

for	IN

long-term	JJ

survival	NN

in	IN

patients	NNS

with	IN

n2	NN

tumors	NNS

for	IN

patients	NNS

with	IN

stage	NN

i	LS

or	CC

ii	LS

non-small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

nsclc	NN

)	NN

,	,

surgical	JJ

resection	NN

is	VBZ

considered	VBN

the	DT

standard	NN

of	IN

care	NN

efforts	NNS

at	IN

improving	VBG

survival	NN

for	IN

early-stage	JJ

nsclc	NN

patients	NNS

have	VB

focused	VBN

on	IN

the	DT

use	NN

of	IN

chemotherapy	NN

administered	VBN

postoperatively	RB

(	NN

adjuvant	JJ

)	NN

or	CC

preoperatively	RB

(	NN

neoadjuvant	NN

or	CC

induction	NN

)	NN

to	TO

eradicate	VB

micrometastatic	JJ

disease	NN

chemotherapy	NN

administered	VBN

before	IN

surgery	NN

or	CC

definitive	JJ

irradiation	NN

has	VBZ

improved	VBN

survival	NN

rates	NNS

in	IN

patients	NNS

with	IN

stage	NN

iii	LS

nsclc	NN

patients	NNS

:	:

patients	NNS

with	IN

a	DT

single	JJ

(	NN

n	NN

=	JJ

2	CD

,	,

764	CD

)	NN

and	CC

synchronous	JJ

nsclc	NN

(	NN

n	NN

=	JJ

85	CD

)	NN

who	WP

underwent	VBD

pulmonary	JJ

resection	NN

background	NN

:	:

prophylactic	NN

cranial	JJ

irradiation	NN

halves	NNS

the	DT

rate	NN

of	IN

brain	NN

metastases	NNS

in	IN

patients	NNS

with	IN

small	JJ

cell	NN

lung	NN

cancer	NN

objectives	NNS

:	:

this	DT

study	NN

aims	NNS

to	TO

test	NN

whether	IN

prophylactic	NN

cranial	JJ

irradiation	NN

prolongs	VBZ

survival	NN

of	IN

patients	NNS

with	IN

small	JJ

cell	NN

lung	NN

cancer	NN

in	IN

complete	JJ

remission	NN

reviewer	NN

's	POS

conclusions	NNS

:	:

prophylactic	NN

cranial	JJ

irradiation	NN

significantly	RB

improves	VBZ

survival	NN

and	CC

disease-free	JJ

survival	NN

for	IN

patients	NNS

with	IN

small	JJ

cell	NN

lung	NN

cancer	NN

in	IN

complete	JJ

remission	NN

methods	NNS

:	:

non-small	JJ

cell	NN

lung	NN

cancer	NN

cells	NNS

were	VBD

treated	VBN

with	IN

gemcitabine	NN

,	,

harvested	VBN

,	,

and	CC

nuclear	JJ

extracts	NNS

analyzed	VBN

for	IN

nf-kappab	JJ

dna	NN

binding	NN

by	IN

electrophoretic	JJ

mobility	NN

shift	NN

assays	NNS

novel	JJ

treatment	NN

strategies	NNS

for	IN

patients	NNS

with	IN

advanced	VBN

nsclc	NN

may	MD

involve	VB

chemotherapy	NN

combined	VBN

with	IN

inhibition	NN

of	IN

nf-kappab-dependent	JJ

cell-survival	JJ

pathways	NNS

combination	NN

chemotherapy	NN

is	VBZ

the	DT

cornerstone	NN

of	IN

treatment	NN

that	IN

confers	VBZ

a	DT

meaningful	JJ

survival	NN

benefit	NN

for	IN

patients	NNS

with	IN

small-cell	NN

lung	NN

cancer	NN

in	IN

single-agent	JJ

phase	NN

ii	LS

studies	NNS

,	,

irinotecan	NN

yielded	VBD

response	NN

rates	NNS

between	IN

16	CD

%	NN

and	CC

47	CD

%	NN

in	IN

patients	NNS

with	IN

previously	RB

treated	VBN

small-cell	NN

lung	NN

cancer	NN

a	DT

phase	NN

ii	LS

study	NN

of	IN

irinotecan	NN

in	IN

combination	NN

with	IN

cisplatin	NN

(	NN

platinol	NN

)	NN

resulted	VBD

in	IN

a	DT

response	NN

rate	NN

of	IN

86	CD

%	NN

and	CC

a	DT

median	NN

survival	NN

of	IN

13.0	CD

months	NNS

in	IN

patients	NNS

with	IN

extensive-disease	NN

small-cell	NN

lung	NN

cancer	NN

based	VBN

on	IN

these	DT

results	NNS

,	,

the	DT

irinotecan	NN

and	CC

cisplatin	NN

combination	NN

is	VBZ

a	DT

new	JJ

standard	NN

regimen	NNS

in	IN

the	DT

treatment	NN

of	IN

extensive-disease	NN

small-cell	NN

lung	NN

cancer	NN

background	NN

:	:

both	DT

gemcitabine	NN

and	CC

etoposide	NN

are	VBP

active	JJ

in	IN

the	DT

treatment	NN

of	IN

small-cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

,	,

and	CC

are	VBP

characterised	VBN

by	IN

mild	JJ

toxicity	NN

profiles	NNS

patients	NNS

and	CC

methods	NNS

:	:

forty-two	CD

chemo-naive	JJ

extensive	JJ

disease	NN

sclc	NN

patients	NNS

were	VBD

enrolled	VBN

to	TO

receive	VB

gemcitabine	NN

1000	CD

mg/m2	NN

,	,

days	NNS

1	CD

,	,

8	CD

and	CC

15	CD

,	,

and	CC

etoposide	NN

80	CD

mg/m2	NN

,	,

days	NNS

8	CD

,	,

9	CD

and	CC

10	CD

of	IN

a	DT

28-day	JJ

cycle	NN

background	NN

:	:

to	TO

find	VB

the	DT

maximum	NN

tolerated	VBN

dose	NN

for	IN

ifosfamide	NN

in	IN

combination	NN

with	IN

paclitaxel	NN

and	CC

carboplatin	NN

in	IN

small-cell	NN

lung	NN

cancer	NN

patients	NNS

(	NN

sclc	NN

)	NN

,	,

who	WP

are	VBP

resistant	JJ

to	TO

cyclophosphamide	NN

,	,

doxorubicin	NN

and	CC

etoposide	NN

(	NN

cde	NN

)	NN

conclusions	NNS

:	:

the	DT

maximum	NN

tolerated	VBN

dose	NN

of	IN

this	DT

combination	NN

for	IN

patients	NNS

with	IN

resistant	JJ

sclc	NN

is	VBZ

ifosfamide	NN

2000	CD

mg/m2	NN

in	IN

combination	NN

with	IN

paclitaxel	NN

175	CD

mg/m2	NN

and	CC

carboplatin	NN

auc	NN

6	CD

mg/ml	NN

min	NN

administered	VBN

on	IN

the	DT

first	RB

day	NN

of	IN

a	DT

21-day	JJ

cycle	NN

many	JJ

endobronchial	JJ

treatment	NN

modalities	NNS

are	VBP

available	JJ

to	TO

supplement	NN

traditional	JJ

therapies	NNS

for	IN

advanced	VBN

lung	NN

cancer	NN

methods	NNS

:	:

the	DT

author	NN

reviews	NNS

the	DT

use	NN

of	IN

several	JJ

endobronchial	JJ

treatment	NN

modalities	NNS

that	IN

can	MD

augment	VBP

standard	NN

antitumor	NN

therapies	NNS

for	IN

advanced	VBN

lung	NN

cancer	NN

,	,

including	VBG

rigid	JJ

and	CC

flexible	JJ

bronchoscopy	NN

,	,

laser	NN

therapy	NN

,	,

endobronchial	JJ

prosthesis	NN

,	,

and	CC

photodynamic	JJ

therapy	NN

conclusions	NNS

:	:

endobronchial	JJ

interventions	NNS

are	VBP

important	JJ

adjuncts	NNS

in	IN

the	DT

multimodality	NN

management	NN

of	IN

lung	NN

cancer	NN

and	CC

should	MD

become	VB

standard	NN

considerations	NNS

in	IN

the	DT

management	NN

of	IN

patients	NNS

with	IN

advanced	VBN

lung	NN

cancer	NN

standard	NN

operations	NNS

for	IN

lung	NN

cancer	NN

patients	NNS

are	VBP

generally	RB

accepted	VBN

as	IN

performing	VBG

lobectomy	NN

or	CC

pneumonectomy	NN

on	IN

the	DT

tumor	NN

baring	VBG

lung	NN

and	CC

ipsilateral	JJ

hilar	JJ

and	CC

mediastinal	JJ

lymphadenectomy	NN

including	VBG

subcarinal	JJ

lymph	NN

nodes	NNS

small	JJ

cell	NN

lung	NN

cancer	NN

is	VBZ

a	DT

frequently	RB

relapsing	VBG

tumor	NN

despite	IN

a	DT

high	JJ

rate	NN

of	IN

response	NN

after	IN

first-line	NN

chemotherapy	NN

for	IN

symptomatic	JJ

metastases	NNS

in	IN

bone	NN

or	CC

brain	NN

,	,

radiotherapy	NN

usually	RB

gives	VBZ

temporary	JJ

palliation	NN

for	IN

intrathoracic	JJ

relapse	NN

and	CC

severe	JJ

obstruction	NN

of	IN

main	JJ

bronchus	NNS

and/or	CC

superior	JJ

caval	NN

vein	NN

,	,

radiotherapy	NN

is	VBZ

a	DT

possibility	NN

if	IN

not	RB

given	VBN

as	IN

part	NN

of	IN

first-line	NN

treatment	NN

tumor	NN

vaccines	NNS

against	IN

gangliosides	NNS

that	IN

are	VBP

expressed	VBN

on	IN

almost	RB

all	DT

human	JJ

sclc	NN

cells	NNS

have	VB

been	VBN

recently	RB

developed	VBN

an	DT

anti-idiotypic	JJ

monoclonal	JJ

antibody	NN

against	IN

the	DT

gd3	NN

ganglioside	NN

,	,

bec-2	NN

,	,

is	VBZ

being	VBG

evaluated	VBN

after	IN

chemotherapy	NN

in	IN

sclc	NN

patients	NNS

in	IN

a	DT

european	NN

study	NN

the	DT

matrix	NN

metalloproteinase	NN

inhibitors	NNS

marimastat	NN

and	CC

bms-275291	NN

are	VBP

under	IN

evaluation	NN

in	IN

sclc	NN

we	PRP

attempted	VBN

a	DT

new	JJ

regimen	NNS

of	IN

intermittent	JJ

administration	NN

of	IN

5-fu	NN

and	CC

low-dose	JJ

isovorin	NN

(	NN

f.i	NNS

)	NN

to	TO

four	CD

patients	NNS

with	IN

advanced	VBN

and	CC

recurrent	JJ

colon	NN

cancer	NN

purpose/objectives	NNS

:	:

to	TO

describe	VBP

the	DT

relationship	NN

between	IN

fatigue	NN

and	CC

nutritional	JJ

status	NN

in	IN

patients	NNS

receiving	VBG

radiation	NN

therapy	NN

for	IN

lung	NN

cancer	NN

sample	NN

:	:

45	CD

adults	NNS

with	IN

primary	JJ

cancer	NN

of	IN

the	DT

lung	NN

receiving	VBG

<	JJR

outpatient	NN

primary	JJ

or	CC

adjuvant	JJ

radiation	NN

therapy	NN

we	PRP

present	JJ

the	DT

case	NN

of	IN

a	DT

patient	NN

with	IN

metastatic	JJ

transitional	JJ

cell	NN

carcinoma	NN

of	IN

the	DT

bladder	NN

and	CC

renal	JJ

failure	NN

who	WP

underwent	VBD

successful	JJ

systemic	JJ

chemotherapy	NN

with	IN

paclitaxel	NN

and	CC

carboplatin	NN

background	NN

:	:

the	DT

objective	NN

of	IN

this	DT

phase	NN

ii	LS

study	NN

was	VBD

to	TO

evaluate	VB

the	DT

concept	NN

of	IN

sequential	JJ

chemotherapy	NN

in	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

advanced	VBN

nonsmall	NN

cell	NN

lung	NN

carcinoma	NN

(	NN

nsclc	NN

)	NN

by	IN

the	DT

administration	NN

of	IN

carboplatin	NN

plus	CC

gemcitabine	NN

followed	VBN

by	IN

of	IN

paclitaxel	NN

conclusions	NNS

:	:

this	DT

study	NN

is	VBZ

the	DT

first	RB

to	TO

evaluate	VB

planned	VBN

sequential	JJ

chemotherapy	NN

in	IN

patients	NNS

with	IN

nsclc	NN

patients	NNS

who	WP

benefit	NN

from	IN

a	DT

surgical	JJ

resection	NN

for	IN

non-small-cell	JJ

lung	NN

cancer	NN

with	IN

aneuploid	NN

dna	NN

content	NN

prove	VB

to	TO

have	VB

a	DT

higher	JJR

risk	NN

of	IN

death	NN

purpose	NN

:	:

this	DT

randomized	VBN

trial	NN

was	VBD

designed	VBN

to	TO

determine	VB

whether	IN

paclitaxel	NN

plus	CC

carboplatin	NN

(	NN

pc	NN

)	NN

offered	VBN

a	DT

survival	NN

advantage	NN

over	IN

vinorelbine	NN

plus	CC

cisplatin	NN

(	NN

vc	NN

)	NN

for	IN

patients	NNS

with	IN

advanced	VBN

non	JJ

--	:

small-cell	NN

lung	NN

cancer	NN

conclusion	NN

:	:

pc	NN

is	VBZ

equally	RB

efficacious	JJ

as	IN

vc	NN

for	IN

the	DT

treatment	NN

of	IN

advanced	VBN

non	JJ

--	:

small-cell	NN

lung	NN

cancer	NN

purpose	NN

:	:

a	DT

prospective	JJ

randomized	VBN

trial	NN

in	IN

small-cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

was	VBD

performed	VBN

to	TO

determine	VB

if	IN

intensification	NN

of	IN

the	DT

platinum	NN

dose	NN

by	IN

giving	VBG

cisplatin	NN

and	CC

carboplatin	NN

in	IN

combination	NN

to	TO

patients	NNS

with	IN

sclc	NN

yields	NNS

higher	JJR

response	NN

rates	NNS

and	CC

survival	NN

,	,

than	IN

carboplatin	NN

alone	RB

in	IN

a	DT

combination	NN

chemotherapy	NN

regimen	NNS

conclusions	NNS

:	:

the	DT

intensification	NN

of	IN

platinum	NN

dose	NN

(	NN

cisplatin	NN

plus	CC

carboplatin	NN

)	NN

in	IN

combination	NN

chemotherapy	NN

significantly	RB

increased	VBN

the	DT

complete	JJ

response	NN

rate	NN

,	,

overall	RB

survival	NN

and	CC

number	NN

of	IN

two-year	JJ

survivors	NNS

among	IN

sclc	NN

patients	NNS

with	IN

limited	JJ

disease	NN

compared	VBN

to	TO

combination	NN

therapy	NN

with	IN

carboplatin	NN

alone	RB

,	,

suggesting	VBG

that	IN

a	DT

more	RBR

aggressive	JJ

treatment	NN

to	TO

this	DT

category	NN

of	IN

patients	NNS

is	VBZ

worthwhile	JJ

,	,

while	IN

no	DT

difference	NN

in	IN

treatment	NN

outcome	NN

was	VBD

observed	VBN

for	IN

patients	NNS

with	IN

extensive	JJ

disease	NN

the	DT

aim	NN

of	IN

this	DT

study	NN

was	VBD

to	TO

investigate	VB

the	DT

relationships	NNS

among	IN

technetium-99m	NN

tetrofosmin	NN

(	NN

tc-tf	NN

)	NN

accumulation	NN

in	IN

untreated	JJ

small	JJ

cell	NN

lung	NN

cancer	NN

(	NN

sclc	NN

)	NN

,	,

the	DT

expression	NN

of	IN

p-glycoprotein	NN

(	NN

pgp	NN

)	NN

and	CC

multidrug	JJ

resistance	NN

related	JJ

protein-1	NN

(	NN

mrp1	NN

)	NN

,	,

and	CC

the	DT

response	NN

to	TO

chemotherapy	NN

in	IN

patients	NNS

with	IN

untreated	JJ

sclc	NN

tc-tf	NN

chest	NN

scintigraphy	NN

correlated	VBD

well	RB

with	IN

pgp	NN

or	CC

mrp1	NN

expression	NN

and	CC

accurately	RB

predicted	VBN

the	DT

response	NN

to	TO

chemotherapy	NN

in	IN

patients	NNS

with	IN

sclc	NN

exploratory	NN

interventions	NNS

,	,

partial	JJ

tumor	NN

resections	NNS

and	CC

lung	NN

resections	NNS

for	IN

metastasis	NN

were	VBD

more	RBR

frequently	RB

performed	VBN

in	IN

young	JJ

patients	NNS

than	IN

in	IN

older	JJR

patients	NNS

in	IN

the	DT

present	JJ

report	NN

,	,

we	PRP

reviewed	VBN

articles	NNS

on	IN

pulmonary	JJ

angiography	NN

for	IN

patients	NNS

with	IN

pulmonary	JJ

hypertension	NN

prophylactic	NN

cranial	JJ

irradiation	NN

(	NN

pci	NN

)	NN

has	VBZ

been	VBN

demonstrated	VBN

to	TO

significantly	RB

reduce	VB

the	DT

incidence	NN

of	IN

brain	NN

relapse	NN

from	IN

limited	JJ

disease	NN

small-cell	NN

lung	NN

cancer	NN

(	NN

ld	NN

sclc	NN

)	NN

,	,

but	CC

concerns	NNS

about	IN

neurologic	JJ

toxicity	NN

remain	VB

thus	RB

,	,

twice-daily	JJ

pci	NN

should	MD

be	VB

considered	VBN

for	IN

patients	NNS

with	IN

ld	NN

sclc	NN

who	WP

achieve	VB

a	DT

complete	JJ

response	NN

to	TO

chemoirradiation	NN

animal	NN

studies	NNS

suggest	VB

that	IN

the	DT

kidney	NN

is	VBZ

involved	VBN

in	IN

the	DT

elimination	NN

of	IN

recombinant	JJ

human	JJ

granulocyte	NN

colony-stimulating	JJ

factor	NN

(	NN

rhg-csf	NN

)	NN

,	,

which	WDT

is	VBZ

used	VBN

for	IN

patients	NNS

with	IN

neutropenia	NN

during	IN

cancer	NN

chemotherapy	NN

amifostine	NN

(	NN

wr-2721	NN

)	NN

is	VBZ

a	DT

cytoprotective	JJ

agent	NN

that	IN

protects	VBZ

a	DT

broad	JJ

range	NN

of	IN

normal	JJ

tissues	NNS

from	IN

the	DT

toxic	JJ

effects	NNS

of	IN

chemotherapy	NN

and	CC

radiotherapy	NN

without	IN

attenuating	VBG

tumour	NN

response	NN

in	IN

a	DT

pivotal	JJ

phase	NN

iii	LS

trial	NN

,	,

242	CD

patients	NNS

with	IN

advanced	VBN

ovarian	JJ

cancer	NN

were	VBD

randomised	VBN

to	TO

receive	VB

treatment	NN

with	IN

cisplatin	NN

100	CD

mg/m2	NN

and	CC

cyclophosphamide	NN

1000	CD

mg/m2	NN

every	DT

3	CD

weeks	NNS

with	IN

or	CC

without	IN

pretreatment	NN

with	IN

intravenous	JJ

amifostine	NN

910	CD

mg/m2	NN

over	IN

6	CD

cycles	NNS

of	IN

therapy	NN

,	,

amifostine	NN

significantly	RB

reduced	VBN

haematological	JJ

,	,

renal	JJ

and	CC

neurological	JJ

toxicities	NNS

:	:

treatment	NN

delays	NNS

,	,

treatment	NN

discontinuation	NN

and	CC

days	NNS

in	IN

hospital	NN

related	JJ

to	TO

these	DT

adverse	JJ

events	NNS

were	VBD

also	RB

significantly	RB

reduced	VBN

in	IN

patients	NNS

receiving	VBG

amifostine	NN

versus	CC

patients	NNS

receiving	VBG

chemotherapy	NN

alone	RB

<	JJR

TO_SEE	NN

>	JJR

in	IN

another	DT

randomised	VBN

phase	NN

iii	LS

trial	NN

in	IN

303	CD

patients	NNS

with	IN

head	NN

and	CC

neck	NN

cancer	NN

undergoing	VBG

irradiation	NN

therapy	NN

(	NN

total	NN

dose	NN

50	CD

to	TO

70gy	JJ

)	NN

,	,

pretreatment	NN

with	IN

intravenous	JJ

amifostine	NN

200	CD

mg/m2	NN

significantly	RB

reduced	VBN

the	DT

incidence	NN

of	IN

acute	JJ

and	CC

late	RB

grade	NN

>	JJR

or	CC

=2	NN

xerostomia	NN

amifostine	NN

(	NN

340	CD

mg/m2	NN

)	NN

also	RB

provided	VBN

significant	JJ

protection	NN

against	IN

pneumonitis	NN

and	CC

oesophagitis	NN

in	IN

patients	NNS

with	IN

lung	NN

cancer	NN

receiving	VBG

thoracic	JJ

irradiation	NN

in	IN

a	DT

preliminary	JJ

report	NN

from	IN

a	DT

phase	NN

iii	LS

trial	NN

(	NN

n	NN

=	JJ

144	CD

)	NN

amifostine	NN

has	VBZ

also	RB

been	VBN

shown	VBN

to	TO

stimulate	VB

haematopoietic	JJ

stem	NN

cells	NNS

and	CC

has	VBZ

been	VBN

investigated	VBN

as	IN

a	DT

therapy	NN

for	IN

patients	NNS

with	IN

myelodysplastic	JJ

syndrome	NN

in	IN

number	NN

of	IN

small	JJ

preliminary	JJ

studies	NNS

<	JJR

TO_SEE	NN

>	JJR

conclusion	NN

:	:

the	DT

results	NNS

of	IN

phase	NN

iii	LS

trials	NNS

have	VB

confirmed	VBN

the	DT

safety	NN

and	CC

efficacy	NN

of	IN

amifostine	NN

as	IN

a	DT

cytoprotectant	NN

to	TO

ameliorate	VB

cisplatin-induced	JJ

cumulative	JJ

renal	JJ

toxicity	NN

,	,

for	IN

which	WDT

it	PRP

is	VBZ

the	DT

only	RB

agent	NN

proven	VBN

to	TO

be	VB

effective	JJ

,	,

and	CC

neutropenia	NN

in	IN

patients	NNS

with	IN

advanced	VBN

ovarian	JJ

cancer	NN

,	,

and	CC

to	TO

reduce	VB

xerostomia	NN

in	IN

patients	NNS

with	IN

head	NN

and	CC

neck	NN

cancer	NN

receiving	VBG

irradiation	NN

therapy	NN

depending	VBG

on	IN

the	DT

outcome	NN

of	IN

numerous	JJ

ongoing	JJ

clinical	JJ

trials	NNS

,	,

amifostine	NN

may	MD

eventually	RB

find	VB

broader	JJR

clinical	JJ

applications	NNS

,	,

both	DT

as	IN

a	DT

cytoprotectant	NN

and	CC

as	IN

a	DT

potential	NN

therapy	NN

in	IN

myelodysplastic	JJ

syndrome	NN

to	TO

perform	VB

a	DT

curative	JJ

operation	NN

for	IN

the	DT

lung	NN

cancer	NN

without	IN

myocardial	JJ

infarction	NN

,	,

minimally	RB

invasive	JJ

direct	JJ

coronary	JJ

artery	NN

bypass	NN

and	CC

left	RB

lower	JJR

lobectomy	NN

with	IN

video-endoscopic	JJ

assistance	NN

were	VBD

performed	VBN

simultaneously	RB

A	DT

review	NN

of	IN

the	DT

fetal-maternal	JJ

carboxyhemoglobin	NN

relationships	NNS

and	CC

the	DT

differences	NNS

in	IN

fetal	JJ

oxyhemoglobin	NN

physiology	NN

are	VBP

used	VBN

to	TO

explain	VB

the	DT

recommendation	NN

that	IN

pregnant	JJ

women	NNS

with	IN

carbon	NN

monoxide	NN

poisoning	NN

should	MD

receive	VB

100	CD

%	NN

oxygen	NN

therapy	NN

for	IN

up	RB

to	TO

five	CD

times	NNS

longer	RB

than	IN

is	VBZ

otherwise	RB

necessary	JJ

The	DT

authors	NNS

describe	VBP

the	DT

case	NN

of	IN

a	DT

child	NN

with	IN

status	NN

epilepticus	NN

in	IN

whom	WP

phenytoin	NN

was	VBD

administered	VBN

via	IN

the	DT

intraosseous	JJ

route	NN

,	,

and	CC

seizure	NN

resolution	NN

and	CC

therapeutic	JJ

serum	NN

levels	NNS

were	VBD

achieved	VBN

A	DT

patient	NN

suffering	VBG

baclofen	NN

overdose	NN

successfully	RB

treated	VBN

with	IN

atropine	NN

is	VBZ

reported	VBN

Atropine	NNP

appears	VBZ

to	TO

be	VB

useful	JJ

in	IN

treating	VBG

cases	NNS

of	IN

baclofen	NN

overdose	NN

complicated	VBN

by	IN

bradycardia	NN

and	CC

hypotension	NN

Therapeutic	JJ

effect	NN

of	IN

a	DT

left	RB

ventricular	JJ

assist	VB

device	NN

on	IN

acute	JJ

myocardial	JJ

infarction	NN

evaluated	VBN

by	IN

magnetic	JJ

resonance	NN

imaging	NN

Continuous	JJ

arteriovenous	JJ

hemofiltration	NN

for	IN

the	DT

treatment	NN

of	IN

anasarca	NN

and	CC

acute	JJ

renal	JJ

failure	NN

in	IN

severely	RB

burned	VBN

patients	NNS

Continuous	JJ

renal	JJ

replacement	NN

therapy	NN

in	IN

patients	NNS

with	IN

acute	JJ

renal	JJ

dysfunction	NN

undergoing	VBG

intraaortic	JJ

balloon	NN

pump	NN

and/or	CC

left	RB

ventricular	JJ

device	NN

support	NN

Continuous	JJ

arterio-venous	JJ

hemofiltration	NN

in	IN

a	DT

wearable	JJ

device	NN

to	TO

treat	NN

end-stage	NN

renal	JJ

disease	NN

The	DT

effectiveness	NN

of	IN

neostigmine	NN

0.07	CD

mg	NN

kg-1	NN

and	CC

edrophonium	NN

0.8	CD

mg	NN

kg-1	NN

as	IN

antagonists	NNS

of	IN

profound	JJ

neuromuscular	JJ

blockade	NN

induced	VBN

by	IN

vecuronium	NN

0.1	CD

mg	NN

kg-1	NN

or	CC

atracurium	NN

0.5	CD

mg	NN

kg-1	NN

was	VBD

studied	VBN

in	IN

59	CD

healthy	JJ

patients	NNS

Antagonism	NN

of	IN

atracurium-induced	JJ

neuromuscular	JJ

blockade	NN

by	IN

neostigmine	NN

or	CC

edrophonium	NN

has	VBZ

been	VBN

studied	VBN

using	VBG

the	DT

tetanic	JJ

(	NN

50	CD

Hz	NN

)	NN

and	CC

train-of-four	NN

(	NN

2	CD

Hz	NN

)	NN

or	CC

single	JJ

twitch	VB

responses	NNS

of	IN

the	DT

adductor	NN

pollicis	NN

muscle	NN

in	IN

22	CD

anaesthetized	VBN

patients	NNS

Active	JJ

forms	NNS

of	IN

vitamin	NN

D3	NN

,	,

1	CD

alpha-hydroxyvitamin	NN

D3	NN

and	CC

1	CD

alpha	NN

,	,

25-dihydroxyvitamin	NN

D3	NN

,	,

were	VBD

administered	VBN

in	IN

an	DT

open-design	JJ

study	NN

to	TO

40	CD

patients	NNS

with	IN

psoriasis	NN

vulgaris	NN

in	IN

three	CD

ways	NNS

:	:

to	TO

17	CD

patients	NNS

1	CD

alpha-hydroxyvitamin	NN

D3	NN

was	VBD

given	VBN

orally	RB

at	IN

a	DT

dose	NN

of	IN

1.0	CD

micrograms/day	NN

for	IN

6	CD

months	NNS

,	,

to	TO

four	CD

patients	NNS

1	CD

alpha	NN

,	,

25-dihydroxyvitamin	NN

D3	NN

was	VBD

given	VBN

orally	RB

at	IN

a	DT

dose	NN

of	IN

0.5	CD

microgram/day	NNS

for	IN

6	CD

months	NNS

,	,

and	CC

19	CD

patients	NNS

were	VBD

given	VBN

1	CD

alpha	NN

,	,

25-dihydroxyvitamin	NN

D3	NN

applied	VBN

topically	RB

at	IN

concentration	NN

of	IN

0.5	CD

microgram/g	NN

of	IN

base	NN

for	IN

8	CD

weeks	NNS

These	DT

data	NNS

suggest	VB

that	IN

psoriasis	NN

may	MD

respond	NN

to	TO

active	JJ

metabolites	NNS

of	IN

vitamin	NN

D3	NN

and	CC

that	IN

abnormalities	NNS

in	IN

vitamin	NN

D	NN

metabolism	NN

or	CC

in	IN

responsiveness	NN

of	IN

the	DT

skin	NN

cells	NNS

to	TO

active	JJ

metabolites	NNS

of	IN

vitamin	NN

D	NN

may	MD

be	VB

involved	VBN

in	IN

the	DT

pathogenesis	NN

of	IN

this	DT

skin	NN

disease	NN

Successful	JJ

treatment	NN

of	IN

psoriasis	NN

with	IN

topical	JJ

application	NN

of	IN

active	JJ

vitamin	NN

D3	NN

analogue	NN

,	,

1	CD

alpha	NN

,	,

24-dihydroxycholecalciferol	JJ

We	PRP

suggest	VB

that	IN

1	CD

alpha	NN

,	,

24	CD

(	NN

OH	NN

)	NN

2D3	NN

merits	NNS

further	RB

investigation	NN

as	IN

a	DT

potentially	RB

useful	JJ

topical	JJ

therapy	NN

for	IN

psoriasis	NN

When	WRB

indomethacin	NN

was	VBD

applied	VBN

immediately	RB

after	IN

irradiation	NN

,	,

UVR	NN

(	NN

ultraviolet	NN

radiation	NN

)	NN

dose-dependent	JJ

suppression	NN

of	IN

erythema	NN

was	VBD

demonstrated	VBN

for	IN

both	DT

wavelengths	NNS

until	IN

36	CD

h	NN

after	IN

irradiation	NN

when	WRB

both	DT

indomethacin	NN

and	CC

control	NN

gel	NN

base-treated	JJ

sites	NNS

were	VBD

equally	RB

erythematous	JJ

Suppression	NN

of	IN

erythema	NN

also	RB

occurred	VBD

when	WRB

application	NN

of	IN

indomethacin	NN

was	VBD

delayed	VBN

until	IN

24	CD

h	NN

after	IN

irradiation	NN

,	,

showing	VBG

that	IN

for	IN

both	DT

wavelengths	NNS

prostaglandin	NN

synthesis	NN

remains	NNS

increased	VBN

throughout	IN

this	DT

period	NN

There	EX

was	VBD

one	CD

retinal	JJ

dialysis	NN

,	,

and	CC

one	CD

lens	NN

dislocation	NN

requiring	VBG

extraction	NN

Rates	NNS

of	IN

superoxide	NN

(	NN

SA	NNP

)	NN

generation	NN

by	IN

blood	NN

monocytes	NNS

stimulated	VBN

ex	FW

vivo	FW

were	VBD

studied	VBN

before	IN

and	CC

during	IN

corticosteroid	NN

treatment	NN

of	IN

rheumatoid	JJ

arthritis	NN

(	NN

RA	NN

)	NN

patients	NNS

,	,

in	IN

control	NN

patients	NNS

and	CC

in	IN

healthy	JJ

controls	NNS

Significant	JJ

inhibition	NN

of	IN

monocyte	NN

SA	NNP

output	NN

stimulated	VBN

with	IN

IgG-treated	JJ

zymosan	NN

(	NN

ITZ	NN

)	NN

and	CC

fluoride	NN

ion	NN

(	NN

F	NN

)	NN

,	,

but	CC

not	RB

serum-treated	JJ

zymosan	NN

(	NN

STZ	NN

)	NN

was	VBD

demonstrated	VBN

following	VBG

steroid	NN

therapy	NN

in	IN

RA	NN

Methotrexate	NNP

(	NN

MTX	NN

)	NN

appears	VBZ

to	TO

be	VB

useful	JJ

in	IN

patients	NNS

with	IN

rheumatoid	JJ

arthritis	NN

(	NN

RA	NN

)	NN

refractory	JJ

to	TO

other	JJ

drugs	NNS

but	CC

its	PRP$

long-term	JJ

toxicity	NN

and	CC

efficacy	NN

are	VBP

uncertain	JJ

MTX	NN

in	IN

a	DT

low-dose	JJ

regimen	NNS

is	VBZ

useful	JJ

in	IN

refractory	JJ

RA	NN

and	CC

superior	JJ

to	TO

low-dose	JJ

purine	NN

analogues	NNS

Twelve	CD

patients	NNS

with	IN

intractable	JJ

rheumatoid	JJ

arthritis	NN

were	VBD

treated	VBN

with	IN

antilymphocyte	NN

globulin	NN

(	NN

ALG	NN

)	NN

,	,

prednisolone	NN

and	CC

a	DT

cytotoxic	JJ

agent	NN

,	,

usually	RB

azathioprine	NN

,	,

and	CC

were	VBD

followed	VBN

for	IN

1	CD

year	NN

Rigid	JJ

ureteroscopy	NN

for	IN

the	DT

treatment	NN

of	IN

ureteric	JJ

calculi	NNS

:	:

experience	NN

in	IN

120	CD

cases	NNS

Over	IN

a	DT

1-year	JJ

period	NN

,	,

rigid	JJ

ureteroscopy	NN

has	VBZ

been	VBN

used	VBN

to	TO

retrieve	VB

ureteric	JJ

calculi	NNS

in	IN

120	CD

patients	NNS

Eleven	CD

patients	NNS

with	IN

vesicoureteric	JJ

reflux	NN

secondary	JJ

to	TO

neuropathic	JJ

bladder	NN

were	VBD

treated	VBN

by	IN

endoscopic	JJ

injection	NN

of	IN

pyrolised	VBN

polytetrafluoroethylene	NN

(	NN

Polytef	NN

)	NN

paste	VB

Two	CD

hundred	CD

and	CC

seventy-seven	CD

patients	NNS

with	IN

advanced	VBN

prostatic	JJ

cancer	NN

were	VBD

treated	VBN

by	IN

either	DT

orchiectomy	NN

or	CC

oestrogen	NN

Use	NN

of	IN

scarred	VBN

flaps	NNS

and	CC

secondary	JJ

flaps	NNS

for	IN

reconstructive	NN

surgery	NN

of	IN

extensive	JJ

burns	NNS

A	DT

patient	NN

with	IN

a	DT

vesico-enteric	JJ

fistula	NN

was	VBD

successfully	RB

treated	VBN

with	IN

resection	NN

of	IN

the	DT

small	JJ

intestine	NN

and	CC

dome	NN

of	IN

the	DT

bladder	NN

and	CC

drainage	NN

of	IN

the	DT

intervening	VBG

abscess	NN

Supramaximal	JJ

horizontal	JJ

rectus	NN

surgery	NN

in	IN

the	DT

management	NN

of	IN

third	JJ

and	CC

sixth	JJ

nerve	NN

palsy	NN

Supramaximal	JJ

medial	JJ

and	CC

lateral	JJ

rectus	NN

surgery	NN

was	VBD

performed	VBN

to	TO

correct	JJ

horizontal	JJ

deviations	NNS

in	IN

seven	CD

cases	NNS

of	IN

sixth	JJ

nerve	NN

palsy	NN

and	CC

three	CD

cases	NNS

of	IN

third	JJ

nerve	NN

palsy	NN

,	,

with	IN

satisfactory	JJ

results	NNS

in	IN

most	RBS

cases	NNS

Steroid	NN

therapy	NN

was	VBD

also	RB

used	VBN

in	IN

two	CD

patients	NNS

with	IN

NSAID-induced	JJ

proteinuria	NN

Recombinant	JJ

leukocyte	NN

A	DT

interferon	NN

(	NN

rIFN-alpha	NN

A	DT

)	NN

in	IN

the	DT

treatment	NN

of	IN

disseminated	VBN

malignant	JJ

melanoma	NN

Ninety-six	CD

patients	NNS

with	IN

disseminated	VBN

malignant	JJ

melanoma	NN

received	VBN

thrice	NN

weekly	RB

intramuscular	JJ

injections	NNS

of	IN

leukocyte	NN

A	DT

recombinant	JJ

interferon	NN

(	NN

rIFN-alpha	NN

A	DT

,	,

Roferon-A	NN

,	,

Hoffmann	NNP

La	NNP

Roche	NNP

)	NN

at	IN

doses	NNS

of	IN

12	CD

X	NN

10	CD

(	NN

6	CD

)	NN

U/m2	NN

or	CC

50	CD

X	NN

10	CD

(	NN

6	CD

)	NN

U/m2	NN

with	IN

or	CC

without	IN

cimetidine	NN

as	IN

an	DT

immunorestorative	JJ

agent	NN

As	IN

noted	VBN

previously	RB

,	,

using	VBG

chemotherapy	NN

,	,

a	DT

small	JJ

proportion	NN

of	IN

patients	NNS

with	IN

advanced	VBN

malignant	JJ

melanoma	NN

,	,

despite	IN

prior	RB

therapy	NN

,	,

may	MD

achieve	VB

prolonged	JJ

objective	NN

regression	NN

with	IN

rIFN-alpha	NN

A	DT

Clinical	JJ

course	NN

of	IN

breast	NN

cancer	NN

patients	NNS

with	IN

osseous	JJ

metastasis	NN

treated	VBN

with	IN

combination	NN

chemotherapy	NN

Between	IN

July	NNP

1973	CD

and	CC

December	NNP

1979	CD

,	,

1171	CD

patients	NNS

with	IN

metastatic	JJ

breast	NN

cancer	NN

were	VBD

treated	VBN

with	IN

doxorubicin-containing	JJ

chemotherapy	NN

Two	CD

patients	NNS

with	IN

metastatic	JJ

dysgerminoma	NN

of	IN

the	DT

ovary	NN

were	VBD

treated	VBN

with	IN

a	DT

combination	NN

of	IN

etoposide	NN

,	,

bleomycin	NN

,	,

and	CC

cisplatin	NN

at	IN

The	DT

University	NNP

of	IN

Texas	NNP

M.D	NN

Chemotherapy	NN

may	MD

be	VB

an	DT

alternative	NN

to	TO

radiotherapy	NN

for	IN

the	DT

treatment	NN

of	IN

metastatic	JJ

dysgerminoma	NN

and	CC

should	MD

also	RB

be	VB

considered	VBN

for	IN

selected	VBN

patients	NNS

with	IN

Stage	NN

I	PRP

disease	NN

Long-term	JJ

survival	NN

and	CC

morbidity	NN

in	IN

patients	NNS

with	IN

metastatic	JJ

malignant	JJ

germ	NN

cell	NN

tumors	NNS

treated	VBN

with	IN

cisplatin-based	JJ

combination	NN

chemotherapy	NN

Treatment	NN

of	IN

advanced	VBN

stage	NN

mycosis	NN

fungoides	NNS

with	IN

bleomycin	NN

,	,

doxorubicin	NN

,	,

and	CC

methotrexate	NN

with	IN

topical	JJ

nitrogen	NN

mustard	NN

(	NN

BAM-M	NN

)	NN

Ten	CD

patients	NNS

with	IN

advanced	VBN

stage	NN

(	NN

TNM	NN

IIB-IVB	NN

)	NN

mycosis	NN

fungoides	NNS

were	VBD

treated	VBN

with	IN

a	DT

combination	NN

chemotherapy	NN

program	NN

consisting	VBG

of	IN

bleomycin	NN

and	CC

methotrexate	NN

weekly	RB

,	,

doxorubicin	NN

every	DT

3	CD

weeks	NNS

,	,

and	CC

topical	JJ

nitrogen	NN

mustard	NN

daily	RB

(	NN

BAM-M	NN

)	NN

Three	CD

patients	NNS

in	IN

whom	WP

splenomegaly	NN

was	VBD

detected	VBN

during	IN

their	PRP$

staging	NN

evaluation	NN

underwent	VBD

splenectomy	NN

This	DT

study	NN

indicates	VBZ

that	IN

BAM-M	NN

is	VBZ

effective	JJ

therapy	NN

for	IN

advanced	VBN

stage	NN

mycosis	NN

fungoides	NNS

and	CC

suggests	VBZ

that	IN

the	DT

therapeutic	JJ

role	NN

of	IN

splenectomy	NN

should	MD

be	VB

evaluated	VBN

further	RB

Only	RB

patients	NNS

whose	WP$

primary	JJ

head	NN

and	CC

neck	NN

tumor	NN

shows	NNS

a	DT

response	NN

to	TO

systemic	JJ

therapy	NN

undergo	VB

Ommaya	NNP

placement	NN

Additional	JJ

chemotherapy	NN

may	MD

thus	RB

have	VB

eradicated	VBN

these	DT

micrometastases	NNS

in	IN

the	DT

older	JJR

children	NNS

,	,

since	IN

the	DT

age	NN

influence	NN

on	IN

Stage	NN

II	NNP

disease	NN

disappeared	VBD

when	WRB

multimodal	JJ

treatment	NN

was	VBD

given	VBN

in	IN

this	DT

study	NN

Traditional	JJ

therapy	NN

for	IN

malignant	JJ

pleural	JJ

effusions	NNS

includes	VBZ

thoracentesis	NN

or	CC

tube	NN

drainage	NN

with	IN

instillation	NN

of	IN

irritants	NNS

to	TO

achieve	VB

pleurodesis	NN

We	PRP

feel	VB

that	IN

pleuroperitoneal	NN

shunting	VBG

is	VBZ

a	DT

valid	JJ

new	JJ

method	NN

for	IN

treatment	NN

of	IN

malignant	JJ

pleural	JJ

effusions	NNS

which	WDT

can	MD

effectively	RB

palliate	VB

respiratory	JJ

symptoms	NNS

with	IN

low	JJ

morbidity	NN

When	WRB

right	RB

ventricular	JJ

failure	NN

prohibits	VBZ

separation	NN

from	IN

cardiopulmonary	JJ

bypass	NN

,	,

standard	NN

methods	NNS

of	IN

increasing	VBG

pulmonary	JJ

blood	NN

flow	NN

should	MD

be	VB

employed	VBN

,	,

including	VBG

correction	NN

of	IN

hypoxia	NN

and	CC

acidosis	NN

,	,

volume	NN

loading	VBG

,	,

and	CC

inotropic	JJ

support	NN

of	IN

the	DT

right	RB

ventricle	NN

For	IN

refractory	JJ

right	RB

ventricular	JJ

failure	NN

following	VBG

the	DT

surgical	JJ

repair	NN

of	IN

congenital	JJ

cardiac	JJ

defects	NNS

in	IN

which	WDT

the	DT

placement	NN

of	IN

right	RB

atrial	IN

and	CC

pulmonary	JJ

artery	NN

cannulae	FW

is	VBZ

not	RB

technically	RB

feasible	JJ

,	,

use	NN

of	IN

high-frequency	VB

high-volume	JJ

ventilation	NN

appears	VBZ

to	TO

be	VB

quite	RB

promising	VBG

Current	JJ

results	NNS

suggest	VB

that	IN

RHBP	NN

remains	NNS

the	DT

gold	NN

standard	NN

for	IN

severe	JJ

RV	NN

failure	NN

,	,

but	CC

further	RB

clinical	JJ

experience	NN

with	IN

PABC	NN

may	MD

more	RBR

clearly	RB

define	VB

its	PRP$

role	NN

in	IN

the	DT

management	NN

of	IN

RV	NN

failure	NN

Guiding	VBG

surgical	JJ

therapy	NN

of	IN

ventricular	JJ

tachycardia	NN

by	IN

preoperative	JJ

endocardial	JJ

catheter	NN

mapping	NN

necessitates	VBZ

improvement	NN

of	IN

the	DT

accuracy	NN

of	IN

localization	NN

of	IN

the	DT

arrhythmogenic	JJ

site	NN

However	RB

,	,

the	DT

results	NNS

of	IN

this	DT

study	NN

indicate	VBP

that	IN

procainamide	NN

may	MD

be	VB

effective	JJ

in	IN

suppressing	VBG

the	DT

induction	NN

of	IN

sustained	JJ

ventricular	JJ

tachycardia	NN

at	IN

a	DT

relatively	RB

low	JJ

plasma	NN

concentration	NN

,	,

but	CC

not	RB

at	IN

a	DT

higher	JJR

plasma	NN

concentration	NN

Coronary	JJ

angioplasty	NN

for	IN

early	RB

postinfarction	NN

unstable	JJ

angina	NN

Coronary	JJ

angioplasty	NN

was	VBD

performed	VBN

in	IN

53	CD

patients	NNS

in	IN

whom	WP

unstable	JJ

angina	NN

had	VBD

reoccurred	VBD

after	IN

48	CD

hr	NN

and	CC

within	IN

30	CD

days	NNS

after	IN

sustained	JJ

myocardial	JJ

infarction	NN

At	IN

6	CD

months	NNS

follow-up	NN

26	CD

%	NN

(	NN

14/53	CD

)	NN

of	IN

all	DT

the	DT

patients	NNS

who	WP

underwent	VBD

angioplasty	NN

had	VBD

recurrence	NN

of	IN

angina	NN

,	,

which	WDT

was	VBD

successfully	RB

treated	VBN

with	IN

repeat	NN

angioplasty	NN

,	,

bypass	NN

surgery	NN

,	,

or	CC

medical	JJ

therapy	NN

Coronary	JJ

dissection	NN

and	CC

total	NN

coronary	JJ

occlusion	NN

leading	VBG

to	TO

emergency	NN

coronary	JJ

surgery	NN

are	VBP

the	DT

most	RBS

frequent	JJ

complications	NNS

of	IN

percutaneous	JJ

transluminal	JJ

coronary	JJ

angioplasty	NN

(	NN

PTCA	NN

)	NN

and	CC

their	PRP$

occurrence	NN

usually	RB

is	VBZ

unpredictable	JJ

Effect	NN

of	IN

zanamivir	NN

on	IN

duration	NN

and	CC

resolution	NN

of	IN

influenza	NN

symptoms	NNS

A	DT

comparison	NN

of	IN

a	DT

five-day	JJ

regimen	NNS

of	IN

cefdinir	NN

with	IN

a	DT

seven-day	JJ

regimen	NNS

of	IN

loracarbef	NN

for	IN

the	DT

treatment	NN

of	IN

acute	JJ

exacerbations	NNS

of	IN

chronic	JJ

bronchitis	NN

Initial	JJ

empiric	JJ

therapy	NN

for	IN

community-acquired	JJ

bacterial	JJ

meningitis	NN

should	MD

be	VB

based	VBN

on	IN

the	DT

possibility	NN

that	IN

penicillin-resistant	JJ

pneumococci	NNS

may	MD

be	VB

the	DT

etiologic	JJ

organisms	NNS

and	CC

,	,

hence	RB

,	,

should	MD

include	VB

a	DT

combination	NN

of	IN

third-generation	NN

cephalosporin	NN

(	NN

cefotaxime	NN

or	CC

ceftriaxone	NN

)	NN

and	CC

vancomycin	NN

Ampicillin	NNP

should	MD

be	VB

included	VBN

if	IN

the	DT

patient	NN

has	VBZ

predisposing	VBG

factors	NNS

that	IN

are	VBP

associated	VBN

with	IN

a	DT

risk	NN

for	IN

infection	NN

with	IN

Listeria	NN

monocytogenes	NNS

Results	NNS

of	IN

clinical	JJ

trials	NNS

and	CC

meta-analysis	NN

suggest	VB

that	IN

dexamethasone	NN

therapy	NN

improves	VBZ

the	DT

outcome	NN

for	IN

patients	NNS

with	IN

bacterial	JJ

meningitis	NN

Placebo-controlled	JJ

trials	NNS

have	VB

shown	VBN

that	IN

vitamin	NN

C	NN

supplementation	NN

decreases	NNS

the	DT

duration	NN

and	CC

severity	NN

of	IN

common	JJ

cold	JJ

infections	NNS

Since	IN

few	JJ

trials	NNS

have	VB

examined	VBN

the	DT

effects	NNS

of	IN

therapeutic	JJ

supplementation	NN

and	CC

their	PRP$

results	NNS

have	VB

been	VBN

variable	JJ

,	,

further	RB

therapeutic	JJ

trials	NNS

are	VBP

required	VBN

to	TO

examine	VB

the	DT

role	NN

of	IN

vitamin	NN

C	NN

in	IN

the	DT

treatment	NN

of	IN

colds	NNS

<	JJR

TO_SEE	NN

>	JJR

Progressive	JJ

multifocal	JJ

leukoencephalopathy	NN

following	VBG

oral	JJ

fludarabine	NN

treatment	NN

of	IN

chronic	JJ

lymphocytic	JJ

leukemia	NN

<	JJR

TO_SEE	NN

>	JJR

PURPOSE	NN

:	:

To	TO

review	NN

reported	VBN

inflammatory	JJ

reactions	NNS

occurring	VBG

after	IN

initiation	NN

of	IN

highly	RB

active	JJ

antiretroviral	JJ

therapy	NN

(	NN

HAART	NNP

)	NN

in	IN

persons	NNS

infected	JJ

with	IN

HIV-1	NN

and	CC

to	TO

explore	VB

the	DT

mechanisms	NNS

leading	VBG

to	TO

these	DT

reactions	NNS

Levofloxacin	NN

versus	CC

intravenous	JJ

ceftriaxone	NN

and	CC

amoxicillin/clavulanate	NN

in	IN

the	DT

treatment	NN

of	IN

community-acquired	JJ

pneumonia	NN

that	IN

require	VB

hospitalization	NN

Overall	RB

1	CD

year	NN

survival	NN

(	NN

operative	NN

deaths	NNS

excluded	VBN

)	NN

was	VBD

68	CD

%	NN

after	IN

tumor	NN

resection	NN

compared	VBN

to	TO

31	CD

%	NN

after	IN

palliative	NN

surgery	NN

(	NN

P	NN

<	JJR

0.001	CD

)	NN

The	DT

results	NNS

of	IN

this	DT

study	NN

show	NN

that	IN

resection	NN

of	IN

extrahepatic	JJ

bile	NN

duct	NN

carcinomas	NNS

,	,

particularly	RB

in	IN

an	DT

upper-third	NN

localization	NN

,	,

is	VBZ

often	RB

associated	VBN

with	IN

worthwhile	JJ

long-term	JJ

survival	NN

Background	NN

:	:

N-acetylcysteine	NN

(	NN

NAC	NN

)	NN

and	CC

ambroxol	NN

(	NN

AMB	NNP

)	NN

have	VB

recently	RB

been	VBN

proposed	VBN

as	IN

possible	JJ

therapeutic	JJ

agents	NNS

in	IN

the	DT

treatment	NN

of	IN

pulmonary	JJ

disorders	NNS

<	JJR

TO_SEE	NN

>	JJR

Postoperative	JJ

alkaline	NN

reflux	NN

after	IN

total	NN

gastrectomy	NN

for	IN

stomach	NN

cancer	NN

Antimicrobial	JJ

therapy	NN

for	IN

respiratory	JJ

disease	NN

Corticosteroids	NNS

for	IN

the	DT

treatment	NN

of	IN

croup	NN

<	JJR

TO_SEE	NN

>	JJR

BACKGROUND	NN

:	:

In	IN

the	DT

present	JJ

study	NN

we	PRP

investigated	VBN

the	DT

efficacy	NN

and	CC

tolerability	NN

of	IN

i.m	NN

.	.

octreotide	NN

acetate	NN

(	NN

octreotide	NN

LAR	NN

)	NN

in	IN

patients	NNS

with	IN

metastatic	JJ

neuroendocrine	NN

tumors	NNS

(	NN

NETs	NNS

)	NN

previously	RB

treated	VBN

and	CC

failed	VBD

on	IN

i.m	NN

.	.

lanreotide	NN

The	DT

PR	NN

was	VBD

observed	VBN

in	IN

one	CD

patient	NN

with	IN

non-functioning	JJ

endocrine	NN

pancreatic	JJ

tumor	NN

with	IN

progressive	JJ

liver	NN

and	CC

lymph	NN

node	NN

metastases	NNS

after	IN

16	CD

months	NNS

of	IN

i.m	NN

.	.

lanreotide	NN

therapy	NN

CONCLUSIONS	NNS

:	:

Octreotide	NN

LAR	NN

20	CD

mg	NN

shows	NNS

significant	JJ

efficacy	NN

in	IN

terms	NNS

of	IN

objective	NN

response	NN

rate	NN

(	NN

PR	NN

+	CC

SD	NN

)	NN

,	,

biochemical	JJ

and	CC

symptomatic	JJ

control	NN

in	IN

patients	NNS

with	IN

metastatic	JJ

NETs	NNS

of	IN

the	DT

GEP	NN

system	NN

pretreated	JJ

and	CC

progressing	VBG

on	IN

slow	JJ

release	NN

lanreotide	NN

Inchinko-to	JJ

(	NN

TJ-135	NN

)	NN

is	VBZ

a	DT

herbal	JJ

medicine	NN

consisting	VBG

of	IN

three	CD

kinds	NNS

of	IN

crude	NN

drugs	NNS

,	,

and	CC

in	IN

Japan	NNP

it	PRP

is	VBZ

administered	VBN

mainly	RB

to	TO

patients	NNS

with	IN

cholestasis	NN

The	DT

present	JJ

study	NN

evaluated	VBN

the	DT

effects	NNS

of	IN

TJ-135	NN

on	IN

concanavalin	NN

A	DT

(	NN

con	RB

A	DT

)	NN

-induced	JJ

hepatitis	NN

in	IN

mice	NNS

in	IN

vivo	FW

and	CC

con	RB

A-induced	JJ

cytokine	NN

production	NN

in	IN

vitro	NN

These	DT

results	NNS

suggest	VB

that	IN

con	RB

A-induced	JJ

hepatitis	NN

was	VBD

ameliorated	VBN

by	IN

pretreatment	NN

with	IN

TJ-135	NN

Therefore	RB

administration	NN

of	IN

TJ-135	NN

may	MD

be	VB

useful	JJ

in	IN

patients	NNS

with	IN

severe	JJ

acute	JJ

hepatitis	NN

accompanying	VBG

cholestasis	NN

or	CC

in	IN

those	DT

with	IN

autoimmune	JJ

hepatitis	NN

Zinc	NN

lozenges	NNS

--	:

a	DT

cure	NN

for	IN

common	JJ

colds	NNS

?	.

T-helper	NN

type	NN

2	CD

cell-directed	JJ

therapy	NN

for	IN

asthma	NN

Effects	NNS

of	IN

the	DT

Japanese	JJ

herbal	JJ

medicine	NN

'Inchinko-to	NN

'	''

(	NN

TJ-135	NN

)	NN

on	IN

concanavalin	NN

A-induced	JJ

hepatitis	NN

in	IN

mice	NNS

Presumed	VBN

cavernomas	NNS

have	VB

been	VBN

documented	VBN

following	VBG

radiation	NN

for	IN

malignancy	NN

(	NN

5-6	CD

)	NN

,	,

and	CC

sterotactic	JJ

cerebral	JJ

biopsy	NN

(	NN

7	CD

)	NN

Surgical	NNP

management	NN

of	IN

syringomyelia	NN

associated	VBN

with	IN

spinal	JJ

adhesive	JJ

arachnoiditis	NN

Discontinuation	NN

of	IN

secondary	JJ

prophylaxis	NN

for	IN

cryptococcal	JJ

meningitis	NN

in	IN

HIV-infected	JJ

patients	NNS

responding	VBG

to	TO

highly	RB

active	JJ

antiretroviral	JJ

therapy	NN

Hepatectomy	NNP

for	IN

cholangiocarcinoma	NN

complicated	VBN

with	IN

right	RB

umbilical	JJ

portion	NN

:	:

anomalous	JJ

configuration	NN

of	IN

the	DT

intrahepatic	JJ

biliary	JJ

tree	NN

Traditionally	RB

,	,

the	DT

therapy	NN

of	IN

symptomatic	JJ

bronchiectasis	NN

is	VBZ

based	VBN

on	IN

antibiotics	NNS

,	,

antibronchoobstructive	JJ

medication	NN

,	,

and	CC

chest	NN

physical	JJ

therapy	NN

Bilateral	JJ

lung	NN

transplantation	NN

should	MD

be	VB

considered	VBN

in	IN

younger	JJR

patients	NNS

with	IN

severe	JJ

,	,

generalized	VBN

bronchiectasis	NN

and	CC

respiratory	JJ

failure	NN

Prospective	JJ

,	,

randomized	VBN

,	,

largescale	JJ

trials	NNS

supporting	VBG

any	DT

of	IN

the	DT

different	JJ

treatment	NN

strategies	NNS

are	VBP

not	RB

available	JJ

,	,

but	CC

antibiotics	NNS

and	CC

surgery	NN

probably	RB

have	VB

improved	VBN

the	DT

long-term	JJ

outcome	NN

of	IN

many	JJ

patients	NNS

with	IN

bronchiectasis	NN

OBJECTIVES	NNS

:	:

Interest	NN

in	IN

zinc	NN

as	IN

a	DT

treatment	NN

for	IN

the	DT

common	JJ

cold	JJ

has	VBZ

grown	VBN

following	VBG

the	DT

recent	JJ

publication	NN

of	IN

several	JJ

controlled	VBN

trials	NNS

The	DT

objective	NN

of	IN

this	DT

review	NN

was	VBD

to	TO

assess	VB

the	DT

effects	NNS

of	IN

zinc	NN

lozenges	NNS

for	IN

cold	JJ

symptoms	NNS

Results	NNS

from	IN

two	CD

trials	NNS

(	NN

04	NN

-	:

Mossad	NNP

;	:

08	CD

-	:

Smith	NNP

)	NN

suggested	VBN

zinc	NN

lozenges	NNS

reduced	VBN

the	DT

severity	NN

and	CC

duration	NN

of	IN

cold	JJ

symptoms	NNS

Given	VBN

the	DT

potential	NN

for	IN

treatment	NN

to	TO

produce	VB

side	NN

effects	NNS

,	,

the	DT

use	NN

of	IN

zinc	NN

lozenges	NNS

to	TO

treat	NN

cold	JJ

symptoms	NNS

deserves	VBZ

further	RB

study	NN

Randomized	VBN

trial	NN

of	IN

interferon-alpha	NN

plus	CC

ursodeoxycholic	JJ

acid	NN

versus	CC

interferon	NN

plus	CC

placebo	NN

in	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

resistant	JJ

to	TO

interferon	NN

We	PRP

describe	VBP

a	DT

rare	JJ

case	NN

of	IN

spontaneous	JJ

rupture	NN

of	IN

a	DT

hepatic	JJ

metastasis	NN

from	IN

renal	JJ

cell	NN

carcinoma	NN

that	IN

was	VBD

treated	VBN

successfully	RB

by	IN

hepatic	JJ

arterial	JJ

embolization	NN

A	DT

65-year-old	JJ

woman	NN

,	,

who	WP

had	VBD

been	VBN

undergoing	VBG

immunotherapy	NN

for	IN

inoperably	RB

disseminated	VBN

renal	JJ

carcinoma	NN

and	CC

lung	NN

metastases	NNS

,	,

presented	VBN

with	IN

severe	JJ

abdominal	JJ

pain	NN

in	IN

a	DT

state	NN

of	IN

hypovolemic	JJ

shock	NN

Although	IN

hepatic	JJ

rupture	NN

due	JJ

to	TO

metastatic	JJ

cancer	NN

is	VBZ

extremely	RB

rare	JJ

,	,

transcatheter	NN

arterial	JJ

embolization	NN

(	NN

TAE	NNP

)	NN

is	VBZ

an	DT

appropriate	JJ

and	CC

useful	JJ

treatment	NN

for	IN

massive	JJ

hemorrhage	NN

caused	VBN

by	IN

spontaneous	JJ

rupture	NN

of	IN

liver	NN

metastasis	NN

Patients	NNS

with	IN

classical	JJ

symptoms	NNS

such	JJ

as	IN

heartburn	NN

and	CC

regurgitation	NN

may	MD

be	VB

treated	VBN

pharmaceutically	RB

combined	VBN

with	IN

life	NN

style	NN

counselling	VBG

Surgical	NNP

treatment	NN

is	VBZ

a	DT

good	JJ

alternative	NN

for	IN

patients	NNS

with	IN

persistent	JJ

severe	JJ

regurgitation	NN

during	IN

medical	JJ

therapy	NN

and	CC

for	IN

young	JJ

patients	NNS

who	WP

prefer	VBP

surgery	NN

to	TO

lifelong	JJ

medication	NN

The	DT

surgical	JJ

treatment	NN

of	IN

lung	NN

lacerations	NNS

and	CC

major	JJ

bronchial	JJ

disruptions	NNS

caused	VBN

by	IN

blunt	JJ

thoracic	JJ

trauma	NN

BACKGROUND	NN

:	:

An	DT

increasing	VBG

number	NN

of	IN

reports	NNS

indicate	VBP

symptomatic	JJ

relief	NN

of	IN

biliary	JJ

colic	JJ

symptoms	NNS

after	IN

cholecystectomy	NN

for	IN

biliary	JJ

dyskinesia	NN

Despite	IN

this	DT

,	,

cholecystectomy	NN

as	IN

a	DT

treatment	NN

for	IN

biliary	JJ

dyskinesia	NN

remains	NNS

controversial	JJ

Our	PRP$

aim	NN

was	VBD

to	TO

determine	VB

efficacy	NN

of	IN

cholecystectomy	NN

in	IN

alleviating	VBG

biliary	JJ

dyskinesia	NN

symptoms	NNS

and	CC

the	DT

correlation	NN

with	IN

histologic	JJ

findings	NNS

CONCLUSIONS	NNS

:	:

Biliary	JJ

dyskinesia	NN

patients	NNS

who	WP

underwent	VBD

cholecystectomy	NN

had	VBD

significantly	RB

greater	JJR

symptom	NN

improvement	NN

compared	VBN

with	IN

nonsurgical	JJ

patients	NNS

Cholecystectomy	NN

should	MD

be	VB

a	DT

first-line	NN

therapy	NN

for	IN

biliary	JJ

dyskinesia	NN

patients	NNS

Transbronchial	JJ

biopsy	NN

revealed	VBD

inflammatory	JJ

nonspecific	JJ

alveolar	JJ

lesions	NNS

suggestive	JJ

of	IN

bronchiolitis	NN

obliterans	NNS

organizing	VBG

pneumonia	NN

,	,

which	WDT

responded	VBD

well	RB

clinically	RB

and	CC

radiologically	RB

to	TO

oral	JJ

corticosteroids	NNS

Novel	JJ

treatment	NN

strategies	NNS

for	IN

patients	NNS

with	IN

advanced	VBN

NSCLC	NN

may	MD

involve	VB

chemotherapy	NN

combined	VBN

with	IN

inhibition	NN

of	IN

NF-kappaB-dependent	JJ

cell-survival	JJ

pathways	NNS

Effectiveness	NN

of	IN

pseudoephedrine	NN

plus	CC

acetaminophen	NN

for	IN

treatment	NN

of	IN

symptoms	NNS

attributed	VBN

to	TO

the	DT

paranasal	NN

sinuses	NNS

associated	VBN

with	IN

the	DT

common	JJ

cold	JJ

OBJECTIVE	NN

:	:

This	DT

retrospective	NN

study	NN

was	VBD

designed	VBN

to	TO

confirm	VB

that	IN

aggressive	JJ

pulmonary	JJ

resection	NN

can	MD

provide	VB

effective	JJ

long-term	JJ

palliation	NN

of	IN

disease	NN

for	IN

patients	NNS

with	IN

pulmonary	JJ

aspergilloma	NN

METHODS	NNS

AND	CC

RESULTS	NNS

:	:

From	IN

1959	CD

to	TO

1998	CD

,	,

84	CD

patients	NNS

underwent	VBD

a	DT

total	NN

of	IN

90	CD

operations	NNS

for	IN

treatment	NN

of	IN

pulmonary	JJ

aspergilloma	NN

in	IN

the	DT

Marie-Lannelongue	NNP

Hospital	NN

The	DT

lesion	NN

was	VBD

resected	JJ

by	IN

video-assisted	JJ

thoracoscopic	JJ

surgery	NN

because	IN

it	PRP

was	VBD

suspected	VBN

of	IN

being	VBG

a	DT

lung	NN

abscess	NN

that	IN

had	VBD

caused	VBN

repeated	VBN

episodes	NNS

of	IN

inflammation	NN

In	IN

this	DT

study	NN

,	,

we	PRP

investigated	VBN

the	DT

expression	NN

and	CC

therapeutic	JJ

potential	NN

of	IN

TRAIL	NN

in	IN

cholangiocarcinoma	NN

,	,

one	CD

of	IN

the	DT

most	RBS

devastating	VBG

human	JJ

hepatic	JJ

malignancies	NNS

Finally	RB

,	,

in	IN

vivo	FW

administration	NN

of	IN

recombinant	JJ

TRAIL	NN

substantially	RB

inhibited	VBD

subcutaneous	JJ

tumor	NN

growth	NN

of	IN

human	JJ

cholangiocarcinoma	NN

cells	NNS

Induction	NN

of	IN

apoptosis	NN

in	IN

tumor	NN

cells	NNS

is	VBZ

possible	JJ

with	IN

a	DT

biologically	RB

active	JJ

TRAIL	NN

,	,

and	CC

suggests	VBZ

that	IN

this	DT

cytokine	NN

is	VBZ

a	DT

promising	VBG

antitumor	NN

agent	NN

against	IN

human	JJ

cholangiocarcinoma	NN

Interferon	NN

plays	NNS

a	DT

critical	JJ

role	NN

in	IN

the	DT

host	NN

's	POS

natural	JJ

defense	NN

against	IN

viral	JJ

infections	NNS

and	CC

in	IN

their	PRP$

treatment	NN

This	DT

study	NN

investigated	VBN

whether	IN

intensive	JJ

chemotherapy	NN

might	MD

have	VB

a	DT

positive	JJ

effect	NN

on	IN

asthma	NN

in	IN

these	DT

special	JJ

cases	NNS

and	CC

whether	IN

asthma	NN

generally	RB

relapses	NNS

after	IN

completion	NN

of	IN

chemotherapy	NN

The	DT

authors	NNS

monitored	VBN

clinical	JJ

outcome	NN

and	CC

lung	NN

function	NN

of	IN

43	CD

children	NNS

with	IN

acute	JJ

lymphoblastic	JJ

leukemia	NN

and	CC

non-Hodgkin	JJ

lymphoma	NN

who	WP

received	VBN

chemotherapy	NN

at	IN

the	DT

University	NNP

Children	NNS

's	POS

Hospital	NN

of	IN

Greifswald	NNP

between	IN

1993	CD

and	CC

1998	CD

She	PRP

was	VBD

diagnosed	VBN

as	IN

miliary	JJ

tuberculosis	NN

and	CC

treated	VBN

with	IN

antituberculous	JJ

drugs	NNS

The	DT

hemorrhage	NN

was	VBD

successfully	RB

stopped	VBD

by	IN

microcoil	NN

embolization	NN

Immunomodulatory	JJ

effects	NNS

of	IN

acupuncture	NN

in	IN

the	DT

treatment	NN

of	IN

allergic	JJ

asthma	NN

:	:

a	DT

randomized	VBN

controlled	VBN

study	NN

An	DT

open-label	JJ

study	NN

of	IN

lamivudine	NN

for	IN

chronic	JJ

hepatitis	NN

B	NN

in	IN

six	CD

patients	NNS

with	IN

chronic	JJ

renal	JJ

failure	NN

before	IN

and	CC

after	IN

kidney	NN

transplantation	NN

CONCLUSION	NN

:	:

The	DT

WDTA	NN

is	VBZ

an	DT

intrinsically	RB

motivating	VBG

educational	JJ

program	NN

that	IN

has	VBZ

the	DT

ability	NN

to	TO

effect	NN

determinants	NNS

of	IN

asthma	NN

self-management	NN

behavior	NN

in	IN

9-	CD

to	TO

13-year-old	JJ

children	NNS

with	IN

asthma	NN

Usefulness	NN

of	IN

percutaneous	JJ

transhepatic	JJ

biliary	JJ

drainage	NN

in	IN

patients	NNS

with	IN

surgical	JJ

jaundice	NN

--	:

a	DT

prospective	JJ

randomised	VBN

study	NN

Neutralization	NN

of	IN

hepatitis	NN

A	DT

virus	NN

(	NN

HAV	NN

)	NN

by	IN

an	DT

immunoadhesin	NN

containing	VBG

the	DT

cysteine-rich	JJ

region	NN

of	IN

HAV	NN

cellular	JJ

receptor-1	NN

To	TO

ascertain	VB

the	DT

results	NNS

of	IN

standard	NN

ABVD	NN

chemotherapy	NN

(	NN

doxorubicin	NN

,	,

bleomycin	NN

,	,

vinblastine	NN

,	,

dacarbazine	NN

)	NN

in	IN

HIV-infected	JJ

patients	NNS

with	IN

newly	RB

diagnosed	VBN

Hodgkin	NN

's	POS

disease	NN

(	NN

HD	NN

)	NN

,	,

a	DT

nonrandomized	JJ

,	,

prospective	JJ

,	,

multiinstitutional	JJ

clinical	JJ

trial	NN

was	VBD

conducted	VBN

by	IN

the	DT

AIDS	NN

Clinical	JJ

Trials	NNS

Group	NNP

(	NN

ACTG	NN

)	NN

,	,

in	IN

HIV-infected	JJ

patients	NNS

with	IN

Hodgkin	NN

's	POS

disease	NN

The	DT

effectiveness	NN

of	IN

glucocorticoids	NNS

in	IN

treating	VBG

croup	NN

:	:

meta-analysis	NN

(	NN

see	VB

comments	NNS

)	NN

PURPOSE	NN

:	:

Inhaled	VBN

corticosteroids	NNS

have	VB

beneficial	JJ

effects	NNS

on	IN

pulmonary	JJ

function	NN

and	CC

inflammation	NN

in	IN

patients	NNS

with	IN

asthma	NN

,	,

but	CC

they	PRP

also	RB

cause	NN

systemic	JJ

adverse	JJ

effects	NNS

,	,

such	JJ

as	IN

adrenal	JJ

suppression	NN

Second	JJ

,	,

children	NNS

in	IN

the	DT

first	RB

year	NN

of	IN

life	NN

are	VBP

at	IN

highest	JJS

risk	NN

of	IN

progression	NN

and	CC

should	MD

be	VB

treated	VBN

with	IN

trimethoprim-sulfamethoxazole	NN

to	TO

prevent	VB

Pneumocystis	NN

carinii	NN

pneumonia	NN

,	,

and	CC

targeted	VBN

for	IN

receiving	VBG

antiretrovirals	NNS

Effectiveness	NN

of	IN

casein	NN

hydrolysate	NN

feedings	NNS

in	IN

infants	NNS

with	IN

colic	JJ

(	NN

see	VB

comments	NNS

)	NN

We	PRP

conclude	VBP

that	IN

antimicrobial/	NN

antituberculous	JJ

agents	NNS

have	VB

only	RB

a	DT

minor	JJ

short-term	JJ

effect	NN

in	IN

long-lasting	JJ

CGM	NNP

of	IN

undetermined	JJ

cause	NN

The	DT

patient	NN

had	VBD

previously	RB

been	VBN

immunized	VBN

with	IN

two	CD

doses	NNS

of	IN

Hib	NN

conjugate	NN

vaccine	NN

(	NN

PRP-T	NN

)	NN

Thus	RB

,	,

s-ECP	NN

appears	VBZ

to	TO

be	VB

a	DT

useful	JJ

marker	NN

for	IN

determining	VBG

when	WRB

a	DT

step-down	JJ

in	IN

iBDP	NN

therapy	NN

is	VBZ

indicated	VBD

,	,

and	CC

thus	RB

may	MD

contribute	VB

to	TO

successful	JJ

long-term	JJ

management	NN

of	IN

chronic	JJ

asthma	NN

Twinrix	NNP

(	NN

SmithKline	NNP

Beecham	NNP

Biologicals	NNS

)	NN

is	VBZ

a	DT

combined	VBN

hepatitis	NN

A	DT

and	CC

B	NN

vaccine	NN

licensed	JJ

with	IN

a	DT

three-dose	JJ

schedule	NN

A	DT

two-dose	JJ

combined	VBN

hepatitis	NN

A	DT

and	CC

B	NN

vaccine	NN

would	MD

facilitate	VB

immunisation	NN

programs	NNS

Therefore	RB

,	,

it	PRP

can	MD

be	VB

concluded	VBD

that	IN

with	IN

two	CD

injections	NNS

of	IN

the	DT

high-dose	JJ

hepatitis	NN

A	DT

and	CC

B	NN

vaccine	NN

,	,

6	CD

months	NNS

apart	RB

,	,

a	DT

similar	JJ

immune	JJ

response	NN

can	MD

be	VB

obtained	VBN

as	IN

induced	VBN

with	IN

three	CD

doses	NNS

of	IN

Twinrix	NNP

at	IN

months	NNS

0	CD

,	,

1	CD

and	CC

6	CD

AIM	NN

:	:

To	TO

assess	VB

the	DT

impact	NN

on	IN

community-based	JJ

pediatricians	NNS

of	IN

the	DT

conclusions	NNS

of	IN

the	DT

10th	JJ

Conference	NN

de	IN

Consensus	NN

en	IN

Therapeutique	NN

Anti-Infectieuse	NNP

(	NN

CCTAI	NN

)	NN

on	IN

the	DT

antibiotic	JJ

treatment	NN

in	IN

acute	JJ

nasopharyngitis	NN

(	NN

ANP	NN

)	NN

CONCLUSIONS	NNS

:	:

These	DT

data	NNS

,	,

the	DT

first	RB

evidence	NN

that	IN

chronic	JJ

stress	NN

can	MD

inhibit	VB

the	DT

stability	NN

of	IN

the	DT

IgG	NN

antibody	NN

response	NN

to	TO

a	DT

bacterial	JJ

vaccine	NN

for	IN

pneumonia	NN

,	,

provide	VB

additional	JJ

evidence	NN

of	IN

health	NN

risks	NNS

associated	VBN

with	IN

dementia	NN

caregiving	NN

We	PRP

assessed	VBN

the	DT

prevalence	NN

of	IN

head	NN

louse	NN

infestation	NN

and	CC

the	DT

effectiveness	NN

of	IN

1	CD

%	NN

permethrin	NN

against	IN

head	NN

lice	NN

in	IN

Kosovar	NNP

refugees	NNS

Refugees	NNS

with	IN

crawling	VBG

lice	NN

were	VBD

treated	VBN

with	IN

a	DT

pediculicide	NN

containing	VBG

1	CD

%	NN

permethrin	NN

We	PRP

conclude	VBP

that	IN

1	CD

%	NN

permethrin	NN

treatment	NN

was	VBD

effective	JJ

in	IN

louse	NN

control	NN

in	IN

this	DT

refugee	NN

population	NN

Antibiotics	NNS

for	IN

Salmonella	FW

meningitis	NN

in	IN

children	NNS

Four	CD

patients	NNS

developed	VBN

mild	JJ

pancreatitis	NN

,	,

one	CD

had	VBD

moderate	JJ

pancreatitis	NN

and	CC

one	CD

had	VBD

leak	NN

of	IN

contrast	NN

,	,

which	WDT

was	VBD

treated	VBN

by	IN

administration	NN

of	IN

clear	JJ

fluids	NNS

orally	RB

for	IN

one	CD

day	NN

We	PRP

treated	VBN

two	CD

children	NNS

with	IN

influenza-associated	JJ

acute	JJ

encephalopathy	NN

by	IN

a	DT

combination	NN

of	IN

mild	JJ

hypothermia	NN

and	CC

steroid	NN

pulse	NN

therapy	NN

Successful	JJ

treatment	NN

of	IN

anaerobic	JJ

pleuropulmonary	JJ

infections	NNS

requires	VBZ

a	DT

combination	NN

of	IN

antibiotic	JJ

therapy	NN

and	CC

surgical	JJ

interventions	NNS

Treatment	NN

of	IN

spontaneous	JJ

carotid-cavernous	JJ

fistula	NN

in	IN

Ehlers-Danlos	NNP

syndrome	NN

by	IN

transvenous	JJ

occlusion	NN

with	IN

Guglielmi	NNP

detachable	JJ

coils	NNS

PURPOSE	NN

:	:

Macrolide	NN

antibiotics	NNS

are	VBP

frequently	RB

prescribed	VBN

to	TO

patients	NNS

with	IN

symptoms	NNS

of	IN

a	DT

common	JJ

cold	JJ

Because	IN

the	DT

symptoms	NNS

of	IN

rhinovirus	NN

colds	NNS

are	VBP

attributed	VBN

to	TO

the	DT

inflammatory	JJ

response	NN

to	TO

infection	NN

,	,

we	PRP

studied	VBN

the	DT

effects	NNS

of	IN

treatment	NN

with	IN

clarithromycin	NN

on	IN

the	DT

symptomatic	JJ

and	CC

inflammatory	JJ

response	NN

to	TO

nasal	JJ

inoculation	NN

with	IN

rhinovirus	NN

Therapeutic	JJ

pneumothorax	NN

(	NN

TP	NN

)	NN

proved	VBN

its	PRP$

efficacy	NN

in	IN

pre-antibiotic	JJ

era	NN

,	,

so	RB

one	CD

can	MD

assume	VB

that	IN

it	PRP

can	MD

be	VB

applied	VBN

with	IN

the	DT

same	JJ

success	NN

in	IN

multidrug	JJ

resistant	JJ

TB	NN

In	IN

conclusion	NN

,	,

in	IN

some	DT

cases	NNS

of	IN

MDR	NN

TB	NN

,	,

the	DT

TP	NN

(	NN

if	IN

there	RB

are	VBP

no	DT

pleural	JJ

adherences	NNS

)	NN

may	MD

lead	NN

to	TO

good	JJ

results	NNS

Acupuncture	NN

treatment	NN

of	IN

common	JJ

cold	JJ

CONCLUSIONS	NNS

:	:

These	DT

data	NNS

,	,

the	DT

first	RB

evidence	NN

that	IN

chronic	JJ

stress	NN

can	MD

inhibit	VB

the	DT

stability	NN

of	IN

the	DT

IgG	NN

antibody	NN

response	NN

to	TO

a	DT

bacterial	JJ

vaccine	NN

for	IN

pneumonia	NN

,	,

provide	VB

additional	JJ

evidence	NN

of	IN

health	NN

risks	NNS

associated	VBN

with	IN

dementia	NN

caregiving	NN

When	WRB

bleeding	VBG

is	VBZ

stopped	VBD

via	IN

surgical	JJ

or	CC

radiological	JJ

methods	NNS

,	,

the	DT

clinical	JJ

course	NN

of	IN

hemobilia-associated	JJ

pancreatitis	NN

appears	VBZ

to	TO

be	VB

benign	JJ

A	DT

case	NN

of	IN

biliary	JJ

stenosis	NN

in	IN

polycystic	JJ

liver	NN

improved	VBN

by	IN

injection	NN

of	IN

minocycline	NN

hydrochloride	NN

to	TO

a	DT

hepatic	JJ

cyst	NN

The	DT

ruptured	VBN

horn	NN

was	VBD

excised	VBN

by	IN

laparotomy	NN

Therapy	NN

designed	VBN

to	TO

control	NN

the	DT

efferent	NN

phase	NN

of	IN

established	VBN

asthma	NN

by	IN

augmenting	VBG

down-regulatory	JJ

Th1	NN

counterbalancing	VBG

mechanisms	NNS

should	MD

be	VB

effective	JJ

All	DT

children	NNS

with	IN

croup	NN

symptoms	NNS

who	WP

demonstrate	VB

increased	VBN

work	NN

of	IN

breathing	NN

in	IN

the	DT

clinics	NNS

or	CC

emergency	NN

departments	NNS

should	MD

be	VB

treated	VBN

with	IN

glucocorticoids	NNS

Increasing	VBG

resistance	NN

among	IN

the	DT

common	JJ

respiratory	JJ

pathogens	NNS

has	VBZ

encouraged	JJ

assessment	NN

of	IN

alternative	NN

agents	NNS

,	,

for	IN

example	NN

,	,

levofloxacin	NN

Unlike	IN

earlier	RB

quinolones	NNS

,	,

levofloxacin	NN

has	VBZ

excellent	JJ

activity	NN

against	IN

Streptococcus	NN

pneumoniae	FW

,	,

including	VBG

strains	NNS

resistant	JJ

to	TO

penicillin	NN

Clinical	JJ

trials	NNS

show	NN

levofloxacin	NN

to	TO

be	VB

as	IN

effective	JJ

as	IN

cephalosporins	NNS

in	IN

acute	JJ

exacerbation	NN

of	IN

chronic	JJ

bronchitis	NN

and	CC

as	IN

effective	JJ

as	IN

co-amoxiclav	NN

,	,

cephalosporins	NNS

or	CC

amoxycillin	NN

in	IN

community-acquired	JJ

pneumonia	NN

Additionally	RB

,	,

epidemiologic	JJ

evidence	NN

of	IN

a	DT

marked	JJ

decline	NN

in	IN

new	JJ

KS	NN

since	IN

the	DT

widespread	JJ

use	NN

of	IN

highly	RB

active	JJ

antiretroviral	JJ

therapy	NN

(	NN

HAART	NNP

)	NN

advocates	NNS

its	PRP$

use	NN

A	DT

field	NN

study	NN

was	VBD

carried	VBD

out	IN

to	TO

evaluate	VB

the	DT

effect	NN

of	IN

vaccination	NN

against	IN

swine	NNS

enzootic	JJ

pneumonia	NN

in	IN

different	JJ

production	NN

systems	NNS

(	NN

closed	VBN

or	CC

one-site	JJ

,	,

and	CC

open	JJ

,	,

two-	CD

or	CC

three-site	JJ

,	,

systems	NNS

)	NN

Humoral	JJ

immune	JJ

response	NN

after	IN

vaccination	NN

against	IN

influenza	NN

in	IN

patients	NNS

with	IN

breast	NN

cancer	NN

Gingyo-san	JJ

and	CC

its	PRP$

components	NNS

were	VBD

administered	VBN

orally	RB

to	TO

mice	NNS

1	CD

day	NN

before	IN

,	,

then	RB

1	CD

and	CC

4	CD

days	NNS

after	IN

the	DT

inhalation	NN

of	IN

a	DT

mouse-adopted	JJ

strain	NN

of	IN

influenza	NN

A2	NN

(	NN

H2N2	NN

)	NN

virus	NN

From	IN

these	DT

results	NNS

Gingyo-san	JJ

was	VBD

shown	VBN

to	TO

be	VB

an	DT

antiviral	JJ

agent	NN

in	IN

mice	NNS

infected	JJ

with	IN

a	DT

lethal	JJ

amount	NN

of	IN

a	DT

mouse-adopted	JJ

strain	NN

of	IN

influenza	NN

A2	NN

virus	NN

The	DT

purpose	NN

of	IN

the	DT

present	JJ

study	NN

was	VBD

to	TO

analyze	VB

the	DT

association	NN

of	IN

recurrent	JJ

abdominal	JJ

pain	NN

and	CC

H.	NNP

pylori	NN

infection	NN

in	IN

children	NNS

and	CC

to	TO

evaluate	VB

the	DT

efficacy	NN

of	IN

antimicrobial	JJ

treatment	NN

in	IN

patients	NNS

with	IN

evidence	NN

of	IN

infection	NN

Patients	NNS

with	IN

evidence	NN

of	IN

infection	NN

with	IN

H.	NNP

pylori	NN

were	VBD

treated	VBN

with	IN

a	DT

combination	NN

of	IN

omeprazole	NN

,	,

amoxicillin	NNP

,	,

and	CC

clarithromycin	NN

Treatment	NN

with	IN

omeprazole	NN

,	,

amoxicillin	NNP

,	,

and	CC

clarithromycin	NN

resulted	VBD

in	IN

eradication	NN

of	IN

the	DT

infection	NN

in	IN

all	DT

and	CC

in	IN

resolution	NN

of	IN

the	DT

clinical	JJ

symptoms	NNS

in	IN

15	CD

(	NN

80	CD

%	NN

)	NN

of	IN

19	CD

patients	NNS

who	WP

had	VBD

a	DT

follow-up	NN

examination	NN

A	DT

combined	VBN

therapy	NN

results	NNS

in	IN

eradication	NN

of	IN

the	DT

bacterium	NN

and	CC

in	IN

improvement	NN

of	IN

the	DT

clinical	JJ

symptoms	NNS

in	IN

a	DT

significant	JJ

majority	NN

of	IN

the	DT

patients	NNS

In	IN

certain	JJ

clinical	JJ

settings	NNS

,	,

interventional	JJ

radiologic	JJ

procedures	NNS

have	VB

become	VB

an	DT

important	JJ

alternative	NN

to	TO

surgery	NN

in	IN

the	DT

treatment	NN

of	IN

gallstones	NNS

and	CC

their	PRP$

complications	NNS

;	:

techniques	NNS

include	VB

percutaneous	JJ

cholecystostomy	NN

and	CC

gallstone	NN

removal	NN

BACKGROUND	NN

:	:

The	DT

administration	NN

of	IN

salbutamol	NN

is	VBZ

permitted	VBN

only	RB

by	IN

inhalation	NN

by	IN

the	DT

International	NNP

Olympic	NNP

Committee	NNP

(	NN

IOC	NNP

)	NN

for	IN

the	DT

management	NN

of	IN

asthma	NN

and	CC

exercise-induced	JJ

asthma	NN

in	IN

athletes	NNS

Urine	NN

was	VBD

also	RB

obtained	VBN

from	IN

subjects	NNS

who	WP

had	VBD

received	VBN

the	DT

maximum	NN

dosage	NN

of	IN

inhaled	VBN

salbutamol	NN

advisable	JJ

for	IN

competing	VBG

athletes	NNS

to	TO

provide	VB

protection	NN

from	IN

exercise-induced	JJ

asthma	NN

and	CC

treatment	NN

of	IN

asthma	NN

(	NN

1600	CD

microg	NN

in	IN

24	CD

h	NN

,	,

800	CD

microg	NN

being	VBG

in	IN

the	DT

last	JJ

4	CD

h	NN

)	NN

Antimicrobials	NNS

were	VBD

prescribed	VBN

to	TO

175	CD

(	NN

83.73	CD

per	IN

cent	NN

)	NN

patients	NNS

with	IN

common	JJ

cold	JJ

and	CC

78	CD

(	NN

82.11	NN

per	IN

cent	NN

)	NN

patients	NNS

with	IN

diarrhea	NN

OBJECTIVE	NN

:	:

to	TO

evaluate	VB

the	DT

possible	JJ

existence	NN

of	IN

the	DT

so-called	JJ

<	JJR

Roux-en-Y	NN

syndrome	NN

>	JJR

in	IN

a	DT

group	NN

of	IN

21	CD

patients	NNS

who	WP

underwent	VBD

surgery	NN

to	TO

correct	JJ

postoperative	JJ

alkaline	NN

reflux	NN

gastritis	NN

All	DT

had	VBD

undergone	VBN

Billroth	NNP

II	NNP

subtotal	JJ

gastrectomy	NN

(	NN

20	CD

for	IN

ulcer	NN

and	CC

1	CD

for	IN

gastric	JJ

cancer	NN

)	NN

CONCLUSIONS	NNS

:	:

we	PRP

found	VBN

no	DT

evidence	NN

of	IN

disturbances	NNS

in	IN

gastric	JJ

remnant	NN

emptying	VBG

after	IN

Roux-en-Y	NN

gastrojejunostomy	NN

to	TO

treat	NN

postoperative	JJ

alkaline	NN

gastric	JJ

reflux	NN

BACKGROUND	NN

:	:

Drainage	NN

methods	NNS

for	IN

the	DT

gastric	JJ

conduit	NN

after	IN

esophagectomy	NN

for	IN

carcinoma	NN

have	VB

been	VBN

controversial	JJ

CONCLUSIONS	NNS

:	:

This	DT

study	NN

indicates	VBZ

that	IN

the	DT

use	NN

of	IN

a	DT

computerized	NN

physician	NN

reminder	NN

and	CC

a	DT

mailed	VBN

patient	NN

reminder	NN

had	VBD

a	DT

positive	JJ

impact	NN

on	IN

influenza	NN

immunizations	NNS

for	IN

older	JJR

adults	NNS

in	IN

a	DT

large	JJ

family	NN

practice	NN

office	NN

Contemporary	NNP

asthma	NN

management	NN

guidelines	NNS

list	NN

inhaled	VBN

corticosteroids	NNS

as	IN

the	DT

preferred	VBN

controller	NN

medication	NN

for	IN

patients	NNS

with	IN

persistent	JJ

asthma	NN

Fluticasone	NN

propionate	NN

is	VBZ

one	CD

of	IN

several	JJ

inhaled	VBN

corticosteroids	NNS

used	VBN

for	IN

the	DT

treatment	NN

of	IN

asthma	NN

A	DT

series	NN

of	IN

comparative	JJ

analyses	NNS

show	NN

that	IN

inhaled	VBN

fluticasone	NN

propionate	NN

is	VBZ

more	RBR

cost	NN

effective	JJ

than	IN

oral	JJ

zafirlukast	NN

and	CC

triamcinolone	NN

acetonide	NN

and	CC

slightly	RB

more	RBR

cost	NN

effective	JJ

than	IN

flunisolide	NN

in	IN

adult	JJ

patients	NNS

with	IN

asthma	NN

Quality-of-life	NN

assessments	NNS

in	IN

patients	NNS

with	IN

mild	JJ

to	TO

moderate	JJ

disease	NN

show	NN

that	IN

inhaled	VBN

fluticasone	NN

propionate	NN

achieved	VBN

improvements	NNS

which	WDT

were	VBD

deemed	VBN

to	TO

be	VB

clinically	RB

meaningful	JJ

in	IN

patients	NNS

with	IN

mild	JJ

to	TO

moderate	JJ

asthma	NN

;	:

these	DT

changes	NNS

were	VBD

significantly	RB

greater	JJR

than	IN

those	DT

achieved	VBN

with	IN

oral	JJ

zafirlukast	NN

,	,

inhaled	VBN

triamcinolone	NN

acetonide	NN

or	CC

placebo	NN

CONCLUSIONS	NNS

:	:

In	IN

addition	NN

to	TO

the	DT

considerable	JJ

body	NN

of	IN

clinical	JJ

evidence	NN

supporting	VBG

the	DT

use	NN

of	IN

inhaled	VBN

fluticasone	NN

propionate	NN

in	IN

patients	NNS

with	IN

asthma	NN

,	,

accumulating	VBG

short	RB

term	NN

cost-effectiveness	NN

data	NNS

also	RB

suggest	VB

that	IN

this	DT

agent	NN

can	MD

be	VB

administered	VBN

for	IN

a	DT

similar	JJ

or	CC

lower	JJR

cost	NN

per	IN

outcome	NN

than	IN

other	JJ

inhaled	VBN

corticosteroids	NNS

or	CC

oral	JJ

zafirlukast	NN

Importantly	RB

,	,

the	DT

clinical	JJ

benefits	NNS

offered	VBN

by	IN

fluticasone	NN

propionate	NN

in	IN

patients	NNS

with	IN

persistent	JJ

asthma	NN

are	VBP

accompanied	VBN

by	IN

clinically	RB

significant	JJ

improvements	NNS

in	IN

quality	NN

of	IN

life	NN

OBJECTIVE	NN

:	:

To	TO

describe	VBP

the	DT

effect	NN

of	IN

influenza	NN

vaccination	NN

on	IN

long-term	JJ

change	NN

in	IN

CD4	NN

count	NN

and	CC

HIV	NN

RNA	NN

level	NN

,	,

and	CC

on	IN

progression	NN

to	TO

AIDS	NN

or	CC

death	NN

Combination	NN

therapy	NN

with	IN

interferon-alpha	NN

(	NN

IFN	NN

alpha	NN

)	NN

plus	CC

Ribavirin	NNP

has	VBZ

been	VBN

shown	VBN

to	TO

improve	VB

the	DT

response	NN

rate	NN

in	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

as	IN

compared	VBN

to	TO

IFN	NN

alpha	NN

alone	RB

To	TO

prove	VB

,	,

whether	IN

Ribavirin	NNP

has	VBZ

any	DT

additional	JJ

effect	NN

on	IN

the	DT

decline	NN

of	IN

hepatitis	NN

C	NN

viremia	NN

during	IN

the	DT

first	RB

weeks	NNS

of	IN

treatment	NN

patients	NNS

with	IN

and	CC

without	IN

combination	NN

therapy	NN

were	VBD

compared	VBN

In	IN

patients	NNS

with	IN

combination	NN

therapy	NN

,	,

a	DT

further	RB

reduction	NN

of	IN

viremia	NN

level	NN

could	MD

be	VB

observed	VBN

,	,

whereas	IN

viremia	NN

levels	NNS

in	IN

patients	NNS

with	IN

IFN	NN

alpha	NN

alone	RB

slightly	RB

increased	VBN

Ribavirin	NNP

in	IN

combination	NN

with	IN

IFN	NN

alpha	NN

exerts	VBZ

an	DT

additional	JJ

anti-viral/immunmodulatory	JJ

effect	NN

which	WDT

manifests	VBZ

itself	PRP

in	IN

phase	NN

2	CD

of	IN

hepatitis	NN

C	NN

viremia	NN

decline	NN

Surgical	NNP

clearance	NN

of	IN

CBD	NN

stones	NNS

was	VBD

achieved	VBN

in	IN

58	CD

patients	NNS

(	NN

93.5	CD

%	NN

;	:

group	NN

Ia	NN

)	NN

Use	NN

of	IN

ES	NN

to	TO

treat	NN

CBD	NN

stones	NNS

on	IN

a	DT

routine	JJ

basis	NN

was	VBD

therefore	RB

not	RB

found	VBN

to	TO

be	VB

any	DT

better	RB

than	IN

one-time	JJ

surgical	JJ

exploration	NN

Effect	NN

of	IN

cholecystectomy	NN

on	IN

gastroesophageal	NN

and	CC

duodenogastric	JJ

reflux	NN

It	PRP

is	VBZ

suggested	VBN

that	IN

damaged	VBN

mucosal	JJ

tissues	NNS

with	IN

AHF	NN

can	MD

be	VB

effectively	RB

compensated	VBN

by	IN

enhanced	VBN

regeneration	NN

response	NN

due	JJ

to	TO

an	DT

adequately	RB

high	JJ

dose	NN

intensity	NN

,	,

suggesting	VBG

a	DT

possible	JJ

tolerability	NN

advantage	NN

for	IN

AHF	NN

Minimally	RB

invasive	JJ

treatment	NN

of	IN

abscesses	NNS

by	IN

CT-controlled	JJ

drainage	NN

with	IN

a	DT

basket	NN

catheter	NN

system	NN

PL	NN

granule	NN

is	VBZ

one	CD

of	IN

the	DT

most	RBS

common	JJ

forms	NNS

of	IN

composite	JJ

medicine	NN

for	IN

colds	NNS

in	IN

Japan	NNP

,	,

including	VBG

acetaminophen	NN

A	DT

72-year	JJ

old	JJ

man	NN

who	WP

had	VBD

been	VBN

prescribed	VBN

amiodarone	NN

for	IN

more	RBR

than	IN

one	CD

year	NN

before	IN

for	IN

arrhythmogenic	JJ

right	RB

ventricular	JJ

dystrophy	NN

,	,

repeatedly	RB

took	VBD

PL	NN

granules	NNS

at	IN

one-week	JJ

intervals	NNS

because	IN

of	IN

sneezing	VBG

and	CC

fever	NN

He	PRP

needed	VBN

mechanical	JJ

ventilation	NN

for	IN

severe	JJ

hypoxemia	NN

,	,

but	CC

recovered	VBN

with	IN

glucocorticoid	NN

pulse	NN

therapy	NN

In	IN

a	DT

follow-up	NN

study	NN

operative	NN

risk	NN

,	,

postoperative	JJ

functional	JJ

disorders	NNS

and	CC

incidence	NN

of	IN

anastomotic	JJ

(	NN

recurrent	JJ

)	NN

ulcer	NN

after	IN

partial	JJ

gastrectomy	NN

with	IN

Roux-en-Y	NN

gastrojejunostomy	NN

for	IN

gastroduodenal	NN

ulcer	NN

were	VBD

evaluated	VBN

in	IN

52	CD

patients	NNS

<	JJR

TO_SEE	NN

>	JJR

With	IN

regard	NN

to	TO

the	DT

high	JJ

rate	NN

of	IN

recurrent	JJ

ulcer	NN

Roux-en-Y	NN

reconstruction	NN

after	IN

partial	JJ

gastrectomy	NN

for	IN

primary	JJ

ulcer	NN

surgery	NN

should	MD

be	VB

avoided	VBN

and	CC

reconstruction	NN

procedures	NNS

preferred	VBN

,	,

which	WDT

guarantee	NN

duodenogastric	JJ

reflux	NN

OBJECTIVE	NN

:	:

The	DT

aim	NN

of	IN

these	DT

studies	NNS

was	VBD

to	TO

compare	VB

the	DT

pharmacokinetics	NNS

of	IN

inhaled	VBN

fluticasone	NN

propionate	NN

(	NN

FP	NN

)	NN

after	IN

repeated	VBN

administration	NN

via	IN

the	DT

Diskus	NNP

or	CC

Diskhaler	NNP

dry	JJ

powder	NN

inhalers	NNS

(	NN

DPIs	NNS

)	NN

to	TO

patients	NNS

with	IN

mild-to-moderate	JJ

asthma	NN

CONCLUSION	NN

:	:

In	IN

patients	NNS

with	IN

asthma	NN

receiving	VBG

repeated	VBN

inhaled	VBN

doses	NNS

of	IN

FP	NN

,	,

the	DT

systemic	JJ

exposure	NN

(	NN

AUC	NN

)	NN

after	IN

inhalation	NN

from	IN

the	DT

Diskus	NNP

was	VBD

similar	JJ

to	TO

that	IN

from	IN

the	DT

Diskhaler	NNP

,	,

with	IN

no	DT

difference	NN

between	IN

the	DT

DPIs	NNS

in	IN

the	DT

effects	NNS

on	IN

cortisol	NN

suppression	NN

DATA	NNP

SYNTHESIS	NN

:	:

Recently	RB

,	,

an	DT

expert	NN

panel	NN

of	IN

the	DT

Centers	NNPS

for	IN

Disease	NN

Control	NN

and	CC

Prevention	NNP

recommended	VBN

use	NN

of	IN

only	RB

three	CD

of	IN

16	CD

systemic	JJ

antibiotics	NNS

approved	VBN

by	IN

the	DT

Food	NNP

and	CC

Drug	NN

Administration	NN

for	IN

treatment	NN

of	IN

AOM	NNP

:	:

amoxicillin	NNP

,	,

cefuroxime	NN

axetil	NN

,	,

and	CC

ceftriaxone	NN

A	DT

three-step	JJ

treatment	NN

algorithm	NN

for	IN

refractory	JJ

AOM	NNP

that	IN

employs	VBZ

amoxicillin	NNP

,	,

trimethoprim/sulfamethoxazole	NN

(	NN

TMP/SMX	NN

)	NN

,	,

or	CC

high-dose	JJ

amoxicillin/clavulanate	NN

(	NN

depending	VBG

on	IN

the	DT

prior	RB

dose	NN

of	IN

and	CC

adherence	NN

to	TO

amoxicillin	NNP

therapy	NN

)	NN

,	,

and	CC

ceftriaxone	NN

or	CC

tympanocentesis	NN

at	IN

steps	NNS

1	CD

,	,

2	CD

,	,

and	CC

3	CD

,	,

respectively	RB

,	,

appears	VBZ

rational	JJ

and	CC

cost-effective	JJ

CONCLUSIONS	NNS

:	:

Amoxicillin	NNP

remains	NNS

the	DT

antibiotic	JJ

of	IN

choice	NN

for	IN

initial	JJ

empiric	JJ

treatment	NN

of	IN

AOM	NNP

,	,

although	IN

the	DT

traditional	JJ

dosage	NN

should	MD

be	VB

increased	VBN

in	IN

patients	NNS

at	IN

risk	NN

for	IN

drug-resistant	JJ

S.	NNP

pneumoniae	FW

We	PRP

support	NN

the	DT

use	NN

of	IN

conjugate	NN

pneumococcal	JJ

vaccine	NN

per	IN

guidelines	NNS

for	IN

prevention	NN

of	IN

Raom	NN

from	IN

the	DT

Advisory	NNP

Committee	NNP

on	IN

Immunization	NN

Practice	NN

of	IN

the	DT

Centers	NNPS

for	IN

Disease	NN

Control	NN

and	CC

Prevention	NNP

,	,

with	IN

consideration	NN

given	VBN

to	TO

influenza	NN

vaccine	NN

for	IN

cases	NNS

of	IN

rAOM	NN

that	IN

historically	RB

worsen	VB

during	IN

the	DT

flu	NN

season	NN

This	DT

model	NN

can	MD

be	VB

used	VBN

to	TO

test	NN

the	DT

safety	NN

and	CC

efficacy	NN

of	IN

liver-assist	NN

devices	NNS

aimed	VBN

at	IN

temporizing	VBG

the	DT

detoxification	NN

functions	NNS

of	IN

the	DT

failing	VBG

liver	NN

Recent	JJ

major	JJ

epidemiologic	JJ

trends	NNS

in	IN

bacterial	JJ

meningitis	NN

include	VB

a	DT

dramatic	JJ

decline	NN

in	IN

the	DT

incidence	NN

of	IN

Haemophilus	NN

influenzae	NNS

meningitis	NN

since	IN

the	DT

introduction	NN

of	IN

the	DT

protein-conjugated	JJ

H.	NNP

influenzae	NNS

vaccines	NNS

,	,

and	CC

a	DT

worldwide	RB

increase	NN

in	IN

infections	NNS

with	IN

antibiotic-resistant	JJ

strains	NNS

of	IN

bacterial	JJ

pathogens	NNS

dverse	NN

outcomes	NNS

and	CC

opioid	NN

analgesic	JJ

administration	NN

in	IN

acute	JJ

abdominal	JJ

pain	NN

We	PRP

examined	VBN

the	DT

remnant	NN

stomach	NN

for	IN

H.	NNP

pylori	NN

infection	NN

after	IN

gastrectomy	NN

for	IN

gastric	JJ

cancer	NN

or	CC

peptic	JJ

ulcer	NN

between	IN

October	NNP

1992	CD

and	CC

July	NNP

1997	CD

The	DT

recent	JJ

introduction	NN

of	IN

ribavirin	NNP

,	,

given	VBN

in	IN

combination	NN

,	,

has	VBZ

led	VBN

to	TO

a	DT

re-appraisal	NN

of	IN

the	DT

management	NN

of	IN

chronic	JJ

hepatitis	NN

C	NN

The	DT

current	JJ

report	NN

considers	VBZ

the	DT

additional	JJ

benefit	NN

of	IN

combination	NN

therapy	NN

(	NN

interferon	NN

alfa	IN

and	CC

ribavirin	NNP

)	NN

compared	VBN

with	IN

monotherapy	NN

(	NN

interferon	NN

alfa	IN

alone	RB

)	NN

for	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

OBJECTIVE	NN

:	:

To	TO

review	NN

the	DT

clinical	JJ

effectiveness	NN

and	CC

cost-effectiveness	NN

of	IN

combination	NN

therapy	NN

with	IN

interferon	NN

alfa	IN

and	CC

ribavirin	NNP

in	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

Sida	NNP

cordifolia	NN

L.	NNP

(	NN

Malvaceae	FW

)	NN

is	VBZ

used	VBN

in	IN

folk	NN

medicine	NN

for	IN

the	DT

treatment	NN

of	IN

inflammation	NN

of	IN

the	DT

oral	JJ

mucosa	NN

,	,

blenorrhea	NN

,	,

asthmatic	JJ

bronchitis	NN

and	CC

nasal	JJ

congestion	NN

Double-blind	JJ

placebo-controlled	JJ

trial	NN

of	IN

Mycobacterium	NN

vaccae	NN

immunotherapy	NN

for	IN

tuberculosis	NN

in	IN

KwaZulu	NNP

,	,

South	NNP

Africa	NNP

,	,

1991-97	CD

OBJECTIVE	NN

:	:

To	TO

evaluate	VB

the	DT

efficacy	NN

of	IN

oral	JJ

tacrolimus	NN

as	IN

an	DT

induction	NN

agent	NN

in	IN

steroid-refractory	JJ

severe	JJ

colitis	NN

.Study	NN

design	NN

:	:

Open-label	JJ

,	,

multicenter	NN

trial	NN

of	IN

oral	JJ

tacrolimus	NN

in	IN

patients	NNS

with	IN

severe	JJ

colitis	NN

CONCLUSION	NN

:	:

Although	IN

tacrolimus	NN

is	VBZ

effective	JJ

induction	NN

therapy	NN

for	IN

severe	JJ

ulcerative	JJ

or	CC

Crohn	NN

's	POS

colitis	NN

,	,

fewer	JJR

than	IN

50	CD

%	NN

of	IN

patients	NNS

treated	VBN

will	MD

successfully	RB

achieve	VB

a	DT

long-term	JJ

remission	NN

Cytomegalovirus	NN

(	NN

CMV	NN

)	NN

infection	NN

was	VBD

one	CD

of	IN

the	DT

most	RBS

common	JJ

opportunistic	JJ

infections	NNS

in	IN

AIDS	NN

patients	NNS

,	,

leading	VBG

to	TO

blindness	NN

or	CC

life-threatening	JJ

disease	NN

in	IN

about	IN

40	CD

%	NN

of	IN

patients	NNS

in	IN

the	DT

later	RB

stages	NNS

of	IN

AIDS	NN

before	IN

highly	RB

active	JJ

antiretroviral	JJ

therapy	NN

(	NN

HAART	NNP

)	NN

New	NNP

vaccines	NNS

are	VBP

under	IN

study	NN

to	TO

further	RB

control	NN

bacterial	JJ

meningitis	NN

The	DT

study	NN

involved	VBN

117	CD

infants	NNS

(	NN

mean	VB

age	NN

2.6	CD

months	NNS

)	NN

,	,

who	WP

needed	VBN

hospital	NN

treatment	NN

because	IN

of	IN

RSV	NN

bronchiolitis	NN

According	VBG

to	TO

the	DT

present	JJ

study	NN

it	PRP

seems	VBZ

that	IN

inhaled	VBN

corticosteroid	NN

treatment	NN

during	IN

and	CC

after	IN

the	DT

acute	JJ

phase	NN

of	IN

infant	NN

RSV	NN

bronchiolitis	NN

may	MD

have	VB

a	DT

beneficial	JJ

effect	NN

on	IN

subsequent	JJ

bronchial	JJ

wheezing	VBG

tendency	NN

OBJECTIVE	NN

:	:

This	DT

study	NN

was	VBD

designed	VBN

to	TO

evaluate	VB

the	DT

safety	NN

and	CC

estimate	NN

the	DT

efficacy	NN

of	IN

oral	JJ

budesonide	NN

in	IN

patients	NNS

with	IN

primary	JJ

sclerosing	VBG

cholangitis	NN

(	NN

PSC	NN

)	NN

Combined	VBN

interferon	NN

and	CC

lamivudine	NN

therapy	NN

:	:

is	VBZ

this	DT

the	DT

treatment	NN

of	IN

choice	NN

for	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

B	NN

virus	NN

infection	NN

?	.

She	PRP

had	VBD

been	VBN

taking	VBG

amitriptyline	NNP

75	CD

mg	NN

at	IN

night	NN

for	IN

depression	NN

for	IN

four	CD

months	NNS

before	IN

her	PRP$

admission	NN

Side	NN

effects	NNS

from	IN

influenza	NN

vaccination	NN

:	:

differences	NNS

between	IN

returned	VBN

and	CC

random	JJ

surveys	NNS

OBJECTIVE	NN

:	:

To	TO

study	NN

the	DT

relationship	NN

between	IN

interleukin-2	NN

(	NN

IL-2	NN

)	NN

,	,

soluble	JJ

interleukin-2	NN

receptor	NN

(	NN

sIL-2R	NN

)	NN

and	CC

the	DT

non-and-hypo-responsiveness	JJ

to	TO

hepatitis	NN

B	NN

vaccine	NN

We	PRP

assessed	VBN

the	DT

effects	NNS

of	IN

early	RB

replacement	NN

therapy	NN

with	IN

protein-C	JJ

concentrate	NN

together	RB

with	IN

continuous	JJ

veno-venous	JJ

haemodiafiltration	NN

and	CC

conventional	JJ

treatment	NN

in	IN

meningococcaemia	NN

The	DT

purpose	NN

of	IN

this	DT

study	NN

was	VBD

to	TO

determine	VB

if	IN

topical	JJ

DL-alpha-tocopherol	NN

(	NN

vitamin	NN

E	NN

)	NN

could	MD

reduce	VB

ultraviolet-induced	JJ

damage	NN

to	TO

the	DT

epidermis	NN

We	PRP

observed	VBN

the	DT

effects	NNS

of	IN

cisapride	NN

in	IN

the	DT

management	NN

of	IN

idiopathic	JJ

constipation	NN

in	IN

children	NNS

METHODS	NNS

:	:

Thirty-seven	CD

children	NNS

with	IN

a	DT

history	NN

of	IN

constipation	NN

(	NN

i.e	NN

.	.

,	,

pain	NN

and	CC

difficulty	NN

or	CC

delay	NN

in	IN

defecation	NN

for	IN

>	JJR

3	CD

months	NNS

)	NN

were	VBD

recruited	VBN

and	CC

randomly	RB

assigned	VBN

to	TO

8	CD

weeks	NNS

of	IN

treatment	NN

with	IN

either	DT

cisapride	NN

,	,

0.2	CD

mg/kg	NN

three	CD

times	NNS

daily	RB

,	,

or	CC

matching	VBG

placebo	NN

after	IN

a	DT

2-week	JJ

run-in	NN

period	NN

in	IN

a	DT

double-blind	JJ

,	,

parallel-group	NN

study	NN

design	NN

Patient	NN

1	CD

demonstrated	VBN

dramatic	JJ

clearing	NN

of	IN

his	PRP$

MCV	NN

lesions	NNS

when	WRB

intravenous	JJ

cidofovir	NN

therapy	NN

was	VBD

started	VBD

for	IN

his	PRP$

treatment-resistant	JJ

bilateral	JJ

CMV	NN

retinitis	NN

and	CC

because	IN

of	IN

cidofovir	NN

's	POS

possible	JJ

activity	NN

against	IN

MCV	NN

In	IN

case	NN

2	CD

,	,

cidofovir	NN

was	VBD

compounded	VBN

as	IN

a	DT

3	CD

%	NN

cream	NN

in	IN

a	DT

combination	NN

vehicle	NN

(	NN

Dermovan	JJ

)	NN

for	IN

extensive	JJ

facial	JJ

involvement	NN

,	,

and	CC

complete	JJ

resolution	NN

of	IN

MCV	NN

was	VBD

seen	VBN

after	IN

1	CD

month	NN

of	IN

therapy	NN

In	IN

case	NN

3	CD

,	,

intravenous	JJ

cidofovir	NN

therapy	NN

was	VBD

started	VBD

both	DT

for	IN

CMV	NN

retinitis	NN

and	CC

in	IN

an	DT

attempt	NN

to	TO

clear	JJ

90	CD

%	NN

facial	JJ

MCV	NN

involvement	NN

;	:

after	IN

1	CD

month	NN

of	IN

treatment	NN

,	,

all	DT

clinical	JJ

evidence	NN

of	IN

MCV	NN

had	VBD

resolved	VBN

CONCLUSIONS	NNS

:	:

Cidofovir	NNP

,	,

a	DT

nucleotide	NN

analog	NN

of	IN

deoxycytidine	NN

monophosphate	NN

,	,

appears	VBZ

to	TO

have	VB

contributed	VBD

to	TO

clearing	NN

of	IN

advanced	VBN

MCV	NN

lesions	NNS

in	IN

these	DT

3	CD

patients	NNS

,	,

thus	RB

providing	VBG

suggestive	JJ

evidence	NN

of	IN

clinical	JJ

activity	NN

against	IN

MCV	NN

Controlled	VBN

trials	NNS

of	IN

cidofovir	NN

therapy	NN

for	IN

MCV	NN

in	IN

persons	NNS

infected	JJ

with	IN

human	JJ

immunodeficiency	NN

virus	NN

are	VBP

warranted	VBN

OBJECTIVE	NN

:	:

This	DT

study	NN

aimed	VBN

to	TO

determine	VB

the	DT

effect	NN

of	IN

external	JJ

beam	NN

radiation	NN

therapy	NN

on	IN

choroidal	NN

neovascularization	NN

(	NN

CNV	NN

)	NN

secondary	JJ

to	TO

age-related	JJ

macular	JJ

degeneration	NN

(	NN

AMD	NNP

)	NN

Thrombolytic	JJ

therapy	NN

has	VBZ

been	VBN

accepted	VBN

in	IN

the	DT

treatment	NN

of	IN

acute	JJ

myocardial	JJ

infarction	NN

A	DT

bolus	NN

infusion	NN

of	IN

tissue	NN

plasminogen	NN

activator	NN

was	VBD

administered	VBN

during	IN

CPR	NNP

in	IN

refractory	JJ

ventricular	JJ

fibrillation	NN

(	NN

two	CD

cases	NNS

)	NN

and	CC

pulseless	JJ

ventricular	JJ

tachycardia	NN

(	NN

one	CD

case	NN

)	NN

We	PRP

conclude	VBP

that	IN

bolus	NN

thrombolytic	JJ

infusions	NNS

during	IN

CPR	NNP

may	MD

facilitate	VB

spontaneous	JJ

return	NN

of	IN

circulation	NN

in	IN

select	JJ

patients	NNS

with	IN

confirmed	VBN

acute	JJ

myocardial	JJ

infarction	NN

,	,

witnessed	VBN

cardiac	JJ

arrest	NN

in	IN

the	DT

ED	NNP

,	,

and	CC

refractory	JJ

ventricular	JJ

fibrillation	NN

or	CC

tachycardia	NN

<	JJR

TO_SEE	NN

>	JJR

CASE	NN

SUMMARY	NN

:	:

A	DT

92-year	JJ

old	JJ

white	JJ

woman	NN

who	WP

was	VBD

receiving	VBG

venlafaxine	NN

for	IN

management	NN

of	IN

depression	NN

was	VBD

found	VBN

to	TO

have	VB

hyponatremia	NN

Touch	NN

sensibility	NN

was	VBD

assessed	VBN

with	IN

von	NN

Frey	NNP

's	POS

monofilaments	NNS

in	IN

the	DT

breasts	NNS

of	IN

10	CD

healthy	JJ

women	NNS

(	NN

controls	NNS

)	NN

and	CC

of	IN

80	CD

women	NNS

with	IN

breast	NN

cancer	NN

who	WP

at	IN

least	JJS

1	CD

year	NN

previously	RB

had	VBD

undergone	VBN

subcutaneous	JJ

mastectomy	NN

and	CC

immediate	JJ

reconstruction	NN

with	IN

a	DT

prosthesis	NN

Although	IN

improved	VBN

glycemic	JJ

control	NN

,	,

maintenance	NN

of	IN

normal	JJ

blood	NN

pressure	NN

,	,

and	CC

use	NN

of	IN

angiotensin-converting	JJ

enzyme	NN

inhibitors	NNS

are	VBP

important	JJ

strategies	NNS

to	TO

avoid	VB

developing	VBG

microalbuminuria	NN

,	,

dietary	JJ

macronutrient	NN

intake	NN

may	MD

also	RB

play	NN

a	DT

role	NN

Local	JJ

injection	NN

of	IN

corticosteroids	NNS

into	IN

refractory	JJ

esophageal	NN

strictures	NNS

to	TO

decrease	NN

the	DT

restenosis	NN

rate	NN

has	VBZ

been	VBN

reported	VBN

We	PRP

systematically	RB

reviewed	VBN

the	DT

evidence	NN

concerning	VBG

the	DT

ability	NN

of	IN

five	CD

systemic	JJ

treatments	NNS

to	TO

induce	VB

remission	NN

in	IN

patients	NNS

with	IN

severe	JJ

psoriasis	NN

:	:

ultraviolet	NN

B	NN

(	NN

UVB	NN

)	NN

,	,

photochemotherapy	NN

(	NN

PUVA	NN

)	NN

,	,

methotrexate	NN

(	NN

MTX	NN

)	NN

,	,

retinoids	NNS

(	NN

RET	NNP

)	NN

and	CC

cyclosporin	NN

A	DT

(	NN

CYA	NNP

)	NN

Consequently	RB

,	,

parenteral	JJ

nutrition	NN

(	NN

PN	NN

)	NN

solutions	NNS

used	VBN

to	TO

treat	NN

malnourished	VBN

patients	NNS

with	IN

chronic	JJ

renal	JJ

failure	NN

usually	RB

are	VBP

prepared	JJ

with	IN

little	RB

supplementation	NN

of	IN

these	DT

cations	NNS

<	JJR

TO_SEE	NN

>	JJR

CONCLUSIONS	NNS

:	:

Malnourished	VBN

patients	NNS

with	IN

chronic	JJ

renal	JJ

failure	NN

receiving	VBG

PN	NN

are	VBP

at	IN

risk	NN

of	IN

developing	VBG

electrolyte	NN

abnormalities	NNS

,	,

particularly	RB

hypophosphatemia	NN

PURPOSE	NN

:	:

We	PRP

report	NN

a	DT

multicenter	NN

experience	NN

using	VBG

tubularized	VBN

incised	VBN

plate	NN

urethroplastym	NN

for	IN

proximal	JJ

hypospadias	NNS

MATERIALS	NNS

AND	CC

METHODS	NNS

:	:

From	IN

August	NNP

1993	CD

to	TO

December	NNP

1996	CD

tubularized	VBN

incised	VBN

plate	NN

urethroplasty	NN

was	VBD

performed	VBN

in	IN

27	CD

boys	NNS

6	CD

months	NNS

to	TO

3	CD

years	NNS

old	JJ

with	IN

mid	JJ

shaft	NN

and	CC

penoscrotal	JJ

hypospadias	NNS

RESULTS	NNS

:	:

Tubularized	VBN

incised	VBN

plate	NN

surgery	NN

created	VBN

a	DT

functional	JJ

neourethra	NN

even	RB

in	IN

penoscrotal	JJ

hypospadias	NNS

CONCLUSIONS	NNS

:	:

Tubularized	VBN

incised	VBN

plate	NN

urethroplasty	NN

is	VBZ

a	DT

versatile	JJ

operation	NN

that	IN

corrects	VBZ

proximal	JJ

hypospadias	NNS

defects	NNS

with	IN

few	JJ

complications	NNS

and	CC

superior	JJ

cosmetic	NN

results	NNS

Aortocoronary	NNP

bypass	NN

grafting	VBG

is	VBZ

an	DT

accepted	VBN

procedure	NN

for	IN

ischemic	JJ

heart	NN

disease	NN

Immunotherapy	NN

of	IN

mice	NNS

with	IN

preexisting	VBG

cancers	NNS

with	IN

heat	NN

shock	NN

protein	NN

preparations	NNS

derived	VBN

from	IN

autologous	JJ

cancer	NN

resulted	VBD

in	IN

retarded	VBN

progression	NN

of	IN

the	DT

primary	JJ

cancer	NN

,	,

a	DT

reduced	VBN

metastatic	JJ

load	NN

,	,

and	CC

prolongation	NN

of	IN

life-span	NN

<	JJR

TO_SEE	NN

>	JJR

Intrapleural	JJ

injection	NN

of	IN

irradiated	JJ

LLC-IL2	NN

cured	VBN

pre-existing	JJ

lung	NN

LLC	NN

tumors	NNS

and	CC

extended	VBN

the	DT

survival	NN

of	IN

the	DT

mice	NNS

but	CC

did	VBD

not	RB

affect	VB

survival	NN

of	IN

mice	NNS

with	IN

pre-existing	JJ

peritoneal	NN

tumors	NNS

nor	CC

did	VBD

it	PRP

affect	VB

the	DT

growth	NN

of	IN

s.c.	NN

tumors	NNS

<	JJR

TO_SEE	NN

>	JJR

Intraperitoneal	JJ

injection	NN

of	IN

irradiated	JJ

LLC-IL2	NN

cured	VBN

pre-existing	JJ

LLC	NN

peritoneal	NN

tumors	NNS

and	CC

extended	VBN

the	DT

survival	NN

of	IN

the	DT

mice	NNS

but	CC

did	VBD

not	RB

affect	VB

survival	NN

of	IN

mice	NNS

bearing	VBG

lung	NN

tumors	NNS

nor	CC

did	VBD

it	PRP

affect	VB

the	DT

growth	NN

of	IN

s.c.	NN

tumors	NNS

Subcutaneous	NNP

injection	NN

of	IN

irradiated	JJ

LLC-IL2	NN

did	VBD

not	RB

affect	VB

the	DT

growth	NN

of	IN

preexisting	VBG

s.c.	NN

tumors	NNS

and	CC

also	RB

did	VBD

not	RB

improve	VB

survival	NN

of	IN

mice	NNS

bearing	VBG

the	DT

lung	NN

or	CC

peritoneal	NN

tumors	NNS

We	PRP

describe	VBP

such	JJ

an	DT

event	NN

in	IN

a	DT

man	NN

who	WP

underwent	VBD

allogeneic	JJ

BMT	NN

for	IN

APL	NN

in	IN

second	JJ

relapse	NN

and	CC

4	CD

years	NNS

later	RB

presented	VBN

with	IN

testicular	JJ

relapse	NN

Olanzapine	NN

is	VBZ

an	DT

atypical	JJ

antipsychotic	JJ

effective	JJ

in	IN

the	DT

treatment	NN

of	IN

schizophrenic	JJ

patients	NNS

After	IN

a	DT

2-	CD

to	TO

9-day	JJ

placebo	NN

lead-in	NN

,	,

79	CD

inpatients	NNS

with	IN

schizophrenia	NN

according	VBG

to	TO

DSM-III-R	NN

criteria	NNS

were	VBD

placed	VBN

on	IN

an	DT

olanzapine	NN

dosage	NN

of	IN

10	CD

mg/day	NN

or	CC

1	CD

mg/day	NN

for	IN

up	RB

to	TO

6	CD

weeks	NNS

Fludarabine	NN

and	CC

ara-C	NN

successfully	RB

eradicated	VBN

bone	NN

marrow	NN

disease	NN

in	IN

16	CD

of	IN

27	CD

patients	NNS

(	NN

59	CD

%	NN

)	NN

,	,

23	CD

patients	NNS

of	IN

which	WDT

had	VBD

been	VBN

treated	VBN

previously	RB

with	IN

high-dose	JJ

ara-C	NN

These	DT

results	NNS

verified	VBN

the	DT

synergistic	JJ

effect	NN

fludarabine	NN

exhibited	VBD

in	IN

augmenting	VBG

ara-CTP	NN

concentrations	NNS

in	IN

patients	NNS

'	''

leukemic	JJ

blasts	NNS

,	,

thus	RB

improving	VBG

the	DT

clinical	JJ

response	NN

in	IN

relapsed	VBD

pediatric	JJ

leukemias	NNS

BACKGROUND	NN

:	:

The	DT

growing	VBG

use	NN

of	IN

heparin	NN

in	IN

acute	JJ

thrombotic	JJ

disorders	NNS

,	,

coupled	VBN

with	IN

the	DT

availability	NN

of	IN

many	JJ

new	JJ

antithrombotic	JJ

agents	NNS

,	,

emphasizes	VBZ

the	DT

need	NN

for	IN

adequate	JJ

characterization	NN

of	IN

the	DT

platelet	NN

effects	NNS

of	IN

the	DT

various	JJ

anticoagulants	NNS

METHODS	NNS

AND	CC

RESULTS	NNS

:	:

Platelet	NN

P-selectin	NN

(	NN

CD62	NN

)	NN

and	CC

activated	VBN

GP	NN

IIb/IIIa	NN

(	NN

PAC-1	NN

)	NN

expression	NN

on	IN

platelet	NN

membrane	NN

was	VBD

quantified	VBN

in	IN

whole	JJ

blood	NN

as	IN

well	RB

as	IN

platelet	NN

aggregation	NN

in	IN

platelet-rich	JJ

plasma	NN

in	IN

43	CD

patients	NNS

with	IN

unstable	JJ

angina	NN

before	IN

and	CC

during	IN

treatment	NN

with	IN

UFH	NN

or	CC

enoxaparin	NN

PURPOSE	NN

:	:

We	PRP

review	NN

our	PRP$

initial	JJ

experience	NN

with	IN

direct	JJ

percutaneous	JJ

transluminal	JJ

angioplasty	NN

(	NN

PTA	NNP

)	NN

as	IN

a	DT

reperfusion	NN

treatment	NN

for	IN

acute	JJ

occlusion	NN

of	IN

the	DT

middle	JJ

cerebral	JJ

artery	NN

<	JJR

TO_SEE	NN

>	JJR

CONCLUSION	NN

:	:

Direct	JJ

PTA	NNP

may	MD

be	VB

performed	VBN

safely	RB

as	IN

an	DT

alternative	NN

to	TO

thrombolytic	JJ

therapy	NN

in	IN

patients	NNS

with	IN

acute	JJ

occlusion	NN

of	IN

the	DT

middle	JJ

cerebral	JJ

artery	NN

when	WRB

early	RB

CT	NN

findings	NNS

and/or	CC

lenticulostriate	NN

artery	NN

involvement	NN

are	VBP

present	JJ

or	CC

when	WRB

superselective	JJ

local	JJ

angiography	NN

shows	NNS

the	DT

presence	NN

of	IN

a	DT

large	JJ

embolus	NN

or	CC

high-grade	JJ

stenosis	NN

Women	NNS

randomised	VBN

to	TO

screen-and-treat	NN

received	VBN

appropriate	JJ

antibiotics	NNS

only	RB

if	IN

screening	NN

proved	VBN

positive	JJ

for	IN

one	CD

or	CC

more	RBR

infection	NN

<	JJR

TO_SEE	NN

>	JJR

A	DT

71-year-old	JJ

woman	NN

with	IN

autoimmune	JJ

hemolytic	JJ

anemia	NN

underwent	VBD

an	DT

emergency	NN

endocardial	JJ

patch	NN

repair	NN

for	IN

ventricular	JJ

septal	JJ

perforation	NN

after	IN

acute	JJ

myocardial	JJ

infarction	NN

Use	NN

of	IN

washed	VBN

red	JJ

blood	NN

cells	NNS

was	VBD

effective	JJ

in	IN

averting	VBG

hemolytic	JJ

crisis	NN

throughout	IN

perioperative	NN

period	NN

Therefore	RB

,	,

prudent	JJ

management	NN

and	CC

use	NN

of	IN

washed	VBN

red	JJ

blood	NN

cells	NNS

transfusion	NN

would	MD

prevent	VB

hemolytic	JJ

aggravation	NN

even	RB

in	IN

open	JJ

heart	NN

surgery	NN

<	JJR

TO_SEE	NN

>	JJR

We	PRP

report	NN

a	DT

case	NN

of	IN

a	DT

29-year-old	JJ

male	NN

chronic	JJ

HBV	NN

carrier	NN

who	WP

developed	VBN

fulminant	JJ

reactivated	VBN

HBV	NN

infection	NN

following	VBG

intensive	JJ

chemotherapy	NN

for	IN

stage	NN

IVB	NN

large	JJ

cell	NN

B-cell	NN

non-Hodgkin	JJ

's	POS

lymphoma	NN

associated	VBN

with	IN

extensive	JJ

central	JJ

nervous	JJ

system	NN

and	CC

bone	NN

marrow	NN

involvement	NN

We	PRP

advise	VB

that	IN

lamivudine	NN

should	MD

be	VB

considered	VBN

during	IN

intensive	JJ

chemotherapy	NN

treatment	NN

of	IN

chronic	JJ

carriers	NNS

of	IN

HBV	NN

OBJECTIVES	NNS

:	:

The	DT

purpose	NN

of	IN

this	DT

analysis	NN

was	VBD

to	TO

determine	VB

the	DT

influence	NN

of	IN

an	DT

additional	JJ

treatment	NN

delay	NN

inherent	JJ

in	IN

transfer	NN

to	TO

an	DT

angioplasty	NN

center	NN

for	IN

primary	JJ

angioplasty	NN

of	IN

patients	NNS

with	IN

acute	JJ

myocardial	JJ

infarction	NN

who	WP

are	VBP

first	RB

admitted	VBN

to	TO

hospitals	NNS

without	IN

angioplasty	NN

facilities	NNS

BACKGROUND	NN

:	:

Several	JJ

randomized	VBN

trials	NNS

have	VB

demonstrated	VBN

the	DT

benefits	NNS

of	IN

primary	JJ

angioplasty	NN

in	IN

acute	JJ

myocardial	JJ

infarction	NN

We	PRP

report	NN

the	DT

first	RB

case	NN

(	NN

to	TO

our	PRP$

knowledge	NN

)	NN

of	IN

an	DT

endoscopic	JJ

removal	NN

of	IN

a	DT

forehead	NN

soft	JJ

tissue	NN

mass	NN

As	IN

the	DT

overview	NN

shows	NNS

,	,

both	DT

groups	NNS

of	IN

substances	NNS

are	VBP

useful	JJ

for	IN

individualized	VBN

treatment	NN

of	IN

benign	JJ

prostatic	JJ

hyperplasia	NN

(	NN

BPH	NNP

)	NN

,	,

provided	VBN

that	IN

conservative	JJ

pharmacological	JJ

treatment	NN

of	IN

BPH	NNP

is	VBZ

basically	RB

accepted	VBN

and	CC

that	IN

the	DT

patients	NNS

'	''

quality	NN

of	IN

life	NN

is	VBZ

also	RB

considered	VBN

The	DT

results	NNS

of	IN

several	JJ

clinical	JJ

investigations	NNS

showed	VBD

the	DT

efficacy	NN

and	CC

safety	NN

of	IN

artichoke	NN

extracts	NNS

(	NN

Cynara	NNP

scolymus	NN

L.	NNP

)	NN

in	IN

the	DT

treatment	NN

of	IN

hepato-biliary	JJ

dysfunction	NN

and	CC

digestive	JJ

complaints	NNS

,	,

such	JJ

as	IN

sensation	NN

of	IN

fullness	NN

,	,

loss	NN

of	IN

appetite	NN

,	,

nausea	NN

and	CC

abdominal	JJ

pain	NN

Besides	IN

the	DT

well-known	JJ

nonsteroidal	JJ

antiinflammatory	JJ

drugs	NNS

(	NN

NSAID	NN

)	NN

for	IN

the	DT

treatment	NN

of	IN

rheumatic	JJ

pain	NN

herbal	JJ

medicine	NN

can	MD

also	RB

be	VB

applied	VBN

successfully	RB

Extracts	NNS

of	IN

the	DT

secondary	JJ

tubers	NNS

of	IN

Devil	NNP

's	POS

Claw	VB

(	NN

Harpagophytum	NN

procumbens	NNS

)	NN

are	VBP

recommended	VBN

for	IN

the	DT

supportive	JJ

treatment	NN

of	IN

degenerative	JJ

painful	JJ

rheumatism	NN

High-dose	JJ

intravenous	JJ

immunoglobulin	NN

(	NN

hdIVIg	NN

)	NN

is	VBZ

increasingly	RB

used	VBN

to	TO

treat	NN

a	DT

range	NN

of	IN

inflammatory	JJ

and	CC

autoimmune	JJ

diseases	NNS

The	DT

current	JJ

dermatological	JJ

uses	NNS

of	IN

hdIVIg	NN

include	VB

the	DT

treatment	NN

of	IN

dermatomyositis	NN

and	CC

the	DT

autoimmune	JJ

bullous	JJ

disorders	NNS

,	,

epidermolysis	NN

bullosa	NN

acquisita	NN

,	,

pemphigoid	NN

,	,

and	CC

pemphigus	NN

Unfortunately	RB

,	,

current	JJ

dermatological	JJ

uses	NNS

of	IN

hdIVIg	NN

have	VB

been	VBN

limited	JJ

to	TO

either	DT

uncontrolled	JJ

trials	NNS

or	CC

anecdotal	JJ

case	NN

reports	NNS

,	,

except	IN

for	IN

a	DT

single	JJ

controlled	VBN

trial	NN

of	IN

hdIVIg	NN

as	IN

adjunctive	JJ

therapy	NN

in	IN

patients	NNS

with	IN

dermatomyositis	NN

,	,

which	WDT

documented	VBN

a	DT

significant	JJ

benefit	NN

We	PRP

describe	VBP

a	DT

technique	NN

that	IN

enables	VBZ

the	DT

autologous	JJ

repair	NN

of	IN

large	JJ

midline	NN

incisional	JJ

hernias	NNS

by	IN

restoring	VBG

the	DT

functional	JJ

musculoaponeurotic	JJ

support	NN

of	IN

the	DT

abdominal	JJ

wall	NN

OBJECTIVE	NN

AND	CC

IMPORTANCE	NN

:	:

The	DT

use	NN

of	IN

chronic	JJ

intrathecal	JJ

morphine	NN

for	IN

the	DT

treatment	NN

of	IN

intractable	JJ

,	,

nonmalignant	JJ

pain	NN

is	VBZ

becoming	VBG

more	RBR

prevalent	JJ

METHODS	NNS

:	:

During	IN

a	DT

19-month	JJ

period	NN

,	,

seven	CD

children	NNS

with	IN

empyema	NN

underwent	VBD

thoracoscopy	NN

<	JJR

TO_SEE	NN

>	JJR

We	PRP

describe	VBP

a	DT

patient	NN

with	IN

left	RB

cardiac	JJ

herniation	NN

presenting	VBG

after	IN

intrapericardial	JJ

pulmonectomy	NN

for	IN

primary	JJ

lung	NN

cancer	NN

The	DT

growing	VBG

use	NN

of	IN

automated	VBN

night-time	JJ

dialysis	NN

(	NN

APD	NN

)	NN

in	IN

peritoneal	NN

dialysis	NN

over	IN

the	DT

last	JJ

few	JJ

years	NNS

shows	NNS

that	IN

this	DT

method	NN

represents	VBZ

a	DT

valid	JJ

alternative	NN

to	TO

continuous	JJ

ambulatory	JJ

peritoneal	NN

dialysis	NN

(	NN

CAPD	NN

)	NN

La	NNP

Serna	NNP

et	FW

al	NNP

.	.

(	NN

Lancet	NNP

1987	CD

;	:

26	CD

:	:

1517	CD

)	NN

were	VBD

the	DT

first	RB

to	TO

treat	NN

adults	NNS

with	IN

recurrent	JJ

pericarditis	NN

with	IN

colchicine	NN

,	,

and	CC

were	VBD

followed	VBN

by	IN

other	JJ

authors	NNS

While	IN

these	DT

findings	NNS

are	VBP

observed	VBN

for	IN

all	DT

classes	NNS

of	IN

oral	JJ

drugs	NNS

,	,

the	DT

issue	NN

is	VBZ

especially	RB

critical	JJ

for	IN

cancer	NN

chemotherapy	NN

,	,

in	IN

which	WDT

a	DT

narrow	JJ

therapeutic	JJ

index	NN

is	VBZ

frequently	RB

observed	VBN

Treatment	NN

for	IN

low-grade	JJ

NHL	NN

during	IN

the	DT

past	IN

30	CD

yr	NN

has	VBZ

consisted	VBD

of	IN

high-dose	JJ

radiation	NN

and	CC

cytotoxic	JJ

agents	NNS

,	,

administered	VBN

alone	RB

or	CC

in	IN

combination	NN

,	,

and	CC

high-dose	JJ

therapy	NN

with	IN

stem	NN

cell	NN

transplant	NN

However	RB

,	,

recent	JJ

clinical	JJ

use	NN

of	IN

monoclonal	JJ

antibodies	NNS

(	NN

mAbs	NNS

)	NN

in	IN

patients	NNS

with	IN

low-grade	JJ

or	CC

transformed	VBN

low-grade	JJ

NHL	NN

has	VBZ

resulted	VBD

in	IN

less	JJR

toxicity	NN

than	IN

conventional	JJ

treatments	NNS

,	,

as	IN

well	RB

as	IN

response	NN

rates	NNS

that	IN

are	VBP

comparable	JJ

or	CC

superior	JJ

to	TO

those	DT

achieved	VBN

with	IN

chemotherapy	NN

Therefore	RB

,	,

interest	NN

is	VBZ

growing	VBG

in	IN

mAbs	NNS

as	IN

therapeutic	JJ

alternatives	NNS

for	IN

patients	NNS

with	IN

low-grade	JJ

NHL	NN

and	CC

those	DT

with	IN

transformed	VBN

histology	NN

CONCLUSION	NN

:	:

The	DT

treatment	NN

paradigm	NN

for	IN

NHL	NN

is	VBZ

expected	VBN

to	TO

change	NN

over	IN

the	DT

next	IN

few	JJ

years	NNS

to	TO

include	VB

radiolabeled	VBN

mAbs	NNS

,	,

administered	VBN

alone	RB

or	CC

in	IN

combination	NN

with	IN

cytotoxic	JJ

agents	NNS

RESULTS	NNS

:	:

Clinical	JJ

trials	NNS

of	IN

UFT	NNP

published	VBN

in	IN

the	DT

Western	NNP

world	NN

have	VB

included	VBN

581	CD

patients	NNS

with	IN

colorectal	JJ

cancer	NN

The	DT

activity	NN

of	IN

oral	JJ

UFT	NNP

in	IN

large-bowel	JJ

cancer	NN

when	WRB

administered	VBN

with	IN

oral	JJ

LV	NN

(	NN

approximately	RB

50	CD

mg/dose	NN

)	NN

has	VBZ

resulted	VBD

in	IN

objective	NN

response	NN

rates	NNS

of	IN

approximately	RB

40	CD

%	NN

CONCLUSION	NN

:	:

UFT	NNP

is	VBZ

a	DT

fluoropyrimidine	NN

active	JJ

in	IN

colorectal	JJ

cancer	NN

BACKGROUND	NN

:	:

Adrenalectomy	NN

is	VBZ

the	DT

current	JJ

treatment	NN

for	IN

phaeochromocytoma	NN

CONCLUSION	NN

:	:

Adrenal-sparing	NN

surgery	NN

is	VBZ

safe	JJ

and	CC

effective	JJ

,	,

and	CC

may	MD

become	VB

the	DT

treatment	NN

of	IN

choice	NN

in	IN

patients	NNS

with	IN

hereditary	JJ

phaeochromocytoma	NN

<	JJR

TO_SEE	NN

>	JJR

PURPOSE	NN

:	:

The	DT

purposes	NNS

of	IN

this	DT

descriptive	JJ

,	,

longitudinal	JJ

study	NN

were	VBD

to	TO

evaluate	VB

the	DT

MacDibbs	NNS

Mouth	NN

Assessment	NNP

instrument	NN

for	IN

the	DT

assessment	NN

of	IN

mucositis	NN

in	IN

the	DT

radiation	NN

therapy	NN

patient	NN

being	VBG

treated	VBN

for	IN

head	NN

and	CC

neck	NN

cancer	NN

and	CC

to	TO

describe	VBP

the	DT

course	NN

of	IN

radiation-induced	JJ

mucositis	NN

in	IN

these	DT

patients	NNS

<	JJR

TO_SEE	NN

>	JJR

As	IN

concomitant	JJ

thrombocytosis	NN

persisted	VBD

despite	IN

treatment	NN

with	IN

hydroxyurea	NN

,	,

the	DT

new	JJ

megakaryocyte	NN

inhibitor	NN

anagrelide	NN

(	NN

Agrelin	NN

)	NN

was	VBD

administered	VBN

and	CC

led	VBN

to	TO

normalization	NN

of	IN

the	DT

platelet	NN

count	NN

within	IN

11	CD

days	NNS

Background	NN

:	:

Troglitazone	NN

is	VBZ

a	DT

new	JJ

drug	NN

for	IN

the	DT

treatment	NN

of	IN

type	NN

2	CD

diabetes	NN

<	JJR

TO_SEE	NN

>	JJR

For	IN

a	DT

subset	NN

of	IN

patients	NNS

with	IN

Kaposi	NN

's	POS

sarcoma	NN

who	WP

were	VBD

treated	VBN

with	IN

recombinant	JJ

interferon	NN

alfa-2a	NN

,	,

the	DT

disease	NN

is	VBZ

in	IN

complete	JJ

remission	NN

,	,

without	IN

opportunistic	JJ

infection	NN

,	,

and	CC

they	PRP

appear	VB

to	TO

be	VB

culture-negative	JJ

for	IN

the	DT

etiologic	JJ

retrovirus	NN

that	IN

causes	NNS

their	PRP$

immune	JJ

deficiency	NN

Interferon	NN

alfa-2a	NN

appears	VBZ

to	TO

have	VB

antineoplastic	JJ

efficacy	NN

,	,

(	NN

and	CC

may	MD

have	VB

antiretroviral	JJ

efficacy	NN

as	IN

well	RB

)	NN

in	IN

this	DT

epidemic	JJ

neoplasm	NN

In	IN

three	CD

consecutive	JJ

Phase	NN

II	NNP

trials	NNS

of	IN

recombinant	JJ

interferon	NN

alfa-2a	NN

(	NN

rIFN	NN

alfa-2a	NN

;	:

Roferon-A	NN

Hoffmann-La	NNP

Roche	NNP

,	,

Nutley	NNP

,	,

NJ	NNP

)	NN

involving	VBG

96	CD

patients	NNS

with	IN

advanced	VBN

malignant	JJ

melanoma	NN

,	,

an	DT

overall	RB

response	NN

rate	NN

of	IN

22	CD

%	NN

was	VBD

observed	VBN

As	IN

single	JJ

agent	NN

therapy	NN

in	IN

malignant	JJ

melanoma	NN

,	,

interferon	NN

alfa-2a	NN

was	VBD

only	RB

marginally	RB

useful	JJ

in	IN

most	RBS

patients	NNS

Studies	NNS

with	IN

various	JJ

interferon	NN

alpha	NN

preparations	NNS

,	,

including	VBG

interferons	NNS

induced	VBN

in	IN

human	JJ

leukocytes	NNS

,	,

interferon	NN

alfa-N1	NN

,	,

interferon	NN

alfa-2a	NN

,	,

and	CC

interferon	NN

alfa-2b	NN

,	,

have	VB

all	DT

provided	VBN

evidence	NN

for	IN

modest	JJ

but	CC

reproducible	JJ

antitumor	NN

activity	NN

in	IN

advanced	VBN

renal	JJ

cell	NN

carcinoma	NN

Preliminary	JJ

evidence	NN

suggests	VBZ

that	IN

interferons	NNS

beta	NN

and	CC

gamma	NN

may	MD

also	RB

induce	VB

regression	NN

of	IN

metastatic	JJ

renal	JJ

cell	NN

carcinoma	NN

The	DT

rationale	NN

for	IN

antileukemic	JJ

therapy	NN

in	IN

hairy	JJ

cell	NN

leukemia	NN

is	VBZ

to	TO

reduce	VB

the	DT

significant	JJ

risk	NN

of	IN

infection	NN

and	CC

other	JJ

potential	NN

serious	JJ

complications	NNS

Splenectomy	NNP

presumably	RB

alleviates	VBZ

the	DT

pancytopenic	JJ

effect	NN

of	IN

hypersplenism	NN

by	IN

removing	VBG

the	DT

preferred	VBN

site	NN

of	IN

leukemic	JJ

cell	NN

proliferation	NN

Recombinant	JJ

and	CC

natural	JJ

forms	NNS

of	IN

interferon	NN

alpha	NN

have	VB

been	VBN

shown	VBN

to	TO

bring	VB

about	IN

tumor	NN

regressions	NNS

in	IN

patients	NNS

with	IN

low-grade	JJ

non-Hodgkin	JJ

's	POS

lymphoma	NN

Current	JJ

studies	NNS

using	VBG

interferon	NN

in	IN

patients	NNS

with	IN

low-grade	JJ

non-Hodgkin	JJ

's	POS

lymphomas	NNS

are	VBP

evaluating	VBG

lower	JJR

,	,

and	CC

perhaps	RB

better	RB

tolerated	VBN

doses	NNS

of	IN

interferon	NN

This	DT

approach	NN

is	VBZ

being	VBG

extended	VBN

to	TO

the	DT

clinic	NN

,	,

and	CC

trials	NNS

are	VBP

now	RB

underway	NN

evaluating	VBG

combinations	NNS

of	IN

interferon	NN

and	CC

various	JJ

cytotoxic	JJ

drugs	NNS

known	VBN

from	IN

previous	JJ

studies	NNS

to	TO

be	VB

active	JJ

in	IN

patients	NNS

with	IN

low-grade	JJ

non-Hodgkin	JJ

's	POS

lymphomas	NNS

While	IN

the	DT

demonstrated	VBN

antiviral	JJ

,	,

antiproliferative	JJ

,	,

and	CC

immunomodulatory	JJ

properties	NNS

of	IN

interferons	NNS

have	VB

led	VBN

to	TO

a	DT

number	NN

of	IN

theories	NNS

regarding	VBG

their	PRP$

potential	NN

use	NN

in	IN

treating	VBG

individuals	NNS

with	IN

chronic	JJ

myelogenous	JJ

leukemia	NN

(	NN

CML	NN

)	NN

,	,

their	PRP$

limited	JJ

availability	NN

has	VBZ

prevented	VBD

thorough	JJ

clinical	JJ

investigation	NN

The	DT

data	NNS

resulting	VBG

from	IN

these	DT

clinical	JJ

trials	NNS

indicate	VBP

that	IN

interferon	NN

alfa-2a	NN

is	VBZ

effective	JJ

in	IN

inducing	VBG

hematologic	JJ

remissions	NNS

in	IN

the	DT

majority	NN

of	IN

minimally	RB

treated	VBN

,	,

benign-phase	NN

CML	NN

,	,

Ph1-positive	JJ

patients	NNS

More	RBR

than	IN

1600	CD

patients	NNS

with	IN

neoplastic	JJ

disorders	NNS

have	VB

received	VBN

recombinant	JJ

human	JJ

interferon	NN

alfa-2a	NN

(	NN

Roferon-A	NN

,	,

Hoffmann-La	NNP

Roche	NNP

,	,

Nutley	NNP

,	,

NJ	NNP

)	NN

as	IN

part	NN

of	IN

ongoing	JJ

or	CC

completed	VBN

clinical	JJ

trials	NNS

PURPOSE	NN

:	:

A	DT

phase	NN

I/II	CD

trial	NN

of	IN

docetaxel	NN

,	,

cisplatin	NN

,	,

fluorouracil	NN

(	NN

5-FU	NN

)	NN

,	,

and	CC

leucovorin	NN

(	NN

TPFL5	NN

)	NN

induction	NN

chemotherapy	NN

for	IN

patients	NNS

with	IN

locally	RB

advanced	VBN

squamous	JJ

cell	NN

carcinoma	NN

of	IN

the	DT

head	NN

and	CC

neck	NN

(	NN

SCCHN	NN

)	NN

PATIENTS	NNS

AND	CC

METHODS	NNS

:	:

Twenty-three	CD

previously	RB

untreated	JJ

patients	NNS

with	IN

stage	NN

III	NNP

or	CC

IV	CD

SCCHN	NN

and	CC

Eastern	NNP

Cooperative	NNP

Oncology	NNP

Group	NNP

functional	JJ

status	NN

less	JJR

than	IN

or	CC

equal	JJ

to	TO

2	CD

were	VBD

treated	VBN

with	IN

TPFL5	NN

Intrathecal	JJ

sufentanil	NN

provides	VBZ

approximately	RB

2	CD

h	NN

of	IN

excellent	JJ

labor	NN

analgesia	NN

with	IN

minimal	JJ

motor	NN

blockade	NN

OBJECTIVE	NN

:	:

We	PRP

report	NN

the	DT

results	NNS

of	IN

a	DT

double-blind	JJ

,	,

double-dummy	JJ

,	,

active-control	NN

study	NN

designed	VBN

to	TO

evaluate	VB

the	DT

efficacy	NN

and	CC

safety	NN

of	IN

lamotrigine	NN

(	NN

LTG	NN

)	NN

administered	VBN

as	IN

monotherapy	NN

to	TO

adult	JJ

outpatients	NNS

with	IN

partial	JJ

seizures	NNS

BACKGROUND	NN

:	:

The	DT

effectiveness	NN

of	IN

LTG	NN

as	IN

add-on	JJ

therapy	NN

for	IN

partial	JJ

seizures	NNS

in	IN

adults	NNS

has	VBZ

previously	RB

been	VBN

established	VBN

CONCLUSIONS	NNS

:	:

We	PRP

conclude	VBP

that	IN

LTG	NN

is	VBZ

effective	JJ

and	CC

well	RB

tolerated	VBN

when	WRB

administered	VBN

as	IN

monotherapy	NN

in	IN

adult	JJ

patients	NNS

with	IN

partial	JJ

seizures	NNS

BACKGROUND	NN

:	:

Omega3	NN

fatty	NN

acids	NNS

may	MD

inhibit	VB

neuronal	JJ

signal	NN

transduction	NN

pathways	NNS

in	IN

a	DT

manner	NN

similar	JJ

to	TO

that	IN

of	IN

lithium	NN

carbonate	NN

and	CC

valproate	NN

,	,

2	CD

effective	JJ

treatments	NNS

for	IN

bipolar	JJ

disorder	NN

The	DT

present	JJ

study	NN

was	VBD

performed	VBN

to	TO

examine	VB

whether	IN

omega3	NN

fatty	NN

acids	NNS

also	RB

exhibit	NN

mood-stabilizing	JJ

properties	NNS

in	IN

bipolar	JJ

disorder	NN

CONCLUSION	NN

:	:

Omega3	NN

fatty	NN

acids	NNS

were	VBD

well	RB

tolerated	VBN

and	CC

improved	VBN

the	DT

short-term	JJ

course	NN

of	IN

illness	NN

in	IN

this	DT

preliminary	JJ

study	NN

of	IN

patients	NNS

with	IN

bipolar	JJ

disorder	NN

Several	JJ

large-scale	JJ

trials	NNS

have	VB

firmly	RB

established	VBN

the	DT

effectiveness	NN

of	IN

thrombolytic	JJ

therapy	NN

,	,

beta	NN

blockers	NNS

,	,

and	CC

aspirin	NN

in	IN

the	DT

treatment	NN

of	IN

AMI	NNP

<	JJR

TO_SEE	NN

>	JJR

While	IN

diastolic	JJ

left	RB

ventricular	JJ

(	NN

LV	NN

)	NN

dysfunction	NN

is	VBZ

frequent	JJ

and	CC

associated	VBN

with	IN

cardiovascular	JJ

complications	NNS

in	IN

end-stage	NN

renal	JJ

disease	NN

treated	VBN

with	IN

dialysis	NN

,	,

controversial	JJ

information	NN

exists	VBZ

on	IN

diastolic	JJ

LV	NN

function	NN

after	IN

renal	JJ

transplantation	NN

METHODS	NNS

:	:

Fluvastatin	NN

40	CD

mg	NN

daily	RB

was	VBD

administered	VBN

to	TO

25	CD

patients	NNS

with	IN

hypercholesterolaemia	NN

for	IN

up	RB

to	TO

24	CD

weeks	NNS

The	DT

inhibitory	JJ

effect	NN

of	IN

n-3	NN

polyunsaturated	JJ

fatty	NN

acids	NNS

on	IN

human	JJ

colorectal	JJ

cancer	NN

has	VBZ

been	VBN

speculated	VBD

on	IN

from	IN

epidemiological	JJ

data	NNS

and	CC

animal	NN

studies	NNS

We	PRP

conducted	VBN

a	DT

long-term	JJ

trial	NN

of	IN

docosahexanoic	JJ

acid	NN

(	NN

DHA	NN

)	NN

-concentrated	JJ

fish	NN

oil	NN

capsules	NNS

for	IN

patients	NNS

in	IN

a	DT

high-risk	JJ

group	NN

for	IN

colorectal	JJ

cancer	NN

Three	CD

patients	NNS

with	IN

FAP	NN

and	CC

two	CD

patients	NNS

with	IN

multiple	JJ

(	NN

more	RBR

than	IN

30	CD

)	NN

colorectal	JJ

polyps	NNS

were	VBD

administered	VBN

DHA-concentrated	JJ

fish	NN

oil	NN

capsules_Hlk427554600	NN

(	NN

2.2	CD

g	NN

of	IN

DHA	NN

and	CC

0.6	CD

g	NN

of	IN

eicosapentanoic	JJ

acid	NN

(	NN

EPA	NNP

)	NN

per	IN

day	NN

)	NN

for	IN

one	CD

or	CC

two	CD

years	NNS

This	DT

article	NN

reviews	NNS

current	JJ

trends	NNS

in	IN

management	NN

of	IN

esophageal	NN

achalasia	NN

,	,

highlighting	VBG

short-term	JJ

outcome	NN

and	CC

cost	NN

comparisons	NNS

of	IN

three	CD

treatments	NNS

:	:

botulinum	NN

toxin	NN

injection	NN

,	,

pneumatic	JJ

dilation	NN

,	,

and	CC

laparoscopic	JJ

myotomy	NN

The	DT

clinical	JJ

application	NN

of	IN

therapeutic	JJ

hysteroscopy	NN

,	,

mainly	RB

in	IN

the	DT

field	NN

of	IN

the	DT

treatment	NN

of	IN

abnormal	JJ

uterine	NN

bleeding	VBG

,	,

started	VBD

in	IN

the	DT

1980s	NNS

<	JJR

TO_SEE	NN

>	JJR

In	IN

this	DT

article	NN

,	,

evidence	NN

of	IN

effectiveness	NN

and	CC

cost-effectiveness	NN

of	IN

the	DT

following	VBG

procedures	NNS

is	VBZ

reviewed	VBN

:	:

(	NN

1	CD

)	NN

laser	NN

treatment	NN

of	IN

bladder	NN

tumors	NNS

;	:

(	NN

2	CD

)	NN

extracorporeal	JJ

shock-wave	NN

lithotripsy	NN

and	CC

percutaneous	JJ

nephrolithotomy	NN

;	:

(	NN

3	CD

)	NN

laparoscopic	JJ

treatment	NN

of	IN

endometriosis	NN

;	:

(	NN

4	CD

)	NN

laparoscopic	JJ

removal	NN

of	IN

ovarian	JJ

cysts	NNS

;	:

(	NN

5	CD

)	NN

laparoscopic	JJ

cholecystectomy	NN

;	:

(	NN

6	CD

)	NN

laparoscopic	JJ

appendectomy	NN

;	:

(	NN

7	CD

)	NN

catheter	NN

treatment	NN

of	IN

coronary	JJ

artery	NN

disease	NN

;	:

(	NN

8	CD

)	NN

palliation	NN

of	IN

colon	NN

cancer	NN

by	IN

endoscopic	JJ

intervention	NN

;	:

(	NN

9	CD

)	NN

treatment	NN

of	IN

upper	JJ

gastrointestinal	JJ

(	NN

UGI	NNP

)	NN

bleeding	VBG

by	IN

endoscopic	JJ

intervention	NN

;	:

and	CC

(	NN

10	CD

)	NN

arthroscopic	NN

knee	NN

surgery	NN

Gene	NN

therapy	NN

of	IN

malignant	JJ

brain	NN

tumors	NNS

Treatment	NN

of	IN

irritable	JJ

bowel	NN

syndrome	NN

with	IN

Chinese	JJ

herbal	JJ

medicine	NN

:	:

a	DT

randomized	VBN

controlled	VBN

trial	NN

Randomised	VBN

trial	NN

of	IN

interferon	NN

alpha2b	NN

plus	CC

ribavirin	NNP

for	IN

48	CD

weeks	NNS

or	CC

for	IN

24	CD

weeks	NNS

versus	CC

interferon	NN

alpha2b	NN

plus	CC

placebo	NN

for	IN

48	CD

weeks	NNS

for	IN

treatment	NN

of	IN

chronic	JJ

infection	NN

with	IN

hepatitis	NN

C	NN

virus	NN

Low-molecular-weight	JJ

heparin	NN

for	IN

immediate	JJ

management	NN

of	IN

thromboembolic	NN

disease	NN

in	IN

pregnancy	NN

Tubularized	VBN

incised	VBN

plate	NN

hypospadias	NNS

repair	NN

for	IN

proximal	JJ

hypospadias	NNS

Comparison	NN

of	IN

radical	NN

prostatectomy	NN

and	CC

iodine	NN

125	CD

interstitial	JJ

radiotherapy	NN

for	IN

the	DT

treatment	NN

of	IN

clinically	RB

localized	JJ

prostate	NN

cancer	NN

:	:

a	DT

7-year	JJ

biochemical	JJ

(	NN

PSA	NN

)	NN

progression	NN

analysis	NN

The	DT

effectiveness	NN

of	IN

acupuncture	NN

in	IN

treating	VBG

acute	JJ

dental	JJ

pain	NN

:	:

a	DT

systematic	JJ

review	NN

Correction	NN

of	IN

cardiac	JJ

defects	NNS

through	IN

a	DT

right	RB

thoracotomy	NN

in	IN

children	NNS

New	NNP

technique	NN

for	IN

mesh	NN

repair	NN

of	IN

paracolostomy	NN

hernias	NNS

Immunotherapy	NN

of	IN

tumors	NNS

with	IN

autologous	JJ

tumor-derived	JJ

heat	NN

shock	NN

protein	NN

preparations	NNS

Comprehensive	NNP

modified	VBN

diet	NN

simplifies	VBZ

nutrition	NN

management	NN

of	IN

adults	NNS

with	IN

short-bowel	NN

syndrome	NN

Extended	VBN

use	NN

of	IN

glatiramer	NN

acetate	NN

(	NN

Copaxone	NN

)	NN

is	VBZ

well	RB

tolerated	VBN

and	CC

maintains	VBZ

its	PRP$

clinical	JJ

effect	NN

on	IN

multiple	JJ

sclerosis	NN

relapse	NN

rate	NN

and	CC

degree	NN

of	IN

disability	NN

European	JJ

register	NN

of	IN

patients	NNS

with	IN

sickle	NN

cell	NN

disease	NN

treated	VBN

with	IN

hydroxyurea	NN

is	VBZ

being	VBG

set	NN

up	RB

Understanding	VBG

the	DT

culture	NN

of	IN

prescribing	VBG

:	:

qualitative	JJ

study	NN

of	IN

general	JJ

practitioners	NNS

'	''

and	CC

patients	NNS

'	''

perceptions	NNS

of	IN

antibiotics	NNS

for	IN

sore	JJ

throats	NNS

Steroid	NN

delivery	NN

in	IN

croup	NN

Haematoma	NN

block	NN

versus	CC

intravenous	JJ

regional	JJ

anaesthesia	NN

in	IN

Colles	NNP

'	''

fractures	NNS

Direct	JJ

percutaneous	JJ

transluminal	JJ

angioplasty	NN

for	IN

acute	JJ

middle	JJ

cerebral	JJ

artery	NN

occlusion	NN

Magnesium	NN

sulphate	NN

for	IN

the	DT

control	NN

of	IN

spasms	NNS

in	IN

severe	JJ

tetanus	NN

Protective	JJ

effect	NN

of	IN

pralidoxime	NN

on	IN

muscle	NN

fiber	NN

necrosis	NN

induced	VBN

by	IN

organophosphate	NN

compounds	NNS

Assessment	NNP

of	IN

atrioventricular	JJ

junction	NN

ablation	NN

and	CC

VVIR	NN

pacemaker	NN

versus	CC

pharmacological	JJ

treatment	NN

in	IN

patients	NNS

with	IN

heart	NN

failure	NN

and	CC

chronic	JJ

atrial	IN

fibrillation	NN

:	:

a	DT

randomized	VBN

,	,

controlled	VBN

study	NN

Statins	NNS

for	IN

prevention	NN

of	IN

stroke	NN

Repair	NN

of	IN

ventral	JJ

hernias	NNS

with	IN

expanded	VBN

polytetrafluoroethylene	NN

patch	NN

Spinal	JJ

manipulation	NN

in	IN

the	DT

treatment	NN

of	IN

episodic	JJ

tension-type	JJ

headache	NN

:	:

a	DT

randomized	VBN

controlled	VBN

trial	NN

Successful	JJ

treatment	NN

with	IN

lamivudine	NN

for	IN

fulminant	JJ

reactivated	VBN

hepatitis	NN

B	NN

infectioN	NN

following	VBG

intensive	JJ

therapy	NN

for	IN

high-grade	JJ

non-Hodgkin	JJ

's	POS

lymphoma	NN

Influence	NN

of	IN

treatment	NN

delay	NN

on	IN

infarct	NN

size	NN

and	CC

clinical	JJ

outcome	NN

in	IN

patients	NNS

with	IN

acute	JJ

myocardial	JJ

infarction	NN

treated	VBN

with	IN

primary	JJ

angioplasty	NN

Should	MD

patients	NNS

with	IN

advanced	VBN

sarcomas	NNS

be	VB

treated	VBN

with	IN

chemotherapy	NN

?	.

Plasma	NN

exchange	NN

and	CC

tacrolimus-mycophenolate	JJ

rescue	NN

for	IN

acute	JJ

humoral	JJ

rejection	NN

in	IN

kidney	NN

transplantation	NN

Hyperbaric	JJ

oxygen	NN

therapy	NN

for	IN

children	NNS

with	IN

cerebral	JJ

palsy	NN

Endoscopic	JJ

excision	NN

of	IN

a	DT

forehead	NN

mass	NN

Effect	NN

of	IN

photodynamic	JJ

therapy	NN

in	IN

combination	NN

with	IN

mitomycin	NN

C	NN

on	IN

a	DT

mitomycin-resistant	JJ

bladder	NN

cancer	NN

cell	NN

line	NN

Is	VBZ

conservative	JJ

surgery	NN

for	IN

tubal	JJ

pregnancy	NN

preferable	JJ

to	TO

salpingectomy	NN

?	.

An	DT

economic	JJ

analysis	NN

Laparoscopic	JJ

cornuostomy	NN

in	IN

the	DT

treatment	NN

of	IN

interstitial	JJ

pregnancy	NN

with	IN

subsequent	JJ

hysterosalpingography	NN

Experimental	JJ

evaluation	NN

of	IN

the	DT

use	NN

of	IN

recombinant	JJ

prourokinase	NN

and	CC

its	PRP$

immobilized	VBN

forms	NNS

in	IN

the	DT

treatment	NN

of	IN

postoperative	JJ

fibrinoid	NN

syndrome	NN

in	IN

ophthalmology	NN

In	IN

vitro	NN

and	CC

in	IN

vivo	FW

comparison	NN

between	IN

the	DT

effects	NNS

of	IN

treatment	NN

with	IN

adenosine	NN

triphosphate	NN

and	CC

treatment	NN

with	IN

buthionine	NN

sulfoximine	NN

on	IN

chemosensitization	NN

and	CC

tumour	NN

growth	NN

of	IN

B16	NN

melanoma	NN

Effects	NNS

of	IN

transpupillary	JJ

thermotherapy	NN

on	IN

immunological	JJ

parameters	NNS

and	CC

apoptosis	NN

in	IN

a	DT

case	NN

of	IN

primary	JJ

uveal	NN

melanoma	NN

Is	VBZ

there	RB

a	DT

rational	JJ

therapy	NN

for	IN

symptomatic	JJ

treatment	NN

of	IN

benign	JJ

prostatic	JJ

hyperplasia	NN

with	IN

phytogenic	JJ

drugs	NNS

?	.

Illustrated	NNP

with	IN

the	DT

example	NN

of	IN

the	DT

prostate	NN

agent	NN

from	IN

Serenoa	NNP

repens	NNS

(	NN

Sabal	NNP

fructus	NN

)	NN

Pharmacological	JJ

and	CC

clinical	JJ

effectiveness	NN

of	IN

a	DT

fixed	VBN

phytogenic	JJ

combination	NN

trembling	VBG

poplar	NN

(	NN

Populus	NN

tremula	NN

)	NN

,	,

true	JJ

goldenrod	NN

(	NN

Solidago	NNP

virgaurea	NN

)	NN

and	CC

ash	JJ

(	NN

Fraxinus	NN

excelsior	NN

)	NN

in	IN

mild	JJ

to	TO

moderate	JJ

rheumatic	JJ

complaints	NNS

Therapy	NN

of	IN

degenerative	JJ

diseases	NNS

of	IN

the	DT

musculoskeletal	JJ

system	NN

with	IN

South	NNP

African	NNP

devil	NNP

's	POS

claw	VB

(	NN

Harpagophytum	NN

procumbens	NNS

DC	NN

)	NN

Treatment	NN

strategy	NN

for	IN

mucin-producing	JJ

intrahepatic	JJ

cholangiocarcinoma	NN

:	:

value	NN

of	IN

percutaneous	JJ

transhepatic	JJ

biliary	JJ

drainage	NN

and	CC

cholangioscopy	NN

Strategy	NN

for	IN

surgical	JJ

management	NN

of	IN

ileocolonic	JJ

anastomotic	JJ

recurrence	NN

in	IN

Crohn	NN

's	POS

disease	NN

Nerve-sparing	JJ

surgery	NN

for	IN

advanced	VBN

rectal	JJ

cancer	NN

patients	NNS

:	:

special	JJ

reference	NN

to	TO

Dukes	NNP

C	NN

patients	NNS

Prognostic	JJ

factors	NNS

in	IN

patients	NNS

with	IN

locally	RB

advanced	VBN

rectal	JJ

adenocarcinoma	NN

treated	VBN

with	IN

preoperative	JJ

radiotherapy	NN

and	CC

surgery	NN

Current	JJ

surgical	JJ

therapy	NN

for	IN

bronchiectasis	NN

Thoracic	JJ

surgery	NN

for	IN

hydatid	NN

disease	NN

Surgical	NNP

treatment	NN

of	IN

postpneumonic	JJ

empyema	NN

Thoracoscopic	NNP

surgery	NN

for	IN

pulmonary	JJ

tuberculosis	NN

Thoracoscopic	NNP

surgery	NN

for	IN

spontaneous	JJ

pneumothorax	NN

Surgery	NN

for	IN

chronic	JJ

thromboembolic	NN

pulmonary	JJ

hypertension	NN

Transabdominal	JJ

extensive	JJ

esophagogastric	JJ

devascularization	NN

with	IN

gastroesophageal	NN

stapling	VBG

for	IN

management	NN

of	IN

noncirrhotic	JJ

portal	NN

hypertension	NN

:	:

long-term	JJ

results	NNS

Surgical	NNP

treatment	NN

for	IN

lung	NN

hydatid	NN

disease	NN

Sliding	VBG

door	NN

technique	NN

for	IN

the	DT

repair	NN

of	IN

midline	NN

incisional	JJ

hernias	NNS

One-lung	JJ

ventilation	NN

in	IN

patients	NNS

with	IN

difficult	JJ

airways	NNS

Thoracoscopy	NNP

for	IN

empyema	NN

in	IN

children	NNS

Sex	NN

differences	NNS

in	IN

the	DT

use	NN

of	IN

asthma	NN

drugs	NNS

:	:

cross	NN

sectional	JJ

study	NN

Conventional	JJ

treatments	NNS

for	IN

non-Hodgkin	JJ

's	POS

lymphoma	NN

:	:

the	DT

need	NN

for	IN

new	JJ

therapies	NNS

Adrenal-sparing	NN

surgery	NN

for	IN

phaeochromocytoma	NN

Antiplatelet	JJ

therapy	NN

in	IN

acute	JJ

cerebral	JJ

ischemia	NN

Laugier-Hunziker	NNP

syndrome	NN

:	:

case	NN

report	NN

and	CC

treatment	NN

with	IN

the	DT

Q-switched	JJ

Nd-Yag	NN

laser	NN

Thoracoscopic	NNP

operation	NN

for	IN

secondary	JJ

pneumothorax	NN

under	IN

local	JJ

and	CC

epidural	JJ

anesthesia	NN

in	IN

high-risk	JJ

patients	NNS

Troglitazone-induced	JJ

hepatic	JJ

failure	NN

leading	VBG

to	TO

liver	NN

transplantation	NN

A	DT

modified	VBN

technique	NN

of	IN

tubeless	JJ

anaesthesia	NN

for	IN

microlaryngoscopy	NN

and	CC

bronchoscopy	NN

in	IN

young	JJ

children	NNS

with	IN

stridor	NN

A	DT

randomized	VBN

trial	NN

of	IN

Lactobacillus	NN

acidophilus	NN

BG2FO4	NN

to	TO

treat	NN

lactose	NN

intolerance	NN

Treatment	NN

of	IN

idiopathic	JJ

thrombopenic	JJ

purpura	NN

in	IN

adolescents	NNS

by	IN

intravenous	JJ

immunoglobulin	NN

Azithromycin	NN

therapy	NN

for	IN

scrub	NN

typhus	NN

during	IN

pregnancy	NN

Excimer	NNP

laser	NN

assisted	VBN

in	IN

situ	FW

keratomileusis	NN

for	IN

hyperopia	NN

Three	CD

consecutive	JJ

phase	NN

II	NNP

studies	NNS

of	IN

recombinant	JJ

interferon	NN

alfa-2a	NN

in	IN

advanced	VBN

malignant	JJ

melanoma	NN

Interferon	NN

treatment	NN

of	IN

renal	JJ

cell	NN

carcinoma	NN

Current	JJ

and	CC

future	NN

uses	NNS

of	IN

recombinant	JJ

interferon	NN

alpha	NN

in	IN

the	DT

treatment	NN

of	IN

low-grade	JJ

non-Hodgkin	JJ

's	POS

lymphoma	NN

Antimicrobial	JJ

treatment	NN

options	NNS

in	IN

the	DT

management	NN

of	IN

odontogenic	JJ

infections	NNS

Recombinant	JJ

glycoprotein	NN

vaccine	NN

for	IN

the	DT

prevention	NN

of	IN

genital	JJ

HSV-2	NN

infection	NN

:	:

two	CD

randomized	VBN

controlled	VBN

trials	NNS

Induction	NN

chemotherapy	NN

with	IN

docetaxel	NN

,	,

cisplatin	NN

,	,

fluorouracil	NN

,	,

and	CC

leucovorin	NN

for	IN

squamous	JJ

cell	NN

carcinoma	NN

of	IN

the	DT

head	NN

and	CC

neck	NN

:	:

a	DT

phase	NN

I/II	CD

trial	NN

Low-dose	JJ

steroids	NNS

reduce	VB

flu-like	JJ

symptoms	NNS

at	IN

the	DT

initiation	NN

of	IN

IFNbeta-1b	NN

in	IN

relapsing-remitting	JJ

MS	NN

Study	NN

of	IN

three	CD

different	JJ

doses	NNS

of	IN

epidural	JJ

neostigmine	NN

coadministered	VBN

with	IN

lidocaine	NN

for	IN

postoperative	JJ

analgesia	NN

An	DT

active-control	NN

trial	NN

of	IN

lamotrigine	NN

monotherapy	NN

for	IN

partial	JJ

seizures	NNS

<	JJR

TO_SEE	NN

>	JJR

Safety	NN

of	IN

intrathecal	JJ

sodium	NN

nitroprusside	NN

for	IN

the	DT

treatment	NN

and	CC

prevention	NN

of	IN

refractory	JJ

cerebral	JJ

vasospasm	NN

and	CC

ischemia	NN

in	IN

humans	NNS

The	DT

effect	NN

of	IN

heliox	NN

in	IN

acute	JJ

severe	JJ

asthma	NN

:	:

a	DT

randomized	VBN

controlled	VBN

trial	NN

.	.

Long-term	JJ

survival	NN

of	IN

patients	NNS

with	IN

unresectable	JJ

colorectal	JJ

cancer	NN

liver	NN

metastases	NNS

following	VBG

infusional	NN

chemotherapy	NN

with	IN

5-fluorouracil	NN

,	,

leucovorin	NN

,	,

oxaliplatin	NN

and	CC

surgery	NN

<	JJR

TO_SEE	NN

>	JJR

Fatal	JJ

acute	JJ

haemolysis	NN

in	IN

an	DT

AIDS	NN

patient	NN

treated	VBN

with	IN

lindinavir	NN

A	DT

simplified	VBN

laparoscopic	JJ

technique	NN

for	IN

mesh	NN

placement	NN

in	IN

ventral	JJ

hernia	NN

repair	NN

Pharmacological	JJ

management	NN

of	IN

acute	JJ

myocardial	JJ

infarction	NN

Mesenteric	JJ

venous	JJ

thrombosis	NN

:	:

successful	JJ

treatment	NN

by	IN

intraarterial	JJ

lytic	JJ

therapy	NN

Gene	NN

therapy	NN

for	IN

myocardial	JJ

angiogenesis	NN

Dipyridamole	NNP

plus	CC

aspirin	NN

in	IN

cerebrovascular	JJ

disease	NN

What	WDT

is	VBZ

the	DT

real	RB

role	NN

of	IN

CD40	NN

in	IN

cancer	NN

immunotherapy	NN

?	.

The	DT

effects	NNS

of	IN

oral	JJ

liarozole	NN

on	IN

epidermal	JJ

proliferation	NN

and	CC

differentiation	NN

in	IN

severe	JJ

plaque	NN

psoriasis	NN

are	VBP

comparable	JJ

with	IN

those	DT

of	IN

acitretin	NN

.	.

Safety	NN

and	CC

potential	NN

effectiveness	NN

of	IN

daunorubicin-containing	JJ

liposomes	NNS

in	IN

patients	NNS

with	IN

advanced	VBN

recurrent	JJ

malignant	JJ

CNS	NNS

tumors	NNS

An	DT

experimental	JJ

application	NN

of	IN

gene	NN

therapy	NN

for	IN

human	JJ

retinoblastoma	NN

Acid	NN

suppression	NN

therapy	NN

in	IN

Barrett	NNP

's	POS

esophagus	NN

:	:

the	DT

importance	NN

of	IN

pH	NN

monitoring	VBG

Surgical	NNP

approaches	NNS

to	TO

pediatric	JJ

defecatory	JJ

disorders	NNS

Lutein	NN

improves	VBZ

visual	JJ

function	NN

in	IN

some	DT

patients	NNS

with	IN

retinal	JJ

degeneration	NN

:	:

a	DT

pilot	NN

study	NN

via	IN

the	DT

Internet	NN

Drug	NN

information	NN

questions	NNS

and	CC

answers	NNS

:	:

new	JJ

for	IN

psoriasis	NN

:	:

colchicine	NN

IPPB	NN

in	IN

severe	JJ

pulmonary	JJ

emphysema	NN

:	:

limited	JJ

applications	NNS

Long-term	JJ

mortality	NN

in	IN

patients	NNS

after	IN

a	DT

British	JJ

trial	NN

of	IN

anticoagulants	NNS

in	IN

acute	JJ

myocardial	JJ

infarction	NN

Our	PRP$

results	NNS

in	IN

the	DT

surgical	JJ

treatment	NN

of	IN

habitual	JJ

shoulder	NN

dislocation	NN

with	IN

special	JJ

reference	NN

to	TO

occupational	JJ

disability	NN

Alkaline	NN

phosphatase	NN

in	IN

neutrophil	NN

leukocytes	NNS

of	IN

patients	NNS

with	IN

infectious	JJ

mononucleosis	NN

and	CC

the	DT

effect	NN

of	IN

corticosteroid	NN

therapy	NN

Surgical	NNP

treatment	NN

of	IN

uterine	NN

cervix	NN

insufficiency	NN

during	IN

the	DT

2d	NN

trimester	NN

of	IN

pregnancy	NN

Physiologic	JJ

treatment	NN

of	IN

depressive	JJ

reactions	NNS

:	:

a	DT

pilot	NN

study	NN

The	DT

use	NN

of	IN

quinidine	NN

sulphate	NN

for	IN

the	DT

treatment	NN

of	IN

atrial	IN

fibrillation	NN

in	IN

twelve	CD

horses	NNS

Synergism	NN

in	IN

the	DT

chemotherapy	NN

of	IN

Eimeria	NNP

infections	NNS

of	IN

chicks	NNS

Treatment	NN

of	IN

hydrocele	NN

and	CC

cysts	NNS

of	IN

the	DT

epididymis	NN

with	IN

sclerosing	VBG

injections	NNS

of	IN

quinine	NN

and	CC

urea	NN

chlorhydrolactate	NN

in	IN

a	DT

30	CD

per	IN

cent	NN

solution	NN

The	DT

single-place	JJ

caisson	NN

in	IN

the	DT

treatment	NN

of	IN

decompression	NN

accidents	NNS

Blood	NN

volume	NN

measurements	NNS

in	IN

burn	VBP

therapy	NN

Phenylbutazone	NN

and	CC

acute	JJ

leukemia	NN

.	.

The	DT

place	NN

of	IN

surgery	NN

in	IN

hypertrophic	JJ

obstructive	JJ

cardiomyopathy	NN

(	NN

idiopathic	JJ

hypertrophic	JJ

subaortic	JJ

stenosis	NN

)	NN

The	DT

treatment	NN

of	IN

autoimmune	JJ

hemolytic	JJ

anemia	NN

with	IN

heparin	NN

Effects	NNS

of	IN

clomiphene	NN

citrate	NN

on	IN

endometrial	JJ

hyperplasia	NN

in	IN

the	DT

premenopausal	JJ

female	NN

Prolonged	JJ

use	NN

of	IN

methyldopa	NN

in	IN

severe	JJ

hypertension	NN

in	IN

pregnancy	NN

The	DT

effects	NNS

of	IN

social	JJ

class	NN

and	CC

friends	NNS

'	''

expectations	NNS

on	IN

oral	JJ

polio	NNP

vaccination	NN

participation	NN

Glutathione	NN

S-transferase	NN

activity	NN

in	IN

epithelial	JJ

ovarian	JJ

cancer	NN

:	:

association	NN

with	IN

response	NN

to	TO

chemotherapy	NN

and	CC

disease	NN

outcome	NN

Interferon-alpha-2b	NN

in	IN

the	DT

management	NN

of	IN

patients	NNS

with	IN

relapsed	VBD

and/or	CC

refractory	JJ

Hodgkin	NN

's	POS

disease	NN

<	JJR

TO_SEE	NN

>	JJR

Frontal	JJ

dysfunction	NN

blocks	NNS

the	DT

therapeutic	JJ

effect	NN

of	IN

THA	NN

on	IN

attention	NN

in	IN

Alzheimer	NN

's	POS

disease	NN

Effects	NNS

of	IN

clomipramine	NN

on	IN

plasma	NN

amino	NN

acids	NNS

and	CC

serotonergic	JJ

parameters	NNS

in	IN

panic	NN

disorder	NN

and	CC

depression	NN

.	.

Thalidomide	NNP

for	IN

aphthous	JJ

ulcers	NNS

in	IN

HIV	NN

infection	NN

Aspirin	NN

therapy	NN

in	IN

diabetes	NN

mellitus	NN

Combined	VBN

pancreas-/kidney	NN

transplantation	NN

as	IN

a	DT

standard	NN

procedure	NN

in	IN

therapy	NN

of	IN

kidney	NN

failure	NN

in	IN

type	NN

I	PRP

diabetic	JJ

patients	NNS

Corticosteroid	NN

injections	NNS

for	IN

sciatica	NN

Flutamide	NN

plus	CC

castration	NN

in	IN

patients	NNS

with	IN

previously	RB

untreated	JJ

prostate	NN

cancer	NN

The	DT

immediate	JJ

effectiveness	NN

of	IN

electrical	JJ

nerve	NN

stimulation	NN

and	CC

electrical	JJ

muscle	NN

stimulation	NN

on	IN

myofascial	JJ

trigger	NN

points	NNS

In	IN

vitro	NN

radiation-induced	JJ

apoptosis	NN

and	CC

tumour	NN

response	NN

to	TO

radiotherapy	NN

:	:

a	DT

prospective	JJ

study	NN

in	IN

patients	NNS

with	IN

non-Hodgkin	JJ

lymphomas	NNS

treated	VBN

by	IN

low-dose	JJ

irradiation	NN

Drug	NN

therapy	NN

for	IN

coronary	JJ

heart	NN

disease	NN

:	:

the	DT

Sheffield	NNP

table	NN

Percutaneous	JJ

drainage	NN

of	IN

hydatid	NN

cysts	NNS

Surgery	NN

for	IN

ectopia	NN

lentis	NN

<	JJR

TO_SEE	NN

>	JJR

Antiplatelet	JJ

therapy	NN

to	TO

prevent	VB

stroke	NN

:	:

risk	NN

of	IN

brain	NN

hemorrhage	NN

and	CC

efficacy	NN

in	IN

atrial	IN

fibrillation	NN

High-dose	JJ

chemotherapy	NN

with	IN

autologous	JJ

hematopoietic	JJ

stem-cell	NN

support	NN

for	IN

breast	NN

cancer	NN

in	IN

North	NNP

America	NNP

Is	VBZ

concomitant	JJ

radiotherapy	NN

and	CC

chemotherapy	NN

superior	JJ

to	TO

optimal	JJ

radiotherapy	NN

alone	RB

in	IN

anal	JJ

cancer	NN

?	.

Standard	NNP

versus	CC

high-dose	JJ

therapy	NN

in	IN

10+	CD

breast	NN

cancer	NN

Anal	JJ

continence	NN

after	IN

surgery	NN

for	IN

rectal	JJ

prolapse	NN

Aspirin	NN

therapy	NN

for	IN

cardiovascular	JJ

disease	NN

Dosing	NN

of	IN

amoxicillin/clavulanate	NN

for	IN

treatment	NN

of	IN

lower	JJR

respiratory	JJ

tract	NN

infection	NN

Pharmacoeconomic	JJ

analysis	NN

of	IN

ampicillin-sulbactam	NN

versus	CC

cefoxitin	NN

in	IN

the	DT

treatment	NN

of	IN

intraabdominal	JJ

infections	NNS

New	NNP

therapies	NNS

for	IN

severe	JJ

meningococcal	JJ

disease	NN

Another	DT

potential	NN

use	NN

of	IN

troglitazone	NN

in	IN

noninsulin-dependent	JJ

diabetes	NN

mellitus	NN

<	JJR

TO_SEE	NN

>	JJR

Jaw	NN

clenching	VBG

following	VBG

Gamma	NN

Knife	NNP

treatment	NN

for	IN

trigeminal	JJ

neuralgia	NN

The	DT

protective	JJ

effect	NN

of	IN

condoms	NNS

and	CC

nonoxynol-9	NN

against	IN

HIV	NN

infection	NN

Evaluation	NN

of	IN

adjuvant	JJ

psychological	JJ

therapy	NN

in	IN

patients	NNS

with	IN

testicular	JJ

cancer	NN

:	:

randomised	VBN

controlled	VBN

trial	NN

The	DT

effect	NN

of	IN

an	DT

endothelin-receptor	NN

antagonist	NN

,	,

bosentan	NN

,	,

on	IN

blood	NN

pressure	NN

in	IN

patients	NNS

with	IN

essential	JJ

hypertension	NN

.	.

Guidelines	NNS

for	IN

the	DT

use	NN

of	IN

antiretroviral	JJ

agents	NNS

in	IN

HIV	NN

-infected	JJ

adults	NNS

and	CC

adolescents	NNS

Long-term	JJ

therapy	NN

with	IN

long-acting	JJ

octreotide	NN

(	NN

Sandostatin-LAR	NN

)	NN

for	IN

the	DT

management	NN

of	IN

acromegaly	RB

Are	VBP

ABVD	NN

and	CC

MOPP/ABV	NN

truly	RB

equivalent	JJ

for	IN

treating	VBG

Hodgkin	NN

's	POS

disease	NN

at	IN

advanced	VBN

stages	NNS

?	.

Paclitaxel	NN

for	IN

the	DT

treatment	NN

of	IN

lymphoma	NN

Montelukast	NN

,	,

a	DT

leukotriene-receptor	NN

antagonist	NN

,	,

for	IN

the	DT

treatment	NN

of	IN

mild	JJ

asthma	NN

and	CC

exercise-induced	JJ

bronchoconstriction	NN

Atypical	JJ

antipsychotic	JJ

agents	NNS

in	IN

the	DT

treatment	NN

of	IN

Schizophrenia	NNP

and	CC

other	JJ

psychiatric	JJ

disorders	NNS

Percutaneous	JJ

transluminal	JJ

angioplasty	NN

in	IN

the	DT

treatment	NN

of	IN

renovascular	JJ

hypertension	NN

:	:

sequential	JJ

prospective	JJ

study	NN

Esophageal	NN

intubation	NN

for	IN

palliative	NN

treatment	NN

in	IN

advanced	VBN

carcinoma	NN

of	IN

the	DT

esophagus	NN

and	CC

cardia	NN

Pathological	JJ

staging	NN

and	CC

biochemical	JJ

recurrence	NN

after	IN

neoadjuvant	NN

androgen	NN

deprivation	NN

therapy	NN

in	IN

combination	NN

with	IN

radical	NN

prostatectomy	NN

in	IN

clinically	RB

localized	JJ

prostate	NN

cancer	NN

How	WRB

often	RB

does	VBZ

surgery	NN

for	IN

peptic	JJ

ulceration	NN

eradicate	VB

Helicobacter	NNP

pylori	NN

?	.

Systematic	JJ

review	NN

of	IN

36	CD

studies	NNS

A	DT

comparison	NN

of	IN

noninvasive	JJ

positive-pressure	NN

ventilation	NN

and	CC

conventional	JJ

mechanical	JJ

ventilation	NN

in	IN

patients	NNS

with	IN

acute	JJ

respiratory	JJ

failure	NN

Long-term	JJ

safety	NN

and	CC

effectiveness	NN

of	IN

iron-chelation	NN

therapy	NN

with	IN

deferiprone	NN

for	IN

thalassemia	NN

major	JJ

Positron	NNP

emission	NN

tomography	NN

in	IN

assessing	VBG

response	NN

to	TO

neoadjuvant	NN

chemotherapy	NN

for	IN

non-small-cell	JJ

lung	NN

cancer	NN

Reconstruction	NN

of	IN

thoracic	JJ

wall	NN

defects	NNS

after	IN

tumor	NN

resection	NN

using	VBG

a	DT

polytetrafluoroethylene	NN

soft	JJ

tissue	NN

(	NN

Gore-Tex	NNP

)	NN

patch	NN

A	DT

comparison	NN

of	IN

rectal	JJ

diazepam	NN

gel	NN

and	CC

placebo	NN

for	IN

acute	JJ

repetitive	JJ

seizures	NNS

Effect	NN

of	IN

long-term	JJ

salmeterol	NN

treatment	NN

on	IN

exercise-induced	JJ

asthma	NN

Randomized	VBN

trial	NN

of	IN

intensive	JJ

cyclophosphamide	NN

,	,

epirubicin	NN

,	,

and	CC

fluorouracil	NN

chemotherapy	NN

compared	VBN

with	IN

cyclophosphamide	NN

,	,

methotrexate	NN

,	,

and	CC

fluorouracil	NN

in	IN

premenopausal	JJ

women	NNS

with	IN

node-positive	JJ

breast	NN

cancer	NN

Acute	JJ

effect	NN

of	IN

lorazepam	NN

on	IN

respiratory	JJ

muscles	NNS

in	IN

patients	NNS

with	IN

chronic	JJ

obstructive	JJ

pulmonary	JJ

disease	NN

Low-molecular-weight	JJ

heparins	NNS

in	IN

the	DT

treatment	NN

of	IN

venous	JJ

thromboembolism	NN

5-year	JJ

outcome	NN

of	IN

surgical	JJ

resection	NN

and	CC

watchful	JJ

waiting	VBG

for	IN

men	NNS

with	IN

moderately	RB

symptomatic	JJ

benign	JJ

prostatic	JJ

hyperplasia	NN

:	:

a	DT

Department	NNP

of	IN

Veterans	NNS

Affairs	NNPS

cooperative	JJ

study	NN

For	IN

how	WRB

long	RB

should	MD

antipsychotic	JJ

medication	NN

be	VB

continued	VBN

after	IN

the	DT

first	RB

psychotic	JJ

episode	NN

in	IN

schizophrenics	NNS

?	.

IDA-FLAG	NN

(	NN

idarubicin	NN

,	,

fludarabine	NN

,	,

cytarabine	NN

,	,

G-CSF	NN

)	NN

,	,

an	DT

effective	JJ

remission-induction	NN

therapy	NN

for	IN

poor-prognosis	NN

AML	NN

of	IN

childhood	NN

prior	RB

to	TO

allogeneic	JJ

or	CC

autologous	JJ

bone	NN

marrow	NN

transplantation	NN

:	:

experiences	NNS

of	IN

a	DT

phase	NN

II	NNP

trial	NN

<	JJR

TO_SEE	NN

>	JJR

Effects	NNS

of	IN

anal	JJ

invasive	JJ

treatment	NN

and	CC

incontinence	NN

on	IN

mental	JJ

health	NN

and	CC

psychosocial	JJ

functioning	VBG

of	IN

adolescents	NNS

with	IN

Hirshsprung	NNP

's	POS

disease	NN

and	CC

low	JJ

anorectal	JJ

anomalies	NNS

Single	JJ

or	CC

double	RB

lung	NN

transplantation	NN

for	IN

pulmonary	JJ

hypertension	NN

Interferon	NN

beta	NN

treatment	NN

for	IN

multiple	JJ

sclerosis	NN

Ten-year	JJ

disease	NN

free	JJ

survival	NN

after	IN

transperineal	NN

sonography-guided	JJ

iodine-125	NN

brachytherapy	NN

with	IN

or	CC

without	IN

45-Gray	NN

external	JJ

beam	NN

irradiation	NN

in	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

clinically	RB

localized	JJ

,	,

low	JJ

to	TO

high	JJ

Gleason	NN

grade	NN

prostate	NN

carcinoma	NN

Partial	JJ

or	CC

near	IN

total	NN

pancreatectomy	NN

for	IN

persistent	JJ

neonatal	JJ

hyperinsulinaemic	JJ

hypoglycaemia	NN

:	:

the	DT

pathologist	NN

's	POS

role	NN

Radical	NNP

prostatectomy	NN

for	IN

prostate	NN

cancer	NN

:	:

the	DT

perineal	NN

approach	NN

increases	NNS

the	DT

risk	NN

of	IN

surgically	RB

induced	VBN

positive	JJ

margins	NNS

and	CC

capsular	JJ

incisions	NNS

Open	VB

capsulorrhaphy	NN

with	IN

suture	NN

anchors	NNS

for	IN

recurrent	JJ

anterior	JJ

dislocation	NN

of	IN

the	DT

shoulder	NN

Intravenous	JJ

immunoglobulin	NN

treatment	NN

in	IN

multiple	JJ

sclerosis	NN

Randomised	VBN

trial	NN

of	IN

irinotecan	NN

versus	CC

fluorouracil	NN

by	IN

continuous	JJ

infusion	NN

after	IN

fluorouracil	NN

failure	NN

in	IN

patients	NNS

with	IN

metastatic	JJ

colorectal	JJ

cancer	NN

The	DT

effectiveness	NN

of	IN

intraocular	JJ

pressure	NN

reduction	NN

in	IN

the	DT

treatment	NN

of	IN

normal-tension	NN

glaucoma	NN

Perceived	VBN

contraindications	NNS

to	TO

thrombolytic	JJ

treatment	NN

in	IN

acute	JJ

myocardial	JJ

infarction	NN

Lignocaine	NN

or	CC

bupivacaine	NN

for	IN

digital	JJ

ring	NN

block	NN

Steroids	NNS

in	IN

lateral	JJ

epicondylitis	NN

Steroids	NNS

in	IN

De	NNP

Quervain	NNP

's	POS

tenosynovitis	NN

Antibiotics	NNS

after	IN

dog	NN

bite	VB

Immobilisation	NN

after	IN

first	RB

anterior	JJ

shoulder	NN

dislocation	NN

Stereotactic	NN

radiosurgery	NN

for	IN

acoustic	JJ

neuroma	NN

:	:

a	DT

Canadian	JJ

perspective	NN

Anticytokine	NN

therapy	NN

--	:

a	DT

new	JJ

era	NN

in	IN

the	DT

treatment	NN

of	IN

rheumatoid	JJ

arthritis	NN

?	.

Control	NN

of	IN

the	DT

malignant	JJ

hyperpyrexic	JJ

syndrome	NN

in	IN

MHS	NN

swine	NNS

by	IN

dantrolene	NN

sodium	NN

Hematopoietic	JJ

stem-cell	NN

transplantation	NN

for	IN

the	DT

treatment	NN

of	IN

severe	JJ

combined	VBN

immunodeficiency	NN

Low-dose	JJ

clozapine	NN

for	IN

the	DT

treatment	NN

of	IN

drug-induced	JJ

psychosis	NN

in	IN

Parkinson	NNP

's	POS

disease	NN

Comparing	VBG

the	DT

efficacy	NN

and	CC

safety	NN

of	IN

fluoxetine	NN

and	CC

venlafaxine	NN

in	IN

outpatient	NN

depression	NN

Cost-effectiveness	NN

of	IN

interferon	NN

treatment	NN

for	IN

hepatitis	NN

C	NN

Hyperbaric	JJ

oxygen	NN

therapy	NN

for	IN

children	NNS

with	IN

cerebral	JJ

palsy	NN

Peripheral	JJ

retinal	JJ

cryotherapy	NN

for	IN

postvitrectomy	NN

diabetic	JJ

vitreous	JJ

hemorrhage	NN

in	IN

phakic	JJ

patients	NNS

Hyperbaric	JJ

or	CC

normobaric	JJ

oxygen	NN

for	IN

acute	JJ

carbon	NN

monoxide	NN

poisoning	NN

:	:

a	DT

randomised	VBN

controlled	VBN

clinical	JJ

trial	NN

Multicentre	NNP

clinical	JJ

evaluation	NN

of	IN

vigabatrin	NN

(	NN

Sabril	NNP

)	NN

in	IN

mild	JJ

to	TO

moderate	JJ

partial	JJ

epilepsies	NNS

Matrix	NNP

metalloproteinase	NN

inhibitors	NNS

in	IN

the	DT

treatment	NN

of	IN

cancer	NN

High	JJ

dose	NN

cyclophosphamide	NN

with	IN

carboplatin	NN

:	:

a	DT

tolerable	JJ

regimen	NNS

suitable	JJ

for	IN

dose	NN

intensification	NN

in	IN

children	NNS

with	IN

solid	JJ

tumors	NNS

Microsurgical	JJ

treatment	NN

of	IN

supratentorial	JJ

cavernous	JJ

malformations	NNS

Microsurgical	JJ

treatment	NN

of	IN

infratentorial	NN

malformations	NNS

Stereotactic	NN

radiosurgery	NN

for	IN

management	NN

of	IN

deep	RB

brain	NN

cavernous	JJ

malformations	NNS

Interferon-antibodies	NNS

and	CC

the	DT

breakthrough	NN

phenomenon	NN

during	IN

ribavirin/interferon-alpha	NN

combination	NN

therapy	NN

and	CC

interferon-alpha	NN

monotherapy	NN

of	IN

patients	NNS

with	IN

chronic	JJ

hepatitis	NN

C	NN

Treatment	NN

of	IN

Barrett	NNP

esophagus	NN

with	IN

argon	NNP

plasma	NN

coagulation	NN

with	IN

acid	NN

suppression	NN

--	:

a	DT

prospective	JJ

study	NN

Meta-analysis	NN

of	IN

typhoid	NN

vaccine	NN

efficacy	NN

trials	NNS

showed	VBD

that	IN

whole	JJ

cell	NN

vaccines	NNS

are	VBP

more	RBR

effective	JJ

than	IN

either	DT

the	DT

oral	JJ

,	,

attenuated	VBN

vaccine	NN

or	CC

the	DT

Vi	NNP

polysaccharide	NN

vaccine	NN

Experimental	JJ

vaccination	NN

against	IN

Mycoplasma	NN

agalactiae	NN

using	VBG

different	JJ

inactivated	VBN

vaccines	NNS

A	DT

randomized	VBN

,	,

controlled	VBN

study	NN

in	IN

adults	NNS

of	IN

the	DT

immunogenicity	NN

of	IN

a	DT

novel	JJ

hepatitis	NN

B	NN

vaccine	NN

containing	VBG

MF59	NN

adjuvant	JJ

Immunogenicity	NN

of	IN

three	CD

Haemophilus	NN

influenzae	NNS

type	NN

b	NN

protein	NN

conjugate	NN

vaccines	NNS

in	IN

HIV	NN

seropositive	JJ

adults	NNS

and	CC

analysis	NN

of	IN

predictors	NNS

of	IN

vaccine	NN

response	NN

Vaccination	NN

against	IN

Schistosoma	NN

mansoni	NNS

infection	NN

using	VBG

74	CD

kDa	NN

Schistosoma	NN

protein	NN

antigen	NN

Phase	NN

1	CD

safety	NN

and	CC

immune	JJ

response	NN

studies	NNS

of	IN

a	DT

DNA	NN

vaccine	NN

encoding	VBG

hepatitis	NN

B	NN

surface	NN

antigen	NN

delivered	VBN

by	IN

a	DT

gene	NN

delivery	NN

device	NN

Protection	NN

of	IN

swine	NNS

from	IN

foot-and-mouth	NN

disease	NN

with	IN

one	CD

dose	NN

of	IN

an	DT

all-D	JJ

retro	NN

peptide	NN

Intranasal	JJ

immunization	NN

with	IN

Chlamydia	NN

trachomatis	NN

,	,

serovar	NN

E	NN

,	,

protects	VBZ

from	IN

a	DT

subsequent	JJ

vaginal	JJ

challenge	NN

with	IN

the	DT

homologous	JJ

serovar	NN

Mutants	NNS

of	IN

cholera	NN

toxin	NN

as	IN

an	DT

effective	JJ

and	CC

safe	JJ

adjuvant	JJ

for	IN

nasal	JJ

influenza	NN

vaccine	NN

Field	NN

evaluation	NN

of	IN

the	DT

clinical	JJ

effectiveness	NN

of	IN

vaccines	NNS

against	IN

pertussis	NN

,	,

measles	NNS

,	,

rubella	NN

and	CC

mumps	NNS

:	:

comments	NNS

Transmural	JJ

drainage	NN

of	IN

pancreatic	JJ

fluid	NN

collections	NNS

without	IN

electrocautery	NN

using	VBG

the	DT

Seldinger	NNP

technique	NN

Echocardiography-guided	JJ

ethanol	NN

septal	JJ

reduction	NN

for	IN

hypertrophic	JJ

obstructive	JJ

cardiomyopathy	NN

Alterations	NNS

of	IN

monocyte	NN

function	NN

in	IN

patients	NNS

with	IN

growth	NN

hormone	NN

(	NN

GH	NN

)	NN

deficiency	NN

:	:

effect	NN

of	IN

substitutive	JJ

GH	NN

therapy	NN

Comparison	NN

of	IN

the	DT

effects	NNS

of	IN

salmeterol	NN

and	CC

ipratropium	NN

bromide	NN

on	IN

exercise	NN

performance	NN

and	CC

breathlessness	NN

in	IN

patients	NNS

with	IN

stable	JJ

chronic	JJ

obstructive	JJ

pulmonary	JJ

disease	NN

.	.

<	JJR

TO_SEE	NN

>	JJR

Safety	NN

trial	NN

with	IN

the	DT

5HT1B/1D	NN

agonist	NN

avitriptan	NN

(	NN

BMS-180048	NN

)	NN

in	IN

patients	NNS

with	IN

migraine	NN

who	WP

have	VB

experienced	JJ

pressure	NN

,	,

tightness	NN

,	,

and/or	CC

pain	NN

in	IN

the	DT

chest	NN

,	,

neck	NN

,	,

and/or	CC

throat	NN

following	VBG

sumatriptan	NN

Double	JJ

blind	JJ

,	,

cluster	NN

randomised	VBN

trial	NN

of	IN

low	JJ

dose	NN

supplementation	NN

with	IN

vitamin	NN

A	DT

or	CC

beta	NN

carotene	NN

on	IN

mortality	NN

related	JJ

to	TO

pregnancy	NN

in	IN

Nepal	NNP

.	.

Medical	NNP

treatments	NNS

for	IN

balding	VBG

in	IN

men	NNS

Carbon	NNP

monoxide	NN

poisoning	NN

treated	VBN

with	IN

hyperbaric	JJ

oxygen	NN

:	:

metabolic	JJ

acidosis	NN

as	IN

a	DT

predictor	NN

of	IN

treatment	NN

requirements	NNS

Medication	NN

received	VBN

by	IN

patients	NNS

with	IN

depression	NN

following	VBG

the	DT

acute	JJ

episode	NN

:	:

adequacy	NN

and	CC

relation	NN

to	TO

outcome	NN

<	JJR

TO_SEE	NN

>	JJR

Reduced	VBN

bone	NN

density	NN

at	IN

completion	NN

of	IN

chemotherapy	NN

for	IN

a	DT

malignancy	NN

<	JJR

TO_SEE	NN

>	JJR

Surgical-site	JJ

complications	NNS

associated	VBN

with	IN

a	DT

morphine	NN

nerve	NN

paste	VB

used	VBN

for	IN

postoperative	JJ

pain	NN

control	NN

after	IN

laminectomy	NN

Splenectomy	NNP

during	IN

pregnancy	NN

:	:

an	DT

option	NN

in	IN

the	DT

treatment	NN

of	IN

autoimmune	JJ

thrombocytopenic	JJ

purpura	NN

Melatonin	NN

treatment	NN

of	IN

sleep-wake	NN

cycle	NN

disorders	NNS

in	IN

children	NNS

and	CC

adolescents	NNS

Randomized	VBN

phase	NN

II	NNP

study	NN

of	IN

the	DT

neurokinin	NN

1	CD

receptor	NN

antagonist	NN

CJ-11	NN

,	,

974	CD

in	IN

the	DT

control	NN

of	IN

cisplatin-induced	JJ

emesis	NN

Cataract	NN

surgery	NN

and	CC

its	PRP$

effect	NN

on	IN

intraocular	JJ

pressure	NN

The	DT

outcome	NN

of	IN

arthroscopic	NN

treatment	NN

of	IN

temporomandibular	JJ

joint	NN

arthropathy	NN

Neostigmine	NN

for	IN

acute	JJ

colonic	JJ

pseudo-obstruction	NN

New	NNP

vaccine	NN

targets	NNS

childhood	NN

pneumonia	NN

A	DT

comparison	NN

of	IN

botulinum	NN

toxin	NN

and	CC

nitroglycerin	NN

ointment	NN

for	IN

chronic	JJ

anal	JJ

fissure	NN

<	JJR

TO_SEE	NN

>	JJR

The	DT

effect	NN

of	IN

bisoprolol	NN

on	IN

perioperative	NN

mortality	NN

and	CC

myocardial	JJ

infarction	NN

in	IN

high-risk	JJ

patients	NNS

undergoing	VBG

vascular	JJ

surgery	NN

Surgical	NNP

management	NN

of	IN

severe	JJ

secondary	JJ

peritonitis	NN

Early	RB

surgical	JJ

treatment	NN

for	IN

supratentorial	JJ

intracerebral	JJ

hemorrhage	NN

:	:

a	DT

randomized	VBN

feasibility	NN

study	NN

Evaluation	NN

of	IN

clomipramine	NN

as	IN

an	DT

adjunct	NN

to	TO

behavioural	NN

therapy	NN

in	IN

the	DT

treatment	NN

of	IN

separation-related	JJ

problems	NNS

in	IN

dogs	NNS

NICE	JJ

to	TO

rule	NN

on	IN

influenza	NN

flu	NN

drug	NN

zanamivir	NN

<	JJR

TO_SEE	NN

>	JJR

Longitudinal	JJ

melanonychia	NN

associated	VBN

with	IN

hydroxyurea	NN

therapy	NN

in	IN

a	DT

patient	NN

with	IN

essential	JJ

thrombocytosis	NN

Biologic	JJ

markers	NNS

as	IN

predictors	NNS

of	IN

clinical	JJ

outcome	NN

from	IN

systemic	JJ

therapy	NN

for	IN

primary	JJ

operable	JJ

breast	NN

cancer	NN

Treatment	NN

of	IN

hypertension	NN

with	IN

ascorbic	JJ

acid	NN

Postoperative	JJ

peritonitis	NN

originating	VBG

from	IN

the	DT

duodenum	NN

:	:

operative	NN

management	NN

by	IN

intubation	NN

and	CC

continuous	JJ

intraluminal	JJ

irrigation	NN

Efficacy	NN

of	IN

open-bite	JJ

treatment	NN

with	IN

the	DT

Thera-spoon	NN

<	JJR

TO_SEE	NN

>	JJR

Pompholyx	NN

(	NN

vesicular	JJ

eczema	NN

)	NN

after	IN

i.v	NN

.	.

immunoglobulin	NN

therapy	NN

for	IN

neurologic	JJ

disease	NN

Mitomycin	NN

,	,

ifosfamide	NN

,	,

and	CC

cisplatin	NN

in	IN

unresectable	JJ

non-small-cell	JJ

lung	NN

cancer	NN

:	:

effects	NNS

on	IN

survival	NN

and	CC

quality	NN

of	IN

life	NN

.	.

Hepatic	JJ

arterial	JJ

infusion	NN

of	IN

chemotherapy	NN

after	IN

resection	NN

of	IN

hepatic	JJ

metastases	NNS

from	IN

colorectal	JJ

cancer	NN

Waiting	VBG

for	IN

the	DT

definitive	JJ

trial	NN

of	IN

hepatic	JJ

arterial	JJ

chemotherapy	NN

for	IN

colorectal	JJ

cancer	NN

Phase	NN

III	NNP

randomized	VBN

study	NN

of	IN

cisplatin	NN

versus	CC

paclitaxel	NN

versus	CC

cisplatin	NN

and	CC

paclitaxel	NN

in	IN

patients	NNS

with	IN

suboptimal	JJ

stage	NN

III	NNP

or	CC

IV	CD

ovarian	JJ

cancer	NN

:	:

a	DT

gynecologic	JJ

oncology	NN

group	NN

study	NN

Evidence	NN

for	IN

double	RB

resistance	NN

to	TO

permethrin	NN

and	CC

malathion	NN

in	IN

head	NN

lice	NN

Urgent	JJ

colonoscopy	NN

for	IN

the	DT

diagnosis	NN

and	CC

treatment	NN

of	IN

severe	JJ

diverticular	JJ

hemorrhage	NN

Treatment	NN

of	IN

Parkinson	NNP

's	POS

disease	NN

should	MD

begin	VB

with	IN

a	DT

dopamine	NN

agonist	NN

<	JJR

TO_SEE	NN

>	JJR

Ulceration	NN

in	IN

an	DT

ileocolic	JJ

anastomosis	NN

treated	VBN

with	IN

ranitidin	NN

Low-molecular-weight	JJ

heparin	NN

vs	CC

heparin	NN

in	IN

the	DT

treatment	NN

of	IN

patients	NNS

with	IN

pulmonary	JJ

embolism	NN

Radiotherapy	NN

in	IN

breast-conserving	JJ

treatment	NN

for	IN

ductal	JJ

carcinoma	NN

in	IN

situ	FW

:	:

first	RB

results	NNS

of	IN

the	DT

EORTC	NN

randomised	VBN

phase	NN

III	NNP

trial	NN

10853	CD

Methadone	NNP

maintenance	NN

vs	CC

180-day	JJ

psychosocially	RB

enriched	JJ

detoxification	NN

for	IN

treatment	NN

of	IN

opioid	NN

dependence	NN

:	:

a	DT

randomized	VBN

controlled	VBN

trial	NN

Cryogen	NN

spray	NN

cooling	VBG

during	IN

Nd	NN

:	:

YAG	NN

laser	NN

treatment	NN

of	IN

hemangiomas	NNS

Effects	NNS

of	IN

tolcapone	NN

,	,

a	DT

catechol-O-methyltransferase	NN

inhibitor	NN

,	,

on	IN

motor	NN

symptoms	NNS

and	CC

pharmacokinetics	NNS

of	IN

levodopa	NN

in	IN

patients	NNS

with	IN

Parkinson	NNP

's	POS

disease	NN

.	.

Gene	NN

therapy	NN

for	IN

cancer	NN

Therapeutic	JJ

effects	NNS

of	IN

LDL	NN

apheresis	NN

in	IN

the	DT

prevention	NN

of	IN

atherosclerosis	NN

Dry	NNP

powdered	JJ

formoterol	NN

,	,

twice	RB

a	DT

day	NN

versus	CC

aerosolized	VBN

salbutamol	NN

,	,

four	CD

times	NNS

a	DT

day	NN

,	,

in	IN

patients	NNS

with	IN

stable	JJ

asthma	NN

Cell-based	JJ

vaccination	NN

against	IN

melanoma	NN

--	:

background	NN

,	,

preliminary	JJ

results	NNS

,	,

and	CC

perspective	NN

Celecoxib	NNP

for	IN

arthritis	NN

Poliomyelitis	NN

prevention	NN

:	:

revised	VBN

recommendations	NNS

for	IN

use	NN

of	IN

inactivated	VBN

and	CC

live	VB

oral	JJ

poliovirus	NN

vaccines	NNS

Mesh	NN

plug	NN

repair	NN

and	CC

groin	NN

hernia	NN

surgery	NN

Brimonidine	NN

tartrate	JJ

0.2	CD

%	NN

twice	RB

daily	RB

vs	CC

timolol	NN

0.5	CD

%	NN

twice	RB

daily	RB

:	:

1-year	JJ

results	NNS

in	IN

glaucoma	NN

patients	NNS

Ticarcillin/clavulanate	NN

versus	CC

imipenem/cilistatin	NN

for	IN

the	DT

treatment	NN

of	IN

infections	NNS

associated	VBN

with	IN

gangrenous	JJ

and	CC

perforated	JJ

appendicitis	NN

Is	VBZ

zero	CD

dose	NN

oral	JJ

polio	NNP

vaccine	NN

effective	JJ

in	IN

preterm	NN

babies	NNS

?	.

An	DT

economic	JJ

analysis	NN

of	IN

different	JJ

strategies	NNS

of	IN

immunization	NN

against	IN

hepatitis	NN

A	DT

virus	NN

in	IN

developed	VBN

countries	NNS

Issues	NNS

and	CC

challenges	NNS

with	IN

antithrombotic	JJ

therapy	NN

in	IN

diabetic	JJ

patients	NNS

with	IN

acute	JJ

coronary	JJ

syndromes	NNS

Global	JJ

risk	NN

assessment	NN

for	IN

lipid	NN

therapy	NN

to	TO

prevent	VB

coronary	JJ

heart	NN

disease	NN

The	DT

role	NN

of	IN

fibric	JJ

acid	NN

derivatives	NNS

in	IN

the	DT

secondary	JJ

prevention	NN

of	IN

coronary	JJ

heart	NN

disease	NN

Epoetin	NN

:	:

a	DT

pharmacoeconomic	JJ

review	NN

of	IN

its	PRP$

use	NN

in	IN

chronic	JJ

renal	JJ

failure	NN

and	CC

its	PRP$

effects	NNS

on	IN

quality	NN

of	IN

life	NN

Rationale	NN

for	IN

the	DT

use	NN

of	IN

antiplatelet	JJ

drugs	NNS

in	IN

patients	NNS

with	IN

peripheral	JJ

vascular	JJ

disease	NN

The	DT

fluoroquinolones	NNS

for	IN

urinary	JJ

tract	NN

infections	NNS

:	:

a	DT

review	NN

Reduction	NN

of	IN

vasoreactivity	NN

and	CC

thrombogenicity	NN

with	IN

laser-thermal	JJ

angioplasty	NN

:	:

comparison	NN

with	IN

balloon	NN

angioplasty	NN

Effects	NNS

of	IN

ultrasound	NN

energy	NN

on	IN

total	NN

peripheral	JJ

artery	NN

occlusions	NNS

:	:

initial	JJ

angiographic	JJ

and	CC

angioscopic	JJ

results	NNS

.	.

High-dose	JJ

chemotherapy	NN

with	IN

autologous	JJ

stem-cell	NN

support	NN

for	IN

epithelial	JJ

ovarian	JJ

cancer	NN

Pelvic	JJ

floor	NN

stimulation	NN

in	IN

the	DT

treatment	NN

of	IN

adult	JJ

urinary	JJ

incontinence	NN

Chronic	JJ

vagus	NN

nerve	NN

stimulation	NN

for	IN

treatment	NN

of	IN

seizures	NNS

``	``

Tandem	NNP

''	''

high-dose	JJ

chemoradiotherapy	NN

with	IN

autologous	JJ

stem-cell	NN

support	NN

in	IN

the	DT

treatment	NN

of	IN

newly	RB

diagnosed	VBN

or	CC

responsive	JJ

multiple	JJ

myeloma	NN

Special	JJ

report	NN

:	:

comparative	JJ

efficacy	NN

of	IN

different	JJ

types	NNS

of	IN

pneumatic	JJ

compression	NN

pumps	NNS

for	IN

the	DT

treatment	NN

of	IN

lymphedema	NN

Special	JJ

report	NN

:	:

pressure-reducing	VBG

support	NN

surfaces	NNS

in	IN

the	DT

prevention	NN

and	CC

treatment	NN

of	IN

pressure	NN

ulcers	NNS

:	:

group	NN

1	CD

technologies	NNS

Intravenous	JJ

immune	JJ

globulin	NN

for	IN

recurrent	JJ

spontaneous	JJ

abortion	NN

External	JJ

counterpulsation	NN

for	IN

treatment	NN

of	IN

chronic	JJ

stable	JJ

angina	NN

pectoris	NN

Intra-articular	JJ

hyaluronan	NN

injections	NNS

for	IN

treatment	NN

of	IN

osteoarthritis	NN

of	IN

the	DT

knee	NN

Pneumococcal	JJ

vaccine	NN

:	:

a	DT

second	JJ

look	NN

